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Kurzdarstellung 
 
Hauptthema (Kapitel 2.): Die Entwicklung, Synthese und Anwendung eines vielseitigen chiralen 
nukleophilen Iridium(III)-Katalysators, welcher als einziges Chiralitätselement ein stereogenes 
oktaedrisches Metallzentrum besitzt ('stereogenic-only-at-metal'), wird vorgestellt. Der ent-
wickelte Katalysator verfügt neben zwei maßgeschneiderten bidentaten cyclometallierten Phenyl-
benzoxazol-Liganden über einen bidentaten deprotonierten 7-Chloro-3H-imidazo[4,5-h]chinolin-
Liganden, welcher als nukleophiles katalytisch aktives Zentrum fungiert. 
Zunächst wurden 28 verschiedene 'stereogenic-only-at-metal' Iridium(III)-Komplexe synthetisiert, 
diese evaluiert und schließlich der leistungsfähigste Komplex ausgewählt. In diesem Zusammen-
hang wurde dargelegt, dass es sich bei dem ausgewähltem Komplex zunächst um die protonierte, 
katalytisch inaktive Präkatalysatorform des eigentlichen Katalysators handelte.  
Es konnte gezeigt werden, dass der entwickelte 'stereogenic-only-at-metal' Komplex als effizien-
ter Katalysator für die asymmetrische Steglich-Umlagerung von O-acylierten Azlactonen (bis zu 
96% ee, bis zu 99% Ausbeute), die asymmetrische Black-Umlagerung von O-acylierten Benzo-
furanonen (bis zu 94% ee, bis zu 99% Ausbeute) und für die asymmetrische Addition von 
2-Cyanopyrrol an Arylalkylketene (bis zu 95% ee, bis zu 99% Ausbeute) dient. 
Einblicke in den Mechanismus der Steglich- und Black-Umlagerungen mit dem entwickelten 
Katalysator, insbesondere in Hinblick auf die Art und Weise der Enantioinduktion, konnten 
erlangt werden mit Hilfe einer Kristallstruktur des Katalysators, mit Hilfe einer Kristallstruktur 
eines Katalyseintermediat-Analogons in Kombination mit DFT-unterstützer Analyse der Zugäng-
lichkeit des katalytisch aktiven Zentrums sowie mit Hilfe der expliziten quantenmechanischen 
Modellierung des stereogenen Schrittes einer exemplarischen Black-Umlagerung mit einem leicht 
vereinfachten Modell des entwickelten Katalysators. Die entsprechenden theoretischen Berech-
nungen wurden in enger Zusammenarbeit geplant und abgestimmt mit und durchgeführt von 
Kooperationspartner Michael G. Medvedev. 
 
Nebenthema (Kapitel 3.): Nebenthema der vorliegenden Dissertation ist die versuchte Entwick-
lung eines kooperativen bifunktionalen 'stereogenic-only-at-metal' Enamin/Wasserstoffbrücken-
bindungs-Katalysators, der als Katalysator für die asymmetrische Michael-Addition von enolisier-
baren Aldehyden und / oder Ketonen an Nitroalkene und / oder Nitroacrylate angedacht war. 
Ein synthetischer Zugang zu den angedachten Katalysatoren konnte erfolgreich etabliert werden, 
jedoch führten Stabilitätsprobleme mit den Komplexen sowie unbefriedigende Katalyseergebnisse 
schließlich zum Abbruch des Projektes. Dessen ungeachtet konnten wichtige Erkenntnisse in 
Bezug auf die Synthese Amin-funktionalisierter bis-cyclometallierter Iridium(III)-Komplexe 
sowie C2-symmetrischer bis-cyclometallierter Bispyrazol-Iridium(III)-Komplexe erlangt werden, 
welche bereits zu erfolgreich abgeschlossenen Projekten des AK Meggers beigetragen haben und 
daher auch für zukünftige Projekte wieder relevant werden könnten. 
 – Kurzdarstellung (Deutsch) / Abstract (English) –   
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Abstract 
 
Main Topic (Chapter 2.): The design, synthesis, and application of a versatile chiral nucleophilic 
iridium(III) catalyst, which features a stereogenic octahedral metal center as its exclusive element 
of chirality ('stereogenic-only-at-metal'), is presented. The devised catalyst features two custom-
tailored bidentate cyclometalated phenylbenzoxazole ligands as well as a bidentate deprotonated 
7-chloro-3H-imidazo[4,5-h]quinoline ligand, which serves as the catalyst's nucleophilic cataly-
tically active site. 
At first, 28 different stereogenic-only-at-metal iridium(III) complexes were synthesized, evalua-
ted, and the best-performing complex eventually selected. In this regard, it was revealed that the 
selected catalyst candidate was in fact the protonated precatalytic form of the actual catalyst.  
Next, it could be demonstrated that the developed stereogenic-only-at-metal complex serves as an 
efficient catalyst for the asymmetric Steglich rearrangement of O-acylated azlactones (up to 
96% ee, up to 99% yield), for the asymmetric Black rearrangement of O-acylated benzofuranones 
(up to 94% ee, up to 99% yield), and for the asymmetric addition of 2-cyanopyrrole to aryl alkyl 
ketenes (up to 95% ee, up to 99% yield). 
Insights into the mechanism of the Steglich and the Black rearrangements with the developed 
stereogenic-only-at-metal catalyst, in particular into the catalyst's manner of enantioinduction, 
could be gained with a crystal structure of the active catalyst, with a crystal structure of a catalysis 
intermediate analog in combination with a DFT-assisted active site accessibility analysis, and with 
the explicit quantum chemical modeling of the stereogenic step of a showcase Black rearrange-
ment with a slightly simplified model of the devised catalyst. The respective theoretical calcu-
lations were planned and coordinated in close collaboration with and performed by cooperation 
partner Michael G. Medvedev. 
 
Secondary Topic (Chapter 3.): Secondary topic of the present thesis is the attempted development 
of a cooperative bifunctional stereogenic-only-at-metal enamine/hydrogen-bonding catalyst, 
which was intended to catalyze Michael additions of enolizable aldehydes and / or ketones to 
nitroalkenes and / or nitroacrylates.  
A synthetic access to the envisioned catalysts could be successfully established, however, stability 
problems with the complexes as well as unsatisfactory catalysis results ultimately led to the 
termination of this project. In spite of that, important knowledge could be attained regarding the 
synthesis of amine-functionalized bis-cyclometalated iridium(III) complexes and C2-symmetric 
bis-cyclometalated bispyrazole iridium(III) complexes, which has already contributed to success-
fully accomplished projects from the Meggers group and which may accordingly be helpful for 
future projects. 
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Design, Synthesis, and Application of a Nucleophilic Octahedral 
Stereogenic-Only-at-Metal Iridium(III) Catalyst 
 
1.  Theoretical Background 
1.1   Nucleophilic Catalysis and Lewis Base Catalysis – Definition of Terms 
The terms 'nucleophilic catalysis' and 'Lewis base catalysis' are often used synonymously in 
the literature.[1–4] In other cases, a much wider field in catalysis is referred to by the term 
'Lewis base catalysis' than by the term 'nucleophilic catalysis', which can be misleading and 
confusing.[5,6] In the present thesis, the terms 'nucleophilic catalysis' and 'nucleophilic catalyst' 
exclusively refer – by definition – to catalysts and catalysis in which a catalyst with a nucleo-
philic / Lewis basic lone pair activates a substrate by an initial n → π* (most common), 
n → σ* (less common), or n → n* (less common) interaction[5] and where the resultant 
catalyst-substrate adduct then reacts without any structural changes of the catalyst-attached 
entity that are caused by the nature of the catalyst itself under transfer of this entity and under 
catalyst regeneration. Reactions, in which the catalyst-attached entity undergoes structural 
changes that are caused by the nature of the catalyst itself before the resultant entity is 
transferred under catalyst regeneration, such as reactions that are catalyzed via enamine or 
iminium ion formation by secondary amines,[7,8] or NHC-catalyzed umpolung reactions via 
Breslow-type intermediates with aldehydes and imines,[9] are not included in the hereby given 
definition of 'nucleophilic catalysis' / 'nucleophilic catalyst' and are beyond the scope of the 
herein discussed reactions.[5,6,10] In contrast, those reactions are explicitely included in the 
very general definition of 'Lewis base catalysis' given by Denmark, Beutner, and Vedejs.[5,6]  
 
 
 
Scheme 1. "Archetypical" nucleophile-catalyzed reaction: Acylation of an alcohol (1) with an anhydride (2) 
catalyzed by 4-dimethylaminopyridine (DMAP; 3). A Brønsted base (B) is added to prevent accumulation of 
acid R2(C=O)OH. 
 
A simple example for a reaction which follows the above given definition of nucleophilic 
catalysis is depicted in Scheme 1, which shows the acylation of an alcohol (1) with an an-
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hydride (2) as acylating reagent and which is catalyzed by "archetypical" nucleophilic catalyst 
4-dimethylaminopyridine (3; DMAP).[11] 
 
1.2  Asymmetric Nucleophilic Catalysis – Overview 
Over the past twenty years, since the introduction of the first "chiral DMAP" reagent by 
Vedejs and Chen in 1996 (38; see Figure 2),[12] a significant amount of work has been carried 
out by research groups all over the world in developing highly active and at the same time 
highly selective nucleophilic catalysts capable of various asymmetric transformations, such as 
(dynamic) kinetic resolutions of racemic compounds (see Scheme 2) and desymmetrizations 
of meso compounds,[13−20] Steglich-type acyl migration reactions (see Scheme 3),[3,20,22−25] 
reactions of ketenes with various substrates (see Scheme 4),[26,27] and others.[28] 
 An example for a kinetic resolution (KR) with a chiral nucleophilic catalyst and at the 
same time an example for a dynamic kinetic resolution (DKR) with the same chiral catalyst 
are shown in Scheme 2. 
 
 
 
Scheme 2. Kinetic resolution (KR) with Fu's planar-chiral nucleophilic catalyst (+)-7a versus dynamic kinetic 
resolution (DKR) with a combination of (+)-7a and Bäckvall's alcohol racemization precatalyst 8.[13e,f,29] 
 
Fu and co-workers initially employed planar-chiral catalyst (+)-7a in the kinetic resolution of 
secondary alcohols (9) with acetic anhydride (10) as acylation reagent (Scheme 2).[13e,f] 
Although they could achieve resolutions with excellent selectivity factors of up to S = 100 
(a definition for S is given in the next paragraph), this approach comes with the limitation that 
at least 50% of starting material 9 or of product 11 are lost in case there is no further use for 
them. Later on, Fu and co-workers were able to get around this shortcoming by the com-
bination of nucleophilic acylation catalyst (+)-7a with Bäckvall's racemization pre-
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catalyst 8,[29] which racemizes secondary alcohols 9 in the presence of KOtBu under 
appropriate reaction conditions.[13e,f,29] With mixed anhydride 12, which serves as a substitute 
for acetic anhydride (10), the combination of catalyst (+)-7a and precatalyst 8 accordingly 
resulted in an elegant dynamic kinetic resolution of secondary alcohols (9) giving the acylated 
products (11) in up to 99% yield and up to 99% ee (Scheme 2).[13e,f]  
At this point, it is necessary to explain the selectivity factor S: This factor is a highly 
useful parameter which allows direct comparisons of kinetic resolutions which have been 
stopped at different conversion levels.[28e,30] The selectivity factor S can be interpreted as the 
quotient of the rate constants of the fast reacting starting material enantiomer (kfast in Eq. 1) 
and the slow reacting starting material enantiomer (kslow in Eq. 1).[28e] In contrast, direct 
comparisons of kinetic resolutions by means of ee values alone are only feasible in case the 
resolutions have been stopped at (almost) identical conversion levels. As a rule of thumb, 
kinetic resolutions start to become synthetically useful when they provide selectivity factors 
of S ≥ 10.[28e] In cases with S ≥ 10 but S < 50 kinetic resolutions have to be stopped at 
conversion levels of (much) more than 50% in order to obtain a sufficiently enriched starting 
material while the ee of the product remains low and synthetically less useful.[28e] Kinetic 
resolutions with S > 50 provide both a highly enriched starting material and a highly enriched 
product at around 50% conversion.[28e] The selectivity factor S of a kinetic resolution can be 
directly calculated from the ee values of the unconsumed starting material S and the formed 
product P at any conversion (C) according to Kagan's equation (Eq. 1).[28e,30]   
 
             퐶 = ee 퐒ee 퐒 + ee 퐏 100          푆 =  
푙푛[1 − 퐶(1 + ee 퐏)]
푙푛[1 − 퐶(1 − ee 퐏)]            푆 =
푘fast푘slow             (Eq. 1) 
                
 
 
An example for a Steglich-type acyl migration reaction, i.e., an intramolecular stereogenic 
acyl migration or rearrangement,[21] is shown in Scheme 3, which shows the Steglich 
rearrangement of achiral O-acylated azlactone 13a with Fu's planar-chiral catalyst (−)-7b to 
chiral C-acylated azlactone 14a.[22a] In the depicted mechanism, the nitrogen atom of the 
fused pyrrolidinopyridine moiety of (–)-7b first attacks the carbonate moiety of 13a, which 
goes along with the formation of N-acylated cation 15a-A and its associated enolate 
counteranion 15a-B, which together constitute N-acyl pyridinium salt 15a.[22a] Enolate 15a-B 
then reacts with N-acylated cation 15a-A under stereogenic C-C bond formation which stereo-
selectively provides C-acylated azlactone 14a under regeneration of catalyst (–)-7b.[22a] 
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Scheme 3. Steglich rearrangement of O-acylated azlactone 13a to C-acylated azlactone 14a with Fu's planar-
chiral nucleophilic catalyst (–)-7b.[22a] 
 
An example for chiral nucleophilic catalysis with ketenes as substrates is shown in Scheme 4, 
which shows the formal [2+2]-cycloaddition between aryl alkyl ketenes (16) and N-Boc-
protected imines (17) giving N-Boc-protected β-lactams (19) from Ye and co-workers (the 
authors denote the reaction as a 'Staudinger reaction').[27a] The reaction is catalyzed by chiral 
N-heterocyclic carbene (NHC) (S)-20, which is formed in situ by deprotonation of imida-
zolium salt (S)-18 with cesium carbonate as Brønsted base.[27a] 
 
 
 
Scheme 4. Asymmetric formal [2+2]-cycloaddition between ketenes (16) and N-Boc-protected imines (17) 
giving N-Boc-protected β-lactams (19) catalyzed by NHC catalyst (S)-20 from Ye and co-workers. Curved 
arrows are only drawn for the final step of each of both cycles.[27a]  
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For the reaction from Scheme 4 two catalytic pathways are plausible:[26f,27a] 
 
• An 'imine-first' cycle[26f] in which NHC catalyst (S)-20 first attacks the imine substrate (17) 
and where the resulting catalyst-substrate adduct (S)-20-Int1 subsequently attacks the 
ketene substrate (16). 
• Or a 'ketene-first' cycle[26f] in which NHC catalyst (S)-20 first attacks the ketene substrate 
(16) and where the resulting catalyst-substrate adduct (S)-20-Int3 subsequently attacks the 
imine substrate (17). 
 
In both cases resulting intermediates (S)-20-Int2 ('imine-first' cycle) and (S)-20-Int4 ('ketene-
first' cycle) fragment to the desired β-lactam (19) and NHC catalyst (S)-20.[26f,27a] 
 
The so far developed chiral nucleophilic catalysts rely in large part on N-nucleophiles 
(Figure 1, A) and here in particular on 4-dimethylaminopyridine (DMAP; 3) or on closely 
related 4-pyrrolidinopyridine (PPY) as their catalytically active entities due to their high 
intrinsic activity (Figure 1, A.1).[1,2,4−6,11,13−17,20,22−25,28,31] 
However, powerful non-DMAP-type N-based nucleophilic catalysts have been developed as 
well, which rely on amidines (Figure 1, A.2),[15,20] isothioureas (Figure 1, A.3),[4,16,20,24] imida-
zoles (Figure 1, A.4),[17,25] and aliphatic (di-)amines (Figure 1, A.5).[32,33]  
There are also notable examples for nucleophilic catalysts which do not rely on N-nucleo-
philes, they rely on O-nucleophiles (Figure 1, B),[3,18] P-nucleophiles (phosphines; Figure 1, 
C),[19] C-nucleophiles (NHCs; Figure 1, D),[26,27] and others.[28] 
 
Generally speaking, the introduction of a steering stereocenter in proximity to a catalyst's 
active site represents a straightforward approach to achieve enantiocontrol in an asymmetric 
transformation. However, as steering stereocenters often comprise sterically demanding 
moieties, this may go along with significant loss of catalytic activity, as it is the case for chiral 
acylation reagent 38 (see Figure 2) from Vedejs and Chen, which has to be employed in its 
N-acylated form in stoichiometric amounts.[12] Hence, from the standpoint of catalytic 
activity, it is desirable to have a remote stereocenter, but this, on the other hand, may be 
detrimental for an efficient enantioinduction.[14a,d,23a,b,g,24,25a] This phenomenon has aptly been 
called the 'selectivity-reactivity dilemma' by Fuji et al.[14a] and is also encountered for systems 
which are not entirely planar, such as catalyst 40 (Figure 2), although it is less pronounced 
there.[4,15,25a] With regard to nucleophilic catalysts, several interesting strategies have been 
devised to circumvent low catalytic activity when aiming for high selectivity, including 
strategies that go beyond "classic" tetrahedral carbon stereocenters as stereogenic elements. 
Selected examples for such catalysts are presented in the next paragraphs.  
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Figure 1. Examples for nucleophilic catalysts relying on different nucleophilic entities. 
 
 
 
Figure 2. Vedejs' asymmetric acylation reagent (38) and four chiral nucleophilic catalysts (7,39,40,22) relying 
on different scaffolds and elements of chirality. 
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In 1996, shortly after Vedejs' and Chen's seminal publication about stoichiometric acylation 
reagent 38,[12] Fu and co-workers introduced planar-chiral ferrocene-fused DMAP derivatives 
as chiral nucleophilic catalysts (7, Figure 2; see also 7a and 7b in Schemes 2 and 3),[13a] 
which have, up to date, been demonstrated to efficiently catalyze a broad array of asymmetric 
transformations and also been extended to analogous ruthenocyl-fused derivatives.[31] Due to 
their unrivaled versatility,[1,2,13,22,26] Fu's ferrocene-fused DMAP derivatives (7) have emerged 
as a reference standard in asymmetric nucleophilic catalysis.[15d,34a] Meanwhile, the concept of 
creating planar-chiral nucleophilic catalysts by ferrocene fusion has been extended by others 
to non-DMAP-type catalysts, such as NHC- and amidine-based systems (see for example 
catalyst 26 from Fossey and Deng in Figure 1).[15d,35] 
Another interesting and early example for a nucleophilic catalyst developed with the 
intention to circumvent the 'selectivity-reactivity dilemma' [14a] is Fuji's catalyst 22 from 1997 
(Scheme 5).[14a] Although relying on "classic" tetrahedral carbon stereocenters, in catalyst 22 
the stereoinformation is apparently too far away from the nucleophilic nitrogen to efficiently 
control the stereochemical outcome of an asymmetric transformation. However, catalyst 22 
was found to be able to give moderate to fair results in kinetic resolutions of chiral secondary 
alcohols, selectivity factors in the range S ~ 5–10 were found.[14a]  
 
 
 
Scheme 5. Fuji's catalyst 22 adapts a closed conformation upon N-acylation (22-Int), probably due to a favo-
rable π-π-interaction, which explains why catalyst 22 is able to discriminate between both enantiomers of chiral 
secondary alcohols.[14a]  
 
 
Fuji and co-workers revealed that catalyst 22 adapts a closed conformation upon N-acylation, 
probably due to a favorable π-π-interaction (22-Int, Scheme 5), which explains why the 
catalyst is able to discriminate between both enantiomers of chiral secondary alcohols.[14a]  
In contrast to that, Ooi and co-workers developed axial-chiral BINOL-derived 
O-nucleophilic ammonium betaines 33 (Figure 1), which they employed as highly selective 
catalysts in Steglich rearrangements of O-acylated azlactones.[3] 
And quite recently, Suga and co-workers reported about axial-chiral BINOL-derived 
DMAP-type catalyst 39 (Figure 2), which they employed as a catalyst in Steglich-type 
rearrangements of O-acylated oxindoles, in kinetic resolutions of alcohols, and in 
desymmetrizations of diols.[23g]  
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Carbery and co-workers developed helicenoidal DMAP derivative 24 (Figure 1), which they 
employed as a catalyst in kinetic resolutions of alcohols.[14h,i] 
In this context, it is worth of mentioning that Suginome and co-workers have very recently 
(2017) reported an "elongated version" of a helical-chiral nucleophilic catalyst (Figure 3).[36] 
 
  
 
Figure 3. DMAP-functionalized single-handed polymeric poly(quinoxaline-2,3-diyl) chains from Suginome and 
co-workers.[36] [Figure of the helix reproduced and adapted with permission from ref. 36. Copyright © 2017, 
American Chemical Society] 
 
Suginome and co-workers attached DMAP (3) via its 3-position to single-handed polymeric 
poly(quinoxaline-2,3-diyl) chains and demonstrated that the resulting polymer chains serve as 
suitable catalysts for asymmetric Steglich rearrangements of O-acylated azlactones (13 → 14, 
Figure 3).[36] An interesting aspect of this chiral nucleophilic chains is the fact that the aryl-
aryl bond between DMAP and the polymeric backbone is not fixed but automatically adapts 
the energetically favored rotamer which is dictated by the helical backbone (Figure 3).[36]  
A nucleophilic catalyst which is also worth mentioning in the context of helical-chiral 
catalysts is photo- and thermally switchable catalyst 23, which has also very recently been 
reported (2017) by Chen, Yu, and co-workers (Scheme 6). 
 
 
 
Scheme 6. Photo- and thermally switchable helical-chiral catalysts (P)-23 and (M)-23' from Chen, Yu, and co-
workers.[23h] Note that (P)-23 and (M)-23' are diastereomers or pseudoenantiomers as they feature two tetra-
hedral carbon stereocenters in their seven-membered rings. 
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Catalyst 23 allows an enantiodivergent Steglich rearrangement of O-acylated azlactones 
(13 → 14) with a single catalyst:[23h] By irradiation with UV-light at λ = 290 nm, catalyst 23 
switches to pseudoenantiomer (M)-23' in a (P)-23 / (M)-23' ratio of up to <1:99. In contrast, 
by irradiation with UV-light at a longer wavelength, namely at λ = 340 nm, an inverse 
(P)-23 / (M)-23' ratio of up to 91:9 is provided. Alternatively, catalyst 23 can be stirred at 
130 °C in p-xylene in the absence of UV-light, which then provides catalyst (P)-23 virtually 
pure in a (P)-23 / (M)-23' ratio of up to >99:1.[23h] While (P)-23 provides 14a in 90% ee with 
respect to the R-enantiomer, (M)-23' provides 14a in 94% ee with respect to the S-enantiomer 
(Scheme 6).[23h]    
 
In the previous paragraphs, selected examples for chiral nucleophilic catalysts relying on 
different scaffolds and elements of chirality have been presented and some discussed in detail. 
Another type of chiral scaffold which could be made use of to develop chiral nucleophilic 
catalysts is represented by octahedral metal complexes which feature a metal stereocenter. For 
such complexes the term 'chiral-at-metal' has been coined and for those complexes which 
feature a stereogenic metal center as their exclusive element of chirality, i.e., with all 
coordinating ligands being achiral, the more restricting term 'chiral-only-at-metal' has been 
introduced.[37−40] However, both terms are somewhat imprecise as 'chirality' is rather a 
property of an object as a whole.[40] For this reason, the alternative terms 'stereogenic-at-
metal' and 'stereogenic-only-at-metal', which rather point at the metal center as the origin of 
the chirality of such complexes, are used throughout this thesis.[40] Coming back to 
nucleophilic catalysis, the merger of an entity capable of nucleophilic catalysis and a stereo-
genic-only-at-metal complex fragment, offers a possibility to design a potentially powerful 
chiral nucleophilic catalyst (Figure 4). 
 
 
 
Figure 4. Basic concept for a chiral nucleophilic octahedral stereogenic-only-at-metal catalyst. 
 
In chapter 2., it will be demonstrated that a powerful chiral nucleophilic stereogenic-only-at-
metal catalyst could indeed be developed based on this concept. But first, chapters 1.3 and 1.4 
will provide a brief summary about the history of stereogenic-at-metal complexes in general 
and an overview of the so far developed stereogenic-at-metal catalysts from the Meggers 
laboratory and other research laboratories. 
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1.3  Stereogenic-at-Metal Catalysts – Introduction and Results from 
Other Research Groups 
In 1899, Swiss chemist and later Nobel Laureate Alfred Werner postulated in a publication 
about the constitution of cobalt(III) complexes that the formation of an octahedral complex 
with two identical bidentate ligands, such as ethylenediamine (en), should entail the existence 
of two enantiomers, provided that both ligands and the two remaining monodentate ligands, or 
a third bidentate ligand, constitute the cis-isomer of the respective complex (i.e., 
cis-[M(en)2XY] or cis-[M(en)2X^Y]) and not the achiral trans-isomer (Figure 5).[41,42] 
Nowadays, both resulting enantiomers are denoted as Λ- and ∆-enantiomer, depending on 
whether they represent a left-handed propeller (Λ) or a right-handed propeller (∆).[40] 
 
 
 
 
Figure 5. Original figures from Werner's publications from 1899 (A, B)[41] and from 1911 (C):[43] (A) Werner 
anticipated that [Co(en)2(C2O4)]+ would most probably exist as cis-isomer (left) and not as trans-isomer (right) 
due to spatial constraints.[41] (B) He correctly recognized that cis-[Co(en)2(C2O4)]+ is chiral and accordingly 
exists as two enantiomers.[41] (C) He also correctly recognized that the same is the case for complexes of type 
cis-[M(en)2AB] or cis-[M(en)2A^B].[43] [Reproduced and adapted with permission from refs. 41, 43. Copyright 
© Wiley-VCH Verlag GmbH & Co. KGaA] 
 
In his 1899 publication, Werner mentions first though unsuccessful attempts to separate such 
racemic complex mixtures.[41,44] It took him and his co-workers twelve additional years until 
they eventually reported the successful separation and characterization of the at that time still 
postulated complex enantiomers (see Scheme 7).[43,45]  
In his 1911 publication, Werner then describes the separation of the Λ- and ∆-configured 
complex cations of cis-[Co(en)2(NH3)Cl]Cl2 and cis-[Co(en)2(NH3)Br](NO3)2.[43] The work-
flow for the separation of the chiral complex cations of cis-[Co(en)2(NH3)Cl]Cl2 (rac-41) is 
depicted in detail in Scheme 7. Werner and co-workers achieved the synthesis of enantiopure 
salts Λ-44 and ∆-44 from rac-41 via replacement of the achiral non-coordinated halide anions 
by chiral (R)-3-bromocamphor-8-sulfonate with silver (R)-3-bromocamphor-8-sulfonate 
((R)-42), subsequent separation of the resulting diastereomeric salts Λ-(R)-43 and ∆-(R)-43 
via fractional crystallization, and finally replacement of (R)-3-bromocamphor-8-sulfonate by 
bromide anions giving salts Λ-44 and ∆-44.[43] As expected for enantiomers, identical 
absolute specific rotation values with opposite leading signs were found for both salts.[43] The 
obtained enantiomeric salts were found to be configurationally stable and did not show any 
signs of racemization, not even in boiling water or after prolonged standing.[43,45]  
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Scheme 7. Synthesis of enantiopure Λ-44 and ∆-44 from Werner and co-workers from 1911.[43] In this context, it 
is worth mentioning that Werner's co-worker V. L. King in 1942 recalled that it took him some 2000 fractional 
crystallization attempts until he eventually utilized silver (R)-3-bromocamphor-8-sulfonate ((R)-42), which then 
allowed the above depicted successful separation via fractional crystallization.[45]  
 
In consideration of what was achieved by Werner and his co-workers more than 100 years ago 
with regard to stereogenic-only-at-metal Co(III) complexes, it is surprising that it was not 
until 2003 that the first research group started to intentionally use stereogenic-only-at-metal 
complexes as catalysts for asymmetric transformations.[37a] 
In 2003, Fontecave and co-workers reported about stereogenic-only-at-metal Ru(II) 
complex Λ/∆-45, which they used as a catalyst for the asymmetric oxidation of sulfides (47) 
to chiral sulfoxides (48; Scheme 8).[37a] In order to obtain enantiopure Λ-45 from rac-45, 
Fontecave and co-workers first selectively precipitated the ∆-configured complex cation of 
rac-45 by the addition of (n-Bu3)NH·Λ-TRISPHAT as Λ-TRISPHAT – salt ∆-(2Λ)-46 
(Scheme 8, Step I). Next, they selectively precipitated enantiopure Λ-45 from the remaining 
solution by the addition of diethyl ether (Scheme 8, Step II).[37a] 
When Fontecave and co-workers added 2 mol% of complex Λ-45 to a solution of sulfide 47 
and hydrogen peroxide in MeOH, desired sulfoxide 48 was produced with 18% ee (S). With 
2 mol% of ∆-(2Λ)-46 desired sulfoxide 48 was also produced with 18% ee (R), which indi-
cated that the two chiral Λ-TRISPHAT – counteranions did not have any influence on the 
enantioselectivity of the reaction 47 → 48. This finding was reaffirmed with a control experi-
ment by Fontecave and co-workers in which they employed 2 mol% rac-45 in the presence of 
4 eq of (n-Bu3)NH·Λ-TRISPHAT, which provided 48 completely racemic (Scheme 8).[37a] 
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Scheme 8. Early use of a stereogenic-only-at-metal catalyst in an asymmetric reaction from Fontecave and co-
workers.[37a] Catalyst Λ-45 catalyzes the oxidation of sulfides (47) to chiral sulfoxides (48) with H2O2 as 
oxidant.[37a] In order to obtain Λ-45, Fontecave and co-workers first precipitated the ∆-enantiomer of rac-45 by 
the addition of (n-Bu3)NH·Λ-TRISPHAT as ∆-(2Λ)-46 (Step I) and obtained then pure Λ-45 from the remaining 
solution by Et2O-induced precipitation of Λ-45 (Step II).[37a] 
 
Even though the enantioselectivities for the sulfoxides (48) are low and far from synthetically 
useful, Fontecave and co-workers demonstrated with this proof-of-principle study that 
stereogenic-only-at-metal complexes are suited as scaffolds for the design of chiral catalysts.  
One year later in 2004, Belokon and co-workers reported about salicylimine-based 
cobaltate(III) complex Λ-(R,R)-49, which they used as a catalyst for the cyanosilylation of 
benzaldehyde (50) with trimethylsilyl cyanide to give the corresponding O-silylated 
cyanohydrin (51) in up to 77% ee (Scheme 9).[46] 
 
 
 
Scheme 9. Belokon's stereogenic-at-metal complex Λ-(R,R)-49 catalyzes the cyanosilylation of benzaldehyde 
(50) with trimethylsilyl cyanide to give the corresponding O-silylated cyanohydrin (51) in up to 77% ee.[46] 
 
However, this catalytic system turned out to be very sensitive to variations of the reaction 
parameters: Exchange of the potassium countercation for other cations, such as Na+, Li+, Cs+, 
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inversion of the cobalt stereocenter (=∆-(R,R)-49), and omission or replacement of co-catalyst 
PPh3, resulted all in a dramatic or even in a total loss of enantioselectivity.[46]  
It is worth noting that Λ-(R,R)-49 represents a stereogenic-at-metal catalyst but not a stereo-
genic-only-at-metal catalyst due to the presence of one carbon-centered stereocenter in each 
of its identical tridentate ligands. Such a catalyst design entails the advantage that the Λ- and 
∆-configured catalysts are diastereomers, which allows a straightforward resolution, for 
example via chromatography or via fractional crystallization.[46,47] In particular cases, spatial 
constraints may even completely prevent the formation of the second diastereomer (e.g., in 
case of Ohkuma's catalyst Λ-(S, S, S)-67 from Scheme 13).[48]  
In 2007, Fontecave and co-workers reported about dinuclear chiral bis-ruthenium com-
plex Λ-52, which consists of a Λ-configured octahedral ruthenium(II) fragment containing the 
stereoinformation of the dinuclear complex and a ruthenium(II) half-sandwich fragment 
serving as the complex's catalytically active site (Scheme 10).[37b] The half-sandwich fragment 
of Λ-52 catalyzes the asymmetric transfer hydrogenation of ketones (53) with sodium formate 
to give chiral secondary alcohols (54).[37b] Though the concept is interesting, only low 
enantioselectivities of not more than 26% ee could be achieved (Scheme 10).[37b] 
 
 
 
Scheme 10. Fontecave's dinuclear transfer hydrogenation catalyst Λ-52.[37b] Both ruthenium complex fragments 
fulfill different tasks: The octahedral chiral-only-at-metal fragment comprises the dinuclear complex's chiral 
information while the half-sandwich fragment serves as the dinuclear complex's catalytically active site.[37b] 
 
One year later in 2008, Gladysz and co-workers used chiral Co(III) tris(ethylenediamine) 
complex Λ-57 as a catalyst for the asymmetric Michael addition of dimethyl malonate (56) to 
cylopentenone (55), which provided addition product 58 in up to 33% ee (Scheme 11).[49] In 
this context, it is worth noting that Werner had already reported the isolation of enantiopure 
complexes Λ-[Co(en)3]X3 with X− = Br−, Cl−, NO3− in 1912,[50] one year after his seminal 
publication from 1911 (see Scheme 7).[43] Surprisingly, such Co(III) tris(ethylenediamine) 
complexes or related complexes had never been applied or reported before as chiral catalysts, 
which may be attributed to their very low solubility in organic solvents.[49] Gladysz and co-
workers addressed this issue in case of Λ-57 by the substitution of the hard anions X− = Br−, 
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Cl−, NO3− for the soft anion X− = BArF24− (tetrakis[3,5-bis(trifluoromethyl)phenyl]borate),[51] 
which renders the [Co(en)3]3+ complex cation as BArF24− salt soluble in a range of common 
organic solvents (Scheme 11).[49] 
 
 
 
 
 
Scheme 11. Gladysz and co-workers replaced in Werner's complex Λ-[Co(en)3]X3[50] the hard anions chloride, 
bromide, and nitrate by the soft anion BArF24− resulting in Λ-[Co(en)3](BArF24)3 (Λ-57), which is well soluble in 
a range of common organic solvents.[49] As a proof-of-principle, Λ-57 was used in form of its tetradecahydrate as 
a catalyst for the asymmetric addition of dimethyl malonate (56) to cyclopentenone (55), which provided 
conjugate addition product 58 in up to 33% ee.[49]  
 
As Co(III) tris(ethylenediamine) complexes are coordinatively inert under the applied con-
ditions, Gladysz and co-workers assume that the reaction is catalyzed via hydrogen-bonding 
catalysis in the ligand sphere without direct participation of the cobalt center.[49] 
 In 2015 and 2016, Gladysz and co-workers presented catalysts Λ-(2S,2S,2S)-59 and 
Λ-(S)-60, which can be considered as '2nd generation catalysts' of catalyst Λ-57 
(Scheme 12).[52−54] Λ-(2S,2S,2S)-59 differs from Λ-57 in that respect that the achiral 
ethylenediamine ligands of Λ-57 are replaced by chiral (S,S)-1,2-diphenylethylenediamine 
ligands.[52] Λ-(2S,2S,2S)-59 showed excellent performance as a catalyst for the Michael 
addition of malonates (61) to nitroalkenes (62)[52] and for the Michael addition of 1,3-di-
carbonyl compounds (64) to di-tert-butyl azodicarboxylate (65)[53] giving the corresponding 
products 63 and 66 in up to 98% ee and in up to >99% ee, respectively (Scheme 12).[52,53] A 
much more subtle change with respect to catalyst Λ-57 was made in case of Λ-(S)-60: 
Gladysz and co-workers formally replaced here only one ethylenediamine ligand of Λ-57 by 
an ethylenediamine ligand bearing a 3-(dimethylamino)propyl residue featuring S-con-
figuration at the junction point.[54] Λ-(S)-60 showed, similar to catalyst Λ-(2S,2S,2S)-59, 
excellent performance as a catalyst for the Michael addition of malonates (61) to nitroalkenes 
(62) giving the corresponding products 63 with up to 99% ee (Scheme 12).[54] 
      – 1.3 Stereogenic-at-Metal Catalysts – Introduction and Results from Other Research Groups –   
 
~ 27 ~ 
 
 
 
 
Scheme 12. Gladysz's '2nd generation catalysts' Λ-(2S,2S,2S)-59[52,53] and Λ-(S)-60[54] and their application as 
catalysts for the Michael addition of malonates (61) to nitroalkenes (62)[52,54] and for the Michael addition of 
1,3-dicarbonyl compounds (64) to di-tert-butyl azodicarboxylate (65).[53] 
 
In 2008, Ohkuma and co-workers reported that Ru(II) complex Λ-(S,S,S)-67, which features 
two S-configured phenylglycinate ligands (phgly) and one S-configured BINAP ligand, is an 
excellent catalyst for the asymmetric cyanosilylation of aldehydes (68 → 69) in combination 
with lithium carbonate as additive (Scheme 13, A).[48] 
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Scheme 13. Ohkuma's catalyst Λ-(S,S,S)-67 is, as lithium salt Λ-(S,S,S)-67·LiX or in combination with a 
lithium salt, a powerful catalyst for the asymmetric cyanosilylation of aldehydes (68 → 69; A),[48] the asym-
metric hydrocyanation of aldehydes (68 → 70; B),[56] the asymmetric conjugate hydrocyanation of α,β-
unsaturated ketones (71 → 72; C),[57] and the related asymmetric conjugate hydrocyanation of α,β-unsaturated 
N-acyl pyrroles (73 → 74; D).[58]  
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Ohkuma and co-workers initially thought that the obtained complex was trans-
[Ru(phgly)2(BINAP)],[55] which would render the complex "non-stereogenic-at-metal". 
However, a crystal structure in a follow-up publication revealed that it was rather 
cis-[Ru(phgly)2(BINAP)] and this crystal structure also revealed that the metal center is 
Λ-configured (see also Figure 5 in this context).[56] Accordingly, the entire stereochemical 
designation of the cis-complex is Λ-(S,S,S)-[Ru(phgly)2(BINAP)] (i.e., Λ-(S,S,S)-67). 
Apart from the asymmetric cyanosilylation of aldehydes (68 → 69; Scheme 13, A),[48] catalyst 
Λ-(S,S,S)-67 was identified – as lithium salt Λ-(S,S,S)-67·LiX or in combination with a 
lithium salt – as a powerful catalyst for the asymmetric hydrocyanation of aldehydes 
(68 → 70; Scheme 13, B),[56] for the asymmetric conjugate hydrocyanation of α,β-unsaturated 
ketones (71 → 72; Scheme 13, C),[57] and for the related asymmetric conjugate hydrocya-
nation of α,β-unsaturated N-acyl pyrroles (73 → 74; Scheme 13, D).[58]  
 In 2013, Belokon and co-workers reported about salicylimine-based cobalt(III) complex 
Λ-(2R,2R)-75 (Scheme 14), which can be considered as a strongly modified derivative of 
Λ-(R,R)-49 from Scheme 9.[59] Due to the formal replacement of two cobalt-coordinating 
carboxylates for two cobalt-coordinating amines, complex Λ-(2R,2R)-75 is, in contrast to 
Λ-(R,R)-49, positively charged. Λ-(2R,2R)-75 was found to be a powerful catalyst for the 
enantioselective α-alkylation of O'Donnell's substrate 76[60] with alkyl halides (77) to give  the 
corresponding α-alkylated products 78 with up to 92% ee (Scheme 14), which can be used as 
precursors for the synthesis of (non-)natural amino acids.[59,60] 
One year later, Belokon and co-workers reported that Λ-(2R,2R)-75 also efficiently catalyzes 
the enantioselective Michael addition of O'Donnell's substrate 76 to EWG-activated alkenes 
(79; EWG: electron-withdrawing group) to give the corresponding α-alkylated products 80 
with up to 96% ee (Scheme 14).[61]  
 
 
Scheme 14. Belokon's salicylimine-based cobalt(III) complex Λ-(2R,2R)-75 serves as an efficient catalyst for 
the asymmetric α-alkylation of O'Donnell's substrate 76[60] with alkyl halides (77)[59] and for the asymmetric 
Michael addition of O'Donnell's substrate 76 to EWG-activated alkenes (79).[61] 
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Finally, Figure 6 shows an overview of the stereogenic-at-metal catalysts which have been 
discussed in chapter 1.3. With regard to the main topic of the present thesis – the design, 
synthesis, and application of a nucleophilic octahedral stereogenic-only-at-metal catalyst – it 
is striking that apparently none of these stereogenic-at-metal or stereogenic-only-at-metal 
catalysts acts as a nucleophilic catalyst. 
 
 
 
 
 
Figure 6. Overview of the stereogenic-at-metal catalysts which have been discussed in chapter 1.3. 
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1.4  Stereogenic-at-Metal Catalysts – Contributions from the Meggers Laboratory 
In 2013, Meggers and co-workers reported about Ir(III)-based stereogenic-only-at-metal com-
plex Λ-81, which serves as an efficient catalyst for the asymmetric transfer hydrogenation of 
β,β-disubstituted nitroalkenes (82) with Hantzsch ester 83 as hydride donor (Scheme 15).[38a] 
 
 
  
Scheme 15. Stereogenic-only-at-metal complex Λ-81 from Meggers and co-workers serves as an efficient bi-
functional cooperative catalyst for the asymmetric transfer hydrogenation of β,β-disubstituted nitroalkenes (82) 
to β-chiral nitroalkanes (84) with Hantzsch ester 83 as hydride donor.[38a] Mechanistic details are provided in the 
text. The model on the right side has been taken from ref. 38a [Model reproduced with permission from ref. 38a. 
Copyright © 2013, American Chemical Society] 
 
As depicted in Scheme 15, it is supposed that Λ-81 acts as a bifunctional cooperative catalyst: 
While the bidentate 5-amino-3-(2-pyridyl)-1H-pyrazole ligand is supposed to activate and 
spatially align a nitroalkene (82) by double hydrogen-bonding (structure highlighted in 
green), a hydroxymethyl group located at one of both cyclometalated phenylbenzoxazole 
ligands (structure highlighted in blue) is supposed to activate and to align Hantzsch ester 83 
via single hydrogen-bonding. Accordingly, both activated substrates 82 and 83 are perfectly 
aligned in the resulting ternary complex to react with each other.[38a] At this point, it is worth 
noting that the catalytic entity of the bidentate 5-amino-3-(2-pyridyl)-1H-pyrazole ligand 
basically mimics the catalytic entity of well-established thiourea-based hydrogen-bonding 
organocatalysts.[38a,62] As depicted in Scheme 15, 0.1–1.0 mol% of Λ-81 were found to be 
sufficient to provide the desired β-chiral nitroalkanes (84) in yields of up to 96% and with 
enantioselectivities of up to 99%. Noteworthy, the introduction of both 3,5-dimethylphenyl 
substituents in Λ-81 was found to enhance both the selectivity and activity of the catalyst in 
case of reaction 82 + 83 → 84.[38a] 
In the same year, Meggers and co-workers also reported about catalyst Λ-85, which was 
developed based on catalyst Λ-81 as a catalyst for the asymmetric Friedel–Crafts alkylation of 
indoles (87) with α-substituted β-nitroacrylates (86) as substrates (Scheme 16).[38b] Catalyst 
Λ-85 differs from catalyst Λ-81 in that respect that the hydroxymethyl groups of Λ-81 are 
replaced by carboxamide groups and that the 3,5-dimethylphenyl groups are replaced by 
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N-carbazolyl groups (Scheme 16). These two modifications improved both the catalyst's acti-
vity and enantioselectivity in case of reaction 86 + 87 → 88 compared to catalyst Λ-81.[38b] 
 
  
 
Scheme 16. Stereogenic-only-at-metal catalyst Λ-85 from Meggers and co-workers serves as an efficient bi-
functional cooperative catalyst for the asymmetric Friedel–Crafts alkylation of indoles (87) with α-substituted 
β-nitroacrylates (86).[38b] The model on the right side has been taken from ref. 38b [Model reproduced with 
permission from ref. 38b. Copyright © Wiley-VCH Verlag GmbH & Co. KGaA] 
 
Catalyst Λ-85 was found to give Friedel–Crafts alkylation products 88, which feature an all-
carbon quaternary stereocenter, with a loading of just 1 mol% of Λ-85 in up to 97% yield and 
with up to 98% ee (Scheme 16).[38b] In analogy to the transfer hydrogenations with Λ-81 from 
Scheme 15, Λ-85 is supposed to activate and align the nitroacrylates (86) by double 
hydrogen-bonding and the indoles (87) via single hydrogen-bonding (Scheme 16).[38b]   
In 2016, Meggers and co-workers reported about catalyst Λ-89 (Scheme 17), which can 
be regarded as a significantly improved version of catalyst Λ-81 for the already mentioned 
transfer hydrogenation of β,β-disubstituted nitroalkenes (82) to β-chiral nitroalkanes (84; see 
Scheme 15).[38a,63]  
 
 
 
Scheme 17. C2-symmetric catalyst Λ-89 from Meggers and co-workers serves as an extraordinarily efficient 
catalyst for the asymmetric reduction of β,β-disubstituted nitroalkenes (82) to β-chiral nitroalkanes (84) with 
Hantzsch ester 83 as hydrogen donor.[63] Loadings of just 0.005–0.05 mol% of Λ-89 (which corresponds in case 
of full turnovers to turnover numbers (TONs) of up to 20000) were found to be sufficient to provide desired 
products 84 with excellent yields and enantioselectivities.[63] 
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At the start of the development of catalyst Λ-89, Meggers and co-workers discovered that 
complex Λ-85 (see Scheme 16) was a better catalyst in terms of selectivity and activity for the 
reaction 82 + 83 → 84 compared to initially used complex Λ-81 (see Scheme 15). Hence, 
complex Λ-85 became the new catalyst platform for further developments.[38a,63] Further 
improvements in terms of activity and selectivity were then achieved 1.) via replacement of 
the N-carbazolyl substituents for 2,6-dimethylphenyl substituents, 2.) via replacement of the 
cyclometalated phenylbenzoxazole ligands for phenylbenzothiazole ligands, and 3.) via 
replacement of the dissymmetric pyridylpyrazole ligand for a symmetric bispyrazole 
ligand.[63] The latter modification renders the complex C2-symmetric. As a consequence, Λ-89 
features two indistinguishable catalytic sites capable of bifunctional cooperative hydrogen-
bonding catalysis.[63] 
Catalyst Λ-89 was found to be extraordinarily effective, giving the desired β-chiral nitro-
alkanes (84) within short reaction times in very good to excellent yields and enantio-
selectivities with loadings of just 0.005–0.05 mol% of Λ-89 (Scheme 17).[63]  
In the same year, Meggers and co-workers reported about catalyst Λ-(R,R)-90 
(Scheme 18), which can be regarded as a significantly improved version of catalyst Λ-85 for 
the already mentioned Friedel–Crafts alkylation of indoles (87) with α-substituted β-nitro-
acrylates (86; see Scheme 16).[64] In case of catalyst Λ-(R,R)-90, exchange of the N-carba-
zolyl groups of Λ-85 for 2,6-dimethylphenyl groups was found to be detrimental for the 
reaction 86 + 87 → 88 and hence the N-carbazolyl groups were retained (compare with Λ-89 
from Scheme 17 and see the previous paragraphs).[64] 
 
 
 
Scheme 18. C2-symmetric catalyst Λ-(R,R)-90 from Meggers and co-workers serves as an extraordinarily 
efficient catalyst for the asymmetric Friedel–Crafts alkylation of indoles (87) with α-substituted β-nitroacrylates 
(86).[64] 0.05–0.2 mol% of Λ-(R,R)-90 were found to be sufficient to provide desired products 88 in good to 
excellent yields and enantioselectivities.[64] 
 
As in case of catalyst Λ-89, 1.) replacement of the dissymmetric pyridylpyrazole ligand by the 
corresponding symmetric bispyrazole ligand and 2.) replacement of the phenylbenzoxazole 
ligands by phenylbenzothiazole ligands both significantly contributed in improving the 
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catalyst.[64] However, catalyst Λ-(R,R)-90 exhibits an additional feature which distinguishes it 
from catalyst Λ-89 in addition to that: Meggers and co-workers recognized that the 
catalytically relevant carboxamide moieties in catalysts Λ-85 and Λ-89 rotate around their 
Caryl–CO-bond. In contrast, only a narrow window of the dihedral angle between the 
benzoxazole plane and the plane of the carbonyl group permits effective cooperative 
catalysis.[64] Hence, it was anticipated that a conformational fixation of the carboxamide 
moiety would result in a perfect alignment of this group for cooperative catalysis, which 
would enhance the catalyst at least in terms of activity. And indeed, replacement of the 
N,N-diethylcarboxamide moieties by proline-derived fused eight-membered lactam moieties, 
giving final catalyst Λ-(R,R)-90 (Scheme 18), not only significantly increased the activity of 
the catalyst but also the enantioselectivity.[64] Interestingly and in accordance with the 
supposed mechanism, Λ-(R,R)-90's diastereomer ∆-(R,R)-90 is virtually inactive as its fixed 
carboxamides are misaligned for cooperative catalysis.[64] 
The sophisticated structure of Λ-(R,R)-90 results in a high catalytic efficiency, which allows 
it provide products 88, which feature an all-carbon quaternary stereocenter, with excellent 
yields of up to 99% and with enantioselectivities of up to 98% with catalyst loadings of just 
0.05–0.2 mol% of Λ-(R,R)-90 (Scheme 18).[64] 
The so far presented stereogenic-at-metal catalysts from the Meggers group – Λ-81, 
Λ-85, Λ-89, and Λ-(R,R)-90 – operate all as bifunctional cooperative catalysts which achieve 
their asymmetric transformations by the combination of 1.) activating an α,β-unsaturated nitro 
compound as Michael acceptor with the catalysts acting as double hydrogen-bond donors and 
2.) by simultaneously activating another substrate with the catalysts acting as single hydro-
gen-bond acceptors. 
Meggers and co-workers reasoned that deprotonation of the amidopyrazole ligand in catalysts 
Λ-81 and Λ-85, electronic fine-tuning of the resulting deprotonated amidopyrazolato ligand, 
and appropriate decoration of the catalyst's cyclometalated ligands could result in a powerful 
metal-templated Brønsted base catalyst.[65,66] And indeed, starting from catalyst Λ-81, cata-
lysts Λ-91 and Λ-92 were developed, which serve as cooperative bifunctional Brønsted base 
catalysts (Scheme 19).[66] 
Catalyst Λ-91 was found to be an efficient catalyst for the asymmetric Michael addition of 
thiols (94) to α,β-unsaturated N-pyrazolylamides (93) to give products 95 in up to 98% yield 
and with up to 97% ee with 0.02–1.0 mol% of catalyst Λ-91.[66] Catalyst Λ-92 was found to 
be an efficient catalyst for the asymmetric aza-Henry reaction between monosubstituted nitro-
methanes (96) and N-Boc-protected imines (97; Scheme 19) to give desired products 98 in up 
to 98% yield and with up to 98% ee with just 0.25–0.75 mol% of Λ-92 (Scheme 19).[66]  
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Scheme 19. Brønsted base catalysts Λ-91 and Λ-92 from Meggers and co-workers.[66] Catalyst Λ-91 serves as an 
efficient catalyst for the Michael addition of thiols (94) to α,β-unsaturated N-pyrazolylamides (93) and catalyst 
Λ-92 serves as an efficient catalyst for the aza-Henry reaction between monosubstituted nitromethanes (96) and 
N-Boc-protected imines (97).[66] The proposed mechanism for the reaction 93 + 94 → 95 with catalyst Λ-91 is 
depicted on the right side.[66] 
 
The proposed mechanism for the reaction 93 + 94 → 95 with Λ-91 as catalyst is depicted on 
the right side of Scheme 19 and is as follows: Thiols (94) are supposed to be activated by 
proton transfer to the pyrazolato ligand with the resulting thiolate being bound to the resulting 
aminopyrazole ligand via two hydrogen bonds.[66] The benzoxazole-attached hydroxymethyl 
moiety is supposed to activate and align α,β-unsaturated N-pyrazolylamides (93) via a three-
center hydrogen bond (Scheme 19).[66] In contrast to catalyst Λ-81 from Scheme 15, the 
hydroxymethyl group does not act as a hydrogen-bond acceptor but as a hydrogen-bond 
donor.[66] 
In case of the aza-Henry reaction (96 + 97 → 98), catalyst Λ-91 only showed a good perfor-
mance when 10 mol% were employed and the selectivity dropped significantly when lower 
loadings were used.[66] Introduction of 3,5-bis(tert-butyl)phenyl substituents next to the 
3,5-bis(n-hexyl)phenyl substituents of Λ-91 giving catalyst Λ-92 solved this problem: Λ-92 
provides aza-Henry reaction products 98 with just 0.25–0.75 mol% loading of Λ-92 in yields 
of up to 98% and with enantioselectivities of up to 98% ee (Scheme 19).[66] 
The proposed mechanism for the reaction 96 + 97 → 98 with Λ-92 as catalyst is as follows: 
The aminopyrazolato ligand of Λ-92 is supposed to deprotonate nitromethanes (96) and the 
resulting nitronates are supposed to be bound to the resulting aminopyrazole ligand by double 
hydrogen-bonding, which resembles the mode of action of catalysts Λ-81, Λ-85, Λ-89, and 
Λ-(R,R)-90 with regard to α,β-unsaturated nitro compounds (see Schemes 15–18).[66] The 
N-Boc imines (97), on the other hand, are then assumed to be activated via single hydrogen-
bonding between the Boc group's carbonyl group and the hydroxymethyl group of catalyst 
Λ-92 with the hydroxymethyl group acting as hydrogen-bond donor.[66] 
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The so far presented stereogenic-at-metal catalysts from the Meggers laboratory essentially all 
rely on a primary double hydrogen-bonding donor motif enabling ligand-sphere-mediated 
'organocatalysis' acting in cooperation with a secondary single hydrogen-bonding donor or 
hydrogen-bonding acceptor motif. 
In 2014, Meggers and co-workers presented catalyst Λ-99, which does, in contrast, not 
rely on such a primary double hydrogen-bonding donor motif (Scheme 20).[67] Catalyst Λ-99 
was found to be an efficient catalyst for the asymmetric α-amination, or rather α-hydrazi-
nation,[68] of enolizable aldehydes (100) with azodicarboxylates (101).[67]  
 
 
 
Scheme 20. Complex Λ-99 from Meggers and co-workers serves as an efficient bifunctional cooperative 
enamine/hydrogen-bonding catalyst for the α-amination, or rather α-hydrazination,[68] of enolizable aldehydes 
(100) with azodicarboxylates (101).[67] The proposed mechanism is shown on the right side and explained in 
detail in the text. 
 
As depicted in Scheme 20, catalyst Λ-99 is supposed to operate as a bifunctional cooperative 
enamine/hydrogen-bonding catalyst.[67] At first, Λ-99 activates an enolizable aldehyde (100) 
via enamine formation. The benzoxazole-attached hydroxymethyl group of Λ-99 then acti-
vates an azodicarboxylate (101) via single hydrogen-bonding, which triggers the conjugate 
addition reaction with the underlying enamine.[67] Next, the resultant iminium species 
hydrolyzes (note that water is formed upon enamine formation), which gives chiral 
α-hydrazino aldehydes (102) as primary products.[67] As these products (102) are prone 
towards racemization, they were usually in situ reduced to the corresponding alcohols and 
cylized to the depicted oxazolidinones (103). Catalyst Λ-99 was found to give oxazolidinone 
products 103 in up to 96% yield and with up to 97% ee with 1 mol% of catalyst Λ-99 
(Scheme 20).[67] 
All of the so far presented stereogenic-at-metal catalysts from the Meggers group 
essentially operate as metal-templated 'organocatalysts', i.e., without direct participation of the 
metal center apart from its electronic influence and its structural role as a "glue" for the 
participating ligands. On the contrary, in 2014 Meggers and co-workers reported about 
stereogenic-only-at-metal catalyst Λ-104, which strongly differs from the previously 
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discussed catalysts by the fact that the metal center is here directly involved in the catalytic 
cycle (Scheme 21).[69] Complex Λ-104 does not bear a third kinetically-inert bidentate ligand 
but two kinetically labile monodentate acetonitrile ligands.[69] Originally, catalyst Λ-104 was 
developed as a catalyst for the enantioselective Friedel–Crafts alkylation of indoles (87) with 
α,β-unsaturated 2-acyl imidazoles (105) as electrophiles (Scheme 21).[69] 
 
 
 
Scheme 21. Lewis acidic stereogenic-only-at-metal catalyst Λ-104 from Meggers and co-workers.[69] Catalyst 
Λ-104 was originally developed as a catalyst for the enantioselective Friedel–Crafts alkylation of indoles (87) 
with α,β-unsaturated 2-acyl imidazoles (105) as electrophiles.[69] The proposed mechanism is shown on the right 
side and explained in detail in the text. 
 
As depicted in Scheme 21, α,β-unsaturated 2-acyl imidazoles (105) are supposed to coordi-
nate to the Lewis acidic Ir(III) center of Λ-104 as bidentate ligands replacing both kinetically 
labile acetonitrile ligands. Coordination to the Lewis acidic Ir(III) center increases the electro-
philicity of the α,β-unsaturated 2-acyl imidazoles (105) to such an extent that indole deri-
vatives (87) are able to react with coordinated 105 in a Friedel–Crafts reaction.[69] One of both 
present benzoxazole-attached tert-butyl substituents is crucial for the enantioselectivity as it 
completely blocks one prochiral face of coordinated 105.[69] 
For catalyst Λ-104, loadings of just 0.25–2.0 mol% of Λ-104 were found to be sufficient to 
provide Friedel–Crafts alkylation products 106 in yields of up to 99% and with up to 98% ee 
(Scheme 21).[69] Strikingly and although the coordination number varies in the course of the 
catalytic cycle, the metal-located stereoinformation is completely retained and no racemi-
zation occurs under the reaction conditions.[69] Meanwhile, a polymer-supported version of 
catalyst Λ-104 has been developed, which did not even show any signs of racemization after 
15 cycles with 105 + 87 → 106 as catalyzed reaction.[70]  
Since the aforementioned publication from 2014, catalyst Λ-104 and derivatives thereof 
have proven to be extraordinarily versatile Lewis acidic catalysts for a broad range of asym-
metric transformations, and that both with and without the participation of photo-
catalysis.[40,47,69–72] A discussion about all the reactions which have been established since 
2014 with Lewis acidic stereogenic-at-metal bisacetonitrile complexes of type Λ-104 would 
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go far beyond the scope of this introduction.[40,47,69–72] Therefore, only an assortment of 
examples will be presented in the subsequent paragraphs. 
 Also in 2014, Meggers and co-workers demonstrated with a groundbreaking publication 
in Nature that catalysts of type Λ-104 are also powerful asymmetric visible-light photoredox 
catalysts (Scheme 22).[71a] 
 
 
 
Scheme 22. Visible-light-driven asymmetric α-alkylation of 2-acyl imidazoles (108) with acceptor-substituted 
benzyl bromides and phenacyl bromides (109) catalyzed by Λ-107.[71a] The depicted mechanism is described in 
detail in the text below.[71a]  
 
While previously established "traditional" asymmetric photoredox systems rely on a dual-
catalyst approach with a photocatalyst / photosensitizer being responsible for substrate acti-
vation by visible light and a chiral catalyst being responsible for asymmetric induction,[73] the 
photoredox catalysts of type Λ-104 are a merger of both: they are photosensitizer and chiral 
catalyst in one molecule.[71a] The first asymmetric visible-light-driven photoredox reaction 
which was established with such a catalyst and reported in the aforementioned Nature 
publication, is the asymmetric α-alkylation of 2-acyl imidazoles (108) with acceptor-sub-
stituted benzyl bromides and phenacyl bromides (109), which is shown in Scheme 22.[71a] 
Although benzoxazole-based complex Λ-104 (see Scheme 21) was found to be a suitable 
catalyst for the visible-light-driven reaction 108 + 109 → 110, its benzothiazole congener 
Λ-107 was found to be a superior catalyst in terms of yield and enantioselectivity, giving the 
desired α-alkylated products (110) in up to >99% yield and with up to 99% ee with just 
2 mol% of catalyst Λ-107 (Scheme 22).[71a] 
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The proposed mechanism for the reaction is depicted in Scheme 22: In analogy to the Friedel–
Crafts alkylation from Scheme 21, 2-acyl imidazole (108) first replaces both acetonitrile 
ligands of Λ-107 and coordinates to the iridium(III) center in a bidendate fashion, which 
results in intermediate Λ-107-Int1.[71a] Weak Brønsted base Na2HPO4 next helps to form the 
corresponding enolate complex Λ-107-Int2.[71a] The next step is assumed to be the stereo-
genic reaction between photo-reductively generated electrophilic radical 109-Rad2 and 
nucleophilic enolate complex Λ-107-Int2, which results in the formation of Ir(III)-coordi-
nated ketyl radical Λ-107-Int3.[71a] Electrophilic radical 109-Rad2 is assumed to be formed 
by fragmentation of radical anion 109-Rad1, which is formed from 109 via single electron 
transfer (SET) with the photoexcited photosensitizer PS* as reductant.[71a] According to 
mechanistic experiments, the effective photosensitizing species is most presumably enolate 
complex Λ-107-Int2.[71a] Ketyl radical Λ-107-Int3 is next assumed to regenerate the oxidized 
photosensitizer PS+ via SET which results in the formation of Ir(III)-coordinated product 
Λ-107-Int4 and regenerated photosensitizer PS. Product 110 is finally released from 
Λ-107-Int4 and the released stereogenic-at-metal Ir(III) complex fragment can start a new 
catalytic cycle with 2-acyl imidazole (108; Scheme 22).[71a] Although mechanistic experi-
ments strongly support this mechanism, alternative pathways or at least their contribution to 
the overall reaction, such as the contribution of a radical–chain pathway or a radical–radical 
recombination pathway, cannot be entirely ruled out.[71a]    
Based on archetypical catalysts Λ-104 and Λ-107, other Lewis acidic bis-cyclometa-
lated stereogenic-at-metal complexes based on Ir(III), Rh(III), and Ru(II) have been 
developed in the Meggers laboratory in recent years, from which an assortment is presented in 
Figure 7.  
 
 
 
Figure 7. Lewis acidic stereogenic-at-metal catalysts from the Meggers laboratory which have been developed 
on the basis of catalysts Λ-104 and Λ-107: A) Congeneric Rh(III) catalysts Λ-111[71b] and Λ-112.[71m] B) 
1-Methylpyrimidine-2,4(1H,3H)-dione-substituted Ir(III) catalyst ∆-113.[71r] C) 2-Phenyl-5,6-(S,S)-pinenopyri-
dine-cyclometalated Ir(III) catalyst ∆-(2S,2S)-114 and its Rh(III) congener ∆-(2S,2S)-115.[47] D) Ru(II)-based 
catalyst Λ-116, which features two pyridyl-substituted N-heterocyclic carbenes as cyclometalating ligands.[71b2] 
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In the following paragraphs, selected applications for the catalysts from Figure 7 are pre-
sented. 
A recent application for Rh(III)-based catalyst Λ-111 is the visible-light-driven asymmetric 
β-amination of α,β-unsaturated 2-acyl imidazoles (105) via proton-coupled electron transfer 
(PCET) with N-aryl carbamates (117) as amination reagents (Scheme 23).[71v] In contrast to 
the reaction from Scheme 22, an iridium(III)-based photosensitizer (118) is added here and 
the role of Rh(III) complex Λ-111 is limited to facilitate the one-electron reduction of the 
coordinated α,β-unsaturated 2-acyl imidazole and to control the stereochemical outcome of 
the radical–radical coupling process.[71v] Interestingly, replacement of benzoxazole-based 
Rh(III) catalyst Λ-111 by benzoxazole-based Ir(III) catalyst Λ-104 or benzothiazole-based 
Rh(III) catalyst Λ-112 both resulted in a sluggish reaction.[71v] Products 120 could be obtained 
in up to 99% yield and with up to 99% ee with 5 mol% of catalyst Λ-111 in combination with 
2 mol% of photosensitizer 118 (Scheme 23).[71v] 
 
 
 
Scheme 23. Visible-light-driven asymmetric β-amination of α,β-unsaturated 2-acyl imidazoles (105) with N-aryl 
carbamates (117) via PCET with stereogenic-only-at-metal catalyst Λ-111 and photosensitizer 118.[71v] 
 
A very recent application for related benzothiazole-based Rh(III) catalyst Λ-112 is the asym-
metric visible-light-driven intermolecular [2+2]-cycloaddition between α,β-unsaturated 
2-acylimidazoles, 2-acylpyrazoles, N-acylpyridines (121) and alkenes (122; Scheme 24).[71w] 
The proposed mechanism for this reaction is depicted in Scheme 24. It is expected that an α,β-
unsaturated compound (121) at first coordinates to the Rh(III) center and that the resulting 
intermediate Λ-112-Int1 is then excited from the electronic ground state (S0 state) to the 
lowest excited singlet state (S1 state → Λ-112-Int1-S1) upon irradiation with blue visible 
light.[71w] Λ-112-Int1-S1 is assumed to next undergo an intersystem crossing (ISC) so that the 
intermediate is then in the lowest excited triplet state (T1 state → Λ-112-Int1-T1). In 
Λ-112-Int1-T1, the two highest occupied molecular orbital electrons (HOMO electrons), 
which are the electrons of the conjugated double bond of Λ-112-Int1-T1, have the same spin 
and hence behave as 1,2-biradicals.[71w,74] This allows Λ-112-Int1-T1 to react with alkene 122 
stepwise via biradical intermediate Λ-112-Int2 to intermediate Λ-112-Int3, which then 
releases product 123 to start a new catalytic cycle with substrate 121.[71w] 
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With 0.5–4 mol% of catalyst Λ-112, desired products 123 could be obtained with 91–99% ee 
and with d.r. values of 6:1–20:1 (Scheme 24).[71w] 
 
 
 
 
Scheme 24. Asymmetric visible-light-driven intermolecular [2+2]-cycloaddition between α,β-unsaturated 
2-acylimidazoles, 2-acylpyrazoles, N-acylpyridines (121) and alkenes (122) catalyzed by Λ-112. The proposed 
mechanism is described in detail in the text.[71w] 
 
The next catalyst from Figure 7, catalyst ∆-113, can be regarded as a merger of catalyst Λ-104 
(see Scheme 21) and catalyst Λ-85 (see Scheme 16) or catalyst Λ-89 (Scheme 17): The 
tert-butyl groups of catalyst Λ-104 are formally replaced in ∆-113 by 1-methylpyrimidine-
2,4(1H,3H)-dione moieties, which render this Lewis acidic catalyst bifunctional as it is able to 
interact with approaching (indole) substrates via these moieties as hydrogen-bond acceptor, 
just like Λ-85 and Λ-89 via their carboxamide moieties.[71r] Complex ∆-113 was found to be a 
powerful catalyst for the asymmetric Friedel–Crafts C2-alkylation of 3-substituted indoles 
(124) with α,β-unsaturated 2-acylimidazoles (105; Scheme 25).[71r]      
 
   
 
 
Scheme 25. Asymmetric Friedel–Crafts C2-alkylation of 3-substituted indoles (124) with α,β-unsaturated 
2-acylimidazoles (105) catalyzed by ∆-113.[71r] The model on the right side shows the proposed mechanism and 
has been taken from ref. 71r. [Model reproduced with permission from ref. 71r. Copyright © 2017, American 
Chemical Society] 
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The proposed mechanism for the reaction 105 + 124 → 125 with ∆-113 as catalyst is depicted 
on the right side of Scheme 25: While coordination of the α,β-unsaturated 2-acylimidazole 
(105) to the Ir(III) center increases its electrophilicity as a Michael acceptor, the approaching 
indole (124) becomes activated via single hydrogen-bonding with one of ∆-113's 1-methyl-
pyrimidine-2,4(1H,3H)-dione moieties acting as hydrogen-bond acceptor. In contrast, the 
remaining 1-methylpyrimidine-2,4(1H,3H)-dione moiety acts as a passive volume and blocks 
the Re-face of the coordinated α,β-unsaturated 2-acylimidazole.[71r] 
As depicted in Scheme 25, 2 mol% of catalyst ∆-113 were able to provide the desired 
C2-alkylated indoles (125) in up to 99% yield and with up to 98% ee.[71r] 
The next catalysts from Figure 7, Ir(III) catalyst ∆-(2S,2S)-114 and its Rh(III) congener 
∆-(2S,2S)-115, feature pinene-derived cyclometalated phenylpyridine ligands instead of 
cyclometalated phenylbenzoxazole or phenylbenzothiazole ligands.[47] ∆-(2S,2S)-115 was 
identified as an efficient catalyst for the asymmetric alkynylation of 2-trifluoroacetyl 
imidazoles (126) with aryl- and alkylacetylenes (127) to give the corresponding alkynylated 
products 128 with 3−6 mol% of ∆-(2S,2S)-115 in up to 99% yield and with up to >99% ee 
(Scheme 26).[47] 
 
 
 
Scheme 26. Asymmetric alkynylation of 2-trifluoroacetyl imidazoles (126) with aryl- and alkylacetylenes (127) 
catalyzed by ∆-(2S,2S)-115.[47] 
 
As Λ- and ∆-configured stereogenic-at-metal complexes Λ-(2S,2S)-115 and ∆-(2S,2S)-115 
are diastereomers, just like Λ-(R,R)-90 and ∆-(R,R)-90 from Scheme 18,[64] they are directly 
separable via conventional silica gel flash chromatography.[47] It is worth noting and in sharp 
contrast to catalyst Λ-(R,R)-90, where the "mismatched" diastereomer ∆-(R,R)-90 is virtually 
inactive,[64] that both catalysts Λ-(2S,2S)-115 and ∆-(2S,2S)-115 almost showed identical 
catalytic activity and enantioselectivity (with inverse R/S ratios) as catalysts for reaction 
126 + 127 → 128.[47] ∆-(2S,2S)-115's Ir(III) congener ∆-(2S,2S)-114 was found to be catalyti-
cally less active and drastically less enantioselective for this reaction.[47]  
The last catalyst from Figure 7 and this chapter, stereogenic-only-at-metal Ru(II) 
catalyst Λ-116, features two pyridyl-substituted N-heterocyclic carbenes as cyclometalating 
ligands and has very recently been devised and identified as a highly active and enantio-
selective catalyst for the asymmetric alkynylation of trifluoromethyl ketones (129) with 
terminal alkynes (127; Scheme 27).[71b2] 
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Scheme 27. Asymmetric alkynylation of trifluoromethyl ketones (129) with aryl- and alkylacetylenes (127) 
catalyzed by Λ-116.[71b2] 
 
With just 0.5 mol% of catalyst Λ-116, alkynylated products 130 were provided in up to 99% 
yield and with up to >99% ee (Scheme 27).[71b2] Interestingly, benzothiazole-based Ir(III) 
catalyst ∆-107 (see Scheme 22) and benzothiazole-based Rh(III) catalyst ∆-112 (see Figure 7)  
were both found to be much less catalytically active in this reaction than catalyst Λ-116 under 
identical reaction conditions.[71b2] 
 
Finally, Figure 8 shows an overview of the stereogenic-at-metal catalysts from the Meggers 
laboratory which have been discussed in chapter 1.4. 
 
 
Figure 8. Overview of the stereogenic-at-metal catalysts from the Meggers laboratory which have been dis-
cussed in chapter 1.4. 
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In summary, the complexes which have been discussed in chapter 1.4 rely on the following 
motifs / moieties that allow them to operate as powerful asymmetric stereogenic-at-metal 
catalysts and in part as bifunctional catalysts by synergistic combinations of them: 
 
 
• Complexes Λ-81,[38a] Λ-85,[38b] Λ-89,[63] Λ-(R,R)-90,[64] Λ-91,[66] and Λ-92[66] feature thio-
urea-mimicking double hydrogen-bonding motifs,[62] which are implemented via amido-
pyrazole / aminopyrazolato moieties. In case of Λ-91 and Λ-92,[66] these motifs form in situ 
in the course of the Brønsted base catalysis cycles (see Schemes 15–19). 
• Complexes Λ-81,[38a] Λ-85,[38b] Λ-89,[63] Λ-(R,R)-90,[64] Λ-91,[66] Λ-92,[66] Λ-99,[67] and 
∆-113[71r] feature single hydrogen-bonding donor or acceptor motifs, which are 
implemented via hydroxymethyl groups acting as single hydrogen-bond acceptors (see 
Scheme 15; Λ-81) or donors (see Schemes 19 and 20; Λ-91, Λ-92 and Λ-99) and via 
carboxamide or urea moieties acting as single hydrogen-bond acceptors (see Schemes 16–
18 and 25; Λ-85, Λ-89, Λ-(R,R)-90, and ∆-113). 
• Stereogenic-only-at-metal Complex Λ-99[67] features a bidentate ligand which comprises a 
cyclic secondary amine, which allows this complex to perform asymmetric enamine cata-
lysis (see Scheme 20). 
• Complexes Λ-104,[69] Λ-107,[71a] Λ-111,[71b] Λ-112,[71m] ∆-113,[71r] Λ-116,[71b2] 
∆-(2S,2S)-114,[47] and ∆-(2S,2S)-115[47] all represent, with regard to both acetonitrile 
ligands, kinetically labile yet configurationally stable octahedral stereogenic-at-metal com-
plexes which feature two vicinal coordination sites enabling Lewis acid catalysis. 
• The latter feature / motif has successfully been combined with photocatalysis. Two cases 
can be distinguished here: a.) Asymmetric visible-light-driven catalysis where the stereo-
genic-at-metal Lewis acid catalyst itself or an in situ formed derivative thereof acts as 
photoactive species. Examples are the reaction from Scheme 22[71a] with catalyst Λ-107 
and the reaction from Scheme 24 with catalyst Λ-112.[71w] b.) And asymmetric visible-
light-driven catalysis where an additional photosensitizer is added and where the stereo-
genic-at-metal catalyst is not or at least not significantly contributing as a photoactive 
species. An example for the latter case is the reaction from Scheme 23 with catalyst 
Λ-111.[71v] 
 
With respect to the main topic of the present thesis, it is again striking that apparently none of 
the catalysts from chapter 1.4 acts as a nucleophilic catalyst, which has been, as a reminder, 
also concluded for the stereogenic-at-metal catalysts from other laboratories from chapter 1.3. 
In a broader sense, catalyst Λ-99[67] can be referred to as a 'nucleophilic catalyst' as its 
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secondary amine attacks an enolizable aldehyde in a nucleophilic fashion to form an 
intermediate enamine (see Scheme 20). However, as explained in chapter 1.1, catalysts and 
reactions which involve enamine or iminium ion formation should be clearly distinguished 
from "classic" nucleophilic catalysts such as DMAP as they catalyze different reactions.[5,6,10] 
This becomes apparent when considering that DMAP and other "classic" nucleophilic 
catalysts are often employed as acyl transfer catalysts (see chapter 1.2 for examples). In 
contrast, Λ-99 is most probably not able to act as an acyl transfer catalyst: Acylation would 
result in the formation of a non-conjugated amide, which is obviously a 'thermodynamic pit' 
rendering acyl transfer catalysis with Λ-99 unfeasible. 
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2.  Design, Synthesis, and Application of a Nucleophilic 
 Octahedral Stereogenic-Only-at-Metal Iridium(III) Catalyst  
2.1  Aim of the Research Project 
In chapter 1.1 of the present thesis the concept of nucleophilic catalysis has been introduced 
and in chapter 1.2 different examples for nucleophilic catalysts relying on different catalyti-
cally active entities and on different elements of chirality have been presented. In chapters 1.3 
and 1.4, stereogenic-at-metal catalysts from the Meggers laboratory and from other research 
laboratories have been presented, discussed, and summarized in Figures 6 and 8. 
Examination of chapters 1.3 and 1.4 and Figures 6 and 8 reveals that apparently no nucleo-
philic stereogenic-at-metal catalyst has been presented so far. And indeed, at the time when 
this project was started there had been no report about such a catalyst, which would allow to 
perform asymmetric nucleophile-catalyzed reactions like those from chapter 1.2, such as 
stereogenic acyl transfer reactions. As a result, it was envisioned to design a nucleophilic 
stereogenic-only-at-metal catalyst, which would complement the family of stereogenic-at-
metal catalysts that are currently developed in the Meggers laboratory.[40,72] 
 
2.2  Preliminary Research Results from Former Members of the Meggers Laboratory 
2.2.1  Preliminary Research Results from Zhijie Lin 
Efforts to design a nucleophilic stereogenic-only-at-metal catalyst can be traced back in the 
Meggers laboratory to the year 2013 and before.[75a] At that time, former PhD student Zhijie 
Lin (Z. L.) attempted to design a nucleophilic stereogenic-at-metal catalyst by means of the 
attachment of DMAP and PPY moieties to bidentate N,N-coordinating ligands of bis-hetero-
leptic bis-cyclometalated Ir(III) complexes (Figure 9).[75a] 
 
  
 
Figure 9. Zhijie Lin's initial layout for a DMAP-type octahedral nucleophilic stereogenic-at-metal Ir(III) cata-
lyst.[75a] C^N represents a bidentate cyclometalated[75b] C,N-coordinating ligand and N^N a non-cyclometa-
lated[75b] bidentate N,N-coordinating ligand.   
 
Altogether, Z. L. synthesized 16 different stereogenic-at-metal complexes of the type depicted 
in Figure 9 by combinations of ten different cyclometalating[75b] ligands C^N and nine 
different DMAP- and PPY-functionalized non-cyclometalating[75b] ligands N^N.[75a] Z. L. 
then tested the obtained stereogenic-at-metal complexes as catalysts in kinetic resolutions of 
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various racemic alcohols with different acetic anhydrides as resolving agents.[75a] Despite 
Z. L.'s efforts, only selectivity factors of usually S ≤ 3 and of S = 3.7 in one single case could 
be achieved. The experiment with S = 3.7 is depicted in Scheme 28 (catalyst: Λ-Z1; identifier 
Z refers to Z. L.). Due to the overall less encouraging results, the nucleophilic stereogenic-at-
metal catalyst project was eventually discontinued by Z. L.[75a] 
 
 
 
Scheme 28. Z. L.'s kinetic resolution of rac-1-(1-naphthyl)ethanol (rac-131) with acetic anhydride (10) as 
resolving agent and Λ-Z1 as nucleophilic catalyst.[75a] This conditions provided a selectivity factor of S = 3.7, 
which represents the best result of all of the kinetic resolutions which were performed by Z. L.[75a]  
 
New impetus to this project was given shortly after Z. L.'s time as a PhD student in 
2013 / 2014 by the development of stereogenic-at-metal complexes Λ-81 and Λ-85 as bifunc-
tional cooperative hydrogen-bonding catalysts (see chapter 1.4, Schemes 15 and 16)[38] and, 
moreover, by the development of Λ-91 and Λ-92 as structurally related Brønsted base 
catalysts (see chapter 1.4, Scheme 19).[66] The primary catalytic motifs / moieties of these 
catalysts, which are a double hydrogen-bonding motif / an aminopyrazole moiety, are 
embedded in the non-cyclometalated ligand's plane, and not, in contrast to Z. L.'s layout, 
tagged to the non-cyclometalated ligand via a (biarylic) single bond (see Figure 9 and 
Scheme 28).[38,66,75a] This embedding of the catalytically active motif / moiety comes with the 
advantage that its spatial orientation is clearly defined and constrained, which renders it easier 
to improve a given catalyst on a rational basis. Moreover, such a layout offers the opportunity 
to place the catalytically active moiety / motif closer to the stereogenic metal center, which is, 
in principle, beneficial for an efficient enantioinduction.  
It was considered difficult to embed DMAP or PPY in the plane of the non-cyclometalated 
ligand without having its nucleophilic nitrogen pointing too far away from the catalyst's metal 
center, which would render it challenging to achieve enantioinduction, and without having it 
pointing to a sterically crowded area, which would result in low catalytic activity. On this 
account, it was reasoned – inspired by chiral amidine-,[15,20] isothiourea,[4,16,20,24] and imida-
zole-based[17,25] nucleophilic catalysts reported by Birman and others – to install a 3H-imi-
dazo[4,5-h]quinoline ligand as bidentate non-cyclometalated ligand, which was expected to 
constitute the catalyst's nucleophilic site after in situ or ex situ deprotonation of the initially 
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formed inactive HX salt (Figure 10). As will be demonstrated in chapter 2.3, this novel 
catalyst layout proved to be highly capable. 
 
 
 
Figure 10. Novel layout for a nucleophilic octahedral stereogenic-at-metal Ir(III) catalyst with a deprotonated 
3H-imidazo[4,5-h]quinoline ligand serving as the catalyst's active site. Zhijie Lins's initial layout from Figure 9 
is depicted on the right side for a direct comparison. C^N represents a cyclometalated bidentate C,N-coordi-
nating ligand and N^N a non-cyclometalated bidentate N,N-coordinating ligand.[75]   
 
2.2.2  Preliminary Research Results from Xiaodong Shen 
In 2013, former PhD student Xiaodong Shen (X. S.) initiated the development of a nucleo-
philic stereogenic-only-at-metal catalyst relying on the catalyst layout depicted in 
Figure 10.[76] As a start, X. S. synthesized Ir(III) complexes Λ-X1– Λ-X8 (identifier X refers 
to X. S.), which all rely on two phenylbenzoxazoles as cyclometalated ligands and a non-
cyclometalated 3H-imidazo[4,5-h]quinoline ligand as scheduled catalytically relevant ligand 
(Figure 11).[76] 
 
 
Figure 11. Complexes Λ-X1–Λ-X8 were synthesized by X. S. as nucleophilic stereogenic-only-at-metal catalyst 
candidates. They all feature a 3H-imidazo[4,5-h]quinoline ligand as scheduled catalytically relevant ligand.[76] 
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For reasons of clarity, complex Λ-X1 is regarded as parent structure and modifications with 
respect to Λ-X1 are highlighted in blue in case of the cyclometalated ligands and in red in 
case of the non-cyclometalated ligand (see Figure 11; the counteranions are not regarded). 
Next, complexes Λ-X1–Λ-X8 were screened by X. S. as catalysts in the kinetic resolution of 
rac-1-(1-naphthyl)ethanol (rac-131) with acetic anhydride (10) as resolving agent, the results 
of this screening are summarized in Table 1.[76] For all entries, the conversion values C and 
the selectivity factors S were calculated according to Kagan's equation[28e,30] (see chapter 1.2, 
Eq. 1) from the ee values of remaining alcohol 131 and produced ester 132.  
As can be seen from Table 1, most of the complexes of the small library Λ-X1–Λ-X8 
displayed high catalytic activity under the applied reaction conditions and some complexes 
also provided moderately encouraging selectivity factors of up to S = 4.0.[76] 
 
Table 1. Kinetic resolution of rac-1-(1-naphthyl)ethanol (rac-131) with acetic anhydride (10) as resolving agent 
and complexes Λ-X1–Λ-X8 as catalysts. Experiments performed by X. S.[76] 
 
     
entry complex complex loading 
(mol%) 
t 
(°C) 
solvent time Ca 
(%) 
ee of 131b 
(%) 
Sa 
1 Λ-X2 2 rt CH2Cl2 50 min 70 35 1.81 
2 Λ-X2 0.2 rt CH2Cl2 50 min 65.5 31 1.84 
3 Λ-X2 0.2 rt TAA 50 min 65 50 2.70 
4 Λ-X2 0.2 0 TAA 50 min 54.5 51 4.00 
5 Λ-X2 0.2 −78 toluene 24 h n.d.c n.d.c n.d.c 
6 Λ-X2 1 −78 toluene 19 h n.d.c n.d.c n.d.c 
7 Λ-X2 1 −40 toluene 6 h 53 33 2.46 
8 Λ-X2d 1 0 TAA 2 h 68 60 3.08 
9 Λ-X3 2 rt TAA n.d.c n.d.c n.d.c n.d.c 
10 Λ-X1 0.2 0 TAA 4 h 47 5 1.17 
11 Λ-X4 5 rt CH2Cl2 2 h 60 20 1.55 
12 Λ-X5 0.2 0 TAA 2 h 56 45 3.16 
13 Λ-X5 0.2 0 CHCl3 2 h 50 36 2.95 
14 Λ-X6 0.2 0 TAA 1 h 50 38 3.16 
15 Λ-X6 0.2 0 TAA 3 h 62 51 3.03 
16 Λ-X7 0.2 rt TAA 3 h 57 27 1.92 
17 Λ-X7 0.2 rt TAA 4 h 60 29 1.90 
18 Λ-X8 0.2 0 TAA 2 h 39 12 1.63 
19 Λ-X8 0.2 0 TAA 7 h 60 23 1.66 
20 − e − e 20 TAA n.d.c n.d.c n.d.c n.d.c 
 
aCalculated according to Kagan's equation (Eq. 1 from chapter 1.2).[28e,30] bEe values of 131 and 132 determined 
from the crude product mixtures by chiral HPLC analysis. cNo significant conversion observed, values not 
determined (n.d.). dReisolated complex was used. eNo complex added; this experiment was performed to rule out 
a significant racemic background reaction. 
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Based on the results from Table 1, the following conclusions were drawn:  
 
• Most of complexes Λ-X1–Λ-X8 are, in combination with i-Pr2NEt and under the applied 
reaction conditions, highly active catalysts, at least for that particular reaction. 
• The introduction of bulky substituents in the 5-position of the cyclometalated phenyl-
benzoxazole ligands appears to be crucial for a significant enantiodiscrimination, which 
becomes clear when comparing the result for Λ-X1 (S ~ 1) with the results for all other 
complexes which provided a significant turnover (S > 1 or even S >> 1). 
• The introduction of bulky aryl substituents in the 5-positions of the cyclometalated phenyl-
benzoxazole ligands (Λ-X2, Λ-X3, Λ-X5, Λ-X6) appears to be superior to the introduction 
of bulky aliphatic substituents (Λ-X4, Λ-X7). Admittedly, the results for Λ-X8 do not 
follow this "rule". 
• The 4-position of the 3H-imidazo[4,5-h]quinoline ligand must remain unoccupied to main-
tain a high catalytic activity (Λ-X3). This is logical as the N-acylation of the catalyst would 
otherwise suffer from emerging 1,3-allylic strain. However, modifications at other posi-
tions of that ligand appear to be feasible (see Λ-X6 and Λ-X8).  
• From the four screened solvents CH2Cl2, CHCl3, toluene, and tert-amyl alcohol (TAA), 
solvent TAA gave the best results in terms of selectivity. 
• From all screened complexes (Λ-X1–Λ-X8), complex Λ-X2 provided the most encou-
raging result (Table 1, entry 4). 
 
With complex Λ-X2 as the most promising complex so far and the conditions from Table 1 
and TAA as solvent, X. S. then shortly studied the kinetic resolution of rac-131 with bulkier 
anhydrides, namely isobutyric anhydride (133) and pivalic anhydride (135), and the kinetic 
resolution of rac-2,2-dimethyl-1-phenyl-1-propanol (rac-137) with acetic anhydride (10; 
Scheme 29).[76] 
The kinetic resolution of rac-131 with isobutyric anhydride (133) proceeded smoothly but 
without satisfying enantioselectivity and the kinetic resolution of rac-131 with pivalic anhy-
dride (135) was found to be very sluggish and resulted in virtually no conversion after 24 h 
even though 2 mol% of Λ-X2 were employed. The kinetic resolution of rac-137 with acetic 
anhydride (10) proceeded smoothly but also without satisfying enantioselectivity (Scheme 29; 
compare with Table 1, entries 1–8).[76] 
Accordingly, the most promising result in terms of catalytic activity and enantioselectivity 
was still the one from Table 1, entry 4 with alcohol rac-131, acetic anhydride (10) as 
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resolving agent, and complex Λ-X2. At that point, all experiments related to kinetic reso-
lutions of racemic alcohols were discontinued by X. S.[76] 
 
 
 
Scheme 29. Kinetic resolutions of rac-1-(1-naphthyl)ethanol (rac-131) with isobutyric anhydride (133) and 
pivalic anhydride (135) and kinetic resolution of rac-2,2-dimethyl-1-phenyl-1-propanol (rac-137) with acetic 
anhydride (10). Experiments performed by X. S.[76] 
 
 
2.3  Results and Discussion 
2.3.1  Catalyst Development and Kinetic Resolution of Racemic Alcohols  
When the nucleophilic stereogenic-at-metal catalyst project was taken over from X. S. in 
September 2014, the results from Table 1 and additional balls-and-sticks modeling with 
complexes of the type depicted in Figure 10 still prompted us to expect that appropriate 
modifications of the catalyst's structure could eventually result in a good or even excellent 
catalyst for the kinetic resolution of racemic alcohols or for other asymmetric nucleophile-
catalyzed transformations. 
On these grounds, complexes Λ-T1–Λ-T13 were synthesized in order to evaluate them as 
nucleophilic stereogenic-at-metal catalyst candidates (Figure 12; identifier T refers to T. C.).  
Complexes Λ-T1–Λ-T13 were, like all stereogenic-at-metal Ir(III) complexes from chapter 2., 
prepared via two different routes which are schematically depicted in Scheme 30. 
For both routes, the respective phenylbenzoxazole (X = O) and phenylbenzothiazole (X = S) 
ligands to be cyclometalated are prepared beforehand, which are then reacted with IrCl3·3H2O 
in 2-ethoxyethanol to the corresponding iridium(III) dimers [IrIII(C^N)2(µ-Cl)]2 according to a 
modified version of Nonoyama's procedure (Scheme 30, A).[77] 
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Figure 12. Complexes Λ-T1−Λ-T13 were synthesized as stereogenic-at-metal nucleophilic catalyst candidates. 
Structural modifications with respect to the cyclometalated ligand of Λ-X1 (see chapter 2.2.2, Figure 11) are 
highlighted in blue and modifications with respect to the non-cyclometalated ligand of Λ-X1 are highlighted in 
red. Λ-T1−Λ-T13 were synthesized according to the two synthesis routes from Scheme 30 (synthetic details for 
each complex are provided in the experimental section). 
 
Route I differs from Route II as follows: In case of Route I, the phenylbenzoxazole and 
phenylbenzothiazole ligands to be cyclometalated already contain the substituent R1 (aryl or 
alkyl) which is later incorporated in the final complex. In case of Route II, the ligands feature 
a triflate group (T) at that position which is later on utilized to introduce aryl substituents in a 
post-complexation approach via Suzuki-Miyaura cross-couplings (see Scheme 30, C2).[78] 
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Scheme 30. General synthesis routes (Route I and II) for complexes Λ/∆-T1−Λ/∆-T28 from chapter 2. Details 
for the synthesis of each complex are provided in the experimental section. 
 
In case of both routes the initially obtained iridium(III) dimers [IrIII(C^N)2(µ-Cl)]2 
(Scheme 30, A) are at first cleaved with a bidentate chiral auxiliary ligand to give chromato-
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graphically separable pairs of Λ-(S)- and ∆-(S)-configured diastereomers (Scheme 30, B).[79] 
Preferably, iPr-substituted (S)-salicylthiazoline (X = S, Y = iPr)[71d] is used as chiral auxiliary 
ligand as it usually provides diastereomers which are stable towards silica gel chromato-
graphy and, moreover, readily separable.[79] However, in some cases the resulting diastereo-
mers were found to be hardly separable. In such cases tBu-substituted (S)-salicyloxazoline 
(X = O, Y = tBu)[80] is used as an alternative auxiliary ligand. The according diastereomers 
are usually less stable towards prolonged silica gel chromatography but usually provide 
diastereomers which feature an excellent separability.[79] 
Next, the auxiliary ligands of the separated diastereopure Λ-(S)- and ∆-(S)-configured 
complexes are cleaved off with triflic acid in acetonitrile to give intermediate enantiopure Λ- 
and ∆-configured bisacetonitrile complexes (not shown). After short column purification of 
these bisacetonitrile intermediates, both semi-labile monodentate acetonitrile ligands are 
replaced by the final bidentate 3H-imidazo[4,5-h]quinoline ligands to give the desired enan-
tiopure Λ- and ∆-configured complexes (Scheme 30, C1).[81,82] In particular cases, either a 
1,7-naphthyridin-8-amine ligand or a 2-(1H-pyrazol-3-yl)pyridine ligand were installed as 
final ligands instead of 3H-imidazo[4,5-h]quinoline (see Figure 12). 
In case of Route II, the separated diastereopure Λ-(S)- and ∆-(S)-configured auxiliary com-
plexes are at first subjected to Suzuki-Miyaura cross-couplings to install the desired aryl 
functionality at the 5-position of their cyclometalated phenylbenzoxazole or phenylbenzo-
thiazole ligands (Scheme 30, C2).[78] At this point, it is worth mentioning that the utilized 
post-complexation cross-coupling procedure, which has been devised by PhD student Thomas 
Mietke in the Meggers laboratory, has been proven to not affect the configuration of the Ir(III) 
stereocenter.[78] After this cross-coupling step, the auxiliary ligands are, just as in case of 
Route I, cleaved off with triflic acid in acetonitrile to give intermediate enantiopure Λ- and ∆-
configured bisacetonitrile complexes (not shown), which are, after short-column purification, 
reacted to the desired Λ- and ∆-configured 3H-imidazo[4,5-h]quinoline-functionalized 
complexes (Scheme 30, C1).[81,82]  
 
Coming back to the complex library depicted in Figure 12, complexes Λ-T1−Λ-T13 were 
prepared to be evaluated for the following reasons: 
 
• Complex Λ-T1 is identical with complex Λ-X2 and was prepared to reconfirm the results 
from X. S. and to ensure reproducibility of the previous experimental results. 
• Complexes Λ-T2 and Λ-T3 featured with a 1,7-naphthyridin-8-amine ligand and a 2-(1H-
pyrazol-3-yl)pyridine ligand potential alternatives to 3H-imidazo[4,5-h]quinoline. 
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• Complexes Λ-T4−Λ-T7, Λ-T9, and Λ-T11 featured untested moieties at the 5-position of 
their cyclometalated phenylbenzoxazole ligands (Λ-T4−Λ-T7, Λ-T9) and phenylbenzo-
thiazole ligands (Λ-T11; compare with Λ-X1−Λ-X8). 
• Complexes Λ-T8 and Λ-T9 both featured additional methyl groups at the 6-positions of 
their cyclometalated phenylbenzoxazole ligands. These modifications were expected to 
(further) constrain the rotational freedom of the aryl substituents at the neighboring 5-
positions. 
• Complexes Λ-T10 and Λ-T11 featured cyclometalated phenylbenzothiazole ligands in-
stead of phenylbenzoxazole ligands.  
• Complex Λ-T12 was prepared to evaluate the influence of the introduction of a methyl 
group at the methylene bridge between both nitrogen atoms of the 3H-imidazo-
[4,5-h]quinoline ligand's fused imidazole. 
• And finally, complex Λ-T13 was prepared to study the influence of the introduction of 
additional aryl substituents at the ortho-positions of the phenylbenzoxazoles' phenyl rings. 
For previously established kinetically-inert stereogenic-at-metal catalysts from the 
Meggers laboratory, the latter modification had been found to be highly beneficial (for 
example in case of catalyst Λ-81; see chapter 1.4 for further details).[38a]  
 
Next, complexes Λ-T1−Λ-T13 were screened as catalysts in the kinetic resolution of 
rac-1-(1-naphthyl)ethanol (rac-131) with acetic anhydride (10) as resolving agent. The results 
of this screening are summarized in Table 2. 
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Table 2. Kinetic resolution of rac-1-(1-naphthyl)ethanol (rac-131) with acetic anhydride (10) as resolving agent 
and complexes Λ-T1−Λ-T13.a 
 
     
entry Complex complex loading 
(mol%) 
t 
(°C) 
solvent time 
(min) 
Cb 
(%) 
ee of 131c 
(%) 
Sb 
1d Λ-T1 (≙Λ-X2) 0.2 0 TAA 50 / 100 45 / 62 30 / 49 2.92 / 2.89 
2d Λ-T1 (≙Λ-X2) 0.2 0 TAA 50 / 110 48 / 65 36 / 56 3.22 / 3.15 
3 Λ-T2 1 0 TAA 50 / 100 ~25 / ~50 < 3 / < 3 ~1.0 / ~1.0 
4e rac-T3 0.5 rt TAA 125 trace f −  f −  f 
5 Λ-T4 0.2 0 TAA 50 / 110 11 / 37 3 / 11 1.65 / 1.64 
6g Λ-T5 − g − g  − g  − g − g − g − g  
7 Λ-T6 0.2 0 TAA 50 / 100 19 / 37 13 / 30 3.80 / 3.92 
8 Λ-T7 0.3 0 TAA 50 / 100 22 / 48 8 / 22 1.99 / 1.97 
9d Λ-T8 0.3 0 TAA 50 / 100 53 / 60 42 / 51 3.21 / 3.19 
10d Λ-T8 0.3 0 TAA 50 / 100 55 / 65 43 / 56 3.06 / 3.05 
11 Λ-T9 0.3 0 TAA 50 / 100 22 / 45 10 / 25 2.35 / 2.36 
12 Λ-T9 0.6 0 TAA 50 / 100 28 / 56 14 / 34 2.35 / 2.35 
13 Λ-T10 0.6 0 TAA 50 / 100 31 / 45 14 / 22 2.16 / 2.14 
14 Λ-T10 1.8 0 TAA 50 / 100 51 / 60 26 / 33 2.11 / 2.08 
15 Λ-T11 0.3 0 TAA 50 / 100 10 / 21 6 / 13 3.11 / 3.35 
16 Λ-T12 0.6 0 TAA 50 / 100 32 / 53 19 / 38 2.84 / 2.86 
17 Λ-T13 0.6 0 TAA 50 / 100 69 / 69 51 / 52 2.49 / 2.49 
18 Λ-T13 0.3 0 TAA 50 / 100 63 / 67 44 / 49 2.52 / 2.51 
19 Λ-T13 0.1 0 TAA 50 / 100 45 / 59 28 / 41 2.62 / 2.56 
 
aStandard reaction conditions: Substrate rac-131 (1.0 eq; 200−400 µmol), 0.7 eq 10, and 0.7 eq i-Pr2NEt with
catalysts Λ-T1−Λ-T13 in the indicated solvent at conc = 0.7 M at the indicated temperature. bCalculated 
according to Kagan's equation (see Eq. 1 from chapter 1.2).[28e,30] cEnantioselectivities of 131 and 132 determined 
from crude product mixtures by chiral HPLC analysis (Chiralpak IB (5 µm, 25 cm x 4.6 mm); n-hexane/i-PrOH 
90:10, λ = 254 nm, flow = 0.5 mL/min, t (column) = 40 °C: 132: tR  = 7.7 min and 8.3 min; 131: tR  = 11.8 min
and 14.2 min). dTwo different freshly prepared batches of catalysts were used. e1.1 eq Ac2O and 1.1 eq i-Pr2NEt 
were added. fDirect comparison with a reference batch without any complex indicated that the trace formation of 
132 exclusively originated from the uncatalyzed racemic background reaction. gNot tested, Λ-T5 was found to 
be unstable, see explanations in text. 
 
 
Based on the results from Table 2, the following conclusions were drawn:  
 
• First of all, the experiments with complex Λ-T1 confirmed the results which had been 
obtained by X. S. with Λ-X2 (Λ-T1 ≙ Λ-X2), though a slightly lower selectivity factor 
was found under identical reaction conditions (Table 2, entry 2: Λ-T1: S = 3.2 vs. Table 1, 
entry 4: Λ-X2: S = 4.0).  
• Complex Λ-T2 with 1,7-naphthyridin-8-amine as scheduled catalytic ligand showed 
indeed significant catalytic activity under the applied reaction conditions but failed to 
achieve any enantiodiscrimination (Table 2, entry 3). 
• In case of catalyst Λ-T3 with 2-(1H-pyrazol-3-yl)pyridine as scheduled catalytic ligand, 
only racemic catalyst rac-T3 was evaluated, which showed no catalytic activity at all under 
the applied reaction conditions (entry 4). 
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• Compound Λ-T5 was prepared via Route II from Scheme 30. However, Λ-T5 could not be 
obtained pure and slowly decomposed in solution. On the contrary, all other complexes 
from the library Λ-T1−Λ-T13 were found to be stable. Consequently, Λ-T5 was not tested 
(entry 6). 
• None of the remaining complexes Λ-T4 and Λ-T6−Λ-T13 could significantly improve the 
selectivity of the resolution. They provided, similar to complexes Λ-X1−Λ-X8 screened by 
X. S. (see chapter 2.2.2, Figure 11 and Table 1), only S-factors ranging between S = 1.6 
(entry 5) and S = 3.9 (entry 7), which is far-off from an S-factor of S ~ 10, which is consi-
dered as the lower limit for a synthetically useful kinetic resolution (see chapter 1.2).[28e]  
 
Due to the overall lack of a clear and significant structure–selectivity relationship, giving no 
real hint how to modify the catalyst in order to improve its selectivity, and due to the so far 
overall disappointing selectivity factors, it was decided at this point to discontinue all 
experiments related to kinetic resolutions of alcohols and to shift the focus on asymmetric 
stereogenic acyl transfer reactions.  
 
2.3.2  Steglich Rearrangement of O-Acylated Azlactones and Catalyst Development 
Having the 13 complexes Λ-T1−Λ-T13 in stock (see chapter 2.3.1, Figure 12), it was antici-
pated that there should be other nucleophile-catalyzed reactions which would better match 
some of these complexes in terms of their enantioinduction abilities and where, moreover, 
their quite different substitution patterns would have a more pronounced influence than in the 
kinetic resolutions from chapter 2.3.1. The latter was regarded as important as a clear 
structure–selectivity relationship would give hints how to modify the complex in order to 
obtain the best catalyst possible in terms of selectivity. 
First, the focus was set on stereogenic Steglich rearrangements of O-acylated azlactones 
(13) to C-acylated azlactones (14),[21] which had also very shortly been examined by X. S. 
with complex Λ-X6.[76] The results of X. S.'s short examination are summarized in Table 3. 
Even though X. S. had only tested single substrate 13a with 2 mol% of Λ-X6 under non-
optimized conditions, he could observe full conversion of 13a to 14a after 15 h at rt and found 
for product 14a promising 59% ee (Table 3, entry 1).[76] This result indicated that there could 
be still a lot of room for improvements with respect to the catalyst's structure, the reaction 
conditions, and the employed azlactone substrates (13). 
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Table 3. Short examination of the Steglich rearrangement 13a → 14a with complex Λ-X6. Experiments perfor-
med by X. S.[76] 
 
     
 
 
entry loading of Λ-X6 
(mol%) 
solvent conc 
(mol/L) 
t 
(°C) 
time 
(h) 
ee of 14aa 
(%) 
conv 
1b 2 CH2Cl2 0.15 rt 15 59 fullb 
2b 1 CH2Cl2 0.15 rt 24 53 fullb 
3 0 CH2Cl2 0.15 0 24 − c − c 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bImportant: It was later 
revealed that the catalyst is only active in case there is a Brønsted base present leading to in situ deprotonation of 
actually inactive complex Λ-X6 (see Table 4 and the associated explanations). Hence, in cases of entries 1 and 2 
there must have either been a trace of Brønsted base present in the reaction mixture or the added catalyst Λ-X6
must have been (partly) deprotonated when it was added to the reaction mixture. cNo conversion found.    
 
 
It is striking that X. S. did not add a Brønsted base in case of all three reactions (reaffirmed in 
a personal dialogue with X. S.),[76] which was regarded as remarkable as complex Λ-X6 
should be catalytically inactive in the absence of a Brønsted base (see chapter 2.2.1, Figure 10 
for an illustration). Accordingly, it was at first investigated whether the reaction 13a → 14a 
could actually take place with complexes of type Λ-X6 in the absence of a Brønsted base or 
not. The results of this investigation are summarized in Table 4. Note that structurally related 
complex Λ-T1 was used instead of complex Λ-X6.   
 
Table 4. Influence of the (non-)presence of a Brønsted base on the reaction 13a → 14a with complex Λ-T1.  
 
 
     
 
 
entry complex complex 
 loading (mol%) 
base base  
loading (mol%) 
t 
(°C) 
solvent conc 
(mol/L) 
time 
(h) 
ee of 14aa 
(%) 
convb 
1 Λ-T1 2 no base − rt CH2Cl2 0.15 15 − c − c 
2 rac-T1 10 no base − rt CH2Cl2 0.26 12 / 43 − c / − c − c / − c 
3 Λ-T1 10 iPr2NEt 20 rt CH2Cl2 0.26 12 / 23 41d / 39d  ~½ / full 
4 Λ-T1 3 Cs2CO3 6 rt CH2Cl2 0.26 17 40 full 
5 no cat. − Cs2CO3 20 rt CH2Cl2 0.26 13 − c − c 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cNo conversion found. dOld HPLC column used 
giving an imperfect peak separation with an uncertainty of about ±1%.    
 
As can be seen from Table 4, complete absence of a Brønsted base resulted in complete 
catalytic inactivity (entries 1 and 2). X. S. successfully used i-Pr2NEt as base additive in 
combination with 3H-imidazo[4,5-h]quinoline-based complexes in the kinetic resolution of 
racemic alcohols (see chapter 2.2.2, Table 1) and this results were confirmed by experiments 
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which are part of this thesis (see chapter 2.3.1, Table 2). i-Pr2NEt was primarily added in that 
case to scavenge the acid which is formed in the course of the acylation process. However, it 
fulfills a second function, it deprotonates the 3H-imidazo[4,5-h]quinoline-based complexes, 
which is crucial to enable catalysis by the according deprotonated complexes. 
For this reason, i-Pr2NEt was added to a mixture of 13a and Λ-T1, which indeed resulted in a 
clean conversion to 14a (Table 4, entry 3). Accordingly, there must have either been a trace of 
a Brønsted base present in the reaction mixture in case of X. S.'s experiments or catalyst Λ-X6 
must have been (partially) deprotonated when it was added (see Table 3). 
However, the reaction rates were low with i-Pr2NEt as additive and high catalyst loadings 
were necessary to achieve full conversion within an acceptable reaction time (Table 4, 
entry 3). For this reason, alternative base additives were screened: Cs2CO3, Na2CO3, Li2CO3, 
Na(OAc), Na2(HPO4), and DBU. From all screened additives, Cs2CO3 was identified as the 
most suitable one as it triggered a rapid rearrangement 13a → 14a requiring only a low 
loading of Λ-T1 and a small amount of base additive compared to i-Pr2NEt. Moreover, it did 
not negatively influence the selectivity of the reaction and triggered no racemic background 
reaction (Table 4, entries 3−5). Apart from DBU, which was found to be almost as effective as 
Cs2CO3 but triggered side reactions, all other screened bases were less effective and so 
Cs2CO3 was eventually selected as the base additive of choice. 
From here on, the inactive HX salts of 3H-imidazo[4,5-h]quinoline-based complexes will be 
referred to as precatalysts and their deprotonated, catalytically active forms as catalysts and 
the latter marked with an apostrophe. Accordingly, the catalytically active form of HX salt 
Λ-T1 is referred to as Λ-T1' (Scheme 31). 
 
 
 
Scheme 31. Deprotonation of 3H-imidazo[4,5-h]quinoline-based iridium(III) complexes with piperidinomethy-
lated polystyrene beads[83] or by washing with aqueous 0.3 M NaOH. Precatalyst Λ-T1 and catalyst Λ-T1' are 
depicted as arbitrary examples for an illustration. 
 
Later on, it was revealed that deprotonated 3H-imidazo[4,5-h]quinoline-based complexes of 
type Λ-T1' are easily accessible in analytically pure form by passing a concentrated solution 
of the respective precatalysts (e.g., Λ-T1) through a short plug of piperidinomethylated poly-
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styrene resin beads[83] or, alternatively, by washing them with aqueous 0.3 M NaOH 
(Scheme 31; details in the experimental section). As the active catalysts of type Λ-T1' were 
found to be highly bench-stable, the active catalysts were later on prepared ex situ by default 
and employed without the need for an additional base additive (see for example Table 10). 
Having revealed that Brønsted base addition is a prerequisite to trigger the rearrangement 
13a → 14a when 3H-imidazo[4,5-h]quinoline-based precatalysts are used and that Cs2CO3 is 
the Brønsted base additive of choice under the applied conditions (see Table 4), now selected 
precatalysts from the library Λ-T1−Λ-T13 were screened to identify the best match for the 
reaction 13a → 14a. The results are summarized in Table 5. 
It is worth mentioning that the rearrangement 13a → 14a proceeded "spot-to-spot". Accor-
dingly, enantioselectivity improvement and retention of a high reaction rate were the primary 
goals of this screening. 
 
Table 5. Screening of selected precatalysts from precatalyst library Λ-T1−Λ-T13 in the reaction 13a → 14a. 
 
 
     
 
entry precatalyst precatalyst  
loading (mol%) 
base base loading 
(mol%) 
t 
(°C) 
solvent conc 
(mol/L) 
time 
(h) 
ee of 14aa 
(%) 
convb 
1 Λ-T1 10 iPr2NEt 20 rt CH2Cl2 0.26 12 / 23 41c / 39c ~½ / full 
2 Λ-T1 3 Cs2CO3 6 rt CH2Cl2 0.26 17 40  full 
3 Λ-T6 10 iPr2NEt 20 rt CH2Cl2 0.26 12 / 23 10c / 10c ~½ / full 
4 Λ-T7 10 iPr2NEt 20 rt CH2Cl2 0.26 12 22c full 
5 Λ-T8 3 Cs2CO3 6 rt CH2Cl2 0.26 11 / 17 44 / 43 ~¾ / full 
6 Λ-T8 3 Cs2CO3 6 0 CH2Cl2 0.26 16 52 full 
7 Λ-T10 3 Cs2CO3 6 rt CH2Cl2 0.26 11 / 17 10 / 9 ~¾ / full 
8 Λ-T11 3 Cs2CO3 6 0 CH2Cl2 0.26 16 37 full 
9 Λ-T12 3 Cs2CO3 6 rt CH2Cl2 0.26 11 / 17 54 / 52 ~½ / ~¾ 
10d Λ-X6d 2 ?e ?e rt CH2Cl2 0.15 15 59 full 
11 Λ-T13 10 iPr2NEt 20 rt CH2Cl2 0.26 12 / 23 69c / 68c ~½ / full 
12 Λ-T13 3 Cs2CO3 6 rt CH2Cl2 0.26 10 68 full 
13 Λ-T13 3 Cs2CO3 6 0 CH2Cl2 0.26 10 / 17 76 / 76 ~¾ / full 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cOld HPLC column used giving an imperfect 
peak separation with an uncertainty of about ±1%. dExperiment performed by X. S.,[76] result copied for clarity 
from Table 3. eSee remark 'b' from Table 3. 
 
 
With precatalyst Λ-T1 as a reference, the following conclusions were drawn from Table 5: 
 
• Larger or more extended aryl substituents than the 2,4,6-trimethylphenyl substituents of 
Λ-T1 not necessarily resulted in a better enantioselectivity: Even though the 3,6-di-tert-
butylcarbazole substituents of Λ-T6 and the 2-(tert-butyl)pyrenyl substituents of Λ-T7 
extend over a larger area, both precatalysts Λ-T6 and Λ-T7 were found to be less selective 
than Λ-T1 in the reaction 13a → 14a (see entries 1−4). 
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• However, replacement of the 2,4,6-trimethylphenyl substituents (Λ-T1) by 2,4,6-triiso-
propylphenyl substituents and chlorine introduction at the 7-position of the 3H-imidazo-
[4,5-h]quinoline ligand (Λ-X6) − which of both was of higher importance was unclear at 
that point − had a strongly positive effect on the selectivity of the studied reaction (see 
entries 1, 2 and 10 for Λ-T1 and Λ-X6). 
• Introduction of methyl substituents at the 6-positions of the phenylbenzoxazole ligands did 
slightly improve the selectivity of the studied reaction (Λ-T8). But not to an extent which 
justified the more complicated synthesis (see entries 1, 2, 5 and 6 for Λ-T1 with Λ-T8). 
• Replacement of the phenylbenzoxazole ligands (Λ-T1) by phenylbenzothiazole (Λ-T10) 
ligands resulted in a significant drop of the enantioselectivity (see entries 2 and 7). Also 
phenylbenzothiazole-based complex Λ-T11 featuring 1-adamantyl substituents could not 
convince in terms of enantioselectivity (see entries 2 and 8). 
• Introduction of a methyl substituent at the methylene bridge between both nitrogen atoms 
of the 3H-imidazo[4,5-h]quinoline ligand's fused imidazole improved the selectivity of the 
studied reaction but came along with a significant reduction of catalytic activity (see 
entries 2 and 9 for Λ-T1 and Λ-T12). 
• Lowering of the temperature from rt to 0 °C significantly improved the selectivity and still 
allowed short reaction times (entries 5 and 6 as well as entries 12 and 13). 
• Attachment of 2,6-dimethylphenyl substituents at the ortho-positions of the phenylbenz-
oxazoles' phenyl rings had a strongly positive effect on the enantioselectivity of the studied 
reaction (compare entries 2, 12, 13 for Λ-T1 and Λ-T13). 
This finding was quite remarkable as simple balls-and-sticks modeling had misleadingly 
indicated that aryl substituents at these positions would be too far away. However, an X-ray 
structure of a catalysis intermediate analog (see chapter 2.3.8, Figure 21), an X-ray-based 
and DFT-assisted molecular surface modeling (see chapter 2.3.8, Figures 22 and 23), and 
an explicit quantum chemical modeling of the stereogenic step of an intramolecular acyl 
migration reaction (see chapter 2.3.8, Figures 25 and 26) later clearly visualized the impor-
tance of one of both 2,6-dimethylphenyl substituents. 
• The overall best result was achieved with precatalyst Λ-T13, which was able to provide 
product 14a in 76% ee under the conditions from entry 13. 
 
Inspired by the insights from this screening and in particular the finding that the introduction 
of sterically demanding aryl groups at the ortho-positions of the phenylbenzoxazoles' phenyl 
rings had a strongly positive effect (Λ-T1 vs. Λ-T13), complexes Λ-T14–Λ-T16 (Figure 13) 
were synthesized next to test them in the reaction 13a → 14a. 
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Figure 13. Complexes Λ-T14−Λ-T16 were prepared as precatalyst candidates for the Steglich rearrangement of 
O-acylated azlactones (13a → 14a). Structural modifications with respect to the cyclometalated ligand of Λ-X1 
(see chapter 2.2.2, Figure 11) are highlighted in blue. 
 
The three complexes Λ-T14−Λ-T16 were prepared with the following intentions: 
 
• Complex Λ-T14 was prepared to evaluate, by comparison with the results for Λ-T1, 
whether bulky aliphatic substituents in the 5-position of the phenylbenzoxazole ligands 
would be less or more favorable than aryl substituents. In this regard, only 1-adamantyl-
substituted Λ-11 had been tested so far (see Table 5), which is benzothiazole-based and 
thus only directly comparable with benzothiazole-based Λ-10 but not with the other com-
plexes that are benzoxazole-based. 
• Complex Λ-T15 was prepared to evaluate whether the positive influence of the intro-
duction of the 2,6-dimethylphenyl substituents in case of Λ-T13 was general or restricted 
to that particular substituents. 
• Complex Λ-T16 was prepared for the following reasons: 
a.) Experiments from Table 5 had revealed that 2,4,6-triisopropylphenyl- and chlorine-sub-
stituted Λ-X6 performs much better than 2,4,6-trimethylphenyl-substituted Λ-T1 lacking 
the chlorine substituent at its 3H-imidazo[4,5-h]quinoline ligand (entries 2 and 10). 
b.) Furthermore, introduction of 2,6-dimethylphenyl substituents at the ortho-positions of 
the phenylbenzoxazoles' phenyl rings had proved to be highly beneficial (compare entries 1 
and 2 with entries 11−13 for Λ-T1 and Λ-T13). 
It was anticipated that Λ-X6's chlorine substituent would only have a minor influence on 
the enantioselectivity of the studied reaction and that, in contrast, the installation of 
2,4,6-triisopropylphenyl substituents at the 5-positions of the phenylbenzoxazoles (→A), 
and the simultaneous attachment of 2,6-dimethylphenyl substituents at the ortho-positions 
of the phenylbenzoxazoles' phenyl rings (→B) would result in a synergistically improved 
highly selective complex (Λ-T16). 
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After preparation of complexes Λ-T14–Λ-T16, they were screened in the reaction 13a → 
14a. The results of this screening are summarized in Table 6. 
 
 Table 6. Screening of precatalysts Λ-T14−Λ-T16 in the reaction 13a → 14a. 
 
 
 
     
 
entry complex complex loading 
(mol%) 
Cs2CO3 loading 
(mol%) 
t 
(°C) 
solvent conc 
(mol/L) 
time 
(h) 
ee of 14aa 
(%) 
convb 
1 Λ-T14 3 6 rt CH2Cl2 0.26 20 20 full 
2c Λ-T1 3 6 rt CH2Cl2 0.26 17 40 full 
3 Λ-T15 3 6 rt CH2Cl2 0.26 11 64 full 
4c Λ-T13 3 6 rt CH2Cl2 0.26 10 68 full 
5 Λ-T16 3 6 rt CH2Cl2 0.26 10 81 full 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cResults for Λ-T1 and Λ-T13 copied from 
Table 5 for clarity and direct comparisons. 
 
With precatalyst Λ-T1 as a reference, the following conclusions were drawn from Table 6: 
 
• Tert-butyl-substituted Λ-T14 performed significantly worse than 2,4,6-trimethylphenyl-
substituted Λ-T1 (compare entries 1 and 2) and, moreover, than the majority of all the 
complexes with aryl substituents at the 5-positions of their benzoxazoles (compare also 
with the results from Table 5).   
• 3,4-Dimethylphenyl-substituted complex Λ-T15 almost reached the performance of 2,6-di-
methylphenyl-substituted complex Λ-T13, which indicated that the introduction of other 
substituents than 2,6-dimethylphenyl at the ortho-positions of the phenylbenzoxazoles' 
phenyl rings had a positive influence on the enantioselectivity as well (see entries 3 and 4).  
• Complex Λ-T16, which had been designed with the anticipation of a strongly synergistic 
effect originating from the simultaneous presence of 2,4,6-triisopropylphenyl substituents 
and 2,6-dimethylphenyl substituents, indeed proved as the most selective complex so far 
and provided product 14a with respectable 81% ee (entry 13). 
 
With the insights from both screenings from Tables 5 and 6, complexes Λ-T17–Λ-T28 were 
prepared next (Figure 14).  
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Figure 14. Complexes Λ-T17–Λ-T28 were prepared as precatalyst candidates for the Steglich rearrangement of 
O-acylated azlactones (13a → 14a). Structural modifications with respect to the cyclometalated ligand of Λ-X1 
(see chapter 2.2.2, Figure 11) are highlighted in blue and modifications with respect to the non-cyclometalated 
ligand of Λ-X1 are highlighted in red. 
 
Complexes Λ-T17–Λ-T28 were prepared to address the following points: 
 
• Complexes Λ-T17–Λ-T23 were prepared to evaluate different substitution patterns of the 
key 3H-imidazo[4,5-h]quinoline ligand. 
• Complex Λ-T24 was prepared to evaluate the replacement of the 3H-imidazo[4,5-h]quino-
line ligand by a 2-(1H-pyrazol-3-yl)pyridine ligand. 
• Since 2,4,6-triisopropylphenyl-substituted Λ-T16 had proven superior compared to 2,4,6-
trimethyl-phenyl-substituted Λ-T13 (see Table 6, entries 4 and 5), 2,4,6-tritertbutyl-phenyl-
substituted Λ-T25 was prepared as a logical consequence. 
• Since the introduction of 2,6-dimethylphenyl (Λ-T13) and 3,4-dimethylphenyl (Λ-T15) 
substituents at the ortho-positions of the phenylbenzoxazoles' phenyl rings had proven 
highly beneficial, complexes Λ-T26 and Λ-T27 featuring 2,4,6-triisopropylphenyl and 
N-carbazolyl substitutents at these positions were prepared as a logical consequence. 
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• Complex Λ-T28 was prepared to evaluate the shift of the 2,6-dimethylphenyl substituents 
from the ortho-positions of the phenylbenzoxazoles' phenyl rings to the according meta-
positions. This modification was inspired by the highly selective cooperative enamine/hy-
drogen-bonding catalyst presented in chapter 1.4 (Λ-99; see Scheme 20).[67] 
 
After preparation of complexes Λ-T17–Λ-T28, the complexes were screened in the Steglich 
rearrangement 13a → 14a. The results of this screening are summarized in Table 7. 
 
Table 7. Screening of precatalysts Λ-T17–Λ-T18 in the reaction 13a → 14a. 
 
 
     
 
entry complex complex  
loading (mol%) 
Cs2CO3 loading 
(mol%) 
t 
(°C) 
solvent conc 
(mol/L) 
time 
(h) 
ee of 
14a (%)a 
convb 
1c Λ-T16 3 6 rt CH2Cl2 0.26 10 81 full 
2 Λ-T17 3 6 rt CH2Cl2 0.26 10 84 full 
3 Λ-T17 3 6 0 CH2Cl2 0.26 10 88 full 
4 Λ-T18 3 6 rt CH2Cl2 0.26 10 85 full 
5 Λ-T18 3 6 0 CH2Cl2 0.26 10 88 full 
6 Λ-T18 0.2 3 0 CH2Cl2 1.0 12 88 full 
7 Λ-T18 0.2 3 0 EtOAc 1.0 12 88 full 
8 Λ-T19 0.2 3 0 CH2Cl2 1.0 12 88 full 
9 Λ-T20 0.2 3 0 CH2Cl2 1.0 12 88 full 
10 Λ-T21 0.5 3 0 EtOAc 0.5 12 78 full 
11 Λ-T22 0.2 3 0 CH2Cl2 1.0 12 82 full 
12 Λ-T23 2 6 0 CH2Cl2 1.0 14 
41 
n.d. 
n.d. 
low 
low 
13 Λ-T23 2 6 rt CH2Cl2 1.0 9 81 full 
14 rac-T24 0.5 3 rt CH2Cl2 1.0 12 − d − d 
15 Λ-T25 0.5 3 0 EtOAc 0.5 12 84 full 
16 Λ-T26 0.2 3 0 CH2Cl2 1.0 10 
22 
35 
n.d. 
n.d. 
n.d. 
low 
low 
low 
17 Λ-T26 2 6 0 CH2Cl2 1.0 9 
21 
n.d. 
65 
low 
full 
18 Λ-T27 0.2 3 0 CH2Cl2 1.0 10 73 full 
19 Λ-T28 0.2 3 0 CH2Cl2 1.0 15 53 full 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cResult for Λ-T16 copied from Table 6 for clarity 
and direct comparisons. dNo conversion found. 
 
The following conclusions were drawn from the results from Table 7: 
 
• Evaluation of different 3H-imidazo[4,5-h]quinoline ligands (Λ-T17−Λ-T23): Introduction 
of a chlorine substituent at the 5-position of the 3H-imidazo[4,5-h]quinoline ligand 
(Λ-T17), introduction of a chlorine substituent at the 7-position of this ligand (Λ-T18), 
introduction of two chlorine substituents at both the 5-position and the 7-position of this 
ligand (Λ-T19), and introduction of a trifluoromethyl substituent at the 5-position of this 
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ligand (Λ-T20) resulted virtually all in the same enhancement in comparison to non-sub-
stituted complex Λ-T16 (see entries 2−9). As the preparation of the 7-chloro-3H-imidazo-
[4,5-h]quinoline ligand is the most straightforward one of all four required 3H-imidazo-
[4,5-h]quinoline ligands, Λ-T18 was chosen as new benchmark and reference complex. 
• It is worth noting that the loading of benchmark precatalyst Λ-T18 could be lowered from 
3 mol% to 0.2 mol% and the Cs2CO3 loading lowered from 6 mol% to 3 mol% without a 
drop in selectivity (in both cases 88% ee) and while still maintaining a short reaction time 
of just 12 h (see entries 5 and 6). Moreover, replacement of solvent CH2Cl2 by EtOAc did 
not show any effect in terms of enantioselectivity (entries 6 and 7).   
• In contrast, the introduction of a methoxy substituent at the 5-position of the 3H-imidazo-
[4,5-h]quinoline ligand resulted in less selective complex (Λ-T21) and the introduction of 
a 3,5-bis(trifluoromethyl)phenyl substituent at the same position (Λ-T22) in a similarly 
selective complex as non-substituted complex Λ-T16 (entries 1, 10, 11). 
• In case of complex Λ-T1, the installation of a methyl group at the methylene bridge 
between both nitrogen atoms of the fused imidazole of the 3H-imidazo[4,5-h]quinoline 
ligand (Λ-T12) had resulted in an improved enantioselectivity for the reaction 13a → 14a, 
albeit at the cost of catalytic activity (see Table 5, entries 2 and 9). A similar finding was 
expected for complex Λ-T23. Complex Λ-T23 was indeed found to be significantly less 
active than Λ-T18 (see Table 7, compare entries 5, 6 and 12, 13) but was, unexpectedly, 
also found to be less selective than Λ-T18 (Table 7, entries 4 and 13). 
• No conversion at all was found with complex rac-T24 (entry 14). This finding is in 
accordance with the result obtained for rac-T3 with respect to the kinetic resolution of 
rac-1-(1-naphthyl)ethanol (chapter 2.3.1; Table 2, entry 4). Both findings underline that 
the 2-(1H-pyrazol-3-yl)pyridine ligand is apparently not suited for the development of a 
nucleophilic stereogenic-at-metal catalyst.   
• Replacement of the 2,4,6-trimethylphenyl groups of Λ-T13 by 2,4,6-triisopropylphenyl 
group had provided with complex Λ-T16 a significantly improved precatalyst (see Table 6, 
entries 4 and 5). A similar finding was expected for 2,4,6-tritertbutylphenyl-substituted 
complex Λ-T25 with regard to Λ-T18. Surprisingly, the opposite was the case: Λ-T25 
proved to be slightly less enantioselective than complex Λ-18. (Table 7, entries 7 and 15).  
• Introduction of 2,6-dimethylphenyl substituents (Λ-T13, Λ-T15) and 3,5-dimethylphenyl 
substituents (Λ-T16) at the ortho-positions of the phenylbenzoxazoles' phenyl rings had 
both resulted in a significantly enhanced selectivity of the studied reaction (see Table 6, 
entries 3–5 and Table 7, entry 1). Accordingly, it was expected that Λ-T26 and / or Λ-T27 
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could provide even better results. However, 2,4,6-triisopropylphenyl-substituted Λ-T26 
(Table 7, entries 16, 17) and N-carbazolyl-substituted Λ-T27 (entry 18) were both found to 
be less selective than complex Λ-T18. Moreover, 2,4,6-triisopropylphenyl-substituted 
Λ-T26 showed a significantly decreased activity (see entries 5, 6 vs. entries 16, 17). 
• Finally, complex Λ-T28 was evaluated where the 2,6-dimethylphenyl substituents of 
Λ-T18 are formally shifted from the ortho-positions of the phenylbenzoxazoles' phenyl 
rings to the according meta-positions. This complex showed a significantly lower enantio-
selectivity than complex Λ-T18 (see entries 6 and 19). 
 
In short, Λ-T18 was identified as new benchmark precatalyst: With just 0.2 mol% of Λ-T18 
in combination with 3 mol% of Cs2CO3 in CH2Cl2 or EtOAc as solvent (conc = 1.0 M), 
Steglich rearrangement product 14a was smoothly provided with this system with respectable 
88% ee at a reaction temperature of 0 °C and after a reaction time of 12 h (entries 6 and 7). 
 
Noticing that the complex structure optimization had somewhat reached a "dead point" and 
having already spent a considerable amount of time on the synthesis of complex library 
Λ-T1–Λ-T28, precatalyst Λ-T18 was, based on the previous screenings (Tables 5–7), 
eventually selected as the final complex of choice for the Steglich rearrangement of 
O-acylated azlactones to C-acylated azlactones (13 → 14).  
The detailed synthesis route for enantiomeric precatalysts Λ- and ∆-T18 and enantio-
meric catalysts Λ- and ∆-T18' is shown in Scheme 32 below and is based on general synthesis 
Route I from Scheme 30. Enantiopurities of >99% ee were found for both enantiomeric 
catalysts Λ- and ∆-T18' by chiral HPLC analysis and the absolute configurations of the 
enantiomeric complexes were assigned by CD spectroscopy (details are provided in the 
experimental section). Figure 15 shows the CD spectra of enantiomeric precatalysts Λ- and 
∆-T18 (left side) and the chiral HPLC traces of catalysts rac-, Λ-, and ∆-T18' (right side). 
Figure 16 shows the three-dimensional structure of active catalyst Λ-T18' from two different 
perspectives. The structure from Figure 16 was deduced from a crystal structure which was 
obtained for racemic catalyst rac-T18' (details are provided in the experimental section). 
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Scheme 32. Synthesis of precatalyst Λ/∆-T18 and catalyst Λ/∆-T18' starting from phenylbenzoxazole 139 and 
IrCl3·3H2O. The here depicted synthesis scheme is based on general synthesis Route I from Scheme 30. Details 
are provided in the experimental section. aYield of deprotonation step D: 99%. bAlternatively, wash a CH2Cl2 
solution of Λ/∆-T18 with aqueous 0.3 M NaOH and water. [Reproduced and adapted with permission from 
ref. 84. Copyright © 2017, American Chemical Society] 
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Figure 15. Left: CD spectra of enantiomeric precatalysts Λ- and ∆-T18. Right: Superposition of absorption-nor-
malized excerpts of the HPLC traces of catalysts rac-, Λ-, and ∆-T18'. Experimental details are provided in the 
experimental section. [Reproduced and adapted with permission from ref. 84. Copyright © 2017, American 
Chemical Society] 
 
 
 
Figure 16. Three-dimensional structure of active catalyst Λ-T18' from two different perspectives with 50% 
probability of thermal ellipsoids.[85] Three-dimensional structures deduced from the crystal structure obtained for 
rac-T18'. Cocrystallized solvent molecules and positional disorder are omitted for clarity. 
 – 2.3.2 Steglich Rearrangement of O-Acylated Azlactones and Catalyst Development –   
 
~ 68 ~ 
 
The high catalytic activity of Λ-T18 in combination with Cs2CO3 (see Table 7, entries 6 
and 7) foreshadowed that further enantioselectivity improvements could be achievable by 
lowering of the temperature and / or by variations of other reaction parameters. 
As a start, a solvent screening was performed at 0 °C with Λ-T18 for the reaction 13a → 14a. 
The results of this screening are summarized in Table 8.  
 
Table 8. Steglich rearrangement 13a → 14a. Solvent screening with complex Λ-T18 at 0 °C. 
 
     
 
entry catalyst loading 
(mol%) 
solvent conc 
(mol/L) 
time 
(h) 
ee of 14aa 
(%) 
convb 
(%) 
1 0.2 CH2Cl2 1.0 12 88 full 
2 0.2 toluene 1.0 12 82 full 
3 0.2 THF 1.0 12 88 full 
4 0.2 CHCl3 1.0 12 86 full 
5 0.2 EtOAc 1.0 12 88 full 
6 0.2 TAA 1.0 12 n.d. tracec 
7 0.5 TAA 0.25 12 62 <50%c 
8 0.2 MTBE 1.0 12 88 full d 
9 0.2 1,4-dioxanee 1.0 12 82 full 
12 0.5 acetone 0.5 12 87 <50% 
13 0.5 DMF 0.5 12 87 <90% 
14 0.5 MeCN 0.5 12 n.d. trace 
15 0.5 i-PrOH 0.25 12 64 full 
16 0.5 DMPU 0.5 12 85 <90% 
17 0.6 NMP 0.5 12 86 <90% 
18 0.5 C6CH5NO2 0.5 12 n.d. trace 
19 0.5 C6H5Cl 0.5 12 77 full 
20 0.5 CH3NO2 0.5 12 n.d. trace 
21 0.5 DME 0.5 12 86 full 
22 0.5 C6H5Cl 0.5 12 77 full 
23 0.5 CPME 0.5 12 82 ~50% 
24 0.5 THP 0.5 12 74 >90% 
25 0.5 α-Me-THF 0.5 12 85 full 
26 0.6 EtOAc / C6F14 8:1 0.5 12 87 full 27 0.5 CPME / C6F14 8:1 0.5 12 85 full  
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cTAA: Very low solubility of 13a under these 
conditions prevented full conversion. dMTBE: Full and clean conversion but solubility of 13a critically low in 
MTBE. e1,4-Dioxane: Reaction performed at rt (mp of 1,4-dioxane approx. 10 °C). 
 
 
The solvent screening from Table 8 revealed that CH2Cl2, THF, and EtOAc all worked 
equally well for the reaction 13a → 14a at 0 °C in terms of enantioselectivity and activity. 
Moreover, no side products were observed with these solvents and the short reaction time of 
12 h in all three cases indicated that the reaction temperature could be further decreased. 
Accordingly, CH2Cl2, THF, and EtOAc were then screened at –20 °C and at –30 °C (Table 9). 
At a temperature of –20 °C, THF and EtOAc both outperformed CH2Cl2 in terms of enantio-
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selectivity and particularly in terms of activity (entries 1–3). THF and EtOAc, which were 
both head-to-head at –20 °C, were next evaluated at –30 °C (entries 4 and 5). While an 
acceptable catalytic activity was maintained in case of EtOAc with full conversion after 66 h, 
the catalytic activity dropped dramatically in case of THF and only ~25% conversion were 
found after 53 h. In case of the reaction with EtOAc which was performed at –30 °C (entry 5), 
product 14a could be isolated by short-column chromatography in excellent 95% yield and 
with respectable 93% ee (entry 5). As a result, EtOAc was chosen as the solvent of choice for 
Steglich rearrangements of O-acylated azlactones (13 → 14). 
 
Table 9. Steglich rearrangement 13a → 14a. Solvent screening with complex Λ-T18 at –20 °C and –30 °C. 
 
     
 
entry solvent t (°C) conc (mol/L) time (h) ee of 14aa  (%) convb 
1 CH2Cl2 –20 0.5 48 87 ~½ 
2 THF –20 0.5 48 90 full 
3 EtOAc –20 0.5 48 90 full 
4 THF –30 0.65 53 n.d. ~¼ 
5 EtOAc –30 0.65 53 / 66 92 / 93 (93c)  >95% / full 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate conver-
sion determined by a combination of TLC and HPLC analysis. cEe of isolated product 14a. 
 
Next, the scope of the Steglich rearrangement (13 → 14) was investigated. For this reason, 
nine O-acylated azlactones 13a–i including test substrate 13a were prepared (Figure 17), used 
as substrates with precatalyst Λ/∆-T18 or catalyst Λ/∆-T18', and resulting products 14a–i iso-
lated and their ee values and yields determined. The results of this study are summarized in 
Table 10. 
 
 
 
 
 
Figure 17. O-Acylated azlactones 13a–i were prepared and screened as substrates in the Steglich rearrangement 
(13 → 14) with precatalyst Λ/∆-T18 / catalyst Λ/∆-T18' (see Table 10). Modifications with respect to compound 
13a are highlighted in blue. 
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Table 10. Scope: Steglich rearrangement of O-acylated azlactones (13 → 14).a 
     
 
 
entry t (°C) time (h) R1 R2 R3 yield (%)b ee (%)b product 
1c,d 0 12 Bn Bn p-MeO-Ph 97 88 14a (R) 
2c,d 0 12 iBu Bn p-MeO-Ph 91 70 14b (R) 
3c,d 0 12 Me Bn p-MeO-Ph 80 45 14c (R) 
4c −30 72 Bn Bn p-MeO-Ph 95 93 14a (R) 
5 −30 72 Bn Me p-MeO-Ph 68 88 14d (R) 
6 −30 72 Bn C(CH3)2CCl3 p-MeO-Ph 99 90 14e (R) 
7 −30 72 Bn Bn p-(tBu)-Ph 89 91 14f (R) 
8 −30 72 Bn Bn 1-Naphtyl 88 91 14g (R) 
9 −30 72 Bn Bn 2-Naphtyl 90 95 14h (R) 
10e,f −30 72 Bn Bn 2-Naphtyl 94 94 14h (R) 
11e −30 72 Bn Bn p-MeO-Ph 97 93 14a (R) 
12e,f −30 72 Bn Bn p-MeO-Ph 93 93 14a (R) 
13e,g −30 72 Bn Bn tBu 91 96 ent-14i (S)g 
14e,g,h −30 72 Bn Bn tBu 90 96 ent-14i (S)g 
 
aStandard reaction conditions: substrate 13 (1.0 eq; approx. 90 µmol) with precatalyst Λ-T18 (1 mol%) and 
Cs2CO3 (3 mol%) in EtOAc (conc = 0.65 M) at the indicated temperature. bIsolated yields; enantioselectivities 
determined from isolated products by chiral HPLC analysis. c0.5 mol% of catalyst were used. dconc = 0.5 M. 
eActive catalyst T18' was used instead of precatalyst T18 (no addition of Cs2CO3). fScaled-up reactions, 
entry 10: 400 mg (919 µmol) of substrate 13h; entry 12: 381 mg (917 µmol) of substrate 13a. g∆-configured 
catalyst ∆-T18' used (major product: S-configuration). hCD2Cl2 solution of ∆-T18' left standing for 7 d at 25 °C 
before usage. 
 
With 0.5 mol% of precatalyst Λ-T18 in the presence of 3 mol% Cs2CO3 at 0 °C, substrate 13a 
provided product 14a in 88% ee and was isolated in 97% yield after 12 h (Table 10, entry 1). 
Substrate 13b with R1 = i-Bu instead of R1 = Bn provided product 14b in 70% ee and was 
isolated in 91% yield after 12 h (entry 2). Substrate 13c with R1 = Me provided product 14c in 
45% ee and was isolated in 80% yield after 12 h (entry 3). 
For substrate 13a being the best performing substrate so far, the temperature was then lowered 
to –30 °C and the reaction time prolonged to 72 h, which pushed the ee of product 14a from 
88% to 93% and product 14a was isolated in 95% yield (entry 4). 
While 0.5 mol% of precatalyst Λ-T18 were used for substrates 13a–c from entries 1–4, the 
precatalyst loading (and later the catalyst loading: see entries 10–14) was increased for all 
following reactions which were screened at –30 °C to 1 mol% in order to ensure complete 
conversion within 72 h. 
With substrate 13d residue R2 = Bn was now exchanged for R2 = Me and product 14d 
obtained in 88% ee and isolated in 68% yield (entry 5). Substrate 13e with R2 = C(CH3)2CCl3 
provided product 14e in 90% ee with 99% yield (entry 6).  
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Finally, variations of the third residue R3 were screened (entries 7–9, 11, 13). The best results 
were obtained here with substrate 13h with R3 = 2-naphtyl, which provided product 14h in 
95% ee and with 90% yield (entry 9), and substrate 13i with R3 = t-Bu, which provided 
product ent-14i in 96% ee and with 91% yield (entry 13; note that the ∆-configured complex 
was used in the latter case instead of the usually used Λ-complex). Importantly, the reactions 
from entries 11 and 13 had been, in contrast to all other discussed reactions so far, performed 
with active catalyst Λ/∆-T18' in the absence of Cs2CO3. Beforehand, it had been recognized 
that both methods − use of HPF6 salt Λ/∆-T18 in combination with Cs2CO3 or use of active 
catalyst Λ/∆-T18' alone − had led to identical results, which is visible from entries 4 and 11. 
In order to study the catalyst's stability in solution, a CH2Cl2 solution of catalyst ∆-T18' was 
left standing for 7 d at 25 °C before usage, which then provided product ent-14i with the same 
selectivity and yield as freshly prepared catalyst ∆-T18' (entry 14, compare with entry 13; 
details in the experimental section). In this context, it is worth mentioning that neither any 
decomposition nor any racemization of precatalysts Λ/∆-T18 and catalysts Λ/∆-T18' was 
observed when they were stored as solvent-free solids for ≥ 6 months at 4 °C under standard 
atmospheric conditions (details are provided in the experimental section).  
Exemplarily, two reactions with substrates 13a and 13h were scaled up by a factor of ten 
(~1 mmol scale) and similar yields and basically identical selectivities for products 14a and 
14h obtained as for the corresponding standard scale examples (see entries 10 and 12, 
compare with entries 9 and 11). 
There are no results shown in Table 10 for substrates 13b and 13c at –30 °C for the 
following reasons: Substrate 13b had been revealed to require much higher catalyst loadings 
or a much longer reaction time than 72 h at already –20 °C to reach completion (1 mol% 
Λ-T18, 3 mol% Cs2CO3, conc = 0.65 M of 13b, t = –20 °C, solvent: EtOAc; about ⅔ 
conversion after 72 h and a crude ee of 75% for 14b). And in case of substrate 13c, a 
preliminary experiment at −20 °C had revealed that temperature lowering was unable to push 
the ee of product 14c in a useful height (same conditions as for 13b at –20 °C; full conversion 
found after 72 h with 46% crude ee for product 14c). As a consequence, no further efforts 
were put in both "mismatched" substrates 13b and 13c.  
Noteworthy, all Steglich rearrangements 13 → 14 presented in Table 10 (and in this 
work in general) were set up under normal atmosphere without any special precautions 
against moisture and oxygen. C-Acylated azlactones 14 which were synthesized with Λ-
configured (pre-)catalyst Λ-T18 / Λ-T18' were unambiguously assigned as R-configured. 
Stereochemical assignment details are provided in the experimental section of this work. 
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As explained above, precatalytic HPF6 salt Λ/∆-T18 in combination with Cs2CO3 and active 
catalyst Λ/∆-T18' alone both gave identical results in case of the investigated Steglich 
rearrangements (13 → 14). As a consequence, all reactions discussed from now on were 
performed with catalyst Λ/∆-T18' instead with precatalyst Λ/∆-T18 and Cs2CO3 as additive.  
 
2.3.3  Black Rearrangement of O-Acylated Benzofuranones 
Having demonstrated that Λ/∆-T18' is a powerful stereogenic-at-metal catalyst for the 
Steglich rearrangement of O-acylated azlactones (13) to C-acylated azlactones (14; chapter 
2.3.2, see Table 10), the objective was now to ascertain whether Λ/∆-T18' would be a suitable 
catalyst for other asymmetric reactions. 
For this reason, the related Black rearrangement[86] of O-acylated benzofuranones (142) to 
C-acylated benzofuranones (143) was investigated next. As a start, substrates 142a and 142b 
were synthesized and tested with catalyst Λ-T18'. The results of this initial screening are 
summarized in Table 11. 
 
Table 11. Initial screening of O-acylated benzofuranones 142a and 142b with catalyst Λ-T18'. 
 
 
 
entry substrate loading  
Λ-T18' (mol%) 
t 
(°C) 
solvent conc 
(mol/L) 
time (h) ee 143 (%)a convb 
1 142a 1 rt CH2Cl2 0.5 11 26 (143a) full 
2 142a 1 rt THF 0.5 11 29 (143a) full 
3 142b 1 rt CH2Cl2 0.5 11 67 (143b) full 
4 142b 1 rt THF 0.5 11 73 (143b) full 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate con-
version determined by a combination of TLC and HPLC analysis. 
 
With 142a in CH2Cl2, 1 mol% of Λ-T18', rt as reaction temperature, and a concentration of 
conc = 0.5 M full conversion was found after 11 h and product 143a provided with 26% ee 
(entry 1), which did not significantly improve when THF was used as solvent (29% ee; 
entry 2). However, when substrate 142b was tested under identical conditions, product 143b 
was provided with promising 67% ee in CH2Cl2 as solvent (entry 3) and with 73% ee in THF 
as solvent (entry 4). As a result, substrate 142b was declared as benchmark substrate and a 
conditions screening was carried out to improve the enantiomeric excess of product 142b. The 
results of this screening are summarized in Table 12.  
At first, additional solvents were screened (Table 12, entries 1−8). TAA, the only alcohol of 
this panel of eight solvents, provided product 143b with 88% ee and thus with the best 
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selectivity by far. Moreover, product 143b could be isolated in excellent 98% yield from this 
reaction via short-column chromatography (entry 8).  
 
Table 12. Conditions screening for the Black rearrangement 142a → 143b with catalyst Λ-T18'. 
 
 
 
entry t 
(°C) 
solvent conc 
(mol/L) 
time 
(h) 
ee 143ba 
(%) 
yield 
(%) 
convb 
1 rt CH2Cl2 0.5 11 67 n.d. full 
2 rt THF 0.5 11 73 n.d. full 
3 rt Et2O 0.5 12 73 n.d. full 
4 rt EtOAc 0.5 12 71 n.d. full 
5 rt toluene 0.5 12 75 n.d. full 
6 rt CPME 0.5 12 74 n.d. full 
7 rt MTBE 0.5 12 76 n.d. full 
8 rt TAAc 0.5 13 88d 98 full 
9 0 TAAc 0.3 10 91d 99 full 
10 0 isopropanole 0.3 10 87 n.d. full 
11 0 2-ethoxyethanole 0.3 10 86 n.d. full 
12 0 DMF 0.3 10 74 n.d. full 
13 −30 MTBE 0.6 13 86 n.d. full 
14 −30 CPME 0.6 13 86 n.d. full 
15 −30 toluene 0.6 13 86 n.d. full 
16 −30 THF 0.6 13 82 n.d. full 
17 −30 EtOAc 0.6 13 81 n.d. full 
18 −15 TAA / MTBE  10:1 0.4 15 92 n.d. incomplete 
19 −15 TAA / CPME  10:1 0.4 15 92d 99 full 
20 −15 TAA / toluene 10:1 0.4 15 92d 99 full 
21 −30 TAA / toluene  2:1 0.2 48 (20) 93d 98 full (20 h: ⅔) 
22 −30 TAA / CPME   1:1 0.2 48 (20) 93d 99 full (20 h: ~90%) 
23 −30 TAA / CPME   2:1 0.2 48 (20) 94d 99 full (20 h: >90%) 
 
aEnantioselectivities determined from crude product mixtures by chiral HPLC analysis. bApproximate con-
version determined by a combination of TLC and HPLC analysis. cMp (TAA): −12 °C.[87] dEe determined from 
isolated product. eFormation of side products observed. 
 
Further improvement could be achieved by reduction of the temperature to 0 °C, which then 
provided 143b with 91% ee and in 99% isolated yield after only 10 h (entry 9). It is worth 
noting that the concentration of 142a was lowered for this experiment due to the low solu-
bility of substrate 142a in alcohols including TAA. 
Encouraged by these results, other protic solvents were screened at 0 °C (entries 10−12). 
However, other alcohols such as isopropanol (entry 10) were found to be less selective than 
TAA and promoted the formation of side products (entries 10 and 11). DMF did not promote 
the formation of side products, but gave product 143b with less selectivity then the screened 
alcohols (entry 12, compare with entries 9−11). 
As TAA provided a clean reaction, high enantioselectivity, and high catalytic activity, it was 
considered to further lower the temperature to improve the enantioselectivity. However, 
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TAA's high melting point of −12 °C precluded that.[87] As a solution, it was intended to 
overcompensate the lower intrinsic selectivity of other screened solvents, namely MTBE, 
CPME, toluene, THF, or EtOAc, by a drastically reduced reaction temperature. However, this 
failed and TAA still provided 143b with a higher selectivity at rt than the other solvents at 
−30 °C (compare entry 8 with entries 13−17). 
As a result, it was decided to screen solvent mixtures in which co-solvent TAA would be –
figuratively speaking – in charge of maintaining a high ee while a second solvent would be in 
charge of keeping TAA and the substrate in solution at very low temperatures. At first, 10:1 
mixtures of TAA and others solvents were screened at −15 °C (entries 18−20). All three 
reactions provided product 143b with slightly improved 92% ee (compare with entry 9) and 
two reactions had run to completion within 15 h, which indicated that further improvements 
could be achievable by further lowering of the temperature. 
Accordingly, further experiments were performed at a reduced temperature of −30 °C. Prior 
to this, experiments had indicated that changes of the solvent mixture ratios would be required 
to keep TAA and the substrate in solution at −30 °C and that a decrease of the concentration 
of 142a would be, moreover, necessary as well. For this reason, a 1:1 and a 2:1 mixture of 
TAA / CPME (entries 21 and 22) as well as a 2:1 mixture of TAA / toluene (entry 23) were 
used at a concentration of conc = 0.2 M for the experiments at −30 °C. From these three 
experiments, the 1:1 TAA / CPME experiment gave the best result in terms of selectivity and 
activity: >90% conversion was found here after 20 h and full conversion after 48 h providing 
product 143b in 99% isolated yield and with 94% ee (entry 23, compare with entries 21 and 
22). As a result, the conditions from entry 23 were defined as conditions of choice for Black 
rearrangements (142 → 143) with catalyst Λ-T18' at temperatures < 0 °C and the conditions 
from entry 9 as conditions of choice for Black rearrangements with catalyst Λ-T18' at 
temperatures ≥ 0 °C. 
 
 
 
 
Figure 18. O-Acylated benzofuranones 142a−i were synthesized and screened as substrates in the Black re-
arrangement (142 → 143) with catalyst Λ/∆-T18' (see Table 13). Modifications with respect to compound 142b 
are highlighted in blue. 
 
Next, the scope of the Black rearrangement was investigated. For this reason, nine O-acylated 
benzofuranones 142a–i including probe substrates 142a and 142b were prepared (Figure 18), 
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used as substrates with catalyst Λ/∆-T18', and resulting products 143a–i isolated and their ee 
values and yields determined. The results of this study are summarized in Table 13. 
 
Table 13. Scope: Black rearrangement of O-acylated benzofuranones (142 → 143).a 
 
 
entry t (°C) time (h) R1 R2 yield (%)b ee (%)b product 
1c,d 0 18 h Ph Ph n.d.c 30 143a (R) 
2d 0 10 h Me Ph 99 91 143b (R) 
3d 0 18 h Me Bn 99 80 143c (R) 
4d,e 0 48 h Me i-Pr 98 82 143d (R) 
5d 0 20 h Bn C(CH3)2CCl3 98 89 143e (S)j 
6 −15 48 h Me Ph 98 92 143b (R) 
7 −15 48 h iBu Ph 99 90 143f (R) 
8 −15 48 h Bn Ph 99 91 143g (R) 
9 −30 48 h Me Ph 99 94 143b (R) 
10f −30 48 h Me Ph 99 94 ent-143b (S)f 
11 −30 48 h Me Me 93 70 143h (R) 
12 −30 48 h Me C(CH3)2CCl3 99 93 143i (S)j 
13g −30 48 h Me C(CH3)2CCl3 99 93 143i (S)j 
14g −30 48 h Me Ph 99 (73h) 92 (98h) 143b (R) 
15i −30 48 h Me Ph 99 93 143b (R) 
 
aStandard reaction conditions: substrate 142 (1.0 eq; 70−90 µmol) with catalyst Λ-T18' (1 mol%) in TAA/CPME 
2:1 (conc = 0.2 M) at the indicated temperature. bIsolated yields; enantioselectivities determined from isolated 
products by chiral HPLC analysis (except entry 1: ee of 143a from crude mixture). cNot determined (n.d.), 
incomplete after 18 h; ~50% conv acc. to TLC. dSolvent: TAA, conc = 0.3 M. e2 mol% catalyst used. 
f∆-configured catalyst used. gScaled-up reactions, entry 13: 252 mg (717 µmol) of substrate 142i; entry 14: 
830 mg (3.09 mmol) of substrate 142b. hYield and ee after recrystallization from methanol. iRecovered catalyst 
used (>99% ee; recovered from entry 14). jNo inversion of the stereocenter, product is S-configured due to 
higher priority of the exocyclic acyl fragment compared to the endocyclic one in this particular case.[88] 
 
At first, substrate 142a with R1, R2 = Ph was tested at 0 °C in TAA in the presence of 1 mol% 
of Λ-T18' (entry 1). Only 50% conversion and 30% ee were found for product 143a after 
18 h. However, when with substrate 142b residue R1 = Ph was replaced by R1 = Me, full 
conversion was found after just 10 h under identical conditions and corresponding product 
143b could be isolated in 91% ee (entry 2). Next, migrating acyl group R2 = Ph was replaced 
with substrate 142c by R2 = Bn (entry 3) and with substrate 142d by R2 = i-Pr (entry 4). This 
modifications resulted in a decreased selectivity for both products, for product 143c 80% ee 
were found and for product 143d 82% ee. Moreover, in case of substrate 142d a higher 
catalyst loading of 2 mol% was necessary to achieve full conversion within 48 h. Substrate 
142e with R1 = Bn and R2 = C(CH3)2CCl3 provided product 143e in 89% ee (entry 5). 
For 142b, being the best performing substrate so far, the temperature was now lowered to 
−15 °C, the solvent switched from TAA to TAA/CPME 2:1, and the reaction time increased 
to 48 h. This pushed the ee for product 143b to 92% (entry 6). Under these conditions, 
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substrates 142f with R1 = i-Bu (entry 7) and 142g with R1 = Bn (entry 8) were tested as well, 
which provided products 143f and 143g with 90% ee and 91% ee, respectively. Next, the 
temperature was further lowered from −15 °C to −30 °C under otherwise identical reaction 
conditions. This improved the selectivity for product 143b from 92% ee to 94% ee (entry 9). 
With enantiomeric catalyst ∆-T18', substrate 142b provided product ent-143b also in 94% ee 
as expected (entry 10; inverted R/S ratio). Under identical reaction conditions, two substrates 
with different acyl groups R2 were tested: While substrate 142h with small R2 = Me provided 
product 143h with only moderate 70% ee (entry 11), substrate 142i with bulky R2 = 
C(CH3)2CCl3 provided product 143i with 93% ee (entry 12) and hence with virtually the same 
selectivity as product 143b (compare with entries 9 and 10). 142b and 142i were exemplarily 
used as substrates in two scaled-up reactions: substrate 142i (0.72 mmol; entry 13) provided 
product 143i with identical and substrate 142b (3.1 mmol; entry 14) product 143b with 
slightly diminished enantioselectivity compared to the standard scale examples (compare with 
entries 9 and 12). Noteworthy, the ee of product 143b from the scaled-up reaction (entry 14) 
could be pushed to 98% by one round of recrystallization from methanol while maintaining an 
acceptable yield of 73% (details in the experimental section). Importantly, catalyst Λ-T18' 
could be recovered from this scaled-up experiment (entry 14) in 94% yield with >99% ee 
(procedure and details in the experimental section) and was then used again in a standard 
scale reaction with substrate 142b, which virtually provided the same result as freshly 
prepared catalyst Λ-T18' (93% ee for 143b, entry 15). 
Just like the Steglich rearrangements from Table 10 (chapter 2.3.2), all Black 
rearrangements from Table 13 were set up under normal atmosphere without any special 
precautions against moisture and oxygen. 
It is worth noting that basically all Black rearrangement products 143 from Table 13 
could be isolated in virtually quantitative yields (93−99% yield) apart from product 143a. 
The C-acylated benzofuranones (143) which were synthesized with Λ-configured 
catalyst Λ-T18' were unambiguously assigned as R-configured, except from products 143e 
and 143i, which are S-configured due to the higher priority of their exocyclic acyl groups 
compared to their endocyclic acyl groups.[88] Stereochemical assignment details for the C-
acylated benzofuranones (143) are provided in the experimental section of this work. With 
respect to that, an X-ray structure of enantiomer (S)-143i could be obtained from the batch of 
product 143i from Table 13, entry 13 (93% ee), which is depicted in Figure 19. Apart from 
optical rotation data, this X-ray structure served to assign the absolute configuration of 
products 143. 
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Figure 19. Left: Structure of both symmetry-independent molecules (S)-143i in the asymmetric unit with 60% 
probability of thermal ellipsoids.[85] Right: Molecular overlay of the two symmetry-independent molecules. 
 
It is apparent that some substrates from Table 13 are not shown for temperatures lower than 
0 °C (142a,c,d,e) or lower than −15 °C (142f,g). The reasons for that are as follows: 
In case of 142a and 142d, it would have been necessary to significantly increase the catalyst 
loading to achieve full conversion within 48 h or to use significantly longer reaction times. In 
case of 142c, a reaction had been performed at −30 °C which had reached ~80−90% con-
version after 48 h and full conversion after 72 h. But unexpectedly, 143c was provided there 
with a decreased selectivity of 77% ee compared to the 80% ee (Table 13, entry 3) which had 
been obtained at 0 °C (solvent: TAA/CPME 2:1, conc = 0.2 M of 142c, 1 mol% Λ-T18'). In 
case of 142f and 142g, it would have been again necessary to increase the catalyst loading to 
achieve full conversion within 48 h at −30 °C or to use significantly longer reaction times. 
And in case of substrate 142e, lower temperatures were not evaluated as 142e had simply 
been prepared at the end of the project to have with product 143e a product with a known 
specific rotation in conjunction with a reliably determined absolute configuration.[22b] 
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2.3.4  Intermolecular C-Acylation of Silyl Ketene Acetals 
Next, the asymmetric intermolecular C-acylation of silyl ketene acetals (145) with different 
anhydrides (144) was investigated.[89] For this reason, four silyl ketene acetals 145a–d were 
prepared at first (Scheme 33). 
 
 
 
 
Scheme 33. Intermolecular C-acylation of silyl ketene acetals (145) with different anhydrides (144) as acylating 
agents and Λ-T18' as catalyst.  
 
Next, 145a–d were screened under different conditions and with different anhydrides 
(144a−d) with Λ-T18' as catalyst. The conditions and results of this screening are sum-
marized in Table 14. 
 
Table 14. Screening of silyl ketene acetals 145a–d with anhydrides 144a–d and Λ-T18' as catalyst. 
 
 
 
entry silyl ketene 
acetal (145) 
anhydride  
(144) (R1) 
eq of 
144 
Λ-T18' 
(mol%) 
solvent conc 
(mM) 
t 
(°C) 
time 
(h) 
yield 
(%)a 
ee 146 
(%)a 
1 145a R1 = Me (144a) 1.3 3 CH2Cl2 80 rt 36 91 17 (146aa) 
2 145b R1 = Me (144a) 1.2 3 CH2Cl2 80 rt 36 88 29 (146ba) 
3 145c R1 = Me (144a) 1.4 3 CH2Cl2 80 rt 36 95 18 (146ca) 
4 145b R1 = Me (144a) 1.2 3 THF 80 rt 36 85 < 5 (146ba) 
5 145b R1 = Me (144a) 1.2 3 toluene 80 rt 36 44b 6 (146ba) 
6 145b R1 = Ph (144b) 1.3 3 CH2Cl2 80 rt 46 88 27 (146bb) 
7 145b R1 = i-Pr (144c) 1.3 3 CH2Cl2 80 rt 46 88 16 (146bc) 
8 145b R1 = Bn (144d) 1.3 3 CH2Cl2 80 rt 46 48c < 5c (146bd) 
9 145d R1 = Me (144a) 1.2 3 CH2Cl2 80 rt 43 37d 66 (146da) 
 
aIsolated yields; enantioselectivities determined from isolated products by chiral HPLC analysis. bReason for low 
yield not further investigated. cSignificant side-product formation observed (possibly due to the enolizability of 
anhydride 144d). dLow yield could be traced back to incomplete conversion of substrate 145d (isolated product 
contained ~30% of the hydrolysis product of silyl ketene acetal 145d). 
 
First, silyl ketene acetals 145a–c were screened with 3 mol% of Λ-T18' at rt in CH2Cl2 as 
solvent at conc = 80 mM and with acetic anhydride (144a) as acylating agent (Table 14, 
entries 1–3). These conditions as well as substrates 145a–c were inspired by a previous work 
from Fu and co-workers dealing with the reaction 144 + 145 → 146.[89] After a reaction time 
of 36 h, products 146aa, 146ba, and 146ca were isolated in promising yields of 88–95% 
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(entries 1–3). However, the enantioselectivities were low and the best selectivity was provi-
ded for product 146ba with 29% ee (entry 2). 
In order to test whether other solvents would be able to improve the selectivity, THF and 
toluene were evaluated as solvents with 145b as substrate (entries 4 and 5). Although the 
reaction in THF provided product 146ba with 85% yield, 146ba was virtually obtained 
racemic with < 5% ee (entry 4). A similar result in terms of selectivity was obtained with 
toluene as solvent, which provided 146ba with 6% ee (entry 5).  
So far, only acetic anhydride (144a) had been employed as acylation agent (entries 1–5). For 
this reason, benzoic anhydride (144b, entry 6), isobutyric anhydride (144c, entry 7), and 
phenylacetic anhydride (144d, entry 8) were evaluated with 145b as substrate. Although 
desired products 146bb, 146bc, and 146bd were formed and could be isolated, the enantio-
selectivity could not be improved (entries 6–8).  
Finally, benzofuranone-based silyl ketene acetal 145d was evaluated (entry 9). Synthesis and 
evaluation of 145d were inspired by the good results which had previously been obtained with 
the Black rearrangement of O-acylated benzofuranones (142 → 143; see chapter 2.3.3, 
Table 13) and there in particular with Me-substituted 142b. And indeed, benzofuranone-based 
silyl ketene acetal 145d, whose structure significantly differs from the structures of the other 
silyl ketene acetals 145a–c, provided desired product 146da with encouraging 66% ee 
(entry 9). Although this final result was promising, experiments with silyl ketene acetals (145) 
were discontinued at this point. 
 
In summary, the screening from Table 14 indicates that Λ-T18' might be a suitable catalyst 
for the reaction 144 + 145 → 146 provided that further steps are taken: Although substrates 
145a–c did not match catalyst Λ-T18' in terms of enantioinduction (entries 1–8), benzofura-
none-based silyl ketene acetal 145d gave, in contrast, product 146da with encouraging 
66% ee under non-optimized conditions (entry 9). Accordingly, silyl ketene acetals which are 
structurally similar to 145d seem to have, in combination with additional conditions scree-
nings, a good chance to result in a highly enantioselective transformation 144 + 145 → 146 
with Λ-T18' as catalyst.  
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2.3.5  Steglich-Type Rearrangements of O-Acylated Oxindoles 
Once again, attention was turned to asymmetric intramolecular O → C acyl migration 
reactions (see chapters 2.3.2 and 2.3.3), now to Steglich-type rearrangements of O-acylated 
oxindoles to chiral C-acylated oxindoles. For this purpose, substrates 147a–b,[90] 149a–b,[23f] 
and 151[22b] were prepared (Scheme 34). These substrates differ structurally from the benzo-
furanone substrates from chapter 2.3.3 (142) by the fact that their benzofused heteroaromatic 
5-membered ring contains a substituted nitrogen atom instead of an oxygen atom. 
 
 
 
 
Scheme 34. O-Acylated oxindoles as substrates for Steglich-type rearrangements to their chiral C-acylated 
analogues with precatalyst Λ-T18 / catalyst Λ-T18': (A) Gliocladine C precursors 147a–b,[90] (B) N,O-diacy-
lated oxindoles 149a–b,[23f] (C) O-acylated N-methyloxindole 151.[22b] 
 
Next, the reactions depicted in Scheme 34 were screened with catalyst Λ-T18' / precatalyst 
Λ-T18. The conditions and the results of this screening are summarized in Table 15. 
 
 
Table 15. Screening of O-acylated oxindole substrates 147a–b, 149 a–b, and 151 with precatalyst Λ-T18 and 
addititve Cs2CO3 (substrates 147a–b) or catalyst Λ-T18' (substrates 149a–b and 151). 
 
 
entry substrate complex complex  
loading (mol%) 
Cs2CO3 
(mol%) 
solvent conc 
(M) 
t 
(°C) 
time 
(h) 
yield 
(%)a 
ee product 
(%)a 
convb 
1 147a Λ-T18 0.5 3 EtOAc 0.5 0 18 – – no conv 
2 147b Λ-T18 0.5 3  EtOAc 0.5 0 18 – – no conv 
3 147a Λ-T18 0.5 3 EtOAc 0.5 50 72 n.d. n.d. tracec 
4 147b Λ-T18 0.5 3  EtOAc 0.5 50 72 n.d. n.d. tracec 
5 147b Λ-T18 5 15  THF 0.5 40 48 
130 
– 
16c 
n.d. 
28 (148b) 
< 50%c 
fullc 
6 149a Λ-T18' 2 – THF 0.4 rt 12 
48 
– 
98 
n.d. 
< 5 (150a) 
80–90% 
full 
7 149b Λ-T18' 2 – THF 0.4 rt 12 
48 
– 
96 
n.d. 
59 (150b) 
~50% 
full 
8 151 Λ-T18' 5 – CH2Cl2 0.5 35 11 n.d. < 5d (152) full 
 
 
aIsolated yields; enantioselectivities determined from isolated products by chiral HPLC analysis. bDetermined 
by a combination of TLC and HPLC analysis. cFormation of large amounts of side-products. dDetermined from 
crude mixture, product not isolated.  
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As a start, O-acylated N-Boc-protected oxindoles 147a–b were tested (Table 15, entries 1–5) 
from which 147b serves as substrate of the stereogenic key step 147b → 148b in Overman's 
enantioselective total synthesis of (+)-gliocladine C.[90] Most likely, substrate 147a could also 
be used for this purpose.[90] With 0.5 mol% of precatalyst Λ-T18 in the presence of 3 mol% 
Cs2CO3 at conc = 0.5 M and at rt, no conversion was found in case of both substrates after 
18 h (entries 1 and 2). Consequently, the temperature was then increased to 50 °C (entries 3 
and 4). After 72 h at 50 °C, trace amounts of products 148a and 148b were found but also 
considerable amounts of side products. A final experiment was performed with substrate 147b 
with a 10-fold increased loading of Λ-T18 and a 5-fold increased loading of Cs2CO3, a 
slightly decreased temperature of 40 °C with the intention to reduce side product formation, 
and with THF as solvent (entry 5). However, after 48 h there was < 50% conversion and a 
considerable amount of side products. After a total reaction time of 130 h, the reaction had 
reached full conversion but desired 148b could only be isolated in low 16% yield and with 
28% ee.  
Next, N,O-diacylated oxindoles 149a–b were screened (entries 6 and 7). With 2 mol% of 
catalyst Λ-T18' in THF at conc = 0.4 M and at rt, about 80–90% conversion was found in 
case of 149a after 12 h and full conversion after 48 h. N,C-diacylated product 150a could be 
isolated in excellent 98% yield but was basically racemic with < 5% ee (entry 6). With low 
expectations, substrate 149b was tested under the same conditions. In this case, about 50% 
conversion was found after 12 h and full conversion after 48 h. Product 150b could be 
isolated in excellent 96% yield and, contrary to the expectations, with encouraging 59% ee 
(entry 7).    
Finally, O-acylated N-methyloxindole 151 was tested with 5 mol% of catalyst Λ-T18' in 
CH2Cl2 at conc = 0.5 M and at a temperature of 35 °C (entry 8). Full and clean conversion 
was found here after 11 h. However, chiral HPLC analysis of the crude product mixture indi-
cated a virtually racemic conversion with < 5% ee for product 152. As a result, no efforts 
were made to isolate 152.  
 
At that point, all experiments with asymmetric intramolecular acyl migrations were stopped as 
highly promising results with ketenes as substrates were obtained at the same time, which 
were given a higher priority (see chapters 2.3.6 and 2.3.7). 
 
The results from Table 15 were interpreted as follows: 
 
• Gliocladine C precursors 147a–b are no suitable substrates for Λ-T18' (entries 1–5). The 
synthetic protocol from Overman and co-workers yet indicates that substrates 147a–b 
intrinsically require a comparatively high catalyst loading.[90] However, the extraordinarily 
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low activity of substrates 147a–b in the presence of catalyst Λ-T18' hints at a deeper lying 
problem: Modeling with Λ-T18' suggests that the enolates which are formed in the course 
of the reaction 147 → 148 (see chapter 2.3.8, Figure 23) are hardly able to attack the 
N-acylated catalysis intermediates due to steric clashes with Λ-T18' 's expanded frame-
work, which manifests in a highly sluggish reaction. 
• In case of N,O-diacylated oxindoles 149a–b, the experiment with 149a was less promising 
(entry 6) as product 150a was provided almost racemic (< 5% ee). In contrast, substrate 
149b provided 150b in encouraging 59% ee. Given that just 2 mol% of Λ-T18' were used 
and that 150b was isolated in 96% yield, there seems to be a realistic chance that reaction 
149 → 150 can be developed into a highly enantioselective reaction with Λ-T18' as cata-
lyst by the evaluation of more N,O-diacylated oxindoles (149) and a systematic reaction 
conditions screening and optimization.  
• The result for O-acylated N-methyloxindole 151 is not promising for further experiments 
as < 5% ee were found for product 152 (entry 8). However, it should be considered that 
phenyl-substituted 151 is structurally very similar to phenyl-substituted benzofuranone 
substrate 142a, which was clearly identified as a "mismatched" substrate for catalyst 
Λ-T18' (see chapter 2.3.3, Table 13, entry 1). In order to draw a final conclusion here, 
more experiments should be performed with O-acylated N-methyloxindoles (151) which 
bear aliphatic substituents at their 3-positions. 
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2.3.6  Asymmetric Reactions with Aryl Alkyl Ketenes as Substrates 
Having demonstrated that stereogenic-only-at-metal catalyst Λ/∆-T18' is capable of cata-
lyzing asymmetric acyl transfer reactions (chapters 2.3.2–2.3.5) and this partly with very high 
and competitive levels of activity and selectivity, as demonstrated for the Steglich rearrange-
ment of O-acylated azlactones (see chapter 2.3.2) and for the related Black rearrangement of 
O-acylated benzofuranones (see chapter 2.3.3), it was now investigated whether Λ/∆-T18' 
would be a suitable catalyst for a different type of asymmetric reaction. And so, the focus was 
shifted on asymmetric nucleophile-catalyzed reactions between aryl alkyl ketenes (153) and 
various reaction partners (Scheme 35). 
At this point, it is worth mentioning that all reactions with aryl alkyl ketenes (153) were, in 
contrast to the acyl transfer reactions from chapters 2.3.1–2.3.5, performed under strict exclu-
sion of moisture and oxygen due to the sensitive nature of ketenes.[91,92]  
 
 
 
Scheme 35. Investigation of different reactions between aryl alkyl ketenes (153) and various reaction partners 
with Λ-T18' as scheduled catalyst: (A) Formal [2+2]-cycloaddition between aryl alkyl ketenes (153) and diethyl 
azodicarboxylate (154);[26j] (B) Nucleophilic α-chlorination of aryl alkyl ketenes (153) with (B1) hexachloro-
acetone (156) and (B2) 2,2,6,6-tetrachlorocyclohexanone (158) as chlorinating agents;[26h,27c] (C) Addition of 
2-tert-butylphenol (160) to aryl alkyl ketenes (153);[26e] (D) Addition of 2-cyanopyrrole (162) to aryl alkyl 
ketenes (153).[26c] 
 
 
Because of the somewhat laborious synthesis of pure aryl alkyl ketenes (153)[91] and their 
limited shelf life,[91,92] the reactions from Scheme 35 were at first only investigated with one 
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single probe ketene, namely with phenyl ethyl ketene (153a with R1 = Ph, R2 = Et). The con-
ditions and the results of the reaction screening are summarized in Table 16. 
 
Table 16. Reaction screening with phenyl ethyl ketene (153a) and Λ-T18'. 
 
 
entry ketene 
(identifier) 
reaction 
partner 
eq reaction 
partner 
Λ-T18' 
(mol%) 
solvent conc 
(mM)
t 
(°C) 
time 
(h) 
yield 
(%)a 
ee (product) 
(%)a 
convb 
1 153a (A) 154 1.07 3 CH2Cl2 14 rt 6 
25 
– c 
12 c 
n.d.  
64 (155a) 
fullc 
fullc 
2 153a (B1) 156 1.20 3 toluene 17 –78 1 94 9 (157a) full 
3 153a (B2) 158 1.20 3 toluene 18 –78 1 – d – – d 
4 153a (B2) 158 1.20 3 toluene 18 –30 
rt 
37 
85 
– d 
– d 
– 
– 
– d 
– d 
5 153a (C) 160 1.04 3 toluene 12 rt 2.5 63 13 (161a) full 
6 153a (D) 162 2.00 2 toluene 12 rt 5.5 92 86 (163a) full 
 
 
aIsolated yields; enantioselectivities determined from isolated products by chiral HPLC analysis. bDetermined by 
a combination of TLC and HPLC analysis. cFormation of one major side product observed. dKetene 153a con-
sumed but reaction partner 158 unconsumed, no formation of product 159 observed.  
 
At first, the formal [2+2]-cycloaddition between aryl alkyl ketenes (153) and diethyl azodi-
carboxylate (154; DEAD) was investigated (Scheme 35, A).[26j] This reaction was investigated 
at first for the following reason: According to the experimental records of former PhD student 
Xiaodong Shen, phenyl ethyl ketene (153a) reacted with DEAD (154) in the presence of 
complex Λ-X2 (see chapter 2.2.2, Figure 11) and base additive Et3N to desired cycloproduct 
155a with 45% ee under the following conditions: 3 mol% Λ-X2; 3 mol% Et3N; solvent: 
CH2Cl2; conc = 50 mM; t = rt; reaction time: 2.5 h.[76] However, 155a's enantiomeric excess 
had only been determined from the crude product mixture and neither had the conversion 
been determined nor had product 155a been isolated.[76] And so, the same reaction was 
performed with 3 mol% of catalyst Λ-T18' and 1.07 eq of DEAD (154) at conc = 14 mM at rt 
in CH2Cl2 (Table 16, entry 1). Full conversion was found after 6 h. However, TLC analysis 
indicated that 155a had not been formed as major product but another unidentified side-
product (remark: the crude product mixture was compared with an authentic racemic sample 
of 155a). The reaction was left running for a total of 25 h, which caused no alteration of the 
TLC pattern and desired cycloaddition product 155a was eventually isolated in 12% yield 
with 64% ee. Noteworthy, an additional experiment was performed at –25 °C (data not inclu-
ded in Table 16), but also this modification was not able to suppress the formation of the 
undesired side-product, which was not characterized.  
Next, the nucleophilic α-chlorination of aryl alkyl ketenes (153) with hexachloroacetone (156) 
and 2,2,6,6-tetrachlorocyclohexanone (158) as chlorinating agents was investigated 
(Scheme 35, B1 and B2).[26h,27c] With 3 mol% of catalyst Λ-T18', 1.20 eq of 156, 
conc = 17 mM, a reaction temperature of –78 °C, and toluene as solvent, phenyl ethyl ketene 
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(153a) provided desired product 157a after a reaction time of 1 h in excellent 94% yield but 
only with 9% ee. (entry 2). Assuming that 2,2,6,6-tetrachlorocyclohexanone (158) would give 
a better result,[26h] phenyl ethyl ketene (153a) was subjected to the same reaction conditions 
but with 158 as chlorinating agent (entry 3). In this case, no formation of desired 159a was 
indicated after 1 h (remark: the crude product mixture was compared with an authentic 
racemic sample of 159a). As this was an unexpected result,[26h] the reaction was repeated 
under the same conditions but with an increased temperature of –30 °C (entry 4). Again, no 
indication for any formation of 159a was found after 37 h reaction at –30 °C, which did not 
change when the mixture was left stirring for another 48 h at rt (entry 4).  
Finally, the asymmetric addition of 2-tert-butylphenol (160) to aryl alkyl ketenes (153) giving 
α-chiral esters (161) (Scheme 35, C)[26e] and the asymmetric addition of 2-cyanopyrrole (162) 
to aryl alkyl ketenes (153) giving α-chiral amides (163; Scheme 35, D)[26c] were investigated.  
With 3 mol% of catalyst Λ-T18', 1.04 eq 2-tert-butylphenol (160), conc = 12 mM, toluene as 
solvent, rt as temperature, and a reaction time of 2.5 h, α-chiral ester 161a could be isolated in 
promising 63% yield but with disappointing 13% ee (entry 5). 
In contrast, with 3 mol% of catalyst Λ-T18', 2.00 eq 2-cyanopyrrole (162), conc = 12 mM, 
toluene as solvent, rt as temperature, and a reaction time of 5.5 h, α-chiral amide 163a could 
be isolated in highly encouraging 92% yield with 86% ee (entry 6). 
 
Since the reaction between phenyl ethyl ketene (153a) and 2-cyanopyrrole (162) was the most 
promising one from all the reactions from Scheme 35 and Table 16 by far, it was decided to 
focus deeper on that reaction (see chapter 2.3.7). 
It is worth noting that also other NH-heterocycles than 2-cyanopyrrole (162) were tested as 
reaction partners for 153a under the conditions from Table 16, entry 6: namely 2-acetyl-
pyrrole, pyrrole, indole, and carbazole.[26c] In case of all these NH-heterocycles, only traces of 
the according amides were found after 2 d reaction time. And so it was decided to stay with 
2-cyanopyrrole (162) as reaction partner.   
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2.3.7  Asymmetric Addition of 2-Cyanopyrrole to Aryl Alkyl Ketenes 
The asymmetric addition of 2-cyanopyrrole (162) to aryl alkyl ketenes (153) giving α-chiral 
amides (163) had proven a match for catalyst Λ-T18' (chapter 2.3.6): In a first non-optimized 
attempt, α-chiral amide 163a had been obtained with 2 mol% of Λ-T18' from phenyl ethyl 
ketene (153a) and 2-cyanopyrrole (162) in encouraging 92% yield with 86% ee (see chapter 
2.3.6, Table 16, entry 6). 
On these grounds, it was decided to further focus on this reaction. First, a solvent screening 
was performed, the results of this screening are summarized in Table 17. 
 
Table 17. Reaction conditions screening for the reaction 153a + 162 → 163a with Λ-T18'. 
 
 
 
 
entry t 
(°C) 
solvent time 
(h) 
conva 
(%) 
crude eeb 
(%) 
yield 
(%) 
isolated eeb 
(%) 
1 25 THF 18 full 69 n.d. n.d. 
2 25 Et2O 18 full 84 93 86 
3 25 CH2Cl2 18 ≤ 10 59 n.d. n.d. 
4 25 MeCN 6.5 ≤ 50 30 n.d. n.d. 
5 25 1,4-dioxane 17 full 81 83 81 
6 25 EtOAc 24 full 80 n.d. n.d. 
7 25 m-xylene 15 full 87 99 86 
8 25 C6H5Cl 15 full 82 n.d. n.d. 
9 25 CPME 14 full 86 86 86 
10 25 DME 20 full 76 n.d. n.d. 
11 25 o-xylene 19 full 86 88 86 
12 25 MTBE 14 full 86 93 87 
13 25 toluene 5.5 full 86 92 86 
 
aEstimated from TLC analysis. bEnantioselectivities determined by chiral HPLC analysis. 
 
Based on the solvent screening from Table 17, toluene and MTBE were chosen as solvents of 
choice (entries 12 and 13) although other solvents had given comparable yields and enantio-
selectivities (e.g., Et2O, m-xylene, CPME, and o-xylene). For this decision, additional factors 
were taken into consideration, such as 1.) permanent availability, e.g., perfectly anhydrous, 
pure toluene was permanently available from a solvent still, and 2.) ease of use, e.g., for the 
reaction 153 + 162 → 163 the required ketenes (153) are slowly added as diluted solutions via 
a microliter syringe – Et2O with its high vapor pressure, its low boiling point, and its low 
viscosity would have been less suitable for practical reasons. 
Next, two additional ketenes, o-tolyl ethyl ketene (153b) and phenyl isopropyl ketene (153c), 
were prepared and screened with toluene and MTBE as solvents. These reactions were 
performed at both rt and 0 °C. The results of this screening are summarized in Table 18.  
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Table 18. Reaction conditions screening with ketenes 153a, 153b, and 153c. 
 
 
entry ketene t 
(°C) 
solvent time 
(h) 
conva 
(%) 
yield 
(%) 
isolated eeb 
(%) 
product 
1c 153a rt MTBE 14 full 93 87 163a 
2c 153a rt toluene 5.5 full 92 86 163a 
3 153b rt MTBE 18 full 98 83 163b 
4 153b rt toluene 20 full 98 80 163b 
5 153c rt MTBE 18 full 99 90 163c 
6 153c rt toluene 19 full 99 91 163c 
7 153a 0 MTBE 48 full 96 89 163a 
8 153b 0 MTBE 48 full 99 84 163b 
9 153c 0 toluene 48 full 99 93 163c 
 
aIndicated by TLC analysis.  bEnantioselectivities determined by chiral HPLC analysis. cResults copied from 
Table 17 for comparison and clarity. 
 
The results from Table 18 were interpreted as follows:  
Entries 1–6 indicated that MTBE was a slightly better solvent for unbranched ketenes such as 
153a and 153b and that toluene was a slightly better one for branched ketenes such as 153c. 
Admittedly, the differences are small and in consideration of the few results this could be a 
random result or limited to those three substrates. However, due to the lack of time for further 
investigations it was decided to generally use MTBE as solvent for unbranched ketenes and 
toluene as solvent for branched ketenes.  
Moreover, it was investigated whether the enantioselectivities could be improved by a reduc-
tion of the temperature to 0 °C (entries 7–9). And indeed, desired N-acyl pyrroles 163a–c 
were provided at 0 °C within 48 h with improved enantioselectivities of 84–93% ee and still 
isolated in virtually quantitative yields of 96–99%.  
Next, five additional ketenes 153d–h were synthesized. All eight prepared ketene substrates 
153a–h including already mentioned 153a–c are depicted in Figure 20. 
 
 
 
Figure 20. Aryl alkyl ketenes 153a–h were prepared and used as substrates in the reaction 153 + 162 → 163 
with Λ-T18' as catalyst (see Table 19). Modifications with respect to phenyl ethyl ketene (153a) are highlighted 
in blue.  
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Substrates 153a–h were then screened as substrates with the optimized conditions from 
Table 18, entries 7–8. The results of these experiments are summarized in Table 19.  
 
Table 19. Scope: asymmetric addition of 2-cyanopyrrole to aryl alkyl ketenes (153 + 162 → 143).a 
 
 
 
entry R1 R2 yield (%)b ee (%)b product 
1c Et Ph 96 89 163a (S) 
2c Et o-Tol 99 84 163b (S) 
3 i-Pr Ph 99 93 163c (S) 
4 i-Pr p-Cl-Ph 99 90 163d (S) 
5 i-Pr p-OMe-Ph 99 91 163e (S) 
6 i-Pr m-Tol 99 95 163f (S) 
7d i-Pr m-Tol 98 95 163f (S) 
8 Cyclopentyl Ph 99 93 163g (S) 
9d Cyclopentyl Ph 99 93 163g (S) 
10 Cyclohexyl Ph 99 93 163h (S) 
 
aStandard reaction conditions: ketene (153; 1.0 eq; 100−130 µmol) and 2-cyanopyrrole (162; 2.0 eq) with cata-
lyst Λ-T18' (2 mol%) in toluene (conc = 12 mM) at 0 °C for 48 h. bIsolated yields; enantioselectivities deter-
mined from isolated products by chiral HPLC analysis. cSolvent: MTBE used instead of toluene. dScaled-up 
reactions, entry 7: 194 mg (1.12 mmol) of ketene 153f; entry 9: 209 mg (1.12 mmol) of ketene 153g. 
 
With phenyl ethyl ketene (153a) as substrate, N-acyl pyrrole 163a was provided in 89% ee 
(Table 19, entry 1). Addition of a methyl group in the ortho-position of the ketene's phenyl 
ring (ketene 153b) caused the ee to drop to 84% for product 163b (entry 2). However, 
replacement of phenyl ethyl ketene (153a) by phenyl isopropyl ketene (153c) improved the ee 
of product 163c to 93% (entry 3). Introduction of a chloro-substituent with ketene 153d and a 
methoxy-substituent with ketene 153e in the para-position of phenyl isopropyl ketene's 
phenyl ring provided corresponding products 163d (entry 4) and 163e (entry 5) with slightly 
diminished, but still high selectivity (90% ee for 163d and 91% ee for 163e). The highest 
selectivity was found for m-tolyl isopropyl ketene (153f) which yielded product 163f in 
95% ee (entry 6). Finally, phenyl isopropyl ketene's isopropyl group was replaced by a cyclo-
pentyl group (153g; entry 8) and a cyclohexyl group (153h; entry 10). In both cases, 
corresponding products 163g and 163h were obtained in 93% ee. 
Exemplarily, two reactions with ketenes 153f and 153g were scaled up by a factor of about 
ten (~1 mmol scale). Also in case of the scaled-up experiments, products 163f and 163g were 
obtained in excellent yields (98% and 99%) and with identical selectivities as in case of the 
corresponding standard scale experiments (entries 7 and 9, compare with entries 6 and 8).  
Notably, all products from Table 19 (163a–h) could be obtained in virtually quantitative 
yields (96–99%). Absolute configurations of chiral N-acyl pyrroles 163d–h were assigned as 
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S-configured by comparison of optical rotation values with literature values.[26c] Experimental 
details for the reactions 153 + 162 → 163 as well as stereochemistry assignment details for 
N-acyl pyrroles 163a–h are provided in the experimental section. 
It is worth noting that Fu and co-workers have demonstrated that α-chiral N-acyl pyrroles 
(163) are useful compounds from a synthetic point of view, as they can be easily converted 
into α-chiral acids, esters, amides, aldehydes, and alcohols.[26c] Taking this and the large 
number of nucleophilic catalysts reported to date into account, it was surprising to find that no 
other publication dealing with this transformation had been published when the presented 
experiments were performed.[93]  
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2.3.8  Mechanistic Experiments I: Steglich Rearrangement and Black Rearrangement 
Now, attention was turned to the mechanisms of the established stereogenic intramolecular 
O → C acyl migration reactions with Λ-T18' as catalyst, that is to say the Steglich rearrange-
ment of O-acylated azlactones from chapter 2.3.2 (13 → 14), the Black rearrangement of 
O-acylated benzofuranones from chapter 2.3.3 (142 → 143), and the Steglich-type rearrange-
ments of O-acylated oxindoles from chapter 2.3.5 (147 → 148, 149 → 150, 151 → 152). 
The objectives here were to experimentally proof the anticipated mechanisms and to attempt 
to rationally understand the catalyst's manner of enantioinduction. The latter was considered 
as important as the development of catalyst Λ-T18' had rather been the outcome of a 
systematic screening strategy than of a rational design strategy (see chapters 2.2, 2.3.1–2.3.7). 
It was envisioned – in case the catalyst's manner of enantioinduction could be put on a 
rational basis – that this might significantly simplify future improvements of catalyst Λ-T18' 
or even offer the possibility to custom tailor Λ-T18' or Λ-T18'-derived catalysts to specific 
substrates or vice versa – if applicable, also with the support of computational methods. 
The proposed mechanism for the Black rearrangements 142 → 143 with Λ-T18' as catalyst is 
depicted in Scheme 36 using the example of substrate 142i.[22b,86] 
 
 
 
Scheme 36. Left: Proposed mechanism for Black rearrangements of O-acylated benzofuranones (142 → 143) 
with catalyst Λ-T18' using the example of substrate 142i.[22b,86] The Steglich rearrangements of O-acylated 
azlactones (13 → 14) from chapter 2.3.2 (see Scheme 39) and the Steglich-type rearrangements of O-acylated 
oxindoles (147 → 148, 149 → 150, 151 → 152) from chapter 2.3.5 are supposed to follow an analogous mecha-
nism. Right: Structure of (S)-143i from the crystal structure of a crystal which was grown from 143i (batch with 
93% ee; see chapter 2.3.3, Table 13, entry 13 and Figure 19 for details).[85] [Scheme on the left side reproduced 
and adapted with permission from ref. 84. Copyright © 2017, American Chemical Society] 
 
At first, the imidazoquinoline ligand's nucleophilic nitrogen atom reacts with the carbonate 
group of substrate 142i, which results in the formation of N-acylated intermediate Λ-T18-Int, 
which is a salt that consists of a +1 charged iridium(III) complex cation and its associated 
benzofuranone enolate counteranion (Scheme 36, Step I). In order to support the formation of 
 – 2.3.8 Mechanistic Experiments I: Steglich Rearrangement and Black Rearrangement – 
 
~ 91 ~ 
 
anticipated Λ-T18-Int experimentally, its analog rac-T18-TfO was prepared as shown in 
Scheme 37. 
 
 
Scheme 37. Preparation of rac-T18-Cl and rac-T18-TfO from rac-T18' and 2,2,2-trichloro-1,1-dimethylethyl 
chloroformate and silver triflate. While all attempts failed to crystallize chloride salt rac-T18-Cl, triflate salt 
rac-T18-TfO could be readily crystallized and studied via XRD analysis (see Figure 21). Further experimental 
details are provided in the experimental section. 
 
In this context, it is worth mentioning that rac-T18' was, in an additional experiment, 
quantitatively converted into Λ-T18-Cl within less than 10 min at rt when rac-T18' was 
mixed in an NMR tube with 3 eq of 2,2,2-trichloro-1,1-dimethylethyl chloroformate in 
CD2Cl2 (conc = 25 mM; further details are provided in the experimental section).  
In T18-TfO, the reactive enolate counteranion of intermediate T18-Int is replaced by an inert 
triflate counteranion and accordingly T18-TfO serves as a catalysis intermediate analog for 
T18-Int. A crystal structure for rac-T18-TfO could be obtained, which allowed to deduce the 
three-dimensional structure of Λ-T18-TfO, which is depicted in Figure 21. 
 
  
 
Figure 21. Three-dimensional structure of catalysis intermediate analog Λ-T18-TfO from two different perspec-
tives, deduced from a crystal structure of rac-T18-TfO. Positional disorder and co-crystallized solvent molecules 
are omitted for clarity; 60% probability of thermal ellipsoids.[85] Detailed crystallographic data of rac-T18-TfO 
is provided in the experimental section. 
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Returning to Scheme 36, product 143i is finally formed via nucleophilic attack of the reactive, 
nucleophilic benzofuranone enolate onto the N-acylated complex cation, which goes along 
with regeneration of catalyst Λ-T18' (Scheme 36, Step II). The stereochemical outcome of the 
reaction depends on with which of its prochiral faces the enolate approaches and reacts with 
the catalyst-bound acyl group. In this context, it is important to note that the enolate is only 
able to approach the acyl group from one of both imidazoquinoline faces as the opposite face 
is completely shielded by a bulky 2,4,6-triisopropylphenyl group (see Figure 21 and 23). In 
the case of Λ-configured catalyst Λ-T18', the approach and reaction of the benzofuranone 
enolate with its Si-face oriented toward the catalyst-bound acyl group is obviously favored, 
leading to predominant formation of the S-enantiomer in case of product 143i (Scheme 36). 
One could expect that intermediates of type Λ-T18-Int interchange their electrostatically 
associated enolate counterions, which would lead to partial formation of scrambled products. 
Indeed, when a crossover experiment was performed with substrates 142g and 142i, 
scrambled products 143b and 143e were formed in addition to non-scrambled products 143g 
and 143i (Scheme 38; more details are provided in the experimental section).  
 
 
 
Scheme 38. Crossover experiment with O-acylated benzofuranones 142g and 142i with rac-T18' as catalyst. 
Non-scrambled and scrambled products were formed in a ratio of 143i:143g:143e:143b of about 4.5:4.5:1:1 
according to 1H NMR analysis of the crude product mixture.  
 
 
Additional evidence for the mechanism proposed in Scheme 36 is provided by the fact that 
protonated precatalyst T18 is, in contrast to catalyst T18', not catalytically active in absence 
of a Brønsted base (see chapter 2.3.2 for details) and that the N-methylated form of catalyst 
T18', T18-Me, is not catalytically active at all – neither in the absence nor in the presence of 
a Brønsted base (details about the preparation of T18-Me and details about the experiments 
with T18-Me are provided in the experimental section).  
The Steglich rearrangement of O-acylated azlactones from chapter 2.3.2 and the Steglich-type 
rearrangements of O-acylated oxindoles from chapter 2.3.5 are supposed to follow an ana-
logous mechanism. The mechanism for the Steglich rearrangements from chapter 2.3.2 is 
depicted in Scheme 39 using the example of substrate 13e.[22a,23h] 
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Scheme 39. Proposed mechanism for the Steglich rearrangement of O-acylated azlactones (13 → 14) catalyzed 
by Λ-T18' using the example of substrate 13e.[22a,23h] Note the similarity to the catalysis cycle from Scheme 36. 
 
As shown in Scheme 39, the mechanism is basically identical with the mechanism from 
Scheme 36, apart from the fact that the formed enolate counteranion of catalysis intermediate 
Λ-T18-Int2 is not a benzofuranone enolate but an azlactone enolate. Eventually, approach 
and reaction of the azlactone enolate with its Si-face oriented toward the catalyst-bound acyl 
group lead to predominant formation of the R-enantiomer in case of product 14e (Scheme 39, 
Step II). As the migrating acyl group of O-acylated azlactone 13e is identical with the one of 
O-acylated benzofuranone 142i, the complex cation of catalysis intermediate Λ-T18-Int2 
from Scheme 39 is identical with the complex cation of catalysis intermediate Λ-T18-Int 
from Scheme 36. As a result, Λ-T18-TfO (Scheme 37 and Figure 21) serves as a catalysis 
intermediate analog for both depicted catalytic cycles.  
 
With the combined aid of... 
 
• ...the unambiguous assignment of the primarily employed enantiomer of catalyst T18' as 
Λ-enantiomer (=Λ-T18') by circular dichroism spectra comparisons (details in the experi-
mental section),... 
• ...the crystal structure obtained for racemic catalysis intermediate analog rac-T18-TfO and 
the three-dimensional structure of Λ-T18-TfO deduced from it (see Scheme 37 and 
Figure 21) and the crystal structure obtained for racemic catalyst rac-T18' and the three-
dimensional structure of Λ-T18' deduced from it (see chapter 2.3.2, Figure 16),... 
• ...and the unambiguous assignment of C-acylated benzofuranone product 143i (93% ee) 
from Table 13, entry 13 – synthesized with catalyst Λ-T18' – as predominantly S-con-
figured by both XRD analysis and comparison of optical rotation data of products 143b–i 
with literature data (details are provided in the experimental section),... 
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...the time had now come to shed light on the catalyst's manner of enantioinduction. In that 
regard, it was decided to mainly focus on Black rearrangements of O-acylated benzofuranones 
(142 → 143). 
Referring to the chiral complex cations of Λ-T18-Int (see Scheme 36), Λ-T18-Int2 (see 
Scheme 39), and Λ-T18-TfO (see Scheme 37 and Figure 21), which are identical for all three 
species as explained above, the following has to be considered when trying to unveil the 
catalyst's manner of enantioinduction: The N-bound acyl group of the complex cation gives, 
in theory, rise to two coplanar conformers A and B, both allowing favorable conjugation with 
the neighboring π-system (Figure 22). However, only conformer A is found in the crystal 
structure obtained for rac-T18-TfO (see Figure 21).  
 
 
 
Figure 22. Schematic representations of both possible π-conjugated conformers of the cation of Λ-T18-Int, 
Λ-T18-Int2, and Λ-T18-TfO and their calculated relative energies (details are given in the text below). 
 
To exclude a misleading crystal packing effect and to ascertain the energy difference between 
both conformers A and B, it was intended to confirm this XRD-based finding by a quantum 
chemical calculation. With the aid of Vladimir A. Larionov, postdoctoral researcher at that 
time in the Meggers laboratory in Marburg, Michael G. Medvedev (M. G. M.), a theoretical 
chemist from Moscow affiliated with the 'A. N. Nesmeyanov Institute of Organoelement 
Compounds RAS'[94] and with the 'N. D. Zelinsky Institute of Organic Chemistry RAS',[95] 
could be won for this task and the subsequent quantum chemical calculations as an external 
cooperation partner. 
M. G. M. performed a quantum chemical modeling of both conformations of the complex 
cation of Λ-T18-TfO in the absence of crystal effects at the PBE0[96]-D3[97]/IMCP-
SR1[98,99]//PBE0-D3/SBKJC[100] SMD[101] (butanol) level of theory for which M. G. M. relied 
on the XRD-derived three-dimensional structure of Λ-T18-TfO from Figure 21 (full compu-
tational details are provided in the experimental section). The PBE0 functional was chosen as 
it is known to be accurate for organic chemistry calculations[96b] and has recently been shown 
to be well-grounded in theory[96c] and the IMCP-SR1 basis set was chosen as it incorporates 
scalar-relativistic effects, which are important for heavy elements, such as iridium in case of 
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the studied system and,[99] moreover, retains the correct nodal structures of atoms.[98a] Solvent 
effects were accounted for by M. G. M. by means of the SMD universal solvation model.[101]  
M. G. M.'s calculations revealed that conformer A is indeed 5.3 kcal·mol−1 lower in energy 
than conformer B, which proves that conformer B's contribution to the overall reaction is 
most probably negligible for further mechanistic considerations (Figure 22).[102] 
Having ruled out excessive conformational freedom of the N-bound acyl group with this cal-
culation, it was now possible to shed light on the prochiral recognition mode of the N-acylated 
catalysis intermediate and hence on the underlying manner of enantioinduction of catalyst 
Λ-T18'. 
At first, a Connolly surface or molecular surface with a probe radius of r = 1.4 Å was added 
to the XRD-derived complex cation structure of intermediate analog Λ-T18-TfO (see 
Figure 21) in order examine its active site accessibility with regard to the benzofuranone 
enolate's approach and stereogenic attack (Figure 23; Connolly surface modeling conceived 
and performed by T. C.).[103,104] 
 
 
 
Figure 23. Left: Molecular surface (probe radius r = 1.4 Å) of the complex cation of Λ-T18-TfO derived from 
the crystal structure obtained for rac-T18-TfO (see Figure 21)[103−105] with view on the sterically accessible face 
of the N-acylated imidazoquinoline ligand. Right: Same structure as left, tilted by 90° resulting in a view on the 
edge of the N-acylated imidazoquinoline ligand. The blue arrows in both representations point into the chiral 
molecular cavity (details provided in the text). [Reproduced with permission from ref. 84. Copyright © 2017, 
American Chemical Society] 
 
 
This approach was considered appropriate for the following reasons: After the formation of 
the N-acylated catalysis intermediate, the enolate has to closely approach the electrophilic 
carbonyl moiety of the acyl group to react with it. In this regard, it is apparent from 
Figures 21 and 23 that there are basically no functionalities in the N-acylated catalysis 
intermediate which could interact with the approaching enolate via pronounced non-covalent 
interactions, such as hydrogen-bonding interactions or dipole-dipole interactions.[106] For this 
reason, it was anticipated that the enolate's spatial approach would be mainly governed by 
steric repulsions, weak Van der Waals interactions, and the separation of charge between 
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complex cation and enolate anion. Moreover, the catalyst's structural rigidity and the clearly 
proved conformational preference of its N-attached acyl group (see Figure 22 and the asso-
ciated discussion) renders a preliminary active site accessibility inspection via a molecular 
surface survey feasible. 
As depicted in Figure 23, the target carbonyl moiety of the acyl group is nestled down in a 
chiral molecular pocket or molecular cavity, which a prochiral enolate has to enter in order to 
react with the acyl group. The "bottom" of this cavity consists of a part of the N-acylated 
imidazoquinoline ligand including the target electrophilic carbonyl moiety. And the "walls" of 
this cavity are shaped of, from left to right, a 2,4,6-triisopropylphenyl moiety, the cyclo-
metalated benzoxazole ligand the latter is bound to, a 2,6-dimethylphenyl moiety being also 
part of this benzoxazole ligand, and finally the tail of the N-bound acyl group, which in case 
of the cation of Λ-T18-TfO is the CMe2CCl3 fragment. Figure 23 clearly shows that the 
second face of the imidazoquinoline ligand is, in contrast, effectively shielded by another 
2,4,6-triisopropylphenyl moiety. Keeping these considerations at the back of one's mind, the 
catalyst screenings from chapter 2.3.2 and the eventual selection of precatalyst Λ-T18 / cata-
lyst Λ-T18' become more intelligible as Figure 23 clearly visualizes that appropriate choice of 
the substituents in the catalyst is essential for both high enantioselectivity and activity.  
To confirm these mechanistic considerations and to establish the mechanism in greater detail, 
cooperation partner M. G. M. was asked to perform a quantum chemical modeling of a Black 
rearrangement's stereogenic step with substrate 142i and catalyst Λ-T18'. However, the com-
putational complexity of this system made it necessary to switch over to less complex catalyst 
model Λ-T18'-QM, which is depicted in Figure 24, and also to less complex benzofuranone 
substrate 142h, in which 142i's CMe2CCl3 group is replaced by a methyl group (see 
chapter 2.3.2, Figure 17). Importantly, in catalyst model Λ-T18'-QM the shape of the active 
center and of the mentioned molecular cavity of Λ-T18' remains entirely untouched (details in 
the experimental section). 
 
 
Figure 24. Simplified model of catalyst Λ-T18' named Λ-T18'-QM. Removed fragments are shown in red. 
Importantly, the shape of the catalyst's active center and molecular cavity remains entirely untouched in 
Λ-T18'-QM. More details are provided in the experimental section. 
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Using an approach which has recently been developed and applied by M. G. M. and 
colleagues to locate all 728 transitions states (TSs) feasible for an SpnF-catalyzed formal 
Diels–Alder cycloaddition,[107] four TSs were located at the PBE0[96]-D3[97]/IMCP-
SR1[98,99]//PBE0-D3/SBKJC[100] SMD[101] (butanol) level of theory (details in the experimental 
section). As parameters for tert-amyl alcohol (TAA) were unavailable for the SMD solvation 
model,[101] the alcohol's influence was taken into consideration with the according parameters 
for n-butanol as already before in case of the conformational analysis of the N-acylated 
complex cation. This was considered appropriate as alcohols had been found − at least in 
terms of enantioselectivity − to generally exert a positive and similar influence on Black 
rearrangements (142 → 143) with Λ/∆-T18' as catalyst (see chapter 2.3.3, Table 12).  
Based on the computed transition states and their relative energies (see Table 20 and 
Figure 25), the stereochemical outcome of the reaction 142h → 143h was then calculated by 
M. G. M. and with this also the modeling itself reaffirmed: In order to account for the 
interplay between the located transition states, the Curtin–Hammett principle was invoked by 
M. G. M., which, in its modern sense, states that the rate (and so the efficacy) of a particular 
reaction path is determined by the relative energies of the corresponding TSs, assuming that 
the rates of substrate conformer interconversions are much higher than the rates of the 
chemical reaction.[108] For any two different transition states with energies E1 and E2, their 
contributions to the reaction C1 and C2 are connected by Eq. 2, in which R is the gas constant 
and T the temperature (in Kelvin).[108] 
 
             C1C2 = 푒푥푝 (
E2 − E1푅푇 )                                               (Eq. 2) 
 
Eq. 2 was used by M. G. M. to calculate the contribution ratios between each TS and the 
lowest TS at the reaction temperature of −30 °C (T = 243.15 K). The individual percentaged 
contributions were then calculated by considering the cumulative contribution to be 100%. 
The calculated contributions of all four TSs are summarized in Table 20 together with their 
types and their computed relative energies.
  
Table 20. Types, relative energies, and calculated contributions of each of the four transition states. 
 
transition state (TS)a type / attacking face relative energy (kcal·mol−1)b contribution (C; in %)c 
TS-Re-A Re +1.808 1.6 
TS-Re-B Re +0.480 24.3 
TS-Si-A Si 0.000 65.6 
TS-Si-B Si +0.981 8.6 
 
aThe corresponding transition states are depicted in Figure 25. bCalculated at the PBE0-D3/IMCP-SR1 SMD(bu-
tanol) level of theory. cCalculated invoking the Curtin–Hammett principle (Eq. 2). 
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Figure 25. Quantum chemical modeling of the stereogenic step of the Black rearrangement 142h → 143h with 
Λ-T18'-QM as catalyst model.[105] Top: Three-dimensional representations of the four calculated transition states 
with their Newman projections (views along the forming C-C bonds) and with their relative energies and their 
Curtin–Hammett-based contributions (C). Bottom: Superpositions of the four calculated TSs from three different 
perspectives. The carbon atoms of the approaching enolate are highlighted in blue and the forming C-C bonds 
are indicated with red dashes.                                                          
 
With the contributions of each TS to the overall reaction, the stereochemical outcome of the 
Black rearrangement 142h → 143h with catalyst model Λ-T18'-QM was calculated to be 
48.4% ee (R), which, in consideration of the applied approximations, is in a very good 
agreement with the observed 70% ee (R). One might raise the question whether the energy 
differences between the four calculated TSs (see Table 20, Figure 25) are not somewhat too 
low for reliable conclusions. As far as that is concerned, it has to be considered that the 
studied transition states only differ in weak interactions, which allows to compute their 
relative energies with a high accuracy in the range of ~0.1 kcal·mol−1[109] Moreover, the 
particular calculations for the studied system benefit from an error cancellation, which rises 
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from the fact that the studied transition states are very similar, so systematic errors in them 
largely cancel out.[107,110] The later is in part a consequence of the rigid framework of the 
catalyst which results in a constrained, well-defined active site.  
Three-dimensional representations of the four calculated TSs and their Newman projections 
with views along the forming C-C bonds are shown in Figure 25 together with their calculated 
relative energies and their Curtin–Hammett-based contributions. The energetically most 
favored transition state TS-Si-A with 65.6% calculated contribution is shown in Figure 26 
with individual molecular surfaces added to the N-acylated catalysis intermediate (grey 
surface) and the approaching enolate (blue surface; probe radius r = 1.4 Å for both surfaces; 
Connolly surface modeling conceived and performed by T. C. with M. G. M.'s calculated 
3D-model for TS-Si-A).[103−105] Figure 26 serves to illustrate the spatial situation of that 
reactive approach in general and for transition state TS-Si-A in particular. 
 
 
 
Figure 26. Quantum chemical modeling of the stereogenic step of the Black rearrangement 142h → 143h with 
Λ-T18'-QM as catalyst model. Main contributing transition state TS-Si-A with molecular surfaces added to both 
the N-acylated complex cation (grey surface) and the approaching enolate (blue surface; both surfaces are 
Connolly surfaces with a probe radius of r = 1.4 Å; angles of view are identical with Figure 23).[103−105] The 
forming C-C bond is indicated with red dashes. [Reproduced with permission from ref. 84. Copyright © 2017, 
American Chemical Society]   
 
In summary, the quantum chemical modeling... 
 
• ...was able to put the catalyst's manner of enantioinduction on a rational basis and helped to 
understand the results of the catalyst screening from chapter 2.3.2,... 
• ...confirmed the underlying idea of a chiral rigid molecular cavity or molecular pocket, 
which must be entered by an enolate in order to react with the acyl group's carbonyl moiety 
to form the chiral rearrangement product (see Figures 22–26),... 
• ...confirmed that the approach of the enolate is mainly governed by nondirectional steric 
repulsions and Van der Waals interactions (see Figure 25),... 
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• ...correctly predicted the stereochemical outcome of the transformation 142h → 143h with 
48.4% ee (R-configuration; computed) vs. 70% ee (R-configuration; experimental).  
 
The results also clearly indicate that the unique rigid framework of Λ-T18' with its con-
strained and well-defined active site represents a well-suited scaffold for the rational design of 
related catalysts: It should readily allow it to custom tailor Λ-T18'-derived catalysts to speci-
fic substrates, or to identify suitable substrates for Λ-T18' via in silico screenings. Such in 
silico screenings could range from simple molecular surface based active site accessibility 
considerations (see Figure 23) to compute-intensive but much more informative DFT-based 
screenings with the here presented methods (see Figure 25 and 26). What kind of approach is 
selected of course depends on what computing resources are available and which efforts are 
projected and feasible.[111] However, in consideration of the protracted and time-consuming 
experimental search for "the best" nucleophilic stereogenic-only-at-metal catalyst described in 
chapters 2.2, 2.3.1, and 2.3.2, in silico screenings could have the potential to accelerate and 
facilitate catalyst enhancement and development in the future and could contribute to 
decreased research expenses.  
The usefulness of the here presented calculations and considerations shall be shortly demon-
strated: Inspection of Figures 23, 25 and 26 illustrates that a small migrating acyl group 
results in a wider molecular cavity, which understandably may result in diminished selec-
tivity, e.g., in case of benzofuranone substrate 142h (see chapter 2.3.3, Table 13). A closer 
look at the four TSs depicted in Figure 25 and at the most favorable transition state TS-Si-A 
depicted in Figure 26 also renders the poor result for benzofuranone substrate 142a (see 
chapter 2.3.3, Table 13) consequential as the occurring all-planar, rigid phenyl-substituted 
enolate is hardly able to enter the resulting, comparatively small molecular cavity, which 
manifests in a sluggish reaction and a poor selectivity. Similarly, the extremely sluggish 
reaction observed with gliocladin C precursor 147 from chapter 2.3.5, Table 15 is just conse-
quential: Also here the formed rigid and bulky enolate is hardly able to enter the resulting 
molecular cavity − in case the preceding nucleophilic attack is not already precluded by 
excessive steric congestion. 
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2.3.9  Mechanistic Experiments II: Addition of 2-Cyanopyrrole to Aryl Alkyl Ketenes 
Now, attention was turned to the mechanism of the asymmetric addition of 2-cyanopyrrole 
(162) to aryl alkyl ketenes (153) providing α-chiral N-acyl pyrroles (163) from chapters 2.3.6 
and 2.3.7. For the asymmetric addition of 2-cyanopyrrole (162) to aryl alkyl ketenes (153) 
two pathways are reasonable which are depicted in Scheme 40 using the example of ketene 
substrate 153c.[26c,34] 
  
 
Scheme 40. Reasonable pathways for the reaction of aryl alkyl ketenes (153) with 2-cyanopyrrole (162) cata-
lyzed by Λ-T18' using the example of ketene substrate 153c.[26c,34] [Reproduced and adapted with permission 
from ref. 84. Copyright © 2017, American Chemical Society] 
 
The first reasonable pathway starts with proton transfer from 2-cyanopyrrole (162) to catalyst 
Λ-T18' followed by addition of the generated pyrrolate to ketene 153c, which eventually 
results in formation of Λ-T18-Int3, a salt consisting of an N-protonated +1 charged 
iridium(III) complex cation and its associated ketene enolate counteranion (Scheme 40, 
Step A). On the assumption that this pathway is operational, the observed stereochemical 
outcome originates from the circumstance that chiral Brønsted acid Λ-T18-Int3 preferentially 
protonates the prochiral ketene enolate from the Re-face, which leads to predominant 
formation of the S-enantiomer of product 163c (Scheme 40, Step B). In Scheme 40, the 
E-enolate is arbitrarily drawn. However, in case this pathway is operational, the ketene 
enolate might be existent as an E/Z mixture.[34a] As discussed for the acyl migration reactions, 
the ketene enolate can only approach the protonated imidazoquinoline ligand from one face as 
the other one is sterically obstructed (see chapter 2.3.8, Figure 23). 
The second reasonable pathway starts with addition of catalyst Λ-T18' to ketene 153c, which 
results in formation of zwitterionic iridium(III) complex Λ-T18-Int4, which might again exist 
as an E/Z mixture (Scheme 40, Step C; E-form arbitrarily drawn).[34a] In case this pathway is 
operational, preferred proton transfer to the Re-face of the catalyst-bound ketene enolate from 
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2-cyanopyrrole (162) eventually leads to predominant formation of the S-enantiomer of 
product 163c (Scheme 40, Step D). Again, 2-cyanopyrrole (162) can only approach the imida-
zoquinoline ligand from one face as the other one is sterically obstructed. 
In an attempt to clarify which of both cycles from Scheme 40 is in operation, the following 
observations were made: When rac-T18' was mixed in dry CD2Cl2 with excess p-chloro-
phenyl isopropyl ketene (153d) at room temperature, only 1H NMR signals belonging to 153d 
and rac-T18' were found but no indication for the formation of a zwitterionic species like 
Λ-T18-Int4. This result is in agreement with observations made by Fu and co-workers for 
their DMAP-derived catalyst (–)-7b (see Scheme 3 in chapter 1.2) and speaks, at first, against 
the right cycle from Scheme 40.[26c] However, ion pair formation was also not observed when 
rac-T18' was mixed with excess 2-cyanopyrrole (162) under identical conditions, only a weak 
hydrogen-bonding interaction between the N-bound proton of 162 and the nitrogen atom of 
rac-T18' could be observed (details of both experiments are provided in the experimental 
section). This is in contrast to observations made by Fu and co-workers for catalyst (–)-7b, 
who report about ion pair formation for this experiment.[26c] Based on their NMR observations 
together with additional experimental data, primarily kinetic data, Fu and co-workers care-
fully assumed that the Brønsted base/acid mechanism should be in operation in case of cata-
lyst (–)-7b.[26c] 
In contrast, a recent thorough computational study from Cheong and co-workers arrived at the 
conclusion that the nucleophilic pathway should be in operation in case of (–)-7b.[34] For the 
reaction between phenyl methyl ketene and 2-cyanopyrrole (162) catalyzed by (–)-7b, Cheong 
and co-workers revealed that... 
 
• ...the decisive rate determining step (RDS) of the nucleophilic pathway is favored by 
8.3 kcal·mol−1 over the RDS of the Brønsted base/acid pathway[34]... 
• ...the NMR-observed ion pair formed between 2-cyanopyrrole (162) and catalyst (–)-7b is 
merely the unproductive resting state of the catalyst[34]... 
• ...the NMR-based non-observation of a zwitterionic intermediate formed between a ketene 
and (–)-7b is consequential as that step is endergonic[34]... 
• ...the experimental primary kinetic isotope effect (KIE) of kH / kD ~ 5 found by Fu and co-
workers coincides with the computed KIE for the nucleophilic pathway (computed: 
kH / kD = 5) but not with the computed KIE for the Brønsted base/acid pathway (computed: 
kH / kD = 1; kH is here the rate constant for the reaction with common 2-cyanopyrrole (162) 
and kD the rate constant for the reaction with N-deuterated 2-cyanopyrrole (162-D).[34] 
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Being aware of the different structures and properties of Fu's catalyst (–)-7b and catalyst 
Λ-T18', it is at the moment assumed, in consideration of the recent calculations from Cheong 
and co-workers for catalyst (–)-7b, that for catalyst Λ-T18' the nucleophilic catalysis pathway 
is in operation as well (Scheme 40, right cycle). At least, it can concluded for sure that the 
lone-pair of the imidazoquinoline's nitrogen atom is indispensable for this reaction either way 
as mixing of N-methylated catalyst (Λ-T18-Me) with ketene 153c and 2-cyanopyrrole (162) 
resulted in no formation of addition product 163c (experimental details and the preparation 
procedure for Λ-T18-Me are provided in the experimental section). 
 
To clarify which of both pathways from Scheme 40 is in operation or at least predominantly 
in operation, a clever combination of in vitro and in silico experiments as presented by 
Cheong and co-workers seems to be the most viable approach.[34] Accordingly, the following 
tasks should be performed: 
 
• Both pathways from Scheme 40 should be studied with catalyst Λ- or ∆-T18' or with a 
suitable simplified model (for example ∆-T18'-QM; see Figure 24) by explicit quantum 
chemical calculations with the aim to obtain the reaction coordinate diagrams for both 
pathways with the energies of their individual transition states and intermediates. This 
would reveal the RDSs of both pathways and their crucial difference in energy.[34] 
• Next, it should be verified whether the above mentioned experimental results for rac-T18' 
with p-chlorophenyl isopropyl ketene (153d) and 2-cyanopyrrole (162) are in accordance 
with the reaction pathway featuring the energetically favored RDS.[34] 
• Then, the rate constants (k) for the reaction between an aryl alkyl ketene (153) and 
2-cyanopyrrole (162; rate constant: kH) and the reaction between the same aryl alkyl ketene 
(153) and N-deuterated 2-cyanopyrrole (162-D; rate constant kD) should be experimentally 
determined with rac-T18' as catalyst, which provides the experimental primary KIE 
(kH / kD). Next, the KIEs should be computed for both pathways.[34] If the computed KIEs 
are not identical or very similar for both pathways, the computed KIE should resemble the 
experimental KIE of the operational pathway.[34] 
• Finally, the stereochemical outcome could be computed for both the favored and the 
unfavored pathway. If they are not identical or very similar, the computed stereochemical 
outcome of the favored pathway should resemble the experimental stereochemical out-
come.[34] 
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2.4  Summary and Outlook  
In summary, complex Λ/∆-T18' has been developed and demonstrated to be a versatile, 
highly active, for several transformations highly enantioselective, air- and moisture-stable 
chiral nucleophilic catalyst featuring a bidentate deprotonated imidazoquinoline ligand as its 
catalytic site and an octahedral Ir(III) stereocenter as its exclusive element of chirality 
(Figure 27).  
 
 
Figure 27. Structural formulas of nucleophilic stereogenic-only-at-metal catalyst Λ-T18' (left) and its enantio-
mer ∆-T18' (right). The catalytically active nucleophilic nitrogen atom is highlighted in blue and the octahedral 
Ir(III) stereocenter is highlighted in red.  
 
Starting from preliminary research results from two former PhD students from the Meggers 
laboratory, namely Zhijie Lin (see chapter 2.2.1)[75a] and Xiaodong Shen (see chapter 
2.2.2),[76] 28 different Ir(III) complexes Λ-T1−Λ-T28 (see chapters 2.3.1 and 2.3.2, Figures 
12−14,) were synthesized and evaluated and complex Λ/∆-T18 eventually selected as the 
most promising nucleophilic catalyst candidate based on the results from Steglich rearrange-
ment reaction 13a → 14a, which accordingly served as a probe reaction (see chapter 2.3.2, 
Tables 5−7). 
In has been revealed that initially formed and isolated complex Λ/∆-T18 is catalytically 
inactive and that instead its deprotonated form Λ/∆-T18', formed by mild Brønsted base 
treatment from Λ/∆-T18, is the actual catalytically active species (see chapter 2.3.2, Table 4 
and Scheme 31; additional experiments are provided in the experimental section). Moreover, 
it has been demonstrated that Λ-T18' and ∆-T18' are both available with >99% ee with the 
employed synthetic route (see chapter 2.3.2, Scheme 32) and their absolute configurations 
have been unambiguously assigned via CD spectroscopy (see chapter 2.3.2, Figure 15; addi-
tional experimental data is provided in the experimental section).    
 
The versatility of newly designed nucleophilic stereogenic-only-at-metal catalyst Λ/∆-T18' 
could be successfully demonstrated for three asymmetric transformations (Scheme 41): 
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• For the Steglich rearrangement of O-acylated azlactones (13) to C-acylated azlactones (14) 
going along with the formation of a quaternary stereocenter (9 examples; up to 99% yield 
and up to 96% ee; see chapter 2.3.2 for details),... 
• ...for the related Black rearrangement of O-acylated benzofuranones (142) to C-acylated 
benzofuranones (143) going along with the formation of an all-carbon quaternary stereo-
center (9 examples; up to 99% yield and up to 94% ee; see chapter 2.3.3 for details),... 
• ...and finally for the addition of 2-cyanopyrrole (162) to aryl alkyl ketenes (153) yielding 
α-chiral N-acyl pyrroles (163; 8 examples, up to 99% yield and up to 95% ee; see chapters 
2.3.6 and 2.3.7 for details), a reaction for which catalyst Λ/∆-T18' is, after Fu's planar-
chiral catalyst (–)-7b, the only other reported chiral catalyst so far.[26c,93] 
 
 
 
Scheme 41. Successfully established reactions with catalyst Λ-T18'. Enantiomeric catalyst ∆-T18' can also be 
employed which leads to products with opposite configurations. 
 
 
Notably, it was possible to perform these transformations with just 0.5–2 mol% of catalyst 
Λ/∆-T18', partially at temperatures as low as −30 °C, which underlines the catalyst's high 
activity (Scheme 41). 
In case of one Black rearrangement, it has been demonstrated that the catalyst can be 
easily recovered in high yield after reaction completion without any deterioration of its 
enantiopurity and reused again (reisolation of Λ-T18': 94% reisolated yield and a reisolated 
ee of >99%; see chapter 2.3.3, Table 13 and the associated text). 
With crystal structures of active catalyst rac-T18' (chapter 2.3.2, Figure 16) and 
N-acylated catalysis intermediate analog rac-T18-TfO (chapter 2.3.8, Figure 21), analysis of 
the degree of conformational freedom in the complex cation of catalysis intermediate analog 
Λ-T18-TfO (chapter 2.3.8, Figure 22; DFT-based conformational analysis performed by 
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cooperation partner M. G. M.), and via analysis of the active site accessibility of the latter 
(chapter 2.3.8, Figure 23), it has been shed light on the catalyst's manner of prochiral recog-
nition and enantioinduction. And in case of the Black rearrangements (142 → 143), the 
herefrom deduced mechanistic conclusions have been explicitely confirmed and further 
refined with a quantum chemical modeling of a Black rearrangement's stereogenic step 
(142h → 143h), which also correctly predicted the stereochemical outcome of the studied 
reaction (chapter 2.3.8, Figures 24–26; quantum chemical modeling of the stereogenic step 
and prediction of the stereochemical outcome performed by cooperation partner M. G. M.).  
In case of the reaction between 2-cyanopyrrole (162) and aryl alkyl ketenes (153) to 
give α-chiral N-acyl pyrroles (163) it remains somewhat elusive for now whether the reaction 
follows a Brønsted base/acid pathway or a nucleophilic pathway (Scheme 40). An additional 
study should be performed here according to the proposed procedure described in the last 
paragraph of chapter 2.3.9 in order to clarify which of both pathways is in operation. Under 
consideration of the aforementioned computational study from Cheong and co-workers, it is at 
the moment assumed that a nucleophilic catalysis pathway is in operation.[34] 
The key results of this research project have been published in ACS Catalysis as a 
research article (ACS Catal. 2017, 7, 5152–5162),[84] which has recently been highlighted in 
Synfacts (Synfacts 2017, 13, 0945).[112] Some of the complex syntheses of Λ-T1−Λ-T28 
which were performed according to Scheme 30, Route II have been included in a publication 
in Chemistry – A European Journal (Chem. – Eur. J. 2017, 23, 12363–12371), which deals 
with the aforementioned post-complexation modification of bis-cyclometalated Ir(III) com-
plexes via Suzuki-Miyaura cross-couplings (see chapter 2.3.1, Scheme 30 and the associated 
text). 
Future experimental studies with Λ/∆-T18' or derivatives thereof should aim at 
identifying other suitable asymmetric transformations beyond those depicted in Scheme 41. In 
this regard, reinvestigation of the intermolecular C-acylation of silyl ketenes acetals 
(144 + 145 → 146) from chapter 2.3.4 could be promising as product 146da had been 
obtained there with encouraging 66% ee (see Table 14). That result could be taken as a 
starting point for an extensive substrate and conditions screening. And also the Steglich-type 
rearrangements of O-acylated oxindoles (149 → 150) from chapter 2.3.5 could be interesting 
in that regard as product 150b had been obtained there in 96% yield with encouraging 59% ee 
(see Table 15).  
Moreover, it would be interesting to shed more light on the iridium center's electronic 
influence on the attached imidazoquinoline ligand and to elucidate its influence on the activity 
of catalyst T18' as a whole. 
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In this regard, it would be also highly interesting to reveal whether catalyst Λ/∆-T18' or a 
similar catalyst of that type could be combined with photochemistry. A suggestion for such an 
application is shown in Scheme 42 with catalyst Λ-T18':  
In the envisioned merger of nucleophilic catalysis with photochemistry from Scheme 42, an 
acylation agent R(C=O)X or an alkylating agent RX first reacts with catalyst Λ-T18'. This 
results in the formation of acylated Λ-T18-A1 or alkylated Λ-T18-B1. Importantly, R should 
be able to stabilize a radical which forms upon homolysis of the R-N bond (Λ-T18-B1) or of 
the R(CO)-N bond (Λ-T18-A1), for instance by resonance. The next steps are only shown for 
Λ-T18-B1 but they are analog for N-acylated Λ-T18-A1. 
 
 
 
Scheme 42. Envisioned merger of nucleophilic catalysis with photochemistry with catalyst Λ-T18'. Detailed 
explanations are provided in the text. 
 
Λ-T18-B1 is expected to be a good photosensitizer and Λ-T18-B1 is expected to become a 
strong oxidant upon photoexcitation, which allows an easy single-electron transfer (SET) 
reduction of excited Λ-T18-B1* by a suitable reductant, e.g., N-methyl dihydroacridine 
(164).[73] This results in the formation of radical species Λ-T18-B1-Rad and the N-methyl 
dihydroacridine radical cation (165). Radical species Λ-T18-B1-Rad may now undergo 
homolysis of its R-N bond, which results in the formation of (resonance stabilized) radical R· 
and regeneration of catalyst Λ-T18'. In case R· is an acyclic, flexible species capable of 
undergoing a stereogenic intramolecular radical cyclization reaction, catalyst Λ-T18' might be 
able to control the stereochemical outcome of that cyclization: The chiral environment of 
Λ-T18-B1 and Λ-T18-B1-Rad forces the chain of residue R into a certain conformation (see 
chapter 2.3.8, Figures 23–26 for an illustration). In case the catalyst is able to force the chain 
in or at least close to a reactive conformation leading to one of both enantiomers, the catalyst 
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should be able to control the stereochemical outcome of the reaction as rapid intramolecular 
radical cyclization after homolysis of Λ-T18-B1* would then "conserve" the catalyst-dictated 
conformation of initially formed radical R·. The resultant chiral cyclized follow-up radical is 
eventually quenched by the N-methyl dihydroacridine radical cation (165), which becomes 
oxidized to the N-methyl acridinium cation (166). Anyway, Scheme 42 only represents a 
suggestion for a merger of nucleophilic catalysis with photochemistry and other applications 
might be conceived.  
Catalyst Λ-T18' represents, in contrast to all other presented kinetically-inert stereo-
genic-at-metal catalysts from the Meggers group (see chapter 1.4, Figure 8), a monofunctional 
catalyst in which the imidazoquinoline ligand acts as the single catalytically active site. 
Accordingly, it could be attempted to develop a bi- or multifunctional nucleophilic catalyst 
starting from Λ-T18'. In this regard, Suga's recently reported bifunctional BINOL-derived 
nucleophilic catalyst 39 could serve as a source of inspiration (Scheme 43).[23g] 
 
 
Scheme 43. In Suga's BINOL-derived nucleophilic catalyst 39, the hydrogen-bonding interaction between the 
approaching enolate and the acylated catalyst is crucial for an efficient enantioinduction in case of the 
rearrangement of N,O-diacylated oxindoles (149 → 150).[23g] In case the hydroxy groups of 39 are methylated 
(167), the enantiomeric excess of products 150 drops significantly.[23g] A similar interaction could be employed 
to render a catalyst based on Λ-T18' bi- or multifunctional.  
 
In case of Suga's catalyst 39, its hydroxy groups proved to be crucial for an efficient enantio-
induction for the rearrangement of N,O-diacylated oxindoles (149 → 150), which has also 
been confirmed by quantum chemical calculations (Scheme 43).[23g] The reason for that is that 
the enolate (Nuc−) synergistically interacts with the catalyst's hydroxy groups via hydrogen-
bonding, which significantly contributes to the prochiral recognition (Scheme 43).[23g]  
A similar interaction could be implemented in a 2nd generation of catalyst Λ-T18' to render 
the catalyst bi- or multifunctional and to improve its enantioselectivity. A good basis for such 
considerations are the calculated transition states for the Black rearrangement 142h → 143h 
with simplified model catalyst Λ-T18'-QM from chapter 2.3.8, Figures 25 and 26: As can be 
seen from the three-dimensional representation of the most favored transition state TS-Si-A, 
the negatively charged part of the approaching enolate comes in close proximity to one of the 
methyl groups of one of the 2,6-dimethylphenyl groups of catalyst Λ-T18' (Figure 28). 
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Accordingly, an appropriately oriented hydrogen-bond donor or a positively charged moiety 
could be installed in lieu of the respective methyl group in order to synergistically interact 
with the approaching enolate and to co-direct its approach  (Figure 28).   
However, it has to be considered that this modification could also positively affect transition 
state TS-Re-B (see chapter 2.3.8, Figure 25), which is the main contributing transition state 
leading to the undesired enantiomer. Accordingly, it might be challenging to improve Λ-T18' 
with such a secondary interaction, at least in case of Black rearrangements (142 → 143). 
 
 
Figure 28. Energetically most favored transition state TS-Si-A of the Black rearrangement 142h → 143h for 
model catalyst Λ-T18'-QM from chapter 2.3.8, Figure 26.[103-105] As can be seen in this three-dimensional 
representation, one of both methyl groups of one of the 2,6-dimethylphenyl substituent of Λ-T18' seems to be a 
good position to install a hydrogen-bond donor or a positively charged moiety, which could then interact with 
the approaching enolate's oxyanion / negative charge and accordingly render the catalyst bifunctional.   
 
Close inspection of the four calculated transition states from chapter 2.3.8, Figure 25 reveals 
that there could be another, much easier way to "improve" the enantioselectivity of the Black 
rearrangements (142 → 143) with catalyst Λ-T18': Aforementioned transition state TS-Re-B, 
which is according to Figure 25 the main contributing transition state leading to the undesired 
enantiomer, seems to be the only transition state which would significantly suffer from the 
introduction of a bulky substituent R3 at the 6-position of the O-acylated benzofuranone 
substrates (142; Figure 29), e.g., from the introduction of a tert-butyl group. 
 
 
 
Figure 29. O-Acylated benzofuranones (142) with a bulky substituent R3 at their 6-position could be intrinsi-
cally favored substrates for catalyst Λ/∆-T18' according to the representations of the computed transition states 
from chapter 2.3.8, Figure 25. The representation on the right side shows transition state TS-Re-B from 
Figure 25 and pinpoints the steric interaction which could emerge from the introduction of a bulky substituent. 
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The reason for that is that bulky groups R3 should collide with one of the isopropyl groups of 
one of the triisopropylphenyl substituents of Λ-T18' (see Figures 25 and 29) in case of that 
particular transition state. Accordingly, such substrates could be potentially predestined for 
catalyst Λ-T18'. 
And finally, there remains another challenge which could be addressed: As presented in 
chapter 1.4, catalysts Λ-89 and Λ-(R,R)-90 were developed as improved C2-symmetric ver-
sions of catalysts Λ-81 and Λ-85. A similar strategy could be utilized to improve catalyst 
Λ-T18' in terms of activity and maybe also in terms of enantioselectivity (Figure 30). 
 
 
 
Figure 30. Suggested catalyst enhancement: Replacement of the imidazoquinoline ligand of Λ-T18' by a bis-
imidazoquinoline ligand would result in C2-symmetric catalyst Λ-T18'-C2, which might exhibit a higher cata-
lytic activity than Λ-T18' due to the presence of two indistinguishable catalytic sites and which might also 
provide enhanced enantioselectivities. 
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3.  Bifunctional Stereogenic-Only-at-Metal Enamine/Hydrogen-Bonding 
 Catalyst 
 
3.1 Aim of the Project 
Before the attention was turned to the nucleophilic stereogenic-only-at-metal catalyst project 
from chapter 2., it was intended to develop a bifunctional stereogenic-only-at-metal catalyst 
based on Ir(III) complex Λ-T29 as parent structure (Scheme 44), which was envisioned to 
catalyze Michael additions of enolizable aldehydes and / or ketones to nitroalkenes and / or 
nitroacrylates by means of cooperative enamine/hydrogen-bonding catalysis. 
Scheme 44 shows an example for a Michael addition which was envisioned to be catalyzed by 
complex Λ-T29, namely the addition of 2-phenylacetaldehyde (167a) to isopropyl (Z)-3-nitro-
2-phenylacrylate (168a) yielding Michael addition product 169aa. 
 
 
 
 
Scheme 44. Left: Complex Λ-T29 as parent structure of the envisioned bifunctional stereogenic-only-at-metal 
enamine/hydrogen-bonding catalyst. Right: Envisioned Michael addition of 2-phenylacetaldehyde (167a) to iso-
propyl (Z)-3-nitro-2-phenylacrylate (168a) yielding Michael addition product 169aa with Λ-T29 as catalyst. 
 
Complex Λ-T29 represents a kinetically-inert, bis-cyclometalated, phenylbenzoxazole-based 
Ir(III) complex, which features an octahedral Ir(III) stereocenter as its exclusive element of 
chirality (highlighted in grey). As in case of the nucleophilic catalysts presented in chapter 2., 
the iridium center is not directly involved in the (envisioned) catalytic cycle (see Scheme 45) 
but plays a crucial role in spatially arranging both organocatalytic entities required for 
cooperative bifunctional catalysis, which are... 
 
• ...an N-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine ligand (highlighted in green), which is 
supposed to activate nitroalkenes and / or nitroacrylates by double hydrogen-bonding, just 
as the amidopyrazole ligands in catalysts Λ-81, Λ-85, Λ-89, and Λ-(R,R)-90 (see 
chapter 1.4, Schemes 15−18)... 
• ...and an isoindoline moiety (highlighted in blue) attached to the cyclometalated phenyl-
benzoxazole ligands, which is supposed to activate enolizable aldehydes or ketones by the 
formation of an enamine intermediate, just as the cyclic secondary amine in catalyst Λ-99 
(see chapter 1.4, Schemes 20). 
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Accordingly, catalyst Λ-T29 was intended − figuratively speaking − to be a merger of double-
hydrogen bonding catalysts Λ-81, Λ-85, Λ-89, or Λ-(R,R)-90 and single-hydrogen-bon-
ding/enamine catalyst Λ-99. 
The envisioned catalytic cycle for Λ-T29 is depicted in Scheme 45 using aldehyde 167a and 
nitroacrylate 168a as substrate examples. 
 
 
 
 
Scheme 45. Envisioned catalytic cycle for the Michael addition of 2-phenylacetaldehyde (167a) to isopropyl (Z)-
3-nitro-2-phenylacrylate (168a) with Λ-T29 as catalyst. This scheme is not able to give a precise picture of the 
spatial situation, please refer to Figure 31 to get an impression of the spatial situation in Λ-T29 and intermediates 
Λ-T29-Int1 and Λ-T29-Int2.  
 
At first, Λ-T29 was expected to react with enolizable aldehyde 167a in a condensation 
reaction to form intermediate enamine Λ-T29-Int1 (Scheme 45, Step I). Next, nitroacrylate 
168a was expected to bind to Λ-T29-Int1 in a non-covalent fashion with the aminopyrazole 
moiety acting as double hydrogen-bond donor, resulting in the formation of ternary complex 
Λ-T29-Int2 (Step II; Steps I and II may also take place in reverse order). The intermediate 
enamine, in theory now well-aligned with the nitroacrylate (see Figure 31 for an illustration), 
was then expected to "intramolecularly" attack the nitroacrylate in a conjugate fashion to give 
Michael addition product 169aa and catalyst Λ-T29 after hydrolysis (Step III). 
Importantly, the double hydrogen-bonded nitroacrylate in Scheme 45 faces the intermediate 
enamine with its Si-face. In theory, it could also face it with its Re-face. However, modeling 
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suggested that the latter would result in steric clashes with the catalyst's phenylbenzoxazole 
framework. This circumstance was anticipated to ensure a good prochiral recognition. 
Figure 31 shows another envisioned catalyst, complex Λ-T30, which differs from 
Λ-T29 by the fact that the phenyl rings of its phenylbenzoxazole ligands feature additional 
2,6-dimethylphenyl substituents. In addition to the structure of Λ-T30's corresponding ternary 
intermediate Λ-T30-Int2, a three-dimensional representation of Λ-T30-Int2 is shown in 
Figure 31, which serves to illustrate the spatial situation in the catalyst and in the inter-
mediates in general. 
 
 
 
Figure 31. Left: Envisioned catalyst Λ-T30 featuring additional 2,6-dimethylphenyl substitutents (red). Center: 
Λ-T30's corresponding ternary intermediate Λ-T30-Int2 formed from Λ-T30, 167a, and 168a. Right: Three-
dimensional representation of Λ-T30-Int2. The two gray dashes represent the hydrogen bonds between the 
nitroacrylate's nitro group and the aminopyrazole moiety and the red dashes connect the nucleophilic C-atom of 
the enamine moiety with the electrophilic C-atom of the underlying nitroacrylate to illustrate their proximity.[105] 
 
As depicted in Figure 31, the nucleophilic C-atom of intermediate enamine Λ-T30-Int2 
should be perfectly aligned with the electrophilic C-atom of the nitroacrylate for a reaction 
(red dashes). It is also apparent that the opposite binding mode of the nitroacrylate, that is to 
say with its Re-face facing the enamine, should be unfavorable due to steric interactions with 
the catalyst's phenylbenzoxazole framework and also with one of the 2,6-dimethylphenyl 
substituents. Accordingly, the introduction of the 2,6-dimethylphenyl substituents in case of 
advanced catalyst Λ-T30 was envisioned to result in an improved version of parent catalyst 
Λ-T29. 
Figure 31 also hints at the possibility that such a catalyst might not only be able to control the 
enantioselectivity but also the diastereoselectivity. Under the assumption that Si-face orien-
tation with regard to the nitroacrylate, as depicted in Figure 31, is energetically favorable, 
only the enamine conformer which is drawn in Figure 31 is perfectly aligned with the under-
lying nitroacrylate. This is crucial as the conformer of the enamine − i.e., with its Re- or with 
its Si-face towards the nitroacrylate − determines the emerging configuration at the α-position 
of resulting aldehyde 169aa. 
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It is worth mentioning that aldehyde 167a could also form an enamine with the remaining 
isoindoline moiety which is present in Λ-T29 and Λ-T30. However, as that isoindoline 
moiety is lacking an appropriately oriented double hydrogen-bonding motif, it was anticipated 
that this enamine would just constitute an unproductive resting state of both catalysts and 
would, if at all, only insignificantly contribute to the reaction.  
In order to synthesize complexes of type Λ-T29, a significant problem had to be overcome at 
first: A method had to be devised to assemble optically pure complexes of type Λ-T29 
featuring free secondary amines / isoindolines (Figure 32). 
 
 
 
Figure 32. Synthetic problem: How to assemble optically pure complexes of type Λ-T29 featuring free secon-
dary amines / isoindolines?  
 
This was considered challenging as the standard synthesis of bis-cyclometalated Ir(III) 
complexes proceeds via Ir(III) dimers of type [IrIII(C^N)2(µ-Cl)]2 (C^N: cyclometaled 
ligand).[77] And they are commonly prepared by means of heating of the respective ligand to 
be cyclometalated in the presence of IrCl3·3H2O in an alcoholic mixture (often 2-ethoxy-
ethanol / water) at > 100 °C (Nonoyama's method)[77] − which are conditions that free amines 
in ligands to be cyclometalated do not tolerate.[113] Moreover, organic and organometallic 
compounds with aliphatic amines are usually highly basic, which implicates that they 
considerably tail on conventional silica gel columns, often even when large amounts of a base 
modifier are present in the eluent. For this reason, it was planned to protect the isoindoline 
moieties of the phenylbenzoxazole ligands to be cyclometalated with a suitable protecting 
group being able to withstand the cyclometalation conditions, and to cleave this protecting 
group as late as possible in the course of the synthesis.  
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3.2  Results and Discussion 
3.2.1 Preparation and Characterization of the Envisioned Iridium(III) Complexes 
The conceived protection-deprotection strategy from Figure 32 could indeed be implemented 
by relying on carboxybenzyl (Cbz) as protecting group and by cleaving the Cbz groups in the 
final step of Λ-T29's synthesis with a modified version of Birkofer's decarbobenzoxylation 
procedure.[114] Scheme 46 shows the synthesis scheme for complex Λ-T29 with the applied 
conditions and the obtained yields. 
 
 
 
Scheme 46. Synthesis of complex Λ-T29 starting from brominated phenylbenzoxazole 170 and N-Cbz-protected 
isoindoline boronic acid 171. Details are provided in the experimental section. 
 
First, brominated phenylbenzoxazole 170 and N-Cbz-protected isoindoline boronic acid 171 
were subjected to Suzuki-Miyaura cross-coupling to give N-Cbz-protected isoindoline-func-
tionalized phenylbenzoxazole 172. Initially, it was expected that the Cbz group in 172 would 
not withstand the comparatively harsh cyclometalation conditions with IrCl3·3H2O in 
2-ethoxyethanol and water at > 100 °C to give rac-T29-dimer ([IrIII(C^N)2(µ-Cl)]2; C^N 
represents cyclometalated 172) according to Nonoyama's procedure.[77] Accordingly, a milder 
method was evaluated at first, namely the reaction between 172 and iridium(I) precursor 
[IrI(coe)2(µ-Cl)]2 (coe = cyclooctene) in dry toluene at 110 °C, which had not been reported at 
that time for 2-phenylbenzoxazoles as cyclometalating ligands (C^N) but for structurally 
related 2-phenylpyridines.[115,116] And indeed, rac-T29-dimer could be obtained in 60% yield 
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with this method under non-optimized conditions (Scheme 46, Method A). It was found to be 
imperative to perform this reaction with strictly degassed toluene due to the sensitivity of Ir(I) 
precursor [IrI(coe)2(µ-Cl)]2 to oxidation. However, Nonoyama's procedure was additionally 
tested.[77] Unexpectedly, compound rac-T29-dimer was formed smoothly with Nonoyama's 
procedure and could be isolated in 73% yield (Method B).  
The next steps were performed with modifications of procedures which were established in 
the Meggers laboratory: First, rac-T29-dimer was cleaved with auxiliary ligand (S)-Aux1 to 
give diastereomeric iridium(III) complexes Λ-(S)-T29 and ∆-(S)-T29, which were separated 
and purified via standard silica flash chromatography.[79] Next, auxiliary ligand (S)-Aux1 was 
cleaved off and replaced by pyridylpyrazole ligand 173 to give complex Λ-T29-Cbz.[38a] 
Cleavage of both Cbz groups of Λ-T29-Cbz was planned as the final step en route to Λ-T29. 
It was originally planned to realize this step by means of Pd(0)-catalyzed hydrogenolytic 
cleavage with palladium on charcoal (Pd/C) as catalyst. This is commonly considered as the 
method of choice for N-Cbz cleavage as it is economic, easy to perform, tolerates a broad 
range of functional groups, and usually proceeds in the absence of side reactions.[117] However, 
when attempts were made to cleave off the Cbz groups from Λ-T29-Cbz by means of that, no 
conversion could be found apart from some decomposition in a few cases (Table 21). 
 
Table 21. Hydrogenolytic Cbz-cleavage experiments with compounds Λ-T29-Cbz, Λ-(S)-T29, Λ-T29-acac, 
172, and Λ-(S)-V1. 
 
 
 
 
 
entry substrate Pd source 
(wt%) 
Pd loading 
(mol%) 
solvent conc 
(mM)
 t 
(°C) 
time 
(h) 
conv 
1 Λ-T29-Cbz Pd/C (10) 21 EtOH 14 rt 3 no conv 
2 Λ-T29-Cbz Pd/C (10) 23 THF / MeOH 4:1 13 rt 13 no conva 
3 Λ-T29-Cbz Pd/C (10) 28 EtOAc / MeOH 4:1 14 rt 13 no conv 
4 Λ-T29-Cbz Pd(OH)2 /C (20)  22 THF / MeOH 1:1 10 rt 19 no conv 
5 Λ-T29-Cbz Pd/C (10) 42 THF / MeOH 1:1 10 40 19 no conva 
6 Λ-T29-Cbz Pd/C (10) 22 THF / EtOH 1:4 12 75 19 no conva 
7 Λ-(S)-T29 Pd/C (10) 20 THF / EtOH 1:4 13 rt 19 no conv 
8 Λ-T29-acac Pd/C (10) 32 THF / EtOH 1:4 12 rt 19 no conv 
9 172 Pd/C (10) 21 THF / EtOH 1:4 12 rt 19 full and cleanb 
10 Λ-(S)-V1[70] Pd/C (10) 30 EtOAc / MeOH 1:4 6 rt 24 full and cleanc 
 
aUnclean reaction, decomposition products observed by TLC. bDesired amine isolated in 73% yield (non-opti-
mized conditions). cDesired bisamine isolated in 93% yield (optimized conditions).[70]  
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The outcome did also not change when higher palladium loadings and elevated temperatures 
were applied (Table 21, entries 5–6). It was initially assumed that the salt character of 
Λ-T29-Cbz would impede its interaction with the palladium's surface and hence preclude Cbz 
cleavage. However, when attempts were made to cleave the Cbz groups of neutral complexes 
Λ-(S)-T29 and Λ-T29-acac, no conversion was found either (entries 7–8). In contrast, purely 
organic ligand 172 could be deprotected without any problems (entry 9). Surprisingly and in 
contrast to Λ-T29-Cbz, Λ-(S)-T29, and Λ-T29-acac, it was possible to cleave off both N-Cbz 
groups from complex Λ-(S)-V1 without any problems (entry 10). Complex Λ-(S)-V1 has 
recently been utilized in the Meggers laboratory as a precursor for the covalent immobili-
zation of a Lewis acidic stereogenic-only-at-metal catalyst.[70] 
Finally, when a strongly modified version of Birkofer's decarbobenzoxylation procedure was 
applied,[114] which relies on in situ reduction of a Pd(II) species to Pd(0) with an amine as 
reductant and triethylsilane as transfer hydrogenation reagent,[114] both Cbz groups of 
Λ-T29-Cbz could be cleaved off smoothly and desired catalyst Λ-T29 could be isolated in a 
respectable yield of 78% (see Scheme 46, final step).  
In order to verify Λ-T29's enantiopurity, a small sample of isolated Λ-T29 was reprotected 
with CbzCl to Λ-T29-Cbz (chiral HPLC conditions had been already established at that time 
for T29-Cbz). Chiral HPLC analysis revealed >99% ee for reprotected Λ-T29-Cbz, which 
indirectly proved that desired Λ-T29 had indeed >99% ee (Figure 33). 
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Figure 33. Left: Reprotection of Λ-T29. Right: Superposition of absorption-normalized excerpts of the chiral 
HPLC traces of rac-T29-Cbz and Λ-T29-Cbz. Chiral HPLC conditions: Chiralpak IB column (5 µm, 25 cm x 
4.6 mm); eluent: MeCN / 0.1% TFA (aq); 40:60 → 80:20 (gradient; 40 min) → 80:20 (isocratic; 10 min), 
λ = 254 nm, flow = 0.75 mL/min, t (column) = 35 °C.  
 
The same synthetic strategy was next utilized to synthesize 2,6-dimethylphenyl substituted 
complex Λ-T30 (Scheme 47). In contrast to Λ-T29 (see Scheme 46), tert-butyl-substituted 
salicyloxazoline auxiliary ligand (S)-Aux2 was used instead of isopropyl-substituted 
salicylthiazoline auxiliary ligand (S)-Aux1 as the diastereomers formed with (S)-Aux1 had 
proven to be virtually inseparable via flash chromatography. 
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Scheme 47. Synthesis of complex Λ-T30 starting from N-Cbz-protected isoindoline-functionalized phenylbenz-
oxazole ligand 174.  
 
As the synthesis routes from Schemes 46 and 47 had proven to be reliable, it was now 
speculated whether it would be possible to replace the catalytically essential pyridylpyrazole 
ligand of Λ-T29 by the according C2-symmetric bispyrazole ligand (Figure 34). 
 
 
 
 
Figure 34. Envisioned catalyst enhancement: Replacement of the dissymmetric pyridylpyrazole ligand of Λ-T29 
by a symmetric bispyrazole ligand should result in the enhanced C2-symmetric catalyst Λ-T29-C2.  
 
 
As explained in chapter 3.1, catalyst Λ-T29 features one bifunctional cooperative catalytic 
site, which consists of one of both isoindoline moieties of Λ-T29 (Figure 34, left, highlighted 
in blue) and the aminopyrazole moiety (Figure 34, left, highlighted in green). While 
examining the catalyst's structure, it was recognized that catalysts of type Λ-T29 suffered 
from a "design flaw" as they comprise a second, basically wasted isoindoline moiety lacking 
an appropriately positioned double hydrogen-bond donor required for cooperative catalysis. 
Accordingly, it was envisioned to synthesize C2-symmetric bispyrazole-based complex 
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Λ-T29-C2, which would comprise two indistinguishable catalytic sites capable of cooperative 
enamine/hydrogen-bonding catalysis (Figure 34, right).  
At that time, no literature reports dealing with metalorganic transition metal complexes with 
bispyrazoles as bidentate ligands were available. Accordingly, to investigate whether bispyra-
zole ligands would coordinate to the Ir(III) center of bis-cyclometalated complexes in the 
anticipated manner and to study their stability and general properties, bispyrazole ligand 180 
was prepared following a straightforward synthetic route from H.-D. Stachel (Scheme 48).[118] 
It is worth noting that this synthesis route does not require any time-consuming chromato-
graphy to provide 180 analytically pure (details are provided in the experimental section).  
 
 
 
Scheme 48. Bispyrazole 180 was prepared according to a synthetic route reported by H.-D. Stachel.[118] 
 
Next, it was attempted to synthesize racemic bispyrazole probe complex rac-T31-C2 from  
Ir(III) dimer rac-T31-dimer (Scheme 49). And indeed, when rac-T31-dimer was stirred with 
bispyrazole 180 in CH2Cl2 / MeOH 4:1 in the presence of silver hexafluorophosphate at rt for 
3 h, desired bispyrazole complex rac-T31-C2 was formed and could be isolated in 92% yield. 
 
 
 
 
Scheme 49. Synthesis of racemic bispyrazole complex rac-T31-C2. 
 
Importantly, bispyrazole probe complex rac-T31-C2 proved to be stable towards silica gel 
flash chromatography and NMR experiments confirmed the anticipated formation of a 
C2-symmetric complex (Figure 35). In order to study the stability of complex rac-T31-C2 in 
solution, this NMR-tube was left standing at rt for 4.5 d (non-degassed, non-dry DMSO-d6 as 
solvent). No sign of any decomposition of rac-T31-C2 could be observed (Figure 35).  
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Figure 35. Complex rac-T31-C2 was kept in non-degassed and non-dry DMSO-d6 at rt for 4.5 d. No change in 
the 1H NMR signal pattern and accordingly no sign of a any decomposition was found.  
 
From these experiments with bispyrazole ligand 180 and bispyrazole probe complex 
rac-T31-C2 it was concluded...  
 
• ...that bispyrazole ligands of type 180 indeed coordinate the Ir(III) center and, moreover, in 
the anticipated fashion, which results in C2-symmetric complexes such as rac-T31-C2,... 
• ...that the resulting complexes should be sufficiently stable in solution and towards silica 
gel chromatography to serve as feasible scaffolds for the design of kinetically-inert stereo-
genic-at-metal catalysts,...  
• ...and that the remarkably simple and straightforward synthetic route to amine-functio-
nalized bispyrazoles from H.-D. Stachel (Scheme 48), which had rarely been used by other 
researchers at that time,[118] should pave the way to the rapid synthesis of a library of 
bispyrazole ligands to be evaluated, which would facilitate the design of bispyrazole-based 
stereogenic-at-metal catalysts. 
 
Having with complexes Λ-T29 and Λ-T30 two of the envisioned enamine/hydrogen-bonding 
catalysts in hand, their catalytic properties were investigated next (chapter 3.2.2).  
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3.2.2  Catalytic Properties of the Prepared Complexes  
With complexes Λ-T29, rac-T29 (synthesis in the experimental section), and Λ-T30 in hand, 
it was next attempted to use them as catalysts for the asymmetric Michael addition of eno-
lizable aldehydes and / or  ketones to nitroacrylates and / or nitroolefins. 
The initial results for the experiments with aldehydes / ketones 167a–f and nitroacrylates 
168a–b with Λ-T29 as intended catalyst are summarized in Table 22. Similar reaction 
conditions were applied which had proven suitable in case of the reduction of nitroalkenes 
with a Hantzsch ester with catalyst Λ-81 (see chapter 1.4, Scheme 15)[38a] and in case of the 
Friedel–Crafts alkylation of indoles with nitroacrylates with catalyst Λ-85 (see chapter 1.4, 
Scheme 16).[38b] In case of all experiments from Table 22, 4 mol% of Λ-T29 were employed 
together with 6 mol% of NaBArF24 to enhance the solubility of complex Λ-T29 in the non-
polar solvents via in situ anion exchange.[49] Prior to this, it had been verified that NaBArF24 
neither promoted any unwanted side-reactions nor catalyzed any background reaction.  
 
Table 22. Attempted conjugate additions of enolizable aldehydes / ketones 167a–f to nitroacrylates 168a–b with 
complex Λ-T29 as intended catalyst. 
 
 
 
entry R1, R2 
(167)a 
eq of 
167 
R3 
(168) 
solvent conc 
(M) 
t 
(°C) 
time 
(h) 
result 
1 hexyl, H (167b) 1.5 iPr (168a) toluene 0.7 rt 20 h / 4 d n.c. / n.c.b 
2 Ph, H (167a) 1.5 iPr (168a) toluene 0.7 rt 15 h / 2 w n.c. / n.c.c 
3 Ph, H (167a) 1.5 Me (168b) toluene 0.7 rt 17 h / 2 w n.c. / n.c.c 
4 Ph, H (167a) 1.5 Me (168b) CH2Cl2 0.7 rt 17 h / 2 w n.c. / n.c.c 
5 Ph, H (167a) 6.0 iPr (168a) toluene 0.7 45 26 h / 4 d n.c. / n.c.c 
6 H, H (167c) 2.0 iPr (168a) toluene 0.7 rt − cat. decomp.d 
7 Me, H (167d) 3.0 iPr (168a) toluene 0.7 rt 19 h / 2 w n.c. / n.c. 
8 OMe, Me (167e) 1.5 iPr (168a) toluene 0.7 rt 19 h / 2 w n.c. / n.c. 
9 cyclohexanone (167f) 1.5 iPr (168a) toluene 0.7 rt 19 h / 2 w n.c. / n.c. 
 
aAll employed aldehydes were distilled before use. bN.c. = no conversion. cConsiderable self-aldolization of the 
aldehyde observed (confirmed by NMR). dCatalyst decomposition within minutes (confirmed by TLC).  
 
 
As shown in Table 22, catalyst Λ-T29 was not able to catalyze any of the screened reactions 
between nitroacrylates 168a–b and enolizable aldehydes / ketones 168a–f. In case of phenyl-
acetaldehyde (167a), considerable amounts of self-aldolization products were observed after 
prolonged reaction times, which were not formed when Λ-T29 was absent (entries 2–5). This 
indicated that at least one of both isoindoline moieties of Λ-T29 was accessible to phenyl-
acetaldehyde (167a) but apparently Λ-T29 only catalyzed its self-aldolization instead of the 
desired conjugate addition to nitroacrylates 168a–b. 
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Next, the intended reaction between aldehyde 167a and nitroacrylate 168a was repeated with 
the reaction conditions from Table 22, entry 2 but complex Λ-T29 was replaced by 8 mol% 
isoindoline hydrochloride salt 181 and 8 mol% Et3N (Scheme 50). Et3N was added to 
deprotonate hydrochloride salt 181 in situ. 8 mol% of 181 were used to account for the two 
isoindoline moieties that are present in complex Λ-T29. 
 
 
 
Scheme 50. Attempted synthesis of 169aa from 167a and 168a with 181 and Et3N. Aldehyde 167a was freshly 
distilled before use. 
 
The experiment from Scheme 50 virtually gave the same result as the experiment from 
Table 22, entry 2: only partial self-aldolization of 167a could be observed. This indicated that 
Λ-T29 did not act as intended, i.e., not as a cooperative catalyst, at least not in case of sub-
strates 167a and 168a, and this supported that at least one of both isoindoline moieties of 
Λ-T29 catalyzed the self-aldolization of 167a. 
 
Subsequently, a similar experiment was performed with octanal (167b) and trans-β-nitro-
styrene (182) as substrates (Scheme 51). 
 
 
 
Scheme 51. Synthesis of 183b from 167b and 182 with 181 and Et3N. Aldehyde 167b was freshly distilled 
before use. 
 
In contrast, this experiment provided desired 183b smoothly within 32 h with a d.r. of 4.7:1. 
Now, it was investigated whether catalysts of type Λ-T29 would give similar results with 
trans-β-nitrostyrene (182) and, moreover, whether these complexes would be able to provide 
products 183 with reasonable levels of enantioselectivity and diastereoselectivity (Table 23). 
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Table 23. Experiments with enolizable aldehydes / ketones (167a–f) and trans-β-nitrostyrene (182) with com-
plexes rac-T29, Λ-T29, and Λ-T30. 
 
 
 
 
entry R1, R2 
(167)a 
eq of 167 catalyst cat. loading 
(mol%) 
NaBArF24 
(mol%) 
conc 
(M) 
t 
(°C) 
time 
 
result 
1 hexyl, H (167b) 1.5 rac-T29 4 6 0.7 rt 30 h full conv (183b) 
69% isolated yield 
d.r. 2.5:1b 
2 hexyl, H (167b) 1.5 rac-T29 1 1.5 0.7 rt 14 d incomplete (183b) 
25% isolated yield 
d.r. 3:1b 
3 Me, Me (167g) 1.5 rac-T29 2 3 0.7 rt 14 d incomplete (183g) 
10% isolated yield 
4 Ph, Me (167h) 1.5 rac-T29 2 3 0.7 rt 14 d incomplete (183h) 
12% isolated yield 
d.r. not determined 
5 Et, Et (167i) 1.5 rac-T29 4 6 0.7 rt 14 d no trace of conv 
6 Bu, Me (167j) 1.5 rac-T29 2 3 0.7 rt 14 d no trace of conv 
7 t-Bu, H (167k) 5.0 rac-T29 2 3 0.7 rt 14 d no trace of conv 
8 cyclohexanone 
(167f) 
5.0 rac-T29 2 3 0.7 rt 14 d incomplete (183f) 
46% isolated yield 
d.r. 3:1b 
9 hexyl, H (167b) 1.5 Λ-T29 4 6 0.7 rt 28 h full conv (183b) 
d.r. 2.9:1c 
major: 17% eed 
minor: 14% eed 
10 hexyl, H (167b) 1.5 Λ-T30 4 6 0.7 rt 28 h full conv (183b) 
d.r. 1.8:1c 
major: 19% eed 
minor: 33% eed 
 
 
aAll employed aldehydes were distilled before use. bD.r. determined from isolated product by 1H NMR analysis. 
cD.r determined from crude product mixture by 1H NMR analysis. dEnanioselectivity determined from crude 
product mixture by chiral HPLC analysis (HPLC traces for entries 9 and 10 are shown in Figure 36) 
 
And indeed, with 4 mol% of complex rac-T29 and substrates 167b and 182, product 183b 
was smoothly provided within 30 h and subsequently isolated in reasonable 69% yield with an 
isolated d.r. of 2.5:1 (Table 23, entry 1). However, when the loading of complex rac-T29 was 
reduced to 1 mol%, the reaction became exceptionally sluggish (entry 2). For sterically de-
manding α-branched aldehydes, either a sluggish reaction was observed (entries 3–4) or no 
conversion at all (entries 5–7). Also with cyclohexanone (167f) as substrate a sluggish 
reaction was observed (entry 8). It was concluded from these results that, if at all, only non-
α-branched aldehydes, such as octanal (167b), were applicable under the used conditions at 
catalyst loadings of approx. 4 mol%. 
Eventually, enantiopure catalysts Λ-T29 and Λ-T30 were employed as catalysts for the 
reaction between octanal (167b) and trans-β-nitrostyrene (182; entries 9–10). As expected, 
both reactions proceeded smoothly to completion within 28 h. NMR analysis of the crude 
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product mixtures of both experiments revealed d.r. values for 183b of 2.9:1 (Λ-T29; entry 9) 
and 1.8:1 (Λ-T30; entry 10). For Λ-T29, chiral HPLC analysis of the crude product mixture 
revealed 17% ee for the major diastereomer of 183b and 14% ee for the minor one (entry 9). 
For Λ-T30, chiral HPLC analysis revealed 19% ee for the major diastereomer of 183b and 
33% ee for the minor one (entry 10). Both chiral HPLC traces are shown in Figure 36.  
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Figure 36. Excerpts from the chiral HPLC traces of racemic 183b and enantioenriched products 183b obtained 
with catalysts Λ-T29 (Table 23, entry 9) and Λ-T30 (Table 23, entry 10). All traces are normalized relative to 
the HPLC trace of racemic 183b. Chiral HPLC conditions: Chiralpak AD-H column (5 µm, 25 cm x 4.6 mm); 
n-hexane / i-PrOH 95:5, λ = 220 nm, flow = 0.5 mL/min, t (column) = 14 °C. 
 
In addition to the overall less promising catalysis results with catalysts of type Λ-T29, another 
not yet mentioned issue eventually led to the termination of the enamine/hydrogen-bonding 
catalyst project: 
During experimentation with catalysts of type Λ-T29, problems with the stability of such 
isoindoline-functionalized Ir(III) complexes became apparent: While all their N-Cbz-pro-
tected precursors were found to be stable in solution for weeks, quick decomposition of the 
deprotected complexes within a couple of hours could be observed. This was initially noticed 
as brightly orange complex solutions gradually turned dark. The decompositions of the 
respective complexes were later on confirmed by TLC and NMR analysis. Moreover, such 
darkened complex batches displayed a reduced catalytic activity compared to freshly prepared 
complex batches. 
Although this decomposition was not studied in detail, it appears to be the result of an oxi-
dation of the deprotected isoindoline moieties. This (presumable) oxidation might be simple 
autoxidation or in part actively phototriggered by the respective Ir(III) complexes them-
selves.[73]  
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3.3 Summary and Outlook 
In summary, the stereogenic-only-at-metal enamine/hydrogen-bonding catalyst project was 
eventually terminated for the following reasons: 
 
• Because of the ascertained narrow reaction scope (see Tables 22 and 23). 
• Because of the strong indication that complexes of type Λ-T29 do not, as anticipated, act 
as cooperative bifunctional catalysts (see Tables 22 and 23 as well as Schemes 50 and 51). 
• Because of the low stereoselectivities found for product 183b which was synthesized with 
catalysts Λ-T29 and Λ-T30 (see Table 23, entries 10–11 and Figure 36).  
• And finally, because of the ascertained low stability of complexes of type Λ-T29 in 
solution, which appears to be the result of a high susceptibility to oxidation.  
 
Especially the second and the fourth point here indicate a serious "design flaw", which should 
be addressed first of all in case a resumption of this project is considered. 
 
Although the designed catalysts did not meet the expected properties, several important tasks 
could be accomplished: 
 
• A synthetic access could be established to complexes of type Λ-T29, which relies on the 
one hand on 1.) previously developed synthetic methods from the Meggers laboratory[79] 
and on the other hand on 2.) a protection-deprotection strategy with carboxybenzyl (Cbz) 
as N-protecting group and a modified version of Birkofer's decarbobenzoxylation proce-
dure for late-stage Cbz cleavage (see Schemes 46 and 47).[114] 
It is worth mentioning in this context that the N-Cbz-protected isoindoline moieties of 
complexes of type Λ-T29 could be nowadays, most likely, much more conveniently intro-
duced by means of a post-complexation cross-coupling protocol, which has recently been 
developed in the Meggers laboratory[78] and which has been utilized to synthesize some of 
complexes Λ-T1–Λ-T28 from chapter 2. (see chapter 2.3.1, Scheme 30, Route II). 
• With the synthesis of bispyrazole 180 (Scheme 48) and its use as a bidentate ligand in 
proof-of-principle complex rac-T31-C2 (Scheme 49 and Figure 35), the way was paved to 
the development of kinetically-inert C2-symmetric bispyrazole-based Ir(III) catalysts (see 
Figure 38 below).[63,64] 
 
Some of the knowledge and know-how which could be attained in the course of this project 
later on significantly contributed to other, successfully accomplished projects: 
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• Accumulated knowledge in terms of N-Cbz-protections and -deprotections in bis-cyclo-
metalated Ir(III) complexes later on significantly accelerated the synthetic implementation 
of polymer-supported Lewis acidic stereogenic-only-at-metal catalyst Λ-V1 (Figure 37).[70]  
 
 
 
Figure 37. Polymer-supported Lewis acidic stereogenic-only-at-metal catalyst Λ-V1.[70] 
 
• Due to the termination of the enamine/hydrogen-bonding catalyst project, the development 
of C2-symmetric versions of such catalysts (see Figure 34) was also discontinued. 
However, the performed preliminary experiments, i.e., experimental verification of H.-D. 
Stachel's route to amine-functionalized bispyrazoles (see Scheme 48),[118] synthesis of 
proof-of-principle bispyrazole complex rac-T31-C2 (see Scheme 49), and confirmation of 
rac-T31-C2's C2-symmetry and its ascertained stability (see Figure 35), paved the way for 
the development of C2-symmetric catalysts Λ-89 (see chapter 1.4, Scheme 17)[63] and 
Λ-(R,R)-90 (see Scheme 18).[64] 
For an illustration, Λ-89 and Λ-(R,R)-90 are shown in Figure 38 together with their first 
generation counterparts Λ-81 and Λ-85.  
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Figure 38. First generation catalysts Λ-81[38a] and Λ-85[38b] and their second generation counterparts Λ-89[63] and 
Λ-(R,R)-90.[64]  
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4.  Experimental Section 
4.1  General Experimental Remarks 
Water and / or oxygen sensitive reactions were carried out under a positive pressure of 
nitrogen gas in flame-dried glassware using standard Schlenk techniques. Solvents were 
freshly distilled under nitrogen atmosphere from calcium hydride (DMF, CH3CN, CH2Cl2), 
sodium / benzophenone (THF), or sodium (Et2O, toluene). All other dry solvents were either 
freshly prepared from HPLC or reagent grade solvents by storage over appropriate freshly 
dehydrated molecular sieves or purchased as dry solvents from commercial suppliers (Acros, 
Alfa Aesar, Sigma Aldrich, TCI) in septum sealed bottles containing molecular sieves. When 
dry solvents were not required, solvents were either used in HPLC or reagent grade quality. 
Triethylamine used for chromatographic purifications was distilled prior to use. 2-Cyano-
pyrrole used for the asymmetric synthesis of N-acyl pyrroles was purchased from Alfa Aesar 
(product number L15330; 99%) and used without further purification. Whenever the term 
'room temperature' (rt) is used, it means that the reaction or operation was performed at an 
ambient temperature of 25 °C without active thermostatization. Reactions were monitored by 
thin layer chromatography (TLC) with silica gel coated fluorescent aluminum sheets 
(type 60 F254 from Merck KGaA). TLC spots were detected by irradiation with UV light by 
fluorescence quenching (excitation at λ = 254 nm) or by fluorescence of fluorescent spots 
(excitation at λ = 366 nm). In case TLC spots were not or less UV active, TLC sheets were 
stained with CAM stain (cerium ammonium molybdate stain; Hanessian's stain). Flash 
chromatography (f. c.) was performed with standard silica gel type 60 M (0.04–0.063 mm, 
230–400 mesh) from Macherey-Nagel and chromatographic purifications were performed 
under standard atmosphere. NMR spectra were recorded on a Bruker AV 250 MHz, a Bruker 
AV II 300 MHz, a Bruker AV III 500 MHz, a Bruker AV III HD 500 MHz and a Bruker 
AV II 600 MHz spectrometer. All 13C NMR spectra were acquired using 1H decoupling during 
acquisition. 1H spectra were calibrated using the residual solvent signals and 13C spectra using 
the deuterated solvent signals as internal standards. Chemical shifts are given in ppm, multi-
plicities are given as s (singlet), d (doublet), t (triplet), q (quartet), sept (septet), m (multiplet). 
In case of multiplets (m), the ppm ranges are reported. NMR spectra were recorded at 300 K 
if not stated otherwise. Infrared spectra were recorded from 4000–400 cm–1 on a Bruker Alpha 
ATR FT-IR instrument. Mass spectra were either recorded on a Finnigan LTQ-FT (Thermo 
Fisher Scientific) mass spectrometer (APCI and ESI method) or on an AccuTOF-GCv (JEOL) 
mass spectrometer (CI, EI, and FD method). For all reported m/z values, it was ensured that 
the observed isotopic pattern was in accordance with the expected isotopic pattern. Chiral 
HPLC analysis was performed using an Agilent 1200 Series, an Agilent 1260 Infinity, and a 
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Shimadzu LC-2030C HPLC system, each equipped with a variable wavelength detector. 
Optical activity of isolated chiral products was determined using a P8000-T polarimeter 
(A. Krüss Optronic GmbH) and a 50.0 mm polarimeter cell, optical activity is given as 
specific rotation [α]D23 (c, solvent) at the sodium D line (λ = 589 nm) at 23 °C in the indicated 
solvent and the concentration c is given in the unit g/100 mL. Correct polarimeter operation 
and measurement were ensured by reproduction of the specific rotation of commercial 
L-valine.[119] CD spectra were recorded on a JASCO J-810 spectropolarimeter using a 
thermostatted CD cell (25.0 °C) with a path length of d = 1.0 mm. Catalysis reactions carried 
out at ≤ 0 °C were conducted using a coverable immersion bath (filled with i-PrOH as 
immersion liquid) equipped with a magnetic stirrer which was kept at the indicated 
temperature with a TC50E-F cryostat (Huber Kaeltemaschinenbau AG). The experimental 
setup ensured that the cooling bath temperature did not oscillate more than ±2 °C around the 
set temperature throughout the reaction. The cooling bath was permanently monitored with a 
second external thermometer to preclude incorrect temperature readings. All catalysis experi-
ments with less than 100 mg of substrate and / or product were performed using a Mettler 
Toledo XP204 high precision analytical balance and the purified product solutions in each 
case filtered through a CH2Cl2-rinsed disposable pipette equipped with a small cotton plug in 
order to remove possible traces of dust and silica gel to provide accurate yields. All other 
reactions were performed using an Ohaus Pioneer P114C analytical balance. 
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4.2  Cyclometalating Ligands of the Ir(III) Complexes from Chapter 2. 
4.2.1 Benzoxazole Ligand 186 
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Scheme 52. Synthesis of benzoxazole ligand 186. 
 
Bromobenzoxazole 170. Compound 170 was prepared following a method reported by Han 
et al.[120] A flask (250 mL) was charged with aminophenol 184[121] (4.00 g, 21.3 mmol, 
1.00 eq), benzaldehyde (2.28 mL, 22.4 mmol, 1.05 eq), and m-xylene (63 mL). The flask was 
equipped with a reflux condenser and the mixture stirred at 135 °C for 40 min. After cooling 
to rt, 4-MeO-TEMPO (200 mg, 1.07 mmol, 5.0 mol%) was added and the mixture put under 
an atmosphere of oxygen gas using a balloon. Then, the mixture was stirred at 135 °C for 10 h 
under an atmosphere of oxygen gas. After cooling to rt, TLC (hexanes/EtOAc 15:1) indicated 
full conversion and all volatiles were removed in vacuo. The dark residue was dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 
50:1 → 40:1). After drying in vacuo, desired bromobenzoxazole 170 was obtained as a color-
less solid (5.40 g, 19.7 mmol, 93%). 1H NMR (300 MHz, CDCl3): δ = 8.29–8.17 (m, 2H), 
7.90 (t, J = 1.2 Hz, 1H), 7.59–7.48 (m, 3H), 7.47–7.43 (m, 2H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 164.3, 149.9, 143.9, 132.1, 129.1 (2C), 128.2, 127.9 (2C), 126.8, 123.2, 117.5, 
111.9 ppm. 
Benzoxazole Ligand 186. A flask (25 mL) was charged with bromobenzoxazole 170 (452 mg, 
1.65 mmol, 1.00 eq), 2,4,6-trimethylphenylboronic acid (185, 406 mg, 2.48 mmol, 1.50 eq), 
and Cs2CO3 (1.08 g, 3.31 mmol, 2.01 eq). Dry toluene (5 mL) was added and the mixture 
purged with nitrogen gas for 5 min. Then, Pd(PPh3)4 (114 mg, 99 µmol, 6.0 mol%) was added, 
the flask equipped with a reflux condenser, and the mixture stirred at 100 °C for 17 h under 
nitrogen atmosphere. After cooling to rt, TLC (hexanes/Et2O 40:3) indicated full conversion 
and the mixture was filtered through a glass filter (porosity G3) and the filter cake rinsed with 
CH2Cl2. All volatiles were removed from the filtrate in vacuo, the residue dissolved in CH2Cl2, 
adsorbed on silica gel, and purified by flash chromatography (hexanes/Et2O 40:3). After 
drying in vacuo, desired benzoxazole ligand 186 was obtained as a colorless oil which crystal-
lized on standing (514 mg, 1.64 mmol, 99%). 1H NMR (300 MHz, CDCl3): δ = 8.35–8.25 (m, 
2H), 7.64 (dd, J = 8.3 Hz, J = 0.6 Hz, 1H), 7.60–7.49 (m, 4H), 7.14 (dd, J = 8.3 Hz, 
J = 1.5 Hz, 1H), 6.99 (s, 2H), 2.37 (s, 3H), 2.04 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): 
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δ = 163.5, 149.8, 142.5, 138.6, 137.9, 136.8, 136.3 (2C), 131.6, 129.0 (2C), 128.3 (2C), 127.7 
(2C), 127.3, 126.7, 120.7, 110.5, 21.1, 20.9 (2C) ppm; IR (film): v~ = 1555, 1465, 1449, 1259, 
1202, 1053, 1024, 850, 813, 776, 706, 688 cm–1; HRMS (ESI): m/z calcd for C22H19N1O1H1: 
314.1539 [M+H]+; found: 314.1536. 
 
4.2.2 Benzoxazole Ligand 189 
 
 
Scheme 53. Synthesis of benzoxazole ligand 189. 
 
 
3,6-Di-tert-butylcarbazole (188). Compound 188 was prepared following a protocol reported 
by Hou et al.[122] A flask (250 mL) was charged with ZnCl2 (5.50 g, 40.4 mmol, 3.06 eq) and 
the flask with the ZnCl2 rigorously flame-dried in vacuo (heat gun, ~450 °C). After cooling to 
rt, a flame-dried stir bar and carbazole (187; 2.20 g, 13.2 mmol, 1.00 eq) were added and the 
flask evacuated and refilled with nitrogen gas (3x). Dry nitromethane (66 mL) and tert-butyl 
chloride (4.40 mL, 40.4 mmol, 3.06 eq) were added and the mixture stirred at rt for 22 h under 
nitrogen atmosphere. The mixture was then quenched by the addition of water (100 mL), the 
organic layer separated, and the aqueous layer extracted with CH2Cl2 (4x). The organic layer 
was washed with water (2x) and brine (1x) and dried over Na2SO4. All volatiles were re-
moved in vacuo, the crude residue dissolved in CH2Cl2, adsorbed on silica gel (45 °C), and 
purified by short-column chromatography (hexanes/EtOAc 10:1 → 5:1). After solvent re-
moval and drying in vacuo, desired 3,6-di-tert-butylcarbazole (188) was obtained as pale-
beige, crystalline solid (3.73 g, 13.3 mmol, quantitative). 1H NMR (300 MHz, CDCl3): 
δ = 8.12 (dd, J = 1.9 Hz, J = 0.6 Hz, 2H), 7.49 (dd, J = 8.6 Hz, J = 2.0 Hz, 2H), 7.32 (d, 
J = 8.5 Hz, 2H), 1.49 (s, 18H) ppm (NH signal not found); HRMS (ESI): m/z calcd for 
C20H25N1H1: 280.2060 [M+H]+; found: 280.2059. 
Benzoxazole Ligand 189. Benzoxazole ligand 189 was prepared following a protocol repor-
ted by Qiu et al.[123] A flame-dried flask (250 mL) was charged with benzoxazole 170 (1.53 g, 
5.58 mmol, 1.00 eq), 3,6-di-tert-butylcarbazole (188; 1.71 g, 6.12 mmol, 1.10 eq), and 
NaOt-Bu (803 mg, 8.36 mmol, 1.50 eq). The flask was then evacuated for 40 min and refilled 
with nitrogen gas. Dry toluene (120 mL), Pd2(dba)3 (154 mg, 168 µmol, 3.0 mol%), and 
P(t-Bu)3 (38 µL, 157 µmol, 2.8 mol%) were added via syringe and the mixture stirred at 
110 °C for 24 h under nitrogen atmosphere. After cooling to rt, the mixture was quenched by 
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the addition of MeOH and the resulting mixture passed through a short silica plug, which was 
subsequently rinsed with EtOAc. All volatiles were removed in vacuo, the residue dissolved 
in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 
50:1 → 40:1). After solvent removal and drying in vacuo, desired benzoxazole ligand 189 
was obtained as a white solid foam (2.47 g, 5.23 mmol, 94%). 1H NMR (300 MHz, CDCl3): 
δ = 8.38–8.29 (m, 2H), 8.20 (d, J = 1.3 Hz, 2H), 7.99 (d, J = 1.5 Hz, 1H), 7.77 (dd, J = 8.6 Hz, 
J = 0.5 Hz, 1H), 7.62–7.52 (m, 4H), 7.49 (dd, J = 8.6 Hz, J = 2.0 Hz, 2H), 7.37 (d, J = 8.7 Hz, 
2H), 1.50 (s, 18H) ppm; 13C NMR (75 MHz, CDCl3): δ = 164.6, 149.7, 143.4, 143.1 (2C), 
139.8 (2C), 135.2, 132.1, 129.2 (2C), 128.0 (2C), 127.0, 124.5, 123.8 (2C), 123.5 (2C), 118.8, 
116.4 (2C), 111.6, 109.2 (2C), 34.9 (2C), 32.2 (6C) ppm; IR (film): v~ = 2955, 1553, 1482, 
1292, 1258, 1234, 808, 701, 662, 612 cm–1; HRMS (ESI): m/z calcd for C33H33N2O1: 
473.2587 [M+H]+; found: 473.2584. 
 
4.2.3 Benzoxazole Ligand 195 
 
Scheme 54. Synthesis of benzoxazole ligand 195. 
 
Aldehyde 192. Compound 192 was prepared following a method reported by Buchwald et 
al.[124] A flame-dried flask (100 mL) was charged with 2,6-dimethylphenylboronic acid (190; 
4.78 g, 30.3 mmol, 1.47 eq), K3PO4 (12.7 g, 59.8 mmol, 2.90 eq), and SPhos (411 mg, 
1.00 mmol, 4.9 mol%) and the flask evacuated and refilled with nitrogen gas (3x). Dry 
toluene (40 mL), Pd2dba3 (460 mg, 500 µmol, 2.4 mol%), and 2-bromobenzaldehyde (191; 
2.40 mL, 20.6 mmol, 1.00 eq) were added, the flask equipped with a reflux condenser, and the 
mixture stirred at 100 °C for 25 h under an atmosphere of nitrogen gas. After cooling to rt, 
TLC (hexanes/EtOAc 10:1) indicated full conversion and the mixture was diluted with 
CH2Cl2 and filtered through a plug of silica gel, which was rinsed with a CH2Cl2/MeOH 
mixture. All volatiles were removed from the filtrate in vacuo, the residue dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 50:1). 
After drying in vacuo, desired aldehyde 192 was obtained as a crystalline colorless solid 
(3.85 g, 18.3 mmol, 89%). 1H NMR (300 MHz, CDCl3): δ = 9.66 (d, J = 0.9 Hz, 1H), 8.05 (dd, 
J = 7.8 Hz, J = 1.0 Hz, 1H), 7.68 (ddd, J = 7.6 Hz, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.51 (dddd, 
J = 7.6 Hz, J = 7.6 Hz, J = 0.9 Hz, J = 0.9 Hz, 1H), 7.26–7.19 (m, 2H), 7.18–7.10 (m, 2H), 
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1.98 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 192.3, 145.2, 137.3, 136.4, 134.5, 133.8, 
130.6, 128.1, 127.9, 127.6 (2C), 127.4, 21.0 (2C) ppm; one overlapping C signal could not be 
located; IR (film): v~ = 1691, 1654, 1595, 1461, 1447, 1394, 1257, 1240, 1194, 829, 767, 749, 
687, 639, 566, 431 cm–1; HRMS (ESI): m/z calcd for C15H14O1Na1: 233.0937 [M+Na]+; 
found: 233.0937. 
Bromobenzoxazole 193. Compound 193 was prepared following a method reported by Han 
et al.[120] A flask (100 mL) was charged with aldehyde 192 (2.50 g, 11.9 mmol, 1.00 eq), 
aminophenol 184[121] (2.23 g, 11.9 mmol, 1.00 eq), and m-xylene (37 mL). The flask was 
equipped with a reflux condenser and the mixture stirred at 125 °C for 45 min. After cooling 
to rt, 4-MeO-TEMPO (115 mg, 617 µmol, 5.2 mol%) was added and the mixture put under an 
atmosphere of oxygen gas using a balloon. Then, the mixture was stirred at 125 °C for 21 h 
under an atmosphere of oxygen gas. After cooling to rt, TLC (hexanes/EtOAc 10:1) indicated 
full conversion and all volatiles were removed in vacuo. The dark residue was dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 50:1). 
After drying in vacuo, desired bromobenzoxazole 193 was obtained as a pale-yellow 
crystalline solid (4.32 g, 11.4 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ = 8.31 (dd, 
J = 7.7 Hz, J = 1.3 Hz, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.62 (ddd, J = 7.5 Hz, J = 7.5 Hz, 
J = 1.5 Hz, 1H), 7.53 (ddd, J = 7.6 Hz, J = 7.6 Hz, J = 1.4 Hz, 1H), 7.33 (dd, J = 8.6 Hz, 
J = 2.0 Hz, 1H), 7.30–7.24 (m, 1H), 7.18 (dd, J = 8.4 Hz, J = 6.7 Hz, 1H), 7.12–7.03 (m, 3H), 
1.95 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 164.7, 149.9, 143.4, 141.6, 140.6, 135.9, 
131.9, 131.1, 130.6, 127.9, 127.7, 127.4, 127.2 (2C), 126.1, 123.1, 117.1, 111.7, 20.7 (2C) 
ppm; one overlapping C signal could not be located; IR (film): v~ = 1570, 1534, 1455, 1440, 
1420, 1329, 1303, 1258, 1194, 1072, 1040, 1033, 910, 857, 821, 802, 767, 749, 707, 681, 589, 
400 cm–1; HRMS (ESI): m/z calcd for C21H1679Br1N1O1Na1: 400.0307 [M+Na]+; found: 
400.0302. 
Benzoxazole Ligand 195. A flask (50 mL) was charged with bromobenzoxazole 193 (2.31 g, 
6.11 mmol, 1.00 eq), 2,4,6-triisopropylphenylboronic acid (194; 2.11 g, 8.50 mmol, 1.39 eq), 
and Cs2CO3 (3.96 g, 12.2 mmol, 1.99 eq). Dry toluene (27 mL) was added and the mixture 
purged with nitrogen gas for 10 min. Then, Pd(PPh3)4 (422 mg, 365 µmol, 6.0 mol%) was 
added, the flask equipped with a reflux condenser, and the mixture stirred at 100 °C for 33 h 
under nitrogen atmosphere. After cooling to rt, TLC (hexanes/EtOAc 10:1) indicated full con-
version and the mixture was passed through a glass filter (type G3) and the filter cake rinsed 
with CH2Cl2. All volatiles were removed from the filtrate in vacuo, the residue dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 50:1). 
After drying in vacuo, desired benzoxazole ligand 195 was obtained as an off-white solid 
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(2.47 g, 4.92 mmol, 81%). 1H NMR (300 MHz, CDCl3): δ = 8.47 (dd, J = 7.6 Hz, J = 1.4 Hz, 
1H), 7.61 (ddd, J = 7.5 Hz, J = 7.5 Hz, J = 1.6 Hz, 1H), 7.54 (ddd, J = 7.6 Hz, J = 7.6 Hz, 
J = 1.6 Hz, 1H), 7.52–7.48 (m, 1H), 7.32–7.08 (m, 5H), 7.05 (s, 2H), 7.02 (dd, J = 8.3 Hz, 
J = 1.7 Hz, 1H), 2.94 (sept, J = 6.9 Hz, 1H), 2.56 (sept, J = 6.9 Hz, 2H), 2.00 (s, 6H), 1.31 (d, 
J = 7.0 Hz, 6H), 1.07 (d, J = 7.0 Hz, 6H), 1.04 (d, J = 7.0 Hz, 6H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 164.2, 149.9, 148.2, 146.9 (2C), 141.5, 141.3, 141.1, 137.4, 136.6, 136.0, 131.6, 
131.2, 130.7, 127.7, 127.3, 127.1 (2C), 126.9, 126.5, 120.9, 120.7 (2C), 109.9, 34.4, 30.4 (2C), 
24.4 (2C), 24.3 (2C), 24.2 (2C), 20.9 (2C) ppm, one overlapping signal could not be located; 
IR (film): v~ = 2959, 2868, 1458, 1322, 1258, 1200, 1029, 911, 880, 816, 768, 734 cm–1; 
HRMS (ESI): m/z calcd for C36H39N1O1H1: 502.3104 [M+H]+; found: 502.3110. 
 
4.2.4 Benzoxazole Ligand 196 
 
 
 
Scheme 55. Synthesis of benzoxazole ligand 196. 
 
Benzoxazole Ligand 196. A flask (25 mL) was charged with bromobenzoxazole 193 (1.15 g, 
3.04 mmol, 1.00 eq), 2,4,6-trimethylphenylboronic acid (185; 748 mg, 4.56 mmol, 1.50 eq), 
and Cs2CO3 (1.99 g, 6.11 mmol, 2.01 eq). Dry toluene (10 mL) was added and the mixture 
purged with nitrogen gas for 10 min. Then, Pd(PPh3)4 (211 mg, 182 µmol, 6.0 mol%) was 
added, the flask equipped with a reflux condenser, and the mixture stirred at 100 °C for 17 h 
under nitrogen atmosphere. After cooling to rt, TLC (hexanes/Et2O 40:3) indicated full 
conversion and the mixture was passed through a glass filter (type G3) and the filter cake sub-
sequently rinsed with CH2Cl2. All volatiles were removed from the filtrate in vacuo, the resi-
due dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/Et2O 40:3). After drying in vacuo, desired benzoxazole ligand 196 was obtained as 
an off-white solid (1.11 g, 2.65 mmol, 87%). 1H NMR (300 MHz, CDCl3): δ = 8.35 (dd, 
J = 7.7 Hz, J = 1.3 Hz, 1H), 7.53 (ddd, J = 7.4 Hz, J = 7.4 Hz, J = 1.6 Hz, 1H), 7.45 (ddd, 
J = 7.6 Hz, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.40–7.35 (m, 1H), 7.24–6.96 (m, 5H), 6.90 (dd, 
J = 8.3 Hz, J = 1.5 Hz, 1H), 6.86 (s, 2H), 2.25 (s, 3H), 1.91 (s, 6H), 1.89 (s, 6H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 164.0, 149.8, 141.7, 141.4, 140.9, 138.7, 137.7, 136.9, 136.3, 
136.0, 131.7, 131.2, 130.7, 128.3 (2C), 127.7, 127.3, 127.2 (2C), 126.5, 126.4, 120.6, 110.4, 
21.2, 21.0 (2C), 20.8 (2C) ppm (two overlapping C signals could not be located); IR (film):  
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v~ = 1461, 1257, 1197, 1027, 817, 766, 709, 430 cm–1; HRMS (ESI): m/z calcd for 
C30H27N1O1H1: 418.2165 [M+H]+; found: 418.2170. 
 
4.2.5 Benzothiazole Ligand 199 
 
 
Scheme 56. Synthesis of benzothiazole ligand 199. 
 
Bromobenzothiazole 198. Compound 198 was prepared following a method reported by 
Al-Mourabit et al.[125] A flame-dried flask was charged with pyridine (2.0 mL), 2,5-dibromo-
nitrobenzene (197; 2.81 g, 10.0 mmol, 1.00 eq), benzylamine (2.75 mL, 25.2 mmol, 2.52 eq), 
and elemental sulfur (481 mg, 15.0 mmol, 1.50 eq). The mixture was stirred at 100 °C under 
nitrogen atmosphere for 22 h. After cooling to rt, the resulting suspension was taken up in 
CH2Cl2/MeOH, adsorbed on silica gel (45 °C), and purified by flash chromatography 
(hexanes/EtOAc 100:1 → 75:1). After solvent removal and drying in vacuo, desired bromo-
benzothiazole 198 was obtained as a colorless crystalline solid (2.11 g, 7.27 mmol, 73%). 
1H NMR (300 MHz, CDCl3): δ = 8.22 (d, J = 1.7 Hz, 1H), 8.11–8.02 (m, 2H), 7.74 (d, 
J = 8.5 Hz, 1H), 7.55–7.43 (m, 4H) ppm; HRMS (ESI): m/z calcd for C13H979Br1N1S1: 
289.9637 [M+H]+; found: 289.9637. 
Benzothiazole Ligand 199. A flask (25 mL) was charged with bromobenzothiazole 198 
(1.00 g, 3.45 mmol, 1.00 eq), boronic acid 185 (854 mg, 5.21 mmol, 1.51 eq), cesium 
carbonate (2.26 g, 6.94 mmol, 2.01 eq), and toluene (11 mL). The mixture was purged with 
nitrogen gas for 5 min. Pd(PPh3)4 (240 mg, 208 µmol, 6.0 mol%) was then added and the 
mixture stirred at 100 °C for 22 h under nitrogen atmosphere. After cooling to rt, the mixture 
was diluted with CH2Cl2 and passed through a glass filter (porosity G4), which was sub-
sequently rinsed with CH2Cl2. All volatiles were removed from the filtrate in vacuo, the crude 
product dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(Hex/EtOAc 30:1 → 20:1). After solvent removal and drying in vacuo, desired benzothiazole 
ligand 199 was obtained as pale-yellow solid foam (1.05 g, 3.20 mmol, 93%). 1H NMR 
(300 MHz, CDCl3): δ = 8.18–8.08 (m, 2H), 7.95 (dd, J = 8.1 Hz, J = 0.6 Hz, 1H), 7.90 (dd, 
J = 1.5 Hz, J = 0.6 Hz, 1H), 7.56–7.46 (m, 3H), 7.19 (dd, J = 8.1 Hz, J = 1.5 Hz, 1H), 7.03–
6.95 (m, 2H), 2.36 (s, 3H), 2.05 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 168.8, 154.4, 
139.9, 138.4, 137.0, 136.2, 133.7, 133.4, 131.3, 129.2 (2C), 128.4 (2C), 127.8 (2C), 127.2, 
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123.9, 121.7, 21.2, 21.0 (2C) ppm (one overlapping C signal could not be located); IR (film):
v~ = 1479, 1445, 1243, 962, 887, 848, 814, 760, 690 cm–1; HRMS (ESI): m/z calcd for 
C22H20N1S1: 330.1322 [M+H]+; found: 330.1314. 
 
4.2.6 Benzoxazole Ligand 202 
 
 
Scheme 57. Synthesis of benzoxazole ligand 202. 
 
Aldehyde 200. A flame-dried flask (100 mL) was charged with boronic acid 194 (3.04 g, 
12.3 mmol, 1.30 eq) and cesium carbonate (6.15 g, 18.9 mmol, 2.00 eq). Toluene (35 mL) 
was added and the mixture purged with nitrogen gas for 5 min. Pd(PPh3)4 (690 mg, 597 µmol, 
6.3 mol%) and 2-bromobenzaldehyde (191; 1.10 mL, 9.42 mmol, 1.00 eq) were then added 
and the mixture stirred at 100 °C for 53 h under nitrogen atmosphere. After cooling to rt, the 
salts were filtered off by passing the mixture through a glass filter (porosity G3), which was 
subsequently rinsed with CH2Cl2. All volatiles were removed from the filtrate in vacuo, the 
residue taken up in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/EtOAc 40:1 → 20:1). After solvent removal and drying in vacuo, desired aldehyde 
200 was obtained as a colorless crystalline solid (2.57 g, 8.33 mmol, 88%). 1H NMR 
(300 MHz, CDCl3): δ = 9.71 (d, J = 0.8 Hz, 1H), 8.04 (ddd, J = 7.8 Hz, J = 1.5 Hz, J = 0.5 Hz, 
1H), 7.63 (td, J = 7.5 Hz, J = 1.6 Hz, 1H), 7.55–7.45 (m, 1H), 7.26 (ddd, J = 7.6 Hz, 
J = 1.3 Hz, J = 0.4 Hz, 1H), 7.11–7.06 (m, 2H), 2.96 (sept, J = 6.9 Hz, 1H), 2.44 (sept, 
J = 6.9 Hz, 2H), 1.32 (d, J = 7.0 Hz, 6H), 1.07 (d, J = 6.8 Hz, 6H), 1.03 (d, J = 6.8 Hz, 
6H) ppm; HRMS (ESI): m/z calcd for C22H28O1Na1: 331.2032 [M+Na]+; found: 331.2037. 
Bromobenzoxazole 201. Compound 201 was prepared following a method reported by Han 
et al.[120] A flask (50 mL) was charged with aldehyde 200 (1.60 g, 5.19 mmol, 1.00 eq), 
aminophenol 184[121] (982 mg, 5.22 mmol, 1.01 eq), and m-xylene (18 mL). The flask was 
equipped with a reflux condenser and the mixture stirred at 130 °C for 50 min. After cooling 
to rt, 4-MeO-TEMPO (48.4 mg, 262 µmol, 5.1 mol%) was added and the mixture put under 
an atmosphere of oxygen gas using a balloon. Then, the mixture was stirred at 130 °C for 37 h 
under an atmosphere of oxygen gas. After cooling to rt, TLC (hexanes/EtOAc 10:1) indicated 
full conversion and all volatiles were removed in vacuo. The dark residue was dissolved in 
        – 4.2 Cyclometalating Ligands of the Ir(III) Complexes from Chapter 2. – 
 
~ 136 ~ 
 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 
30:1 → 15:1). After drying in vacuo, desired bromobenzoxazole 201 was obtained as a pale-
yellow crystalline solid (2.38 g, 5.00 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ = 8.38–
8.27 (m, 1H), 7.79 (d, J = 1.7 Hz, 1H), 7.63–7.47 (m, 2H), 7.37–7.27 (m, 2H), 7.06–6.99 (m, 
2H), 6.95 (d, J = 8.5 Hz, 1H), 2.96 (sept, J = 6.9 Hz, 1H), 2.49 (sept, J = 6.8 Hz, 2H), 1.32 (d, 
J = 6.8 Hz, 6H), 1.05 (d, J = 6.8 Hz, 6H), 0.87 (d, J = 7.0 Hz, 6H) ppm; HRMS (ESI): m/z 
calcd for C28H3079Br1N1O1Na1: 498.1403 [M+Na]+; found: 498.1421. 
Benzoxazole Ligand 202. A flame-dried flask (25 mL) was charged with bromobenzoxazole 
201 (1.26 g, 2.64 mmol, 1.00 eq), boronic acid 194 (860 mg, 3.47 mmol, 1.31 eq), and cesium 
carbonate (1.72 g, 5.28 mmol, 2.00 eq). The flask was evacuated for 15 min and then 
carefully refilled with nitrogen gas. Toluene (12 mL) and Pd(PPh3)4 (186 mg, 161 µmol, 
6.1 mol%) were added and the mixture stirred at 100 °C for 32 h under nitrogen atmosphere. 
After cooling to rt, the salts were filtered off by passing the mixture through a glass filter 
(porosity G3), which was subsequently rinsed with CH2Cl2. All volatiles were removed from 
the filtrate in vacuo, the remaining residue taken up in CH2Cl2, adsorbed on silica gel, and 
purified by flash chromatography (hexanes/EtOAc 70:1). After solvent removal, desired benz-
oxazole ligand 202 was obtained as a colorless solid (1.23 g, 2.05 mmol, 78%). 1H NMR 
(300 MHz, CDCl3): δ = 8.50–8.38 (m, 1H), 7.60–7.52 (m, 2H), 7.52–7.48 (m, 1H), 7.39–7.31 
(m, 1H), 7.12–7.03 (m, 5H), 7.01 (dd, J = 8.2 Hz, J = 1.6 Hz, 1H), 3.08–2.87 (m, 2H), 2.66–
2.44 (m, 4H), 1.35 (d, J = 7.0 Hz, 6H), 1.32 (d, J = 6.8 Hz, 6H), 1.14–1.01 (m, 18H), 0.94 (d, 
J = 6.8 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 164.4, 149.7, 148.4, 148.2, 147.0 (2C), 
146.4 (2C), 141.4, 141.2, 137.3, 136.7, 135.8, 132.1, 130.9, 130.2, 127.5  (2C), 126.9, 121.0, 
120.7 (2C), 120.5 (2C), 109.5, 34.6, 34.4, 30.8 (2C), 30.4 (2C), 24.8 (2C), 24.4 (4C), 24.2 
(4C), 23.5 (2C) ppm; IR (film): v~ = 2960, 2928, 2869, 1458, 911, 879, 815, 769, 732 cm–1; 
HRMS (ESI): m/z calcd for C43H53N1O1H1: 600.4200 [M+H]+; found: 600.4213. 
 
4.2.7  Benzoxazole Ligand 206 
 
 Scheme 58. Synthesis of benzoxazole ligand 206. 
 
Aldehyde 204. A flame-dried three-neck flask equipped with a reflux condenser was charged 
with carbazole (187; 2.50 g, 15.0 mmol, 1.00 eq) and KOtBu (2.51 g, 22.4 mmol, 1.50 eq). 
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Dry DMF (60 mL) was added and the mixture stirred at 110 °C while 2-fluorobenzaldehyde 
(203; 2.40 mL, 22.8 mmol, 1.52 eq) was added dropwise over 30 min via syringe and the 
mixture then stirred at 110 °C for 21 h under nitrogen atmosphere. After cooling to rt, the 
mixture was diluted with CH2Cl2 and water, the organic layer separated, and the aqueous 
layer extracted with CH2Cl2 (5x). The combined organic layers were dried over Na2SO4, all 
volatiles removed in vacuo, the residue dissolved in CH2Cl2, adsorbed on silica gel, and 
purified by flash chromatography (hexanes/EtOAc 30:1). After solvent removal and drying in 
vacuo, desired aldehyde 204 was obtained as a pale-yellow crystalline solid (3.23 g, 
11.9 mmol, 79%). 1H NMR (300 MHz, CDCl3): δ = 9.61 (d, J = 0.9 Hz, 1H), 8.23 (dd, 
J = 7.8 Hz, J = 1.8 Hz, 1H), 8.21–8.15 (m, 2H), 7.85 (ddd, J = 7.7 Hz, J = 7.5 Hz, J = 1.7 Hz, 
1H), 7.68 (tt, J = 7.6 Hz, J = 1.0 Hz, 1H), 7.55 (dd, J = 7.9 Hz, J = 0.8 Hz, 1H), 7.48–7.39 (m, 
2H), 7.38–7.30 (m, 2H), 7.22–7.15 (m, 2H) ppm; HRMS (ESI): m/z calcd for C19H13N1O1Na1: 
294.0889 [M+Na]+; found: 294.0902. 
Bromobenzoxazole 205. Bromobenzoxazole 205 was prepared following a method reported 
by Han et al.[120] A flask (100 mL) was charged with aldehyde 204 (1.71 g, 6.30 mmol, 
1.00 eq), aminophenol 184[121] (1.18 g, 6.28 mmol, 1.00 eq), and m-xylene (21 mL). The flask 
was equipped with a reflux condenser and the mixture stirred at 130 °C for 50 min. After 
cooling to rt, 4-MeO-TEMPO (59.2 mg, 318 µmol, 5.1 mol%) was added and the mixture put 
under an atmosphere of oxygen gas using a balloon. Then, the mixture was stirred at 130 °C 
for 27 h under an atmosphere of oxygen gas. After cooling to rt, TLC (hexanes/EtOAc 10:1) 
indicated full conversion and all volatiles were removed in vacuo. The dark residue was 
dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/EtOAc 30:1 → 15:1). After drying in vacuo, desired bromobenzoxazole 205 was 
obtained as a colorless solid foam (2.35 g, 5.35 mmol, 85%). 1H NMR (300 MHz, CDCl3): 
δ = 8.38 (dd, J = 7.7 Hz, J = 1.7 Hz, 1H), 8.10–8.01 (m, 2H), 7.68 (td, J = 7.6 Hz, J = 1.7 Hz, 
1H), 7.61 (dd, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.59–7.53 (m, 2H), 7.24–7.09 (m, 4H), 7.07 (dd, 
J = 8.7 Hz, J = 1.9 Hz, 1H), 7.03–6.95 (m, 2H), 6.63 (d, J = 8.5 Hz, 1H) ppm; HRMS (ESI): 
m/z calcd for C25H1579Br1N2O1Na1: 461.0260 [M+Na]+; found: 461.0284. 
Benzoxazole Ligand 206. A flame-dried flask (25 mL) was charged with bromobenzoxazole 
205 (1.10 g, 2.50 mmol, 1.00 eq), boronic acid 194 (890 mg, 3.59 mmol, 1.43 eq), and cesium 
carbonate (1.63 g, 5.00 mmol, 2.00 eq). The flask was evacuated for 5 min and then carefully 
refilled with nitrogen gas. Toluene (12 mL) and Pd(PPh3)4 (180 mg, 156 µmol, 6.2 mol%) 
were added and the mixture stirred at 100 °C for 48 h under nitrogen atmosphere. After 
cooling to rt, the salts were filtered off by passing the mixture through a glass filter (porosity 
G3), which was subsequently rinsed with CH2Cl2. All volatiles were removed from the filtrate 
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in vacuo, the remaining residue taken up in CH2Cl2, adsorbed on silica gel, and purified by 
flash chromatography (hexanes/EtOAc 30:1 → 20:1). After solvent removal, desired benz-
oxazole ligand 206 was obtained as a colorless solid foam (1.18 g, 2.10 mmol, 84%). 
1H NMR (300 MHz, CDCl3): δ = 8.49 (dd, J = 7.7 Hz, J = 1.7 Hz, 1H), 8.13–8.02 (m, 2H), 
7.69 (td, J = 7.5 Hz, J = 1.8 Hz, 1H), 7.62 (td, J = 7.5 Hz, J = 1.6 Hz, 1H), 7.56 (dd, 
J = 7.6 Hz, J = 1.7 Hz, 1H), 7.28 (d, J = 1.1 Hz, 1H), 7.25–7.10 (m, 4H), 7.06-6.99 (m, 2H), 
6.93 (s, 2H), 6.79 (dd, J = 8.3 Hz, J = 1.5 Hz, 1H), 6.72 (d, J = 8.3 Hz, 1H), 2.83 (sept, 
J = 6.9 Hz, 1H), 2.34 (sept, J = 6.8 Hz, 2H), 1.20 (d, J = 6.8 Hz, 6H), 0.93 (d, J = 7.0 Hz, 6H), 
0.90 (d, J = 7.0 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 161.5, 149.6, 148.2, 146.8 
(2C), 142.2, 141.2, 137.4, 136.6, 136.5, 132.8, 131.9, 131.1, 129.1, 127.2, 126.8, 126.0 (2C), 
123.8, 120.9, 120.7 (2C), 120.3 (2C), 119.9 (2C), 109.8, 109.7 (2C), 34.4, 30.3 (2C), 24.3 
(2C), 24.2 (4C) ppm (two overlapping C signals could not be located); IR (film): v~ = 2960, 
2928, 1602, 1455, 1318, 1232, 911, 816, 745, 727 cm–1; HRMS (ESI): m/z calcd for 
C40H39N2O1: 563.3057 [M+H]+; found: 563.3075. 
 
4.2.8  Benzoxazole Ligand 210 
 
 
 
Scheme 59. Synthesis of benzoxazole ligand 210. 
 
Aldehyde 208. Compound 208 was prepared following a method reported by Buchwald et 
al.[124] A flame-dried flask was charged with 2,6-dimethylphenylboronic acid (190; 2.82 g, 
18.8 mmol, 1.57 eq), K3PO4 (7.74 g, 36.4 mmol, 3.03 eq), and SPhos (243 mg, 0.59 mmol, 
4.9 mol%). The flask was evacuated for 30 min and then carefully refilled with nitrogen gas. 
Dry toluene (24 mL), 3-bromobenzaldehyde (207; 1.40 mL, 12.0 mmol, 1.00 eq), and 
Pd2(dba)3 (270 mg, 0.30 mmol, 2.5 mol%) were added and the mixture stirred at 100 °C for 
35 h under nitrogen atmosphere. After cooling to rt, the mixture was diluted with CH2Cl2, 
passed through a plug of celite, and all volatiles removed from the filtrate in vacuo. The 
residue was dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/EtOAc 50:1). After solvent removal and drying in vacuo, desired aldehyde 208 was 
obtained as a colorless oil (2.14 g, 10.2 mmol, 85%). 1H NMR (300 MHz, CDCl3): δ = 10.06 
(s, 1H), 7.88 (dt, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.69 (td, J = 1.7 Hz, J = 0.4 Hz, 1H), 7.61 (t, 
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J = 7.6 Hz, 1H), 7.44 (dt, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.24–7.16 (m, 1H), 7.16–7.09 (m, 2H), 
2.02 (s, 6H) ppm; HRMS (ESI): m/z calcd for C15H15O1: 211.1117 [M+H]+; found: 211.1124. 
Bromobenzoxazole 209. Bromobenzoxazole 209 was prepared following a method reported 
by Han et al.[120] A flask was charged with aldehyde 208 (1.20 g, 5.70 mmol, 1.05 eq), amino-
phenol 184[121] (1.02 g, 5.42 mmol, 1.00 eq), and m-xylene (20 mL). The flask was equipped 
with a reflux condenser and the mixture stirred at 130 °C for 1 h. After cooling to rt, 4-MeO-
TEMPO (57.5 mg, 0.31 mmol, 5.7 mol%) was added and the mixture put under an atmos-
phere of oxygen gas using a balloon. Then, the mixture was stirred at 130 °C for 26 h under 
an atmosphere of oxygen gas. After cooling to rt, all volatiles were removed in vacuo, the 
dark residue dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromato-
graphy (hexanes/EtOAc 40:1). After drying in vacuo, desired bromobenzoxazole 209 was 
obtained as a colorless solid (1.65 g, 4.36 mmol, 76%). 1H NMR (300 MHz, CDCl3): δ = 8.23 
(dt, J = 7.9 Hz, J = 1.4 Hz, 1H), 8.06 (t, J = 1.5 Hz, 1H), 7.90 (dd, J = 1.6 Hz, J = 0.7 Hz, 1H), 
7.61 (t, J = 7.7 Hz, 1H), 7.50–7.41 (m, 2H), 7.37 (dt, J = 7.6 Hz, J = 1.4 Hz, 1H), 7.24–7.17 
(m, 1H), 7.17–7.10 (m, 2H), 2.07 (s, 6H) ppm; HRMS (ESI): m/z calcd for C21H1779Br1N1O1: 
378.0488 [M+H]+; found: 378.0499. 
Benzoxazole Ligand 210. A flame-dried flask was charged with bromobenzoxazole 209 
(1.01 g, 2.67 mmol, 1.00 eq), boronic acid 194 (860 mg, 3.47 mmol, 1.30 eq), and cesium 
carbonate (1.76 g, 5.41 mmol, 2.03 eq). The flask was evacuated for 15 min and then 
carefully refilled with nitrogen gas. Toluene (13 mL) and Pd(PPh3)4 (186 mg, 0.16 mmol, 
6.0 mol%) were added and the mixture stirred at 100 °C for 25 h under nitrogen atmosphere. 
After cooling to rt, the mixture was diluted with CH2Cl2 and passed through a plug of celite. 
The crude product was adsorbed on silica gel and purified by flash chromatography 
(hexanes/EtOAc 10:1). After solvent removal and drying in vacuo, desired benzoxazole 
ligand 210 was obtained as a colorless foam (936 mg, 1.87 mmol, 70%). 1H NMR (300 MHz, 
CDCl3): δ = 8.29 (ddd, J = 7.8 Hz, J = 1.7 Hz, J = 1.2 Hz, 1H), 8.12 (t, J = 1.4 Hz, 1H), 7.67–
7.55 (m, 3H), 7.37 (dt, J = 7.7 Hz, J = 1.3 Hz, 1H), 7.25–7.11 (m, 4H), 7.09 (s, 2H), 2.97 
(sept, J = 6.9 Hz, 1H), 2.63 (sept, J = 6.9 Hz, 2H), 2.09 (s, 6H), 1.33 (d, J = 6.8 Hz, 6H), 1.09 
(d, J = 6.8 Hz, 12H) ppm; 13C NMR (75 MHz, CDCl3): δ = 163.7, 149.8, 148.3, 146.9 (2C), 
142.3, 142.1, 140.9, 137.8, 136.6, 136.1 (2C), 132.6, 129.4, 128.5, 127.6, 127.6, 127.6 (2C), 
127.3, 126.2, 121.1, 120.8 (2C), 110.3, 34.5, 30.5 (2C), 24.4 (2C), 24.3 (2C), 24.2 (2C), 21.0 
(2C) ppm; IR (film): v~ = 2959, 1551, 1461, 1262, 1200, 1058, 878, 840, 806, 769, 738, 730, 
702 cm–1; HRMS (ESI): m/z calcd for C36H40N1O1: 502.3104 [M+H]+; found: 502.3119. 
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4.2.9 Benzoxazole Ligand 217 
 
 
 
Scheme 60. Synthesis of benzoxazole ligand 217. 
 
Compound 212. Compound 212 was synthesized following a protocol from Neeb et al.[126] A 
round-bottom flask (250 mL) was charged with 2,5-dimethoxytoluene (211; 8.70 mL, 
60.0 mmol, 1.00 eq) and acetic acid (30 mL). The resulting mixture was warmed to 40 °C and 
65% HNO3 (4.80 mL, 67.8 mmol, 1.13 eq) in acetic acid (15 mL) was added dropwise over 
15 min. After stirring at 40 °C for 1 h, the mixture was allowed to cool to rt and the formed 
yellow precipitate was filtered off, thoroughly washed with water, and dried in vacuo. Desired 
compound 212 was obtained as a bright yellow powder without the need for further puri-
fication (11.1 g, 56.4 mmol, 94%). 1H NMR (300 MHz, CDCl3): δ = 7.39 (s, 1H), 6.89 (s, 1H), 
3.92 (s, 3H), 3.83 (s, 3H), 2.27 (s, 3H) ppm; HRMS (ESI): m/z calcd for C9H12N1O4: 
198.0761 [M+H]+, found: 198.0760. 
Compound 213. Compound 213 was synthesized following a protocol from Neeb et al.[126] A 
flame-dried nitrogen-flask (250 mL) was charged with compound 212 (6.00 g, 30.4 mmol, 
1.00 eq) and dry CH2Cl2 (30 mL). The solution was cooled to −20 °C and BCl3 (1M in 
CH2Cl2; 31.0 mL, 31.0 mmol, 1.02 eq) was added dropwise over 10 min. Then, the mixture 
was allowed to warm to rt and stirred for 24 h under nitrogen atmosphere. The mixture was 
carefully quenched with aqueous sat. Na2CO3 and diluted with CH2Cl2 and H2O. The organic 
layer was separated and the aqueous layer was extracted with CH2Cl2 (3x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo. Desired product 
213 was obtained in form of yellow-orange crystals without the need for further purification 
(5.56 g, 30.4 mmol, quantitative). 1H NMR (300 MHz, CDCl3): δ = 10.45 (s, 1H), 7.38 (s, 
1H), 6.93 (s, 1H), 3.84 (s, 3H), 2.26 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 151.4, 
150.3, 140.8, 131.2, 121.1, 103.5, 56.1, 17.1 ppm. 
Compound 214. Compound 214 was synthesized following a protocol from Neeb et al.[126] A 
nitrogen-flask (500 mL) was charged with compound 213 (5.54 g, 30.2 mmol, 1.00 eq) and 
EtOAc (150 mL). The resulting solution was purged with nitrogen gas for 10 min. Then, Pd/C 
(10 wt%; 0.45 g, 0.42 mmol, 1.4 mol%) was added under nitrogen atmosphere. The nitrogen 
        – 4.2 Cyclometalating Ligands of the Ir(III) Complexes from Chapter 2. – 
 
~ 141 ~ 
 
atmosphere was replaced by a hydrogen atmosphere via H2-balloon and the mixture 
vigorously stirred for 24 h under hydrogen atmosphere. The resulting mixture was filtered 
through a plug of celite, which was subsequently thoroughly rinsed with EtOAc. All volatiles 
were removed from the filtrate and the obtained residue was dried in vacuo. Desired product 
214 was obtained in form of an off-white crystalline solid without the need for further puri-
fication (4.63 g, 30.2 mmol, quantitative). 1H NMR (300 MHz, DMSO-d6): δ = 8.28 (s, 1H), 
6.41 (s, 1H), 6.26 (s, 1H), 4.32 (s, 2H), 3.61 (s, 3H), 1.94 (s, 3H) ppm; HRMS (ESI): m/z 
calcd for C8H12N1O2: 154.0863 [M+H]+, found: 154.0863. 
Compound 215. Compound 215 was prepared following a method reported by Han et al.[120] 
A nitrogen-flask (250 mL) was charged with compound 214 (1.30 g, 8.49 mmol, 1.00 eq), 
m-xylene (28 mL), and benzaldehyde (0.91 mL, 8.95 mmol, 1.05 eq). This mixture was 
heated to 135 °C for 30 min. After cooling to rt, 4-MeO-TEMPO (86 mg, 0.46 mmol, 
5.4 mol%) was added and the flask's atmosphere replaced by an oxygen atmosphere 
(O2-balloon) and the mixture stirred at 135 °C for 24 h under oxygen atmosphere. After 
cooling to rt, all volatiles were removed in vacuo, the residue dissolved in CH2Cl2 and 
adsorbed on silica gel, and the crude product purified by flash chromatography 
(hexanes/EtOAc 20:1 → 15:1). After drying in vacuo, desired product 215 was obtained as an 
off-white crystalline solid (1.75 g, 7.31 mmol, 86%). 1H NMR (300 MHz, CDCl3): δ = 8.28–
8.13 (m, 2H), 7.54–7.46 (m, 3H), 7.33 (s, 1H), 7.19 (s, 1H), 3.89 (s, 3H), 2.34 (s, 3H) ppm; 
HRMS (ESI): m/z calcd for C15H14N1O2: 240.1019 [M+H]+, found: 240.1018. 
Compound 216. A nitrogen-flask (250 mL) was charged with compound 215 (1.74 g, 
7.27 mmol, 1.00 eq) and dried in vacuo for 1 h. Then, dry CH2Cl2 (52 mL) was added under 
nitrogen atmosphere. The resulting solution was cooled to −78 °C and BBr3 (2.50 mL, 
25.9 mmol, 3.57 eq) was added dropwise over 15 min. The mixture was then allowed to warm 
to rt and stirred for 18 h. Then, the mixture was cooled to 0 °C and carefully quenched with 
aqueous sat. Na2CO3 and the resulting mixture diluted with EtOAc and H2O. The organic 
layer was separated and the aqueous layer extracted with EtOAc (3x). The combined organic 
layers were washed with brine and dried over Na2SO4. All volatiles were removed and the 
residue dried in vacuo. Desired product 216 was obtained as an off-white crystalline solid 
without the need for further purification (1.66 g, 7.37 mmol, quantitative). 1H NMR 
(500 MHz, DMSO-d6): δ = 9.51 (s, 1H), 8.16–8.10 (m, 2H), 7.62–7.53 (m, 3H), 7.47 (s, 1H), 
7.12 (s, 1H), 2.25 (s, 3H) ppm; HRMS (ESI): m/z calcd for C14H12N1O2: 226.0863 [M+H]+, 
found: 226.0861. 
Benzoxazole Ligand 217. A nitrogen-flask (250 mL) was charged with compound 216 
(1.64 g, 7.28 mmol, 1.00 eq) and dried in vacuo for 1 h. Then, dry CH2Cl2 (96 mL) and dry 
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pyridine (5.50 mL, 68.0 mmol, 9.34 eq) were added under nitrogen atmosphere. The mixture 
was cooled to −78 °C and Tf2O (1.80 mL, 10.7 mmol, 1.47 eq) was added dropwise over 
5 min. The mixture was stirred at −78 °C for 30 min and then allowed to warm to 0 °C and 
stirred for 1 h. Next, the mixture was allowed to warm to rt and stirred for another 5 h. The 
reaction was quenched by the addition of H2O and the quenched mixture was stirred for 
10 min at rt. The organic layer was separated, the aqueous layer extracted with CH2Cl2 (4x), 
the combined organic layers dried over Na2SO4, and the solvent removed in vacuo. The 
residue was dissolved in CH2Cl2, adsorbed on silica gel, and purified by short-column 
chromatography (hexanes/EtOAc 6:1). After drying in vacuo, desired benzoxazole ligand 217 
was obtained as an off-white crystalline solid (2.55 g, 7.14 mmol, 98%). 1H NMR (300 MHz, 
acetone-d6): δ = 8.27–8.18 (m, 2H), 7.78 (s, 1H), 7.74 (s, 1H), 7.69–7.56 (m, 3H), 2.53 (s, 
3H) ppm; 13C NMR (75 MHz, acetone-d6): δ = 165.6, 150.8, 146.2, 142.1, 133.1, 130.1 (2C), 
129.5, 128.5 (2C), 127.4, 119.6 (q, JC-F = 319 Hz), 114.0, 113.5, 17.1 ppm; 19F NMR 
(282 MHz, acetone-d6): δ = –74.9 (s, 3F, CF3) ppm; IR (film): v~ = 1550, 1460, 1414, 1246, 
1206, 1133, 1054, 883, 834, 777, 697, 598, 502, 438 cm–1; HRMS (ESI): m/z calcd for 
C15H11F3N1O4S1: 358.0355 [M+H]+, found: 358.0354. 
 
4.2.10 Benzoxazole Ligand 222 
 
 
 
 
Scheme 61. Synthesis of benzoxazole ligand 222. 
 
Compound 219. A nitrogen-flask (1 L) was charged with 4-methoxy-2-nitrophenol (218; 
12.1 g, 71.8 mmol, 1.00 eq), MeOH (300 mL), and Pd/C (10 wt%; 2.43 g, 2.30 mmol, 
3.2 mol%). The resultant mixture was purged with nitrogen gas for 10 min. Then, the flask's 
nitrogen atmosphere was replaced by a hydrogen atmosphere with an H2-ballon and the mix-
ture vigorously stirred at rt under hydrogen atmosphere for 30 h. The mixture was purged 
with nitrogen gas for 15 min and then passed through a plug of celite, which was subsequently 
rinsed with EtOAc/MeOH 1:1. All volatiles were removed from the filtrate in vacuo, which 
gave desired product 219 as an off-white, almost colorless crystalline solid without the need 
for further purification (9.91 g, 71.2 mmol, 99%). 1H NMR (300 MHz, DMSO-d6): δ = 8.42 (s, 
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1H), 6.52 (d, J = 8.5 Hz, 1H), 6.20 (d, J = 3.0 Hz, 1H), 5.95 (dd, J = 8.5 Hz, J = 2.8 Hz, 1H), 
4.52 (s, 2H), 3.58 (s, 3H) ppm; HRMS (ESI): m/z calcd for C7H10N1O2 [M+H]+: 140.0706, 
found: 140.0706. 
Compound 220. A flask (250 mL) was charged with compound 219 (3.50 g, 25.1 mmol, 
1.00 eq), m-xylene (80 mL), and benzaldehyde (2.70 mL, 26.4 mmol, 1.05 eq). The resulting 
mixture was heated to 135 °C for 1 h. After cooling to rt, 4-MeO-TEMPO (252 mg, 
1.36 mmol, 5.4 mol%) was added, the atmosphere in the flask replaced with an oxygen atmos-
phere (O2-balloon), and the mixture stirred at 135 °C for 72 h under oxygen atmosphere. After 
cooling to rt, all volatiles were removed in vacuo, the residue dissolved in CH2Cl2 and ad-
sorbed on silica gel, and the crude product purified by flash chromatography (hexanes/EtOAc 
1:1). After drying in vacuo, desired product 220 was obtained as a pale-beige solid (5.01 g, 
22.2 mmol, 89%). 1H NMR (300 MHz, CDCl3): δ = 8.29–8.18 (m, 2H), 7.57–7.49 (m, 3H), 
7.47 (d, J = 8.9 Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 6.96 (dd, J = 8.9 Hz, J = 2.6 Hz, 1H), 3.88 
(s, 3H) ppm; HRMS (ESI): m/z calcd for C14H12N1O2 [M+H]+: 226.0868, found: 226.0874. 
Compound 221. A nitrogen-flask (100 mL) was charged with compound 220 (3.00 g, 
13.3 mmol, 1.00 eq) and dry CH2Cl2 (45 mL). The resulting solution was cooled to −78 °C 
and BBr3 (4.60 mL, 11.9 mmol, 3.60 eq) was added dropwise over 10 min. Then, the mixture 
was allowed to warm to rt and stirred for 24 h. Subsequently, the mixture was cooled to 0 °C 
and carefully quenched with aqueous sat. Na2CO3 and the resulting mixture diluted with 
EtOAc and H2O. The organic layer was separated, the aqueous layer extracted with EtOAc 
(3x), and the combined organic layers washed with brine and dried over Na2SO4. All volatiles 
were removed in vacuo, the residue dissolved in CH2Cl2 and adsorbed on silica gel, and the 
crude product purified by flash chromatography (hexanes/EtOAc 15:1). After solvent removal 
and drying in vacuo, desired product 221 was obtained as a beige solid (2.79 g, 13.2 mmol, 
quantitative). 1H NMR (500 MHz, DMSO-d6): δ = 9.51 (s, 1H), 8.16–8.10 (m, 2H), 7.62–7.53 
(m, 3H), 7.47 (s, 1H), 7.12 (s, 1H), 2.25 (s, 3H) ppm; HRMS (ESI): m/z calcd for 
C14H12N1O2: 226.0863 [M+H]+, found: 226.0861. 
Benzoxazole Ligand 222. A nitrogen-flask (500 mL) was charged with compound 221 
(3.00 g, 14.2 mmol, 1.00 eq), dry CH2Cl2 (175 mL), and dry pyridine (10.7 mL, 133 mmol, 
9.34 eq). The mixture was cooled to −78 °C and Tf2O (3.51 mL, 5.89 mmol, 1.47 eq) was 
added dropwise over 10 min. The mixture was stirred at −78 °C for 30 min and then allowed 
to warm to rt and stirred for 1.5 h. The reaction was quenched by the addition of H2O, the 
organic layer was separated, and the aqueous layer extracted with CH2Cl2 (4x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo. The crude product 
was dissolved in CH2Cl2, adsorbed on silica gel, and purified by short-column chromato-
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graphy (hexanes/EtOAc 3:1). After solvent removal and drying in vacuo, desired benzoxazole 
ligand 222 was obtained as an off-white solid (4.10 g, 11.9 mmol, 84%). 1H NMR (300 MHz, 
CD2Cl2): δ = 8.30–8.20 (m, 2H), 7.71 (d, J = 2.5 Hz, 1H), 7.67 (d, J = 8.9 Hz, 1H), 7.64–7.51 
(m, 3H), 7.31 (dd, J = 8.9 Hz, J = 2.6 Hz, 1H) ppm; 13C NMR (75 MHz, CD2Cl2): δ = 166.0, 
150.4, 146.8, 143.8, 132.7, 129.5 (2C), 128.3 (2C), 126.9, 119.2 (q, JC-F = 322 Hz, CF3), 
118.8, 113.7, 112.0 ppm; 19F NMR (282 MHz, CD2Cl2): δ = –73.2 ppm; IR (film): v~ = 1550, 
1423, 1228, 1197, 1133, 1096, 1055, 1020, 947, 876, 816, 788, 701, 599, 499 cm–1; HRMS 
(ESI): m/z calcd for C36H40N1O1: 502.3104 [M+H]+; found: 502.3119. 
 
4.3  Cyclometalating Ligands of the Ir(III) Complexes from Chapter 3. 
4.3.1  Benzoxazole Ligand 172 
 
 
Scheme 62. Synthesis of N-Cbz-protected benzoxazole ligand 172. 
 
Compound 224. A flask (25 mL) was charged with 4-bromoisoindoline hydrochloride (223; 
301 mg, 1.28 mmol, 1.00 eq), CH2Cl2 (13 mL), and water (4.3 mL). The mixture was cooled 
to 0 °C and Na2CO3 (814 mg, 7.68 mmol, 6.00 eq) and CbzCl (230 µL, 1.61 mmol, 1.26 eq) 
were added under stirring. The mixture was allowed to warm to rt and intensely stirred for 
4.5 h. Then, the mixture was quenched by the addition of aqueous sat. NH4Cl, the organic 
layer separated, and the aqueous layer extracted with CH2Cl2 (2x). The combined organic 
layers were dried over Na2SO4, all volatiles removed in vacuo, the residue dissolved in 
CH2Cl2 and adsorbed on silica gel, and the crude product purified by flash chromatography 
(hexanes/EtOAc 9:1 → 5:1). After solvent removal and drying in vacuo, desired compound 
224 was obtained as a white solid (422 mg, 1.27 mmol, 99%). 1H NMR (300 MHz, CDCl3): 
δ = 7.52–7.28 (m, 6H), 7.25–7.10 (m, 2H), 5.31–5.18 (m, 2H), 4.93–4.79 (m, 2H), 4.79–4.66 
(m, 2H) ppm; HRMS (ESI): m/z calcd for C16H1479Br1N1O2Na1 [M+Na]+: 354.0100, found: 
354.0096. 
Boronic acid 171. A flask (100 mL) was charged with compound 224 (3.12 g, 9.39 mmol, 
1.00 eq), bis(pinacolato)diboron (225; 3.02 g, 11.9 mmol, 1.27 eq), KOAc (1.85 g, 18.9 mmol, 
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2.01 eq), and dioxane (48 mL). This mixture was purged with nitrogen gas for 15 min. Then, 
Pd(dppf)Cl2 (345 mg, 472 µmol, 5.0 mol%) was added and the mixture stirred at 80 °C for 
17 h under nitrogen atmosphere. After cooling to rt, the mixture was diluted with CH2Cl2 and 
the salts filtered off with a glass filter (porosity G3). All volatiles were removed from the 
filtrate in vacuo, the residue dissolved in CH2Cl2 and adsorbed on silica gel, and the crude 
product purified by flash chromatography (hexanes/EtOAc 10:1 → 6:1). After solvent 
removal and drying in vacuo, desired boronic acid 171 was obtained as a colorless crystalline 
solid (3.26 g, 8.60 mmol, 92%). 1H NMR (300 MHz, CDCl3): δ = 7.80–7.65 (m, 1H), 7.53–
7.18 (m, 7H), 5.33–5.13 (m, 2H), 5.03–4.84 (m, 2H), 4.81–4.66 (m, 2H), 1.39–1.23 (m, 
12H) ppm; HRMS (ESI): m/z calcd for C22H27B1N1O4 [M+H]+: 380.2032, found: 380.2027. 
N-Cbz-Protected Benzoxazole Ligand 172. A flask was charged with bromobenzoxazole 
170 (1.61 g, 5.86 mmol, 1.00 eq), boronic acid 171 (2.55 g, 6.72 mmol, 1.15 eq), 1,2-di-
methoxyethane (60 mL), and water (15 mL). Na2CO3 (1.36 g, 12.8 mmol, 2.19 eq) was 
carefully added to this mixture under stirring. The resulting mixture was then purged with 
nitrogen gas for 15 min followed by the addition of Pd(PPh3)4 (340 mg, 294 µmol, 5.0 mol%). 
The mixture was then stirred at 80 °C for 20 h under nitrogen atmosphere. After cooling to rt, 
the mixture was diluted with EtOAc and water, the organic layer was separated, and the 
aqueous layer extracted with EtOAc (2x). The combined organic layers were washed with 
brine, dried over Na2SO4, and all volatiles removed in vacuo. The residue was dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 
6:1 → 3:1). After solvent removal and drying in vacuo, desired compound 172 was obtained 
as a pale-yellow solid (2.66 g, 5.95 mmol, quantitative). 1H NMR (300 MHz, CDCl3): 
δ = 8.38–8.21 (m, 2H), 7.80 (dd, J = 5.3 Hz, J = 1.3 Hz, 1H), 7.64 (dd, J = 8.3 Hz, J = 1.7 Hz, 
1H), 7.60–7.51 (m, 3H), 7.48–7.22 (m, 9H), 5.20 (d, J = 8.1 Hz, 2H), 4.93–4.74 (m, 4H) ppm; 
13C NMR: complex spectrum due to hindered rotation of the Cbz group (signals split up and 
broadened); IR (film): v~ = 1700, 1461, 1449, 1409, 1362, 1347, 1099, 776, 755, 705, 
689 cm−1; HRMS (ESI): m/z calcd for C29H23N2O3: 447.1703 [M+H]+; found: 447.1695. 
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4.3.2 Benzoxazole Ligand 174 
 
 
 
Scheme 63. Synthesis of N-Cbz-protected benzoxazole ligand 174. 
 
Benzoxazole Ligand 174. A flask was charged with bromobenzoxazole 193 (2.00 g, 
5.28 mmol, 1.00 eq), boronic acid 171 (2.30 g, 6.06 mmol, 1.15 eq), 1,2-dimethoxyethane 
(55 mL), and water (13 mL). Na2CO3 (1.12 g, 10.6 mmol, 2.00 eq) was added to this mixture 
under stirring. The resulting mixture was purged with nitrogen gas for 15 min followed by the 
addition of Pd(PPh3)4 (310 mg, 268 µmol, 5.1 mol%). The mixture was stirred at 80 °C for 
15 h under nitrogen atmosphere. After cooling to rt, the mixture was diluted with EtOAc and 
water, the organic layer was separated, and the aqueous layer extracted with EtOAc (2x). The 
combined organic layers were washed with brine, dried over Na2SO4, and all volatiles 
removed in vacuo. The residue was dissolved in CH2Cl2, adsorbed on silica gel, and purified 
by flash chromatography (hexanes/EtOAc 10:1 → 5:1). After solvent removal and drying in 
vacuo, desired N-Cbz-protected benzoxazole ligand 174 was obtained as a pale-yellow solid 
(2.68 g, 4.87 mmol, 92%). 1H NMR (300 MHz, CDCl3): δ = 8.46–8.34 (m, 1H), 7.69 (s, 1H), 
7.63 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.56 (td, J = 7.6 Hz, J = 1.3 Hz, 1H), 7.46–7.22 (m, 
11H), 7.19 (d, J = 7.7 Hz, 1H), 7.15–7.06 (m, 2H), 5.20 (d, J = 7.2 Hz, 2H), 4.83 (d, 
J = 7.0 Hz, 2H), 4.78 (d, J = 10.4 Hz, 2H), 1.99 (s, 3H), 1.99 (s, 3H) ppm; 13C NMR: complex 
spectrum due to hindered rotation of the Cbz group (signals split up and broadened); IR 
(film): v~ = 1697, 1459, 1446, 1415, 1362, 1347, 1201, 1184, 1089, 1029, 916, 819, 791, 757, 
744, 713, 697, 654 cm–1; HRMS (ESI): m/z calcd for C37H31N2O3: 551.2329 [M+H]+; found: 
551.2308. 
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4.4  Chiral Auxiliary Ligands (S)-Aux1 and (S)-Aux2 
4.4.1  Salicylthiazoline Auxiliary Ligand (S)-Aux1 
 
 
Scheme 64. Synthesis of salicylthiazoline auxiliary ligand (S)-Aux1. 
 
Compound 227. Compound 227 was synthesized following a protocol reported by Aitken et 
al.[127] A flask (500 mL) was charged with methanol (245 mL), Et3N (6.97 mL, 50.0 mmol, 
1.10 eq), and L-valinol[128] (225; 4.69 g, 45.5 mmol, 1.00 eq). The mixture was cooled to 0 °C 
and 2-methoxybenzoyl chloride (226; 7.45 mL, 50.0 mmol, 1.10 eq) was added dropwise via 
syringe and the mixture allowed to warm to rt. After stirring at rt for 2 h, full conversion was 
indicated by TLC analysis (hexanes/EtOAc 1:1). All volatiles were removed in vacuo and the 
residue taken up in 250 mL EtOAc/H2O (1:1). The organic layer was separated and the 
aqueous layer extracted with EtOAc (3x). The combined organic layers were washed with 
brine, dried over Na2SO4, the solvent removed in vacuo, the remaining oil dissolved in 
CH2Cl2 and adsorbed on silica gel, and the crude product purified by short-column chromato-
graphy (hexanes/EtOAc 2:1 → 1:2). After solvent removal and drying in vacuo, desired 
compound 227 was obtained as a colorless oil which slowly crystallized on standing (9.10 g, 
38.3 mmol, 84%). 1H NMR (300 MHz, CDCl3): δ = 8.19 (dd, J = 7.7 Hz, J = 1.9 Hz, 1H), 
8.14 (s, 1H), 7.46 (ddd, J = 8.3 Hz, J = 7.3 Hz, J = 1.8 Hz, 1H), 7.08 (td, J = 7.6 Hz, 
J = 0.9 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 4.05–3.93 (m, 1H), 3.98 (s, 3H), 3.80 (dd, 
J = 11.1 Hz, J = 3.5 Hz, 1H), 3.73 (dd, J = 11.0 Hz, J = 6.8 Hz, 1H), 3.33 (s, 1H), 2.11–1.94 
(m, 1H), 1.03 (d, J = 7.1 Hz, 3H), 1.00 (d, J = 7.1 Hz, 3H) ppm; HRMS (ESI): m/z calcd for 
C13H19N1O3H1: 238.1438 [M+H]+; found: 238.1443. 
Compound 228. Compound 228 was synthesized following a protocol reported by Aitken et 
al.[127] A flame-dried flask (250 mL) was charged with compound 227 (4.61 g, 19.4 mmol, 
1.00 eq), dry CH2Cl2 (115 mL), and phosphorus pentasulfide (6.80 g, 30.6 mmol, 1.57 eq). 
The flask was equipped with a reflux condenser and the resulting suspension stirred at reflux 
for 46 h under nitrogen atmosphere after which clean and full conversion was indicated by 
TLC analysis. The yellow precipitate was filtered off with a glass filter (porosity G3) and the 
resultant filter cake thoroughly rinsed with CH2Cl2. The filtrate was washed with aqueous 
2 M NaOH (2x 40 mL), water, and brine and the resulting organic layer dried over Na2SO4. 
All volatiles were removed in vacuo, the remaining oil dissolved in CH2Cl2, adsorbed on 
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silica gel, and purified by flash chromatography (hexanes/EtOAc 10:1). After solvent removal 
and drying in vacuo, desired product 228 was obtained as a pale-yellow colorless oil (4.23 g, 
18.0 mmol, 92%). 1H NMR (300 MHz, CDCl3): δ = 7.86 (dd, J = 7.7 Hz, J = 1.7 Hz, 1H), 
7.38 (ddd, J = 8.3 Hz, J = 7.4 Hz, J = 1.7 Hz, 1H), 6.99 (dd, J = 7.6 Hz, J = 1.1 Hz, 1H), 6.94 
(dd, J = 8.1 Hz, J = 0.7 Hz, 1H), 4.41–4.28 (m, 1H), 3.89 (s, 3H), 3.32 (dd, J = 10.8 Hz, 
J = 8.9 Hz, 1H), 3.05 (dd, J = 10.8 Hz, J = 9.8 Hz, 1H), 2.21–2.02 (m, 1H), 1.11 (d, 
J = 6.8 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C13H17N1O1S1H1: 
236.1104 [M+H]+; found: 236.1105. 
Auxiliary Ligand (S)-Aux1. A flame-dried flask (10 mL) was charged with compound 228 
(200 mg, 850 µmol, 1.00 eq) and dry CH2Cl2 (5 mL). The resulting solution was cooled to 
−78 °C and BBr3 (100 µL, 1.05 mmol, 1.24 eq) was added dropwise under stirring at –78 °C. 
The mixture was then allowed to warm to rt and after 3 h stirring at rt full conversion was 
indicated by TLC analysis. The mixture was quenched via dropwise addition of triethanol-
amine (2 mL, 15.1 mmol, 17.8 eq) whereupon a yellow precipitate formed. The resulting 
yellow suspension was taken up in water (50 mL) and EtOAc (50 mL), the organic layer was 
separated, and the aqueous layer extracted with EtOAc. The combined organic layers were 
dried over MgSO4 and all volatiles were removed in vacuo. The resulting yellow oil was 
dissolved in MeOH (3 mL) and triethanolamine (3 mL) and the resulting mixture was stirred 
at 50 °C for 3 h. After cooling to rt, the mixture was taken up in water (50 mL) and EtOAc 
(50 mL), the organic layer was separated, and the aqueous layer extracted with EtOAc. The 
combined organic layers were dried over MgSO4, the solvent removed in vacuo, and the 
resulting oil purified by flash chromatography (hexanes/EtOAc 20:1). After solvent removal 
and drying in vacuo, desired thiazoline auxiliary ligand (S)-Aux1 was obtained as a viscous 
yellow oil (151 mg, 682 µmol, 80%). 1H NMR (300 MHz, CDCl3): δ = 12.85 (s, 1H), 
7.44−7.31 (m, 2H), 7.05 (dd, J = 8.3 Hz, J = 0.8 Hz, 1H), 6.88 (dd, J = 7.6 Hz, J = 1.1 Hz, 
1H), 4.54–4.40 (m, 1H), 3.41 (dd, J = 11.0 Hz, J = 8.7 Hz, 1H), 3.11 (dd, J = 10.9 Hz, 
J = 9.5 Hz, 1H), 2.14–1.96 (m, 1H), 1.11 (d, J = 6.6 Hz, 3H), 1.05 (d, J = 6.8 Hz, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 171.5, 159.5, 133.3, 130.7, 119.0, 117.3, 116.3, 82.2, 34.1, 
33.3, 19.7, 19.4 ppm; IR (film): v~ = 1594, 1569, 1489, 1456, 1254, 1218, 1154, 1025, 991, 
959, 946, 814, 748, 689 cm–1; HRMS (ESI): m/z calcd for C12H15N1O1S1H: 222.0947 [M+H]+; 
found: 222.0945. 
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4.4.2  Salicyloxazoline Auxiliary Ligand (S)-Aux2 
 
 
 
 
Scheme 65. Synthesis of salicyloxazoline auxiliary ligand (S)-Aux2. 
 
 
 
Auxiliary Ligand (S)-Aux2. Auxiliary ligand (S)-Aux2 was synthesized following a proce-
dure from Iwata et al.[80b] A flame-dried flask (25 mL) was charged with zinc chloride 
(54.0 mg, 396 µmol, 5 mol%) and rigorously flame-dried in vacuo (heat gun; approx. 5 min at 
450 °C). After cooling to rt, a flame-dried stir bar, 2-hydroxybenzonitrile (229; 944 mg, 
7.92 mmol, 1.00 eq), L-tert-leucinol (230; 1.20 g, 11.6 mmol, 1.47 eq), and dry chlorobenzene 
(8.0 mL) were added and the mixture stirred at 125 °C (reflux) for 24 h under nitrogen atmos-
phere. After cooling to rt, the solvent was removed in vacuo, the residue taken up in CH2Cl2 
and water, the organic layer separated, and the aqueous layer extracted with CH2Cl2 (3x). The 
combined organic layers were dried over Na2SO4, adsorbed on silica gel (40 °C), and purified 
by flash chromatography (hexanes/EtOAc 20:1). After solvent removal and drying in vacuo, 
desired (S)-Aux2 was obtained as a colorless liquid which crystallized on standing at 4 °C 
(1.55 g, 7.08 mmol, 89%). [α]D23 = −20 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): 
δ = 12.40 (s, 1H), 7.64 (dd, J = 7.7 Hz, J = 1.7 Hz, 1H), 7.37 (ddd, J = 8.4 Hz, J = 7.3 Hz, 
J = 1.7 Hz, 1H), 7.02 (dd, J = 8.4 Hz, J = 0.8 Hz, 1H), 6.92–6.82 (m, 1H), 4.35 (dd, 
J = 10.0 Hz, J = 8.5 Hz, 1H), 4.22 (dd, J = 8.5 Hz, J = 7.7 Hz, 1H), 4.11 (dd, J = 10.0 Hz, 
J = 7.7 Hz, 1H), 0.95 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 165.2, 160.2, 133.4, 
128.1, 118.6, 116.8, 110.7, 75.0. 68.2, 33.9, 25.9 (3C) ppm; IR (film): v~ = 2958, 1641, 1619, 
1491, 1361, 1310, 1259, 1232, 1155, 1129, 1075, 1058, 959, 752, 668 cm–1; HRMS (ESI): 
m/z calcd for C13H17N1O2H: 220.1332 [M+H]+; found: 220.1330. 
 
4.5  Achiral Non-Cyclometalating Ligands from Chapter 2.  
4.5.1  Imidazoquinoline Ligand 233 
 
 
NH
N
NNH2
NO2
N
NO2
N
1.) 3 mol% Pd/C, H2
MeOH, 20 h, rt
2.) 10 mol% I2
HC(OEt)3
MeCN, rt, 13 h 233, 54% yield231 232, 89% yield
TMHI
DMSO
rt, 22 h
 
 
Scheme 66. Synthesis of imidazoquinoline ligand 233. 
 
8-Nitroquinolin-7-amine (232). Compound 232 was prepared according to a modified proce-
dure reported by Grzegożek.[129] A flame-dried flask (100 mL) was charged with 8-nitro-
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quinoline (231; 1.75 g, 10.0 mmol, 1.00 eq), 1,1,1-trimethylhydrazinium iodide[130] (3.06 g, 
15.1 mmol, 1.51 eq), and dry DMSO (60 mL). The mixture was cooled with a water bath and 
KOtBu (3.38 g, 30.1 mmol, 3.01 eq) was added to the mixture at once. After 10 min, the 
mixture was allowed to stir at rt for 22 h under an atmosphere of nitrogen gas. TLC analysis 
(hexanes/EtOAc 1:1) indicated full conversion and the mixture was quenched with aqueous 
NH4Cl and diluted with water and CH2Cl2. The organic layer was separated, the aqueous layer 
extracted with CH2Cl2 (10x), the combined organic layers washed with water (2x) and brine, 
dried over Na2SO4, and the crude product adsorbed on silica gel and purified by flash 
chromatography (CHCl3/EtOAc 1:1[131]). After solvent removal and drying in vacuo, desired 
product 232 was obtained as an orange crystalline solid (1.68 g, 8.88 mmol, 89%). 1H NMR 
(300 MHz, DMSO-d6): δ = 8.72 (dd, J = 4.4 Hz, J = 1.8 Hz, 1H), 8.17 (dd, J = 8.1 Hz, 
J = 1.7 Hz, 1H), 7.81 (d, J = 9.1 Hz, 1H), 7.29 (dd, J = 8.1 Hz, J = 4.3 Hz, 1H), 7.19 (d, 
J = 9.1 Hz, 1H), 6.85 (s, 2H) ppm. 
Imidazoquinoline Ligand 233. A flask (100 mL) was charged with 8-nitroquinolin-7-amine 
232 (700 mg, 3.70 mmol, 1.00 eq) and MeOH (24 mL). The mixture was purged with 
nitrogen gas for 5 min. Then, Pd/C (10 wt%; 113 mg, 106 µmol, 3 mol%) was added and the 
mixture put under an atmosphere of hydrogen gas using a balloon. The mixture was 
vigorously stirred for 20 h at rt under an atmosphere of hydrogen gas. Then, the mixture was 
purged with nitrogen gas for 5 min and filtered through a plug of celite, which was thoroughly 
rinsed with CH2Cl2/MeOH 1:1. The filtrate was concentrated in vacuo and the remaining 
brown solid transferred into a new flask (25 mL). The subsequent construction of the imi-
dazole ring was achieved with a modified procedure reported by Zhang et al.[132] Iodine 
(95 mg, 0.37 mmol, 10 mol%), dry MeCN (5 mL), and triethyl orthoformate (0.81 mL, 
4.92 mmol, 1.33 eq) were added, the flask sealed with a septum, and the mixture stirred at rt 
for 13 h. Then, all volatiles were removed in vacuo, the residue taken up in CH2Cl2/MeOH, 
adsorbed on silica gel, and purified by flash chromatography (EtOAc/MeOH 10:1). After 
solvent removal and drying in vacuo, desired imidazoquinoline ligand 233 was obtained as a 
brown solid (341 mg, 2.02 mmol, 54%). 1H NMR (300 MHz, CD3OD): δ = 8.86 (dd, 
J = 4.3 Hz, J = 1.5 Hz, 1H), 8.37 (dd, J = 8.3 Hz, J = 1.5 Hz, 1H), 8.31 (s, 1H) ppm; 
13C NMR (75 MHz, DMSO-d6): δ = 140.8, 132.3, 131.2, 130.6, 128.8, 122.7, 117.3, 114.5, 
111.8, 109.5 ppm; IR (film): v~ = 3038, 2811, 1530, 1361, 1243, 940, 819, 796, 765, 700, 
627 cm–1; HRMS (ESI): m/z calcd for C10H7N3H1: 170.0713 [M+H]+; found: 170.0712. 
  
      – 4.5 Achiral Non-Cyclometalating Ligands from Chapter 2. – 
 
~ 151 ~ 
 
4.5.2 Imidazoquinoline Ligand 236 
 
 
 
Scheme 67. Synthesis of imidazoquinoline ligand 236. 
 
3-Chloro-8-nitroquinoline (234). Compound 234 was prepared following a modified proce-
dure reported by Gershon et al.[133] A two-neck flask (100 mL) equipped with a reflux 
condenser was charged with acetic acid (40 mL) and 8-nitroquinoline (231; 2.52 g, 
14.5 mmol, 1.00 eq). The mixture was heated to 105 °C and NCS (3.39 g, 24.5 mmol, 
1.75 eq) was added portionwise over a period of 1 h. When the addition was complete, the 
mixture was stirred at 120 °C (reflux) for 2 h. After cooling to rt, TLC (hexanes/EtOAc 6:1) 
indicated full conversion and the mixture was poured into water (300 mL) and the mixture 
stirred vigorously for 5 min. The formed yellow precipitate was filtered off (glass filter; 
porosity G4), the precipitate dissolved in CH2Cl2, and the resulting organic layer dried over 
Na2SO4. The crude product was dissolved in CH2Cl2, adsorbed on silica gel, and purified by 
flash chromatography (hexanes/EtOAc 10:1 → 8:1). After drying in vacuo, desired product 
234 was obtained as a yellow crystalline solid (2.05 g, 9.83 mmol, 68%). 1H NMR (300 MHz, 
CDCl3): δ = 8.94 (d, J = 2.3 Hz, 1H), 8.24 (d, J = 2.3 Hz, 1H), 8.10–7.90 (m, 2H), 7.66 (dd, 
J = 7.7 Hz, J = 7.7 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δ = 152.0, 148.4, 137.6, 134.1, 
131.2, 130.7, 129.3, 126.8, 124.0 ppm; IR (film): v~ = 3064, 1528, 1490, 1356, 1189, 1092, 
910, 763, 653 cm–1; HRMS (ESI): m/z calcd for C9H5Cl1N2O2Na: 230.9932 [M+Na]+; found: 
230.9933. 
3-Chloro-8-nitroquinolin-7-amine (235). Compound 235 was prepared according to a modi-
fied procedure reported by Grzegożek.[129] A flame-dried flask (250 mL) was charged with 
3-chloro-8-nitroquinoline (234; 1.50 g, 7.19 mmol, 1.00 eq), 1,1,1-trimethylhydrazinium 
iodide[130] (2.25 g, 11.1 mmol, 1.55 eq), and dry DMSO (40 mL). The mixture was cooled 
with a water bath and KOtBu (2.46 g, 21.9 mmol, 3.05 eq) was added to the mixture at once. 
After 10 min, the mixture was allowed to stir at rt for 20 h under an atmosphere of nitrogen 
gas. TLC (hexanes/EtOAc 1:1) indicated full conversion and the mixture was quenched with 
aqueous sat. NH4Cl and diluted with water (500 mL) and CH2Cl2 (250 mL). The organic layer 
was separated and the aqueous layer extracted with CH2Cl2 (6x). The combined organic layers 
were washed with water (2x) and brine, dried over Na2SO4, adsorbed on silica gel, and 
purified by flash chromatography (CHCl3/EtOAc 6:1 → 3:1[131]). After drying in vacuo, 
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desired product 235 was obtained as an orange crystalline solid (1.25 g, 5.59 mmol, 78%). 
1H NMR (300 MHz, DMSO-d6): δ = 8.71 (d, J = 2.5 Hz, 1H), 8.36 (d, J = 2.5 Hz, 1H), 7.80 
(d, J = 9.3 Hz, 1H), 7.25 (d, J = 9.1 Hz, 1H), 7.01 (s, 2H) ppm; 13C NMR (75 MHz, 
DMSO-d6): δ = 149.5, 143.6, 140.5, 134.2, 130.9, 127.7, 124.5, 121.5, 120.3 ppm; IR (film):
v~ = 3416, 3302, 3176, 1639, 1548, 1503, 1471, 1272, 1107, 900, 576, 526 cm–1; HRMS 
(ESI): m/z calcd for C9H6Cl1N3O2H: 224.0221 [M+H]+; found: 224.0223. 
Imidazoquinoline Ligand 236. A flask (25 mL) was charged with compound 235 (461 mg, 
2.06 mmol, 1.00 eq), SnCl2·2H2O (1.48 g, 6.56 mmol, 3.18 eq), and EtOH (14 mL) and the 
mixture was stirred at reflux for 8.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (3x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo, which yielded a 
brown crystalline solid which was dried in vacuo and transferred into a new flask (25 mL). 
The subsequent construction of the imidazole ring was achieved with a modified procedure 
reported by Zhang et al.[132] Iodine (52 mg, 205 µmol, 10 mol%), dry MeCN (6.3 mL), and 
triethyl orthoformate (650 µL, 3.91 mmol, 1.90 eq) were added, the flask sealed with a 
septum and the mixture stirred at rt for 22 h. All volatiles were removed in vacuo, the dark 
residue taken up in CH2Cl2/MeOH, adsorbed on silica gel, and purified by flash 
chromatography (EtOAc/MeOH 30:1). After solvent removal and drying in vacuo, desired 
imidazoquinoline ligand 236 was obtained as a brown solid (357 mg, 1.76 mmol, 86%). 
1H NMR (300 MHz, DMSO-d6): δ = 13.62 (s, 1H), 8.91 (d, J = 2.5 Hz, 1H), 8.64 (d, 
J = 2.5 Hz, 1H), 8.39 (s, 1H), 7.94 (d, J = 8.7 Hz, 1H), 7.71 (d, J = 8.9 Hz, 1H) ppm; 
13C NMR (75 MHz, DMSO-d6): δ = 147.4, 141.5, 140.6, 136.7, 134.8, 130.8, 125.9, 125.1, 
121.1, 120.1 ppm; IR (film): v~ = 2576, 1718, 1479, 1359, 1308, 1270, 1180, 1103, 948, 919, 
885, 854, 796, 755, 697, 628, 514 cm–1; HRMS (ESI): m/z calcd for C10H6N3Cl1Na: 226.0142 
[M+Na]+; found: 226.0149. 
 
4.5.3 Imidazoquinoline Ligand 238 
 
 
 
Scheme 68. Synthesis of imidazoquinoline ligand 238. 
 
Quinoline-7,8-diamine (237). A flask (100 mL) was charged with 8-nitroquinolin-7-amine 
(232; 700 mg, 3.70 mmol, 1.00 eq), Pd/C (10 wt%; 112 mg, 105 µmol, 3 mol%), and MeOH 
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(24 mL). The resulting mixture was purged with nitrogen gas for 10 min. Then, the mixture 
was placed under an atmosphere of hydrogen gas (H2-ballon) and vigorously stirred for 20 h. 
The resulting mixture was purged with nitrogen gas for 10 min, diluted with CH2Cl2/MeOH, 
and passed through a short plug of celite, which was subsequently rinsed with CH2Cl2/MeOH. 
All volatiles were removed from the filtrate and the residue dried in vacuo. Desired quinoline-
7,8-diamine (237) was obtained as a dark-brown solid without the need for further purifi-
cation (588 mg, 3.69 mmol, quantitative). 1H NMR (300 MHz, CD3OD): δ = 8.62 (dd, 
J = 4.3 Hz, J = 1.5 Hz, 1H), 8.02 (dd, J = 8.3 Hz, J = 1.5 Hz, 1H), 7.21–7.13 (m, 2H), 7.11 (d, 
J = 8.7 Hz, 1H) ppm (the signals belonging to the NH2 groups could not be found due to rapid 
exchange); HRMS (ESI): m/z calcd for C9H9N3H: 160.0869 [M+H]+; found: 160.0873. 
Imidazoquinoline Ligand 238. Compound 238 was synthesized following a method reported 
by Zhang et al.[132] A flask was charged with quinoline-7,8-diamine (237; 170 mg, 1.07 mmol, 
1.00 eq), iodine (27.4 mg, 108 µmol, 10 mol%), triethyl orthoacetate (270 µL, 1.47 mmol, 
1.38 eq), and dry MeCN (1.7 mL). The mixture was stirred at rt for 15 h under an atmosphere 
of nitrogen gas. The resulting dark slurry was then diluted with CH2Cl2/MeOH 1:1, adsorbed 
on silica gel, and purified by flash chromatography (EtOAc/MeOH 20:1 → 15:1). After 
solvent removal and drying in vacuo, desired imidazoquinoline ligand 238 was obtained as a 
light-brown nacre-like crystalline solid (165 mg, 901 µmol, 84%). 1H NMR (300 MHz, 
CD3OD): δ = 8.81 (dd, J = 4.4 Hz, J = 1.6 Hz, 1H), 8.30 (dd, J = 8.2 Hz, J = 1.6 Hz, 1H), 7.60 
(d, J = 8.7 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.42 (dd, J = 8.2 Hz, J = 4.4 Hz), 2.66 (s, 
3H) ppm; 13C NMR (75 MHz, CD3OD): δ = 152.4, 150.3, 141.9, 139.5, 138.2, 132.3, 126.5, 
123.4, 121.0, 118.9, 14.5 ppm; IR (film): v~ = 1608, 1541, 1508, 1428, 1396, 1362, 1328, 
1304, 1255, 1019, 825, 799, 767, 707, 650, 532, 500, 412 cm–1; HRMS (ESI): m/z calcd for 
C11H9N3H1: 184.0869 [M+H]+; found: 184.0873. 
 
4.5.4 Imidazoquinoline Ligand 241 
 
 
 
Scheme 69. Synthesis of imidazoquinoline ligand 241. 
 
3,5-Dichloro-8-nitroquinoline (239). A flask (50 mL) was charged with 3-chloro-8-nitro-
quinoline (234; 283 mg, 1.36 mmol, 1.00 eq) and glacial acetic acid (5 mL). The mixture was 
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heated to 110 °C, NCS (210 mg, 1.57 mmol, 1.16 eq) was added at once, and the mixture 
stirred at 110 °C for 15 min. As TLC indicated incomplete conversion, additional NCS 
(113 mg, 0.85 mmol, 0.62 eq) was added and the mixture stirred at 110 °C for 6.5 h. As TLC 
now indicated full conversion, the mixture was allowed to cool to rt, all volatiles were 
removed in vacuo, and acetic acid traces removed as an azeotrope with toluene (4x). The 
crude residue was dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash 
chromatography (hexanes/EtOAc 50:1 → 40:1). After solvent removal and drying in vacuo, 
desired dichlorinated compound 239 was obtained as a colorless crystalline solid (108 mg, 
444 µmol, 33%). 1H NMR (300 MHz, CDCl3): δ = 9.00 (d, J = 2.3 Hz, 1H), 8.63 (d, 
J = 2.3 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H) ppm; HRMS (ESI): m/z 
calcd for C9H4Cl2N2O2H: 242.9723 [M+H]+; found: 242.9723. 
Compound 240. Compound 240 was prepared according to a modified procedure reported by 
Grzegożek.[129] A flask (10 mL) was charged with compound 239 (107 mg, 440 µmol, 
1.00 eq) and dried in vacuo for 1 h. Then, 1,1,1-trimethylhydrazinium iodide[130] (130 mg, 
643 µmol, 1.46 eq), dry DMSO (3.2 mL), and KOtBu (143 mg, 1.27 mmol, 2.89 eq) were 
added and the mixture stirred at rt for 20 h under nitrogen atmosphere. Then, the mixture was 
diluted with CH2Cl2 and quenched by the addition of aqueous NH4Cl. The organic layer was 
separated and the aqueous layer extracted with CH2Cl2 (10x). The combined organic layers 
were washed with brine and dried over Na2SO4. All volatiles were removed in vacuo, the resi-
due dissolved in CH2Cl2/MeOH, adsorbed on silica gel, and purified by flash chromatography 
(CHCl3/EtOAc 3:1[131]). After solvent removal and drying in vacuo, desired compound 240 
was obtained as an orange-brown solid (76.4 mg, 296 µmol, 67%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.82 (d, J = 2.5 Hz, 1H), 8.37 (dd, J = 2.3 Hz, 1H), 7.46 (s, 1H), 7.15 (s, 
2H) ppm. 
Imidazoquinoline Ligand 241. A flask (10 mL) was charged with compound 240 (76.0 mg, 
294 µmol, 1.00 eq), SnCl2·2H2O (204 mg, 904 µmol, 3.07 eq), and EtOH (1.6 mL) and the 
mixture was stirred at reflux for 2.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (3x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo, which yielded a 
yellow-brown solid which was dried in vacuo and transferred into a new flask (10 mL). The 
subsequent construction of the imidazole ring was achieved with a modified procedure repor-
ted by Zhang et al.[132] Iodine (8.1 mg, 31.9 µmol, 11 mol%), dry MeCN (0.8 mL), and tri-
ethyl orthoformate (75 µL, 454 µmol, 1.55 eq) were added, the flask sealed with a septum and 
the mixture stirred at rt for 12 h. Then, the dark slurry was diluted with CH2Cl2/MeOH and 
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the crude product adsorbed on silica gel and purified by flash chromatography (EtOAc/MeOH 
100:1). After solvent removal and drying in vacuo, desired dichlorinated imidazoquinoline 
ligand 241 was obtained as an orange-grey solid (18.4 mg, 77.3 µmol, 26%). 1H NMR 
(300 MHz, DMSO-d6): δ = 13.81 (s, 1H), 9.03 (d, J = 2.3 Hz, 1H), 8.66 (d, J = 2.3 Hz, 1H), 
8.43 (s, 1H), 8.18 (s, 1H) ppm; IR (film): v~ = 3344, 1610, 1540, 1495, 1451, 1423, 1340, 
1283, 1259, 1208, 1022, 959, 809, 781 cm–1; HRMS (ESI): m/z calcd for C10H5Cl2N3H: 
237.9933 [M+H]+; found: 237.9935. 
 
4.5.5 Imidazoquinoline Ligand 245 
 
 
 
 
Scheme 70. Synthesis of imidazoquinoline ligand 245. 
 
8-Nitro-5-(trifluoromethyl)quinoline (243). A flask (10 mL) was charged with glycerin 
(1.58 g, 21.5 mmol, 4.24 eq) and the glycerin heated to 160 °C for 1 h 15 min. The resulting 
mixture was allowed to cool to 110 °C and 2-nitro-5-(trifluoromethyl)aniline (242; 1.05 g, 
5.07 mmol, 1.00 eq) and NaI (25.1 mg, 167 µmol, 3.3 mol%) were added and the mixture 
heated to 150 °C. Concentrated H2SO4 (1.11 mL, 20.8 mmol, 4.11 eq) was carefully added 
dropwise at 150 °C under stirring and the mixture was stirred for 1 h at 150 °C. After cooling 
to rt, the resulting dark slurry was diluted with large amounts of water and CH2Cl2, the 
organic layer separated, the aqueous layer extracted with CH2Cl2 (5x), and the combined 
organic layers dried over Na2SO4. All volatiles were removed in vacuo, the residue dissolved 
in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 6:1). 
After solvent removal and drying in vacuo, desired quinoline 243 was obtained as an orange 
crystalline solid (511 mg, 2.11 mmol, 42%). 1H NMR (300 MHz, CDCl3): δ = 9.13 (dd, 
J = 4.3 Hz, J = 1.5 Hz, 1H), 8.58 (dquin, J = 8.8 Hz, J = 1.8 Hz, 1H), 8.10–7.93 (m, 2H), 7.71 
(dd, J = 8.9 Hz, J = 4.2 Hz, 1H) ppm; HRMS (ESI): m/z calcd for C10H5F3N2O2H: 243.0376 
[M+H]+; found: 243.0375. 
Compound 244. Compound 244 was prepared according to a modified procedure reported by 
Grzegożek.[129] A flame-dried flask (10 mL) was charged with quinoline 243 (292 mg, 
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1.21 mmol, 1.00 eq), 1,1,1-trimethylhydrazinium iodide[130] (293 mg, 1.45 mmol, 1.20 eq), 
dry DMSO (7.5 mL), and KOtBu (406 mg, 3.62 mmol, 2.99 eq) and the mixture stirred at rt 
for 2.5 h under nitrogen atmosphere. The mixture was diluted with CH2Cl2 and quenched by 
the addition of aqueous NH4Cl, the organic layer separated, and the aqueous layer extracted 
with CH2Cl2 (8x). The combined organic layers were washed with brine, dried over Na2SO4, 
all volatiles removed in vacuo, the residue dissolved in CH2Cl2/MeOH and adsorbed on silica 
gel, and the crude product purified by flash chromatography (CHCl3/EtOAc 10:1[131]). After 
solvent removal and drying in vacuo, desired compound 244 was obtained as an orange-
brown crystalline solid (192 mg, 747 µmol, 62%). 1H NMR (300 MHz, DMSO-d6): δ = 8.84 
(dd, J = 4.3 Hz, J = 1.3 Hz, 1H), 8.25 (dt, J = 8.5 Hz, J = 1.8 Hz, 1H), 7.77 (s, 1H), 7.45 (dd, 
J = 8.5 Hz, J = 4.3 Hz, 1H), 7.02 (s, 2H) ppm; HRMS (ESI): m/z calcd for C10H6F3N3O2H: 
258.0485 [M+H]+; found: 258.0485. 
Imidazoquinoline Ligand 245. A flask (25 mL) was charged with compound 244 (295 mg, 
1.15 mmol, 1.00 eq), SnCl2·2H2O (776 mg, 3.44 mmol, 3.00 eq), and EtOH (6.0 mL) and the 
mixture was stirred at reflux for 2.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (4x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo, which yielded a 
yellow-brown solid which was dried in vacuo and transferred into a new flask (10 mL). The 
subsequent construction of the imidazole ring was achieved with a modified procedure 
reported by Zhang et al.[132] Iodine (29 mg, 114 µmol, 10 mol%), dry MeCN (2.5 mL), and 
triethyl orthoformate (290 µL, 1.74 µmol, 1.52 eq) were added, the flask sealed with a septum 
and the mixture stirred at rt for 12 h. Then, the dark slurry was diluted with CH2Cl2/MeOH 
and the crude product adsorbed on silica gel and purified by flash chromatography 
(EtOAc/MeOH 60:1). After solvent removal and drying in vacuo, desired trifluoromethylated 
ligand 245 was obtained as a brown crystalline solid (221 mg, 933 µmol, 81%). 1H NMR 
(300 MHz, DMSO-d6): δ = 14.07 (s, 1H), 9.07 (dd, J = 4.2 Hz, J = 1.4 Hz, 1H), 8.64–8.54 (m, 
2H), 8.53 (s, 1H), 8.40 (s, 1H), 7.74 (dd, J = 8.7 Hz, J = 4.3 Hz, 1H) ppm; IR (film): v~ = 1342, 
1279, 1222, 1139, 1103, 944, 879, 786, 698, 630 cm–1; HRMS (ESI): m/z calcd for 
C11H6F3N3Na: 260.0406 [M+Na]+; found: 260.0407. 
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4.5.6 Imidazoquinoline Ligand 251 
 
 
Scheme 71. Synthesis of imidazoquinoline ligand 251. 
 
5-Bromo-8-nitroquinoline (247). A flask (25 mL) was charged with 5-bromoquinoline (246; 
2.50 g, 12.0 mmol, 1.00 eq) and concentrated H2SO4 (10 mL) was added at 0 °C. Then, KNO3 
(1.98 g, 19.6 mmol, 1.63 eq) was added portionwise over 15 min. The resulting mixture was 
then allowed to warm to rt and stirred for 2 h. Then, the resulting mixture was poured into ice-
water, CH2Cl2 was added, the organic layer separated, and the aqueous layer extracted with 
CH2Cl2 (6x). The combined organic layers were washed with brine, dried over Na2SO4, and 
the solvent removed in vacuo. After drying in vacuo, desired compound 247 was obtained as a 
colorless solid without the need for further purification (3.01 g, 11.9 mmol, 99%). 1H NMR 
(300 MHz, CDCl3): δ = 9.09 (dd, J = 4.2 Hz, J = 1.6 Hz, 1H), 8.63 (dd, J = 8.7 Hz, 
J = 1.7 Hz, 1H), 7.98–7.85 (m, 2H), 7.67 (dd, J = 8.6 Hz, J = 4.2 Hz, 1H) ppm; HRMS (ESI): 
m/z calcd for C9H5Br1N2O2Na: 274.9427 [M+Na]+; found: 274.9429. 
Compound 249. A flame-dried flask (10 mL) was charged with compound 247 (300 mg, 
1.19 mmol, 1.00 eq), 3,5-bis(trifluoromethyl)phenylboronic acid (248; 465 mg, 1.80 mmol, 
1.52 eq), and Na2CO3 (369 mg, 3.48 mmol, 2.94 eq). 1,2-Dimethoxyethane (4.2 mL) and 
water (0.42 mL) were added and the mixture purged with nitrogen gas for 10 min. The 
mixture was stirred at 90 °C under nitrogen atmosphere for 40 h. TLC (hexanes/EtOAc 3:1) 
indicated that the reaction was incomplete. The mixture was diluted with water and EtOAc, 
the organic layer separated, the aqueous layer extracted with EtOAc (3x), the combined or-
ganic layers dried over Na2SO4, and the solvent removed in vacuo. As crude 1H NMR 
indicated a ratio 249/247 of about 2:1 and as product 249 and substrate 247 proved to be 
hardly resolvable by standard flash chromatography, the obtained crude product was put in a 
new flask (10 mL) and boronic acid 248 (163 mg, 634 µmol, 0.53 eq), Cs2CO3 (260 mg, 
798 µmol, 0.67 eq), and toluene (2.2 mL) were added and the resulting mixture degassed (4x; 
      – 4.5 Achiral Non-Cyclometalating Ligands from Chapter 2. – 
 
~ 158 ~ 
 
freeze-pump-thaw technique). Pd(PPh3)4 (29 mg, 25.1 µmol, 2.1 mol%) was added and the 
resulting mixture stirred at 100 °C for 31 h under nitrogen atmosphere. As TLC indicated full 
conversion, the mixture was allowed to cool to rt, diluted with CH2Cl2 and the salts removed 
by filtration through a glass filter (porosity G4). All volatiles were removed from the filtrate 
in vacuo, the residue dissolved in CH2Cl2, and the crude product purified by flash 
chromatography (hexanes/EtOAc 10:1). After solvent removal and drying in vacuo, desired 
compound 249 was obtained as an off-white solid (345 mg, 893 µmol, 75%). 1H NMR 
(300 MHz, CDCl3): δ = 9.12 (dd, J = 4.2 Hz, J = 1.5 Hz, 1H), 8.11 (dd, J = 8.6 Hz, 
J = 1.6 Hz, 1H), 8.10 (d, J = 7.6 Hz, 1H), 8.06 (s, 1H), 7.93 (s, 2H), 7.63 (d, J = 7.7 Hz, 1H), 
7.61 (dd, J = 8.7 Hz, J = 4.2 Hz, 1H) ppm; HRMS (ESI): m/z calcd for C17H8F6N2O2H: 
387.0563 [M+H]+; found: 387.0562. 
Compound 250. Compound 250 was prepared according to a modified procedure reported by 
Grzegożek.[129] A flame-dried flask (25 mL) was charged with compound 249 (340 mg, 
880 µmol, 1.00 eq). Then, 1,1,1-trimethylhydrazinium iodide[130] (217 mg, 1.07 mmol, 
1.22 eq), dry DMSO (5.5 mL), and KOtBu (302 mg, 2.69 mmol, 3.06 eq) were added and the 
mixture stirred at rt for 2.5 h under nitrogen atmosphere. The mixture was diluted with 
CH2Cl2 and quenched by the addition of aqueous NH4Cl. The organic layer was separated, the 
aqueous layer extracted with CH2Cl2 (8x), and the combined organic layers washed with brine 
and dried over Na2SO4. All volatiles were removed in vacuo, the residue dissolved in 
CH2Cl2/MeOH, adsorbed on silica gel, and purified by flash chromatography (CHCl3/EtOAc 
10:1[131]). After solvent removal and drying in vacuo, desired compound 250 was obtained as 
a yellow-green crystalline solid (255 mg, 636 µmol, 72%). 1H NMR (300 MHz, DMSO-d6): 
δ = 8.77 (dd, J = 4.3 Hz, J = 1.7 Hz, 1H), 8.39–8.15 (m, 3H), 7.83 (dd, J = 8.3 Hz, J = 1.7 Hz, 
1H), 7.31 (dd, J = 8.5 Hz, J = 4.3 Hz, 1H), 7.24 (s, 1H), 6.88 (s, 2H) ppm; HRMS (ESI): m/z 
calcd for C17H9F6N3O2H: 402.0672 [M+H]+; found: 402.0672. 
Imidazoquinoline Ligand 251. A flask (25 mL) was charged with compound 250 (252 mg, 
628 µmol, 1.00 eq), SnCl2·2H2O (430 mg, 1.91 mmol, 3.03 eq), and EtOH (4.0 mL) and the 
mixture was stirred at reflux for 2.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (4x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo, which yielded an 
ocher-green solid which was dried in vacuo and transferred into a new flask (10 mL). The 
subsequent construction of the imidazole ring was achieved with a modified procedure 
reported by Zhang et al.[132] Iodine (18 mg, 70.9 µmol, 11 mol%), dry MeCN (1.5 mL), and 
triethyl orthoformate (160 µL, 962 µmol, 1.53 eq) were added, the flask sealed with a septum, 
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and the mixture stirred at rt for 12 h. Then, the dark slurry was diluted with CH2Cl2/MeOH 
and the crude product adsorbed on silica gel and purified by flash chromatography 
(EtOAc/MeOH 60:1). After solvent removal and drying in vacuo, desired imidazoquinoline 
ligand 251 was obtained as a pale-ocher solid (186 mg, 487 µmol, 77%). 1H NMR (300 MHz, 
DMSO-d6): δ = 13.80 (s, 1H), 8.98 (dd, J = 4.3 Hz, J = 1.5 Hz, 1H), 8.43 (s, 1H), 8.22 (s, 3H), 
8.13 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 7.98 (s, 1H), 7.56 (dd, J = 8.6 Hz, J = 4.2 Hz, 1H) ppm; 
IR (film): v~ = 1382, 1351, 1287, 1165, 1116, 924, 894, 846, 788, 716, 683, 629 cm–1; HRMS 
(ESI): m/z calcd for C18H9F6N3H: 382.0773 [M+H]+; found: 382.0773. 
 
4.5.7 Imidazoquinoline Ligand 252 
 
 
 
Scheme 72. Synthesis of imidazoquinoline ligand 252. 
 
Imidazoquinoline Ligand 252. A flask was charged with 3-chloro-8-nitroquinolin-7-amine 
(235; 1.00 g, 4.47 mmol, 1.00 eq), SnCl2·2H2O (3.07 g, 13.6 mmol, 3.04 eq), and EtOH 
(23 mL) and the mixture was stirred at reflux for 9 h. After cooling to rt, the mixture was 
diluted with water and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with 
aqueous 2 M NaOH. The organic layer was separated and the aqueous layer extracted with 
EtOAc (3x). The combined organic layers were dried over Na2SO4 and the solvent removed in 
vacuo, which yielded the according intermediate diamine as a brown-yellow solid (866 mg, 
4.47 mmol, quantitative). 80.3 mg (415 µmol, set as 1.00 eq) of this intermediate product 
were then transferred into a new flask (10 mL). The subsequent construction of the imidazole 
ring was achieved with a modified procedure reported by Zhang et al.[132] Iodine (10.4 mg, 
41.0 µmol, 10 mol%), dry MeCN (0.67 mL), and triethyl orthoacetate (105 µL, 573 µmol, 
1.38 eq) were added, the flask sealed with a septum, and the mixture stirred at rt for 22 h. The 
dark slurry was diluted with CH2Cl2/MeOH and the crude product adsorbed on silica gel and 
purified by flash chromatography (EtOAc/MeOH 30:1 → 20:1). After solvent removal and 
drying in vacuo, desired imidazoquinoline ligand 252 was obtained as a brown-ocher solid 
(68.8 mg, 316 µmol, 76%). 1H NMR (300 MHz, DMSO-d6): δ = 13.43 (s, 1H), 8.87 (d, 
J = 2.5 Hz, 1H), 8.61 (d, J = 1.9 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.65 (d, J = 8.7 Hz, 1H), 
2.57 (s, 3H) ppm; IR (film): v~ = 2229, 1508, 1389, 1359, 1312, 1277, 1097, 1007, 911, 886, 
795, 701, 669, 625, 521, 475 cm–1; HRMS (ESI): m/z calcd for C11H8Cl1N3H: 218.0480 
[M+H]+; found: 218.0488. 
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4.5.8 Imidazoquinoline Ligand 255 
 
 
 
Scheme 73. Synthesis of imidazoquinoline ligand 255. 
 
 
5-Chloro-8-nitroquinolin-7-amine (254). Compound 254 was prepared according to a modi-
fied procedure reported by Grzegożek.[129] A flame-dried flask (25 mL) was charged with 
5-chloro-8-nitroquinoline 254[134] (339 mg, 1.63 mmol, 1.00 eq). Then, 1,1,1-trimethylhydra-
zinium iodide[130] (497 mg, 2.46 mmol, 1.51 eq), dry DMSO (11 mL), and KOtBu (548 mg, 
4.88 mmol, 2.99 eq) were added and the mixture stirred at rt for 4 h under nitrogen 
atmosphere. The mixture was diluted with CH2Cl2, quenched by the addition of aqueous 
NH4Cl, the organic layer separated, the aqueous layer extracted with CH2Cl2 (10x), and the 
combined organic layers were washed with brine and dried over Na2SO4. All volatiles were 
removed in vacuo, the residue dissolved in CH2Cl2/MeOH, adsorbed on silica gel, and 
purified by flash chromatography (CHCl3/EtOAc 5:1 → 2:1[131]). After solvent removal and 
drying in vacuo, desired 5-chloro-8-nitroquinolin-7-amine (254) was obtained as a yellow-
orange crystalline solid (248 mg, 1.11 mmol, 68%). 1H NMR (300 MHz, DMSO-d6): δ = 8.81 
(dd, J = 4.3 Hz, J = 1.7 Hz, 1H), 8.36 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 7.43 (dd, J = 8.3 Hz, 
J = 4.3 Hz, 1H), 7.41 (s, 1H), 6.98 (s, 2H) ppm; HRMS (ESI): m/z calcd for C9H6N3O2Cl1H: 
224.0221 [M+H]+; found: 224.0226. 
Imidazoquinoline Ligand 255. A flask (25 mL) was charged with compound 254 (240 mg, 
1.07 mmol, 1.00 eq), SnCl2·2H2O (736 mg, 3.26 mmol, 3.04 eq), and EtOH (5.5 mL) and the 
mixture was stirred at reflux for 2.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (3x). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo, which yielded the 
according intermediate diamine as a pale-brown solid (217 mg, 1.12 mmol, quantitative). 
100 mg of the intermediate diamine (516 µmol, set as 1.00 eq) were then transferred into a 
new flask. The subsequent construction of the imidazole ring was achieved with a modified 
procedure reported by Zhang et al.[132] Iodine (13.0 mg, 51.2 µmol, 9.9 mol%), dry MeCN 
(1.0 mL), and triethyl orthoformate (130 µL, 789 µmol, 1.53 eq) were added, the flask sealed 
with a septum and the mixture stirred at rt for 18 h. Then, the dark slurry was diluted with 
CH2Cl2/MeOH and the crude product adsorbed on silica gel and purified by flash 
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chromatography (EtOAc/MeOH 10:1). After solvent removal and drying in vacuo, desired 
imidazoquinoline ligand 255 was obtained as brown-grey solid (92.5 mg, 454 µmol, 
88%). 1H NMR (300 MHz, DMSO-d6): δ = 13.81 (s, 1H), 9.02 (dd, J = 4.2 Hz, J = 1.4 Hz, 
1H), 8.66 (dd, J = 8.6 Hz, J = 1.4 Hz, 1H), 8.40 (s, 1H), 8.11 (s, 1H), 7.70 (dd, J = 8.5 Hz, 
J = 4.3 Hz, 1H) ppm; IR (film): v~ = 1617, 1519, 1349, 1287, 1149, 928, 859, 776, 718, 626, 
578, 437 cm–1; HRMS (ESI): m/z calcd for C10H6Cl1N3Na: 226.0142 [M+Na]+; found: 
226.0150. 
 
4.5.9 Imidazoquinoline Ligand 260 
 
 
 
Scheme 74. Synthesis of imidazoquinoline ligand 260. 
 
5-Methoxy-2-nitroaniline (257). A flame-dried flask (100 mL) was charged with 5-chloro-
2-nitroaniline (256; 5.00 g, 29.0 mmol, 1.00 eq) and dry DMF (25 mL). A solution of NaOMe 
(4.50 g, 83.3 mmol, 2.17 eq) in dry MeOH (11 mL) was added and the resulting mixture 
stirred at 80 °C for 12 h under nitrogen atmosphere. Then, the mixture was allowed to cool to 
rt and diluted with water and EtOAc. The organic layer was separated, the aqueous layer 
extracted with CH2Cl2 (2x), and the combined organic layers washed with brine (2x) and 
dried over Na2SO4. The solvent was removed in vacuo, the crude product dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 3:1 → 
3:2). Desired 5-methoxy-2-nitroaniline (257) was obtained as a crystalline solid (1.77 g, 
10.5 mmol, 36%). 1H NMR (300 MHz, CDCl3): δ = 8.06 (d, J = 9.6 Hz, 1H), 6.27 (dd, 
J = 9.5 Hz, J = 2.5 Hz, 1H), 6.22 (s, 2H), 6.15 (d, J = 2.5 Hz, 1H), 3.82 (s, 3H) ppm; 
HRMS (ESI): m/z calcd for C7H8N2O3Na: 191.0438 [M+Na]+; found: 191.0428. 
5-Methoxy-8-nitroquinoline (258). A flask was charged with glycerin (2.05 mL, 27.8 mmol, 
2.69 eq) and the glycerin stirred at 160 °C for 1 h. Then, the mixture was allowed to cool to rt 
and compound 257 (1.65 g, 9.80 mmol, 1.00 eq) and NaI (31.0 mg, 0.21 mmol, 2.0 mol%) 
were added and the mixture heated to 150 °C. Concentrated H2SO4 (1.29 mL, 24.2 mmol, 
2.34 eq) was added dropwise and the resulting mixture stirred at 150 °C for 1 h. After cooling 
to rt, the mixture was diluted with water and CH2Cl2, the organic layer separated, and the 
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aqueous layer extracted with CH2Cl2 (5x). The combined organic layers were dried over 
Na2SO4 and all volatiles were removed in vacuo. The resulting residue was dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 2:1). 
After solvent removal and drying in vacuo, desired 5-methoxy-8-nitroquinoline (258) was 
obtained as a yellow-orange crystalline solid (560 mg, 2.74 mmol, 28%). 1H NMR (300 MHz, 
CDCl3): δ = 9.08 (dd, J = 4.2 Hz, J = 1.8 Hz, 1H), 8.62 (dd, J = 8.5 Hz, J = 1.7 Hz, 1H), 8.18 
(d, J = 8.5 Hz, 1H), 7.51 (dd, J = 8.6 Hz, J = 4.2 Hz, 1H), 6.84 (d, J = 8.7 Hz, 1H), 4.09 (s, 
3H) ppm; HRMS (ESI): m/z calcd for C10H8N2O3Na: 227.0427 [M+Na]+; found: 227.0429. 
Compound 259. Compound 259 was prepared according to a modified procedure reported by 
Grzegożek.[129] A flame-dried flask (25 mL) was charged with 5-methoxy-8-nitroquinoline 
(258; 0.55 g, 2.69 mmol, 1.00 eq). Then, 1,1,1-trimethylhydrazinium iodide[130] (0.66 g, 
3.28 mmol, 1.22 eq), dry DMSO (5.5 mL), and KOtBu (0.92 g, 8.23 mmol, 3.06 eq) were 
added and the mixture stirred at rt for 2 h under nitrogen atmosphere. The mixture was diluted 
with CH2Cl2, quenched by the addition of aqueous NH4Cl, the organic layer separated, the 
aqueous layer extracted with CH2Cl2 (8x), and the combined organic layers dried over 
Na2SO4. All volatiles were removed in vacuo, the residue dissolved in CH2Cl2/MeOH, 
adsorbed on silica gel, and purified by flash chromatography (CHCl3/EtOAc 1:1[131]). After 
solvent removal and drying in vacuo, desired compound 259 was obtained as a yellow-orange 
crystalline solid (0.48 g, 2.19 mmol, 81%). 1H NMR (300 MHz, DMSO-d6): δ = 8.73 (dd, 
J = 4.4 Hz, J = 1.8 Hz, 1H), 8.26 (dd, J = 8.2 Hz, J = 1.8 Hz, 1H), 7.27 (dd, J = 8.3 Hz, 
J = 4.3 Hz, 1H), 7.22 (s, 2H), 6.60 (s, 1H), 3.96 (s, 3H) ppm; HRMS (ESI): m/z calcd for 
C10H9N3O3H: 220.0717 [M+H]+; found: 220.0717. 
Imidazoquinoline Ligand 260. A flask (25 mL) was charged with compound 259 (420 mg, 
1.92 mmol, 1.00 eq), SnCl2·2H2O (1.31 g, 5.82 mmol, 3.03 eq), and EtOH (6 mL) and the 
mixture was stirred at reflux for 2.5 h. After cooling to rt, the mixture was diluted with water 
and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with aqueous 2 M NaOH. The 
organic layer was separated and the aqueous layer extracted with EtOAc (4x). The combined 
organic layers were washed with brine, dried over Na2SO4, and the solvent removed in vacuo, 
which yielded the according intermediate diamine as a pale-brown solid (0.39 g, 2.06 mmol, 
quantitative). All of the obtained diamine was then transferred into a new flask. The sub-
sequent construction of the imidazole ring was achieved with a modified procedure reported 
by Zhang et al.[132] Iodine (53.0 mg, 0.21 mmol, 11 mol%), dry MeCN (1.50 mL), and triethyl 
orthoformate (0.49 mL, 2.94 mmol, 1.53 eq) were added, the flask sealed with a septum, and 
the mixture stirred at rt for 2.5 d. Then, the dark slurry was diluted with CH2Cl2/MeOH, the 
crude product adsorbed on silica gel, and purified by flash chromatography (EtOAc/MeOH 
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20:1 → 10:1). After solvent removal and drying in vacuo, desired imidazoquinoline ligand 
260 was obtained as an olive-green solid (0.20 g, 1.00 mmol, 52%). 1H NMR (300 MHz, 
methanol-d4): δ = 8.88 (dd, J = 4.3 Hz, J = 1.5 Hz, 1H), 8.70 (dd, J = 8.4 Hz, J = 1.4 Hz, 1H), 
8.19 (s, 1H), 7.50 (dd, J = 8.4 Hz, J = 4.4 Hz, 1H), 7.23 (s, 1H), 4.07 (s, 3H) ppm (NH signal 
not observed due to rapid H-D exchange). 
 
4.5.10 N-Methylated Imidazoquinoline Ligand 262 
 
 
 
 
Scheme 75. Synthesis of imidazoquinoline ligand 262. 
 
3-Chloro-N-methyl-8-nitroquinolin-7-amine (261). Compound 261 was synthesized based 
on a modified protocol from Skrydstrup et al.[135] A flame-dried flask (100 mL) was charged 
with compound 235 (500 mg, 2.24 mmol, 1.00 eq), NaOMe (906 mg, 16.8 mmol, 7.50 eq), 
paraformaldehyde (504 mg, 16.8 mmol, 7.51 eq), and dry MeOH (60 mL). The flask was 
equipped with a reflux condenser and the mixture stirred at 70 °C (reflux) for 5 h under 
nitrogen atmosphere. Then, the mixture was cooled to 0 °C, NaBH4 (633 mg, 16.7 mmol, 
7.48 eq) carefully added, and the mixture stirred at reflux for another 4 h under nitrogen 
atmosphere. After cooling to rt, the mixture was diluted with water and EtOAc, the organic 
layer separated, and the aqueous layer extracted with EtOAc (4x). The combined organic 
layers were dried over Na2SO4, the solvent removed in vacuo, the crude residue dissolved in 
CH2Cl2/MeOH, adsorbed on silica gel, and purified by flash chromatography (toluene/acetone 
15:1). After drying in vacuo, desired product 261 was obtained as a brown crystalline solid 
(335 mg, 1.41 mmol, 63%). 1H NMR (300 MHz, DMSO-d6): δ = 8.71 (d, J = 2.5 Hz, 
1H), 8.37 (d, J = 2.5 Hz, 1H), 7.89 (d, J = 9.4 Hz, 1H), 7.34 (d, J = 9.4 Hz, 1H), 7.15–7.00 
(m, 1H), 2.93 (d, J = 4.7 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C10H8Cl1N3O2Na: 
260.0197 [M+Na]+; found: 260.0201. 
N-Methylated Imidazoquinoline Ligand 262. A flask (25 mL) was charged with compound 
261 (392 mg, 1.65 mmol, 1.00 eq), SnCl2·2H2O (1.21 g, 5.36 mmol, 3.25 eq), and EtOH 
(11 mL) and the mixture was stirred at reflux for 5 h. After cooling to rt, the mixture was dilu-
ted with water and EtOAc and the pH of the aqueous layer was set to pH ≥ 12 with 2 M 
NaOH (aq). The organic layer was separated and the aqueous layer extracted with EtOAc 
(4x). The combined organic layers were dried over Na2SO4 and the solvent removed in vacuo, 
which yielded a brown solid which was dried in vacuo and transferred into a new flask 
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(25 mL). The subsequent construction of the imidazole ring was achieved with a modified 
procedure reported by Zhang et al.[132] Iodine (43 mg, 0.17 mmol, 10 mol%), dry MeCN 
(5.1 mL), and triethyl orthoformate (520 µL, 3.13 mmol, 1.90 eq) were added, the flask sealed 
with a septum, and the mixture stirred at rt for 24 h. All volatiles were removed in vacuo, the 
residue taken up in CH2Cl2/MeOH, adsorbed on silica gel, and purified by flash chromato-
graphy (EtOAc/MeOH 10:1 → 5:1). After drying in vacuo, desired N-methylated imidazo-
quinoline ligand 262 was obtained as a beige solid (331 mg, 1.52 mmol, 92%). 1H NMR 
(300 MHz, DMSO-d6): δ = 8.89 (s, 1H), 8.61 (d, J = 2.5 Hz, 1H), 8.37 (s, 1H), 7.95 (d, 
J = 8.7 Hz, 1H), 7.79 (d, J = 8.7 Hz, 1H), 3.99 (s, 3H) ppm; 13C NMR (75 MHz, DMSO-d6): 
δ = 147.9, 143.6, 139.7, 138.1, 134.8, 134.2, 125.7, 124.9, 121.9, 113.5, 31.1 ppm; IR (film):
v~ = 1516, 1365, 1342, 1104, 896, 793, 698, 634 cm–1; HRMS (ESI): m/z calcd for 
C11H8Cl1N3Na: 240.0299 [M+Na]+; found: 240.0305. 
 
4.5.11 2-(1H-Pyrazol-3-yl)pyridine Ligand (265) 
 
N N NHN O
N
H2N-NH2.H2O
ethanol
80 °C, 4 h
DMF-DMA
toluene
95 °C 120 °C
25 h
N O
263 264, 64% yield 265, 91% yield  
 
Scheme 76. Synthesis of 2-(1H-pyrazol-3-yl)pyridine ligand (265). 
 
Compound 264. Compound 264 was synthesized according to a protocol from Milani et 
al.[136] A flame-dried flask (25 mL) was charged with 2-acetylpyridine (263; 1.16 mL, 
10.3 mmol, 1.00 eq), N,N-dimethylformamide dimethyl acetal (3.14 mL, 23.7 mmol, 2.29 eq), 
and toluene (6.5 mL). The mixture was stirred at 95 °C for 24 h and evolving MeOH was 
continuously distilled off. Finally, the temperature was raised to 120 °C for 1 h to remove 
residual MeOH and to push the reaction to completion. Subsequently, the mixture was 
allowed to cool to rt, all volatiles removed, and the remaining residue dried in vacuo, which 
yielded desired compound 264 as a yellow-brown crystalline solid without the need for 
further purification (1.16 g, 6.57 mmol, 64%). 1H NMR (300 MHz, CDCl3): δ = 8.67−8.47 
(m, 1H), 8.13 (dd, J = 7.9 Hz, J = 0.9 Hz, 1H), 7.89 (d, J = 12.5 Hz, 1H), 7.79 (td, J = 7.7 Hz, 
J = 1.8 Hz, 1H), 7.35 (ddd, J = 7.6 Hz, J = 4.8 Hz, J = 1.2 Hz, 1H), 6.45 (d, J = 12.7 Hz, 1H), 
3.15 (s, 3H), 2.98 (s, 3H) ppm; HRMS (ESI): m/z calcd for C10H12N2O1H: 177.1022 [M+H]+; 
found: 177.1022. 
2-(1H-Pyrazol-3-yl)pyridine (265). Compound 265 was synthesized according to a protocol 
from Thiel et al.[137] A flask (10 mL) was charged with compound 264 (151 mg, 857 µmol, 
1.00 eq) and EtOH (1.5 mL). Then, hydrazine hydrate (80 wt%; 320 µL, 5.26 mmol, 6.14 eq) 
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was added and the resulting mixture stirred at 80 °C for 4 h. After cooling to rt, all volatiles 
were removed in vacuo and the resulting yellow crystalline solid was recrystallized from 
EtOAc (ca. 0.3–0.5 mL). The recrystallized precipitate was washed with hexanes and after 
drying in vacuo, desired 2-(1H-pyrazol-3-yl)pyridine (265) was obtained as a colorless 
crystalline solid (114 mg, 782 µmol, 91%). 1H NMR (300 MHz, CDCl3): δ = 12.14 (s, 1H), 
8.70 (dt, J = 4.9 Hz, J = 1.3 Hz, 1H), 7.83–7.70 (m, 2H), 7.67 (d, J = 2.1 Hz, 1H), 7.28–7.19 
(m, 1H), 6.83 (d, J = 2.1 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δ = 149.5, 149.3, 145.0, 
137.4, 137.2, 122.9, 120.5, 103.7 ppm; IR (film): v~ = 1590, 1501, 1416, 759, 704, 615, 
403 cm–1; HRMS (ESI): m/z calcd for C8H7N3H: 146.0713 [M+H]+; found: 146.0712. 
 
4.6  Achiral Non-Cyclometalating Ligands from Chapter 3. 
4.6.1  N-Phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine Ligand (173) 
 
 
 
Scheme 77. Synthesis of N-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine (173). 
 
Compound 266. Compound 266 was synthesized according to a modified procedure from 
Junjappa et al.[138] A flame-dried flask (250 mL) was charged with KOtBu (9.70 g, 
86.4 mmol, 2.11 eq) and dry THF (200 mL). The flask was cooled with a water bath and 
2-acetylpyridine (263; 4.60 mL, 41.0 mmol, 1.00 eq) was added dropwise over 10 min under 
stirring. The resulting mixture was stirred at rt for 15 min whereupon a pale-yellow 
suspension was formed. Then, carbon disulfide (2.62 mL, 43.7 mmol, 1.07 eq) was added 
dropwise over 30 min at rt. Next, methyl iodide (5.40 mL, 86.7 mmol, 2.12 eq) was added 
dropwise over 40 min and the mixture was stirred at rt for 15 h under nitrogen atmosphere. 
The resulting mixture was poured into ice-water (0.5 L) and the resulting suspension 
vigorously stirred for 1.5 h. The resulting yellow precipitate was filtered off with a glass filter 
(porosity G3), thoroughly washed with water, and dried in vacuo. Desired compound 266 was 
obtained as a yellow powder without the need for further purification (6.76 g, 30.0 mmol, 
73%). 1H NMR (300 MHz, CDCl3): δ = 8.64 (d, J = 4.0 Hz, 1H), 8.17 (d, J = 7.9 Hz, 1H), 
7.84 (td, J = 7.7 Hz, J = 1.7 Hz, 1H), 7.64 (s, 1H), 7.40 (ddd, J = 7.5 Hz, J = 4.8 Hz, 
J = 1.1 Hz, 1H), 2.64 (s, 3H), 2.55 (s, 3H) ppm; HRMS (ESI): m/z calcd for C10H12N1O1S2: 
226.0355 [M+H]+; found: 226.0355. 
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N-Phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine (173). Compound 173 was synthesized 
according to a modified procedure from Junjappa et al.[138] A flame-dried flask (250 mL) was 
charged with aniline (1.78 mL, 19.5 mmol, 1.10 eq) and dry THF (75 mL). The mixture was 
cooled to 0 °C and n-BuLi (2.5 M in hexanes; 7.80 mL, 19.5 mmol, 1.10 eq) was added 
dropwise over 10 min. The resulting mixture was stirred for 30 min at 0 °C and then allowed 
to warm to rt and stirred for 45 min. Then, compound 266 (4.00 g, 17.8 mmol, 1.00 eq) in dry 
THF (35 mL) was added dropwise over 15 min at 0 °C. The resulting mixture was allowed to 
warm to rt and stirred for 2.5 h and then stirred at 65 °C (reflux) for 8 h. After cooling to rt, 
the mixture was diluted with water and EtOAc and the organic layer separated and the 
aqueous layer extracted with EtOAc (3x). The combined organic layers were washed with 
brine, dried over Na2SO4, the solvent removed in vacuo, the residue dissolved in CH2Cl2 and 
adsorbed on silica gel, and the intermediate crude product purified by flash chromatography 
(hexanes/EtOAc 3:1). After solvent removal and drying in vacuo, a yellow crystalline solid 
(4.37 g; intermediate dithioketene acetal) was obtained, which was transferred into a new 
flask (100 mL). t-BuOH (80 mL), hydrazine hydrate (80 wt%; 1.50 mL, 24.7 mmol, 1.53 eq), 
and acetic acid (1.10 mL, 19.2 mmol, 1.19 eq) were added and the mixture stirred at reflux for 
4 h. After cooling to rt, the resulting mixture was diluted with water and EtOAc, the organic 
layer separated, and the aqueous layer extracted with EtOAc (5x). The combined organic 
layers were washed with brine, dried over Na2SO4, and the solvent removed in vacuo. The 
resulting residue was dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash 
chromatography (hexanes/EtOAc 2:1 → 1:2). After solvent removal and drying in vacuo, 
N-phenyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine (173) was obtained as a colorless crystalline 
solid (2.32 g, 9.81 mmol, 55%). 1H NMR (300 MHz, DMSO-d6): δ = 12.69 (s, 1H), 8.60 (d, 
J = 4.7 Hz, 1H), 8.48 (s, 1H), 7.95–7.75 (m, 2H), 7.43–7.27 (m, 3H), 7.27–7.12 (m, 2H), 6.71 
(t, J = 7.3 Hz, 1H), 6.44 (d, J = 2.1 Hz, 1H) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 152.2, 
149.3, 148.1, 143.8, 141.5, 135.2, 128.7 (2C), 122.8, 119.8, 117.9, 114.8 (2C), 92.2 ppm; 
IR (film): v~ = 3259, 1597, 1549, 1494, 1458, 1433, 1421, 997, 757, 740, 704, 687, 622, 489, 
462, 401 cm–1; HRMS (ESI): m/z calcd for C14H12N4H: 237.1135 [M+H]+; found: 237.1129. 
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4.6.2 Bispyrazole Ligand 180 
 
 
Scheme 78. Synthesis of bispyrazole ligand 180. 
 
1,1-Diethoxyethene (176). Compound 176 was prepared following a literature protocol from 
DeHaven-Hudkins et al.[139] A flame-dried flask (250 mL) was charged with dry THF (75 mL) 
and KOtBu (22.3 g, 199 mmol, 1.19 eq). The flask was cooled to 0 °C and bromo-
acetaldehyde diethyl acetal (175; 25.1 mL, 167 mmol, 1.00 eq) was added dropwise over 
30 min. The mixture was subsequently stirred at 70 °C (reflux) for 1 h under nitrogen 
atmosphere. After cooling to rt, THF was carefully removed in vacuo and the residue 
transferred with dry CH2Cl2 into a new flame-dried flask (100 mL). The solvent was carefully 
removed in vacuo and the product purified by short-path distillation (70−75 °C, 
180−190 mbar). Desired 1,1-diethoxyethene (176; 15.0 g, 129 mmol, 78%) was obtained as a 
clear colorless liquid and stored in a well-sealed Schlenk tube (note that 176 is moisture-
sensitive). 1H NMR (300 MHz, CDCl3): δ = 3.79 (q, J = 7.0 Hz, 4H), 3.05 (s, 2H), 1.29 (t, 
J = 7.1 Hz, 6H) ppm; 13C NMR (75 MHz, CD2Cl2): δ = 165.1, 63.7 (2C), 55.7, 14.5 
(2C) ppm; IR (film): v~ = 2982, 1642, 1372, 1274, 1046, 972, 875, 709 cm–1; HRMS (ESI): m/z 
calcd for C6H12O2H: 117.0910 [M+H]+; found: 117.0910. 
Compound 179. Compound 179 was prepared following a protocol from H.-D. Stachel.[118a,b] 
A flame-dried flask (100 mL) was charged with dry Et2O (46 mL) and 1,1-diethoxyethene 
(176; 4.70 g, 40.4 mmol, 6.05 eq). The resulting solution was cooled to 0 °C and oxalyl 
chloride (177; 570 µL, 6.69 mmol, 1.00 eq) was added dropwise, which resulted in the 
formation of a yellow precipitate. This mixture was stirred at 0 °C overnight under nitrogen 
atmosphere. The next day, the clear yellow supernatant was carefully removed with a syringe 
and the yellow precipitate repeatedly washed with dry, ice-cold Et2O (4x 15 mL) under 
nitrogen atmosphere. The resulting supernatant was each time carefully removed with a 
syringe (the yellow precipitate, which is the according moisture-sensitive intermediate 
oxalylketene acetal,[118a,b] is virtually insoluble in Et2O). Then, dry Et2O (20 mL) and aniline 
(1.59 mL, 17.5 mmol, 2.61 eq) were added to the remaining precipitate and the mixture stirred 
at rt overnight under nitrogen atmosphere. The next day, the resulting yellow precipitate was 
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filtered off with a glass filter (porosity G4) and washed with ice-cold Et2O. After drying in 
vacuo, desired compound 179 was obtained as a bright yellow powder (1.37 g, 3.61 mmol, 
54%) without the need for further purification. 1H NMR (300 MHz, CD2Cl2): δ = 13.01 (s, 
2H), 7.46−7.27 (m, 8H), 7.20−7.05 (m, 2H), 6.01 (s, 2H), 4.32 (q, J = 7.0 Hz, 4H), 1.47 (t, 
J = 7.0 Hz, 6H) ppm; 13C NMR (75 MHz, CD2Cl2): δ = 185.1 (2C), 167.9 (2C), 138.1 (2C), 
129.6 (4C), 124.8 (2C), 122.2 (4C), 74.7 (2C), 66.3 (2C), 14.7 (2C) ppm; IR (film): v~ = 1622, 
1574, 1554, 1510, 1493, 1463, 1440, 1393, 1369, 1311, 1275, 1203, 1152, 1046, 779, 749, 
689, 652, 463 cm–1; HRMS (ESI): m/z calcd for C22H24N2O4H: 381.1809 [M+H]+; found: 
381.1800. 
Bispyrazole Ligand 180. Bispyrazole ligand 180 was prepared following a protocol from 
H.-D. Stachel.[118c] A flask (25 mL) was charged with compound 179 (500 mg, 1.31 mmol, 
1.00 eq) and 1-propanol (12 mL). The mixture was heated to 100 °C (reflux) and hydrazine 
hydrate (80% wt%; 480 µL, 7.90 mmol, 6.01 eq) was added at once under stirring when 
substrate 179 was completely dissolved. The mixture was stirred at 100 °C for 3 min where-
upon the yellow color of the mixture disappeared. The resulting mixture was allowed to cool 
to rt whereupon a colorless crystalline precipitate formed. To accelerate and to push the 
precipitation to completion, the mixture was kept at −20 °C for 1 h. Then, the colorless 
precipitate was filtered off with a glass filter (porosity G4) and washed with hexanes 
(insoluble) and Et2O (slightly soluble). After drying in vacuo, desired bispyrazole ligand 180 
(300 mg, 949 µmol, 72%) was obtained as a colorless crystalline powder without the need for 
further purification. 1H NMR (300 MHz, DMSO-d6): δ = 12.45 (s, 2H), 8.51 (s, 2H), 7.35 (d, 
J = 7.8 Hz, 4H), 7.19 (t, J = 7.6 Hz, 4H), 6.72 (t, J = 6.6 Hz, 2H). 6.26 (s, 2H) ppm; 13C NMR 
(75 MHz, DMSO-d6): δ = 152.0 (2C), 143.8 (2C), 132.7 (2C), 128.7 (4C), 118.0 (2C), 114.8 
(4C), 90.8 (2C) ppm; IR (film): v~ = 3421, 1593, 1532, 1497, 1484, 1454, 1236, 1008, 793, 748, 
692, 502 cm–1; HRMS (ESI): m/z calcd for C18H16N6H: 317.1509 [M+H]+; found: 317.1504. 
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4.7  Synthesis of Iridium(III) Complexes Λ/∆-T1–Λ/∆-T28 from Chapter 2. 
 
 
Scheme 79. General synthesis routes for iridium(III) complexes Λ/∆-T1–Λ/∆-T28.  
 
Scheme 79 reproduces and specifies Scheme 30 from chapter 2.3.1 and serves to illustrate the 
notation system which is used below for complexes Λ/∆-T1–Λ/∆-T28 and their precursors.  
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In case of Route I (Scheme 79; highlighted in blue), the precursing auxiliary complex of a 
final complex Λ/∆-T# (# is a placeholder for a complex number) is denoted as Λ/∆-(S)-T# 
(for example for Λ-T1: Λ-(S)-T1). And the precursing iridium(III) dimer of an auxiliary 
complex Λ/∆-(S)-T# is denoted as rac-T#-dimer (for example for Λ-(S)-T1: rac-T1-dimer). 
 
In case of Route II (Scheme 79; highlighted in red), the OTf-functionalized dimers are de-
noted as rac-T#-dimer-CC and the according OTf-functionalized auxiliary complexes, which 
are employed in the post-complexation cross-coupling step, are denoted as Λ/∆-(S)-T#-CC. 
 
Remark: In case a complex Λ/∆-T# is synthesized from a precursor of another complex 
Λ/∆-T# whose synthesis has already been presented, the precursor keeps the original 
number (#) of the complex with which it has been presented first (no double numbering!).  
 
4.7.1 General Procedures A1)–A5)  
General Procedure A1). 
Synthesis of Iridium(III) Dimers (rac-T#-dimer and rac-T#-dimer-CC). 
Iridium(III) dimers (rac-T#-dimer and rac-T#-dimer-CC) were synthesized according to a 
modified version of Nonoyama's procedure.[77] A flask was charged with IrCl3·3H2O (1.00 eq), 
the indicated amount of the respective phenylbenzoxazole or phenylbenzothiazole ligand 
(2.0–2.4 eq), and 2-ethoxyethanol (conc = 30 mM) and the mixture purged with nitrogen gas 
for 15 min. Then, the flask was equipped with a reflux condenser and the mixture stirred at 
130 °C for the indicated time under exclusion of light under nitrogen atmosphere. After 
cooling to rt, aqueous 1 M HCl (3–4 times the volume of the reaction mixture) was added 
under stirring whereupon a yellow precipitate formed. This precipitate was filtered off with a 
glass filter (porosity G3) and thoroughly washed with 1 M HCl and finally with a small 
amount of MeOH. The precipitate was dissolved in CH2Cl2, passed as solution through the 
filter, and the resulting clear organic layer dried over Na2SO4. After solvent removal and 
drying in vacuo, the desired iridium(III) dimer (rac-T#-dimer or rac-T#-dimer-CC) was 
obtained. 
 
General Procedure A2). 
Synthesis / Resolution of Λ-(S)- and ∆-(S)-Diastereomers (rac-T#-dimer → Λ/∆-(S)-T#). 
A flask was charged with the respective iridium(III) dimer (rac-T#-dimer; 1.00 eq), auxiliary 
ligand (S)-Aux1 or (S)-Aux2 (2.50 eq), Na2CO3 (15.0 eq), AgOTf (2.25 eq), and 2-ethoxy-
ethanol (conc = 10 mM) and the mixture was purged with nitrogen gas for 5–10 min. Then, 
the mixture was stirred at 85 °C for 8 h under exclusion of light under nitrogen atmosphere. 
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After cooling to rt, the mixture was diluted with CH2Cl2 and passed through a short plug of 
silica gel with CH2Cl2 as eluent to remove the salts. All volatiles were removed in vacuo 
(40 °C) and the crude diastereomer mixture purified and resolved by standard flash 
chromatography with the indicated eluent. After drying in vacuo, diastereomers Λ-(S)-T# and 
∆-(S)-T# were obtained (in most cases, only Λ-(S)-T# was isolated and purified). 
 
General Procedure A3). 
Synthesis and Resolution of OTf-Functionalized Λ-(S)- and ∆-(S)-Diastereomers 
(rac-T#-dimer-CC → Λ/∆-(S)-T#-CC).[78] 
A flask was charged with the respective OTf-functionalized iridium(III) dimer 
(rac-T#-dimer-CC; 1.00 eq), auxiliary ligand (S)-Aux1 or (S)-Aux2 (2.50 eq), Et3N (10 eq), 
AgOTf (2.25 eq), and ethanol (conc = 15 mM) and the mixture purged with nitrogen gas for 
5−10 min. Then, the mixture was stirred at 80 °C for the indicated time under exclusion of 
light under nitrogen atmosphere. After cooling to rt, the mixture was diluted with CH2Cl2 and 
passed through a short plug of silica gel with CH2Cl2 as eluent to remove the salts. All vola-
tiles were removed from the filtrate in vacuo (40 °C) and the crude Λ/∆-diastereomer mixture 
purified and resolved by standard flash chromatography with the indicated eluent. After 
drying in vacuo, diastereomers Λ-(S)-T#-CC and ∆-(S)-T#-CC were obtained (in most cases, 
only Λ-(S)-T#-CC was isolated and purified). 
Remark: General procedure A3) is a modified version of general procedure A2) since OTf-
functionalized complexes are not compatible with the conditions from general procedure A2) 
(the triflate groups are cleaved off under those conditions). 
 
General Procedure A4). 
Post-Complexation Cross-Coupling with OTf-Functionalized Λ-(S)- and  
∆-(S)-Diastereomers (Λ/∆-(S)-T#-CC → Λ/∆-(S)-T#).[78] 
 
 
 
Scheme 80: Post-complexation Suzuki-Miyaura cross-couplings with OTf-functionalized diastereomers.[78] 
 
A Schlenk tube (10 mL; threaded PTFE plug) was charged with finely ground K3PO4 
(4.00 eq) and a PTFE stir bar and the Schlenk tube flame-dried in vacuo for 5 min (heat gun; 
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approx. 300 °C). Then, the respective OTf-functionalized diastereomer Λ- or ∆-(S)-T#-CC 
(1.00 eq), SPhos (20 mol%), Pd(OAc)2 (12 mol%), and the respective boronic acid or boronic 
ester (4.00 eq) were added. The Schlenk tube was evacuated for 5 min and then carefully 
refilled with nitrogen gas. Dry and degassed toluene (conc = 50–60 mM) was added, the 
Schlenk tube sealed, and the mixture stirred at 95 °C under nitrogen atmosphere and under 
exclusion of light for the indicated time. Subsequently, all volatiles were removed in vacuo 
and the desired crude product purified by flash chromatography with the indicated eluent. 
After drying in vacuo, the desired cross-coupled diastereomer Λ- or ∆-(S)-T# was obtained.  
 
General Procedure A5). 
Synthesis of Λ- and ∆-Complexes / Precatalysts (Λ/∆-(S)-T# → Λ/∆-T#). 
A flask was charged with the respective diastereomer Λ- or ∆-(S)-T# (1.00 eq) and MeCN 
(conc = 10 mM). Triflic acid (5.00 eq) was added and the resulting mixture stirred for 15 min 
at rt. Then, all volatiles were removed in vacuo (40 °C) and the resulting bisacetonitrile 
intermediate (Λ- or ∆-T#-(MeCN)2, both depicted in Figure 39) purified by short-column 
chromatography. Eluent was in all cases hexanes/EtOAc/MeCN 4:2:1 → 4:4:2.[140] 
 
 
Figure 39. Intermediate bisacetonitrile complexes Λ- and ∆-T#-(MeCN)2.[140] 
 
 
Then, a new flask was charged with the purified bisacetonitrile intermediate (Λ- or 
∆-T#-(MeCN)2), the respective imidazoquinoline ligand (3.00 eq), and a 3:1 mixture of 
CH2Cl2/MeOH (conc = 10 mM). The resulting mixture was stirred overnight (≥ 15 h) at rt.[81] 
All volatiles were then removed in vacuo (40 °C), NH4PF6 (100 eq) and MeOH 
(conc = 5 mM) added, and the resulting mixture vigorously stirred for 2 h at rt.[82] Again, all 
volatiles were removed in vacuo (40 °C) and the crude product purified by flash chromato-
graphy with the indicated eluent. After drying in vacuo, the desired Λ- or ∆-configured 
complex / precatalyst (Λ- or ∆-T#) was obtained.  
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4.7.2  Synthetic Procedures and Characterizations 
4.7.2.1  Precatalyst Λ-T1 
Precatalyst Λ-T1 was prepared according to general procedures 
A1), A2), and A5) from benzoxazole ligand 186, IrCl3·3H2O, 
auxiliary ligand (S)-Aux1, and imidazoquinoline ligand 233. 
Rac-T1-dimer. General procedure A1) was followed using benz-
oxazole ligand 186 (512 mg, 1.63 mmol, 2.40 eq) and IrCl3·3H2O 
(239 mg, 678 µmol, 1.00 eq); reaction time: 20 h; Ir(III) dimer 
rac-T1-dimer was obtained as an orange crystalline solid (458 mg, 269 µmol, 79%). 
1H NMR (300 MHz, CD2Cl2): δ = 8.22 (d, J = 1.3 Hz, 4H), 7.45 (d, J = 8.3 Hz, 4H), 7.32 (dd, 
J = 7.6 Hz, J = 1.1 Hz, 4H), 7.11 (dd, J = 8.5 Hz, J = 1.7 Hz, 4H), 7.02 (s, 4H), 6.83–6.69 (m, 
8H), 6.54 (td, J = 7.6 Hz, J = 1.5 Hz, 4H), 6.00 (d, J = 7.6 Hz, 4H), 2.30 (s, 12H), 2.21 (s, 
12H), 1.79 (s, 12H) ppm; HRMS (ESI): m/z calcd for C88H72Cl2Ir2N4O4Na: 1727.4073 
[M+Na]+; found: 1727.4080.  
Λ-(S)-T1. General procedure A2) was followed using rac-T1-dimer (502 mg, 294 µmol) and 
auxiliary ligand (S)-Aux1; the crude diastereomer mixture was adsorbed on silica gel (40 °C) 
and purified and resolved by f. c. with hexanes/EtOAc 15:1; only the Λ-(S)-diastereomer was 
isolated and characterized; diastereomer Λ-(S)-T1 was obtained as an orange solid (208 mg, 
201 µmol, 34%). 1H NMR (500 MHz, CD2Cl2): δ = 7.75 (dd, J = 7.6 Hz, J = 0.8 Hz, 1H), 
7.74–7.65 (m, 4H), 7.30 (dd, J = 8.1 Hz, J = 1.8 Hz, 1H), 7.25 (d, J = 1.3 Hz, 1H), 7.20 (ddd, 
J = 8.5 Hz, J = 7.2 Hz, J = 1.6 Hz, 2H), 7.00–6.86 (m, 7H), 6.81–6.76 (m, 2H), 6.66 (d, 
J = 7.5 Hz, 1H), 6.52 (d, J = 7.5 Hz, 1H), 6.48 (dd, J = 8.5 Hz, J = 1.0 Hz, 1H), 6.20 (ddd, 
J = 8.1 Hz, J = 6.8 Hz, J = 1.2 Hz, 1H), 4.60 (ddd, J = 7.9 Hz, J = 3.4 Hz, J = 3.2 Hz, 1H), 
2.79–2.69 (m, 2H), 2.34 (s, 3H), 2.28 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.95 (s, 3H), 1.61 (s, 
3H), 0.80–0.69 (m, 1H), 0.20 (t, J = 7.3 Hz, 6H) ppm; HRMS (ESI): m/z calcd for 
C56H50IrN3O3SNa: 1060.3097 [M+Na]+; found: 1060.3089. 
Precatalyst Λ-T1. General procedure A5) was followed using Λ-(S)-T1 (20.2 mg, 
19.5 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 40:1; precatalyst 
Λ-T1 was obtained as a greenish yellow solid (19.4 mg, 17.2 µmol, 88%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.10 (s, 1H), 8.34 (dd, J = 8.2 Hz, J = 0.9 Hz, 1H), 8.09 (dd, 
J = 5.0 Hz, J = 1.1 Hz, 1H), 8.00–7.94 (m, 2H), 7.90 (dd, J = 7.6 Hz, J = 0.8 Hz, 1H), 7.88–
7.83 (m, 2H), 7.65 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.41 (dd, J = 8.2 Hz, 
J = 5.0 Hz, 1H), 7.19 (td, J = 7.5 Hz, J = 0.9 Hz, 1H), 7.17–7.10 (m, 2H), 7.10–7.00 (m, 3H), 
6.91 (s, 1H), 6.89–6.80 (m, 4H), 6.74 (s, 1H), 6.04 (d, J = 1.1 Hz, 1H), 5.17 (d, J = 1.1 Hz, 
1H), 2.27 (s, 3H), 2.26 (s, 3H), 1.98 (s, 3H), 1.88 (s, 3H), 1.23 (s, 3H), 1.11 (s, 3H) ppm; 
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13C NMR (125 MHz, CD2Cl2): δ = 178.4, 178.3, 151.8, 149.7, 149.6, 146.2, 144.0, 143.4, 
142.7, 141.5, 140.2, 139.9, 138.8, 138.4, 138.1, 137.8, 137.5, 137.4, 137.3, 136.0, 135.8, 
135.7, 135.5, 134.5, 134.2, 133.4, 133.1, 133.0, 130.5, 130.4, 129.1, 129.0, 128.6, 128.6, 
128.4, 128.0, 127.1, 126.9, 125.9, 125.7, 123.6 (2C), 123.1, 117.2, 116.7, 115.8, 112.5, 112.2, 
21.3, 21.2, 21.1, 21.0, 20.4, 20.3 ppm; IR (film): v~ = 1443, 1380, 836, 734, 705, 552 cm–1; 
HRMS (ESI): m/z calcd for C54H43IrN5O2: 986.3044 [M–PF6]+; found: 986.3034.  
 
4.7.2.2  Complex Λ-T2 
A flask was charged with diastereomer Λ-(S)-T1 (see 4.7.2.1; 
24.9 mg, 24.0 µmol, 1.00 eq), 1,7-naphthyridin-8-amine (3.0 mg, 
20.7 µmol, 0.86 eq → 1,7-naphthyridin-8-amine elutes with com-
plex Λ-T2), NH4PF6 (39.0 mg, 239 µmol, 9.97 eq), and MeCN 
(2.0 mL). The mixture was stirred at 65 °C for 12 h under 
nitrogen atmosphere and under exclusion of light. TLC indicated 
full conversion with respect to 1,7-naphthyridin-8-amine. All volatiles were removed in vacuo 
(40 °C) and the crude product purified by flash chromatography (CH2Cl2/MeOH 100:1). After 
solvent removal and drying in vacuo, desired complex Λ-T2 was obtained as a yellow-orange 
solid (13.0 mg, 11.7 µmol, 57%). 1H NMR (500 MHz, CD2Cl2): δ = 7.88 (dd, J = 5.0 Hz, 
J = 1.3 Hz, 1H), 7.85 (dd, J = 7.7 Hz, J = 0.8 Hz, 1H), 7.81 (dd, J = 7.7 Hz, J = 1.0 Hz, 1H), 
7.77 (s, 1H), 7.72 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.66 (dd, J = 8.2 Hz, 
J = 1.3 Hz, 1H), 7.40 (d, J = 1.1 Hz, 1H), 7.34 (dd, J = 8.2 Hz, J = 5.2 Hz, 1H), 7.21 (dd, 
J = 8.5 Hz, J = 1.6 Hz, 1H), 7.16–7.10 (m, 2H), 7.09 (d, J = 7.1 Hz, 1H), 7.05 (td, J = 7.5 Hz, 
J =1.1 Hz, 1H), 7.00 (td, J = 7.5 Hz, J =1.4 Hz, 1H), 6.92 (td, J = 7.5 Hz, J =1.5 Hz, 1H), 6.90 
(s, 1H), 6.88–6.83 (m, 2H), 6.81 (s, 1H), 6.79 (d, J = 7.3 Hz, 1H), 6.67 (d, J = 7.5 Hz, 1H), 
6.16 (d, J = 7.1 Hz, 1H), 2.27 (s, 3H), 2.24 (s, 3H), 2.00 (s, 3H), 1.89 (s, 3H), 1.71 (s, 3H), 
1.54 (s, 3H) ppm (two NH signals could not be found due to rapid exchange); 13C NMR 
(125 MHz, CD2Cl2): δ = 178.6, 178.3, 161.1, 152.7, 151.6, 149.9, 149.7, 146.7, 144.7, 140.5, 
139.8, 138.4, 138.4, 137.7, 137.7, 137.6, 137.4, 136.4, 136.4, 136.1, 135.9, 135.9, 135.6, 
134.3, 134.1, 133.1, 132.7, 132.3, 130.6, 130.0, 129.2, 129.0, 128.8, 128.6 (2C), 128.3, 127.7, 
126.9, 126.7, 123.1, 122.9, 117.8, 115.7, 112.6, 112.0, 102.9, 21.3, 21.2, 21.1, 21.1, 20.8, 
20.7 ppm; IR (film): v~ = 1638, 1588, 1514, 1433, 1383, 1284, 1226, 1154, 1026, 815, 736, 
631, 512 cm–1; HRMS (ESI): m/z calcd for C52H43Ir1N5O2: 962.3044 [M–PF6]+; found: 
962.3032. 
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4.7.2.3  Complex rac-T3 
An amber glass vial was charged with 
iridium(III) dimer rac-T1-dimer (see 
4.7.2.1; 35.1 mg, 20.6 µmol, 1.00 eq), 
2-(1H-pyrazol-3-yl)pyridine ligand (265, 
7.5 mg, 51.7 µmol, 2.51 eq), AgPF6 
(22.5 mg, 89.0 µmol, 4.32 eq), and 
CH2Cl2/MeOH 2:1 (6 mL) and the 
mixture was stirred at rt for 20 h under exclusion of light. All volatiles were removed in vacuo 
(40 °C) and the crude product purified by flash chromatography (CH2Cl2/MeOH 35:1). After 
solvent removal and drying in vacuo, desired racemic complex rac-T3 was obtained as a 
green crystalline solid (35.8 mg, 32.3 µmol, 78%). 1H NMR (300 MHz, CD2Cl2):  δ = 8.07 (d, 
J = 5.5 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.90–7.82 (m, 3H), 7.75–7.66 (m, 3H), 7.25–7.11 
(m, 5H), 7.06 (td, J = 7.6 Hz, J = 1.5 Hz, 1H), 7.03 (td, 7.6 Hz, J = 1.4 Hz, 1H), 6.98 
(d,  J = 2.9 Hz, 1H), 6.93–6.83 (m, 4H), 6.73 (t, J = 7.4 Hz, 2H), 5.61 (d, J = 1.4 Hz, 1H), 
5.55 (d, J = 1.5 Hz, 1H), 2.28 (s, 3H), 2.28 (s, 3H), 1.96 (s, 3H), 1.91 (s, 3H), 1.69 (s, 3H), 
1.66 (s, 3H) ppm (NH signal could not be found due to rapid exchange); IR (film): v~ = 1591, 
1517, 1448, 1381, 1256, 1039, 836, 772, 735, 553 cm–1; HRMS (ESI): m/z calcd for 
C52H43Ir1N5O2: 962.3044 [M–PF6]+; found: 962.3028. 
 
4.7.2.4  Precatalyst Λ-T4 
General procedure A5) was followed using Λ-(S)-T4 (13.0 mg, 
12.3 µmol; obtained from PhD student T. Mietke; contained 
(S)-Aux1 as coordinating auxiliary ligand) and imidazoquino-
line ligand 233; eluent for f. c.: CH2Cl2/MeOH 50:1; precatalyst 
Λ-T4 was obtained as a greenish yellow solid (11.5 mg, 
10.0 µmol, 82%). 1H NMR (500 MHz, CD2Cl2): δ = 8.56 (dd, 
J = 8.4 Hz, J = 1.3 Hz, 1H), 8.30 (dd, J = 5.0 Hz, J = 1.2 Hz, 1H), 8.23 (s, 1H), 8.12 (d, 
J = 8.9 Hz, 1H), 7.99 (s, 1H), 7.98 (s, 1H), 7.92–7.84 (m, 5H), 7.82 (d, J = 8.9 Hz, 1H), 7.80 
(dd, J = 8.0 Hz, J = 0.6 Hz, 1H), 7.77 (dd, J = 8.6 Hz, J = 1.7 Hz, 1H), 7.74 (dd, J = 3.4 Hz, 
J = 0.6 Hz, 1H), 7.72 (dd, J = 3.3 Hz, J = 0.6 Hz, 1H), 7.68–7.65 (m, 2H), 7.61 (dd, 
J = 8.4 Hz, J = 5.0 Hz, 1H), 7.58–7.46 (m, 4H), 7.34 (d, J = 1.6 Hz, 1H), 7.24 (dd, J = 8.6 Hz, 
J = 1.9 Hz, 1H), 7.19 (td, J = 7.5 Hz, J = 1.1 Hz, 1H), 7.15 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 
7.11–7.06 (m, 2H), 7.04 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 6.89–6.85 (m, 2H), 6.50 (dd, 
J = 1.7 Hz, J = 0.6 Hz, 1H), 5.76 (dd, J = 1.8 Hz, J = 0.5 Hz, 1H) ppm, NH signal could not 
be found due to rapid exchange; 13C NMR (125 MHz, CD2Cl2): δ = 178.8, 178.7, 152.2, 150.4, 
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150.3, 146.2, 144.3, 143.6, 143.2 (2C), 142.0, 140.4, 140.2, 139.2, 139.1, 138.9, 137.3, 136.8, 
134.5, 134.2, 134.1, 134.0, 133.7, 133.4, 133.3, 133.3, 130.3, 130.3, 129.9, 129.1, 128.8, 
128.4, 128.3, 128.2, 127.4, 127.3, 127.2, 127.1, 127.0, 127.0, 126.3, 126.2 (2C), 126.0, 125.7, 
125.6, 125.5, 124.9, 123.7 (2C), 123.3, 117.6, 113.9, 113.5, 113.0, 112.8 ppm; IR (film): 
v~ = 1589, 1446, 1379, 1260, 1037, 835, 804, 735, 703, 552, 474 cm–1; HRMS (ESI): m/z 
calcd for C56H35Ir1N5O2: 1002.2419 [M–PF6]+; found: 1002.2404.  
 
4.7.2.5  Precatalyst Λ-T5 
It was attempted to synthesize precatalyst Λ-T5 from the 
according diastereomer (Λ-(S)-T5; obtained from PhD student 
T. Mietke; contained (S)-Aux1 as auxiliary ligand) and imida-
zoquinoline ligand 233 according to general procedure A5). 
However, the resulting product complex, supposably Λ-T5, 
decomposed in solution and hence the scheduled experiments 
with Λ-T5 were cancelled. 
 
4.7.2.6  Precatalyst Λ-T6 
Precatalyst Λ-T6 was prepared according to general procedures 
A1), A2), and A5) from benzoxazole ligand 189, IrCl3·3H2O, 
auxiliary ligand (S)-Aux1, and imidazoquinoline ligand 233. 
Rac-T6-dimer. General procedure A1) was followed using 
benzoxazole ligand 189 (970 mg, 2.05 mmol, 2.05 eq) and 
IrCl3·3H2O (353 mg, 1.00 mmol, 1.00 eq); reaction time: 24 h. 
Rac-T6-dimer, which was prepared according to general pro-
cedure A1), was additionally purified via flash chromatography: Crude rac-T6-dimer was 
dissolved in CH2Cl2, adsorbed on silica gel (36 °C), and purified by f. c. (hexanes/EtOAc 
20:1). After solvent removal and drying in vacuo, dimer rac-T6-dimer was obtained as an 
orange solid (644 mg, 275 µmol, 55%). 1H NMR (500 MHz, CD2Cl2): δ = 8.60 (d, J = 2.0 Hz, 
4H), 8.20 (d, J = 1.8 Hz, 8H), 7.56 (dd, J = 8.8 Hz, J = 2.2 Hz, 4H), 7.42 (dd, J = 8.7 Hz, 
J = 1.6 Hz, 8H), 7.35–7.29 (m, 12H), 6.78–6.73 (m, 4H), 6.63–6.59 (m, 8H), 6.14–6.10 (m, 
4H), 1.49 (s, 72H) ppm; HRMS (ESI): m/z calcd for C132H124Cl2Ir2N8O4Na: 2364.8295 
[M+Na]+; found: 2364.8276.  
Λ-(S)-T6. General procedure A2) was followed using rac-T6-dimer (339 mg, 145 µmol) and 
auxiliary ligand (S)-Aux1; the crude diastereomer mixture was purified and resolved by f. c. 
with CH2Cl2/hexanes 2:1; only the Λ-(S)-diastereomer was isolated and characterized; dia-
stereomer Λ-(S)-T6 was obtained as an orange-red solid (98.6 mg, 72.7 µmol, 25%). 1H NMR 
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(500 MHz, CD2Cl2): δ = 8.19 (d, J = 10.1 Hz, 2H), 8.13 (d, J = 2.1 Hz, 1H), 8.11 (d, 
J = 1.6 Hz, 2H), 7.88 (d, J = 8.7 Hz, 1H), 7.85 (dd, J = 8.2 Hz, J = 0.9 Hz, 1H), 7.79 (dd, 
J = 7.6 Hz, J = 0.9 Hz, 1H), 7.74 (dd, J = 7.6 Hz, J = 0.9 Hz, 1H), 7.69 (dd, J = 8.8 Hz, 
J = 2.2 Hz, 1H), 7.65–7.60 (m, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H), 7.40 (d, 
J = 8.9 Hz, 1H), 7.38–7.30 (m, 3H), 7.26 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.5 Hz, 1H), 7.03 
(td, J = 7.5 Hz, J = 1.3 Hz, 1H), 7.01–6.93 (m, 2H), 6.88 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 6.77 
(d, J = 7.6 Hz, 1H), 6.66 (ddd, J = 8.6 Hz, J = 6.8 Hz, J = 1.8 Hz, 1H), 6.54 (d, J = 7.3 Hz, 
1H), 6.36 (dd, J = 8.6 Hz, J = 1.0 Hz, 1H), 6.19 (ddd, J = 8.1 Hz, J = 6.8 Hz, J = 1.1 Hz, 1H), 
4.70–4.62 (m, 1H), 2.52–2.44 (m, 2H), 1.53–1.43 (m, 36H), 0.87–0.77 (m, 1H), 0.20 (d, 
J = 7.1 Hz, 3H), 0.15 (d, J = 7.1 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C78H77Ir1N5O3S1: 
1356.5377 [M+H]+; found: 1356.5388.  
Precatalyst Λ-T6. General procedure A5) was followed using Λ-(S)-T6 (30.3 mg, 
22.3 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1; precata-
lyst Λ-T6 was obtained as a yellow crystalline solid (18.1 mg, 12.5 µmol, 56%). 1H NMR 
(600 MHz, CD2Cl2): δ = 11.08 (s, 1H), 8.17 (d, J = 1.9 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H), 8.12 
(d, J = 1.7 Hz, 2H), 8.11–8.06 (m, 3H), 7.96–7.88 (m, 3H), 7.83 (d, J = 5.2 Hz, 1H), 7.81 (d, 
J = 5.2 Hz, 1H), 7.58 (dd, J = 8.7 Hz, J = 2.0 Hz, 1H), 7.53 (dd, J = 8.7 Hz, J = 2.0 Hz, 1H), 
7.50–7.25 (m, 4H), 7.22 (dd, J = 7.6 Hz, J = 1.0 Hz, 1H), 7.18 (td, J = 7.5 Hz, J = 0.8 Hz, 1H), 
7.16 (dd, J = 8.3 Hz, J = 4.8 Hz, 1H), 7.12 (td, J = 7.6 Hz, J = 1.4 Hz, 1H), 7.09 (td, 
J = 7.5 Hz, J = 1.4 Hz, 1H), 6.92 (d, J = 7.6 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 6.45 (d, 
J = 1.9 Hz, 1H), 5.70 (d, J = 2.1 Hz, 1H), 1.58–1.45 (m, 36H) ppm (the signals of four 
protons could not be located due to severe signal broadening → probably due to hindered 
rotation of the carbazole moieties); 13C NMR (150 MHz, CD2Cl2): δ = 179.5, 179.4, 152.0, 
149.1, 148.8, 146.4, 144.4, 144.1, 143.9, 143.6, 143.0, 141.6, 139.4, 139.2, 139.2, 139.1, 
139.0, 137.3, 137.0, 134.5, 134.1, 134.0, 133.6, 133.2, 130.0, 129.9, 127.4, 127.3, 125.9, 
125.9, 124.6, 124.3, 124.2, 124.2, 12.9, 123.9, 123.8, 123.2, 117.4, 117.3, 116.9, 113.9, 113.7, 
113.1, 112.7, 109.1, 108.5, 35.3, 35.2, 32.4, 32.3 ppm (severe signal broadening → probably 
due to hindered rotation of the carbazole moieties); IR (film): v~ = 2955, 1592, 1483, 1444, 
1369, 1295, 1260, 1232, 838, 735, 705, 612, 554 cm–1; HRMS (ESI): m/z calcd for 
C76H69Ir1N7O2: 1304.5144 [M–PF6]+; found: 1304.5126. 
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4.7.2.7  Precatalyst Λ-T7 
I.)  Synthesis of Boronic Ester 269[141] 
 
 
Scheme 81. Synthesis of pinacol boronic ester 269 starting from pyrene (267).[141] 
 
2-(tert-Butyl)pyrene (268). Compound 268 was prepared according to a modified literature 
protocol from Marder et al.[141] A flame-dried flask (100 mL) was charged with pyrene (267; 
5.00 g, 24.7 mmol, 1.00 eq), dry CH2Cl2 (50 mL), and tert-butyl chloride (3.04 mL, 
27.2 mmol, 1.10 eq). The mixture was cooled to 0 °C and AlCl3 (3.29 g, 24.7 mmol, 1.00 eq) 
was added portionwise giving a red suspension. Then, the mixture was allowed to warm to rt 
and stirred for 5 h. The mixture was quenched by the careful addition of water at 0 °C, diluted 
with CH2Cl2, and stirred vigorously for 10 min. The organic layer was separated and the 
aqueous layer extracted with CH2Cl2 (3x). The combined organic layers were washed with 
brine, dried over Na2SO4, and the solvent removed in vacuo. The resulting brown crude 
product was recrystallized from methanol to give 2-(tert-butyl)pyrene (268; 3.01 g, 
11.7 mmol, 49%) as a beige solid. 1H NMR (300 MHz, CDCl3): δ = 8.26–8.11 (m, 4H), 8.10–
7.91 (m, 5H), 1.59 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 149.2, 131.2 (2C), 131.2, 
127.7 (2C), 127.6, 127.4 (2C), 125.6 (2C), 124.9 (2C), 122.4 (2C), 122.2, 35.4, 32.1 
(3C) ppm; HRMS (ESI): m/z calcd for C20H18 [M+H]+: 259.1492; found 259.1487.   
Boronic ester 269. Compound 269 was prepared according to a modified literature protocol 
from Marder et. al.[141] A flame-dried Schlenk tube (10 mL; threaded PTFE plug) equipped 
with a stir bar was charged with [Ir(µ-OMe)(1,5-cod)]2 (33.7 mg, 50.8 µmol, 1.3 mol%), 
4,4'-di-tert-butyl-2,2'-bipyridine (dtbpy; 27.3 mg, 102 µmol, 2.6 mol%), and bis(pinacolato)-
diboron (225; 50.0 mg, 197 µmol, 5.0 mol%). Dry n-hexane (2 mL) was added and the re-
sulting suspension heated to 50 °C under nitrogen atmosphere until the yellow suspension had 
turned into a red solution. The resulting red solution was transferred with a syringe into 
another flame-dried Schlenk tube (10 mL; threaded PTFE plug) which contained a solution of 
2-(tert-butyl)pyrene (268; 1.01 g, 3.91 mmol, 1.00 eq) and bis(pinacolato)diboron (225; 
1.27 g, 5.00 mmol, 1.28 eq) in dry n-hexane (10 mL). The resulting mixture was then stirred 
in the sealed Schlenk tube at 80 °C for 16 h under nitrogen atmosphere. Then, the resulting 
reaction mixture was filtered through a plug of silica gel which was thoroughly rinsed with 
excess CH2Cl2 (0.5 L). The solvent was removed in vacuo to give a yellow solid residue 
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which was purified via recrystallization from hexanes. The obtained recrystallized precipitate 
was washed with cold hexanes and after drying in vacuo, desired boronic ester 269 was 
obtained as a beige solid (0.79 g, 2.06 mmol, 53%). 1H NMR (300 MHz, CDCl3): δ = 8.61 (s, 
2H), 8.21 (s, 2H), 8.09 (d, J = 9.0 Hz, 2H), 8.04 (d, J = 9.0 Hz, 2H), 1.59 (s, 9H), 1.47 (s, 
12H) ppm; 13C NMR (75 MHz, CDCl3): δ = 149.7, 131.7 (2C), 131.3 (2C), 130.4 (2C), 127.8 
(2C), 127.6 (2C), 126.5, 123.0, 122.3 (2C), 84.3 (2C), 35.4, 32.1 (3C), 25.2 (4C) ppm (one C 
signal could not be observed (C-B)); IR (film): v~ = 2966, 1460, 1358, 1323, 1294, 1231, 1135, 
964, 900, 886, 846, 807, 714 cm–1; HRMS (ESI): m/z calcd for C26H29B1O2Na [M+Na]+: 
407.2157, found: 407.2161. 
 
II.)  Synthesis of Precatalyst Λ-T7 
Precatalyst Λ-T7 was prepared according to general pro-
cedures A1), A3), A4), and A5) from benzoxazole ligand 
222, IrCl3·3H2O, auxiliary ligand (S)-Aux1, boronic ester 
269, and imidazoquinoline ligand 233. 
Rac-T7-dimer-CC. General procedure A1) was followed 
using benzoxazole ligand 222 (2.50 g, 7.30 mmol, 2.10 eq) 
and IrCl3·3H2O (1.34 g, 3.48 mmol, 1.00 eq); reaction time: 24 h; in contrast to general 
procedure A1), rac-T7-dimer-CC was not purified by precipitation but via flash chromato-
graphy. Accordingly, all volatiles were removed in vacuo after reaction completion and the 
crude dimer purified by f. c. (CH2Cl2/hexanes 1:1). Rac-T7-dimer-CC was obtained as an 
orange solid (2.51 g, 1.37 mmol, 79%). 1H NMR (300 MHz, CD2Cl2): δ = 8.20 (d, J = 2.5 Hz, 
4H), 7.70 (dd, J = 7.6 Hz, J = 1.1 Hz, 4H), 7.56 (d, J = 9.1 Hz, 4H), 7.16 (dd, J = 9.1 Hz, 
J = 2.6 Hz, 4H), 6.95 (td, J = 7.5 Hz, J = 0.7 Hz, 4H), 6.74 (td, J = 7.6 Hz, J = 1.4 Hz, 4H), 
6.12 (d, J = 7.7 Hz, 4H) ppm. 
Λ-(S)-T7-CC. General procedure A3) was followed using rac-T7-dimer-CC (500 mg, 
274 µmol); reaction time: 8 h; the crude diastereomer mixture was purified and resolved by 
f. c. with CH2Cl2/hexanes 6:1 → 8:1 → 10:1; only the Λ-(S)-diastereomer was isolated and 
characterized; diastereomer Λ-(S)-T7-CC was obtained as a red-orange solid (220 mg, 
201 µmol, 37%). 1H NMR (300 MHz, CD2Cl2): δ = 7.88 (d, J = 2.6 Hz, 1H), 7.80 (d, 
J = 9.0 Hz, 1H), 7.76 (ddd, J = 7.8 Hz, J = 1.5 Hz, J = 0.6 Hz, 1H), 7.74 (d, J = 8.9 Hz, 1H), 
7.69 (ddd, J = 7.6 Hz, J = 1.5 Hz, J = 0.5 Hz, 1H), 7.46 (dd, J = 8.1 Hz, J = 1.7 Hz, 1H), 
7.43–7.34 (m, 3H), 7.16 (ddd, J = 8.6 Hz, J = 6.8 Hz, J = 1.8 Hz, 1H), 7.00 (dd, J = 7.4 Hz, 
J = 1.1 Hz, 1H), 6.95 (dd, J = 7.3 Hz, J = 1.0 Hz, 1H), 6.89 (td, J = 7.5 Hz, J = 1.7 Hz, 1H), 
6.83 (td, J = 7.5 Hz, J = 1.4 Hz, 1H), 6.68 (dd, J = 8.7 Hz, J = 1.1 Hz, 1H), 6.62 (d, J = 7.5 Hz, 
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1H), 6.37–6.27 (m, 2H), 4.64 (dt, J = 10.2 Hz,  J = 2.1 Hz, 1H), 3.37 (dd, J = 11.9 Hz, J = 9.8 
Hz, 1H), 3.01 (dd, J = 11.9 Hz, J = 1.9 Hz, 1H), 0.75–0.59 (m, 1H), 0.25 (d, J = 7.2 Hz, 3H), 
0.22 (d, J = 7.2 Hz, 3H) ppm. 
Λ-(S)-T7. General procedure A4) was followed using Λ-(S)-T7-CC (50.0 mg, 45.6 µmol); 
instead of toluene, a 10:1 mixture of toluene and H2O was used as solvent; employed boronic 
ester: 269; reaction time: 16 h; the crude product was purified by f. c. with CH2Cl2/hexanes 
6:1 → CH2Cl2; Λ-(S)-T7 was obtained as an orange solid (46.9 mg, 35.7 µmol, 78%). 
1H NMR (300 MHz, CD2Cl2): δ = 8.52 (d, J = 1.5 Hz, 1H), 8.45 (s, 2H), 8.32 (s, 2H), 8.26 
(d, J = 12 Hz, 4H), 8.12 (s, 4H), 8.10–7.98 (m, 5H), 7.94–7.83 (m, 3H), 7.81–7.72 (m, 3H), 
7.67 (d, J = 8.4 Hz, 1H), 7.38 (ddd, J = 8.6 Hz, J = 6.8 Hz, J = 1.8 Hz, 1H), 7.09 (dd, 
J = 8.6 Hz, J = 1.0 Hz, 1H), 7.04 (td, J = 7.5 Hz, J = 1.1 Hz, 1H), 6.99–6.88 (m, 2H), 6.82–
6.72 (m, 2H), 6.59 (ddd, J = 8.1 Hz, J = 6.8 Hz, J = 1.2 Hz, 1H), 6.53 (d, J = 7.2 Hz, 1H), 
4.98–4.86 (m, 1H), 3.16 (dd, J = 11.6 Hz, J = 9.9 Hz, 1H), 2.85 (dd, J = 11.7 Hz, J = 1.1 Hz, 
1H), 1.61 (s, 9H), 1.61 (s, 9H), 1.06–0.83 (m, 1H), 0.29 (d, J = 7.0 Hz, 3H), 0.09 (d, 
J = 7.0 Hz, 3H) ppm; 13C NMR (75 MHz, CD2Cl2): δ = 179.3, 179.0, 168.2, 167.4, 151.1, 
150.7, 150.5, 150.4, 150.1, 150.0, 140.8, 140.6, 140.1, 139.9, 138.3, 137.7, 135.4, 134.5, 
134.4, 132.5, 132.5, 132.2 (3C), 132.0 (2C), 131.8, 131.7 (2C), 131.6 (2C), 131.2, 128.7 (2C), 
128.6 (2C), 128.0 (2C), 127.7 (2C), 126.8, 126.5, 126.0, 125.6, 125.0, 124.5, 124.4, 124.2 
(2C), 124.1 (2C), 123.3, 123.2 (3C), 123.1 (2C), 122.6, 121.5, 118.9, 117.4, 115.4, 114.1, 
112.6, 112.2, 86.5, 35.8 (2C), 32.3 (6C), 32.2, 28.0, 19.1, 14.6 ppm; IR (film): v~ = 2956, 1594, 
1557, 1517, 1439, 1377, 1195, 1010, 877, 811, 737, 709 cm–1; HRMS (ESI): m/z calcd for 
C78H62Ir1N3O3S1Na: 1336.4041 [M+Na]+, found: 1336.4074. 
Precatalyst Λ-T7. General procedure A5) was followed using Λ-(S)-T7 (27.2 mg, 
25.5 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1; 
precatalyst Λ-T7 was obtained as a greenish yellow solid (17.3 mg, 14.9 µmol, 59%). 
1H NMR (600 MHz, CD2Cl2): δ = 11.74 (s, 1H), 8.58 (dd, J = 8.5 Hz, J = 0.9 Hz, 1H), 8.35–
8.31 (m, 2H), 8.29 (s, 2H), 8.24 (s, 2H), 8.22 (d, J = 9.0 Hz, 1H), 8.16–8.08 (m, 6H), 8.05 (d, 
J = 9.0 Hz, 1H), 8.01 (d, J = 9.0 Hz, 2H), 7.93 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 7.92–7.87 (m, 
4H), 7.80–7.73 (m, 3H), 7.66 (s, 2H), 7.60 (dd, J = 8.5 Hz, J = 5.1 Hz, 1H), 7.21 (td, 
J = 7.5 Hz, J = 0.8 Hz, 1H), 7.16 (td, J = 7.5 Hz, J = 0.8 Hz, 1H), 7.10 (td, J = 7.5 Hz, 
J = 1.5 Hz, 1H), 7.06 (td, J = 7.5 Hz, J = 1.3 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1H), 6.91 (d, 
J = 7.5 Hz, 1H), 6.76 (d, J = 1.5 Hz, 1H), 5.83 (d, J = 1.5 Hz, 1H), 1.60 (s, 9H), 1.55 (s, 
9H) ppm; 13C NMR (150 MHz, CD2Cl2): δ = 178.8, 178.7, 152.3, 150.5, 150.4, 150.3, 150.2, 
146.2, 144.4, 143.6, 143.3, 142.1, 140.8, 140.7, 139.3, 139.1, 138.9, 137.3, 136.6, 134.6, 
134.2, 133.7, 133.5, 133.3, 132.2 (2C), 131.9 (2C), 131.6 (2C), 131.5 (2C), 130.3, 130.3, 
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129.2 (2C), 129.1 (2C), 127.8 (2C), 127.4 (2C), 127.2, 127.1, 126.2, 126.2, 126.2, 126.1, 
124.4, 124.4, 123.7, 123.7, 123.5 (2C), 123.4 (3C), 123.3 (2C), 123.0 (3C), 122.9, 117.6, 
114.3, 114.1, 113.1, 112.9, 35.8, 35.7, 32.2 (3C), 32.2 (3C) ppm; IR (film): v~ = 2960, 1595, 
1443, 1382, 1261, 1090, 1035, 843, 738, 711, 557 cm–1; HRMS (ESI): m/z calcd for 
C76H55Ir1N5O2: 1262.3987 [M–PF6]+; found: 1262.3997. 
 
4.7.2.8  Precatalyst Λ-T8 
Precatalyst Λ-T8 was prepared according to general procedures 
A1), A3), A4), and A5) from benzoxazole ligand 217, IrCl3·3H2O, 
auxiliary ligand (S)-Aux1, 2,4,6-trimethylphenylboronic acid, 
and imidazoquinoline ligand 233. 
Rac-T8-dimer-CC. General procedure A1) was followed using 
benzoxazole ligand 217 (510 mg, 1.43 mmol, 2.04 eq) and 
IrCl3·3H2O (246 mg, 698 µmol, 1.00 eq); reaction time: 24 h; in 
contrast to general procedure A1), rac-T8-dimer-CC was not purified by precipitation but via 
flash chromatography. Accordingly, all volatiles were removed in vacuo after reaction 
completion and the crude product purified by f. c. (CH2Cl2/hexanes 1:1). Ir(III) dimer 
rac-T8-dimer-CC was obtained as an orange solid (584 mg, 310 µmol, 89%). 1H NMR 
(500 MHz, CD2Cl2): δ = 8.10 (s, 4H), 7.65 (dd, J = 7.6 Hz, J = 0.9 Hz, 4H), 7.45 (s, 4H), 6.93 
(ddd, J = 7.4 Hz, J = 7.6 Hz, J = 0.7 Hz, 4H), 6.72 (ddd, J = 7.9 Hz, J = 7.3 Hz, J = 1.4 Hz, 
4H), 6.12 (d, J = 7.8 Hz, 4H), 2.47 (s, 12H) ppm; 19F NMR (471 MHz, CD2Cl2): δ = −73.9 (s, 
3F, 4x CF3) ppm; HRMS (ESI): m/z calcd for C60H36Cl2F12Ir2N4O16S4Na: 1902.9324 
[M+Na]+, found: 1902.9318. 
Λ-(S)-T8-CC. General procedure A3) was followed using rac-T8-dimer-CC (585 mg, 
311 µmol); reaction time: 8 h; the crude diastereomer mixture was purified and resolved by 
f. c. with CH2Cl2/hexanes 3:1; only the Λ-(S)-diastereomer was isolated and characterized; 
diastereomer Λ-(S)-T8-CC was obtained as a red-orange solid (282 mg, 250 µmol, 40%). 
1H NMR (500 MHz, CD2Cl2): δ = 7.89 (s, 1H), 7.73 (dd, J = 7.8 Hz, J = 1.0 Hz, 1H), 7.68 (s, 
1H), 7.65–7.59 (m, 1H), 7.53 (d, J = 5.9 Hz, 1H), 7.49–7.43 (m, 1H), 7.40 (s, 1H), 7.16–7.07 
(m, 1H), 6.95 (ddd, J = 7.5 Hz, J = 7.5 Hz, J = 1.0 Hz, 2H), 6.87 (ddd, J = 7.5 Hz, J = 7.5 Hz, 
J = 1.4 Hz, 1H), 6.84–6.79 (m, 1H), 6.71–6.66 (m, 1H), 6.65 (d, J = 7.7 Hz, 1H), 6.34 (d, 
J = 7.7 Hz, 1H), 6.32–6.26 (m, 1H), 4.63–4.55 (m, 1H), 3.42 (dd, J = 11.7 Hz, J = 10.1 Hz, 
1H), 2.98 (d, J = 11.7 Hz, 1H), 2.55 (s, 3H), 2.48 (s, 3H), 0.77–0.62 (m, 1H), 0.27 (d, 
J = 7.0 Hz, 3H), 0.24 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 180.5, 
180.0, 169.7, 167.9, 151.6, 150.5, 150.0, 149.6, 147.1, 145.7, 138.0, 137.9, 135.4, 134.1, 
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133.9, 133.1, 132.5, 132.0, 130.6, 130.4, 129.9, 129.3, 127.2, 126.9, 124.5, 122.6, 121.6, 
119.2 (q, JC-F = 320 Hz), 119.0 (q, JC-F = 321 Hz), 118.5, 114.8, 114.4, 114.1, 111.7, 110.3, 
85.0, 32.4, 27.3, 19.2, 17.9, 17.3, 14.3 ppm; 19F NMR (471 MHz, CD2Cl2): δ = −73.9 (s, 3F, 
CF3), −74.2 (s, 3F, CF3) ppm; IR (film): v~ = 1594, 1557, 1518, 1463, 1414, 1205, 1130, 1063, 
1012, 961, 882, 851, 735, 607, 508, 446 cm–1; HRMS (ESI): m/z calcd for 
C42H32F6Ir1N3O9S3Na: 1148.0724 [M+Na]+, found: 1148.0725. 
Λ-(S)-T8. General procedure A4) was followed using Λ-(S)-T8-CC (30.2 mg, 26.8 µmol); 
boronic acid: 2,4,6-trimethylphenylboronic acid; reaction time: 11 h; the crude product was 
purified by f. c. with CH2Cl2/hexanes 3:1 → CH2Cl2; Λ-(S)-Ir8 was obtained as a bright 
orange solid (26.8 mg, 25.2 µmol, 94%). 1H NMR (300 MHz, CD2Cl2): δ = 7.71 (dd, 
J = 7.6 Hz, J = 0.8 Hz, 1H), 7.64 (dd, J = 7.6 Hz, J = 1.0 Hz, 1H), 7.61 (s, 1H), 7.58 (s, 1H), 
7.48 (s, 1H), 7.24 (dd, J = 8.1 Hz, J = 1.7 Hz, 1H), 7.11 (s, 1H), 7.02–6.83 (m, 7H), 6.81 (s, 
1H), 6.75 (dd, J = 7.5 Hz, J = 1.5 Hz, 1H), 6.61 (d, J = 7.2 Hz, 1H), 6.55–6.47 (m, 1H), 6.41 
(dd, J = 8.7 Hz, J = 1.1 Hz, 1H), 6.14 (ddd, J = 8.1 Hz, J = 6.8 Hz, J = 1.1 Hz, 1H), 4.53 (ddd, 
J = 9.6 Hz, J = 2.3 Hz, J = 2.3 Hz, 1H), 2.71 (dd, J = 11.7 Hz, J = 2.1 Hz, 1H), 2.62 (dd, 
J = 11.5 Hz, J = 9.4 Hz, 1H), 2.34 (s, 3H), 2.29 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 1.94 (s, 3H), 
1.93 (s, 3H), 1.87 (s, 3H), 1.54 (s, 3H), 0.83–0.62 (m, 1H), 0.20 (d, J = 7.0 Hz, 1H), 0.18 (d, 
J = 7.0 Hz, 1H) ppm. 13C NMR (75 MHz, CD2Cl2): δ = 178.0, 177.8, 169.0, 168.3, 151.1, 
150.4, 150.2, 149.9, 139.9, 139.8, 137.6, 137.6, 137.5, 137.5, 137.3, 137.1, 136.7, 136.2, 
136.1, 135.7, 135.0, 134.9, 134.7, 133.6, 133.5, 132.6, 132.0, 131.9, 131.6, 131.4, 128.8, 
128.6, 128.5, 128.5, 126.4, 126.0, 124.1, 122.2, 121.1, 119.1, 118.7, 116.7, 113.3, 113.1, 
112.5, 85.1, 32.2, 27.7, 21.5, 21.4, 20.8, 20.6, 20.3, 20.3, 19.2, 14.5 ppm; IR (film): v~ = 2957, 
2917, 1596, 1557, 1518, 1441, 1378, 1280, 1194, 1153, 1036, 1011, 849, 736, 445 cm–1; 
HRMS (ESI): m/z calcd for C58H54Ir1N3O3S1Na: 1088.3410 [M+Na]+, found: 1088.3456. 
Precatalyst Λ-T8. General procedure A5) was followed using Λ-(S)-T8 (35.4 mg, 
33.2 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1 → 50:1; 
precatalyst Λ-T8 was obtained as a greenish yellow solid (23.2 mg, 20.0 µmol, 60%). 
1H NMR (300 MHz, CD2Cl2): δ = 11.15 (s, 1H), 8.24 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H), 8.03 
(dd, J = 5.1 Hz, J = 1.1 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 7.90 (s, 1H), 7.86 (dd, J = 7.7 Hz, 
J = 0.9 Hz, 1H), 7.84–7.78 (m, 2H), 7.54 (s, 1H), 7.50 (s, 1H), 7.32 (dd, J = 8.3 Hz, 
J = 4.9 Hz, 1H), 7.22–7.08 (m, 2H), 7.05 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 7.01 (td, J = 7.6 Hz, 
J = 1.8 Hz, 1H), 6.91 (s, 1H), 6.89–6.79 (m, 4H), 6.76 (s, 1H), 5.92 (s, 1H), 4.86 (s, 1H), 2.28 
(s, 6H), 1.97 (s, 3H), 1.91 (s, 3H), 1.86 (s, 3H), 1.74 (s, 3H), 1.17 (s, 3H), 1.04 (s, 3H) ppm; 
13C NMR (75 MHz, CD2Cl2): δ = 177.6, 177.6, 151.8, 150.2, 150.2, 146.0, 144.1, 143.2, 
142.6, 141.6, 140.3, 139.8, 138.7, 137.8, 137.4, 136.8, 136.7, 136.7, 136.2, 136.0, 135.8, 
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135.6 (2C), 135.6, 135.3, 134.6, 134.2, 133.2, 133.0, 132.8, 130.7, 130.7, 128.9, 128.9, 128.5 
(2C), 126.8, 126.7, 125.8, 125.6, 123.5 (2C), 122.9, 117.1, 116.0, 115.0, 113.6, 113.3, 21.3, 
21.3, 20.4 (2C), 20.3, 20.3, 20.0 (2C) ppm; IR (film): v~ = 1450, 1380, 834, 775, 736, 704, 
553 cm–1; HRMS (ESI): m/z calcd for C56H47Ir1N5O2: 1014.3358 [M–PF6]+; found: 1014.3364.  
 
4.7.2.9  Precatalyst Λ-T9 
Precatalyst Λ-T9 was prepared according to general 
procedures A4) and A5) from OTf-functionalized dia-
stereomer Λ-(S)-T8-CC (see 4.7.2.8), boronic ester 269 
(see 4.7.2.7), and imidazoquinoline ligand 233. 
Λ-(S)-T9. General procedure A4) was followed using 
Λ-(S)-T8-CC (70.1 mg, 62.3 µmol); instead of toluene, a 
10:1 mixture of toluene and H2O was used as solvent; 
employed boronic ester: 269; reaction time: 14 h; the crude product was purified by f. c. with 
CH2Cl2/hexanes 3:1 → 6:1; diastereomer Λ-(S)-T9 was obtained as an orange solid (71.5 mg, 
53.3 µmol, 86%). 1H NMR (600 MHz, CD2Cl2): δ = 8.32 (s, 2H), 8.31 (s, 2H), 8.29 (s, 2H), 
8.16 (d, J = 9.0 Hz, 2H), 8.15–8.11 (m, 4H), 8.08 (d, J = 9.0 Hz, 2H), 8.05 (s, 2H), 7.99 (s, 
1H), 7.77 (ddd, J = 7.6 Hz, J = 7.6 Hz, J = 1.0 Hz, 1H), 7.73 (ddd, J = 7.7 Hz, J = 1.4 Hz, 
J = 0.5 Hz, 1H), 7.70 (s, 1H), 7.61 (dd, J = 8.2 Hz, J = 1.7 Hz, 1H), 7.61 (s, 1H), 7.57 (s, 1H), 
7.02 (ddd, J = 7.5 Hz, J = 7.5 Hz, J = 1.1 Hz, 1H), 6.98–6.91 (m, 2H), 6.84–6.77 (m, 3H), 
6.57 (dd, J = 8.2 Hz, J = 1.1 Hz, 1H), 6.51 (d, J = 7.5 Hz, 1H), 6.31 (ddd, J = 8.0 Hz, 
J = 6.7 Hz, J = 1.2 Hz, 1H), 4.81 (ddd, J = 9.9 Hz, J = 2.3 Hz, J = 2.3 Hz, 1H), 2.69 (dd, 
J = 11.4 Hz, J = 9.9 Hz, 1H), 2.63–2.54 (m, 1H), 2.57 (s, 3H), 2.49 (s, 3H), 1.64 (s, 9H), 1.63 
(s, 9H), 0.99–0.89 (m, 1H), 0.26 (d, J = 7.0 Hz, 3H), 0.09 (d, J = 7.0 Hz, 3H) ppm; 13C NMR 
(150 MHz, CD2Cl2): δ = 178.3, 178.1, 168.4, 167.4, 151.0, 150.5, 150.3, 150.2, 150.0, 149.8, 
141.4, 141.2, 138.9, 138.7, 137.4, 137.2, 135.4, 134.5, 134.5, 134.0, 133.6, 132.4, 132.1, 
131.9, 131.7, 131.6 (3C), 131.6 (2C), 131.4 (2C), 131.3, 131.3 (2C), 128.6 (2C), 128.3 (2C), 
128.0 (2C), 127.8 (2C), 126.5 (2C), 126.5, 126.7 (2C), 126.1, 124.4, 124.2, 124.0, 123.2, 
123.1 (2C), 123.0 (2C), 122.3, 121.2, 120.1, 118.7, 117.7, 113.6, 113.4, 113.0, 86.0, 35.8, 
35.8, 32.3 (9C), 32.1, 27.6, 22.1, 21.7, 19.0, 14.5 ppm; IR (film): v~ = 3041, 2956, 2867, 1595, 
1556, 1517, 1441, 1378, 1254, 1226, 1192, 1150, 1126, 1033, 1009, 874, 848, 801, 715, 444 
cm–1; HRMS (ESI): m/z calcd for C80H66Ir1N3O3S1Na: 1364.4353 [M+Na]+, found: 1364.4386. 
Precatalyst Λ-T9. General procedure A5) was followed using Λ-(S)-T9 (71.0 mg, 
52.9 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1; pre-
catalyst Λ-T9 was obtained as a greenish yellow solid (35.2 mg, 24.5 µmol, 46%). 1H NMR 
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(500 MHz, CD2Cl2): δ = 11.21 (s, 1H), 8.31 (s, 2H), 8.29 (s, 2H), 8.17–8.08 (m, 7H), 8.03 (s, 
1H), 8.02 (s, 1H), 8.01–7.95 (m, 4H), 7.88 (dd, J = 7.6 Hz, J = 0.9 Hz, 1H), 7.84 (dd, 
J = 7.6 Hz, J = 0.9 Hz, 1H), 7.71 (s, 2H), 7.60 (s, 1H), 7.55 (s, 1H), 7.47 (s, 2H), 7.19 (td, 
J = 7.6 Hz, J = 1.0 Hz, 1H), 7.16–7.11 (s, 2H), 7.08 (td, J = 7.6 Hz, J = 1.6 Hz, 1H), 7.06 (td, 
J = 7.6 Hz, J = 1.5 Hz, 1H), 6.94 (d, J = 7.3 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 6.37 (s, 1H), 
5.23 (s, 1H), 2.39 (s, 3H), 2.35 (s, 3H), 1.62 (9H), 1.59 (9H) ppm; 13C NMR (150 MHz, 
CD2Cl2): δ = 177.9, 177.9, 152.1, 150.3, 150.2, 150.2, 150.1, 146.0, 144.3, 143.4, 142.9, 
141.9, 141.7, 141.3, 138.7, 138.2, 138.0, 136.7, 136.0, 135.6, 135.1, 134.6, 134.1, 133.3, 
133.1, 132.9, 131.6 (2C), 131.5 (2C), 131.5 (2C), 131.2 (2C), 130.5, 130.5, 129.0 (2C), 128.8 
(2C), 127.5 (2C), 127.4 (2C), 126.9, 126.8, 126.0, 125.8, 125.6 (2C), 125.5 (2C), 124.1, 124.0, 
123.6, 123.5, 123.3 (2C), 123.3 (2C), 123.1, 123.0, 123.0, 117.3, 117.0, 116.4, 113.7, 113.7, 
35.8, 35.8, 32.2 (3C), 32.2 (3C), 21.9, 21.6 ppm; IR (film): v~ = 2958, 1596, 1447, 1383, 1038, 
840, 728, 557 cm–1; HRMS (ESI): m/z calcd for C78H59Ir1N5O2: 1290.4300 [M–PF6]+; found: 
1290.4313. 
 
4.7.2.10  Precatalyst Λ-T10 
Precatalyst Λ-T10 was prepared according to general procedures 
A1), A2), and A5) from benzothiazole ligand 199, IrCl3·3H2O, 
auxiliary ligand (S)-Aux1, and imidazoquinoline ligand 233. 
Rac-T10-dimer. General procedure A1) was followed using 
benzothiazole ligand 199 (1.04 g, 3.16 mmol, 2.05 eq) and 
IrCl3·3H2O (542 mg, 1.54 mmol, 1.00 eq); reaction time: 11.5 h; 
Ir(III) dimer rac-T10-dimer was obtained as a deeply red solid (1.40 g, 0.79 mmol, quan-
titative). 1H NMR (300 MHz, CD2Cl2): δ = 9.00–8.87 (m, 4H), 8.01 (d, J = 8.1 Hz, 4H), 7.65 
(d, J = 7.9 Hz, 4H), 7.32 (dd, J = 8.2 Hz, J = 1.2 Hz, 4H), 7.00–6.84 (m, 12H), 6.67 (td, 
J = 7.5 Hz, J = 1.2 Hz, 4H), 6.37 (d, J = 7.7 Hz, 4H), 2.30 (s, 12H), 2.11 (s, 12H), 1.99 (s, 
12H) ppm; HRMS (ESI): m/z calcd for C88H72Cl1Ir2N4S4: 1733.3572 [M–Cl]+; found: 
1733.3632.  
Λ-(S)-T10. General procedure A2) was followed using rac-T10-dimer (501 mg, 283 µmol) 
and auxiliary ligand (S)-Aux1; the crude diastereomer mixture was dissolved in CH2Cl2, 
adsorbed on silica gel (40 °C), and purified and resolved by f. c. with hexanes/EtOAc 20:1 → 
10:1; only the Λ-(S)-diastereomer was isolated and characterized; diastereomer Λ-(S)-T10 
was obtained as a red solid (156 mg, 146 µmol, 26%). 1H NMR (500 MHz, CD2Cl2): δ = 8.60 
(d, J = 1.1 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 7.5, 1H), 
7.65 (dd, J = 7.6 Hz, J = 0.8 Hz, 1H), 7.56 (d, J = 1.1 Hz, 1H), 7.23 (d, J = 1.5 Hz, 1H), 7.22 
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(d, J = 1.3 Hz, 1H), 7.18 (dd, J = 8.2 Hz, J = 1.7 Hz, 1H), 6.98 (s, 1H), 6.95–6.87 (m, 3H), 
6.84 (s, 1H), 6.83–6.79 (m, 1H), 6.75 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 6.71–6.64 (m, 3H), 
6.31 (d, J = 7.5, 1H), 6.26 (dd, J = 8.6 Hz, J = 0.9 Hz, 1H), 6.15–6.10 (m, 1H), 4.34 (d, 
J = 10.5 Hz, 1H), 2.51 (dd, J = 11.7 Hz, J = 1.5 Hz, 1H), 2.32 (s, 3H), 2.25 (s, 3H), 2.19 (dd, 
J = 11.6 Hz, J = 9.7 Hz, 1H), 2.05 (s, 3H), 1.99 (s, 6H), 1.51 (s, 3H), 0.69–0.57 (m, 1H), 0.24 
(d, J = 7.2 Hz, 3H), 0.10 (d, J = 7.2 Hz, 3H) ppm; HRMS (ESI): m/z calcd for 
C56H50Ir1N3O1S3Na: 1092.2637 [M+Na]+; found: 1092.2642.   
Precatalyst Λ-T10. General procedure A5) was followed using Λ-(S)-T10 (25.0 mg, 
23.4 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 35:1; precatalyst 
Λ-T10 was obtained as a yellow-orange crystalline solid (14.3 mg, 12.3 µmol, 53%). 
1H NMR (500 MHz, CD2Cl2): δ = 11.21 (s, 1H), 8.04 (dd, J = 8.3 Hz, J = 1.0 Hz, 1H), 7.94–
7.78 (m, 7H), 7.77 (d, J = 9.0 Hz, 1H), 7.20–7.05 (m, 4H), 7.00 (dd, J = 8.3 Hz, J = 1.5 Hz, 
1H), 6.93 (td, J = 7.6 Hz, J = 1.4 Hz, 1H), 6.91–6.86 (m, 2H), 6.83 (s, 1H), 6.81 (s, 1H), 6.73 
(s, 1H), 6.70 (d, J = 7.7 Hz, 1H), 6.66 (d, J = 7.7 Hz, 1H), 6.55 (d, J = 0.9 Hz, 1H), 5.43 (d, 
J = 0.9 Hz, 1H), 2.30 (s, 3H), 2.28 (s, 3H), 1.90 (s, 3H), 1.74 (s, 3H), 0.94 (s, 3H), 0.92 (s, 
3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 182.1, 181.6, 150.6, 150.5, 150.1, 147.2, 144.4, 
143.8, 141.9, 141.9, 141.6, 141.5, 141.5, 141.1, 138.6, 138.1, 137.5, 137.4, 137.2, 135.6, 
135.5, 135.5, 135.1, 134.7, 134.4, 133.1, 132.2, 131.9, 130.2, 130.0, 128.9, 128.7, 128.3, 
128.2, 128.1, 127.4, 126.9, 126.8, 126.0, 125.7, 123.7, 123.6, 123.6, 123.4, 123.0, 124.5, 
119.4, 116.9, 21.3, 21.1, 21.0, 20.8, 20.3, 20.0 ppm; IR (film): v~ = 1442, 1410, 841, 764, 733, 
557 cm–1; HRMS (ESI): m/z calcd for C54H43Ir1N5S2: 1018.2584 [M–PF6]+; found: 1018.2594. 
 
4.7.2.11  Precatalyst Λ-T11 
Precatalyst Λ-T11 was prepared according to general procedures 
A2) and A5) from iridium(III) dimer rac-T11-dimer (received 
from former PhD student Haohua Huo), auxiliary ligand (S)-Aux1, 
and imidazoquinoline ligand 233. 
Λ-(S)-T11. General procedure A2) was followed using 
rac-T11-dimer (122 mg, 66.5 µmol) and auxiliary ligand 
(S)-Aux1; the crude diastereomer mixture was dissolved in CH2Cl2, adsorbed on silica gel 
(40 °C), and purified and resolved by f. c. with hexanes/EtOAc 20:1; only the Λ-(S)-
diastereomer was isolated and characterized; diastereomer Λ-(S)-T11 was obtained as a red 
solid (36.0 mg, 32.7 µmol, 25%). 1H NMR (300 MHz, CD2Cl2): δ = 8.93 (d, J = 1.7 Hz, 1H), 
7.86 (d, J = 8.5 Hz, 1H), 7.80–7.68 (m, 3H), 7.61 (dd, J = 7.6 Hz, J = 0.9 Hz, 1H), 7.49 (dt, 
J = 8.7 Hz, J = 1.8 Hz, 2H), 7.29 (dd, J = 8.1 Hz, J = 1.7 Hz, 1H), 6.98 (ddd, J = 8.6 Hz, 
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J = 6.8 Hz, J = 1.8 Hz, 1H), 6.93–6.84 (m, 2H), 6.82–6.76 (m, 1H), 6.72 (td, J = 7.5 Hz, 
J = 1.3 Hz, 1H), 6.69–6.59 (m, 2H), 6.17–6.07 (m, 2H), 4.47 (dt, J = 9.9 Hz, J = 2.0 Hz, 1H), 
3.43 (dd, J = 11.4 Hz, J = 9.7 Hz, 1H), 2.98 (dd, J = 11.5 Hz, J = 1.7 Hz, 1H), 2.25–1.48 (m, 
30H), 0.74–0.56 (m, 1H), 0.32 (d, J = 7.0 Hz, 3H), 0.03 (d, J = 6.8 Hz, 3H) ppm; HRMS 
(ESI): m/z calcd for C58H58IrN3OS3Na: 1124.3263 [M+Na]+; found: 1124.3304.   
Precatalyst Λ-T11. General procedure A5) was followed using Λ-(S)-T11 (35.8 mg, 
32.5 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1 → 50:1; 
precatalyst Λ-T11 was obtained as a greenish yellow crystalline solid (28.6 mg, 23.9 µmol, 
74%). 1H NMR (500 MHz, CD2Cl2): δ = 11.50 (s, 1H), 8.47 (dd, J = 8.3 Hz, J = 1.2 Hz, 1H), 
8.19 (dd, J = 5.0 Hz, J = 1.3 Hz, 1H), 8.11 (d, J = 0.7 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.92 
(d, J = 9.0 Hz, 1H), 7.85 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 7.81 (dd, J = 7.7 Hz, J = 0.9 Hz, 
1H), 7.78–7.72 (m, 2H), 7.61 (dd, J = 8.3 Hz, J = 5.0 Hz, 1H), 7.33 (dd, J = 8.5 Hz, 
J = 1.7 Hz, 1H), 7.30 (dd, J = 8.5 Hz, J = 1.7 Hz, 1H), 7.11 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 
7.06 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.89 (td, J = 7.5 Hz, J = 1.5 Hz, 1H), 6.85 (td, 
J = 7.5 Hz, J = 1.3 Hz, 1H), 6.58 (d, J = 7.3 Hz, 1H), 6.54 (d, J = 1.7 Hz, 1H), 6.51 (d, 
J = 7.5 Hz, 1H), 6.25 (d, J = 1.7 Hz, 1H), 2.03–1.06 (m, 30H) ppm; 13C NMR (125 MHz, 
CD2Cl2): δ = 181.8, 181.5, 152.7, 152.3, 150.6, 150.5, 150.4, 146.8, 143.9, 143.8, 142.1, 
141.7, 141.6, 141.5, 138.6, 134.4, 134.3, 133.3, 132.1, 131.8, 128.9, 128.7, 126.6, 126.4, 
126.3, 125.8, 124.1, 123.9, 123.8, 123.5, 123.4, 123.1, 122.9, 117.0, 115.3, 115.0, 43.4 (3C), 
43.2 (3C), 36.9 (3C), 36.8 (3C), 36.5, 36.3, 29.1 (3C), 29.1 (3C) ppm; IR (film): v~ = 2900, 
1441, 839, 766, 732, 668, 554, 454 cm–1; HRMS (ESI): m/z calcd for C56H51IrN5S2: 
1050.3211 [M–PF6]+; found: 1050.3208.  
 
4.7.2.12  Precatalyst Λ-T12 
Precatalyst Λ-T12 was prepared according to general procedure 
A5) from diastereomer Λ-(S)-T1 (see 4.7.2.1; 25.0 mg, 
24.1 µmol) and imidazoquinoline ligand 238; eluent for f. c.: 
CH2Cl2/MeOH 100:1 → 50:1; precatalyst Λ-T12 was obtained as 
a yellow crystalline solid (15.4 mg, 13.4 µmol, 56%). 1H NMR 
(300 MHz, CD2Cl2): δ = 10.75 (s, 1H), 8.28 (dd, J = 8.4 Hz, 
J = 1.0 Hz, 1H), 8.06 (dd, J = 5.1 Hz, J = 1.1 Hz, 1H), 7.94–7.81 
(m, 3H), 7.75 (d, J = 8.9 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 8.5 Hz, 1H), 7.35 (dd, 
J = 8.4 Hz, J = 5.0 Hz, 1H), 7.24–7.11 (m, 3H), 7.11–7.00 (m, 3H), 6.92 (s, 1H), 6.90–6.80 
(m, 4H), 6.75 (s, 1H), 6.05 (d, J = 1.1 Hz, 1H), 5.12 (d, J = 1.1 Hz, 1H), 2.28 (s, 3H), 2.27 (s, 
3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.88 (s, 3H), 1.31 (s, 3H), 1.12 (s, 3H) ppm; 13C NMR 
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(75 MHz, CD2Cl2): δ = 178.5, 178.3, 155.2, 151.6, 149.7, 149.7, 146.4, 144.6, 143.6, 141.8, 
140.6, 140.0, 138.8, 138.6, 138.1, 137.9, 137.5, 137.5, 137.3, 135.8, 135.8, 135.7, 135.6, 
134.5, 134.1, 133.7, 133.5, 133.1, 130.6, 130.5, 129.1 (2C), 128.7 (2C), 128.5, 128.1, 127.1, 
127.1, 125.6, 124.6, 123.7, 123.6, 122.6, 116.7, 116.5, 115.9, 112.6, 112.4, 21.3, 21.3, 21.0, 
21.0, 20.5, 20.4, 13.3 ppm; IR (film): v~ = 1611, 1592, 1518, 1466, 1449, 1428, 1380, 1041, 
843, 735, 705, 557 cm–1; HRMS (ESI): m/z calcd for C55H45Ir1N5O2: 1000.3201 [M–PF6]+; 
found: 1000.3239. 
 
4.7.2.13  Precatalyst Λ-T13 
Precatalyst Λ-T13 was prepared according to general procedures 
A1), A2), and A5) from benzoxazole ligand 196, IrCl3·3H2O, 
auxiliary ligand (S)-Aux1, and imidazoquinoline ligand 233. 
Rac-T13-dimer. General procedure A1) was followed using 
benzoxazole ligand 196 (1.08 g, 2.59 mmol, 2.00 eq) and 
IrCl3·3H2O (457 mg, 1.30 mmol, 1.00 eq); reaction time: 45 h; 
Ir(III) dimer rac-T13-dimer was obtained as an orange solid 
(1.37 g, 646 µmol, 99%) which was employed in the next step without characterization. 
Λ-(S)-T13. General procedure A2) was followed using rac-T13-dimer (500 mg, 236 µmol) 
and auxiliary ligand (S)-Aux1; the crude diastereomer mixture was adsorbed on silica gel 
(40 °C) and purified and resolved by f. c. with hexanes/EtOAc 30:1; only the Λ-(S)-dia-
stereomer was isolated and characterized; diastereomer Λ-(S)-T13 was obtained as an orange 
solid (86.3 mg, 69.3 µmol, 15%). 1H NMR (500 MHz, CD2Cl2): δ = 7.57 (dd, J = 1.7 Hz, 
J = 0.6 Hz, 1H), 7.32–7.21 (m, 7H), 7.19–7.12 (m, 3H), 7.07 (ddd, J = 8.5 Hz, J = 1.6 Hz, 
J = 0.8 Hz, 2H), 6.97–6.86 (m, 5H), 6.80–6.75 (m, 2H), 6.64 (dd, J = 7.4 Hz, J = 1.0 Hz, 1H), 
6.59 (dd, J = 7.3 Hz, J = 1.1 Hz, 1H), 6.56 (dd, J = 7.6 Hz, J = 1.0 Hz, 1H), 6.49 (dd, 
J = 8.6 Hz, J = 1.1 Hz, 1H), 6.44 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 6.18 (ddd, J = 8.1 Hz, 
J = 6.8 Hz, J = 1.2 Hz, 1H), 4.90 (dt, J = 10.0 Hz, J = 2.5 Hz, 1H), 2.84 (dd, J = 11.6 Hz, 
J = 2.1 Hz, 1H), 2.77 (dd, J = 11.6 Hz, J = 9.8 Hz, 1H), 2.33 (s, 3H), 2.27 (s, 3H), 2.12 (s, 3H), 
2.07 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.88 (s, 3H), 1.83 (s, 3H), 1.78 (s, 3H), 1.57 (s, 3H), 
0.98–0.87 (m, 1H), 0.35 (d, J = 7.0 Hz, 3H), 0.15 (d, J = 7.0 Hz, 3H) ppm; HRMS (ESI): m/z 
calcd for C72H66IrN3O3SNa: 1268.4351 [M+Na]+; found: 1268.4355.   
Precatalyst Λ-T13. General procedure A5) was followed using Λ-(S)-T13 (22.8 mg, 
18.3 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 35:1; precatalyst 
Λ-T13 was obtained as a greenish yellow solid (18.1 mg, 13.5 µmol, 74%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.46 (s, 1H), 8.35 (dd, J = 8.4 Hz, J = 1.1 Hz, 1H), 8.19 (dd, 
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J = 5.0 Hz, J = 1.2 Hz, 1H), 8.02–7.97 (m, 2H), 7.86 (d, J = 8.8 Hz, 1H), 7.43 (dd, J = 8.3 Hz, 
J = 5.0 Hz, 1H), 7.33–7.15 (m, 8H), 7.10 (t, J = 7.6 Hz, 1H), 7.06 (t, J = 7.6 Hz, 1H), 6.99 (dd, 
J = 8.4 Hz, J = 1.7 Hz, 1H), 6.93 (dd, J = 7.5 Hz, J = 1.1 Hz, 1H), 6.91 (dd, J = 8.5 Hz, 
J = 1.6 Hz, 1H), 6.90–6.86 (m, 2H), 6.84–6.79 (m, 4H), 6.72 (s, 1H), 6.00 (d, J = 1.1 Hz, 1H), 
5.20 (d, J = 1.1 Hz, 1H), 2.26 (s, 3H), 2.25 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 
2.04 (s, 3H), 1.94 (s, 3H), 1.84 (s, 3H), 1.14 (s, 3H), 1.03 (s, 3H) ppm; 13C NMR (125 MHz, 
CD2Cl2): δ = 178.3, 178.2, 151.2, 149.5, 149.4, 148.3, 145.5, 144.0, 142.4 (2C), 142.2, 141.5, 
140.1, 139.7, 139.7, 139.7, 138.9, 138.0, 137.8, 137.7, 137.4 (2C), 137.3, 136.7, 136.6, 136.4, 
136.1, 135.9, 135.7, 135.6, 135.4, 133.2, 133.2, 133.1, 132.8, 132.8, 129.1, 128.9, 128.6, 
128.6, 128.5, 128.5, 128.3, 128.1, 128.1, 127.9, 127.9, 127.8, 127.7, 127.6, 125.9, 125.7, 
125.3, 125.2, 123.0, 117.3, 116.5, 115.6, 112.4, 112.0, 21.3, 21.2, 21.2, 21.1, 21.1, 21.1 (2C), 
21.0, 20.3, 20.2 ppm; IR (film): v~ = 1569, 1464, 1439, 1412, 841, 771, 708, 556 cm–1; HRMS 
(ESI): m/z calcd for C70H59IrN5O2: 1194.4299 [M–PF6]+; found: 1194.4314.  
 
4.7.2.14  Precatalyst Λ-T14 
General procedure A5) was followed using diastereomer 
Λ-(S)-T14[69] (obtained from former PhD student Haohua Huo; 
36.1 mg, 39.5 µmol, 1.00 eq; contained (S)-Aux1 as coordinating 
auxiliary ligand) and imidazoquinoline ligand 233; eluent for f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T14 was obtained as a greenish 
yellow crystalline solid (30.1 mg, 29.9 µmol, 76%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.46 (s, 1H), 8.54 (dd, J = 8.2 Hz, J = 1.1 Hz, 1H), 8.27 (dd, 
J = 5.1 Hz, J = 1.2 Hz, 1H), 8.18 (d, J = 1.0 Hz, 1H), 8.07 (d, J = 9.0 Hz, 1H), 7.96 (d, 
J = 9.0 Hz, 1H), 7.82 (ddd, J = 7.6 Hz, J = 7.0 Hz, J = 1.0 Hz, 2H), 7.63 (dd, J = 8.4 Hz, 
J = 5.0 Hz, 1H), 7.54 (d, J = 5.3 Hz, 1H), 7.52 (d, J = 5.3 Hz, 1H), 7.38 (dd, J = 8.8 Hz, 
J = 1.9 Hz, 1H), 7.34 (dd, J = 8.8 Hz, J = 1.9 Hz, 1H), 7.16 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 
7.11 (td, J = 7.5 Hz, J = 1.0 Hz, 1H), 7.04 (td, J = 7.5 Hz, J = 1.4 Hz, 1H), 6.99 (td, 
J = 7.5 Hz, J = 1.3 Hz, 1H), 6.79 (d, J = 7.6 Hz, 1H), 6.76 (d, J = 7.6 Hz, 1H), 6.05 (d, 
J = 1.7 Hz, 1H), 5.59 (d, J = 1.7 Hz, 1H), 1.04 (s, 9H), 0.87 (s, 9H) ppm; 13C NMR (125 MHz, 
CD2Cl2): δ = 178.1, 178.0, 151.9, 151.1, 150.5, 148.8, 148.7, 145.9, 144.2, 143.3, 142.9, 
141.9, 139.1, 138.1, 138.1, 134.3, 134.0, 133.3, 133.1, 132.9, 130.6, 130.5, 126.8, 126.6, 
126.1, 125.9, 124.3, 124.0, 123.4 (2C), 123.4, 117.1, 111.9 (2C), 111.7, 111.5, 35.3, 35.2, 
31.6 (3C), 31.5 (3C) ppm; IR (film): v~ = 1594, 1444, 1384, 842, 737, 558 cm–1; HRMS (ESI): 
m/z calcd for C44H39IrN5O2: 862.2730 [M–PF6]+; found: 862.2734.  
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4.7.2.15  Precatalyst Λ-T15 
 
Precatalst Λ-T15 was prepared according to general procedures 
A4) and A5) from diastereomer Λ-(S)-T15-CC (obtained from 
PhD student Thomas Mietke; contained (S)-Aux1 as coordi-
nating auxiliary ligand), 2,4,6-trimethylphenylboronic acid, and 
imidazoquinoline ligand 233. 
Λ-(S)-T15. General procedure A4) was followed using 
Λ-(S)-T15-CC (80.8 mg, 61.9 µmol) and 2,4,6-trimethylphenyl-
boronic acid; reaction time: 8 h; the crude diastereomer mixture was purified by f. c. 
(CH2Cl2/hexanes 1:1 → 2:1); Λ-(S)-T15 was obtained as an orange solid (56.4 mg, 45.3 µmol, 
73%). 1H NMR (300 MHz, CD2Cl2): δ = 7.76–7.72 (m, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.39 (d, 
J = 8.3 Hz, 1H), 7.31 (dd, J = 8.1 Hz, J = 1.7 Hz, 1H), 7.24 (d, J = 0.9 Hz, 1H), 7.19–7.05 (m, 
8H), 7.04–6.85 (m, 6H), 6.85–6.73 (m, 3H), 6.63 (dd, J = 7.3 Hz, J = 1.4 Hz, 1H), 6.59 (dd, 
J = 7.5 Hz, J = 1.4 Hz, 1H), 6.56 (dd, J = 8.7 Hz, J = 1.1 Hz, 1H), 6.22 (ddd, J = 8.1 Hz, 
J = 6.8 Hz, J = 1.3 Hz, 1H), 4.71–4.60 (m, 1H), 2.83–2.60 (m, 2H), 2.45 (s, 6H), 2.39 (s, 6H), 
2.33 (s, 3H), 2.28 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H), 1.54 (s, 3H), 0.85–0.69 (m, 
1H), 0.31 (d, J = 7.0 Hz, 3H), 0.17 (d, J = 7.0 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): 
δ = 178.8, 178.4, 169.2, 167.8, 153.5, 152.6, 149.4, 149.3, 144.0, 143.5, 140.9, 140.7, 140.1, 
139.8, 138.9, 138.8, 138.4, 138.2, 137.9 (2C), 137.7 (2C), 137.4, 137.1, 136.8, 136.5, 136.1, 
135.9, 134.1, 133.8, 133.7, 131.5, 131.5, 131.2, 130.9, 129.7, 129.6, 129.3, 129.0, 128.7, 
128.6, 128.6, 128.5, 128.4, 127.8, 127.5, 126.8, 125.2, 124.3, 124.0, 119.8, 118.5, 116.9, 
113.5, 112.1, 111.2, 85.0, 39.4, 32.3, 27.8, 21.8, 21.7, 21.4, 21.3 (2C), 21.3, 21.1, 20.6, 19.4, 
14.5, 14.4, 11.4 ppm; IR (film): v~ = 2956, 2921, 1603, 1561, 1523, 1464, 1438, 1402, 1355, 
1265, 1011, 850, 816, 791, 743, 710 cm–1; HRMS (ESI): m/z calcd for C72H66Ir1N3O3S1Na: 
1268.4351 [M+Na]+, found: 1268.4344. 
Precatalyst Λ-T15. General procedure A5) was followed using Λ-(S)-T15 (42.8 mg, 
34.4 µmol) and imidazoquinoline ligand 233; eluent for f. c.: CH2Cl2/MeOH 50:1; precatalyst 
Λ-T15 was obtained as a greenish yellow solid (40.9 mg, 30.5 µmol, 89%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.30 (s, 1H), 8.35 (dd, J = 8.3 Hz, J = 0.9 Hz, 1H), 8.19 (dd, 
J = 5.0 Hz, J = 1.0 Hz, 1H), 8.07 (s, 1H), 8.00 (d, J = 8.9 Hz, 1H), 7.87 (d, J = 9.0 Hz, 1H), 
7.46 (dd, J = 8.3 Hz, J = 5.0 Hz, 1H), 7.34 (d, J = 9.0 Hz, 1H), 7.32 (d, J = 8.7 Hz, 1H), 7.19–
7.12 (m, 6H), 7.10–7.00 (m, 5H), 6.95 (dd, J = 8.4 Hz, J = 1.5 Hz, 1H), 6.90 (s, 1H), 6.86 (dd, 
J = 4.9 Hz, J = 3.8 Hz, 1H), 6.84–6.80 (m, 3H), 6.73 (s, 1H), 6.04 (d, J = 1.1 Hz, 1H), 5.14 (d, 
J = 1.1 Hz, 1H), 2.42 (s, 6H), 2.42 (s, 6H), 2.27 (s, 3H), 2.26 (s, 3H), 1.96 (s, 3H), 1.84 (s, 
3H), 1.17 (s, 3H), 1.06 (s, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 178.3, 178.2, 151.6, 
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149.3, 149.2, 148.4, 145.6, 144.4, 144.2, 143.9, 142.6, 141.5, 140.1, 140.1, 140.0, 139.7, 
138.8, 138.1 (2C), 138.0 (2C), 137.8, 137.7, 137.4, 137.4, 137.3, 135.9, 135.7, 135.7, 135.3, 
133.3, 133.1, 133.0, 132.6, 132.2, 130.0, 129.9, 129.0, 129.0, 128.6, 128.5, 128.3, 127.8 (3C), 
127.8 (3C), 127.7, 127.7, 126.4, 126.3, 125.9, 125.7, 123.2, 117.2, 116.6, 115.6, 112.3, 112.0, 
21.7 (2C), 21.7 (2C), 21.3, 21.2, 21.1, 21.0, 20.3, 20.3 ppm; IR (film): v~ = 1567, 1466, 1436, 
1407, 1266, 844, 710, 557 cm–1; HRMS (ESI): m/z calcd for C70H59Ir1N5O2: 1194.4299 
[M−PF6]+; found: 1194.4302. 
 
4.7.2.16  Precatalyst Λ-T16 
General procedure A5) was followed using diastereomer 
Λ-(S)-T18 (see 4.7.2.18; 15.3 mg, 10.8 µmol) and imidazoqui-
noline ligand 233; eluent for f. c.: CH2Cl2/MeOH 100:1; 
precatalyst Λ-T16 was obtained as a greenish yellow crystalline 
solid (13.8 mg, 9.15 µmol, 85%). 1H NMR (500 MHz, CD2Cl2): 
δ = 11.31 (s, 1H), 8.26 (dd, J = 8.4 Hz, J = 0.9 Hz, 1H), 8.06 (dd, 
J = 4.9 Hz, J = 1.0 Hz, 1H), 7.92 (s, 1H), 7.89 (d, J = 8.9 Hz, 1H), 
7.74 (d, J = 8.9 Hz, 1H), 7.35 (dd, J = 8.4 Hz, J = 5.1 Hz, 1H), 7.33–7.26 (m, 2H), 7.26–7.16 
(m, 6H), 7.10 (t, J = 7.6 Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.03–6.99 (m, 2H), 6.96–6.91 (m, 
3H), 6.91–6.86 (m, 2H), 6.84–6.76 (m, 3H), 6.13 (d, J = 1.0 Hz, 1H), 5.30 (d, J = 1.0 Hz, 1H), 
2.95–2.81 (m, 2H), 2.35 (sept, J = 6.8 Hz, 1H), 2.25 (sept, J = 6.9 Hz, 1H), 2.10–2.01 (m, 
12H), 1.80–1.66 (m, 2H), 1.29–1.21 (m, 12H), 1.09 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.8 Hz, 
3H), 1.01 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.76 (d, J = 7.0 Hz, 3H), 0.74 (d, 
J = 7.0 Hz, 3H), 0.15 (d, J = 6.8 Hz, 3H), 0.06 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (125 MHz, 
CD2Cl2): δ = 178.3, 178.2, 150.9, 149.6, 149.5 (2C), 149.1, 148.5, 146.9, 146.8, 146.6, 146.3, 
145.4, 143.9, 142.4, 142.2, 142.0, 141.3, 140.2, 139.8, 139.7, 139.6, 138.9, 137.8, 137.5, 
136.7, 136.5, 136.4, 136.0, 135.7, 135.5, 133.2 133.2, 133.2, 132.8, 132.8, 128.6, 128.3, 128.2, 
128.1, 128.0, 127.9, 127.8, 127.7 (2C), 126.0, 125.8, 125.4, 125.3, 122.8, 121.2, 121.1, 120.8, 
120.7, 117.3, 116.7, 115.9, 112.1, 111.7, 34.9, 34.8, 30.9, 30.8, 30.5, 30.3, 25.1, 24.9, 24.4 
(2C), 24.3 (2C), 24.3, 24.0, 23.9, 23.7, 23.4, 23.3, 21.2, 21.1, 21.1 (2C) ppm (one overlapping 
signal could not be located); IR (film): v~ = 2960, 1570, 1460, 1414, 845 cm–1; HRMS (ESI): 
m/z calcd for C82H83IrN5O2: 1362.6179 [M–PF6]+; found: 1362.6134.  
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4.7.2.17  Precatalyst Λ-T17 
General procedure A5) was followed using diastereomer 
Λ-(S)-T18 (see 4.7.2.18; 15.1 mg, 10.7 µmol) and imidazo-
quinoline ligand 255; eluent for f. c.: CH2Cl2/MeOH 100:1; 
precatalyst Λ-T17 was obtained as a yellow-green crystalline 
solid (8.7 mg, 5.6 µmol, 53%). 1H NMR (500 MHz, CD2Cl2): 
δ = 11.03 (s, 1H), 8.52 (dd, J = 8.5 Hz, J = 1.0 Hz, 1H), 8.10 (dd, 
J = 5.0 Hz, J = 1.0 Hz, 1H), 8.02 (s, 1H), 7.90 (s, 1H), 7.43 (dd, 
J = 8.6 Hz, J = 5.0 Hz, 1H),  7.32–7.26 (m, 2H), 7.25–7.16 (m, 6H), 7.10 (t, J = 7.6 Hz, 1H), 
7.05 (t, J = 7.6 Hz, 1H), 7.04–6.99 (m, 2H), 6.97–6.91 (m, 3H), 6.90 (d, J = 1.5 Hz, 1H), 6.88 
(dd, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.84 (d, J = 1.6 Hz, 1H), 6.81 (dd, J = 7.7 Hz, J = 0.9 Hz, 
1H), 6.77 (dd, J = 7.6 Hz, J = 0.9 Hz, 1H), 6.09 (d, J = 1.1 Hz, 1H), 5.27 (d, J = 1.0 Hz, 1H), 
2.93–2.82 (m, 2H), 2.34 (sept, J = 6.9 Hz, 1H), 2.24 (sept, J = 6.9 Hz, 1H), 2.07 (s, 3H), 2.05 
(s, 6H), 2.96 (s, 3H), 1.80–1.70 (m, 2H), 1.25 (d, J = 7.0 Hz, 6H), 1.25 (d, J = 6.9 Hz, 6H), 
1.08 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 1.00 (d, J = 6.9 Hz, 3H), 0.91 (d, J = 6.9 Hz, 
3H), 0.78 (d, J = 6.9 Hz, 3H), 0.76 (d, J = 6.9 Hz, 3H), 0.19 (d, J = 6.9 Hz, 3H), 0.07 (d, 
J = 6.9 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 178.3, 178.2, 151.5, 149.5, 149.4 
(2C), 149.2, 148.4, 146.9, 146.8, 146.6, 146.3, 145.1, 143.8, 143.1, 142.5, 142.2, 140.6, 140.2, 
139.8, 139.6, 139.6, 137.7, 137.5, 136.7, 136.6 (2C), 136.5, 136.4, 135.9, 135.6, 135.5, 133.3, 
133.1, 132.8 (2C), 129.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (2C), 
125.4, 125.4, 124.3, 123.2, 121.2, 121.1, 120.8 (2C), 117.4, 116.6, 115.8, 112.1, 111.8, 34.8 
(2C), 30.9, 30.8, 30.5, 30.4, 25.1, 24.9, 24.4, 24.3 (2C), 24.3, 24.1, 23.9, 23.9, 23.7, 23.3, 23.2, 
21.2, 21.1, 21.1, 21.1 ppm; IR (film): v~ = 2959, 2926, 1572, 1464, 1444, 1413, 1261, 845, 772, 
558 cm–1; HRMS (ESI): m/z calcd for C82H82Cl1Ir1N5O2: 1396.5784 [M–PF6]+; found: 
1396.6061.  
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4.7.2.18  Precatalysts rac-, Λ-, and ∆-T18, Catalysts rac-, Λ-, and ∆-T18', and 
Bisacetonitrile Intermediates Λ- and ∆-T18-(MeCN)2 
 
 
 
Precatalysts Λ- and ∆-T18 as well as bisacetonitrile intermediates Λ- and ∆-T18-(MeCN)2 
were prepared according to general procedures A1), A2), and A5) from benzoxazole ligand 
195, IrCl3·3H2O, auxiliary ligand (S)-Aux2, and imidazoquinoline ligand 236 (ligand 236 is 
not required for the synthesis of Λ/∆-T18-(MeCN)2). 
Rac-T18-dimer. General procedure A1) was followed using IrCl3·3H2O (531 mg, 1.51 mmol, 
1.00 eq) and benzoxazole ligand 195 (1.50 g, 2.99 mmol, 1.99 eq); reaction time: 35 h; Ir(III) 
dimer rac-T18-dimer was obtained as a red-orange solid (1.85 g, 753 µmol, quantitative). 
1H NMR and 13C NMR: NMR characterization unfeasible due to complex spectra; IR (film):
v~ = 2959, 2927, 2029, 1569, 1458, 1413, 1413, 1358, 1101, 817, 770, 710 cm–1; HRMS 
(ESI): m/z calcd for C144H152Cl1Ir2N4O4: 2422.0772 [M–Cl]+; found: 2422.0791; XRD: X-ray 
quality crystals of rac-T18-dimer were obtained by slow diffusion of MeOH into a concen-
trated acetone solution of rac-T18-dimer at rt (vapor diffusion technique). Crystal structure 
and crystallographic data are provided in the crystallographic section. 
Diastereomers Λ-(S)-T18 and ∆-(S)-T18. General procedure A2) was followed using iri-
dium(III) dimer rac-T18-dimer (203 mg, 82.6 µmol, 1.00 eq) and auxiliary ligand (S)-Aux2; 
the obtained crude diastereomer mixture was purified and resolved by f. c. with hexanes/ 
CH2Cl2 2:1 → 1:1 → 1:2. After solvent removal and drying in vacuo, both diastereomers 
Λ-(S)-T18 (first eluting) and ∆-(S)-T18 (second eluting) were obtained as orange solids 
(Λ-(S)-T18: 52.7 mg, 37.3 µmol, 23%; ∆-(S)-T18: 96.5 mg, 68.3 µmol, 41%; combined 
yield: 64%).  
 
Analytical data for Λ-(S)-T18: 1H NMR (500 MHz, CD2Cl2): δ = 7.90 (d, J = 1.4 Hz, 1H), 
7.39 (d, J = 1.1 Hz, 1H), 7.36 (dd, J = 8.2 Hz, J = 1.9 Hz, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.28 
(d, J = 7.5 Hz, 1H), 7.25–7.18 (m, 4H), 7.17–7.08 (m, 6H), 7.05 (d, J = 1.7 Hz, 1H), 6.95 (d, 
J = 1.7 Hz, 1H), 6.91–6.84 (m, 2H), 6.76 (d, J = 2.9 Hz, 1H), 6.75 (s, 1H), 6.64 (dd, 
J = 7.4 Hz, J = 0.9 Hz, 1H), 6.61 (dd, J = 5.7 Hz, J = 2.8 Hz, 1H), 6.35 (dd, J = 8.6 Hz, 
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J = 1.0 Hz, 1H), 6.27 (dd, J = 7.8 Hz, J = 1.0 Hz, 1H), 6.05 (ddd, J = 8.1 Hz, J = 6.9 Hz, 
J = 1.1 Hz, 1H), 4.21 (dd, J = 9.7 Hz, J = 2.7 Hz, 1H), 3.91 (t, J = 9.1 Hz, 1H), 3.73 (dd, 
J = 8.5 Hz, J = 2.7 Hz, 1H), 2.98 (sept, J = 6.9 Hz, 1H), 2.90 (sept, J = 6.9 Hz, 1H), 2.68 (sept, 
J = 6.9 Hz, 1H), 2.65 (sept, J = 6.9 Hz, 1H), 2.55 (sept, J = 6.9 Hz, 1H), 2.48 (sept, J = 6.9 Hz, 
1H), 2.12 (s, 3H), 2.01 (s, 3H), 1.91 (s, 3H), 1.88 (s, 3H), 1.33 (d, J = 7.0 Hz, 3H), 1.33 (d, 
J = 6.9 Hz, 3H), 1.27 (d, J = 6.9 Hz, 3H), 1.27 (d, J = 6.9 Hz, 3H), 1.23 (d, J = 6.8 Hz, 3H), 
1.16–1.09 (m, 9H), 1.04 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H), 
0.68 (d, J = 6.8 Hz, 3H), 0.31 (s, 9H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 179.2 (Cq), 
178.3 (Cq), 173.1 (Cq), 167.4 (Cq), 152.9 (Cq), 151.7 (Cq), 149.8 (Cq), 149.3 (Cq), 149.2 (Cq), 
148.7 (Cq), 147.3 (3C; Cq), 147.0 (Cq), 141.7 (Cq), 141.2 (Cq), 140.6 (Cq), 140.5 (Cq), 139.2 
(Cq), 139.1 (Cq), 138.9 (Cq), 138.8 (Cq), 137.4 (Cq), 136.9 (Cq), 136.7 (Cq), 136.5 (Cq), 136.4 
(Cq), 136.2 (Cq), 134.6 (CHarom), 133.8 (CHarom), 131.5 (CHarom), 130.8 (CHarom), 130.7 
(CHarom), 130.6 (CHarom), 130.5 (Cq), 129.5 (Cq), 127.8 (CHarom), 127.6 (2C; CHarom), 127.6 
(CHarom), 127.6 (CHarom), 127.4 (2C; CHarom), 127.0 (CHarom), 124.2 (CHarom), 123.8 (CHarom), 
122.6 (CHarom), 121.2 (CHarom), 121.1 (3C; CHarom), 120.2 (CHarom), 116.7 (CHarom), 112.5 
(CHarom), 112.1 (Cq), 111.5 (CHarom), 110.8 (CHarom), 76.3 (CH(Me)3), 68.4 (S(CH2)), 35.4 
(C(Me)3), 35.0 (CH(Me)2), 34.9 (CH(Me)2), 31.0 (CH(Me)2), 30.9 (CH(Me)2), 30.9 
(CH(Me)2), 30.6 (CH(Me)2), 25.9 (3C; C(CH3)3), 25.2 (CH3), 24.8 (CH3), 24.8 (CH3), 24.6 
(CH3), 24.5 (2C; CH3), 24.4 (2C; CH3), 24.4 (CH3), 24.3 (CH3), 24.2 (CH3), 23.8 (CH3), 21.2 
(CH3), 21.2 (CH3), 21.0 (CH3), 20.9 (CH3) ppm; IR (film): v~ = 2960, 2927, 1607, 1573, 1465, 
1409, 1357, 771 cm–1; HRMS (ESI): m/z calcd for C85H92IrN3O4Na: 1434.6618 [M+Na]+; 
found: 1434.6668; CD (MeOH, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 472 (−7), 446 (−8), 368 
(+44), 344 (+34), 333 (+43), 309 (−43), 299 (−47), 249 (+11), 220 (−40), 212 (+6). 
 
Analytical data for ∆-(S)-T18: 1H NMR (500 MHz, CD2Cl2): δ = 7.49 (d, J = 1.1 Hz, 1H), 
7.44 (d, J = 1.1 Hz, 1H), 7.34–7.26 (m, 3H), 7.25–7.18 (m, 6H), 7.09 (dd, J = 8.5 Hz, 
J = 1.7 Hz, 1H), 7.05 (dd, J = 8.4 Hz, J = 1.5 Hz, 1H), 7.01 (d, J = 1.6 Hz, 1H), 6.99 (d, 
J = 1.5 Hz, 1H), 6.97 (d, J = 1.6 Hz, 1H), 6.92 (d, J = 1.6 Hz, 1H), 6.90–6.83 (m, 2H), 6.74 (t, 
J = 7.6 Hz, 1H), 6.69 (dd, J = 7.4 Hz, J = 1.0 Hz, 1H), 6.64–6.59 (m, 2H), 6.56 (dd, 
J = 7.7 Hz, J = 1.0 Hz, 1H), 6.40 (dd, J = 8.5 Hz, J = 0.7 Hz, 1H), 6.15 (ddd, J = 7.8 Hz, 
J = 7.0 Hz, J = 0.9 Hz, 1H), 4.26 (dd, J = 8.9 Hz, J = 1.8 Hz, 1H), 3.09 (t, J = 8.7 Hz, 1H), 
2.96–2.82 (m, 3H), 2.52 (sept, J = 6.8 Hz, 1H), 2.42 (sept, J = 6.8 Hz, 1H), 2.37 (sept, 
J = 6.9 Hz, 1H), 2.19 (s, 3H), 2.17 (sept, J = 6.9 Hz, 1H), 2.14 (s, 3H), 1.98 (s, 3H), 1.98 (s, 
3H), 1.28–1.23 (m, 12H), 1.10–1.05 (m, 6H), 1.03 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.8 Hz, 
3H), 0.88–0.83 (m, 9H), 0.82 (d, J = 6.8 Hz, 3H), 0.52 (s, 9H) ppm; 13C NMR (125 MHz, 
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CD2Cl2): δ = 180.0 (Cq), 179.3 (Cq), 171.5 (Cq), 167.4 (Cq), 155.2 (Cq), 151.2 (Cq), 149.6 (Cq), 
149.2 (Cq), 148.8 (Cq), 148.8 (Cq), 147.2 (Cq), 147.2 (Cq), 147.0 (Cq), 146.8 (Cq), 141.8 (Cq), 
141.3 (Cq), 140.7 (Cq), 140.7 (Cq), 139.6 (Cq), 138.9 (Cq), 138.7 (Cq), 138.4 (Cq), 137.0 (Cq), 
136.9 (Cq), 136.8 (Cq), 136.6 (Cq), 136.4 (Cq), 136.1 (Cq), 135.8 (CHarom), 133.2 (CHarom), 
131.9 (CHarom), 131.5 (CHarom), 131.1 (CHarom), 129.6 (CHarom), 128.9 (Cq), 128.2 (CHarom), 
128.0 (Cq), 127.8 (CHarom), 127.8 (CHarom), 127.4 (CHarom), 127.6 (2C; CHarom), 127.5 
(CHarom), 127.5 (CHarom), 123.5 (CHarom), 123.3 (CHarom), 122.3 (CHarom), 121.2 (CHarom), 
120.9 (CHarom), 120.7 (CHarom), 120.6 (CHarom), 118.4 (CHarom), 118.4 (CHarom), 113.5 (Cq), 
112.8 (CHarom), 110.9 (CHarom), 110.8 (CHarom), 73.0 (CH(Me)3), 70.9 (S(CH2)), 35.2 
(C(Me)3), 34.9 (CH(Me)2), 34.8 (CH(Me)2), 30.9 (CH(Me)2), 30.7 (CH(Me)2), 30.5 
(CH(Me)2), 30.5 (CH(Me)2), 26.6 (3C; C(CH3)3), 25.6 (CH3), 25.2 (CH3), 24.9 (CH3), 24.7 
(CH3), 24.5 (CH3), 24.4 (CH3), 24.4 (CH3), 24.4 (CH3), 24.3 (CH3), 24.2 (CH3), 23.9 (CH3), 
23.7 (CH3), 21.6 (CH3), 21.5 (CH3), 21.1 (CH3), 20.9 (CH3) ppm; IR (film): v~ = 2960, 2928, 
1610, 1572, 1465, 1409, 1356, 771 cm–1; HRMS (ESI): m/z calcd for C85H92IrN3O4Na: 
1434.6618 [M+Na]+; found: 1434.6674; CD (MeOH, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 465 
(+15), 455 (+15), 368 (−17), 345 (−12), 332 (−16), 286 (+33), 251 (−26), 222 (+20), 215 (+1). 
 
Precatalyst Λ-T18 and Bisacetonitrile intermediate Λ-T18-(MeCN)2. 
General procedure A5) was followed 
using Λ-(S)-T18 (83.2 mg, 58.9 µmol, 
1.00 eq) and imidazoquinoline ligand 
236; intermediate bisacetonitrile com-
plex Λ-T18-(MeCN)2 was isolated and 
fully characterized; eluent for final f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T18 
was obtained as a greenish yellow crystalline solid (78.8 mg, 51.1 µmol, 87%).  
 
Precatalyst ∆-T18 and Bisacetonitrile intermediate ∆-T18-(MeCN)2.  
General procedure A5) was followed 
using ∆-(S)-T18 (90.5 mg, 64.1 µmol, 
1.00 eq) and imidazoquinoline ligand 
236; intermediate bisacetonitrile com-
plex ∆-T18-(MeCN)2 was isolated and 
fully characterized; eluent for final f. c.: 
CH2Cl2/MeOH 100:1; precatalyst ∆-T18 
was obtained as a greenish yellow crystalline solid (81.8 mg, 53.0 µmol, 83%). 
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I.) Analytical data for precatalyst Λ/∆-T18: 1H NMR (500 MHz, CD2Cl2): δ = 11.38 (s, 1H), 
8.23 (d, J = 1.9 Hz, 1H), 7.97 (s, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.93 (s, 1H), 7.68 (d, 
J = 8.9 Hz, 1H), 7.33–7.27 (m, 2H), 7.27–7.16 (m, 6H), 7.13 (t, J = 7.6 Hz, 1H), 7.08–7.01 (m, 
3H), 6.99 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 6.98–6.94 (m, 2H), 6.92–6.88 (m, 2H), 6.86 (dd, 
J = 7.6 Hz, J = 1.0 Hz, 1H), 6.84 (d, J = 1.6 Hz, 1H), 6.71 (dd, J = 7.6 Hz, J = 0.9 Hz, 1H), 
6.23 (d, J = 1.2 Hz, 1H), 5.20 (d, J = 1.1 Hz, 1H), 2.95–2.83 (m, 2H), 2.36 (sept, J = 6.9 Hz, 
1H), 2.24 (sept, J = 6.9 Hz, 1H), 2.09 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 1.81–
1.70 (m, 2H), 1.28–1.23 (m, 12H), 1.10 (d, J = 6.9 Hz, 3H), 1.03 (t, J = 7.0 Hz, 6H), 0.94 (d, 
J = 6.8 Hz, 3H), 0.81 (d, J = 6.8 Hz, 3H), 0.74 (d, J = 6.9 Hz, 3H), 0.16 (d, J = 6.8 Hz, 3H), 
0.05 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 178.2 (Cq), 178.1 (Cq), 
150.2 (CHarom), 149.6 (Cq), 149.5 (Cq), 149.5 (Cq), 149.3 (Cq), 147.6 (Cq), 146.9 (Cq), 146.8 
(Cq), 146.5 (Cq), 146.2 (Cq), 144.3 (Cq), 142.6 (Cq), 142.3 (Cq), 141.9 (Cq), 141.1 (Cq), 140.3 
(Cq), 140.0 (Cq), 139.6 (Cq), 139.5 (Cq), 137.7 (Cq), 137.4 (CHarom), 137.3 (Cq), 136.6 (Cq), 
136.5 (Cq), 136.4 (Cq), 136.0 (Cq), 135.5 (Cq), 135.5 (Cq), 133.4 (Cq), 133.4 (CHarom), 133.3 
(CHarom), 132.9 (CHarom), 132.7 (CHarom), 130.3 (Cq), 128.6 (Cq), 128.4 (Cq), 128.3 (CHarom), 
128.2 (2C, CHarom), 128.0 (CHarom), 127.9 (CHarom), 127.8 (CHarom), 127.7 (CHarom), 127.6 
(CHarom), 125.9 (Cq), 125.7 (CHarom), 125.5 (CHarom), 124.9 (CHarom), 121.2 (CHarom), 121.1 
(CHarom), 120.8 (CHarom), 120.7 (CHarom), 118.7 (CHarom), 116.6 (CHarom), 115.9 (CHarom), 
112.2 (CHarom), 111.8 (CHarom), 34.9 (CH(Me)2), 34.9 (CH(Me)2), 30.9 (CH(Me)2), 30.8 
(CH(Me)2), 30.5 (CH(Me)2), 30.3 (CH(Me)2), 25.0 (CH3), 24.9 (CH3), 24.5 (CH3), 24.5 (CH3), 
24.3 (2C; CH3), 24.3 (CH3), 24.0 (CH3), 23.9 (CH3), 23.7 (CH3), 23.3 (2C; CH3), 21.3 (CH3), 
21.1 (CH3), 21.1 (CH3), 21.1 (CH3) ppm; 19F NMR (282 MHz, CD2Cl2): δ = −72.3 (d, 
JF-P = 711 Hz, PF6) ppm; 31P NMR (101 MHz, CD2Cl2): −143.6 (sept, JF-P = 711 Hz, PF6); 
IR (film): v~ = 2960, 2928, 1569, 1461, 1415, 845, 773, 558 cm–1. 
HPLC analysis of precatalyst Λ/∆-T18: See HPLC analysis of catalyst Λ/∆-T18', please note 
the remark there. 
Circular dichroism data for precatalyst Λ-T18: 
CD (MeCN, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 418 (−13), 360 (+25), 339 (+32), 317 (+39), 
286 (+7), 273 (+14), 257 (−82), 240 (−21), 233 (−23), 228 (−21), 223 (−24), 211 (+5). 
Circular dichroism data for precatalyst ∆-T18: 
CD (MeCN, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 417 (+13), 360 (−26), 338 (−33), 315 (−41), 
284 (−8), 272 (−15), 257 (+83), 240 (+21), 234 (+26), 227 (+21), 220 (+24), 212 (−9). 
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II.) Analytical data for bisacetonitrile intermediate Λ/∆-T18-(MeCN)2: 1H NMR (300 MHz, 
CD3CN): δ = 7.56 (d, J = 0.9 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.36–7.19 (m, 8H), 7.17–7.09 
(m, 4H), 6.93 (t, J = 7.6 Hz, 2H), 6.72 (dd, J = 7.5 Hz, J = 0.8 Hz, 2H), 6.44 (dd, J = 7.6 Hz, 
J = 0.8 Hz, 2H), 2.94 (sept, J = 6.9 Hz, 2H), 2.72–2.49 (m, 4H), 1.99 (s, 6H), 1.86 (s, 6H), 
1.26 (d, J = 6.8 Hz, 12H), 1.15–1.04 (m, 18H), 1.01 (d, J = 6.8 Hz, 6H) ppm (due to a rapid 
CH3CN → CD3CN exchange, a signal belonging to CH3CN is missing (6H, 2x CH3CN)); 
13C NMR (75 MHz, CD3CN): δ = 178.3 (2C), 150.3 (2C), 149.8 (2C), 147.7 (2C), 147.6 (2C), 
145.1 (2C), 142.2 (2C), 140.5 (2C), 140.1 (2C), 138.6 (2C), 136.9 (2C), 136.8 (2x 2C), 133.0 
(2C), 132.1 (2C), 129.1 (2C), 128.9 (2C), 128.8 (2C), 128.3 (2x 2C), 125.8 (2C), 122.2 (d, 
JC-F = 321 Hz, 1C; CF3SO3), 121.8 (2C), 121.8 (2C), 118.3 (2C), 112.2 (2C), 35.1 (2C), 31.4 
(4C), 24.8 (2C), 24.7 (2C), 24.4 (2x 2C), 24.2 (2C), 24.1 (2C), 20.8 (2C), 20.8 (2C) ppm (due 
to a rapid CH3CN → CD3CN exchange, the signals belonging to CH3CN are missing (4C, 
2x CH3CN)); 19F NMR (282 MHz, CD3CN): −78.5 (s, 3F, CF3SO3) ppm; IR (film): v~ = 2960, 
1570, 1457, 1416, 1263, 1169, 1032, 773, 639 cm–1; HRMS (ESI): m/z calcd for 
C76H82IrN4O2: 1275.6069 [M–CF3SO3]+; found: 1275.6074. 
Circular dichroism data for intermediate Λ-T18-(MeCN)2: 
CD (MeCN, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 405 (−15), 354 (+30), 335 (+25), 322 (+2), 316 
(+7), 262 (−22), 245 (+5), 237 (±0), 231 (+2), 218 (−33). 
Circular dichroism data for intermediate ∆-T18-(MeCN)2: 
CD (MeCN, 0.20 mM): λ, nm (∆ε, M–1·cm–1) 405 (+16), 354 (−33), 335 (−26), 322 (−2), 316 
(−7), 262 (+24), 246 (−5), 237 (+2), 231 (−2), 217 (+31). 
 
Active Catalysts Λ-T18' and ∆-T18' 
Catalyst Λ-T18'. Precatalyst Λ-T18 (78.8 mg, 51.1 µmol) was 
dissolved in CH2Cl2 (2 mL) and passed through a disposable glass 
pipette charged with a slurry of CH2Cl2-swelled piperidinomethy-
lated polystyrene beads (200–400 mesh, f = 3−4 mmol/g; pipette 
packing dimensions in diameter x length: 0.5 cm x 8.0 cm).[83]  
The polystyrene beads were rinsed with CH2Cl2 until the eluent 
became virtually colorless. After solvent removal and drying in 
vacuo, catalyst Λ-T18' was obtained analytically pure as a greenish yellow crystalline solid 
(70.8 mg, 50.7 µmol, 99%). 
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Catalyst ∆-T18'. Following the procedure described above for 
catalyst Λ-T18', precatalyst ∆-T18 (81.8 mg, 53.0 µmol) was 
converted to active catalyst ∆-T18'. Catalyst ∆-T18' was obtained 
as a greenish yellow crystalline solid (73.4 mg, 52.6 µmol, 99%). 
Alternatively, catalyst Λ- and ∆-T18' can be obtained analytically 
pure by washing a CH2Cl2 solution of Λ/∆-T18 with aqueous 
0.3 M NaOH followed by repetitive washing of the organic layer 
with water (5x) and drying of the organic layer over Na2SO4. 
 
Analytical data for active catalyst Λ/∆-T18': 
1H NMR (500 MHz, CD2Cl2): δ = 7.99 (d, J = 2.0 Hz, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.74 (d, 
J = 2.0 Hz, 1H), 7.60 (s, 1H), 7.31–7.20 (m, 4H), 7.20–7.06 (m, 6H), 7.04–6.99 (m, 2H), 6.97 
(d, J = 1.5 Hz, 1H), 6.93 (dd, J = 8.4 Hz, J = 1.7 Hz, 1H), 6.91–6.86 (m, 5H), 6.86–6.81 (m, 
2H), 6.06 (d, J = 1.2 Hz, 1H), 5.54 (d, J = 1.1 Hz, 1H), 2.92 (sept, J = 6.8 Hz, 1H), 2.88 (sept, 
J = 6.8 Hz, 1H), 2.40–2.27 (m, 2H), 2.13 (s, 3H), 2.12 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 1.76 
(sept, J = 6.9 Hz, 1H), 1.71 (sept, J = 6.9 Hz, 1H), 1.29 (d, J = 6.8 Hz, 3H), 1.29 (d, 
J = 7.0 Hz, 3H), 1.28–1.24 (m, 6H), 1.07 (d, J = 6.7 Hz, 3H), 1.06 (d, J = 6.8 Hz, 3H), 1.02 (d, 
J = 6.9 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.9 Hz, 3H), 0.75 (d, J = 6.9 Hz, 3H), 
0.18 (d, J = 6.9 Hz, 3H), 0.07 (d, J = 6.7 Hz, 3H) ppm. 13C NMR (125 MHz, CD2Cl2): 
δ = 178.6 (Cq), 178.3 (Cq), 153.2 (Cq), 150.8 (CHarom), 149.5 (Cq), 149.4 (Cq), 149.0 (Cq), 
148.9 (Cq), 148.2 (Cq), 147.1 (Cq), 147.0 (Cq), 146.7 (CHarom), 146.7 (Cq), 146.6 (Cq), 146.6 
(Cq), 144.0 (Cq), 142.3 (Cq), 141.9 (Cq), 141.5 (Cq), 140.2 (Cq), 140.2 (Cq), 139.6 (Cq), 139.4 
(Cq), 138.0 (Cq), 138.0 (Cq), 136.8 (Cq), 136.6 (Cq), 136.4 (Cq), 136.3 (Cq), 136.2 (CHarom), 
136.2 (Cq), 135.9 (Cq), 133.5 (CHarom), 133.3 (CHarom), 132.8 (CHarom), 132.0 (CHarom), 129.2 
(Cq), 128.5 (Cq), 128.0 (CHarom), 127.9 (CHarom), 127.7 (2C; CHarom), 127.7 (CHarom), 127.5 
(CHarom), 127.4 (CHarom), 126.8 (CHarom), 125.6 (Cq), 124.4 (CHarom), 124.4 (CHarom), 124.0 
(CHarom), 124.0 (Cq), 121.0 (CHarom), 120.8 (CHarom), 120.7 (CHarom), 120.5 (CHarom), 117.7 
(CHarom), 117.6 (CHarom), 116.8 (CHarom), 111.5 (CHarom), 111.1 (CHarom), 34.9 (CH(Me)2), 
34.8 (CH(Me)2), 30.9 (CH(Me)2), 30.8 (CH(Me)2), 30.5 (CH(Me)2), 30.3 (CH(Me)2), 25.1 
(CH3), 25.0 (CH3), 24.5 (CH3), 24.4 (CH3), 24.3 (CH3) 24.3 (CH3), 24.2 (CH3), 24.1 (CH3), 
23.8 (CH3), 23.7 (CH3), 23.4 (CH3), 23.3 (CH3), 21.2 (2C; CH3), 21.2 (CH3), 21.0 (CH3) ppm; 
19F NMR (282 MHz, CD2Cl2): Only noise, no signals (absence of the PF6− counteranion in 
neutral Λ/∆-T18'); 31P NMR (101 MHz, CD2Cl2): Only noise, no signals (absence of the PF6− 
counteranion in neutral Λ/∆-T18'). IR (film): v~ = 2960, 2927, 1569, 1508, 1460, 1412, 1360, 
1279, 1258, 1184, 802, 772 cm−1. 
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Chiral HPLC: Chiralpak IC column (5 µm, 250 mm x 4.6 mm); eluent A: n-hexane with 
2.0 vol% ethanol and 0.3 vol% diethylamine as modifiers; eluent B: isopropanol; linear 
gradient: 95:5 A/B → 88:12 A/B over 20 min; λ = 254 nm, flow = 0.5 mL/min, t (column) = 
10 °C; tR1 (Λ-T18') = 14.6 min, tR2 (∆-T18') = 16.6 min. Determined enantiomeric excess: 
>99% ee for both Λ- and ∆-T18'. 
Remark: Chiral HPLC conditions for precatalyst Λ/∆-T18 and catalyst Λ/∆-T18' are identical 
under the aforementioned conditions as a small amount of injected Λ/∆-T18 is instantly 
deprotonated to Λ/∆-T18' by the basic eluent modifier diethylamine. 
Analytical data for precatalyst Λ-T18 and catalyst Λ-T18': 
HRMS (ESI): m/z calcd for C82H82Cl1Ir1N5O2: 1396.5781 [M–PF6]+ (Λ-T18) [M+H]+ 
(Λ-T18'); found (for both): 1396.5796. 
Analytical data for precatalyst ∆-T18 and catalyst ∆-T18': 
HRMS (ESI): m/z calcd for C82H82Cl1Ir1N5O2: 1396.5781 [M–PF6]+ (∆-T18) [M+H]+ 
(∆-T18'); found (for both): 1396.5809. 
 
Racemic Precatalyst rac-T18 and Racemic Catalyst rac-T18' 
A flask (25 mL) was charged with iri-
dium(III) dimer rac-T18-dimer (450 mg, 
183 µmol, 1.00 eq), imidazoquinoline 236 
(87.0 mg, 427 µmol, 2.33 eq), AgPF6 
(111 mg, 439 µmol, 2.40 eq), and a 5:1 
mixture of CH2Cl2/MeOH (18 mL) and 
the mixture stirred for 24 h under exclu-
sion of light. Then, the mixture was diluted with CH2Cl2 and passed through a short plug of 
silica gel with CH2Cl2 as eluent to remove the salts. All volatiles were removed in vacuo 
(40 °C) and the crude product purified by flash chromatography (CH2Cl2/MeOH 100:1). After 
solvent removal and drying in vacuo, desired racemic precatalyst rac-T18 was obtained as a 
greenish yellow crystalline solid (380 mg, 246 µmol, 67%). Active catalyst rac-T18' was 
obtained from precatalyst rac-T18 as described above for enantiopure Λ- and ∆-T18'. 
XRD: X-ray quality crystals of rac-T18' were grown at rt by slow evaporation of CH2Cl2 
from a CH2Cl2/MeCN solution of rac-T18'. Crystal structure and crystallographic data are 
provided in the crystallographic section. 
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4.7.2.19  Precatalyst Λ-T19 
Precatalyst Λ-T19 was prepared according to general procedure 
A5) from diastereomer Λ-(S)-T18 (see 4.7.2.18; 12.3 mg, 
8.7 µmol) and imidazoquinoline ligand 241; eluent for f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T19 was obtained as a 
yellow-green solid (8.1 mg, 5.1 µmol, 59%). 1H NMR (500 MHz, 
CD2Cl2): δ = 8.50 (d, J = 1.8 Hz, 1H), 8.05 (s, 1H), 7.98 (d, 
J = 2.0 Hz, 1H), 7.96 (s, 1H), 7.33–7.17 (m, 8H), 7.13 (t, 
J = 7.6 Hz, 1H), 7.09–6.99 (m, 4H), 6.99–6.96 (m, 2H), 6.91 (d, J = 1.7 Hz, 1H), 6.90 (dd, 
J = 7.5 Hz, J = 0.9 Hz, 1H), 6.86 (d, J = 1.7 Hz, 1H), 6.85 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 
6.71 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 6.18 (d, J = 1.1 Hz, 1H), 5.20 (d, J = 1.1 Hz, 1H), 2.95–
2.85 (m, 2H), 2.36 (sept, J = 6.9 Hz, 1H), 2.25 (sept, J = 6.9 Hz, 1H), 2.09 (s, 3H), 2.08 (s, 
3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.87-1.73 (m, 2H), 1.26 (d, J = 7.0 Hz, 6H), 1.25 (d, 
J = 7.0 Hz, 6H), 1.10 (d, J = 6.8 Hz, 3H), 1.05 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 
0.94 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H), 0.20 (d, J = 7.0 Hz, 
3H), 0.07 (d, J = 6.8 Hz, 3H) ppm (NH signal could not be found due to rapid exchange); 
13C NMR (125 MHz, CD2Cl2): δ = 178.2, 178.1, 151.0, 149.6, 149.5, 149.5, 149.4, 147.5, 
146.9, 146.8, 146.5, 146.3, 144.1, 143.7, 142.7, 142.4, 141.8, 140.5, 140.4, 140.1, 139.5, 
139.5, 137.6, 137.3, 136.6, 136.5, 136.4, 136.0, 135.5 (2C), 135.4, 133.5, 133.2, 132.9, 132.7, 
131.1, 128.6, 128.4, 128.3, 128.3, 128.3, 128.0, 127.9, 127.8, 127.8, 127.6, 125.8, 125.6, 
124.4, 121.3, 121.2, 120.9, 120.8, 118.5, 116.6, 115.9 (2C), 112.3, 111.9, 35.0, 34.9, 30.9, 
30.9, 30.6, 30.4, 25.1, 24.9, 24.5, 24.3 (2C), 24.3, 24.2, 24.0, 23.9, 23.7, 23.3, 23.2, 21.3, 21.1, 
21.1 (2C) ppm (one 13C signal could not be located); IR (film): v~ = 2960, 2927, 1569, 1460, 
1415, 1365, 845, 773, 558 cm–1; HRMS (ESI): m/z calcd for C82H81Cl2Ir1N5O2: 1430.5385 
[M–PF6]+; found: 1430.5375. 
 
4.7.2.20  Precatalyst Λ-T20 
Precatalyst Λ-T20 was prepared according to general procedure 
A5) from diastereomer Λ-(S)-T18 (see 4.7.2.18; 13.5 mg, 
9.6 µmol) and imidazoquinoline ligand 245; eluent for f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T20 was obtained as a 
yellow-green solid (8.8 mg, 5.6 µmol, 58%). 1H NMR (500 MHz, 
CD2Cl2): δ = 8.48 (d, J = 8.5 Hz, 1H), 8.32 (s, 1H), 8.18 (dd, 
J = 4.9 Hz, J = 0.8 Hz, 1H), 8.02 (s, 1H), 7.46 (dd, J = 8.7 Hz, 
J = 5.0 Hz, 1H), 7.32–7.27 (m, 2H), 7.25–7.16 (m, 6H), 7.11 (t, J = 7.6 Hz, 1H), 7.06 (t, 
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J = 7.6 Hz, 1H), 7.02 (d, J = 1.6 Hz, 1H), 7.00 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 6.98 (dd, 
J = 8.4 Hz, J = 1.6 Hz, 1H), 6.95–6.93 (m, 2H), 6.91–6.87 (m, 2H), 6.82 (d, J = 1.6 Hz, 1H), 
6.80 (dd, J = 1.8 Hz, J = 1.0 Hz, 1H), 6.78 (dd, J = 1.8 Hz, J = 1.1 Hz, 1H), 5.91 (d, 
J = 1.1 Hz, 1H), 5.39 (d, J = 0.9 Hz, 1H), 2.95–2.82 (m, 2H), 2.38–2.25 (m, 2H), 2.07 (s, 3H), 
2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.80–1.67 (m, 2H), 1.25 (d, J = 6.9 Hz, 6H), 1.24 (dd, 
J = 6.9 Hz, J = 0.9 Hz, 6H), 1.08 (d, J = 6.9 Hz, 3H), 1.05 (d, J = 6.9 Hz, 3H), 1.00 (d, 
J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 6.9 Hz, 3H), 0.75 (d, J = 6.9 Hz, 3H), 
0.11 (d, J = 6.9 Hz, 3H), 0.08 (d, J = 6.8 Hz, 3H) ppm (NH signal could not be found due to 
rapid exchange); 13C NMR (125 MHz, CD2Cl2): δ = 178.3, 178.3, 151.5, 149.6, 149.5, 149.4, 
149.2, 148.6, 146.9, 146.7, 146.6, 146.2, 145.6, 145.1, 144.0, 143.9, 142.5, 142.3, 140.2, 
139.9, 139.6, 139.6, 137.6, 137.6, 136.7, 136.5, 136.4, 136.3, 135.9, 135.5, 135.5, 133.3, 
133.0, 132.8, 132.7, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.7, 
125.4, 125.3, 123.5, 122.2, 121.2, 121.0, 120.8 (2C), 117.9, 116.4, 115.9, 112.1, 111.8, 34.8 
(2C), 30.9, 30.8, 30.5, 30.3, 25.1, 24.9, 24.4, 24.3, 24.3, 24.2, 24.2, 24.0, 23.8, 23.8, 23.3, 
23.0, 21.2, 21.1, 21.1 (2C) ppm (three 13C signals could not be located; complicated spectrum 
due to C-F coupling); IR (film): v~ = 2960, 1569, 1413, 1351, 1181, 1126, 842, 773, 710, 
556 cm–1; HRMS (ESI): m/z calcd for C83H82F3Ir1N5O2: 1430.6053 [M–PF6]+; found: 
1430.6033. 
 
4.7.2.21  Precatalyst Λ-T21 
Precatalyst Λ-T21 was prepared according to general procedure 
A5) from diastereomer Λ-(S)-T18 (see 4.7.2.18; 9.0 mg, 
6.4 µmol) and imidazoquinoline ligand 260; eluent for f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T21 was obtained as a 
yellow-green crystalline solid (8.0 mg, 5.2 µmol, 82%). 1H NMR 
(500 MHz, CD2Cl2): δ = 10.86 (s, 1H), 8.46 (dd, J = 8.4 Hz, 
J = 1.3 Hz, 1H), 8.01 (dd, J = 5.0 Hz, J = 1.2 Hz, 1H), 7.71 (s, 
1H), 7.31–7.22 (m, 4H), 7.22–7.15 (m, 6H), 7.08 (t, J = 7.6 Hz, 1H), 7.03 (t, J = 7.6 Hz, 1H), 
7.03–6.99 (m, 2H), 6.95–6.91 (m, 3H), 6.90 (d, J = 1.7 Hz, 1H), 6.87 (dd, J = 7.4 Hz, 
J = 1.0 Hz, 1H), 6.82 (d, J = 1.7 Hz, 1H), 6.80 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 6.77 (dd, 
J = 7.6 Hz, J = 1.0 Hz, 1H), 6.18 (d, J = 1.1 Hz, 1H), 5.25 (d, J = 1.1 Hz, 1H), 3.98 (s, 3H), 
2.95–2.81 (m, 2H), 2.35 (sept, J = 6.9 Hz, 1H), 2.23 (sept, J = 6.9 Hz, 1H), 2.06 (s, 3H), 2.05 
(s, 3H), 2.04 (s, 6H), 1.84–1.70 (m, 2H), 1.26 (d, J = 6.8 Hz, 6H), 1.24 (d, J = 7.0 Hz, 6H), 
1.08 (d, J = 7.0 Hz, 3H), 1.03 (d, J = 7.0 Hz, 3H), 0.99 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 7.0 Hz, 
3H), 0.78 (d, J = 7.1 Hz, 3H), 0.76 (d, J = 7.0 Hz, 3H), 0.21 (d, J = 6.8 Hz, 3H), 0.11 (d, 
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J = 7.0 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C83H85Ir1N5O3: 1392.6285 [M–PF6]+; found: 
1392.6283. 
 
4.7.2.22  Precatalyst Λ-T22 
Precatalyst Λ-T22 was prepared according to general 
procedure A5) from diastereomer Λ-(S)-T18 (see 4.7.2.18; 
13.5 mg, 9.6 µmol) and imidazoquinoline ligand 251; eluent 
for f. c.: CH2Cl2/MeOH 100:1; precatalyst Λ-T22 was obtained 
as a yellow-green solid (10.9 mg, 6.3 µmol, 66%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.35 (s, 1H), 8.17 (dd, J = 5.0 Hz, 
J = 1.1 Hz, 1H), 8.08–8.04 (m, 2H), 8.01 (s, 1H), 7.95 (s, 1H), 
7.79 (s, 2H), 7.39 (dd, J = 8.6 Hz, J = 5.0 Hz, 1H), 7.32–7.28 (m, 2H), 7.27–7.15 (m, 6H), 
7.12 (t, J = 7.6 Hz, 1H), 7.08 (t, J = 7.5 Hz, 1H), 7.05–7.02 (m, 2H), 6.98 (dd, J = 8.4 Hz, 
J = 1.6 Hz, 1H), 6.95 (dd, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.94–6.89 (m, 3H), 6.82 (dd, 
J = 1.7 Hz, J = 1.1 Hz, 1H), 6.80 (dd, J = 1.7 Hz, J = 1.1 Hz, 1H), 6.79 (d, J = 1.6 Hz, 1H), 
6.02 (d, J = 1.1 Hz, 1H), 5.49 (d, J = 1.0 Hz, 1H), 2.89 (sept, J = 7.0 Hz, 1H), 2.83 (sept, 
J = 7.0 Hz, 1H), 2.34 (sept, J = 6.9 Hz, 1H), 2.29 (sept, J = 6.9 Hz, 1H), 2.09 (s, 3H), 2.07 (s, 
3H), 2.06 (s, 3H), 2.05 (s, 3H), 1.90–1.76 (m, 2H), 1.25 (d, J = 7.0 Hz, 6H), 1.20 (d, 
J = 7.0 Hz, 3H), 1.19 (d, J = 6.9 Hz, 3H), 1.09 (d, J = 6.9 Hz, 3H), 1.05 (d, J = 7.1 Hz, 3H), 
1.03 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H), 0.81 (d, J = 6.8 Hz, 3H), 0.79 (d, J = 7.0 Hz, 
3H), 0.21 (d, J = 6.9 Hz, 3H), 0.02 (d, J = 6.9 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): 
δ = 178.4, 178.3, 151.4, 149.6, 149.6, 149.5, 149.2, 148.4, 146.9, 146.8, 146.5, 146.0, 144.9, 
144.0, 143.2, 142.5, 142.3, 141.5, 140.3, 139.9, 139.9, 139.6, 139.6, 137.7 (2C), 136.8, 136.7, 
136.5, 136.4, 135.9, 135.8, 135.6, 135.4, 133.4, 133.0 (2C), 132.9, 132.8, 132.7, 132.5, 130.7, 
128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 125.5, 124.5, 123.4, 123.1, 
121.3, 121.1, 120.8, 120.8, 118.3, 116.5, 115.8, 112.3, 111.9, 34.9, 34.7, 31.0, 30.8, 30.6, 30.3, 
25.2, 25.0, 24.7, 24.3, 24.3 (3C), 24.2, 23.9, 23.7, 23.3, 23.1, 21.2, 21.1, 21.1 (2C) ppm (five 
13C signals could not be located; complicated spectrum due to C-F couplings); IR (film): 
v~ = 2961, 1570, 1459, 1416, 1373, 1279, 1181, 1140, 845, 774 cm–1; HRMS (ESI): m/z calcd 
for C90H85F6Ir1N5O2: 1574.6241 [M–PF6]+; found: 1574.6199. 
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4.7.2.23  Precatalyst Λ-T23 
Precatalyst Λ-T23 was prepared according to general procedure 
A5) from diastereomer Λ-(S)-T18 (see 4.7.2.18; 20.5 mg, 
14.5 µmol) and imidazoquinoline ligand 252; eluent for f. c.: 
CH2Cl2/MeOH 100:1; precatalyst Λ-T23 was obtained as a 
yellow-green solid (11.9 mg, 7.7 µmol, 53%). 1H NMR 
(500 MHz, CD2Cl2): δ = 10.90 (s, 1H), 8.18 (d, J = 1.9 Hz, 1H), 
7.90 (d, J = 1.9 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.58 (d, 
J = 9.0 Hz, 1H), 7.33–7.28 (m, 2H), 7.27–7.21 (m, 5H), 7.20–7.17 (d, J = 6.9 Hz, 1H), 7.13 (t, 
J = 7.6 Hz, 1H), 7.07 (t, J = 7.6 Hz, 1H), 7.04 (dd, J = 8.3 Hz, J = 1.6 Hz, 1H), 7.03–7.00 (m, 
2H), 6.97–6.94 (m, 2H), 6.92 (d, J = 1.6 Hz, 1H), 6.90 (dd, J = 7.5 Hz, J = 1.0 Hz, 1H), 6.87 
(dd, J = 7.7 Hz, J = 1.0 Hz, 1H), 6.84 (d, J = 1.6 Hz, 1H), 6.64 (dd, J = 7.7 Hz, J = 1.0 Hz, 
1H), 6.15 (d, J = 1.1 Hz, 1H), 5.13 (d, J = 1.1 Hz, 1H), 2.96–2.84 (m, 2H), 2.39 (sept, 
J = 6.8 Hz, 1H), 2.22 (sept, J = 6.9 Hz, 1H), 2.15 (s, 3H), 2.09 (s, 3H), 2.07 (s, 6H), 1.99 (s, 
3H), 1.78 (sept, J = 6.9 Hz, 1H), 1.72 (sept, J = 6.9 Hz, 1H), 1.27 (d, J = 7.2 Hz, 6H), 1.26 (d, 
J = 7.0 Hz, 6H), 1.10 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H), 
0.92 (d, J = 6.9 Hz, 3H), 0.82 (d, J = 6.9 Hz, 3H), 0.76 (d, J = 7.0 Hz, 3H), 0.12 (d, J = 6.9 Hz, 
3H), 0.04 (d, J = 6.9 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 178.2, 178.1, 155.6, 
150.1, 149.6, 149.6, 149.5, 149.3, 147.8, 146.8, 146.6, 146.5, 146.2, 145.5, 142.6, 142.5, 
141.4, 141.3, 140.5, 140.1, 139.5, 139.5, 137.6, 137.4, 137.2, 136.6 (2C), 136.1, 136.0, 135.5, 
135.3, 134.1, 133.4, 133.2, 133.0, 132.1, 129.6, 128.5, 128.3, 128.3, 128.2, 128.1, 127.9 (2C), 
127.8, 127.8, 127.6, 125.7, 125.4 (2C), 123.8, 121.1, 121.1, 120.8, 120.6, 118.1, 116.4, 116.1, 
112.1, 112.0, 34.9, 34.8, 30.9, 30.9, 30.5, 30.4, 25.0, 24.9, 24.5, 24.4, 24.3 (2C), 24.2, 24.1, 
23.7, 23.7, 23.3, 23.2, 21.3, 21.2, 21.1, 21.0, 13.9 ppm; IR (film): v~ = 2960, 1568, 1457, 1413, 
841, 773, 737, 707, 557 cm–1; HRMS (ESI): m/z calcd for C83H84Cl1Ir1N5O2: 1410.5937 
[M−PF6]+; found: 1410.5925. 
 
4.7.2.24  Precatalyst rac-T24 
An amber glass vial was charged 
with iridium(III) dimer Λ-(S)-T18 
(see 4.7.2.18; 20.6 mg, 8.38 µmol, 
1.00 eq), 2-(1H-pyrazol-3-yl)pyridine 
ligand (265; 3.3 mg, 23 µmol, 2.7 eq), 
AgPF6 (5.5 mg, 22 µmol, 2.6 eq), and 
CH2Cl2/ MeOH 10:1 (0.88 mL) and 
the mixture stirred at rt for 20 h under exclusion of light. All volatiles were removed in vacuo 
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(40 °C) and the crude product purified by flash chromatography (CH2Cl2/MeOH 100:1). After 
solvent removal and drying in vacuo, desired complex rac-T24 was obtained as a green-
yellow solid (16.6 mg, 11.2 µmol, 67%). 1H NMR (300 MHz, CD2Cl2): δ = 8.13 (d, 
J = 5.5 Hz, 1H), 7.83–7.67 (m, 3H), 7.33–6.84 (m, 20H), 6.70 (d, J = 7.6 Hz, 1H), 6.56 (d, 
J = 7.7 Hz, 1H), 5.61 (d, J = 0.9 Hz, 1H), 5.37 (d, J = 1.1 Hz, 1H), 2.98–2.79 (m, 2H), 2.44–
2.20 (m, 2H), 2.11 (s, 3H), 2.05 (s, 3H), 2.11–1.88 (m, 2H), 1.90 (s, 3H), 1.84 (s, 3H), 1.26 (d, 
J = 7.1, 12H), 1.06 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.90 
(d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.8 Hz, 6H), 0.73 (d, J = 7.0 Hz, 3H), 0.68 (d, J = 6.8 Hz, 
3H) ppm (NH signal could not be found due to rapid exchange); IR (film): v~ = 2960, 1569, 
1457, 1414, 841, 773, 557 cm–1; HRMS (ESI): m/z calcd for C80H83Ir1N5O2: 1338.6178 
[M−PF6]+; found: 1338.6194. 
 
4.7.2.25  Precatalyst Λ-T25 
Precatalyst Λ-T25 was prepared according to general 
procedures A1), A2), and A5) from benzoxazole ligand 270 (see 
left; received from PhD student Thomas Mietke), IrCl3·3H2O, 
auxiliary ligand (S)-Aux2, and imidazoquinoline ligand 236. 
Rac-T25-dimer. General procedure A1) was followed using 
benzoxazole ligand 270 (168 mg, 309 µmol, 1.89 eq) and 
IrCl3·3H2O (57.6 mg, 163 µmol, 1.00 eq); reaction time: 24 h; 
Ir(III) dimer rac-T25-dimer was obtained as an orange solid 
(205 mg, 78.1 µmol, quantitative). Rac-T25-dimer was pushed 
forward into the next step without characterization. 
Λ-(S)-T25. General procedure A2) was followed using 
rac-T25-dimer (199 mg, 75.8 µmol) and auxiliary ligand (S)-Aux2; the crude diastereomer 
mixture was purified and resolved by preparative TLC with CH2Cl2/hexanes 2:1 as eluent; 
only the Λ-(S)-diastereomer was isolated; diastereomer Λ-(S)-T25 was obtained as an orange-
red solid (30.9 mg, 20.7 µmol, 27%). 1H NMR (500 MHz, CD2Cl2): δ = 8.03–8.00 (m, 1H), 
7.55 (d, J = 2.1 Hz, 1H), 7.53 (d, J = 2.0 Hz, 1H), 7.49 (d, J = 1.4 Hz, 1H), 7.48 (d, J = 2.0 Hz, 
1H), 7.41–7.35 (m, 2H), 7.32 (dd, J = 8.4 Hz, J = 1.7 Hz, 1H), 7.29–7.09 (m, 9H), 6.84–6.78 
(m, 2H), 6.76 (t, J = 7.5 Hz, 1H), 6.68 (dd, J = 7.6 Hz, J = 1.1 Hz, 1H), 6.62–6.56 (m, 2H), 
6.28 (dd, J = 8.6 Hz, J = 1.0 Hz, 1H), 6.09–6.02 (m, 2H), 4.18 (dd, J = 9.5 Hz, J = 2.5 Hz, 
1H), 3.91 (t, J = 8.9 Hz, 1H), 3.82 (dd, J = 8.3 Hz, J = 2.5 Hz, 1H), 2.12 (s, 3H), 2.02 (s, 3H), 
1.82 (s, 3H), 1.77 (s, 3H), 1.39 (s, 9H), 1.34 (s, 9H), 1.12 (s, 9H), 1.04 (s, 9H), 0.99 (s, 9H), 
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0.82 (s, 9H), 0.31 (s, 9H) ppm; HRMS (ESI): m/z calcd for C91H104Ir1N3O4H: 1496.7739 
[M+H]+; found: 1496.7730. 
Precatalyst Λ-T25. General procedure A5) was followed using Λ-(S)-T25 (20.2 mg, 
13.5 µmol) and imidazoquinoline ligand 236; eluent for f. c.: CH2Cl2/MeOH 100:1; 
precatalyst Λ-T25 was obtained as a yellow-green crystalline solid (17.5 mg, 10.8 µmol, 
80%). 1H NMR (500 MHz, CD2Cl2): δ = 11.28 (s, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.98 (s, 1H), 
7.96 (dd, J = 8.9 Hz, J = 1.0 Hz, 1H), 7.93 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.47 
(d, J = 2.0 Hz, 1H), 7.40 (d, J = 2.0 Hz, 1H), 7.34 (d, J = 2.0 Hz, 1H), 7.32–7.16 (m, 9H), 
7.13–7.06 (m, 3H), 7.03 (t, J = 7.7 Hz, 1H), 6.95 (dd, J = 7.5 Hz, J = 0.9 Hz, 1H), 6.88 (dd, 
J = 7.5 Hz, J = 1.1 Hz, 1H), 6.77 (dd, J = 7.7 Hz, J = 0.9 Hz, 1H), 6.61 (dd, J = 7.7 Hz, 
J = 0.9 Hz, 1H), 6.38 (d, J = 1.2 Hz, 1H), 5.26 (d, J = 1.2 Hz, 1H), 2.11 (s, 3H), 2.07 (s, 3H), 
2.06 (s, 3H), 2.04 (s, 3H), 1.33 (s, 9H), 1.32 (s, 9H), 1.03 (s, 9H), 0.96 (s, 9H), 0.34 (s, 9H), 
0.31 (s, 9H) ppm; HRMS (ESI): m/z calcd for C88H94Cl1Ir1N5O2: 1480.6721 [M–PF6]+; found: 
1480.6775. 
 
4.7.2.26  Precatalyst Λ-T26 
Precatalyst Λ-T26 was prepared according to general pro-
cedures A1), A2), and A5) from benzoxazole ligand 202, 
IrCl3·3H2O, auxiliary ligand (S)-Aux2, and imidazoquinoline 
ligand 236. 
Rac-T26-dimer. General procedure A1) was followed using 
benzoxazole ligand 202 (451 mg, 752 µmol, 1.76 eq) and 
IrCl3·3H2O (151 mg, 428 µmol, 1.00 eq); reaction time: 22 h; 
Ir(III) dimer rac-T26-dimer was obtained as an orange solid 
(504 mg, 176 µmol, 94%). Rac-T26-dimer was pushed forward into the next step without 
characterization.  
Λ-(S)-T26: General procedure A2) was followed using rac-T26-dimer (212 mg, 74.4 µmol) 
and auxiliary ligand (S)-Aux2; the crude diastereomer mixture was purified and resolved by 
f. c. with CH2Cl2/hexanes 2:1; only the Λ-(S)-diastereomer was isolated; diastereomer 
Λ-(S)-T26 was obtained as an orange-red solid (39.5 mg, 25.6 µmol, 17%). IR (film): 
v~ = 2960, 2929, 2870, 1607, 1572, 1462, 1359 cm–1; HRMS (ESI): m/z calcd for 
C99H120Ir1N3O4Na: 1630.8812 [M+Na]+; found: 1630.9024. Λ-(S)-T26 was pushed forward 
into the next step without further characterization. 
Precatalyst Λ-T26. General procedure A5) was followed using Λ-(S)-T26 (14.2 mg, 
8.83 µmol) and imidazoquinoline ligand 236; eluent for f. c.: CH2Cl2/MeOH 200:1; 
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precatalyst Λ-T26 was obtained as a yellow-green solid (7.6 mg, 4.4 µmol, 50%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.32 (s, 1H), 8.24 (d, J = 1.8 Hz, 1H), 7.99–7.93 (m, 3H), 7.68 (d, 
J = 9.0 Hz, 1H), 7.22 (d, J = 1.7 Hz, 1H), 7.19 (d, J = 1.7 Hz, 1H), 7.18–7.15 (m, 2H), 7.14 (d, 
J = 3.9 Hz, 1H), 7.12 (d, J = 4.0 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 7.04–6.97 (m, 5H), 6.96 (d, 
J = 1.7 Hz, 1H), 6.94 (dd, J = 7.6 Hz, J = 0.8 Hz, 1H), 6.91 (d, J = 1.7 Hz, 1H), 6.85 (d, 
J = 1.5 Hz, 1H), 6.71 (dd, J = 7.5 Hz, J = 0.9 Hz, 1H), 6.58 (dd, J = 7.5 Hz, J = 0.9 Hz, 1H), 
6.22 (d, J = 1.1 Hz, 1H), 5.12 (d, J = 1.3 Hz, 1H), 3.09–2.99 (m, 2H), 2.94–2.83 (m, 2H), 2.70 
(sept, J = 6.8 Hz, 1H), 2.63 (sept, J = 6.8 Hz, 1H), 2.62–2.50 (m, 2H), 2.37 (sept, J = 6.8 Hz, 
1H), 2.23 (sept, J = 6.9 Hz, 1H), 1.86–1.74 (m, 2H), 1.42–1.34 (m, 12H), 1.26 (d, J = 7.0 Hz, 
12H), 1.22 (d, J = 6.8 Hz, 3H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 1.09 (d, 
J = 6.6 Hz, 3H), 1.07 (d, J = 7.0 Hz, 3H), 1.04 (d, J = 7.0 Hz, 3H), 1.03–1.00 (m, 9H), 0.94 (d, 
J = 6.8 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H), 0.82 (d, J = 7.0 Hz, 3H), 
0.75 (d, J = 7.0 Hz, 3H), 0.18 (d, J = 6.8 Hz, 3H), 0.12 (d, J = 6.8 Hz, 3H) ppm; 13C NMR 
(125 MHz, CD2Cl2): δ = 178.4, 178.4, 150.2, 149.7, 149.6, 149.5, 149.3, 149.3, 149.2, 147.1 
(2C), 147.0 (2C), 146.9, 146.6, 146.6, 146.4, 144.0, 142.5, 142.4 (2C), 142.3, 142.1, 141.2, 
140.3, 140.1, 137.6, 137.5, 137.2, 135.5, 135.4, 134.5 (2C), 133.5, 132.8, 132.8, 132.3, 132.3, 
130.1, 129.9, 129.7, 128.3, 127.6, 126.7, 126.5, 125.9, 125.0, 121.4, 121.3, 121.3, 121.2, 
121.1, 121.1, 120.9, 120.7, 118.7, 116.7, 115.8, 111.8, 111.5, 35.1, 35.1, 35.0, 34.9, 31.7, 31.5, 
31.3, 31.3, 30.9, 30.8, 30.4, 30.3, 25.1, 25.0, 24.9 (2C), 24.8, 24.7 (3C), 24.6 (2C), 24.6, 24.5, 
24.3, 24.3, 24.3 24.2, 24.1 (4C), 24.0, 23.8, 23.5 (2C) ppm; IR (film): v~ = 2960, 2928, 1568, 
1461, 1421, 846 cm–1; HRMS (ESI): m/z calcd for C96H110Cl1Ir1N5O2: 1592.7975 [M–PF6]+; 
found: 1592.8004. 
 
4.7.2.27  Precatalyst Λ-T27 
Precatalyst Λ-T27 was prepared according to general pro-
cedures A1), A2), and A5) from benzoxazole ligand 206, 
IrCl3·3H2O, auxiliary ligand (S)-Aux2, and imidazoquinoline 
ligand 236. 
Rac-T27-dimer. General procedure A1) was followed using 
benzoxazole ligand 206 (501 mg, 890 µmol, 1.99 eq) and 
IrCl3·3H2O (158 mg, 448 µmol, 1.00 eq); reaction time: 35 h;  
Ir(III) dimer rac-T27-dimer was obtained as an orange solid (483 mg, 179 µmol, 80%). 
Rac-T27-dimer was pushed forward into the next step without characterization.  
Λ-(S)-T27. General procedure A2) was followed using rac-T27-dimer (199 mg, 73.6 µmol) 
and auxiliary ligand (S)-Aux2; the crude diastereomer mixture was purified and resolved by 
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f. c. with CH2Cl2/hexanes 3:2 → 1:1; only the Λ-(S)-diastereomer was isolated; Λ-(S)-T27 
was obtained as an orange-red solid (93.9 mg, 61.2 µmol, 42%). Λ-(S)-T27 was pushed 
forward into the next step without characterization. 
Precatalyst Λ-T27. General procedure A5) was followed using Λ-(S)-T27 (14.1 mg, 
9.2 µmol) and imidazoquinoline ligand 236; eluent for f. c.: CH2Cl2/MeOH 200:1; precatalyst 
Λ-T27 was obtained as a yellow-green solid (5.1 mg, 3.1 µmol, 33%). 1H NMR (500 MHz, 
CD2Cl2): δ = 11.41 (s, 1H), 8.33–8.23 (m, 5H), 8.21 (s, 1H), 8.13 (d, J = 1.9 Hz, 1H), 7.94 (d, 
J = 9.0 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 7.48–7.28 (m, 12H), 7.26 (d, J = 8.2 Hz, 1H), 7.23 
(d, J = 8.1 Hz, 1H), 7.22–7.16 (m, 2H), 7.07–7.04 (m, 1H), 7.01 (d, J = 1.5 Hz, 1H), 6.97–
6.89 (m, 6H), 6.87 (d, J = 1.5 Hz, 1H), 6.82 (d, J = 1.5 Hz, 1H), 6.09 (d, J = 0.9 Hz, 1H), 5.20 
(s, 1H), 2.95–2.83 (m, 2H), 2.29 (sept, J = 6.9 Hz, 1H), 2.19 (sept, J = 6.8 Hz, 1H), 1.72–1.57 
(m, 2H), 1.25 (d, J = 6.8 Hz, 12H), 1.05 (d, J = 6.9 Hz, 3H), 1.04–0.99 (m, 6H), 0.95 (d, 
J = 6.8 Hz, 3H), 0.76 (d, J = 6.8 Hz, 3H), 0.70 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.8 Hz, 3H), 
0.06 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (125 MHz, CD2Cl2): δ = 176.3, 176.2, 150.4, 149.6, 
149.4, 149.4, 149.2, 148.8, 146.8, 146.7, 146.5, 146.1, 145.2, 143.2, 142.7, 142.6, 142.5, 
142.5, 141.8, 141.1, 140.8, 140.4, 137.8, 137.2 (2C), 137.0, 136.9, 135.3, 135.1, 134.7, 134.7, 
134.2, 134.1, 133.4, 130.4, 129.2, 128.8, 128.8, 128.2, 127.1, 126.8, 126.6, 126.5, 126.0, 
125.5, 125.2, 125.1, 124.4, 124.3, 124.2, 124.2, 121.3, 121.2, 121.1, 121.0, 121.0, 120.9, 
120.8, 120.8, 120.7, 120.7, 120.6, 120.5, 118.8, 116.5, 115.9, 112.2, 111.8, 110.4, 110.3, 
110.2, 109.7, 34.9, 34.8, 30.9, 30.8, 30.4, 30.3, 25.1, 25.0, 24.5, 24.4, 24.3, 24.3, 24.3, 24.1, 
23.8, 23.6, 23.2, 23.2 ppm; IR (film): v~ = 2960, 2928, 1574, 1456, 1425, 1228, 845, 748 cm–1; 
HRMS (ESI): m/z calcd for C90H80Cl1Ir1N7O2: 1518.5687 [M–PF6]+; found: 1518.5708. 
 
4.7.2.28  Precatalyst Λ-T28 
Precatalyst Λ-T28 was prepared according to general 
procedures A1), A2), and A5) from benzoxazole ligand 
210, IrCl3·3H2O, auxiliary ligand (S)-Aux2, and imidazo-
quinoline ligand 236. 
Rac-T28-dimer. General procedure A1) was followed 
using benzoxazole ligand 210 (399 mg, 796 µmol, 
1.80 eq) and IrCl3·3H2O (156 mg, 443 µmol, 1.00 eq); 
reaction time: 23 h; Ir(III) dimer rac-T28-dimer was obtained as an orange solid (437 mg, 
178 µmol, 89%). Rac-T28-dimer was pushed forward into the next step without 
characterization.  
Λ-(S)-T28. General procedure A2) was followed using rac-T28-dimer (202 mg, 82.0 µmol) 
and auxiliary ligand (S)-Aux2; the crude diastereomer mixture was purified and resolved by 
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f. c. with CH2Cl2/hexanes 1:1; only the Λ-(S)-diastereomer was isolated; Λ-(S)-T28 was 
obtained as an orange-red solid (20.6 mg, 14.6 µmol, 18%) and pushed into the next step 
without characterization. 
Precatalyst Λ-T28. General procedure A5) was followed using Λ-(S)-T28 (20.6 mg, 
14.6 µmol) and imidazoquinoline ligand 236; eluent for f. c.: CH2Cl2/MeOH 200:1; 
precatalyst Λ-T28 was obtained as a yellow-green solid (16.0 mg, 10.6 µmol, 73%). 1H NMR 
(500 MHz, CD2Cl2): δ = 11.32 (s, 1H), 8.24 (d, J = 1.9 Hz, 1H), 7.98 (d, J = 9.0 Hz, 1H), 7.95 
(s, 1H), 7.78 (d, J = 1.9 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.70 (d, 
J = 9.0 Hz, 1H), 7.66–7.61 (m, 2H), 7.23–7.10 (m, 9H), 7.04 (d, J = 1.5 Hz, 1H), 7.01 (d, 
J = 7.7 Hz, 1H), 6.98–6.92 (m, 3H), 6.90 (dd, J = 7.9 Hz, J = 1.9 Hz, 1H), 6.87 (d, J = 1.5 Hz, 
1H), 6.43 (d, J = 1.0 Hz, 1H), 5.26 (d, J = 1.0 Hz, 1H), 2.98–2.83 (m, 2H), 2.44 (sept, 
J = 6.9 Hz, 1H), 2.31 (sept, J = 6.8 Hz, 1H), 2.14 (s, 6H), 2.10 (s, 3H), 2.10 (s, 3H), 1.91–1.77 
(m, 2H), 1.27 (d, J = 7.1 Hz, 12H), 1.11 (d, J = 6.9 Hz, 3H), 1.04 (d, J = 6.9 Hz, 3H), 1.02 (d, 
J = 6.9 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H), 0.85 (d, J = 6.9 Hz, 3H), 0.80 (d, J = 6.9 Hz, 3H), 
0.19 (d, J = 6.9 Hz, 3H), 0.07 (d, J = 6.7 Hz, 3H) ppm; IR (film): v~ = 2960, 2927, 1604, 1531, 
1456, 1371, 1258, 1184, 1090, 1042, 943, 842, 771, 739, 557 cm–1; HRMS (ESI): m/z calcd 
for C82H82Cl1Ir1N5O2: 1396.5781 [M–PF6]+; found: 1396.5778. 
 
4.7.2.29  N-Methylated Catalyst Λ-T18-Me 
General procedure A5) was followed using diastereomer 
Λ-(S)-T18 (see 4.7.2.18; 85.3 mg, 60.4 µmol) and N-methyla-
ted imidazoquinoline ligand 262; eluent for f. c.: CH2Cl2/ 
MeOH 100:1 → 50:1; N-methylated complex Λ-T18-Me was 
obtained as a greenish-yellow crystalline solid (63.0 mg, 
40.5 µmol, 67%). 1H NMR (300 MHz, CD2Cl2): δ = 8.30 (d, 
J = 1.9 Hz, 1H), 7.99 (d, J = 1.9 Hz, 1H), 7.85–7.72 (m, 3H), 
7.36–7.17 (m, 8H), 7.14 (t, J = 7.6 Hz, 1H), 7.11–6.95 (m, 6H), 6.95–6.88 (m, 2H), 6.87–6.78 
(m, 2H), 6.71 (d, J = 7.6 Hz, 1H), 6.00 (d, J = 0.9 Hz, 1H), 5.28 (d, J = 0.9 Hz, 1H), 3.81 (s, 
3H), 3.00–2.79 (m, 2H), 2.38 (sept, J = 6.8 Hz, 1H), 2.25 (sept, J = 6.8 Hz, 1H), 2.12–1.98 (m, 
12H), 1.88–1.67 (m, 2H), 1.35–1.20 (m, 12H), 1.11 (d, J = 7.0 Hz, 3H), 1.09–0.99 (m, 6H), 
0.95 (d, J = 7.0 Hz, 3H), 0.85–0.73 (m, 6H), 0.15 (d, J = 6.8 Hz, 3H), 0.05 (d, J = 6.8 Hz, 
3H) ppm; 13C NMR (75 MHz, CD2Cl2): δ = 178.3, 178.2, 150.7, 149.7, 149.6 (2C), 149.5, 
147.2, 147.0, 146.9, 146.5, 146.3, 144.2, 144.1, 142.8, 142.5, 142.1, 141.7, 140.2, 140.1, 
139.6, 139.4, 137.7, 137.6, 137.5, 136.6 (2C), 136.2, 136.0, 135.7, 135.4, 134.8, 133.6, 133.2, 
133.0, 132.5, 130.8, 128.5, 128.4 (2C), 128.4, 128.1, 128.0, 127.9 (3C), 127.8, 126.1, 125.9, 
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125.6 (2C), 121.3, 121.0, 121.0, 120.8, 116.5, 116.2, 116.1, 112.1, 112.1, 35.0 (2C), 33.6, 
31.0, 30.9, 30.5, 30.5, 25.1 (2C), 24.5, 24.4 (2C), 24.4 (2C), 24.3, 23.9, 23.7, 23.4, 23.3, 21.3, 
21.1, 21.1, 21.1 ppm; 19F NMR (282 MHz, CD2Cl2): δ = −73.4 (d, JF-P = 710 Hz, PF6) ppm; 
31P NMR (101 MHz, CD2Cl2): −144.0 (sept, JF-P = 710 Hz, PF6) ppm; IR (film): v~ = 2959, 
1568, 1458, 1414, 837, 772, 734, 705, 556 cm–1; HRMS (ESI): m/z calcd for 
C83H84Cl1Ir1N5O2: 1410.5938 [M–PF6]+; found: 1410.5936. 
 
4.8  Synthesis of Iridium(III) Complexes Λ-T29, Λ-T30, rac-T31-C2 from Chapter 3. 
4.8.1  Complex Λ-T29 
 
 
Scheme 82. Synthesis of complex Λ-T29 from phenylbenzoxazole 172, IrCl3·3H2O, and aminopyrazole 173. 
 
Rac-T29-dimer. Method A.[116] Although Ir(I) complex [Ir(coe)2(µ-Cl)]2 is insensitive as a 
solvent-free powder, it becomes quickly oxidized in solution, in particular at elevated tem-
peratures. Consequently, rigorous exclusion of oxygen was found to be imperative for this 
protocol. A flame-dried flask (10 mL) was charged with benzoxazole ligand 172 (311 mg, 
697 µmol, 4.17 eq) and [Ir(coe)2(µ-Cl)]2 (150 mg, 167 µmol, 1.00 eq). Then, the flask was 
evacuated and carefully refilled with nitrogen gas (3x). Dry and degassed toluene (6.5 mL; 
from a solvent still, additionally degassed (3x) via freeze-pump-thaw technique) was added 
and the mixture stirred at 110 °C for 92 h under nitrogen atmosphere and under exclusion of 
light, which gave a clear, deeply orange solution. After cooling to rt, all volatiles were 
removed in vacuo and the crude product purified via flash chromatography (CH2Cl2/MeOH 
400:1 → 250:1 → 150:1). After solvent removal and drying in vacuo, desired rac-T29-dimer 
was obtained as a deeply orange solid (223 mg, 100 µmol, 60%). 
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Method B.[77] A flask (50 mL) was charged with IrCl3·3H2O (193 mg, 547 µmol, 1.00 eq), 
benzoxazole ligand 172 (500 mg, 1.12 mmol, 2.05 eq), and a 3:1 mixture of 2-ethoxyethanol 
and H2O (24 mL). The resulting mixture was purged with nitrogen gas for 10 min. Then, the 
mixture was stirred at 115 °C for 40 h under exclusion of light. After cooling to rt, H2O 
(25 mL) was added which caused the formation of a yellow precipitate. The precipitate was 
filtered off and thoroughly washed with excess water and a small amount of Et2O (20 mL). 
The precipitate was then dissolved in CH2Cl2, the resulting organic layer dried over Na2SO4, 
and the organic layer passed through a plug of celite which was subsequently rinsed with 
CH2Cl2. After solvent removal and drying in vacuo, desired rac-T29-dimer was obtained as a 
brown-orange solid without the need for further purification (449 mg, 201 µmol, 73%). 
1H NMR (500 MHz, CDCl3): δ = 8.60–8.38 (m, 4H), 7.61–6.99 (m, 44H), 6.90–6.52 (m, 8H), 
6.30–6.10 (m, 4H), 5.39–4.51 (m, 24H) ppm; 13C NMR (125 MHz, CDCl3): δ = 178.0–177.8 
(4x Cq), 155.1–154.8 (4x Cq), 149.4–149.1 (4x Cq), 144.9–144.1 (4x Cq), 140.5–140.0 (4x Cq), 
138.1–137.5 (4x Cq), 137.4–136.9 (8x Cq), 136.2–135.9 (4x Cq), 134.9–134.3 (4x Cq), 133.2–
132.5 (4x CH), 132.5–131.7 (4x CH), 129.3–128.9 (4x Cq), 128.9–127.7 (28x CH), 125.8–
125.4 (4x CH), 124.5–123.7 (4x CH), 122.3–121.4 (8x CH), 118.5–117.6 (4x CH), 111.1–
110.5 (4x CH), 67.5–66.7 (4x CH2), 53.1–52.6 (4x CH2), 52.4–51.9 (4x CH2) ppm (1H and 
13C signals are split up into complex signals due to hindered rotation of the four Cbz groups); 
IR (film): v~ = 1699, 1589, 1446, 1408, 1386, 1362, 1346, 1282, 1099, 1072, 1037, 779, 769, 
726, 696, 454 cm–1; HRMS (ESI): m/z calcd for C116H84Cl2Ir2N8O12: 2259.4736 [M+Na]+; 
found: 2259.4724. 
Λ-(S)-T29 and ∆-(S)-T29. A flask (10 mL) was charged with rac-T29-dimer (100 mg, 
44.9 µmol, 1.00 eq), auxiliary ligand (S)-Aux1 (24.8 mg, 112 µmol, 2.50 eq), AgOTf 
(27.5 mg, 107 µmol, 2.38 eq), and an 8:1 mixture of ethanol and CH2Cl2 (8.2 mL). The mix-
ture was purged with nitrogen gas for 5 min. Then, Et3N (62.5 µL, 448 µmol, 10.0 eq) was 
added and the mixture stirred at 80 °C for 15 h under exclusion of light and under nitrogen 
atmosphere. After cooling to rt, the solvent was removed in vacuo and the crude diastereomer 
mixture purified and resolved via flash chromatography (CH2Cl2/MeOH 300:1 → 200:1). 
Both diastereomers were isolated as deeply orange solids (Λ-(S)-T29: 42.4 mg, 32.5 µmol, 
36%;  ∆-(S)-T29: 58.4 mg, 44.8 µmol, 50%). 
Analytic data for Λ-(S)-T29: 
1H NMR (500 MHz, CD2Cl2): δ = 7.90–7.85 (m, 1H), 7.79–7.64 (m, 4H), 7.58–7.17 (m, 19H), 
7.16–7.05 (m, 1H), 7.05–6.90 (m, 3H), 6.90–6.82 (m, 1H), 6.81–6.73 (m, 1H), 6.71–6.65 (m, 
1H), 6.61–6.49 (m, 1H), 6.44–6.34 (m, 1H), 6.32–6.16 (m, 1H), 5.31–4.45 (m, 12H), 4.44–
4.21 (m, 1H), 3.00–2.91 (m, 1H), 2.88–2.77 (m, 1H), 0.90–0.74 (m, 1H), 0.26–0.12 (m, 
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6H) ppm (1H signals are split up into complex signals due to hindered rotation of the two Cbz 
groups); HRMS (ESI): m/z calcd for C70H56Ir1N5O7S1H: 1304.3607 [M+H]+; found: 
1304.3591. 
Analytic data for ∆-(S)-T29: 
1H NMR (400 MHz, CDCl3): δ = 8.00–7.89 (m, 1H), 7.82–6.63 (m, 30H), 6.53–6.36 (m, 2H), 
6.31–6.11 (m, 1H), 5.33–5.09 (m, 4H), 4.94–4.47 (m, 8H), 3.65–3.53 (m, 1H), 2.91–2.63 (m, 
2H), 2.04–1.89 (m, 1H), 0.70–0.54 (m, 3H), 0.07–0.04 (m, 3H) ppm (1H signals are split up 
into complex signals due to hindered rotation of the two Cbz groups); HRMS (ESI): m/z calcd 
for C70H56Ir1N5O7S1H: 1304.3607 [M+H]+; found: 1304.3590. 
Λ-T29-Cbz. A flask (10 mL) was charged with Λ-(S)-T29 (34.8 mg, 26.7 µmol, 1.00 eq), 
aminopyrazole ligand 173 (14.6 mg, 61.8 µmol, 2.31 eq), NH4PF6 (21.9 mg, 134 µmol, 
5.03 eq), and MeCN (2.7 mL). The mixture was purged with nitrogen gas for 5 min and then 
stirred at 65 °C for 4 h. After cooling to rt, all volatiles were removed in vacuo and the crude 
product purified by flash chromatography (CH2Cl2/MeOH 300:1 → 100:1). After solvent re-
moval and drying in vacuo, Λ-T29-Cbz was obtained as a yellow solid (35.9 mg, 24.5 µmol, 
92%). 1H NMR (300 MHz, CD2Cl2): δ = 12.22–11.70 (m, 1H), 10.75–10.40 (m, 1H), 8.18–
6.60 (m, 38H), 6.45–6.20 (m, 1H), 6.05–5.78 (m, 1H), 5.28–4.99 (m, 4H), 4.88–4.14 (m, 
8H) ppm (1H signals are split up into complex signals due to hindered rotation of the two Cbz 
groups); HRMS (ESI): m/z calcd for C72H54Ir1N8O6: 1319.3797 [M–PF6]+; found: 1319.3798.  
Complex Λ-T29. A flask (10 mL) was charged with Λ-T29-Cbz (39.7 mg, 27.1 µmol, 
1.00 eq) and PdCl2 (1.7 mg, 9.6 µmol, 35 mol%). The flask was evacuated and carefully 
refilled with nitrogen gas (3x). Then, CH2Cl2 (1.3 mL) and Et3N (4.6 µL, 33 µmol, 1.2 eq) 
were added and the mixture vigorously stirred at rt for 15 min under nitrogen atmosphere. 
Then, Et3SiH (1.30 mL, 8.14 mmol, 300 eq) was added at once and the mixture vigorously 
stirred at rt for 56 h under nitrogen atmosphere after which TLC (CH2Cl2/MeOH 10:1 + trace 
of Et3N) indicated full conversion. MeOH (6 mL) was added and the mixture stirred at rt until 
the gas evolution ceased (1 h). Then, a solution of AgPF6 (6.9 mg, 27.3 µmol, 1.01 eq) in 
MeOH (2 mL) was added and the mixture stirred for 15 min at rt under exclusion of light. The 
resulting mixture was passed through a glass filter (porosity G4), all volatiles removed in 
vacuo, and the crude product purified by flash chromatography (CH2Cl2/MeOH/Et3N 
500:20:10 → 500:30:10 → 500:40:10). After solvent removal, the product was taken up in 
CH2Cl2 and the organic layer washed with water (2x), aqueous KPF6 (1x), and again with 
water (2x). After solvent removal and drying in vacuo, Λ-T29 was obtained as a yellow-ocher 
solid (25.4 mg, 21.2 µmol, 78%). Chiral HPLC analysis: >99% ee according to the applied 
indirect procedure, which is explained in detail in chapter 3.2.1. 1H NMR (600 MHz, 
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DMSO-d6): δ = 12.38–12.25 (m, 1H), 8.43 (s, 1H), 8.00–7.76 (m, 6H), 7.72 (d, J = 7.1 Hz, 
1H), 7.49 (d, J = 8.6 Hz, 2H), 7.30–7.22 (m, 2H), 7.17–6.85 (m, 11H), 6.83 (dd, J = 6.0 Hz, 
J = 1.8 Hz, 1H), 6.71 (d, J = 7.4 Hz, 1H), 6.63–6.51 (m, 3H), 6.43 (d, J = 1.0 Hz, 1H), 6.00 (d, 
J = 1.0 Hz, 1H), 4.80–3.20 (br m, 3H), 4.33 (d, J = 14.0 Hz, 1H), 4.15 (s, 2H), 4.06–3.92 (m, 
4H), 3.84 (d, J = 13.8 Hz, 1H) ppm; 13C NMR (125 MHz, DMSO-d6): δ = 177.9 (Cq), 177.6 
(Cq), 156.8 (Cq), 155.6 (Cq), 152.4 (Cq), 151.9 (Cq), 150.6 (CH), 149.7 (Cq), 148.9 (Cq), 
148.9 (Cq), 144.4 (Cq), 142.3 (Cq), 141.2 (Cq), 138.9 (CH), 138.7 (Cq), 138.3 (Cq), 138.2 (Cq), 
138.1 (Cq), 137.9 (Cq), 137.3 (Cq), 134.8 (Cq), 134.6 (Cq), 133.5 (CH), 132.8 (2x CH), 
131.9 (CH), 129.6 (Cq), 128.7 (2x CH), 128.5 (Cq), 127.6 (CH), 127.5 (CH), 126.9 (CH), 
126.7 (CH), 126.2 (CH), 125.7 (CH), 125.6 (CH), 125.5 (CH), 122.0 (CH), 121.9 (2x CH), 
121.6 (CH), 121.2 (CH), 119.3 (CH), 116.8 (CH), 115.5 (CH), 113.7 (2x CH), 113.5 (CH), 
112.5 (CH), 112.1 (CH), 90.2 (CH), 52.1 (CH2), 51.7 (2x CH2), 51.6 (CH2) ppm; IR (film): 
v~ = 1561, 1504, 1446, 1405, 1177, 770, 746, 709 cm–1; HRMS (ESI): m/z calcd for 
C56H42Ir1N8O2: 1051.3060 [M–PF6]+, found: 1051.3047.  
 
4.8.2  Complex Λ-T30 
 
Scheme 83. Synthesis of complex Λ-T30 from phenylbenzoxazole 174, IrCl3·3H2O, and aminopyrazole 173. 
 
Rac-T30-dimer. A flask (50 mL) was charged with IrCl3·3H2O (304 mg, 862 µmol, 1.00 eq), 
benzoxazole ligand 174 (1.00 g, 1.82 mmol, 2.11 eq), and a 3:1 mixture of 2-ethoxyethanol 
and H2O (40 mL). The resulting mixture was purged with nitrogen gas for 15 min. Then, the 
mixture was stirred at 115 °C for 36 h under exclusion of light and under nitrogen atmosphere. 
After cooling to rt, H2O (50 mL) was added, which caused the formation of a yellow preci-
pitate. The precipitate was filtered off and thoroughly washed with excess water and a small 
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amount of Et2O (20 mL). The precipitate was then dissolved in CH2Cl2, the resulting organic 
layer dried over Na2SO4, and the organic layer passed through a plug of celite which was 
subsequently rinsed with CH2Cl2. After solvent removal and drying in vacuo, desired 
rac-T30-dimer was obtained as an orange solid without the need for further purification 
(977 mg, 368 µmol, 85%). 
1H NMR (300 MHz, CD2Cl2): δ = 8.15–7.96 (m, 4H), 7.60–6.74 (m, 52H), 6.74–6.53 (m, 4H), 
6.50–6.32 (m, 4H), 6.19–5.98 (m, 4H), 5.33–4.71 (m, 20H), 4.34–4.11 (m, 4H), 1.80–1.61 (m, 
12H), 1.39–1.19 (m, 12H) ppm (1H signals are split up into complex signals due to hindered 
rotation of the four Cbz groups); HRMS (ESI): m/z calcd for C74H58Ir1N4O6: 1291.3987 
[½M−Cl]+; found: 1291.3999. 
Λ-(S)-T30. A flask (25 mL) was charged with rac-T30-dimer (300 mg, 113 µmol, 1.00 eq), 
auxiliary ligand (S)-Aux2 (62.0 mg, 283 µmol, 2.50 eq), Na2CO3 (182 mg, 1.72 mmol, 
15.2 eq), and 2-ethoxyethanol (11.5 mL). The mixture was purged with nitrogen gas for 
15 min and then stirred at 80 °C for 8 h under exclusion of light and under nitrogen 
atmosphere. After cooling to rt, all volatiles were removed in vacuo and the remaining residue 
purified by flash chromatography (CH2Cl2/MeOH/Et3N 500:1:1 → 500:3:1). Only the Λ-(S)-
diastereomer was isolated; diastereomer Λ-(S)-T30 was obtained as a red-orange solid 
(88.9 mg, 58.9 µmol, 26%). 1H NMR: Complex 1H signals due to hindered rotation of the two 
Cbz groups, interpretation unfeasible; HRMS (ESI): m/z calcd for C87H75Ir1N5O8: 1510.5249 
[M+H]+, found: 1510.5225. 
Λ-T30-Cbz. A flask (10 mL) was charged with Λ-(S)-T30 (88.9 mg, 58.9 µmol, 1.00 eq), 
aminopyrazole ligand 173 (32.7 mg, 138 µmol, 2.35 eq), NH4PF6 (48.2 mg, 296 µmol, 
5.02 eq), and MeCN (6.0 mL). The mixture was purged with nitrogen gas for 5 min and then 
stirred at 65 °C for 4 h. After cooling to rt, all volatiles were removed in vacuo and the crude 
product purified by flash chromatography (CH2Cl2 300:1 → 150:1). After solvent removal 
and drying in vacuo, desired Λ-T30-Cbz was obtained as a green-yellow solid (83.8 mg, 
50.1 µmol, 85%). 1H NMR (300 MHz, CD2Cl2): δ = 13.19–12.94 (m, 1H), 10.93–10.73 (m, 
1H), 8.34–6.38 (m, 42H), 6.35–6.15 (m, 1H), 5.89–5.69 (m, 1H), 5.28–5.02 (m, 4H), 4.89–
3.86 (m, 8H), 2.41–1.80 (m, 12H) ppm (1H signals are split up into complex signals due to 
hindered rotation of the two Cbz groups); IR (film): v~ = 1702, 1576, 1463, 1445, 1408, 1349, 
1283, 1179, 1100, 838, 769, 747, 696, 556 cm–1; HRMS (ESI): m/z calcd for C88H70Ir1N8O6: 
1527.5051 [M–PF6]+, found: 1527.5040.  
Complex Λ-T30. A flask (25 mL) was charged with Λ-T30-Cbz (107 mg, 64.0 µmol, 
1.00 eq) and PdCl2 (35 mg, 19.7 µmol, 31 mol%). The flask was evacuated and then carefully 
refilled with nitrogen gas (3x). Then, CH2Cl2 (3.0 mL) and Et3N (10.7 µL, 76.8 µmol, 
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1.20 eq) were added and the mixture vigorously stirred at rt for 15 min under nitrogen 
atmosphere. Et3SiH (3.1 mL, 19.4 mmol, 303 eq) was added at once and the mixture 
vigorously stirred at rt for 65 h under nitrogen atmosphere after which TLC (CH2Cl2/MeOH 
10:1 + a trace of Et3N) indicated full conversion. The flask was cooled to 0 °C and MeOH 
(15 mL) was added and the mixture stirred at rt until the gas evolution ceased (1 h). Then, a 
solution of AgPF6 (16 mg, 63 µmol, 1.0 eq) in MeOH (2 mL) was added and the mixture 
stirred at rt for 15 min under exclusion of light. The resulting mixture was passed through a 
glass filter (porosity G4), all volatiles removed in vacuo (40 °C), and the crude product 
purified by flash chromatography (CH2Cl2/MeOH/Et3N 500:15:10 → 500:20:10). After sol-
vent removal, the residue was taken up in CH2Cl2 and the organic layer washed with water 
(2x), aqueous KPF6 (1x), and again with water (2x). After solvent removal and drying in 
vacuo, Λ-T30 was obtained as a yellow-ocher solid (42.2 mg, 30.0 µmol, 47%). 1H NMR 
(500 MHz, DMSO-d6): δ = 12.41–12.20 (m, 1H), 8.40 (s, 1H), 8.00–7.85 (m, 2H), 7.81 (t, 
J = 7.4 Hz, 1H), 7.44–7.30 (m, 4H), 7.29–7.09 (m, 10H), 7.08–6.97 (m, 6H), 6.97–6.87 (m, 
2H), 6.76 (d, J = 6.9 Hz, 1H), 6.73 (d, J = 7.3 Hz, 1H), 6.65 (d, J = 7.3 Hz, 1H), 6.62 (d, 
J = 7.6 Hz, 1H), 6.57 (t, J = 6.7 Hz, 1H), 6.55–6.48 (m, 2H), 6.42 (s, 1H), 5.99 (s, 1H), 4.17–
3.70 (m, 8H), 3.38 (br s, 2H), 2.08 (s, 3H), 1.96 (s, 3H), 1.88 (s, 3H), 1.84 (s, 3H) ppm; 
13C NMR (100 MHz, DMSO-d6): δ = 177.8 (Cq), 177.7 (Cq), 157.5 (Cq), 156.8 (Cq), 153.7 
(Cq), 152.9 (Cq), 150.2 (CH), 149.5 (Cq), 148.5 (Cq), 148.5 (Cq), 144.4 (Cq), 143.2 (Cq), 142.6 
(Cq), 140.9 (Cq), 140.4 (Cq), 139.6 (Cq), 139.4 (Cq), 139.3 (2x Cq), 139.0 (CH), 138.5 (Cq), 
138.4 (Cq), 137.7 (Cq), 136.8 (Cq), 135.4 (2x Cq), 135.3 (Cq), 135.0 (Cq), 134.5 (Cq), 134.5 
(Cq), 132.4 (CH), 131.7 (CH), 131.5 (CH), 131.1 (CH), 128.5 (2x CH), 127.7 (Cq), 127.4 
(CH), 127.3 (2x CH), 127.2 (CH), 127.1 (3x CH), 127.0 (CH), 126.6 (CH), 126.5 (Cq), 126.4 
(CH), 125.6 (CH), 125.4 (CH), 123.2 (CH), 122.3 (CH), 121.9 (CH), 121.8 (CH), 121.4 (CH), 
119.5 (CH), 116.7 (CH), 115.6 (CH), 113.9 (2x CH), 113.5 (CH), 111.9 (CH), 111.3 (CH), 
90.1 (CH), 52.4 (CH2), 52.3 (CH2), 52.2 (CH2), 52.0 (CH2), 20.7 (CH3), 20.3 (CH3), 20.3 
(CH3), 20.2 (CH3) ppm; IR (film): v~ = 1599, 1561, 1504, 1459, 1446, 1405, 1260, 1177, 822, 
770, 747, 709 cm–1; HRMS (ESI): m/z calcd for C72H58Ir1N8O2: 1259.4313 [M–PF6]+, found: 
1259.4137.  
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4.8.3 Bispyrazole Complex rac-T31-C2 
 
 
 
Scheme 84. Synthesis of complex rac-T31-C2 from Ir(III) dimer rac-T31-dimer and bispyrazole ligand 180. 
 
An amber glas vial with a stir bar was charged with rac-T31-dimer (obtained from former 
PhD student Haohua Huo; 34.1 mg, 15.2 µmol, 1.00 eq), bispyrazole ligand 180 (12.5 mg, 
39.5 µmol, 2.60 eq), AgPF6 (10.0 mg, 39.6 µmol, 2.60 eq), and a 4:1 mixture of CH2Cl2 and 
MeOH (1.0 mL) and the resulting mixture stirred at rt for 3 h. As TLC (CH2Cl2/MeOH 35:1) 
indicated full, all volatiles were removed in vacuo and the crude product purified by flash 
chromatography (CH2Cl2/MeOH 300:1 → 200:1). After solvent removal and drying in vacuo, 
desired bispyrazole complex rac-T31-C2 was obtained as a yellow solid (48.5 mg, 31.4 µmol, 
92%). 1H NMR (500 MHz, DMSO-d6): δ = 12.79 (s, 2H), 9.86 (s, 2H), 8.44 (s, 2H), 7.39 (d, 
J = 9.2 Hz, 2H), 7.30–7.24 (m, 4H), 7.15–7.08 (m, 6H), 7.07 (s, 2H), 7.05 (s, 2H), 6.95 (t, 
J = 7.7 Hz, 2H), 6.92–6.84 (m, 8H), 6.47 (dd, J = 7.6 Hz, J = 0.8 Hz, 2H), 5.61 (d, J = 2.4 Hz, 
2H), 2.37 (s, 12H) ppm; 13C NMR (125 MHz, DMSO-d6): δ = 177.2 (2x Cq), 156.1 (2x Cq), 
148.2 (2x Cq), 148.0 (2x Cq), 146.7 (2x Cq), 142.7 (2x Cq), 142.2 (2x Cq), 142.1 (2x Cq), 139.5 
(2x Cq), 137.3 (2x Cq), 136.7 (4x Cq), 131.8 (2x CH), 131.2 (2x CH), 129.4 (4x CH), 129.1 
(2x CH), 127.1 (4x CH), 126.9 (2x Cq), 124.8 (2x CH), 120.5 (2x CH), 115.6 (4x CH), 114.0 
(2x CH), 112.2 (2x CH), 100.3 (2x CH), 90.8 (2x CH), 21.0 (4x CH3) ppm; IR (film): 
v~ = 1571, 1478, 1439, 1410, 1163, 830, 794, 740, 689, 557 cm–1; HRMS (ESI): m/z calcd for 
C60H48Ir1N8O4: 1137.3427 [M–PF6]+, found: 1137.3465. 
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4.9  Synthesis of Catalysis Substrates 
4.9.1  O-Acylated Azlactones (13a–i) 
 
 
 
 
Scheme 85. Synthesis of O-acylated azlactones (13) from N-acylated acids (271). 
 
 
Literature reported O-acylated azlactones 13a–c,[22a] 13d,[142] and 13e[143] were synthesized 
according to the reported procedures. 13f–i were synthesized analogously: First, the respec-
tive N-acylated acids (271) were synthesized either by a Schotten–Baumann reaction of the 
respective α-amino acid and the appropriate acid chloride or by N-acylation of the respective 
α-amino acid ester hydrochloride and subsequent ester saponification.[22a] The N-acylated 
acids (271) were then subjected to DCC-promoted cyclization to the according azlactones 
(272), which were finally acylated with the appropriate chloroformates to give O-acylated 
azlactones  (13; Scheme 85). 
 
4.9.1.1  General Procedures B1)–B3) 
General Procedure B1). Synthesis of N-acylated acids (271).[22a] 
A flask was charged with the indicated α-amino acid ester hydrochloride (1.00 eq) and dry 
CH2Cl2 (conc = 0.3 M). The mixture was cooled to 0 °C and the indicated amounts of acid 
chloride and Et3N were added. The mixture was kept at 0 °C for 10 min and then allowed to 
warm to rt and stirred for the indicated time. Then, the mixture was diluted with CH2Cl2 and 
washed with 1 M HCl (2x), aqueous NaHCO3, and brine and dried over Na2SO4. All volatiles 
were removed in vacuo and the remaining residue was suspended in a 2:1 mixture of 
MeOH and aqueous 2 M NaOH (conc = 0.35 M; recommended: dissolve residue first in 
MeOH, then add aqueous NaOH). The resulting suspension was vigorously stirred until a 
clear solution was obtained (1 h). MeOH was then selectively removed in vacuo and the 
remaining aqueous layer was diluted with water and washed with CH2Cl2 (2x). The resulting 
organic layer was disposed and the remaining aqueous layer acidified to pH ≤ 2 with 1 M HCl, 
which caused the formation of a white precipitate. CH2Cl2 was added causing precipitate 
dissolution. The resulting organic layer was separated, the aqueous layer extracted with 
CH2Cl2 (3x), and the combined organic layers dried over Na2SO4. After solvent removal and 
drying in vacuo, the desired N-acylated acid (271) was obtained without the need for further 
purification. 
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General Procedure B2). DCC-promoted cyclization of N-acylated acids to azlactones 
(271 → 272).[22a] 
A flame-dried flask was charged with the indicated N-acylated acid (271; 1.00 eq) and dry 
CH2Cl2 (conc = 0.15 M). The mixture was cooled to 0 °C, DCC added (1.01 eq), and the 
resulting mixture allowed to warm to rt and stirred for the indicated time under nitrogen 
atmosphere. The resulting white precipitate was filtered off with a glass filter (porosity G3), 
which was subsequently rinsed with CH2Cl2. The filtrate was concentrated in vacuo and the 
resulting crude product purified by short-column chromatography with the indicated eluent. 
After drying in vacuo, the desired azlactone (272) was obtained. 
 
General Procedure B3). Acylation of azlactones to O-acylated azlactones (272 → 13).[22a] 
A flame-dried flask was charged with the indicated azlactone (272; 1.00 eq) and dry THF 
(conc = 0.1 M). The mixture was cooled to 0 °C, the indicated amounts of Et3N and 
chloroformate were added, and the mixture was allowed to warm to rt and stirred for the 
indicated time. Then, the mixture was diluted with MTBE and 1 M HCl. The aqueous layer 
was extracted with MTBE (1x) and the combined organic layers were washed with 1 M HCl 
and brine and dried over Na2SO4. After solvent removal, the remaining residue was dissolved 
in CH2Cl2, adsorbed on silica gel (40 °C), and purified by flash chromatography with the 
indicated eluent. After drying in vacuo, the desired O-acylated azlactone (13) was obtained. 
 
4.9.1.2  Synthetic Procedures and Characterizations 
Benzyl (4-benzyl-2-(4-methoxyphenyl)oxazol-5-yl) carbonate (13a)[22a] 
13a was synthesized according to procedures reported by Fu et 
al.[22a] in a three-step synthesis starting with 1.) Schotten–
Baumann reaction between phenylalanine (1.00 eq) and p-anisoyl 
chloride followed by 2.) DCC-promoted cyclization and finally 
3.) O-acylation with benzyl chloroformate. 13a was obtained as a pale-yellow oil which 
slowly crystallized on standing to an almost colorless solid (2.43 g, 5.84 mmol, 77% over 
three steps). 1H NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 8.9 Hz, 2H), 7.48–7.15 (m, 10H), 
6.92 (d, J = 9.1 Hz, 2H), 5.21 (s, 2H), 3.92–3.77 (m, 5H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 161.5, 155.4, 151.6, 146.1, 137.7, 134.0, 129.2, 129.0 (2C), 128.9 (2C), 128.8 (2C), 128.6 
(2C), 127.9 (2C), 126.6, 123.1, 120.0, 114.3 (2C), 71.8, 55.5, 31.6 ppm; IR (film): v~ = 1765, 
1496, 1255, 1215, 1161, 1109, 1029, 953, 831, 739, 693, 513 cm–1; HRMS (EI): m/z calcd for 
C25H21N1O5: 415.1420 [M]+; found: 415.1413. 
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Benzyl (4-isobutyl-2-(4-methoxyphenyl)oxazol-5-yl) carbonate (13b)[22a] 
13b was synthesized according to procedures reported by Fu et 
al.[22a] in a three-step synthesis starting with 1.) N-acylation of 
leucine methyl ester hydrochloride (1.00 eq) with p-anisoyl 
chloride and subsequent saponification with aqueous 2 M NaOH 
in MeOH followed by 2.) DCC-promoted cyclization and finally 3.) O-acylation with benzyl 
chloroformate. 13b was obtained as a colorless oil (709 mg, 1.86 mmol, 77% over three steps). 
1H NMR (300 MHz, CDCl3): δ = 7.98–7.81 (m, 2H), 7.53–7.32 (m, 5H), 7.02–6.85 (m, 2H), 
5.32 (s, 2H), 3.85 (s, 3H), 2.32 (d, J = 7.0 Hz, 2H), 2.13–1.92 (m, 1H), 0.93 (d, J = 6.6 Hz, 
6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 161.6, 155.2, 151.9, 146.2, 134.2, 129.3, 129.0 
(2C), 128.8 (2C), 127.9 (2C), 123.5, 120.1, 114.3 (2C), 71.8, 55.5, 33.9, 27.7, 22.5 (2C) ppm; 
IR (film): v~ = 1785, 1450, 1254, 1218, 1174 cm–1; HRMS (ESI): m/z calcd for 
C22H23N1O5Na: 404.1468 [M+Na]+; found: 404.1476. 
 
Benzyl (2-(4-methoxyphenyl)-4-methyloxazol-5-yl) carbonate (13c)[22a] 
13c was synthesized according to procedures reported by Fu et 
al.[22a] in a three-step synthesis starting with 1.) N-acylation of 
alanine methyl ester hydrochloride (1.00 eq) with p-anisoyl 
chloride and subsequent saponification with aqueous 2 M NaOH 
in MeOH followed by 2.) DCC-promoted cyclization and finally 3.) O-acylation with benzyl 
chloroformate. 13c was obtained as a colorless crystalline solid (548 mg, 1.61 mmol, 48% 
over three steps). 1H NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 8.9 Hz, 2H), 7.56–7.32 (m, 
5H), 6.94 (d, J = 8.9 Hz, 2H), 5.33 (s, 2H), 3.85 (s, 3H), 2.12 (s, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 161.6, 155.1, 151.8, 145.8, 134.1, 129.3, 129.0 (2C), 128.8 (2C), 127.8 (2C), 
120.1, 120.0, 114.4 (2C), 71.9, 55.5, 10.3 ppm; IR (film): v~ = 1782, 1498, 1251, 1204, 1175, 
1028, 837, 742 cm–1; HRMS (ESI): m/z calcd for C19H17N1O5Na: 362.0999 [M+Na]+; found: 
362.0998. 
 
4-Benzyl-2-(4-methoxyphenyl)oxazol-5-yl methyl carbonate (13d)[22a,142] 
13d was synthesized according to procedures reported by Fu[22a] 
and Smith[142] in a three-step synthesis starting with 1.) Schotten–
Baumann reaction between phenylalanine (1.00 eq) and p-
anisoyl chloride[22a] followed by 2.) DCC-promoted 
cyclization[22a] and finally 3.) O-acylation with methyl chloroformate.[142] 13d was obtained as 
a pale yellow oil which slowly crystallized on standing to an almost colorless solid (579 mg, 
1.70 mmol, 68% over three steps). 1H NMR (300 MHz, CDCl3): δ = 7.89 (d, J = 8.7 Hz, 2H), 
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7.41–7.12 (m, 5H), 6.93 (d, J = 8.7 Hz, 2H), 3.92–3.85 (m, 5H), 3.85 (s, 3H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 161.7, 155.4, 152.2, 146.1, 137.7, 129.1 (2C), 128.6 (2C), 128.0 (2C), 
126.6, 123.0, 119.9, 114.3 (2C), 56.6, 55.5, 31.6 ppm; IR (film): v~ = 1786, 1612, 1498, 1222, 
1169, 1028, 924, 705 cm–1; HRMS (ESI): m/z calcd for C19H17N1O5H: 340.1179 [M+H]+; 
found: 340.1180. 
 
4-Benzyl-2-(4-methoxyphenyl)oxazol-5-yl 3,3,3-trichloro-2,2-dimethylpropanoate 
(13e)[22a,142] 
13e was synthesized according to procedures reported by 
Fu[22a] and Smith[142] in a three-step synthesis starting with 
1.) Schotten–Baumann reaction between phenylalanine 
(1.00 eq) and p-anisoyl chloride[22a] followed by 2.) DCC-
promoted cyclization[22a] and finally 3.) O-acylation with 2,2,2-trichloro-1,1-dimethylethyl 
chloroformate.[142] 13e was obtained as a colorless crystalline solid (1.20 g, 2.49 mmol, 79% 
over three steps). 1H NMR (300 MHz, CDCl3): δ = 7.94–7.86 (m, 2H), 7.36–7.15 (m, 5H), 
6.98–6.88 (m, 2H), 3.89 (s, 2H), 3.85 (s, 3H), 1.92 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 161.6, 155.4, 148.3, 145.7, 137.6, 129.0 (2C), 128.6 (2C), 127.9 (2C), 126.7, 123.2, 120.0, 
114.3 (2C), 104.6, 92.3, 55.5, 31.8, 21.1 (2C) ppm; IR (film): v~ = 1787, 1613, 1498, 1230, 
1208, 1145, 1025, 802, 738, 708 cm–1; HRMS (ESI): m/z calcd for C22H20Cl3N1O5H: 
484.0480 [M+H]+; found: 484.0480. 
 
Benzyl (4-benzyl-2-(4-(tert-butyl)phenyl)oxazol-5-yl) carbonate (13f) 
N-acylated Acid 271f. General procedure B1) was followed: Phe-
nylalanine methyl ester hydrochloride (1.89 g, 8.76 mmol, 
1.00 eq), 4-tert-butylbenzoyl chloride (1.71 mL, 8.76 mmol, 
1.00 eq), Et3N (2.54 mL, 18.3 mmol, 2.09 eq); reaction time: 24 h; 
271f was obtained as a white solid (2.33 g, 7.17 mmol, 82%). 1H NMR (300 MHz, CDCl3): 
δ = 10.92 (s, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.28–7.04 (m, 5H), 6.64–
6.29 (m, 1H), 5.10–4.92 (m, 1H), 3.29 (dd, J = 13.9 Hz, J = 5.6 Hz, 1H), 3.18 (dd, J = 14.0 
Hz, J = 5.9 Hz, 1H), 1.24 (s, 9H) ppm. 
Azlactone 272f. General procedure B2) was followed: N-Acylated acid 271f (2.33 g, 
7.17 mmol); reaction time: 24 h; eluent: CH2Cl2/MeOH 200:1; 272f was obtained as a pale 
yellow solid (1.57 g, 5.11 mmol, 71%). 1H NMR (300 MHz, CDCl3): δ = 7.75 (d, J = 8.6 Hz, 
2H), 7.36 (d, J = 8.6 Hz, 2H), 7.25–7.03 (m, 5H), 4.57 (dd, J = 6.5 Hz, J = 5.0 Hz, 1H), 3.26 
(dd, J = 14.0 Hz, J = 4.9 Hz, 1H), 3.08 (dd, J = 14.0 Hz, J = 6.6 Hz, 1H), 1.24 (s, 9H) ppm. 
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O-Acylated Azlactone 13f. General procedure B3) was followed: Azlactone 272f (1.43 g, 
4.65 mmol), benzyl chloroformate (0.73 mL, 5.12 mmol, 1.10 eq), Et3N (0.74 mL, 5.35 mmol, 
1.15 eq); reaction time: 20 h; eluent: hexanes/MTBE 15:1; 13f was obtained as a pale yellow 
oil which crystallized on standing (1.56 g, 3.53 mmol, 76%). 1H NMR (300 MHz, CDCl3): 
δ = 7.78 (d, J = 8.6 Hz, 2H), 7.34 (d, J = 8.7 Hz, 2H), 7.31–7.05 (m, 10H), 5.11 (s, 2H), 3.77 
(s, 2H), 1.24 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 155.4, 153.8, 151.5, 146.3, 137.7, 
134.0, 129.2, 129.0 (2C), 128.9 (2C), 128.7 (2C), 128.5 (2C), 126.6, 126.0 (2C), 125.7 (2C), 
124.5, 123.3, 71.7, 35.0, 31.6, 31.3 (3C) ppm; IR (film): v~ = 1783, 1203, 1116, 901, 839, 740, 
699, 552 cm–1; HRMS (ESI): m/z calcd for C28H27N1O4Na: 464.1832 [M+Na]+; found: 
464.1834. 
 
Benzyl (4-benzyl-2-(naphthalen-1-yl)oxazol-5-yl) carbonate (13g) 
N-acylated Acid 271g. General procedure B1) was followed: Phenyl-
alanine methyl ester hydrochloride (2.00 g, 9.25 mmol, 1.00 eq), 
1-naphthoyl chloride (1.40 mL, 9.29 mmol, 1.00 eq), Et3N (2.70 mL, 
19.4 mmol, 2.09 eq); reaction time: 23 h; 271g was obtained as a 
colorless crystalline solid (2.93 g, 9.17 mmol, 99%). 1H NMR (300 MHz, DMSO-d6): 
δ = 12.84 (s, 1H), 8.85 (d, J = 8.3 Hz, 1H), 8.03–7.82 (m, 3H), 7.61–7.18 (m, 9H), 4.78 (ddd, 
J = 11.0 Hz, J = 8.3 Hz, J = 4.3 Hz, 1H), 3.25 (dd, J = 13.8 Hz, J = 4.3 Hz, 1H), 3.01 (dd, 
J = 13.8 Hz, J = 11.0 Hz, 1H) ppm. 
Azlactone 272g. General procedure B2) was followed: N-Acylated acid 271g (2.91 g, 
9.11 mmol); reaction time: 22 h; eluent: CH2Cl2/MeOH 200:1; 272g was obtained as a white 
crystalline solid (2.65 g, 8.79 mmol, 97%). 1H NMR (300 MHz, CDCl3): δ = 8.94 (d, 
J = 8.5 Hz, 1H), 7.98–7.85 (m, 2H), 7.85–7.75 (m, 1H), 7.59–7.43 (m, 2H), 7.39 (t, J = 7.7 Hz, 
1H), 7.31–7.06 (m, 5H), 4.76 (dd, J = 6.2 Hz, J = 5.1 Hz, 1H), 3.39 (dd, J = 13.9 Hz, 
J = 5.1 Hz, 1H), 3.22 (dd, J = 13.9 Hz, J = 6.3 Hz, 1H) ppm. 
O-Acylated Azlactone 13g. General procedure B3) was followed: Intermediate 272g (603 mg, 
2.00 mmol), benzyl chloroformate (315 µL, 2.21 mmol, 1.10 eq), Et3N (310 µL, 2.22 mmol, 
1.11 eq); reaction time: 14 h; eluent: hexanes/MTBE 9:2 → 3:1; 13g was obtained as a color-
less crystalline solid (764 mg, 1.75 mmol, 88%). 1H NMR (300 MHz, CDCl3): δ = 9.08 (d, 
J = 8.7 Hz, 1H), 8.02 (d, J = 7.4 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 
7.60-7.03 (m, 13H), 5.16 (s, 2H), 3.88 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3): δ = 155.3, 
151.5, 146.6, 137.8, 134.1, 134.0, 131.4, 130.3, 129.3, 129.1 (2C), 129.0 (2C), 128.8 (2C), 
128.7, 128.6 (2C), 127.9, 127.7, 126.7, 126.4, 126.3, 125.0, 123.6, 123.4, 71.9, 31.8 ppm; IR 
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(film): v~ = 1783, 1663, 1204, 1137, 773, 736, 702 cm–1; HRMS (ESI): m/z calcd for 
C28H21N1O4Na: 458.1363 [M+Na]+; found: 458.1363. 
 
Benzyl (4-benzyl-2-(naphthalen-2-yl)oxazol-5-yl) carbonate (13h) 
N-acylated Acid 271h. General procedure B1) was followed: 
Phenylalanine methyl ester hydrochloride (3.00 g, 13.9 mmol, 
1.00 eq), 2-naphthoyl chloride (2.09 mL, 13.9 mmol, 1.00 eq), Et3N 
(4.05 mL, 29.1 mmol, 2.09 eq); reaction time: 24 h; 271h was 
obtained as a colorless crystalline solid (3.80 g, 11.9 mmol, 86%). 1H NMR (300 MHz, 
DMSO-d6): δ = 12.78 (s, 1H), 8.86 (d, J = 8.3 Hz, 1H), 8.41 (s, 1H), 8.06–7.92 (m, 3H), 7.87 
(dd, J = 8.5 Hz, J = 1.6 Hz, 1H), 7.66–7.54 (m, 2H), 7.38–7.22 (m, 4H), 7.22–7.13 (m, 1H), 
4.77–4.60 (m, 1H), 3.23 (dd, J = 13.8 Hz, J = 4.7 Hz, 1H), 3.12 (dd, J = 13.7 Hz, J = 10.4 Hz, 
1H) ppm. 
Azlactone 272h: General procedure B2) was followed: N-acylated acid 271h (3.44 g, 
10.8 mmol); reaction time: 24 h; eluent: CH2Cl2/MeOH 200:1; 272h was obtained as colorless 
crystalline solid (2.90 g, 9.62 mmol, 89%). 1H NMR (300 MHz, CDCl3): δ = 8.25 (s, 1H), 
7.90 (dd, J = 8.7 Hz, J = 1.7 Hz, 1H), 7.83–7.67 (m, 3H), 7.53–7.35 (m, 2H), 7.28–6.99 (m, 
5H), 4.62 (dd, J = 6.6 Hz, J = 4.9 Hz, 1H), 3.29 (dd, J = 14.0 Hz, J = 5.0 Hz, 1H), 3.11 (dd, 
J = 14.0 Hz, J = 6.7 Hz, 1H) ppm. 
O-Acylated Azlactone 13h: General procedure B3) was followed: Azlactone 272h (2.82 g, 
9.36 mmol, 1.00 eq), benzyl chloroformate (1.47 mL, 10.3 mmol, 1.10 eq), Et3N (1.50 mL, 
10.8 mmol, 1.15 eq); reaction time: 24 h; eluent: hexanes/MTBE 6:1; 13h was obtained as a 
pale yellow oil which crystallized on standing (3.47 g, 7.97 mmol, 85%). 1H NMR (300 MHz, 
CDCl3): δ = 8.54 (s, 1H), 8.16 (dd, J = 8.7 Hz, J = 1.7 Hz, 1H), 8.03–7.84 (m, 3H), 7.64–7.54 
(m, 2H), 7.54–7.27 (m, 10H), 5.33 (s, 2H), 4.05 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 155.3, 151.5, 146.5, 137.6, 134.1, 133.9, 133.0, 129.1, 129.0 (2C), 128.8 (2C), 128.7 (2C), 
128.7, 128.6, 128.5 (2C), 127.9, 127.2, 126.7, 126.6, 126.0, 124.4, 123.7, 122.9, 71.7, 
31.6 ppm; IR (film): v~ = 1782, 1658, 1202, 1127, 1066, 955, 898, 820, 741, 698, 471 cm–1; 
HRMS (ESI): m/z calcd for C28H21N1O4Na: 458.1363 [M+Na]+; found: 458.1368. 
 
Benzyl (4-benzyl-2-(tert-butyl)oxazol-5-yl) carbonate (13i) 
N-acylated Acid 271i: General procedure B1) was followed: Phenyl-
alanine methyl ester hydrochloride (3.00 g, 13.9 mmol, 1.00 eq), pivaloyl 
chloride (1.71 mL, 13.9 mmol, 1.00 eq), Et3N (4.10 mL, 29.4 mmol, 
2.11 eq); reaction time: 21 h; 271i was obtained as a white crystalline 
solid (3.34 g, 13.4 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ = 10.55 (s, 1H), 7.38–7.21 (m, 
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3H), 7.21–7.10 (m, 2H), 6.14 (d, J = 7.4 Hz, 1H), 4.96–4.78 (m, 1H), 3.27 (dd, J = 14.0 Hz, 
J = 5.6 Hz, 1H), 3.15 (dd, J = 14.0 Hz, J = 6.0 Hz, 1H), 1.13 (s, 9H) ppm. 
Azlactone 272i: General procedure B2) was followed: N-acylated acid 271i (3.32 g, 
13.3 mmol); reaction time: 18 h; eluent: CH2Cl2/MeOH 100:1; 272i was obtained as a 
colorless oil (2.86 g, 12.4 mmol, 93%). 1H NMR (300 MHz, CDCl3): δ = 7.34–7.07 (m, 5H), 
4.47 (t, J = 5.0 Hz, 1H), 3.28 (dd, J = 13.7 Hz, J = 5.2 Hz, 1H), 3.18 (dd, J = 13.7 Hz, 
J = 4.8 Hz, 1H), 1.06 (s, 9H) ppm. 
O-Acylated Azlactone 13i: General procedure B3) was followed: Azlactone 272i (1.60 g, 
6.92 mmol), benzyl chloroformate (3.06 mmol, 21.4 mmol, 3.10 eq), Et3N (3.06 mL, 
21.9 mmol, 3.17 eq); reaction time: 40 h; eluent: hexanes/MTBE 10:1; 1i was obtained as a 
colorless oil which crystallized on standing (1.72 g, 4.71 mmol, 68%). 1H NMR (300 MHz, 
CDCl3): δ = 7.36–7.23 (m, 5H), 7.19–7.04 (m, 5H), 5.07 (s, 2H), 3.70 (s, 2H), 1.26 (s, 
9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 164.6, 151.5, 145.9, 137.8, 134.1, 129.2, 129.0 
(2C), 128.9 (2C), 128.7 (2C), 128.5 (2C), 126.5, 121.1, 71.6, 33.9, 31.7, 28.5 (3C) ppm; IR 
(film): v~ = 1782, 1208, 1144, 1104, 738, 702 cm–1; HRMS (ESI): m/z calcd for 
C22H23N1O4Na: 388.1519 [M+Na]+; found: 388.1523. 
 
4.9.2  O-Acylated Benzofuranones (142a–i) 
 
 
 
 
Scheme 86. Synthesis of O-acylated benzofuranones (142) from benzofuran-2(3H)-ones (273–276). 
 
O-Acylated benzofuranones (142) were synthesized from the corresponding 3-substituted 
benzofuran-2(3H)-ones (273–276) and the latter were synthesized according to literature pro-
cedures (Scheme 86).[23b,144,145] 
 
4.9.2.1  General Procedure C1). Synthesis of O-acylated benzofuranones (142).[23b] 
A flame-dried flask was charged with the appropriate benzofuran-2(3H)-one (273–276; 
1.00 eq) and dry THF (conc = 0.3 M). The mixture was cooled to 0 °C and the indicated 
amounts of Et3N and chloroformate were added. The mixture was stirred at 0 °C for the 
indicated time and then diluted with Et2O and quenched with 0.1 M HCl. The organic layer 
was separated and the aqueous layer extracted with Et2O (3x). The combined organic layers 
were washed with brine and dried over Na2SO4. All volatiles were removed in vacuo, the 
obtained residue dissolved in CH2Cl2, adsorbed on silica gel (40 °C), and purified by flash 
chromatography, which yielded the desired O-acylated benzofuranone (142). 
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4.9.2.2  Synthetic Procedures and Characterizations 
3-Phenylbenzofuran-2(3H)-one (273) 
Compound 273 was synthesized according to a protocol from Lee et al.[144] 
A flask (250 mL) was charged with mandelic acid (15.2 g, 100 mmol, 
1.00 eq) and phenol (13.3 g, 141 mmol, 1.41 eq). The flask was cooled to 
0 °C and H2SO4 (70 wt%; 40 mL) was added and the resulting mixture stirred at 0 °C for 
30 min. Subsequently, the mixture was stirred at 115 °C for 45 min. After cooling to rt, the 
resulting mixture was poured into ice-water and the mixture extracted with CH2Cl2 (3x). The 
combined organic layers were washed water (1x), aqueous NaHCO3 (1x), and brine (1x) and 
dried over Na2SO4. After solvent removal and drying in vacuo, a pale-yellow crystalline solid 
was obtained, which was recrystallized from ethanol (15 mL). The recrystallized precipitate 
was filtered off and washed with ice-cold EtOH and hexanes. After drying in vacuo, 3-phe-
nylbenzofuran-2(3H)-one (273) was obtained as a colorless crystalline solid (5.60 g, 
26.6 mmol, 27%). 1H NMR (300 MHz, CDCl3): δ = 7.35–7.20 (m, 4H), 7.19–7.04 (m, 5H), 
4.80 (s, 1H) ppm; HRMS (ESI): m/z calcd for C14H10O2Na: 233.0573 [M+Na]+; found: 
233.0577. 
 
3-Methylbenzofuran-2(3H)-one (274) 
Compound 274 was synthesized according to a protocol from Piccolo et 
al.[145] A flame-dried flask (250 mL) was charged phenol (2.43 g, 
25.8 mmol, 1.00 eq) and the flask cooled to 0 °C. TiCl4 (2.85 mL, 
26.0 mmol, 1.01 eq) was added and the mixture stirred at 0 °C for 30 min. Then, ethyl 
pyruvate (2.88 mL, 25.9 mmol, 1.00 eq) was added and the mixture stirred at 10 °C for 
10 min. Next, Zn powder (2.58 g, 39.5 mmol, 1.53 eq) and glacial acetic acid (20 mL; 
caution: gas evolution!) were added at 0 °C. The mixture was allowed to warm to rt and 
CH2Cl2 was selectively removed from the mixture under reduced pressure. The remaining 
mixture was stirred at 90 °C (reflux) for 3 h. After cooling to rt, Et2O (100 mL) and aqueous 
10% HCl (100 mL) were added and the mixture violently stirred at rt for 3 h. The organic 
layer was separated, the aqueous layer extracted with Et2O (3x), and the combined organic 
layers washed with water and dried over Na2SO4. All volatiles were removed in vacuo and 
traces of acetic acid were removed as an azeotrope with toluene (3x). The resulting residue 
was dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/EtOAc 30:1). After solvent removal and drying in vacuo, 3-methylbenzofuran-
2(3H)-one (274) was obtained as a clear colorless oil (1.76 g, 11.9 mmol, 46%). 1H NMR 
(300 MHz, CDCl3): δ = 7.35–7.21 (m, 2H), 7.19–7.05 (m, 2H), 3.72 (q, J = 7.6 Hz, 1H), 1.57 
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(d, J = 7.7 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C9H8O2Na: 171.0417 [M+Na]+; found: 
171.0420. 
3-Benzylbenzofuran-2(3H)-one (275) 
Compound 275 was synthesized according to a protocol from Smith et 
al.[23b] A flame-dried flask was charged with NaH (60 wt% in mineral oil; 
1.25 g, 31.3 mmol, 1.15 eq) and dry DMF (6 mL). 2-Methoxyphenylaceto-
nitrile (4.00 g, 27.2 mmol, 1.00 eq) was added and the mixture stirred at rt for 1 h. The 
resulting mixture was cooled to 0 °C and benzyl bromide (3.40 mL, 28.6 mmol, 1.05 eq) was 
added and the mixture allowed to warm to rt and stirred for 15 h. The mixture was then 
quenched by the addition of aqueous sat. NH4Cl and Et2O and the organic layer was separated. 
The aqueous layer was extracted with Et2O (3x) and the combined organic layers were 
washed with sat. NaCl and dried over Na2SO4. After solvent removal and drying in vacuo, a 
yellow oil was obtained as intermediate product (6.80 g). Half of this intermediate product 
(i.e., 3.40 g) were transferred into a new flask (250 mL), aqueous 48% HBr (75 mL) was 
added, and the resulting mixture stirred at reflux for 4 d. After cooling to rt, the mixture was 
neutralized with aqueous 3 M NaOH while ice was continuously added for cooling. The 
resulting mixture was extracted with Et2O (4x) and the combined organic layers were washed 
with brine and dried over Na2SO4. All volatiles were removed in vacuo, the residue dissolved 
in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/Et2O 
40:1 → 30:1). After solvent removal and drying in vacuo, desired 3-benzylbenzofuran-2(3H)-
one (275) was obtained as a yellow oil which crystallized on standing (1.26 g, 5.62 mmol, 
41%). 1H NMR (300 MHz, CDCl3): δ = 7.34–7.21 (m, 4H), 7.21–7.13 (m, 2H), 7.08–6.98 (m, 
2H), 6.85–6.77 (m, 1H), 4.02 (dd, J = 9.0 Hz, J = 4.8 Hz, 1H), 3.51 (dd, J = 13.8 Hz, 
J = 4.9 Hz, 1H), 3.05 (dd, J = 13.8 Hz, J = 8.9 Hz, 1H) ppm; HRMS (ESI): m/z calcd for 
C15H12O2Na: 247.0730 [M+Na]+; found: 247.0729. 
 
3-Isobutylbenzofuran-2(3H)-one (276) 
Compound 276 was synthesized according to a procedure from Smith et 
al.[23b] A flame-dried flask was charged with NaH (60 wt% in mineral oil; 
0.62 g, 15.5 mmol, 1.14 eq) and dry DMF (3.5 mL). 2-Methoxyphenyl-
acetonitrile (2.00 g, 13.6 mmol, 1.00 eq) was added and the mixture stirred at 
rt for 1 h. The resulting mixture was cooled to 0 °C and isobutyl iodide (1.60 mL, 13.9 mmol, 
1.02 eq) was added. As the mixture became barely stirrable, additional dry DMF (4 mL) was 
added. The mixture was then allowed to warm to rt and stirred for 15 h. Then, the mixture was 
quenched by the addition of aqueous sat. NH4Cl and Et2O and the organic layer was separated. 
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The aqueous layer was extracted with Et2O (3x) and the combined organic layers were 
washed with brine and dried over Na2SO4. After solvent removal and drying in vacuo, 
aqueous 48% HBr (70 mL) was added and the mixture stirred at reflux for 48 h. After cooling 
to rt, the mixture was neutralized with aqueous 3 M NaOH while ice was continuously added 
for cooling. The resulting mixture was extracted with Et2O (3x) and the combined organic 
layers were washed with brine and dried over Na2SO4. All volatiles were removed in vacuo, 
the residue dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/Et2O 40:1 → 30:1). After solvent removal and drying in vacuo, 3-isobutylbenzo-
furan-2(3H)-one (276) was obtained as a pale-yellow oil (1.30 g, 6.92 mmol, 51%). 1H NMR 
(300 MHz, CDCl3): δ = 7.34–7.21 (m, 2H), 7.18–7.06 (m, 2H), 3.72 (t, J = 7.1 Hz, 1H), 2.02 
(sept, J = 6.8 Hz, 1H), 1.96–1.84 (m, 1H), 1.82–1.68 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.97 
(d, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 177.6, 153.8, 128.8, 128.1, 124.5, 
124.1, 110.9, 41.7, 40.6, 25.3, 22.7, 22.3 ppm. 
 
Phenyl (3-phenylbenzofuran-2-yl) carbonate (142a)[86b] 
General procedure C1) was followed: Benzofuranone 273 (567 mg, 
2.70 mmol), phenyl chloroformate (340 µL, 2.71 mmol, 1.00 eq), Et3N 
(570 µL, 4.09 mmol, 1.52 eq); reaction time: 1 h; eluent: hexanes/Et2O 
30:1; 142a was obtained as a colorless oil (704 mg, 2.13 mmol, 79%). 1H NMR (300 MHz, 
CDCl3): δ = 7.73–7.52 (m, 3H), 7.49–7.00 (m, 11H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 151.0, 150.0, 150.0, 148.9, 130.1, 129.8 (2C), 129.2 (2C), 128.4 (2C), 127.9, 127.7, 126.9, 
124.8, 123.8, 120.7 (2C), 120.5, 111.6, 105.1 ppm; IR (film): v~ = 1795, 1453, 1223, 1163, 
1015, 744, 693 cm–1; HRMS (ESI): m/z calcd for C21H14O4Na: 353.0784 [M+Na]+; found: 
353.0786. 
 
3-Methylbenzofuran-2-yl phenyl carbonate (142b)[23b] 
General procedure C1) was followed: Benzofuranone 274 (449 mg, 
3.03 mmol), phenyl chloroformate (570 µL, 4.54 mmol, 1.50 eq), 
Et3N (640 µL, 4.59 mmol, 1.52 eq); reaction time: 1.5 h; eluent: 
hexanes/Et2O 10:1; 142b was obtained as a colorless crystalline solid (791 mg, 2.95 mmol, 
97%). 1H NMR (300 MHz, CDCl3): δ = 7.44–7.30 (m, 4H), 7.27–7.16 (m, 5H), 2.12 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 151.0, 150.3, 149.8, 149.3, 129.9 (2C), 129.6, 
126.9, 124.3, 123.1, 120.8 (2C), 119.6, 111.2, 98.8, 6.7 ppm; IR (film): v~ = 1793, 1452, 1215, 
1165, 1109, 1001, 742 cm–1; HRMS (ESI): m/z calcd for C16H12O4Na: 291.0628 [M+Na]+; 
found: 291.0632. 
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Benzyl (3-methylbenzofuran-2-yl) carbonate (142c)[86b] 
General procedure C1) was followed: Benzofuranone 274 (320 mg, 
2.16 mmol), benzyl chloroformate (440 mL, 3.09 mmol, 1.43 eq), Et3N 
(440 µL, 3.16 mmol, 1.46 eq); reaction time: 1 h; eluent: hexanes/Et2O 
20:1; 142c was obtained as a colorless crystalline solid (554 mg, 1.96 mmol, 91%). 1H NMR 
(300 MHz, CDCl3): δ = 7.41–7.24 (m, 7H), 7.22–7.11 (m, 2H), 5.24 (s, 2H), 2.03 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 151.9, 149.7, 149.6, 134.3, 129.6, 129.2, 128.9 
(2C), 128.7 (2C), 124.2, 123.0, 119.5, 111.1, 98.6, 71.6, 6.7 ppm; IR (film): v~ = 1779, 1452, 
1220, 1177, 1132, 740, 698 cm–1; HRMS (ESI): m/z calcd for C17H14O4Na: 305.0784 
[M+Na]+; found: 305.0788. 
 
Isopropyl (3-methylbenzofuran-2-yl) carbonate (142d)  
General procedure C1) was followed: Benzofuranone 274 (237 mg, 
1.60 mmol), isopropyl chloroformate (2.0 M in toluene, 1.20 mL, 
2.40 mmol, 1.50 eq), Et3N (335 µL, 2.40 mmol, 1.50 eq); reaction time: 
2 h; eluent: hexanes/Et2O 10:1; 142d was obtained as a colorless crystalline solid (355 mg, 
1.52 mmol, 95%). 1H NMR (300 MHz, CDCl3): δ = 7.41–7.34 (m, 1H), 7.33–7.26 (m, 1H), 
7.23–7.11 (m, 2H), 4.95 (sept, J = 6.3 Hz, 1H), 2.05 (s, 3H), 1.33 (d, J = 6.4 Hz, 6H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 151.3, 149.8, 149.7, 129.7, 124.0, 123.0, 119.4, 111.1, 98.4, 
74.9, 21.7 (2C), 6.7 ppm; IR (film): v~ = 1776, 1455, 1230, 1191, 1176, 1132, 1095, 908, 
741 cm–1; HRMS (APCI): m/z calcd for C13H14O4H: 235.0965 [M+H]+; found: 235.0964. 
 
3-Benzylbenzofuran-2-yl (1,1,1-trichloro-2-methylpropan-2-yl) carbonate (142e)[22b] 
General procedure C1) was followed: Benzofuranone 275 (180 mg, 
803 µmol), 2,2,2-trichloro-1,1-dimethylethyl chloroformate (262 mg, 
1.09 mmol, 1.36 eq), Et3N (160 µL, 1.15 mmol, 1.43 eq); reaction 
time: 2.5 h; eluent: hexanes/Et2O 20:1; 142e was obtained as a colorless crystalline solid 
(325 mg, 761 µmol, 95%). 1H NMR (300 MHz, CDCl3): δ = 7.32 (d, J = 8.1 Hz, 1H), 7.25–
7.02 (m, 8H), 3.88 (s, 2H), 1.89 (s, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 149.9, 149.7, 
148.8, 138.4, 128.7, 128.7 (2C), 128.7 (2C), 128.6, 126.6, 124.3, 123.2, 120.1, 111.2, 104.8, 
102.1, 92.2, 28.7, 21.2 (2C) ppm; IR (film): v~ = 1785, 1454, 1237, 1203, 1138, 1101, 800, 
743, 702 cm–1; HRMS (ESI): m/z calcd for C20H17Cl3O4Na: 449.0085 [M+Na]+; found: 
449.0082. 
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3-Isobutylbenzofuran-2-yl phenyl carbonate (142f)[23b] 
General procedure C1) was followed: Benzofuranone 276 (260 mg, 
1.38 mmol), phenyl chloroformate (260 µL, 2.07 mmol, 1.50 eq), Et3N 
(290 µL, 2.08 mmol, 1.51 eq); reaction time: 1.5 h; eluent: hexanes/ 
Et2O 20:1; 142f was obtained as a colorless oil (391 mg, 1.26 mmol, 
91%). 1H NMR (300 MHz, CDCl3): δ = 7.46–7.40 (m, 1H), 7.40–7.29 (m, 3H), 7.26–7.12 (m, 
5H), 2.45 (d, J = 7.2 Hz, 2H), 1.99 (sept, J = 6.8 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 151.0, 150.4, 149.9, 149.7, 129.9 (2C), 129.2, 126.9, 124.2, 
123.1, 120.8 (2C), 120.1, 111.3, 102.5, 31.6, 28.4, 22.8 (2C) ppm; IR (film): v~ = 1794, 1456, 
1208, 1164, 1007, 742, 686 cm–1; HRMS (ESI): m/z calcd for C19H18O4Na: 333.1097 
[M+Na]+; found: 333.1098. 
 
3-Benzylbenzofuran-2-yl phenyl carbonate (142g)[23b] 
General procedure C1) was followed: Benzofuranone 275 (250 mg, 
1.11 mmol), phenyl chloroformate (220 µL, 1.75 mmol, 1.57 eq), Et3N 
(240 µL, 1.72 mmol, 1.55 eq); reaction time: 3 h; eluent: hexanes/Et2O 
40:1 → 30:1; 142g was obtained as a colorless crystalline solid (315 mg, 914 µmol, 82%). 
1H NMR (300 MHz, CDCl3): δ = 7.36–7.02 (m, 14H), 3.90 (s, 2H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 150.9, 150.2, 149.9, 149.7, 138.3, 129.8 (2C), 128.7 (2C), 128.7 (2C), 128.6, 
126.8, 126.6, 124.4, 123.2, 120.7 (2C), 120.2, 111.3, 102.2, 28.7 ppm; IR (film): v~ = 1792, 
1453, 1189, 1158, 1099, 1010, 740, 694, 499 cm–1; HRMS (ESI): m/z calcd for C22H16O4Na: 
367.0941 [M+Na]+; found: 367.0942. 
 
Methyl (3-methylbenzofuran-2-yl) carbonate (142h) 
General procedure C1) was followed: Benzofuranone 274 (280 mg, 
1.89 mmol), methyl chloroformate (220 µL, 2.85 mmol, 1.51 eq), Et3N 
(400 µL, 2.87 mmol, 1.52 eq); reaction time: 2 h; eluent: hexanes/Et2O 
20:1; 142h was obtained as a colorless oil (360 mg, 1.75 mmol, 92%; product is volatile in 
vacuo). 1H NMR (300 MHz, CDCl3): δ = 7.42–7.35 (m, 1H), 7.33–7.27 (m, 1H), 7.24–7.12 
(m, 2H), 3.89 (s, 3H), 2.05 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 152.5, 149.7, 149.6, 
129.6, 124.2, 123.0, 119.5, 111.1, 98.5, 56.4, 6.6 ppm; IR (film): v~ = 1783, 1665, 1446, 1233, 
1178, 1130, 925, 743, 438 cm–1; HRMS (ESI): m/z calcd for C11H10O4Na: 229.0471 [M+Na]+; 
found: 229.0471. 
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3-Methylbenzofuran-2-yl (1,1,1-trichloro-2-methylpropan-2-yl) carbonate (142i) 
General procedure C1) was followed: Benzofuranone 274 (337 mg, 
2.27 mmol), 2,2,2-trichloro-1,1-dimethylethyl chloroformate (729 mg, 
3.04 mmol, 1.34 eq), Et3N (440 µL, 3.16 mmol, 1.39 eq); reaction 
time: 1.5 h; eluent: hexanes/Et2O 20:1; 142i was obtained as a colorless crystalline solid 
(769 mg, 2.19 mmol, 96%). 1H NMR (300 MHz, CDCl3): δ = 7.42–7.35 (m, 1H), 7.34–
7.27 (m, 1H), 7.23–7.13 (m, 2H), 2.07 (s, 3H),  1.95 (s, 6H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 149.8, 149.3, 148.9, 129.6, 124.2, 123.1, 119.5, 111.1, 104.8, 98.7, 92.2, 21.3, 
6.7 ppm; IR (film): v~ = 1785, 1454, 1237, 1188, 1140, 1109, 801, 744 cm–1; HRMS (FD): m/z 
calcd for C14H13Cl3O4: 349.9879 [M]+; found: 349.9880. 
 
4.9.3  Aryl Alkyl Ketenes (153a–h) 
Aryl alkyl ketenes (153) were synthesized in a two-step procedure (Scheme 87). In case the 
required α-alkyl-α-arylacetic acids (277) were not available, they were synthesized before-
hand from a commercial precursor. The α-alkyl-α-arylacetic acids acids (277) were converted 
to the according acid chlorides (278) via thionyl chloride treatment and the resulting acid 
chlorides (278) were finally converted to the desired ketenes (153) via base-induced 
β-elimination. 
 
 
 
Scheme 87. Synthesis of aryl alkyl ketenes (153) from α-alkyl-α-arylacetic acids (277). 
 
EtNMe2 was employed as base for the final β-elimination step due to its high volatility, which 
ensured its easy removal from the ketenes during their distillative purification.[26a] 
 
4.9.3.1  General Procedures D1)–D3) 
General Procedure D1).  Synthesis of α-alkyl-α-arylacetic acids (277) from 
α-arylacetic acids:[146] 
A flame-dried flask was charged with the indicated commercial α-arylacetic acid (1.00 eq) 
and dry THF (conc = 0.35 M). The mixture was cooled to −78 °C and n-BuLi (2.5 M in 
hexanes, 4.00 eq) was added over 10 min and the mixture stirred for 2 h at −78 °C. The 
indicated alkyl bromide (4.00 eq) was added and the mixture allowed to warm to rt and stirred 
for the indicated time. Then, the mixture was quenched with 0.1 M HCl, diluted with CH2Cl2, 
the organic layer separated, and the aqueous layer extracted with CH2Cl2 (3x). The combined 
organic layers were washed with aqueous 10% Na2S2O3 and dried over Na2SO4. After drying 
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in vacuo, the desired α-alkyl-α-arylacetic acid (277) was obtained without the need for further 
purification. 
 
General Procedure D2). Synthesis of acid chlorides from α-alkyl-α-arylacetic acids 
(277 → 278). 
A flame-dried flask was charged with the respective α-alkyl-α-arylacetic acid (277; 1.00 eq) 
and thionyl chloride (2.50 eq) and the flask equipped with a reflux condenser. Then, the 
mixture was stirred at 70 °C (reflux) for the indicated time under nitrogen atmosphere. After 
cooling to rt, excess thionyl chloride was carefully removed in vacuo and the remaining crude 
acid chloride (278) purified via short-path distillation at the indicated pressure and tem-
perature. 
 
General Procedure D3). Synthesis of aryl alkyl ketenes from acid chlorides (153 → 278).[26a] 
A flame-dried flask was charged with the respective acid chloride (278; 1.00 eq) and dry THF 
(conc = 0.50 M). The mixture was cooled to 0 °C and EtNMe2 (4.00 eq) was added under 
stirring. Then, the mixture was allowed to warm to rt and stirred for the indicated time under 
nitrogen atmosphere. The formed white precipitate (EtNMe2·HCl) was filtered off using a 
flame-dried Schlenk frit (porosity G4) equipped with a flame-dried receiving flask. The 
filtered off precipitate was thoroughly rinsed under nitrogen atmosphere with dry THF. Then, 
solvent and excess EtNMe2 were carefully removed from the filtrate in vacuo and remaining 
crude ketene (153) distilled via short-path distillation at the indicated pressure and tempera-
ture. 
Remark: All operations were performed under strict exclusion of moisture and air and all 
isolated ketenes were immediately stored after their distillation in well-sealed, flame-dried 
Schlenk mini-tubes (5 mL; threaded PTFE plug) at −20 °C under exclusion of light and under 
nitrogen atmosphere and used for catalysis experiments within two weeks after preparation. 
 
4.9.3.2  Synthetic Procedures and Characterizations 
Phenyl ethyl ketene (153a)[147] 
2-Phenylbutanoyl chloride (278a). General procedure D2) was followed: 
Commercial 2-phenylbutanoic acid (277a; 10.5 g, 63.6 mmol); reaction 
time: 18 h; distillation: 110–150 °C (15 mbar); 278a was obtained as a 
colorless oil (11.6 g, 63.5 mmol, quant.). 1H NMR (300 MHz, C6D6): 
δ = 7.10–6.92 (m, 5H), 3.49 (t, J = 7.5 Hz, 1H), 1.96–1.77 (m, 1H), 1.61–1.42 (m, 1H), 0.57 (t, 
J = 7.5 Hz, 3H) ppm; 13C NMR (75 MHz, C6D6): δ = 175.0, 136.6, 129.6 (2C), 129.0 (2C), 
128.6, 65.6, 27.0, 11.8 ppm. 
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Phenyl ethyl ketene (153a). General procedure D3) was followed: 2-Phenylbutanoyl chloride 
(278a, 2.70 g, 14.8 mmol); reaction time: 15 h; distillation: 40–50 °C (1.0 mbar); 153a was 
obtained as a yellow oil (1.84 g, 12.6 mmol, 85%). 1H NMR (300 MHz, C6D6): δ = 7.14–6.80 
(m, 5H), 1.97 (q, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (75 MHz, C6D6): 
δ = 206.2, 133.4, 129.6 (2C), 124.8, 124.8 (2C), 42.4, 17.4, 13.1 ppm. 
 
o-Tolyl ethyl ketene (153b)[26c] 
2-(o-Tolyl)butanoyl chloride (278b). General procedure D2) was 
followed: 2-(o-Tolyl)butanoic acid[146] (277b; 6.06 g, 34.0 mmol); reaction 
time: 8 h; distillation: 100–125 °C (5 mbar); 278b was obtained as a pale 
yellow oil (6.51 g, 33.1 mmol, 97%). 1H NMR (300 MHz, C6D6): δ = 7.09–
6.88 (m, 4H), 3.86 (t, J = 7.4 Hz, 1H), 2.09 (s, 3H), 1.99–1.80 (m, 1H), 1.64-1.44 (m, 1H), 
0.59 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (75 MHz, C6D6): δ = 174.9, 137.3, 135.3, 131.6, 
128.5, 127.7, 127.5, 61.2, 27.0. 20.0, 11.8 ppm.  
o-Tolyl ethyl ketene (153b). General procedure D3) was followed: 2-(o-Tolyl)butanoyl 
chloride (278b; 2.94 g, 14.9 mmol); reaction time: 15 h; distillation: 40–50 °C (1.0 mbar); 
153b was obtained as a yellow oil (1.92 g, 12.0 mmol, 80%). 1H NMR (300 MHz, C6D6): 
δ = 7.12–6.84 (m, 4H), 2.15 (s, 3H), 2.08 (q, J = 7.4 Hz, 2H), 0.88 (t, J = 7.4 Hz, 3H) ppm; 
13C NMR (75 MHz, C6D6): δ = 201.2, 136.2, 131.4, 131.3, 127.4, 127.1, 126.4, 38.3, 21.1, 
20.5, 13.4 ppm. 
 
Phenyl isopropyl ketene (153c)[148] 
3-Methyl-2-phenylbutanoyl chloride (278c). General procedure D2) was 
followed: 3-Methyl-2-phenylbutanoic acid[149] (277c; 8.96 g, 50.3 mmol); 
reaction time: 8 h; distillation: 85–110 °C (5 mbar); 278c was obtained as a 
pale yellow oil (9.69 g, 49.3 mmol, 98%). 1H NMR (300 MHz, C6D6): 
δ = 7.11–6.95 (m, 5H), 3.42 (d, J = 10.0 Hz, 1H), 2.30–2.10 (m, 1H), 0.90 (d, J = 6.4 Hz, 3H), 
0.46 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz, C6D6): δ = 174.8, 135.7, 129.5 (2C), 129.5 
(2C), 128.7, 72.2, 32.5, 21.4, 20.0 ppm.  
Phenyl isopropyl ketene (153c). General procedure D3) was followed: 3-Methyl-2-phenyl-
butanoyl chloride (278c; 3.03 g, 15.4 mmol); reaction time: 15 h; distillation: 40–50 °C 
(1.0 mbar); 153c was obtained as a yellow oil (1.97 g, 12.3 mmol, 80%). 1H NMR (300 MHz, 
C6D6): δ = 7.14–6.83 (m, 5H), 2.44 (sept, J = 6.6 Hz, 1H), 0.95 (d, J = 6.6 Hz, 6H) ppm; 
13C NMR (75 MHz, C6D6): δ = 205.2, 133.0, 129.7 (2C), 125.6 (2C), 125.0, 48.5, 24.5, 22.3 
(2C) ppm. 
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p-Chlorophenyl isopropyl ketene (153d)[148] 
2-(4-Chlorophenyl)-3-methylbutanoyl chloride (278d). General proce-
dure D2) was followed: Commercial 2-(4-chlorophenyl)-3-methylbutanoic 
acid (277d; 7.05 g, 33.2 mmol); reaction time: 20 h; distillation: 120–
130 °C (5 mbar); 278d was obtained as a pale yellow oil (7.28 g, 
31.5 mmol, 95%). 1H NMR (300 MHz, C6D6): δ = 7.05–6.91 (m, 2H), 6.80–6.65 (m, 2H), 
3.26 (d, J = 10.0 Hz, 1H), 2.16–1.95 (m, 1H), 0.84 (d, J = 6.6 Hz, 3H), 0.37 (d, J = 6.8 Hz, 
3H) ppm; 13C NMR (75 MHz, C6D6): δ = 174.5, 134.9, 134.1, 130.7 (2C), 129.7 (2C), 71.2, 
32.3, 21.3, 19.8 ppm. 
p-Chlorophenyl isopropyl ketene (153d). General procedure D3) was followed: 2-(4-Chlo-
rophenyl)-3-methylbutanoyl chloride (278d; 2.34 g, 10.1 mmol); reaction time: 15 h; distil-
lation: 60–65 °C (0.5 mbar); 153d was obtained as a yellow oil (1.73 g, 8.88 mmol, 88%). 
1H NMR (300 MHz, C6D6): δ = 7.09–6.98 (m, 2H), 6.63–6.51 (m, 2H), 2.27 (sept, J = 6.7 Hz, 
1H), 0.88 (d, J = 6.6 Hz, 6H) ppm; 13C NMR (75 MHz, C6D6): δ = 204.2, 131.6, 130.4, 129.8 
(2C), 126.7 (2C), 48.1, 24.4, 22.2 (2C) ppm. 
 
p-Methoxyphenyl isopropyl ketene (153e)[26i] 
2-(4-Methoxyphenyl)-3-methylbutanoic acid (277e). General proce-
dure D1) was followed: Commercial 4-methoxyphenylacetic acid 
(4.99 g, 30.0 mmol); alkyl bromide: 2-bromopropane; reaction time: 
22 h; 277e was obtained as a colorless crystalline solid (6.05 g, 
29.1 mmol, 97%); 1H NMR (300 MHz, DMSO-d6): δ = 12.18 (s, 1H), 7.22 (d, J = 8.7 Hz, 2H), 
6.88 (d, J = 8.7 Hz, 2H), 3.73 (s, 3H), 3.03 (d, J = 10.4 Hz, 1H), 2.25–2.05 (m, 1H), 0.98 (d, 
J = 6.4 Hz, 3H), 0.63 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz, DMSO-d6): δ = 174.9, 
158.2, 130.7, 129.2 (2C), 113.7 (2C), 58.4, 55.0, 31.0, 21.2, 19.8 ppm; IR (film): v~ = 2961, 
1701, 1510, 1297, 1255, 1179, 1029, 830 cm–1; HRMS (ESI): m/z calcd for C12H16O3Na: 
231.0992 [M+Na]+; found: 231.0994. 
2-(4-Methoxyphenyl)-3-methylbutanoyl chloride (278e). General procedure D2) was 
followed: 2-(4-Methoxyphenyl)-3-methylbutanoic acid (277e; 6.20 g, 29.8 mmol); reaction 
time: 2.5 h; distillation: 100–130 °C (5 mbar); 278e was obtained as a yellow oil (6.16 g, 
27.2 mmol, 91%). 1H NMR (300 MHz, C6D6): δ = 6.99 (d, J = 8.7 Hz, 2H), 6.68 (d, 
J = 8.7 Hz, 2H), 3.41 (d, J = 10.2 Hz, 1H), 3.36–3.21 (m, 3H), 2.33–2.12 (m, 1H), 0.94 (d, 
J = 6.6 Hz, 3H), 0.52 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz, C6D6): δ = 175.0, 160.4, 
130.6 (2C), 127.5, 115.1 (2C), 71.4, 55.2, 32.4, 21.5, 20.0 ppm.  
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p-Methoxyphenyl isopropyl ketene (153e). General procedure D3) was followed: 2-(4-
Methoxyphenyl)-3-methylbutanoyl chloride (278e, 2.12 g, 9.35 mmol); reaction time: 45 h; 
distillation: 70 °C (0.7 mbar); 153e was obtained as a yellow oil (1.30 g, 6.81 mmol, 73%). 
1H NMR (300 MHz, C6D6): δ = 6.94–6.83 (m, 2H), 6.80–6.68 (m, 2H), 3.32 (s, 3H), 2.46 
(sept, J = 6.7 Hz, 1H), 0.99 (d, J = 6.6 Hz, 6H) ppm; 13C NMR (75 MHz, C6D6): δ = 206.7, 
158.2, 127.5 (2C), 124.2, 115.5 (2C), 55.2, 47.1, 25.2, 22.4 (2C) ppm. 
 
m-Tolyl isopropyl ketene (153f) 
3-Methyl-2-(m-tolyl)butanoic acid (277f). General procedure D1) was 
followed: Commercial m-tolylacetic acid (3.81 g, 25.4 mmol); alkyl 
bromide: 2-bromopropane; reaction time: 26 h; 277f was obtained as a 
colorless crystalline solid (4.87 g, 25.3 mmol, quant.); 1H NMR 
(300 MHz, CDCl3): δ = 10.74 (s, 1H), 7.27–7.03 (m, 4H), 3.11 (d, J = 10.6 Hz, 1H), 2.43–
2.23 (m, 1H), 2.35 (s, 3H), 1.09 (d, J = 6.6 Hz, 3H), 0.72 (d, J = 6.6 Hz, 3H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 180.4, 138.3, 137.8, 129.5, 128.6, 128.4, 125.8, 60.1, 31.6, 21.6, 21.6, 
20.3 ppm. IR (film): v~ = 3022, 1700, 1290, 1210, 780, 718 cm–1; HRMS (ESI): m/z calcd for 
C12H16O2Na: 215.1043 [M+Na]+; found: 215.1045. 
3-Methyl-2-(m-tolyl)butanoyl chloride (278f). General procedure D2) was followed: 
3-Methyl-2-(m-tolyl)butanoic acid (277f; 4.84 g, 25.2 mmol); reaction time: 4 h; distillation: 
70 °C (0.4 mbar); 278f was obtained as a colorless oil (5.13 g, 24.3 mmol, 97%). 1H NMR 
(300 MHz, C6D6): δ = 7.01 (t, J = 7.7 Hz, 1H), 6.69–6.79 (m, 3H), 3.43 (d, J = 10.2 Hz, 1H), 
2.34–2.12 (m, 1H), 2.02 (s, 3H), 0.93 (d, J = 6.4 Hz, 3H), 0.49 (d, J = 6.6 Hz, 3H) ppm; 
13C NMR (75 MHz, C6D6): δ = 174.9, 139.2, 135.7, 130.1, 129.6, 129.5, 126.6, 72.3, 32.6, 
21.6, 21.5, 20.1 ppm.  
m-Tolyl isopropyl ketene (153f). General procedure D3) was followed: 3-Methyl-2-
(m-tolyl)butanoyl chloride (278f; 2.11 g, 10.0 mmol); reaction time: 43 h; distillation: 
45−55 °C (0.4 mbar); 153f was obtained as a yellow oil (1.34 g, 7.71 mmol, 77%). 1H NMR 
(300 MHz, C6D6): δ = 7.07 (d, J = 7.6 Hz, 1H), 6.88–6.69 (m, 3H), 2.50 (sept, J = 6.8 Hz, 1H), 
2.08 (s, 3H), 0.99 (d, J = 6.8 Hz, 6H) ppm; 13C NMR (75 MHz, C6D6): δ = 205.5, 139.1, 
132.9, 129.6, 126.5, 126.0, 122.9, 48.4, 24.5, 22.4 (2C), 21.8 ppm. 
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Phenyl cyclopentyl ketene (153g)[148] 
2-Cyclopentyl-2-phenylacetyl chloride (278g). General procedure D2) 
was followed: Commercial 2-cyclopentyl-2-phenylacetic acid (277g; 5.75 g, 
28.2 mmol); reaction time: 5 h; distillation: 85 °C (0.3 mbar); 278g was 
obtained as a pale yellow oil (6.02 g, 27.0 mmol, 96%). 1H NMR (300 MHz, 
C6D6): δ = 7.13–6.89 (m, 5H), 3.52 (d, J = 10.8 Hz, 1H), 2.52–2.25 (m, 1H), 1.99–1.75 (m, 
1H), 1.52–0.94 (m, 6H), 0.80–0.56 (m, 1H) ppm; 13C NMR (75 MHz, C6D6): δ = 174.8, 136.6, 
129.6 (2C), 129.2 (2C), 128.7, 70.4, 44.0, 31.9, 31.0, 25.8, 25.3 ppm.  
Phenyl cyclopentyl ketene (153g). General procedure D3) was followed: 2-Cyclopentyl-2-
phenylacetyl chloride (278g; 2.18 g, 9.79 mmol); reaction time: 38 h; distillation: 70–75 °C 
(0.5 mbar); 153g was obtained as a yellow oil (1.19 g, 6.36 mmol, 65%). 1H NMR (300 MHz, 
C6D6): δ = 7.17–7.04 (m, 2H), 7.01–6.85 (m, 2H), 2.56 (quint, J = 7.4 Hz, 1H), 1.87–1.67 (m, 
2H), 1.58–1.30 (m, 4H), 1.30–1.11 (m, 2H) ppm; 13C NMR (75 MHz, C6D6): δ = 205.6, 133.8, 
129.6 (2C), 125.4 (2C), 124.9, 46.5, 35.0, 33.1 (2C), 25.2 (2C) ppm. 
 
Phenyl cyclohexyl ketene (153h)[148] 
2-Cyclohexyl-2-phenylacetyl chloride (278h). General procedure D2) 
was followed: Commercial 2-cyclohexyl-2-phenylacetic acid (277h, 4.98 g, 
22.8 mmol); reaction time: 4 h; distillation: 110–120 °C (0.5 mbar); 278h 
was obtained as a pale yellow oil (5.28 g, 22.3 mmol, 98%). 1H NMR 
(300 MHz, C6D6): δ = 7.15–6.87 (m, 5H), 3.54 (d, J = 10.2 Hz, 1H), 2.11–1.79 (m, 2H), 1.63–
0.72 (m, 9H), 0.58–0.35 (m, 1H) ppm; 13C NMR (75 MHz, C6D6): δ = 174.8, 135.3, 129.6 
(4C), 128.7, 71.4, 41.7, 32.2, 30.4, 26.7, 26.4, 26.3 ppm.  
Phenyl cyclohexyl ketene (153h). General procedure D3) was followed: 2-Cyclohexyl-
2-phenylacetyl chloride (278h; 2.00 g, 8.45 mmol); reaction time: 44 h; distillation: 80–90 °C 
(0.4 mbar); 153h was obtained as a yellow oil (1.26 g, 6.29 mmol, 75%). 1H NMR (300 MHz, 
C6D6): δ = 7.18–6.84 (m, 5H), 2.30–2.09 (m, 1H), 1.93–1.74 (m, 2H), 1.64–0.82 (m, 
8H) ppm; 13C NMR (75 MHz, C6D6): δ = 205.4, 132.9, 129.7 (2C), 125.7 (2C), 125.0, 47.3, 
33.8, 33.2 (2C), 26.9 (2C), 26.7 ppm. 
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4.9.4  O-Acylated Oxindoles (147a–b, 149a–b, 151) 
Gliocladin C Precursors 147a and 147b[90,150] 
N
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Scheme 88. Synthesis of gliocladin C precursors 147a and 147a. 
 
Compound 280. Compound 280 was synthesized according to a modified protocol from 
Bergman et al.[150] A flask (250 mL) was charged with isatin (279; 2.21 g, 15.0 mmol, 
1.00 eq), indole (1.76 g, 15.0 mmol, 1.00 eq), ethanol (45 mL), and piperidine (148 µL, 
1.50 mmol, 10 mol%). The resulting mixture was stirred at 45 °C for 1.5 h. After cooling to rt, 
all volatiles were removed in vacuo, the crude product dissolved in MeOH, adsorbed on silica 
gel, and purified by short-column flash chromatography (hexanes/EtOAc 1:1 → EtOAc). 
After drying in vacuo, compound 280 was obtained as a beige crystalline solid (3.71 g, 
14.0 mmol, 94%). 1H NMR (300 MHz, DMSO-d6): δ = 10.98 (d, J = 1.3 Hz, 1H), 10.34 (s, 
1H), 7.44–7.31 (m, 2H), 7.31–7.20 (m, 2H), 7.09 (d, J = 2.6 Hz, 1H), 7.04 (td, J = 7.6 Hz, 
J = 1.1 Hz, 1H), 7.00–6.83 (m, 3H), 6.36 (s, 1H) ppm; HRMS (ESI): m/z calcd for 
C16H12N2O2Na: 287.0791 [M+Na]+; found: 287.0793. 
Compound 281. Compound 281 was synthesized according to a protocol from Overman et 
al.[90] A flask (250 mL) was charged with compound 280 (3.65 g, 13.8 mmol, 1.00 eq), 
evacuated for 2 h, and carefully refilled with nitrogen gas. Dry CH2Cl2 (55 mL) and 
triethylsilane (6.60 mL, 41.4 mmol, 3.00 eq) were added and the resulting mixture cooled to 
0 °C. Trifluoroacetic acid (5.20 mL, 68.0 mmol, 4.92 eq) was added dropwise over 5 min and 
the resulting mixture stirred at 0 °C for 2.5 h. The mixture was then quenched at 0 °C by the 
addition of aqueous 5% sodium citrate (330 mL). This mixture was diluted with EtOAc and 
the organic layer separated. The aqueous layer was extracted with EtOAc (3x), the combined 
organic layers washed with water and brine, and the solvent removed in vacuo. Solvent traces 
were removed from the residue as an azeotrope with m-xylene (2x 50 mL). The obtained solid 
was then triturated with hexanes (70 mL) and the hexane layer removed by filtration through a 
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glass filter (porosity G3). The precipitate was collected, dried in vacuo, and transferred into a 
new flask (250 mL). CH2Cl2 (90 mL) was added and the resulting suspension cooled with a 
water bath. Then, Boc2O (8.38 g, 38.4 mmol, 2.78 eq) and DMAP (268 mg, 2.19 mmol, 
16 mol%) were added (caution: gas evolution!). The resulting mixture was stirred at rt for 7 h 
under nitrogen atmosphere whereupon the suspension turned into a solution. Then, MeOH 
(45 mL) was added and the mixture stirred at rt for 16 h. Subsequently, the resulting mixture 
was diluted with EtOAc and aqueous sat. NH4Cl. The organic layer was separated and the 
aqueous layer extracted with EtOAc (3x). The combined organic layers were dried over 
Na2SO4 and the solvent removed in vacuo. The crude product was dissolved in CH2Cl2, 
adsorbed on silica gel, and purified by flash chromatography (hexanes/EtOAc 20:1 → 10:1). 
After drying in vacuo, compound 281 was obtained as a pale-yellow solid foam (3.60 g, 
8.02 mmol, 58%). 1H NMR (300 MHz, CDCl3): δ = 8.14 (d, J = 8.3 Hz, 1H), 7.97 (d, 
J = 8.1 Hz, 1H), 7.49 (s, 1H), 7.43–7.35 (m, 1H), 7.34–7.11 (m, 5H), 1.66 (s, 9H), 1.64 (s, 
9H) ppm; HRMS (ESI): m/z calcd for C26H28N2O5Na: 471.1890 [M+Na]+; found: 471.1891. 
Gliocladin C Precursor 147a. Compound 147a was synthesized according to a modified 
protocol from Overman et al.[90] A flame-dried flask (10 mL) was charged with compound 
281 (400 mg, 892 µmol, 1.00 eq), dry THF (3.6 mL), and Et3N (300 µL, 2.16 mmol, 2.42 eq). 
This mixture was cooled to 0 °C and CbzCl (280 µL, 1.96 mmol, 2.20 eq) was added. The 
resulting mixture was allowed to warm to rt and stirred for 10 h at rt and then quenched by the 
addition of aqueous sat. NH4Cl. The mixture was diluted with water and EtOAc, the organic 
layer separated, the aqueous layer extracted with EtOAc (2x), and the combined organic 
layers washed with water (2x) and dried over Na2SO4. The solvent was removed in vacuo, the 
residue dissolved in CH2Cl2 and adsorbed on silica gel (40 °C), and the crude product purified 
by flash chromatography (hexanes/Et2O 10:1 → 5:1). After drying in vacuo, gliocladin C 
precursor 147a was obtained as a colorless solid foam (426 mg, 731 µmol, 82%). 1H NMR 
(300 MHz, CDCl3): δ = 8.23 (d, J = 8.3 Hz, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.76 (s, 1H), 7.56 (t, 
J = 7.7 Hz, 2H), 7.42–7.33 (m, 2H), 7.33–7.13 (m, 7H), 5.22 (s, 2H), 1.70 (s, 9H), 1.63 (s, 
9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 152.5, 149.8, 149.0, 138.2, 135.7, 134.4, 132.6, 
129.8, 128.8, 128.7 (2C), 128.4 (2C), 127.0, 125.1, 124.9, 124.8, 123.4, 122.9, 121.1, 120.2, 
115.7, 115.4, 110.7, 102.9, 84.9, 84.0, 71.2, 28.4 (3C), 28.3 (3C) ppm; IR (film): v~ = 1778, 
1734, 1453, 1363, 1315, 1249, 1213, 1149, 1115, 1068, 738 cm–1; HRMS (ESI): m/z calcd for 
C34H34N2O7Na: 605.2258 [M+Na]+; found: 605.2259. 
Gliocladin C precursor 147b. Compound 147b was synthesized according to a modified 
protocol from Overman et al.[90] A flame-dried flask (25 mL) was charged with compound 
281 (800 mg, 1.78 mmol, 1.00 eq), dry THF (7.2 mL), and Et3N (300 µL, 2.16 mmol, 1.21 eq). 
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This mixture was cooled to 0 °C and 2,2,2-trichloro-1,1-dimethylethyl chloroformate (471 mg, 
1.96 mmol, 1.10 eq) was added. The resulting mixture was stirred at 0 °C for 2 h and then 
quenched by the addition of aqueous sat. NH4Cl and diluted with water and EtOAc. The 
organic layer was separated, the aqueous layer extracted with EtOAc (2x), and the combined 
organic layers washed with water (1x) and brine (1x) and dried over Na2SO4. The solvent was 
removed in vacuo, the residue dissolved in CH2Cl2 and adsorbed on silica gel (40 °C), and the 
crude product purified by flash chromatography (hexanes/Et2O 20:1 → 10:1). After solvent 
removal and drying in vacuo, gliocladin C precursor 147b was obtained as a colorless solid 
foam (1.01 g, 1.55 mmol, 87%). 1H NMR (300 MHz, CDCl3): δ = 8.23 (d, J = 8.1 Hz, 1H), 
8.12 (d, J = 8.5 Hz, 1H), 7.76 (s, 1H), 7.56 (t, J = 7.4 Hz, 2H), 7.42–7.32 (m, 2H), 7.30–7.17 
(m, 2H), 1.87 (s, 6H), 1.71 (s, 9H), 1.69 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 149.7, 
149.1, 148.9, 138.2, 135.7, 132.4, 129.7, 126.8, 124.9, 124.8, 124.8, 123.4, 122.9, 121.1, 
120.3, 115.6, 115.4, 110.7, 105.0, 102.7, 91.8, 85.0, 84.1, 28.4 (3C), 28.4 (3C), 21.1 
(2C) ppm; IR (film): v~ = 1783, 1736, 1453, 1365, 1315, 1248, 1211, 1154, 1115, 1069, 802, 
742 cm–1; HRMS (ESI): m/z calcd for C31H33Cl3N2O7Na: 673.1246 [M+Na]+; found: 
673.1250. 
 
N,O-Diacylated Oxindoles (149a–b) 
N,O-Diacylated Oxindole 149a 
Compound 149a was synthesized according to a procedure from Suga 
et al.[23f] A flame-dried flask (25 mL) was charged with commercial 
3-methyl-2-oxindole (386 mg, 2.62 mmol, 1.00 eq) and dry THF 
(10 mL). Et3N (1.55 mL, 11.1 mmol, 4.24 eq) and phenyl chloro-
formate (1.32 mL, 10.5 mmol, 4.02 eq) were added and the mixture stirred at rt for 1 h. The 
mixture was then diluted with CH2Cl2 and quenched with 1 M HCl. The organic layer was 
separated and the aqueous layer extracted with CH2Cl2 (3x). The combined organic layers 
were dried over Na2SO4, the solvent removed in vacuo, the crude product dissolved in CH2Cl2, 
adsorbed on silica gel (42 °C), and purified by short-column chromatography (hexanes/Et2O 
10:1). After drying in vacuo, desired N,O-diacylated oxindole 149 was obtained as a colorless 
oil which crystallized on standing (1.02 g, 2.63 mmol, quant.). 1H NMR (300 MHz, CDCl3): 
δ = 8.14–8.02 (m, 1H), 7.50–7.10 (m, 11H), 7.09–6.98 (m, 2H), 2.19 (s, 3H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 151.3, 151.1, 150.2, 148.7, 137.4, 132.4, 129.9 (2C), 129.7 (2C), 128.3, 
126.8, 126.7, 125.3, 123.9, 121.7 (2C), 120.9 (2C), 119.2, 115.7, 106.5, 7.2 ppm; IR (film): v~
= 1789, 1747, 1455, 1355, 1328, 1187, 1070, 999, 741, 687 cm–1; HRMS (ESI): m/z calcd for 
C23H17N1O5Na: 410.0999 [M+Na]+; found: 410.1007. 
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N,O-Diacylated Oxindole 149b 
 
 
Scheme 89. Synthesis of N,O-diacylated oxindole 149b. 
 
2-Benzylindolin-2-one (283). Compound 283 was synthesized according to a protocol from 
Melchiorre et al.[151] A flame-dried flask was charged with commercial indolin-2-one (282; 
500 mg, 3.76 mmol, 1.00 eq), dry MeOH (4.0 mL), piperidine (740 µL, 7.49 mmol, 2.00 eq), 
and benzaldehyde (420 µL, 4.13 mmol, 1.10 eq). The resulting mixture was stirred at reflux 
for 3.5 h. After cooling to rt, all volatiles were removed and the resulting yellow-orange solid 
dried in vacuo. Then, dry MeOH (12 mL) was added, the resulting suspension cooled to 0 °C, 
and NaBH4 (500 mg, 13.2 mmol, 3.52 eq) carefully added (gas evolution!). After the gas 
evolution had ceased, the mixture was allowed to warm to rt and stirred for 1 h under nitrogen 
atmosphere. Then, the mixture was quenched by the addition of aqueous NH4Cl and diluted 
with water and EtOAc. The organic layer was separated, the aqueous layer extracted with 
EtOAc (3x), and the combined organic layers dried over Na2SO4. All volatiles were removed 
in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica gel, and purified by short-
column flash chromatography (hexanes/EtOAc 3:1). After drying in vacuo, desired 2-benzyl-
indolin-2-one (283) was obtained as a pale-yellow crystalline solid (803 mg, 3.59 mmol, 
96%). 1H NMR (300 MHz, CDCl3): δ = 9.08 (s, 1H), 7.23–7.01 (m, 6H), 6.86–6.72 (m, 2H), 
6.65 (d, J = 7.4 Hz, 1H), 3.67 (dd, J = 9.3 Hz, J = 4.5 Hz, 1H), 3.41 (dd, J = 13.8 Hz, 
J = 4.5 Hz, 1H), 2.85 (dd, J = 13.6 Hz, J = 9.3 Hz, 1H) ppm; HRMS (ESI): m/z calcd for 
C15H13N1O1H: 224.1070 [M+H]+; found: 224.1072. 
N,O-Diacylated oxindole 149b. Compound 149b was synthesized according to a protocol 
from Suga et al.[23f] A flame-dried flask (10 mL) was charged with 2-benzylindolin-2-one 
(283; 350 mg, 1.57 mmol, 1.00 eq) and dry THF (5 mL). Et3N was added (550 µL, 3.95 mmol, 
2.52 eq) and the mixture cooled to 0 °C. Then, phenyl chloroformate (490 µL, 3.91 mmol, 
2.50 eq) was added and the mixture allowed to warm to rt and stirred for 2 h. The mixture was 
diluted with CH2Cl2 and quenched with 1 M HCl. The organic layer was separated and the 
aqueous layer extracted with CH2Cl2 (2x). The combined organic layers were dried over 
Na2SO4, the solvent removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on 
silica gel (40 °C), and purified by short-column chromatography (hexanes/Et2O 10:1). After 
drying in vacuo, N,O-diacylated oxindole 149b was obtained as a colorless crystalline solid 
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(730 mg, 1.58 mmol, quant.). 1H NMR (300 MHz, CDCl3): δ = 8.19 (d, J = 8.1 Hz, 1H), 
7.53–7.11 (m, 16H), 7.09–7.01 (m, 2H), 4.12 (s, 2H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 151.2, 151.1, 150.2, 148.7, 138.6, 138.0, 132.6, 129.9 (2C), 129.7 (2C), 129.3, 128.8 (3C), 
127.5, 126.8, 126.7, 126.6, 125.3, 124.0, 121.7 (2C), 120.9 (2C), 119.8, 115.8, 109.5, 
29.0 ppm; IR (film): v~ = 2923, 1790, 1748, 1718, 1456, 1360, 1329, 1229, 1186, 1112, 1015, 
745, 692 cm–1; HRMS (ESI): m/z calcd for C29H21NO5Na: 486.1312 [M+Na]+; found: 
486.1313. 
 
O-Acylated, N-Methylated Indole 151 
Compound 151 was synthesized according to a procedure from Trost et al. (Scheme 90).[152]  
 
 
 
Scheme 90. Synthesis of O-acylated, N-methylated indole 151.[152] 
 
Compound 284. A flame-dried flask was charged with isatin (279; 4.00 g, 27.2 mmol, 
1.00 eq) and dry DMF (80 mL) and the mixture cooled to 0 °C. Sodium hydride (60 wt% in 
mineral oil; 1.30 g, 32.6 mmol, 1.20 eq) was gradually added to the mixture under stirring. 
5 min after addition completion, methyl iodide (2.54 mL, 40.8 mmol, 1.50 eq) was added and 
the mixture stirred at 0 °C for 30 min. The resulting mixture was quenched by the addition of 
aqueous sat. NH4Cl and diluted with water and EtOAc. The organic layer was separated and 
the aqueous layer extracted with EtOAc (4x). The combined organic layers were washed with 
water (3x) and brine and dried over MgSO4. After solvent removal and drying in vacuo, 
compound 284 was obtained as a red solid without the need for further purification (4.64 g, 
28.8 mmol, quant.). 1H NMR (300 MHz, CDCl3): δ = 7.64–7.52 (m, 2H), 7.11 (td, J = 7.6 Hz, 
J = 0.8 Hz, 1H), 6.88 (d, J = 7.9 Hz, 1H), 3.23 (s, 3H) ppm; HRMS (ESI): m/z calcd for 
C9H7N1O2Na: 184.0369 [M+Na]+; found: 184.0372. 
Compound 285. A flame-dried flask was charged with compound 284 (0.50 g, 3.10 mmol, 
1.00 eq) and dry THF (80 mL) and the resulting mixture cooled to –78 °C. Then, a solution of 
PhMgBr (3 M in Et2O; 1.19 mL, 3.57 mmol, 1.15 eq) was added dropwise. The mixture was 
stirred at –78 °C for 1 h and then allowed to warm to rt and stirred for 60 h. The resulting 
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mixture was quenched with aqueous sat. NH4Cl, diluted with water and CH2Cl2, the organic 
layer separated, and the aqueous layer extracted with CH2Cl2 (3x). The combined organic 
layers were washed with brine and dried over MgSO4. The solvent was removed in vacuo, 
which yielded a yellow oil which was transferred into a new flask (250 mL). A 15:1 mixture 
of glacial acetic acid and concentrated HCl (90 mL) as well as SnCl2·2H2O (1.68 g, 
7.44 mmol, 2.00 eq) were added and the mixture stirred at 80 °C (reflux) for 1.5 h. After 
cooling to rt, the mixture was diluted with Et2O and water and the organic layer separated. 
The aqueous layer was extracted with Et2O (3x) and the combined organic layers washed with 
aqueous 1 M NaOH and dried over MgSO4. The solvent was removed in vacuo, the crude 
product dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/Et2O 7:3). Desired product 285 was obtained as a pale yellow crystalline solid 
(0.37 g, 1.65 mmol, 53%). 1H NMR (300 MHz, CDCl3): δ = 7.46–7.24 (m, 4H), 7.24–7.13 (m, 
3H), 7.11–7.02 (m, 1H), 6.90 (d, J = 7.7 Hz, 1H), 4.61 (s, 1H), 3.26 (s, 3H) ppm. 
O-Acylated, N-methylated indole 151. A flame-dried flask was charged with sodium 
hydride (60 wt% in mineral oil; 38.0 mg, 950 µmol, 1.15 eq) and dry THF (5.0 mL). 
Compound 285 (185 mg, 830 µmol, 1.00 eq) was added and the resulting mixture stirred at rt 
for 30 min. Methyl chloroformate (74.0 µL, 950 µmol, 1.15 eq) was added and the mixture 
stirred for 24 h at rt. The mixture was diluted with water and Et2O and the organic layer 
separated. The aqueous layer was extracted with Et2O (3x) and the combined organic layers 
washed with brine and dried over Na2SO4. The solvent was removed in vacuo, the crude 
product dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromatography 
(hexanes/Et2O 8:2). After solvent removal and drying in vacuo, desired O-acylated, N-methy-
lated indole 151 was obtained as a colorless solid (160 mg, 570 µmol, 69%). 1H NMR 
(300 MHz, CDCl3): δ = 7.82 (d, J = 7.9 Hz, 1H), 7.65–7.55 (m, 2H), 7.51–7.40 (m, 2H), 
7.37–7.24 (m, 3H), 7.24–7.15 (m, 1H), 3.89 (s, 3H), 3.68 (s, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 153.1, 139.0, 133.1, 132.8, 128.9 (2C), 128.5 (2C), 126.3, 124.9, 122.3, 120.7, 
119.8, 109.4, 56.4, 28.5 ppm (one signal could not be located due to low S/N ratio); IR (film):
v~ = 1773, 1574, 1474, 1433, 1405, 1369, 1235, 1139, 1081, 924, 770, 739, 698, 640, 496, 
442 cm–1; HRMS (ESI): m/z calcd for C17H15N1O3Na: 304.0944 [M+Na]+; found: 304.0944. 
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4.9.5  Silyl Ketene Acetals (145a–d) 
Silyl Ketene Acetal 145a  
 
 
Scheme 91. Synthesis of silyl ketene acetal 145a. 
 
Compound 287. Compound 287 was synthesized according to a protocol from Fu et al.[89] A 
flask (250 mL) was charged with dry THF (40 mL) and diisopropylamine (6.55 mL, 
46.7 mmol, 3.12 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M in hexanes; 
18.1 mL, 45.2 mmol, 3.02 eq) was added. The resulting mixture was stirred at –78 °C for 
15 min and then allowed to stir at 0 °C for 10 min. Phenylacetic acid (286; 2.04 g, 15.0 mmol, 
1.00 eq) in dry THF (15 mL) was added and the mixture stirred at 50 °C for 1 h under nitro-
gen atmosphere. Then, the mixture was allowed to cool to rt and isobutylene oxide (1.35 mL, 
15.2 mmol, 1.01 eq) was added and the resulting mixture stirred at 60 °C for 20 h under 
nitrogen atmosphere. After cooling to rt, water (35 mL) was added and the mixture vigorously 
stirred at 70 °C (reflux) for 2 h. After cooling to rt, the mixture was diluted with Et2O and 
water, the aqueous layer separated, washed with Et2O (3x), and the organic layers disposed. 
Traces of Et2O were selectively removed from the aqueous layer in vacuo. Then, aqueous 6 M 
HCl (25 mL) and EtOH (50 mL) were added to the aqueous layer and the resulting mixture 
stirred at 80 °C (reflux) for 4 h. After cooling to rt, the mixture was extracted with CHCl3 (4x) 
and the resulting organic layer washed with aqueous NaHCO3 and brine and dried over 
Na2SO4. After solvent removal and drying in vacuo, compound 287 was obtained as a 
colorless crystalline solid without the need for further purification (2.32 g, 12.2 mmol, 81%). 
1H NMR (300 MHz, CDCl3): δ = 7.40–7.07 (m, 5H), 3.95 (dd, J = 11.7 Hz, J = 9.3 Hz, 1H), 
2.49 (dd, J = 12.8 Hz, J = 9.3 Hz, 1H), 2.15 (t, J = 12.3 Hz, 1H), 1.46 (s, 3H), 1.41 (s, 
3H) ppm; HRMS (ESI): m/z calcd for C12H14O2Na [M+Na]+: 214.0886, found: 214.0887. 
Silyl Ketene Acetal 145a. Compound 145a was synthesized according to a protocol from Fu 
et al.[89] A flame-dried flask (50 mL) was charged with dry THF (10 mL) and diisopropyl-
amine (1.64 mL, 11.7 mmol, 1.06 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M 
in hexanes; 4.68 mL, 11.7 mmol, 1.06 eq) was added and the mixture stirred at –78 °C for 1 h. 
Then, compound 287 (2.10 g, 11.0 mmol, 1.00 eq) was added in dry THF (13 mL) and the 
resulting mixture stirred at –78 °C for 1 h. Me3SiCl (1.50 mL, 11.8 mmol, 1.07 eq) was added 
at –78 °C, the mixture allowed to warm to rt, and the mixture stirred at rt for 20 h under 
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nitrogen atmosphere. Then, the solvent was carefully removed in vacuo (moisture exclusion!) 
and the remaining residue taken up in dry pentane. The resulting mixture was passed under 
nitrogen atmosphere through a flame-dried Schlenk frit (porosity G4) charged with a plug of 
flame-dried florisil (60–100 mesh) and which was equipped with a flame-dried receiving 
flask. The solvent was removed from the resulting clear filtrate in vacuo (exclusion of 
moisture!), which yielded silyl ketene acetal 145a after drying in vacuo as a pale yellow oil 
(2.79 g, 10.6 mmol, 97%; moisture-sensitive). 1H NMR (300 MHz, C6D6): δ = 7.80–7.65 (m, 
2H), 7.54–7.38 (m, 2H), 7.21–7.09 (m, 1H), 2.68 (s, 2H), 1.30 (s, 6H), 0.35 (s, 9H) ppm; 
13C NMR (75 MHz, C6D6): δ = 153.5, 137.3, 128.8 (2C), 124.7 (2C), 123.7, 82.9, 81.5, 43.9, 
28.9 (2C), 0.9 (3C) ppm. 
 
Silyl Ketene Acetal 145b 
 
 
 
Scheme 92. Synthesis of silyl ketene acetal 145b. 
 
Compound 289. Compound 289 was synthesized according to a protocol from Fu et al.[89] A 
flask (250 mL) was charged with dry THF (40 mL) and diisopropylamine (8.13 mL, 
58.0 mmol, 3.86 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M in hexanes; 
22.0 mL, 55.0 mmol, 3.66 eq) was added. The resulting mixture was stirred at –78 °C for 
15 min and then allowed to stir at 0 °C for 10 min. (4-Methoxyphenyl)acetic acid (288; 
2.50 g, 15.0 mmol, 1.00 eq) in dry THF (15 mL) was then added and the mixture stirred at 
50 °C for 1 h under nitrogen atmosphere. The mixture was allowed to cool to rt and 
isobutylene oxide (1.35 mL, 15.2 mmol, 1.01 eq) was added and the resulting mixture stirred 
at 60 °C for 20 h under nitrogen atmosphere. After cooling to rt, water (35 mL) was added 
and the resulting mixture vigorously stirred at 70 °C (reflux) for 2 h. After cooling to rt, the 
mixture was diluted with Et2O and water, the aqueous layer separated, washed with Et2O (3x), 
and the organic layers disposed. Traces of Et2O were selectively removed from the aqueous 
layer in vacuo. Then, aqueous 6 M HCl (25 mL) and EtOH (50 mL) were added to the 
aqueous layer and the resulting mixture stirred 80 °C (reflux) for 4 h. After cooling to rt, the 
mixture was extracted with CHCl3 (4x) and the resulting organic layer washed with aqueous 
NaHCO3 and brine and dried over Na2SO4. After solvent removal and drying in vacuo, 
desired compound 289 was obtained as a pale yellow crystalline solid without the need for 
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further purification (2.42 g, 11.0 mmol, 73%). 1H NMR (300 MHz, CDCl3): δ = 7.20 (d, 
J = 8.7 Hz, 2H), 6.89 (d, J = 8.1 Hz, 2H), 3.98 (dd, J = 11.8 Hz, J = 9.2 Hz, 1H), 3.79 (s, 3H), 
2.54 (dd, J = 12.7 Hz, J = 9.2 Hz, 1H), 2.19 (t, J = 12.3 Hz, 1H), 1.53 (s, 3H), 1.48 (s, 
3H) ppm; HRMS (ESI): m/z calcd for C13H16O3Na [M+Na]+: 243.0992, found: 243.0993. 
Silyl Ketene Acetal 145b. Compound 145b was synthesized according to a protocol from Fu 
et al.[89] A flame-dried flask (50 mL) was charged with dry THF (10 mL) and diisopropyl-
amine (1.48 mL, 10.6 mmol, 1.06 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M 
in hexanes; 4.20 mL, 10.5 mmol, 1.05 eq) was added and the mixture stirred at –78 °C for 1 h. 
Then, compound 289 (2.20 g, 9.99 mmol, 1.00 eq) was added in dry THF (11 mL) and the 
mixture stirred at –78 °C for 1 h. Me3SiCl (1.35 mL, 10.6 mmol, 1.06 eq) was added at 
−78 °C, the mixture allowed to warm to rt, and the mixture stirred at rt for 20 h under nitrogen 
atmosphere. Then, the solvent was removed in vacuo (moisture exclusion!) and the remaining 
residue taken up in dry pentane. The resulting mixture was passed under nitrogen atmosphere 
through a flame-dried Schlenk frit (porosity G4) charged with a plug of flame-dried florisil 
(60–100 mesh) and which was equipped with a flame-dried receiving flask. The solvent was 
removed from the clear filtrate in vacuo (exclusion of moisture!), which yielded desired silyl 
ketene acetal 145b after drying in vacuo as an off-white crystalline solid (2.68 g, 9.15 mmol, 
92%; moisture-sensitive). 1H NMR (300 MHz, C6D6): δ = 7.62−7.48 (m, 2H), 7.05−6.91 (m, 
2H), 3.41 (s, 3H), 1.22 (s, 2H), 0.26 (s, 9H) ppm; 13C NMR (75 MHz, C6D6): δ = 157.0, 
152.2, 130.1, 125.8 (2C), 114.6 (2C), 82.4, 81.1, 55.2, 44.3, 29.0 (2C), 0.9 (3C) ppm. 
 
Silyl Ketene Acetal 145c  
 
 
Scheme 93. Synthesis of silyl ketene acetal 145c. 
 
Compound 291. Compound 291 was synthesized according to a protocol from Fu et al.[89] A 
flask (250 mL) was charged with dry THF (60 mL) and diisopropylamine (7.01 mL, 
50.0 mmol, 3.11 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M in hexanes; 
19.3 mL, 48.3 mmol, 3.00 eq) was added. The resulting mixture was stirred at –78 °C for 
30 min and then allowed to stir at 0 °C for 10 min. 1-Naphthaleneacetic acid (290; 3.00 g, 
16.1 mmol, 1.00 eq) in dry THF (12 mL) was added and the mixture stirred at 50 °C for 1 h 
under nitrogen atmosphere. The mixture was allowed to cool to rt and isobutylene oxide 
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(1.45 mL, 16.3 mmol, 1.01 eq) was added and the resulting mixture stirred at 60 °C for 14 h 
under nitrogen atmosphere. After cooling to rt, water (36 mL) was added and the resulting 
mixture vigorously stirred at 70 °C (reflux) for 2 h. After cooling to rt, the mixture was 
diluted with Et2O and water, the aqueous layer separated, washed with Et2O (3x), and the 
organic layers disposed. Traces of Et2O were selectively removed from the aqueous layer in 
vacuo. Then, aqueous 6 M HCl (35 mL) and EtOH (60 mL) were added to the aqueous layer 
and the mixture stirred at 80 °C (reflux) for 3.5 h. After cooling to rt, the resulting mixture 
was extracted with CHCl3 (3x) and the organic layer washed with aqueous NaHCO3 and brine 
and dried over Na2SO4. After solvent removal and drying in vacuo, desired compound 291 
was obtained as a pale yellow crystalline solid without the need for further purification 
(3.13 g, 13.0 mmol, 81%). 1H NMR (300 MHz, CDCl3): δ = 7.98−7.72 (m, 3H), 7.62−7.38 
(m, 4H), 4.71 (dd, J = 10.5 Hz, J = 9.7 Hz, 1H), 2.73 (dd, J = 12.9 Hz, J = 9.5 Hz, 1H), 2.29 
(dd, J = 12.9 Hz, J = 10.7 Hz, 1H), 1.58 (s, 3H), 1.56 (s, 3H) ppm; HRMS (ESI): m/z calcd for 
C16H16O2Na [M+Na]+: 263.1043, found: 263.1041. 
Silyl Ketene Acetal 145c. Compound 145c was synthesized according to a protocol from Fu 
et al.[89] A flame-dried flask (50 mL) was charged with dry THF (10 mL) and diisopropyl-
amine (1.15 mL, 8.20 mmol, 1.10 eq). This mixture was cooled to –78 °C and n-BuLi (2.5 M 
in hexanes; 3.19 mL, 7.98 mmol, 1.06 eq) was added and the mixture stirred at –78 °C for 1 h. 
Then, compound 291 (1.80 g, 7.49 mmol, 1.00 eq) was added in dry THF (10 mL) and the 
mixture stirred at –78 °C for 1 h. Me3SiCl (1.01 mL, 7.96 mmol, 1.06 eq) was added at 
−78 °C, the mixture allowed to warm to rt, and the mixture stirred at rt for 18 h under nitrogen 
atmosphere. Then, the solvent was removed in vacuo (moisture exclusion!) and the remaining 
residue taken up in dry pentane. The resulting mixture was passed under nitrogen atmosphere 
through a flame-dried Schlenk frit (porosity G4) charged with a plug of flame-dried florisil 
(60–100 mesh) and which was equipped with a flame-dried receiving flask. The solvent was 
removed from the clear filtrate in vacuo (exclusion of moisture!), which yielded silyl ketene 
acetal 145c after drying in vacuo as a pale yellow crystalline solid (2.02 g, 6.48 mmol, 86%; 
moisture-sensitive). 1H NMR (300 MHz, C6D6): δ = 8.35 (d, J = 8.5 Hz, 1H), 7.72 (d, 
J = 7.9 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.50−7.25 (m, 4H), 2.83 (s, 2H), 1.34 (s, 3H), 0.06 
(s, 9H) ppm; 13C NMR (75 MHz, C6D6): δ = 152.9, 135.2, 135.0, 132.8, 129.1, 127.9, 126.7, 
126.3, 126.1, 126.0, 125.4, 81.9, 81.6, 47.4, 28.8 (2C), 0.6 (3C) ppm. 
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Silyl Ketene Acetal 145d 
 
 
Scheme 94. Synthesis of silyl ketene acetal 145d. 
 
Silyl Ketene Acetal 145d. Compound 145d was synthesized according to a modified protocol 
from Fu et al.[89] A flame-dried flask (50 mL) was charged with dry THF (7.2 mL) and diiso-
propylamine (850 µL, 6.06 mmol, 1.12 eq). This mixture was cooled to –78 °C and n-BuLi 
(2.5 M in hexanes; 2.35 mL, 5.88 mmol, 1.09 eq) was added and the mixture stirred at –78 °C 
for 1 h. Then, benzofuranone 274 (1.03 g, 5.41 mmol, 1.00 eq) was added in dry THF 
(7.2 mL) and the mixture stirred at –78 °C for 1 h. Me3SiCl (740 µL, 5.83 mmol, 1.08 eq) was 
added at –78 °C, the mixture allowed to warm to rt, and the mixture stirred at rt for 35 h under 
nitrogen atmosphere. The solvent was removed in vacuo (exclusion of moisture!) and the 
remaining residue taken up in dry pentane. The resulting mixture was passed under nitrogen 
atmosphere through a flame-dried Schlenk frit (porosity G4) charged with a plug of flame-
dried florisil (60–100 mesh) and which was equipped with a flame-dried receiving flask. The 
solvent was removed from the clear filtrate in vacuo (exclusion of moisture!), which yielded 
silyl ketene acetal 145d after drying in vacuo as a colorless oil (1.34 g, 5.11 mmol, 94%; 
moisture-sensitive). 1H NMR (300 MHz, C6D6): δ = 7.36–7.28 (m, 1H), 7.25 (d, J = 8.1 Hz, 
1H), 7.18–7.08 (m, 1H), 7.02 (t, J = 7.7 Hz, 1H), 2.45 (d, J = 7.2 Hz, 2H), 2.03 (sept, 
J = 6.8 Hz, 1H), 0.96 (d, J = 6.6 Hz, 6H), 0.23 (s, 9H) ppm; 13C NMR (75 MHz, C6D6): 
δ = 156.6, 149.2, 132.0, 123.2, 122.1, 118.9, 110.6, 92.6, 32.2, 29.2, 23.1 (2C), 0.5 (3C) ppm.  
 
4.9.6  Nitroacrylates (168a–b) 
Nitroacrylate 168a 
Nitroacrylate 168a was synthesized according to a protocol from List et al.[153] 
 
 
 
Scheme 95. Synthesis of nitroacrylate 168a.[153] 
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Isopropyl 2-oxo-2-phenylacetate (293). A flame-dried flask (100 mL) was charged with dry 
toluene (48 mL) and phenylglyoxalic acid (292; 3.00 g, 20.0 mmol, 1.00 eq). The mixture was 
cooled to 0 °C and DCC (4.12 g, 20.0 mmol, 1.00 eq) and isopropanol (3.20 mL, 41.8 mmol, 
2.09 eq) were added. The mixture was then allowed to warm to rt and stirred at rt for 44 h 
under nitrogen atmosphere. Subsequently, the resulting mixture was passed through a plug of 
celite which was subsequently rinsed with toluene. All volatiles were removed from the 
filtrate in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica gel, and purified 
by flash chromatography (hexanes/EtOAc 20:1). After solvent removal and drying in vacuo, 
product 293 was obtained as a quite volatile, pale-yellow oil (1.92 g, 10.0 mmol, 50%). 
1H NMR (300 MHz, CDCl3): δ = 8.05–7.93 (m, 2H), 7.70–7.61 (m, 1H), 7.56–7.46 (m, 2H), 
5.32 (sept, J = 6.3 Hz, 1H), 1.41 (d, J = 6.2 Hz, 6H) ppm; HRMS (ESI): m/z calcd for 
C11H12O3Na: 215.0690 [M+Na]+; found: 215.0675. 
Compound 294. A flask (100 mL) was charged with compound 293 (1.91 g, 9.94 mmol, 
1.00 eq), nitromethane (40 mL), and Et3N (300 µL, 2.15 mmol, 0.22 eq) and the mixture was 
stirred at rt in a septum-sealed flask. TLC (hexanes/EtOAc 10:1) indicated incomplete 
conversion after 2 d and after 4 d almost complete conversion (small trace of 293 still visible 
on TLC). The reaction was stopped after 4 d and the solvent removed in vacuo. The crude 
product was dissolved in CH2Cl2, adsorbed on silica gel, and purified by flash chromato-
graphy (hexanes/EtOAc 15:1 → 10:1). After solvent removal and drying in vacuo, compound 
294 was obtained as a colorless crystalline solid (2.23 g, 8.81 mmol, 89%). 1H NMR 
(300 MHz, CDCl3): δ = 7.73–7.54 (m, 2H), 7.51–7.32 (m, 3H), 5.35–5.09 (m, 2H), 4.67 (d, 
J = 14.0 Hz, 1H), 4.23 (s, 1H), 1.35 (d, J = 6.2 Hz, 3H), 1.29 (d, J = 6.4 Hz, 3H) ppm; HRMS 
(ESI): m/z calcd for C12H15N1O5Na: 276.0842 [M+Na]+; found: 276.0840. 
Nitroacrylate 168a. A flame-dried flask (25 mL) was charged with compound 294 (1.41 g, 
5.55 mmol, 1.00 eq), dry DMSO (17.5 mL), and acetic anhydride (1.60 mL, 16.9 mmol, 
3.05 eq). The mixture was stirred at rt for 48 h under nitrogen atmosphere. Then, the mixture 
was diluted with water and CH2Cl2, the organic layer separated, and the aqueous layer 
extracted with CH2Cl2 (4x). The combined organic layers were washed with aqueous 
NaHCO3 and dried over Na2SO4. The solvent was removed in vacuo, the crude product 
dissolved in CH2Cl2, adsorbed on silica gel (42 °C), and purified by flash chromatography 
(hexanes/EtOAc 30:1 → 25:1). After solvent removal and drying in vacuo, desired 
nitroacrylate 168a was obtained as a pale yellow crystalline solid (1.11 g, 4.72 mmol, 85%). 
1H NMR (300 MHz, CDCl3): δ = 7.59–7.41 (m, 5H), 7.34 (s, 1H), 5.38 (sept, J = 6.3 Hz, 1H), 
1.39 (d, J = 6.4 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ = 164.4, 143.6, 134.4, 132.2, 
129.9, 129.7 (2C), 127.6 (2C), 71.0, 21.7 (2C) ppm; IR (film): v~ = 1725, 1622, 1514, 1447, 
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1360, 1340, 1247, 1207, 1180, 1096, 1018, 907, 850, 825, 767, 748, 687, 678, 669, 586 cm–1; 
HRMS (ESI): m/z calcd for C12H13N1O4Na: 258.0737 [M+Na]+; found: 258.0734. 
 
Nitroacrylate 168b 
Nitroacrylate 168b was synthesized according to a protocol from List et al.[153] 
 
 
 
 
 
Scheme 96. Synthesis of nitroacrylate 168b.[153] 
 
Compound 296. A flask (50 mL) was charged with commercial methyl benzoylformate  
(295; 1.45 mL, 10.2 mmol, 1.00 eq), nitromethane (40 mL), and Et3N (300 µL, 2.15 mmol, 
0.22 eq) and the mixture stirred at rt in a septum-sealed flask. TLC (hexanes/EtOAc 10:1) 
indicated incomplete conversion after 2 d and complete conversion after 5 d. The solvent was 
removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica gel, and purified 
by flash chromatography (hexanes/EtOAc 10:1 → 8:1 → 5:1). After solvent removal and 
drying in vacuo, compound 296 was obtained as a colorless crystalline solid (2.15 g, 
9.52 mmol, 93%). 1H NMR (300 MHz, CDCl3): δ = 7.66–7.53 (m, 2H), 7.47–7.34 (m, 3H),  
5.27 (d, J = 14.2 Hz, 1H), 4.69 (d, J = 14.2 Hz, 1H), 3.91 (s, 2H) ppm; HRMS (ESI): m/z 
calcd for C10H11N1O5Na: 248.0529 [M+Na]+; found: 248.0528. 
Nitroacrylate 168b. A flame-dried flask (50 mL) was charged with compound 296 (2.13 g, 
9.45 mmol, 1.00 eq), dry DMSO (30 mL), and acetic anhydride (2.70 mL, 28.6 mmol, 
3.02 eq). The mixture was stirred at rt for 38 h under nitrogen atmosphere. Then, the mixture 
was diluted with water and CH2Cl2, the organic layer separated, and the aqueous layer 
extracted with CH2Cl2 (4x). The combined organic layers were washed with aqueous 
NaHCO3 and dried over Na2SO4. The solvent was removed in vacuo, the crude product 
dissolved in CH2Cl2, adsorbed on silica gel (42 °C), and purified by flash chromatography 
(hexanes/EtOAc 20:1 → 15:1). After solvent removal and drying in vacuo, desired 
nitroacrylate 168b was obtained as a yellow crystalline solid (1.22 g, 5.91 mmol, 63%). 
1H NMR (300 MHz, CDCl3): δ = 7.59–7.41 (m, 5H), 7.36 (s, 1H), 4.00 (s, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 165.4, 143.3, 134.8, 132.3, 129.7 (2C), 129.6, 127.7 (2C), 
53.6 ppm; IR (film): v~ = 1732, 1501, 1333, 1251, 1215, 1178, 965, 842, 770, 678, 663, 584, 
464 cm–1; HRMS (ESI): m/z calcd for C10H9N1O4Na: 230.0424 [M+Na]+; found: 230.0423. 
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4.10  Asymmetric Reactions with Precatalyst Λ/∆-T18 and Catalyst Λ/∆-T18'  
4.10.1  Steglich Rearrangements of O-Acylated Azlactones (13 → 14) 
Absolute configurations of chiral C-acylated azlactones 14 were assigned by comparison of 
measured optical rotation values with literature reported values of products 14a,[4,22a] 14b,[22a] 
14c,[22a] and 14d.[4] All other products 14 were assigned by analogy. Absolute stereochemical 
assignments from ref. 22a with respect to C-acylated azlactones 14 are based on X-ray struc-
tural analysis of a ring-opened derivative of C-acylated azlactone 14a.[22a] 
 
4.10.1.1  General Procedures E1)–E3) 
General Procedure E1). Steglich rearrangements of O-acylated azlactones. 
Table 10, entries 1–9: Standard-scale reactions (approx. 90 µmol substrate) with precatalyst 
Λ/∆-T18 and Cs2CO3. 
An amber glass vial (2 mL)[154] was charged with the indicated amount of the respective 
O-acylated azlactone (13; 1.00 eq), Cs2CO3 (3 mol%), and a micro stir bar. The vial bottom 
was precooled for 5 s by immersion cooling at the indicated reaction temperature, which was 
directly followed by addition of a solution of precatalyst Λ-T18 or ∆-T18 (1 mol% or 
0.5 mol%) in EtOAc (reactions at 0 °C: conc = 0.5 M; reactions at −30 °C: conc = 0.65 M). 
The vial was then immediately sealed with a PTFE screw cap[154] and the mixture stirred at 
the indicated temperature for the indicated time. In all cases, reaction completion was verified 
by TLC analysis. The solvent was removed in vacuo, the resulting residue taken up in a small 
amount of CH2Cl2, and purified by short-column chromatography with the indicated eluent. 
After drying in vacuo, the desired C-acylated azlactone (14) was obtained.  
 
General Procedure E2). Steglich rearrangements of O-acylated azlactones.  
Table 10, entries 11, 13, and 14: Standard-scale reactions (approx. 90 µmol substrate) with 
catalyst Λ/∆-T18' (without Cs2CO3). 
Same procedure as general procedure E1) except that no Cs2CO3 is added and that catalyst 
Λ/∆-T18' is used instead of precatalyst Λ/∆-T18. 
 
General Procedure E3). Steglich rearrangements of O-acylated azlactones.  
Table 10, entries 10 and 12: Scaled-up reactions reactions (approx. 1 mmol substrate) with 
catalyst Λ/∆-T18' (without Cs2CO3). 
Same procedure as general procedure E2) except that a larger threaded round-bottom glas vial 
(5 mL volume) with a PTFE screw cap was used as reaction vessel.  
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4.10.1.2  Synthetic Procedures and Characterizations 
Benzyl (R)-4-benzyl-2-(4-methoxyphenyl)-5-oxo-4,5-dihydrooxazole-4-carboxylate 
(14a)[4,22a]  
Table 10, entry 1: General procedure E1) was followed: O-Acy-
lated azlactone 13a (36.9 mg, 88.8 µmol); 0.5 mol% precatalyst 
Λ-T18; conc = 0.5 M, t = 0 °C, reaction time: 12 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14a was obtained as a 
viscous oil (35.8 mg, 86.2 µmol, 97%). Enantiomeric excess determined by chiral HPLC 
analysis: 88% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, 
λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 9.7 min, tR (minor) = 11.6 min). 
1H NMR (300 MHz, CDCl3): δ = 7.82 (d, J = 9.1 Hz, 2H), 7.42–7.27 (m, 5H), 7.23–7.08 (m, 
5H), 6.91 (d, J = 8.9 Hz, 2H), 5.30 (d, J = 12.4 Hz, 1H), 5.24 (d, J = 12.4 Hz, 1H), 3.84 (s, 
3H), 3.64 (d, J = 13.7 Hz, 1H), 3.50 (d, J = 13.7 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 173.9, 165.9, 163.7, 162.9, 135.0, 133.1, 130.5 (2C), 130.3 (2C), 128.8 (2C), 128.6, 128.3 
(2C), 128.1 (2C), 127.6, 117.5, 114.3 (2C), 77.7, 68.4, 55.6, 40.3 ppm; IR (film): v~ = 1820, 
1748, 1643, 1606, 1509, 1255, 1223, 1172, 1054, 975, 840, 734, 695, 602 cm–1; HRMS (ESI): 
m/z calcd for C25H21NO5Na: 438.1323 [M+Na]+; found: 438.1311. 
 
Table 10, entry 4: General procedure E1) was followed: O-Acylated azlactone 13a (37.0 mg, 
89.1 µmol); 0.5 mol% precatalyst Λ-T18; conc = 0.65 M, t = −30 °C, reaction time: 72 h; 
eluent: hexanes/MTBE 3:1; C-acylated azlactone 14a was obtained as a viscous oil (35.3 mg, 
85.0 µmol, 95%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee; [α]D23 = 
+128 (c 1.0, CHCl3). 
 
Table 10, entry 11: General procedure E2) was followed: O-Acylated azlactone 13a (36.8 mg, 
88.6 µmol); 1 mol% catalyst Λ-T18'; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14a was obtained as a viscous oil (35.8 mg, 
86.2 µmol, 97%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee. 
 
Table 10, entry 12: General procedure E3) was followed: O-Acylated azlactone 13a (381 mg, 
917 µmol); 1 mol% catalyst Λ-T18'; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14a was obtained as a viscous oil (354 mg, 
852 µmol, 93%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee. 
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Benzyl (R)-4-isobutyl-2-(4-methoxyphenyl)-5-oxo-4,5-dihydrooxazole-4-carboxylate 
(14b)[22a] 
Table 10, entry 2: General procedure E1) was followed: O-Acy-
lated azlactone 13b (33.9 mg, 88.9 µmol); 0.5 mol% precatalyst 
Λ-T18; conc = 0.5 M, t = 0 °C, reaction time: 12 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14b was obtained as a 
viscous oil (30.8 mg, 80.7 µmol, 91%). Enantiomeric excess determined by chiral HPLC 
analysis: 70% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, 
λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 6.6 min, tR (minor) = 7.8 min). 
[α]D23 = +8 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.98 (d, J = 8.9 Hz, 2H), 7.41–
7.22 (m, 5H), 6.99 (d, J = 8.9 Hz, 2H), 5.30–5.14 (m, 2H), 3.88 (s, 3H), 2.39 (dd, J = 14.3 Hz, 
J = 5.8 Hz, 1H), 2.06 (dd, J = 14.4 Hz, J = 7.2 Hz, 1H), 1.79–1.63 (m, 1H), 0.92 (d, 
J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (125 MHz, CDCl3): δ = 175.1, 166.2, 
163.8, 162.7, 135.0, 130.4 (2C), 128.7 (2C), 128.6, 128.0 (2C), 117.6, 114.5 (2C), 76.5, 68.2, 
55.7, 42.8, 24.7, 24.9, 23.2 ppm; IR (film): v~ = 1821, 1750, 1646, 1608, 1511, 1306, 1259, 
1223, 1171, 1030, 971, 697 cm–1; HRMS (APCI): m/z calcd for C22H23NO5H: 382.1649 
[M+H]+; found: 382.1643. 
 
Benzyl (R)-2-(4-methoxyphenyl)-4-methyl-5-oxo-4,5-dihydrooxazole-4-carboxylate 
(14c)[22a] 
Table 10, entry 3: General procedure E1) was followed: O-Acy-
lated azlactone 13c (30.2 mg, 89.0 µmol); 0.5 mol% of 
precatalyst Λ-T18; conc = 0.5 M, t = 0 °C, reaction time: 12 h; 
eluent: hexanes/MTBE 3:1; C-acylated azlactone 14c was 
obtained as a viscous oil (24.3 mg, 71.6 µmol, 80%). Enantiomeric excess determined by 
chiral HPLC analysis: 45% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexanes/i-PrOH 
90:10, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 8.8 min, 
tR (minor) = 12.3 min). [α]D23 = +7 (c 0.4, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.96 (d, 
J = 8.9 Hz, 2H), 7.40–7.20 (m, 5H), 6.98 (d, J = 9.1 Hz, 2H), 5.26 (d, J = 12.4 Hz, 1H), 5.19 
(d, J = 12.4 Hz, 1H), 3.88 (s, 3H), 1.78 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 175.3, 
166.2, 163.9, 163.1, 135.0, 130.4 (2C), 128.7 (2C), 128.6, 127.9 (2C), 117.7, 114.5 (2C), 73.0, 
68.3, 55.7, 20.7 ppm; IR (film): v~ = 1823, 1751, 1644, 1607, 1510, 1304, 1258, 1163, 1121, 
1091, 1020 cm–1; HRMS (ESI): m/z calcd for C19H17N1O5Na: 362.0999 [M+Na]+; found: 
362.1003. 
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Methyl (R)-4-benzyl-2-(4-methoxyphenyl)-5-oxo-4,5-dihydrooxazole-4-carboxylate 
(14d)[4] 
Table 10, entry 5: General procedure E1) was followed: O-Acy-
lated azlactone 13d (30.2 mg, 89.0 µmol); 1 mol% of precatalyst 
Λ-T18; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14d was obtained as a 
viscous oil (20.4 mg, 60.1 µmol, 68%). Enantiomeric excess determined by chiral HPLC 
analysis: 88% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, 
λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 8.2 min, tR (minor) = 9.5 min). 
[α]D23 = +184 (c 0.9, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.83 (d, J = 9.1 Hz, 2H), 
7.24–7.11 (m, 5H), 6.92 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 3.62 (d, J = 13.7 Hz, 
1H), 3.49 (d, J = 13.7 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3): δ = 173.9, 166.5, 163.7, 
162.8, 133.0, 130.6 (2C), 130.3 (2C), 128.4 (2C), 127.7, 117.3, 114.4 (2C), 77.5, 55.6, 53.8, 
40.4 ppm; IR (film): v~ = 1822, 1751, 1645, 1607, 1511, 1257, 1174, 1057, 981 cm–1; HRMS 
(APCI): m/z calcd for C19H17NO5H: 340.1179 [M+H]+; found: 340.1179. 
 
1,1,1-Trichloro-2-methylpropan-2-yl (R)-4-benzyl-2-(4-methoxyphenyl)-5-oxo-4,5-
dihydrooxazole-4-carboxylate (14e)[143] 
Table 10, entry 6: General procedure E1) was followed: 
O-Acylated azlactone 13e (43.3 mg, 89.5 µmol); 1 mol% of 
precatalyst Λ-T18; conc = 0.65 M, t = −30 °C, reaction time: 
72 h; eluent: hexanes/MTBE 3:1; C-acylated azlactone 14e 
was obtained as an oil which crystallized on standing (43.2 mg, 89.3 µmol, >99%). 
Enantiomeric excess determined by chiral HPLC analysis: 90% ee (Chiralcel OD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 99.6:0.4, λ = 254 nm, 0.8 mL/min, t (column) = 25 °C; 
tR (major) = 33.9 min, tR (minor) = 38.7 min). [α]D23 = +147 (c 1.0, CHCl3); 1H NMR 
(300 MHz, CDCl3): δ = 7.80 (d, J = 8.9 Hz, 2H), 7.24–7.10 (m, 5H), 6.90 (d, J = 9.1 Hz, 2H), 
3.84 (s, 3H), 3.60 (d, J = 13.8 Hz, 1H), 3.49 (d, J = 13.8 Hz, 1H), 1.95 (s, 3H), 1.92 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 173.8, 163.7, 163.6, 163.5, 133.2, 130.5 (2C), 
130.2 (2C), 128.4 (2C), 127.6, 117.5, 114.3 (2C), 105.3, 91.1, 78.3, 55.6, 39.2, 21.3 
(2C) ppm; IR (film): v~ = 1821, 1757, 1645, 1607, 1511, 1256, 1151, 979, 796 cm–1; HRMS 
(ESI): m/z calcd for C22H20Cl3N1O5Na: 506.0299 [M+Na]+; found: 506.0294. 
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Benzyl (R)-4-benzyl-2-(4-(tert-butyl)phenyl)-5-oxo-4,5-dihydrooxazole-4-carboxylate 
(14f) 
Table 10, entry 7: General procedure E1) was followed: O-Acy-
lated azlactone 13f (39.2 mg, 88.8 µmol); 1 mol% of precatalyst 
Λ-T18; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14f was obtained as a 
viscous oil (34.9 mg, 79.1 µmol, 89%). Enantiomeric excess determined by chiral HPLC 
analysis: 91% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, 
λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 5.8 min, tR (minor) = 6.9 min). 
[α]D23 = +131 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.81 (d, J = 8.5 Hz, 2H), 7.45 
(d, J = 8.5 Hz, 2H), 7.40–7.27 (m, 5H), 7.25–7.12 (m, 5H), 5.30 (d, J = 12.4 Hz, 1H), 5.23 (d, 
J = 12.4 Hz, 1H), 3.66 (d, J = 13.8 Hz, 1H), 3.52 (d, J = 13.8 Hz, 1H), 1.33 (s, 9H) ppm; 
13C NMR (125 MHz, CDCl3): δ = 173.8, 165.7, 163.3, 157.2, 134.9, 133.0, 130.5 (2C), 128.8 
(2C), 128.6, 128.4 (2C), 128.2 (2C), 128.1 (2C), 127.7, 125.9 (2C), 122.3, 77.7, 68.4, 40.2, 
35.3, 31.2 (3C) ppm; IR (film): v~ = 1823, 1751, 1646, 1225, 1093, 1055, 978, 698 cm–1; 
HRMS (ESI): m/z calcd for C28H27N1O4Na: 464.1832 [M+Na]+; found: 464.1830. 
 
Benzyl (R)-4-benzyl-2-(naphthalen-1-yl)-5-oxo-4,5-dihydrooxazole-4-carboxylate (14g) 
Table 10, entry 8: General procedure E1) was followed: O-Acylated 
azlactone 13g (38.8 mg, 89.1 µmol); 1 mol% of precatalyst Λ-T18; 
conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: hexanes/ 
MTBE 3:1; C-acylated azlactone 14g was obtained as a viscous oil 
(34.1 mg, 78.3 µmol, 88%). Enantiomeric excess determined by chiral HPLC analysis: 
91% ee (Chiralpak AD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 98:2, λ = 254 nm, 
1.0 mL/min, t (column) = 25 °C; tR (minor) = 14.8 min, tR (major) = 16.5 min). [α]D23 = +120 
(c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 8.90–8.79 (m, 1H), 8.00 (d, J = 8.3 Hz, 1H), 
7.93–7.84 (m, 1H), 7.81 (dd, J = 7.3 Hz, J = 1.2 Hz, 1H), 7.63–7.51 (m, 2H), 7.43 (dd, 
J = 8.2 Hz, J = 7.5 Hz, 1H), 7.39–7.29 (m, 5H), 7.29–7.11 (m, 5H), 5.37–5.25 (m, 2H), 3.74 
(d, J = 13.6 Hz, 1H), 3.62 (d, J = 13.8 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δ = 173.6, 
165.6, 163.4, 134.9, 133.9 (2C), 133.8, 133.1, 130.8, 130.6 (2C), 130.2, 128.8 (2C), 128.7, 
128.5 (2C), 128.2, 128.1 (2C), 127.8, 126.7, 126.0, 124.7, 121.6, 78.4, 68.5, 40.1 ppm; IR 
(film): v~ = 1819, 1749, 1641, 1250, 1225, 1095, 955, 776, 698 cm–1; HRMS (ESI): m/z calcd 
for C28H21N1O4H: 436.1543 [M+H]+; found: 436.1546. 
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Benzyl (R)-4-benzyl-2-(naphthalen-2-yl)-5-oxo-4,5-dihydrooxazole-4-carboxylate (14h) 
Table 10, entry 9: General procedure E1) was followed: O-Acy-
lated azlactone 13h (38.8 mg, 89.1 µmol); 1 mol% of precatalyst 
Λ-T18; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14h was obtained as an 
oil which crystallized on standing (35.0 mg, 80.4 µmol, 90%). Enantiomeric excess deter-
mined by chiral HPLC analysis: 95% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-
PrOH 90:10, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 8.7 min, tR (minor) 
= 10.7 min). [α]D23 = +167 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 8.33 (d, 
J = 0.9 Hz, 1H), 7.99 (dd, J = 8.7 Hz, J = 1.7 Hz, 1H), 7.93–7.82 (m, 3H), 7.65–7.49 (m, 2H), 
7.40–7.28 (m, 5H), 7.26–7.20 (m, 2H), 7.20–7.09 (m, 3H), 5.33 (d, J = 12.5 Hz, 1H), 5.27 (d, 
J = 12.5 Hz, 1H), 3.71 (d, J = 13.6 Hz, 1H), 3.57 (d, J = 13.6 Hz, 1H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 173.7, 165.7, 163.4, 135.7, 134.9, 132.9, 132.6, 130.5 (2C), 129.9, 
129.3, 128.9, 128.8 (2C), 128.7, 128.7, 128.4 (2C), 128.1 (2C), 128.0, 127.7, 127.2, 123.6, 
122.3, 77.9, 68.5, 40.4 ppm; IR (film): v~ = 1822, 1750, 1645, 1227, 1054, 988, 944, 902, 752, 
699 cm–1; HRMS (EI): m/z calcd for C28H21NO4: 435.1471 [M]+; found: 435.1462. 
 
Table 10, entry 10: General procedure E3) was followed: O-Acylated azlactone 13h (400 mg, 
919 µmol); 1 mol% catalyst Λ-T18'; conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: 
hexanes/MTBE 3:1; C-acylated azlactone 14a was obtained as a viscous oil which crystal-
lized on standing (375 mg, 861 µmol, 94%). Enantiomeric excess determined by chiral HPLC 
analysis: 94% ee. 
 
Benzyl (S)-4-benzyl-2-(tert-butyl)-5-oxo-4,5-dihydrooxazole-4-carboxylate (ent-14i) 
Table 10, entry 13: General procedure E2) was followed: O-Acylated 
azlactone 13i (32.5 mg, 88.9 µmol); 1 mol% of catalyst ∆-T18'; 
conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: hexanes/MTBE 
3:1; C-acylated azlactone ent-14i was obtained as a viscous oil 
(29.5 mg, 80.7 µmol, 91%). Enantiomeric excess determined by chiral HPLC analysis: 
96% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 99:1, λ = 254 nm, 
1.0 mL/min, t (column) = 10 °C; tR (major) = 10.4 min, tR (minor) = 11.8 min). [α]D23 = −14 
(c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.42–7.28 (m, 5H), 7.28–7.18 (m, 3H), 
7.18–7.08 (m, 2H), 5.30 (d, J = 12.5 Hz, 1H), 5.20 (d, J = 12.5 Hz, 1H), 3.53 (d, J = 13.8 Hz, 
1H), 3.45 (d, J = 13.6 Hz, 1H), 0.99 (s, 9H) ppm; 13C NMR (75 MHz, CDCl3): δ = 174.7, 
173.6, 165.6, 134.9, 133.0, 130.7 (2C), 128.8 (2C), 128.7, 128.3 (2C), 128.0 (2C), 127.7, 77.0, 
68.3, 39.5, 34.1, 26.4 (3C) ppm; IR (film): v~ = 1822, 1753, 1663, 1228, 1093, 1064, 993, 903, 
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736, 699 cm–1; HRMS (APCI): m/z calcd for C22H23N1O4H: 366.1700 [M+H]+; found: 
366.1703. 
 
Table 10, entry 14: General procedure E2) was followed: O-Acylated azlactone 13i (32.5 mg, 
88.9 µmol); 1 mol% catalyst ∆-T18' (catalyst was left for 7 d in CD2Cl2 in an NMR tube at 
25 °C before usage), conc = 0.65 M, t = −30 °C, reaction time: 72 h; eluent: hexanes/MTBE 
3:1; C-acylated azlactone ent-14i was obtained as a viscous oil (29.4 mg, 80.5 µmol, 90%). 
Enantiomeric excess determined by chiral HPLC analysis: 96% ee; [α]D23 = −14 (c 1.0, 
CHCl3). 
 
4.10.2  Black Rearrangements of O-Acylated Benzofuranones (142 → 143) 
Absolute configurations of chiral C-acylated benzofuranones 143 were established by  
1.) comparison of the measured optical rotation of product 143e with the according literature 
reported value[22b] and 2.) by X-ray diffraction analysis of a crystal obtained from 143i (grown 
from the batch from Table 13, entry 13 with 93% ee; see crystallographic section for further 
details). All other products 143 were assigned by analogy. Absolute stereochemical assign-
ments from ref. 22b with respect to C-acylated benzofuranones 143 are based on X-ray 
structural analysis of the closely related C-acylated benzofuranone with R1 = Ph and 
R2 = CMe2CCl3 (143e: R1 = Bn and R2 = CMe2CCl3).[22b]  
 
4.10.2.1  General Procedure F1) 
Black rearrangements of O-acylated benzofuranones; Table 13. 
An amber glass vial (2 mL)[154] was charged with the indicated amount of the respective 
O-acylated benzofuranone (142; 1.00 eq) and a micro stir bar. The vial bottom was precooled 
for 5 s by immersion cooling at the indicated reaction temperature, which was directly 
followed by addition of a solution of catalyst Λ-Ir5' or ∆-Ir5' (1 mol% or 2 mol%) in TAA or 
2:1 TAA/CPME (reactions at 0 °C: TAA, conc = 0.3 M; reactions at −15 °C and −30 °C: 2:1 
TAA/CPME, conc = 0.2 M). The vial was then immediately sealed with a PTFE screw cap[154] 
and the mixture stirred at the indicated temperature for the indicated time. Reaction 
completion was verified by TLC analysis. The solvent was removed in vacuo and the 
resulting residue taken up in a small amount of CH2Cl2 and purified by short-column 
chromatography with CH2Cl2 as eluent. After drying in vacuo, the desired C-acylated 
benzofuranone (143) was obtained. 
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4.10.2.2  Synthetic Procedures and Characterizations 
Phenyl (R)-2-oxo-3-phenyl-2,3-dihydrobenzofuran-3-carboxylate (143a)[86b] 
Table 13, entry 1: General procedure F1) was followed: O-Acylated 
benzofuranone 142a (23.6 mg, 71.4 µmol); 1 mol% of catalyst Λ-T18'; 
solvent: TAA; conc = 0.3 M, t = 0 °C, reaction time: 18 h; TLC indi-
cated sluggish conversion to 143a (~50%) and the experiment was stopped, the experiment 
was not repeated, optimized, or worked up due to the low ee found for the crude product. 
Enantiomeric excess determined by chiral HPLC analysis: 30% ee (determined from crude 
mixture) (Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, λ = 254 nm, 
0.7 mL/min, t (column) = 40 °C; tR (major) = 36.9 min, tR (minor) = 39.8 min); 1H NMR 
(300 MHz, CDCl3): δ = 7.60–6.89 (m, 14H) ppm; 13C NMR (75 MHz, CDCl3): δ = 171.2, 
166.2, 154.0, 150.5, 134.3, 131.0, 129.6 (2C), 129.2 (2C), 128.4, 127.8 (2C), 126.3, 126.5, 
125.3, 125.0, 121.0 (2C), 111.7, 62.8 ppm; IR (film): v~ = 1812, 1758, 1486, 1467, 1181, 1126, 
1060, 992, 955, 907, 875, 738, 685, 493 cm–1; HRMS (ESI): m/z calcd for C21H14O4NH4: 
348.1230 [M+NH4]+; found: 348.1230. Analytical data obtained from isolated racemic sample, 
identity with catalysis crude product verified by 1H- and 13C NMR spectra superposition. 
 
Phenyl (R)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143b)[23b] 
Table 13, entry 2: General procedure F1) was followed: O-Acylated 
benzofuranone 142b (23.5 mg, 87.6 µmol); 1 mol% of catalyst Λ-T18'; 
solvent: TAA; conc = 0.3 M, t = 0 °C, reaction time: 10 h; C-acylated 
benzofuranone 143b was obtained as a viscous oil (23.3 mg, 86.9 µmol, 99%). Enantiomeric 
excess determined by chiral HPLC analysis: 91% ee (Chiralcel OD-H, 5 µm, 25 cm x 
4.6 mm; n-hexane/i-PrOH 97.5:2.5, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (minor) = 
9.1 min, tR (major) = 11.1 min); 1H NMR (300 MHz, CDCl3): δ = 7.39–7.29 (m, 2H), 7.29–
7.20 (m, 2H), 7.20–7.09 (m, 3H), 6.94–6.85 (m, 2H), 1.81 (s, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 173.8, 167.0, 153.5, 150.4, 130.4, 129.6 (2C), 128.4, 126.6, 125.0, 123.5, 121.1 
(2C), 111.5, 54.1, 20.3 ppm; IR (film): v~ = 2922, 1811, 1187, 1155, 1095, 1034, 746, 
683 cm−1; HRMS (ESI): m/z calcd for C16H12O4Na: 291.0628 [M+Na]+; found: 291.0635. 
 
Table 13, entry 6: General procedure F1) was followed: O-Acylated benzofuranone 142b 
(19.3 mg, 71.9 µmol); 1 mol% of catalyst Λ-T18'; solvent: 2:1 TAA/CPME; conc = 0.2 M, 
t = −15 °C, reaction time: 48 h; C-acylated benzofuranone 143b was obtained as a viscous oil 
(18.9 mg, 70.4 µmol, 98%). Enantiomeric excess determined by chiral HPLC analysis: 
92% ee. 
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Table 13, entry 9: General procedure F1) was followed: O-Acylated benzofuranone 142b 
(19.5 mg, 72.7 µmol); 1 mol% of catalyst Λ-T18'; solvent: 2:1 TAA/CPME; conc = 0.2 M, 
t = −30 °C, reaction time: 48 h; C-acylated benzofuranone 143b was obtained as a viscous oil 
(19.4 mg, 72.3 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 
94% ee; [α]D23 = +96 (c 1.0, CHCl3). 
 
Table 13, entry 14: A flask (25 mL) was charged with O-acylated benzofuranone 142b 
(830 mg, 3.09 mmol) and 2:1 TAA/CPME (10.0 mL; final concentration: conc = 0.2 M). The 
flask was sealed with a septum, the mixture stirred until all of 142b was dissolved, and the 
mixture cooled to −30 °C. Under stirring, catalyst Λ-T18' (45.2 mg, 32.4 µmol, 1.0 mol%) 
was added in 2:1 TAA/CPME (4.5 mL) at −30 °C via syringe. The mixture was stirred at 
−30 °C for 48 h under exclusion of light, after which TLC analysis indicated full conversion. 
All volatiles were removed in vacuo (40 °C), the residue dissolved in a small amount of the 
eluent CH2Cl2, and product 143b isolated via short-column chromatography (CH2Cl2). After 
drying in vacuo, product 143b was obtained as a colorless viscous oil which slowly 
crystallized on standing (822 mg, 3.06 mmol, 99%). Enantiomeric excess determined by 
chiral HPLC analysis: 92% ee; [α]D23 = +92 (c 1.0, CHCl3). 
 
Reisolation of catalyst Λ-T18'. 
Under the conditions mentioned above, the catalyst does not elute from the silica gel column 
and remains at the baseline. After complete elution of product 143b, the yellow catalyst band 
was eluted by switching over from CH2Cl2 to 100:1:1 CH2Cl2/MeOH/Et3N and the catalyst 
band was collected. All volatiles were removed in vacuo (40 °C), the remaining yellow 
residue dissolved in CH2Cl2 and washed with H2O (2x), and the organic layer dried over 
Na2SO4. The CH2Cl2 layer was concentrated in vacuo (40 °C) and passed through a plug of 
piperidinomethylated polystyrene beads[83] (see synthesis of Λ- and ∆-T18' in chapter 
4.7.2.18 for details; identical plug dimensions). After drying in vacuo, catalyst Λ-T18' was 
recovered in 94% yield (42.4 mg, 30.4 µmol) and indistinguishable from freshly prepared 
Λ-T18' according to 1H NMR analysis and an enantiomeric excess of >99% was found 
(spectra comparison shown in chaper 4.13.2, chiral HPLC trace shown in chaper 5.2). 
 
Recrystallization of product 143b from methanol. 
583 mg of product 143b from Table 13, entry 14 with 92% ee were dissolved in MeOH 
(1.3 mL) at reflux. Upon cooling to rt, the product started to crystallize from the resulting 
solution. The mixture was then kept at −15 °C for 30 min and the supernatant carefully 
removed at −15 °C from crystallized 143b with a syringe. The remaining crystalline preci-
   – 4.10.2 Black Rearrangements of O-Acylated Benzofuranones (142 → 143) – 
 
~ 255 ~ 
 
pitate was washed with cold MeOH at −15 °C (2x 0.4 mL). Remaining crystalline 143b was 
then fully dissolved in CH2Cl2 and an enantiomeric excess of 98% found via chiral HPLC 
analysis. After drying in vacuo, 430 mg of 143b were obtained as a viscous oil which slowly 
crystallized on standing (combined yield for isolation and recrystallization: 73%). 
 
Table 13, entry 15: General procedure F1) was followed: O-Acylated benzofuranone 142b 
(22.3 mg, 83.1 µmol); 1 mol% of reisolated catalyst Λ-T18' (see procedure above belonging 
to Table 13, entry 14); solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −30 °C, reaction time: 
48 h; C-acylated benzofuranone 143b was obtained as a viscous oil (22.0 mg, 82.0 µmol, 
99%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee; [α]D23 = +95 (c 1.0, 
CHCl3). 
 
Phenyl (S)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (ent-143b) 
Table 13, entry 10: General procedure F1) was followed: O-Acy-
lated benzofuranone 142b (21.2 mg, 79.0 µmol); 1 mol% of catalyst 
∆-T18'; solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −30 °C, 
reaction time: 48 h; C-acylated benzofuranone ent-143b was obtained as a viscous oil 
(21.0 mg, 78.3 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 
94% ee; [α]D23 = −97 (c 1.0, CHCl3). See product 143b above for further analytical data.  
 
Benzyl (R)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143c)[86b] 
Table 13, entry 3: General procedure F1) was followed: O-Acylated 
benzofuranone 142c (20.1 mg, 71.2 µmol); 1 mol% of catalyst Λ-T18'; 
solvent: TAA; conc = 0.3 M, t = 0 °C, reaction time: 18 h; C-acylated 
benzofuranone 143c was obtained as a viscous oil (19.8 mg, 70.1 µmol, 99%). Enantiomeric 
excess determined by chiral HPLC analysis: 80% ee (Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; 
n-hexane/i-PrOH 85:15, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 18.3 min, 
tR (minor) = 24.4 min); [α]D23 = +55 (c 0.8, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.40–
7.32 (m, 1H), 7.32–7.20 (m, 4H), 7.20–7.08 (m, 4H), 5.20–5.09 (m, 2H), 1.79 (s, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 174.1, 168.1, 153.4, 135.0, 130.1, 128.7 (2C), 128.6, 128.5, 
127.6 (2C), 124.7, 123.6, 111.3, 68.0, 54.0, 20.7 ppm; IR (film): v~ = 1809, 1742, 1220, 1110, 
1034, 892, 747, 696 cm–1; HRMS (ESI): m/z calcd for C17H14O4Na: 305.0784 [M+Na]+; 
found: 305.0785. 
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Isopropyl (R)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143d) 
Table 13, entry 4: General procedure F1) was followed: O-Acylated 
benzofuranone 142d (19.6 mg, 83.7 µmol); 2 mol% of catalyst 
Λ-T18'; solvent: TAA; conc = 0.3 M, t = 0 °C, reaction time: 48 h; 
C-acylated benzofuranone 143d was obtained as a viscous oil (19.3 mg, 82.4 µmol, 98%). 
Enantiomeric excess determined by chiral HPLC analysis: 82% ee (Chiralpak AD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 99.2:0.8, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; 
tR (major) = 6.3 min, tR (minor) = 6.6 min); [α]D23 = +84 (c 0.8, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.35 (ddd, J = 7.7 Hz, J = 7.7 Hz, J = 1.4 Hz, 1H), 7.30–7.24 (m, 1H), 7.20–7.11 
(m, 2H), 5.00 (sept, J = 6.3 Hz, 1H), 1.75 (s, 3H), 1.22 (d, J = 6.4 Hz, 3H), 1.08 (d, J = 6.2 Hz, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 174.4, 167.8, 153.4, 129.9, 128.9, 124.7, 123.4, 
111.2, 70.6, 54.2, 21.5, 21.4, 20.6 ppm; IR (film): v~ = 1811, 1737, 1458, 1232, 1099, 1073, 
1033, 894, 754 cm–1; HRMS (ESI): m/z calcd for C13H14O4Na: 257.0784 [M+Na]+; found: 
257.0784. 
 
1,1,1-Trichloro-2-methylpropan-2-yl (S)-3-benzyl-2-oxo-2,3-dihydrobenzofuran-3-
carboxylate (143e)[22b] 
Note: Switching from R → S not caused by actual inversion of the stereocenter but by higher 
priority of the exocyclic acyl fragment according to CIP rules.[88] 
Table 13, entry 5: General procedure F1) was followed: O-Acylated 
benzofuranone 142e (38.8 mg, 90.7 µmol); 1 mol% of catalyst 
Λ-T18'; solvent: TAA; conc = 0.3 M, t = 0 °C, reaction time: 20 h; 
C-acylated benzofuranone 143e was obtained as a colorless solid (38.2 mg, 89.3 µmol, 98%). 
Enantiomeric excess determined by chiral HPLC analysis: 89% ee (Chiralcel OD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 98:2, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; 
tR (minor) = 6.6 min, tR (major) = 7.6 min); [α]D23 = +99 (c 0.9, CH2Cl2); 1H NMR (300 MHz, 
CDCl3): δ = 7.38 (dd, J = 7.5 Hz, J = 1.2 Hz, 1H), 7.31–7.22 (m, 1H), 7.18 (dd, J = 7.5 Hz, 
J = 1.0 Hz, 1H), 7.15–7.04 (m, 3H), 6.97–6.87 (m, 3H), 3.60 (s, 2H), 1.92 (s, 3H), 1.83 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 172.3, 165.4, 153.9, 133.6, 130.3, 130.2 (2C), 
128.4 (2C), 127.5, 125.9, 124.4, 124.2, 111.1, 105.3, 90.9, 61.3, 39.6, 21.5, 21.2 ppm; IR 
(film): v~ = 1796, 1749, 1459, 1232, 1206, 1148, 1070, 1022, 885, 794, 761, 732, 702, 585, 
518 cm–1; HRMS (ESI): m/z calcd for C20H17Cl3O4Na: 449.0085 [M+Na]+; found: 449.0084. 
  
   – 4.10.2 Black Rearrangements of O-Acylated Benzofuranones (142 → 143) – 
 
~ 257 ~ 
 
Phenyl (R)-3-isobutyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143f)[23b] 
Table 13, entry 7: General procedure F1) was followed: O-Acylated 
benzofuranone 142f (22.1 mg, 71.2 µmol); 1 mol% of catalyst Λ-T18'; 
solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −15 °C, reaction time: 48 h; 
C-acylated benzofuranone 143f was obtained as a viscous oil (21.9 mg, 
70.6 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 90% ee 
(Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (major) = 12.2 min, tR (minor) = 16.6 min); [α]D23 = +83 (c 1.0, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.47–7.28 (m, 4H), 7.28–7.16 (m, 3H), 7.01–6.90 
(m, 2H), 2.45 (dd, J = 14.4 Hz, J = 5.9 Hz, 1H), 2.36 (dd, J = 14.4 Hz, J = 7.7 Hz, 1H), 1.66–
1.49 (m, 1H), 0.86 (d, J = 6.6 Hz, 3H), 0.78 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 173.5, 166.9, 153.8, 150.4, 130.3, 129.6 (2C), 126.6, 126.5, 124.8, 124.3, 121.1 
(2C), 111.4, 58.4, 42.5, 25.1, 23.9, 22.8 ppm; IR (film): v~ = 1810, 1759, 1184, 1117, 1051, 
986, 747, 683 cm–1; HRMS (ESI): m/z calcd for C19H18O4Na: 333.1097 [M+Na]+; found: 
333.1099. 
 
Phenyl (R)-3-benzyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143g)[23b] 
Table 13, entry 8: General procedure F1) was followed: O-Acylated 
benzofuranone 142g (24.6 mg, 71.4 µmol); 1 mol% of catalyst Λ-T18'; 
solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −15 °C, reaction time: 48 h; 
C-acylated benzofuranone 143g was obtained as a viscous oil (24.4 mg, 
70.9 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 91% ee 
(Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (minor) = 35.0 min, tR (major) = 42.7 min); [α]D23 = +116 (c 1.0, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.41 (dd, J = 7.4 Hz, J = 1.1 Hz, 1H), 7.37–7.24 (m, 
3H), 7.24–7.17 (m, 2H), 7.15–7.03 (m, 3H), 7.02–6.86 (m, 5H), 3.67 (s, 2H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 172.5, 166.5, 153.8, 150.4, 133.4, 130.5, 130.2 (2C), 129.7 (2C), 128.4 
(2C), 127.6, 126.6, 125.8, 124.6, 124.4, 121.2 (2C), 111.3, 60.4, 40.5 ppm; IR (film): v~
= 1808, 1757, 1220, 1180, 1060, 992, 746, 689, 498 cm–1; HRMS (ESI): m/z calcd for 
C22H16O4Na: 367.0941 [M+Na]+; found: 367.0942. 
 
Methyl (R)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (143h)[23b] 
Table 13, entry 11: General procedure F1) was followed: O-Acylated 
benzofuranone 142h (19.6 mg, 95.0 µmol); 1 mol% of catalyst 
Λ-T18'; solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −30 °C, reaction 
time: 48 h; C-acylated benzofuranone 143h was obtained as a viscous oil (18.2 mg, 88.3 µmol, 
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93%; product volatile in vacuo). Enantiomeric excess determined by chiral HPLC analysis: 
70% ee (Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 90:10, λ = 254 nm, 
1.0 mL/min, t (column) = 10 °C; tR (major) = 17.6 min, tR (minor) = 19.0 min); [α]D23 = +88 
(c 0.8, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.36 (ddd, J = 7.8 Hz, J = 7.8 Hz, J = 1.4 Hz, 
1H), 7.32–7.25 (m, 1H), 7.21–7.11 (m, 2H), 3.71 (s, 3H), 1.78 (s, 3H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 174.1, 168.7, 153.2, 130.0, 128.5, 124.7, 123.5, 111.1, 53.6, 53.5, 
20.7 ppm; IR (film): v~ = 1808, 1741, 1229, 1112, 1034, 895, 753 cm–1; HRMS (ESI): m/z 
calcd for C11H10O4Na: 229.0471 [M+Na]+; found: 229.0472. 
 
1,1,1-Trichloro-2-methylpropan-2-yl (S)-3-methyl-2-oxo-2,3-dihydrobenzofuran-3-
carboxylate (143i) 
Note: Switching from R → S not caused by actual inversion of the stereocenter but by higher 
priority of the exocyclic acyl fragment according to CIP rules.[88] 
Table 13, entry 12: General procedure F1) was followed: O-Acylated 
benzofuranone 142i (25.2 mg, 71.7 µmol); 1 mol% of catalyst 
Λ-T18'; solvent: 2:1 TAA/CPME; conc = 0.2 M, t = −30 °C, reaction 
time: 48 h; C-acylated benzofuranone 143i was obtained as colorless crystalline solid 
(25.0 mg, 71.1 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 
93% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 98.5:1.5, λ = 254 nm, 
1.0 mL/min, t (column) = 25 °C; tR (minor) = 5.3 min, tR (major) = 5.7 min); [α]D23 = +77 
(c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.35 (ddd, J = 7.8 Hz, J = 7.8 Hz, J = 1.5 Hz, 
1H), 7.32–7.27 (m, 1H), 7.21–7.11 (m, 2H), 1.88 (s, 3H), 1.77 (s, 3H), 1.77 (s, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 173.7, 165.9, 153.6, 130.2, 128.5, 124.7, 123.3, 111.3, 105.3, 
90.6, 55.0, 21.4, 21.1, 19.8 ppm; IR (film): v~ = 1811, 1749, 1233, 1215, 1153, 1118, 1036, 
791, 752 cm–1; HRMS (ESI): m/z calcd for C14H13Cl3O4Na: 372.9772 [M+Na]+; found: 
372.9773. 
 
Table 13, entry 13: A flask (10 mL) was charged with O-Acylated benzofuranone 142i 
(252 mg, 717 µmol) and 2:1 TAA/CPME (2.4 mL; final concentration: conc = 0.2 M). The 
flask was sealed with a septum, the mixture stirred until all of 142i was dissolved, and the 
mixture then cooled to −30 °C. Under stirring, catalyst Λ-T18' (11.3 mg, 8.1 µmol, 
1.1 mol%) in 2:1 TAA/CPME (1.0 mL) was added at −30 °C via syringe. The mixture was 
stirred at −30 °C for 48 h under exclusion of light, after which TLC analysis indicated full 
conversion. All volatiles were removed in vacuo (40 °C), the residue dissolved in a small 
amount of the eluent CH2Cl2, and product 143i isolated by short-column chromatography 
(CH2Cl2). After drying in vacuo, product 143i was obtained as colorless crystalline solid 
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(250 mg, 711 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee. 
XRD: X-ray quality crystals of 143i were obtained by slow evaporation of the solvent from an 
Et2O solution of 143i at 4 °C (more details in the crystallographic data section). 
 
4.10.3  Addition of 2-Cyanopyrrole to Aryl Alkyl Ketenes (153 + 162 → 163) 
Absolute configurations of α-chiral N-acyl pyrroles (163) were assigned by comparison of 
measured optical rotation values with literature reported values of products 163a,[26c] 
163b,[26c] and 163c.[26c] All other products (163) were assigned by analogy. Absolute stereo-
chemical assignments from ref. 26c with respect to N-acyl pyrroles (163) were established by 
reduction of enantioenriched N-acyl pyrroles (163) to the corresponding alcohols and 
trifluoroacetylation of those alcohols and comparison of their chiral GC retention times with 
the identical trifluoroacetylated products obtained from commercial enantiopure α-branched 
acids.[26c] 
 
4.10.3.1  General Procedures G1) and G2) 
General Procedure G1). Addition of 2-cyanopyrrole to aryl alkyl ketenes; Table 19, entries 
1–6, 8, and 10: Standard-scale reactions (100−130 µmol ketene). 
A flame-dried Schlenk tube (10 mL; threaded PTFE plug) equipped with a stir bar was 
charged with a solution of catalyst Λ-T18' (2 mol%) in CH2Cl2 (2 mL). Under stirring, the 
solvent was carefully removed in vacuo and the Schlenk tube with the solidified catalyst dried 
in vacuo for 1 h. Then, dry solvent (entries 1, 2: MTBE, entries 3–6, 8, 10: toluene; final 
concentration in both cases: conc = 12 mM; note that each ketene is added in a total volume of 
0.5 mL of solvent) and 2-cyanopyrrole (162; 2.00 eq; addition via dry microliter syringe[155]) 
were added. Another flame-dried Schlenk tube (2 mL; threaded PTFE plug) was charged with 
the indicated amount of ketene (153; 1.00 eq; addition via dry microliter syringe;[155] amount 
of ketene was determined by weighting the syringe before and after the addition with a high 
precision analytical balance) and the ketene dissolved in dry solvent (0.25 mL). The Schlenk 
tube containing the solution of Λ-T18' and 2-cyanopyrrole (162) was cooled to 0 °C and the 
prepared ketene solution was added over 15 min with a well-sealed, dry microliter syringe.[155] 
The Schlenk tube which contained the ketene solution was rinsed with another 0.25 mL of dry 
solvent and the resulting solution added to the reaction's Schlenk tube with the same 
microliter syringe in order to transfer the ketene (153) as completely as possible. The 
reaction's Schlenk tube was then tightly sealed and stirred at 0 °C for 48 h under nitrogen 
atmosphere and under exclusion of light (note that all operations until here were strictly 
performed under nitrogen atmosphere and under exclusion of moisture). Then, all volatiles 
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were removed in vacuo and the crude product purified by short-column chromatography with 
the indicated eluent. After solvent removal and drying in vacuo, the desired α-chiral N-acyl 
pyrrole (163) was obtained. 
 
General Procedure G2). Addition of 2-cyanopyrrole to aryl alkyl ketenes; Table 19, entries 7 
and 9: Scaled-up reactions (approx. 1 mmol ketene). 
In principle the same procedure as general procedure G1, some details had to be modified 
because of the increased reaction scale. 
A flame-dried septum-sealed nitrogen flask (100 mL) equipped with a stir bar was charged 
with a solution of catalyst Λ-T18' (2 mol%) in CH2Cl2 (2 mL). Under stirring, the solvent was 
carefully removed in vacuo and the nitrogen flask with the solidified catalyst dried in vacuo 
for 1 h. Then, dry toluene (final reaction concentration: conc = 12 mM; note that each ketene 
is added in a total volume of 5.0 mL of toluene) and 2-cyanopyrrole (162; 2.00 eq; addition 
via dry microliter syringe[155]) were added. A flame-dried Schlenk tube (10 mL; threaded 
PTFE plug) was charged with the indicated amount of ketene (153; 1.00 eq; addition via dry 
microliter syringe;[155] amount of added ketene was determined by weighting the syringe 
before and after the addition with a high precision analytical balance) and the ketene 
dissolved in dry toluene (2.5 mL). The nitrogen flask containing the solution of Λ-T18' and 
2-cyanopyrrole (162) was cooled to 0 °C and the prepared ketene solution was added through 
the flask's septum via canula with a well-sealed, dry microliter syringe over 15 min.[155] The 
Schlenk tube which contained the ketene solution was rinsed with another 2.5 mL of dry 
toluene and the resulting solution added to the reaction's flask with the same microliter 
syringe in order to transfer the ketene (153) as completely as possible. The resulting reaction 
mixture was then stirred at 0 °C for 48 h under nitrogen atmosphere and under exclusion of 
light (note that all operations until here were strictly performed under nitrogen atmosphere 
and under exclusion of moisture). Then, all solvents were removed in vacuo and the crude 
product purified by short-column chromatography with the indicated eluent. After solvent 
removal and drying in vacuo, the desired α-chiral N-acyl pyrrole (163) was obtained. 
 
4.10.3.2  Synthetic Procedures and Characterizations 
(S)-1-(2-Phenylbutanoyl)-1H-pyrrole-2-carbonitrile (163a)[26c] 
Table 19, entry 1: General procedure G1) was followed: Phenyl ethyl 
ketene (153a; 18.4 mg, 126 µmol); solvent: dry MTBE; conc = 
12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone in toluene; 
N-acyl pyrrole 163a was obtained as a viscous oil (28.9 mg, 121 µmol, 96%). Enantiomeric 
excess determined by chiral HPLC analysis: 89% ee (Chiralpak AD-H, 5 µm, 25 cm x 
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4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 
9.1 min, tR (minor) = 10.2 min); [α]D23 = +211 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): 
δ = 7.37–7.14 (m, 6H), 6.88 (dd, J = 3.6 Hz, J = 1.3 Hz, 1H), 6.17 (t, J = 3.4 Hz, 1H), 4.07 (t, 
J = 7.3 Hz, 1H), 2.28–2.08 (m, 1H), 1.95–1.75 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 170.1, 137.6, 129.5 (2C), 128.1, 127.9 (2C), 126.6, 124.8, 
113.3, 113.1, 103.8, 53.2, 27.9, 12.1 ppm; IR (film): v~ = 2223, 1728, 1450, 1354, 1276, 1247, 
1226, 1121, 820, 733, 699, 586, 507 cm–1; HRMS (ESI): m/z calcd for C15H14N2O1Na: 
261.0998 [M+Na]+; found: 261.1005. 
 
(S)-1-(2-(o-Tolyl)butanoyl)-1H-pyrrole-2-carbonitrile (163b)[26c] 
Table 19, entry 2: General procedure G1) was followed: o-Tolyl 
ethyl ketene (153b; 18.9 mg, 118 µmol); solvent: dry MTBE; 
conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone 
in toluene; N-acyl pyrrole 163b was obtained as a viscous oil (29.6 mg, 117 µmol, 99%). 
Enantiomeric excess determined by chiral HPLC analysis: 84% ee (Chiralpak AD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, t (column) = 40 °C; 
tR (major) = 6.2 min, tR (minor) = 7.4 min); [α]D23 = +279 (c 1.0, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.21–7.03 (m, 4H), 7.00 (dd, J = 3.2 Hz, J = 1.3 Hz, 1H), 6.86 (dd, J = 3.5 Hz, 
J = 1.2 Hz, 1H), 6.13 (t, J = 3.4 Hz, 1H), 4.23 (dd, J = 8.1 Hz, J = 5.9 Hz, 1H), 2.40 (s, 3H), 
2.27–2.06 (m, 1H), 1.84–1.65 (m, 1H), 0.94 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 170.5, 136.6, 134.7, 131.4, 127.9, 127.3, 126.8, 126.3, 124.2, 113.2, 113.1, 103.9, 
49.5, 27.3, 19.7, 12.4 ppm; IR (film): v~ = 2224, 1731, 1451, 1352, 1275, 1250, 1226, 1113, 
832, 754, 731 cm–1; HRMS (ESI): m/z calcd for C16H16N2O1Na: 275.1155 [M+Na]+; found: 
275.1157. 
 
(S)-1-(3-Methyl-2-phenylbutanoyl)-1H-pyrrole-2-carbonitrile (163c)[26c] 
Table 19, entry 3: General procedure G1) was followed: Phenyl 
isopropyl ketene (153c; 18.9 mg, 118 µmol); solvent: dry toluene; 
conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone in 
toluene; N-acyl pyrrole 163c was obtained as a viscous oil (29.5 mg, 117 µmol, 99%). 
Enantiomeric excess determined by chiral HPLC analysis: 93% ee (Chiralpak AD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 99:1, λ = 254 nm, 1.0 mL/min, t (column) = 40 °C; 
tR (major) = 9.8 min, tR (minor) = 10.8 min); [α]D23 = +154 (c 1.0, CHCl3); 1H NMR 
(300 MHz, CDCl3): δ = 7.36 (dd, J = 3.2 Hz, J = 1.3 Hz, 1H), 7.32–7.13 (m, 5H), 6.89 (dd, 
J = 3.5 Hz, J = 1.4 Hz, 1H), 6.19 (t, J = 3.4 Hz, 1H), 3.80 (d, J = 9.6 Hz, 1H), 2.50 (dsept, 
J = 9.8 Hz, J = 6.6 Hz, 1H), 1.03 (d, J = 6.6 Hz, 3H), 0.70 (d, J = 6.8 Hz, 3H) ppm; 13C NMR 
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(75 MHz, CDCl3): δ = 170.2, 136.6, 129.3 (2C), 128.5 (2C), 128.2, 126.8, 124.7, 113.4, 113.0, 
103.8, 59.1, 32.6, 21.9, 20.2 ppm; IR (film): v~ = 2223, 1728, 1450, 1351, 1298, 1248, 1225, 
1110, 811, 740, 702 cm–1; HRMS (ESI): m/z calcd for C16H16N2O1Na: 275.1155 [M+Na]+; 
found: 275.1157. 
 
(S)-1-(2-(4-Chlorophenyl)-3-methylbutanoyl)-1H-pyrrole-2-carbonitrile (163d) 
Table 19, entry 4: General procedure G1) was followed: p-Chloro-
phenyl isopropyl ketene (153d; 22.7 mg, 117 µmol); solvent: dry 
toluene; conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% 
acetone in toluene; N-acyl pyrrole 163d was obtained as a viscous oil (33.3 mg, 116 µmol, 
99%). Enantiomeric excess determined by chiral HPLC analysis: 90% ee (Chiralcel OD-H, 
5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 95:5), λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; 
tR (major) = 7.2 min, tR (minor) = 9.9 min); [α]D23 = +138 (c 1.1, CHCl3); 1H NMR (300 MHz, 
CDCl3): δ = 7.42 (dd, J = 3.3 Hz, J = 1.4 Hz, 1H), 7.37–7.24 (m, 4H), 6.99 (dd, J = 3.6 Hz, 
J = 1.3 Hz, 1H), 6.30 (t, J = 3.5 Hz, 1H), 3.90 (d, J = 9.8 Hz, 1H), 2.53 (dsept, J = 9.9 Hz, 
J = 6.6 Hz, 1H), 1.09 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 170.1, 135.0, 134.2, 129.8 (2C), 129.5 (2C), 127.1, 124.6, 113.3, 113.3, 103.8, 
58.2, 32.8, 21.8, 20.1 ppm; IR (film): v~ = 2224, 1728, 1450, 1345, 1297, 1247, 1226, 1098, 
789, 731, 523 cm–1; HRMS (ESI): m/z calcd for C16H15Cl1N2O1Na: 309.0765 [M+Na]+; 
found: 309.0769. 
 
(S)-1-(2-(4-Methoxyphenyl)-3-methylbutanoyl)-1H-pyrrole-2-carbonitrile (163e) 
Table 19, entry 5: General procedure G1) was followed: 
p-Methoxyphenyl isopropyl ketene (153e; 21.3 mg, 112 µmol); 
solvent: dry toluene; conc = 12 mM, t = 0 °C, reaction time: 48 h; 
eluent: 2.5% acetone in toluene; N-acyl pyrrole 163e was obtained as a viscous oil (31.5 mg, 
112 µmol, >99%). Enantiomeric excess determined by chiral HPLC analysis: 91% ee 
(Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (major) = 9.4 min), tR (minor) = 12.5 min); [α]D23 = +147 (c 1.0, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.43 (dd, J = 3.1 Hz, J = 1.2 Hz, 1H), 7.25 (d, 
J = 8.7 Hz, 2H), 6.96 (dd, J = 3.4 Hz, J = 1.3 Hz, 1H), 6.86 (d, J = 8.7 Hz, 2H), 6.26 (t, 
J = 3.5 Hz, 1H), 3.82 (d, J = 9.8 Hz, 1H), 3.77 (s, 3H), 2.52 (dsept, J = 9.8 Hz, J = 6.5 Hz, 
1H), 1.08 (d, J = 6.4 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 170.5, 159.5, 129.5 (2C), 128.5, 126.7, 124.7, 114.7 (2C), 113.4, 113.0, 103.7, 58.2, 55.4, 
32.5, 21.8, 20.1 ppm; IR (film): v~ = 2223, 1728, 1510, 1449, 1346, 1298, 1249, 1226, 1179, 
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1107, 1031, 801, 774, 732 cm–1; HRMS (ESI): m/z calcd for C17H18N2O2Na: 305.1260 
[M+Na]+; found: 305.1263. 
 
(S)-1-(3-Methyl-2-(m-tolyl)butanoyl)-1H-pyrrole-2-carbonitrile (163f) 
Table 19, entry 6: General procedure G1) was followed: m-Tolyl 
isopropyl ketene (153f; 19.5 mg, 112 µmol); solvent: dry toluene; 
conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone in 
toluene; N-acyl pyrrole 163f was obtained as a viscous oil (29.8 mg, 112 µmol, >99%). 
Enantiomeric excess determined by chiral HPLC analysis: 95% ee (Chiralcel OD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; 
tR (major) = 7.9 min, tR (minor) = 14.9 min); [α]D23 = +170 (c 1.0, CHCl3); 1H NMR 
(300 MHz, CDCl3): δ = 7.44 (dd, J = 3.2 Hz, J = 1.3 Hz, 1H), 7.22 (t, J = 7.5 Hz, 1H), 7.18–
7.04 (m, 3H), 6.96 (dd, J = 3.6 Hz, J = 1.3 Hz, 1H), 6.26 (t, J = 3.5 Hz, 1H), 3.82 (d, 
J = 9.8 Hz, 1H), 2.66–2.45 (m, 1H), 2.33 (s, 3H), 1.10 (d, J = 6.4 Hz, 3H), 0.77 (d, J = 6.8 Hz, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 170.2, 139.1, 136.5, 129.1, 129.0, 128.9, 126.7, 
125.7, 124.7, 113.4, 113.0, 103.8, 59.1, 32.6, 21.9, 21.6, 20.2 ppm; IR (film): v~ = 2224, 1729, 
1449, 1346, 1296, 1248, 1223, 1110, 828, 767, 735 cm–1; HRMS (ESI): m/z calcd for 
C17H18N2O1Na: 289.1311 [M+Na]+; found: 289.1313. 
 
Table 19, entry 7: General procedure G2) was followed: m-Tolyl isopropyl ketene (153f; 
194 mg, 1.11 mmol); solvent: dry toluene; conc = 12 mM, t = 0 °C, reaction time: 48 h; 
eluent: 2.5% acetone in toluene; N-acyl pyrrole 163f was obtained as a viscous oil (292 mg, 
1.10 mmol, 98%). Enantiomeric excess determined by chiral HPLC analysis: 95% ee. 
 
(S)-1-(2-Cyclopentyl-2-phenylacetyl)-1H-pyrrole-2-carbonitrile (163g) 
Table 19, entry 8: General procedure G1) was followed: Phenyl cyclo-
pentyl ketene (153g; 20.8 mg, 112 µmol); solvent: dry toluene; 
conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone in 
toluene; N-acyl pyrrole 163g was obtained as a viscous oil (30.9 mg, 
111 µmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee 
(Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (major) = 7.5 min, tR (minor) = 12.5 min); [α]D23 = +145 (c 1.0, 
CHCl3); 1H NMR (300 MHz, CDCl3): δ = 7.34 (dd, J = 3.2 Hz, J = 1.3 Hz, 1H), 7.32–7.13 (m, 
5H), 6.88 (dd, J = 3.6 Hz, J = 1.3 Hz, 1H), 6.18 (t, J = 3.4 Hz, 1H), 3.93 (d, J = 10.4 Hz, 1H), 
2.76–2.54 (m, 1H), 2.09–1.89 (m, 1H), 1.69–0.92 (m, 7H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 170.2, 137.4, 129.3 (2C), 128.1 (2C), 128.1, 126.7, 124.7, 113.4, 113.0, 103.8, 57.3, 44.4, 
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32.0, 30.7, 25.2, 24.8 ppm; IR (film): v~ = 2953, 2223, 1728, 1449, 1344, 1282, 1248, 1225, 
1114, 811, 736, 701, 636 cm–1; HRMS (ESI): m/z calcd for C18H18N2O1Na: 301.1311 
[M+Na]+; found: 301.1313. 
Table 19, entry 9: General procedure G2) was followed: Phenyl cyclopentyl ketene (153g; 
209 mg, 1.12 µmol); solvent: dry toluene; conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 
2.5% acetone in toluene; N-acyl pyrrole 163g was obtained as a viscous oil (308 mg, 
1.11 mmol, 99%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee. 
 
(S)-1-(2-Cyclohexyl-2-phenylacetyl)-1H-pyrrole-2-carbonitrile (163h) 
Table 19, entry 10: General procedure G1) was followed: Phenyl 
cyclohexyl ketene (153h; 21.1 mg, 105 µmol); solvent: dry toluene; 
conc = 12 mM, t = 0 °C, reaction time: 48 h; eluent: 2.5% acetone in 
toluene; N-acyl pyrrole 163h was obtained as a viscous oil (30.7 mg, 
105 µmol, >99%). Enantiomeric excess determined by chiral HPLC analysis: 93% ee 
(Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (major) = 6.5 min, tR (minor) = 10.3 min); [α]D23 = +93 (c 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): δ = 7.37 (dd, J = 3.2 Hz, J = 1.3 Hz, 1H), 7.33–7.09 (m, 5H), 
6.89 (dd, J = 3.5 Hz, J = 1.4 Hz, 1H), 6.19 (t, J = 3.4 Hz, 1H), 3.88 (d, J = 10.0 Hz, 1H), 
2.27–2.09 (m, 1H), 1.94–1.79 (m, 1H), 1.74–1.45 (m, 3H), 1.39–0.64 (m, 6H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 170.2, 136.1, 129.2 (2C), 128.6 (2C), 128.1, 126.8, 124.7, 113.4, 113.0, 
103.7, 57.9, 41.7, 32.5, 30.4, 26.3, 26.1 (2C) ppm; IR (film): v~ = 2927, 2224, 1728, 1449, 
1349, 1294, 1253, 1222, 1114, 818, 738, 702 cm–1; HRMS (ESI): m/z calcd for 
C19H20N2O1Na: 315.1468 [M+Na]+; found: 315.1470. 
 
4.10.4  Intermolecular C-Acylations of Silyl Ketene Acetals (144 + 145 → 146) 
The experiments from Table 14 with the best results in terms of enantioselectivity for each 
tested silyl ketene acetal (145a–d) are described in detail below, which are the experiments 
from entry 1 (145a), entry 2 (145b), entry 3 (145c), and entry 9 (145d). All other experiments 
from Table 14 were analogously performed.  
 
Methyl 5,5-dimethyl-2-oxo-3-phenyltetrahydrofuran-3-carboxylate (146aa)[89] 
Table 14, entry 1: A flame-dried Schlenk tube (10 mL; threaded PTFE 
plug) was charged with silyl ketene acetal 145a (24.0 mg, 91.5 µmol, 
1.00 eq) and with a flame-dried stir bar. Another flame-dried Schlenk 
tube (2 mL; threaded PTFE plug) was charged with a solution of catalyst 
Λ-T18' (3.8 mg, 2.7 µmol, 3 mol%) in CH2Cl2, the CH2Cl2 subsequently carefully removed in 
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vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo for 1 h. Then, the 
catalyst was dissolved in dry CH2Cl2 (1.1 mL) and this solution transferred to the Schlenk 
tube containing 145a. Finally, acetic anhydride (144a; 11.2 µL, 118 µmol, 1.30 eq) was added 
via microliter syringe[155] and the resulting mixture stirred at rt for 36 h under nitrogen 
atmosphere. Full conversion was indicated by TLC analysis (hexanes/Et2O 3:1). All volatiles 
were removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica gel, and 
purified by flash chromatography (hexanes/Et2O 5:1). After solvent removal and drying in 
vacuo, product 146aa was obtained as a colorless oil (19.3 mg, 83.1 µmol, 91%). 
Enantiomeric excess determined by chiral HPLC analysis: 17% ee (Chiralcel OD-H, 5 µm, 
25 cm x 4.6 mm; n-hexane/i-PrOH 98.5:1.5, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; 
tR (major) = 6.2 min, tR (minor) = 7.2 min); 1H NMR (300 MHz, CDCl3): δ = 7.45–7.27 (m, 
5H), 3.39 (d, J = 13.4 Hz, 1H), 2.25 (d, J = 13.6 Hz, 1H), 2.21 (s, 3H), 1.42 (s, 3H), 1.26 (s, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 201.3, 172.8, 138.9, 129.6 (2C), 128.2, 126.7 (2C), 
82.5, 68.6, 44.7, 29.1, 28.9, 26.4 ppm; IR (film): v~ = 1753, 1714, 1271, 1180, 1135, 1100, 
1034, 702 cm–1; HRMS (ESI): m/z calcd for C14H16O3Na: 255.1003 [M+Na]+; found: 
255.0990. 
 
Methyl 3-(4-methoxyphenyl)-5,5-dimethyl-2-oxotetrahydrofuran-3-carboxylate 
(146ba)[89] 
Table 14, entry 2: A flame-dried Schlenk tube (10 mL; threaded PTFE 
plug) was charged with silyl ketene acetal 145b (39.4 mg, 135 µmol, 
1.00 eq) and with a flame-dried stir bar. Another flame-dried Schlenk 
tube (2 mL; threaded PTFE plug) was charged with a solution of catalyst 
Λ-T18' (5.3 mg, 3.8 µmol, 3 mol%) in CH2Cl2, the CH2Cl2 subsequently 
carefully removed in vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo 
for 1 h. Then, the catalyst was dissolved in dry CH2Cl2 (1.5 mL) and this solution transferred 
to the Schlenk tube containing 145b. Finally, acetic anhydride (144a; 15.5 µL, 164 µmol, 
1.21 eq) was added via microliter syringe[155] and the resulting mixture stirred at rt for 36 h 
under nitrogen atmosphere. Full conversion was indicated by TLC analysis (hexanes/Et2O 
3:1). All volatiles were removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on 
silica gel, and purified by flash chromatography (hexanes/Et2O 5:1). After solvent removal 
and drying in vacuo, product 146ba was obtained as a colorless crystalline solid (31.2 mg, 
119 µmol, 88%). Enantiomeric excess determined by chiral HPLC analysis: 29% ee 
(Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 96:4, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (minor) = 20.9 min, tR (major) = 23.0 min); 1H NMR (300 MHz, 
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CDCl3): δ = 7.27–7.16 (m, 2H), 6.88–6.75 (m, 2H), 3.74 (s, 3H), 3.28 (d, J = 13.4 Hz, 1H), 
2.17 (d, J = 13.6 Hz, 1H), 2.14 (s, 3H), 1.34 (s, 3H), 1.19 (s, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 201.6, 173.0, 159.5, 130.7, 127.9 (2C), 114.9 (2C), 82.4, 67.7, 55.4, 44.7, 29.0, 
28.9, 26.2 ppm; IR (film): v~ = 1752, 1713, 1510, 1252, 1180, 1138, 1031, 836, 597 cm–1; 
HRMS (ESI): m/z calcd for C15H18O4Na: 285.1097 [M+Na]+; found: 285.1096. 
 
Methyl 5,5-dimethyl-3-(naphthalen-1-yl)-2-oxotetrahydrofuran-3-carboxylate (146ca)[89] 
Table 14, entry 3: A flame-dried Schlenk tube (10 mL; threaded PTFE 
plug) was charged with silyl ketene acetal 145c (30.1 mg, 96.3 µmol, 
1.00 eq) and with a flame-dried stir bar. Another flame-dried Schlenk 
tube (2 mL; threaded PTFE plug) was charged with a solution of catalyst 
Λ-T18' (4.3 mg, 3.1 µmol, 3 mol%) in CH2Cl2, the CH2Cl2 subsequently carefully removed in 
vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo for 1 h. Then, the 
catalyst was dissolved in dry CH2Cl2 (1.3 mL) and this solution transferred to the Schlenk 
tube containing 145c. Finally, acetic anhydride (144a; 12.6 µL, 133 µmol, 1.38 eq) was added 
via microliter syringe[155] and the resulting mixture stirred at rt for 36 h under nitrogen 
atmosphere. Full conversion was indicated by TLC analysis (hexanes/Et2O 3:1). All volatiles 
were removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica gel, and 
purified by flash chromatography (hexanes/Et2O 5:1). After solvent removal and drying in 
vacuo, product 146ca was obtained as a colorless oil (25.8 mg, 91.4 µmol, 95%). Enantio-
meric excess determined by chiral HPLC analysis: 18% ee (Chiralcel OD-H, 5 µm, 25 cm x 
4.6 mm; n-hexane/i-PrOH 99:1, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 
7.7 min, tR (minor) = 8.8 min); 1H NMR (300 MHz, CDCl3): δ = 7.98–7.80 (m, 2H), 7.75 (dd, 
J = 7.4 Hz, J = 1.1 Hz, 1H), 7.58–7.36 (m, 4H), 3.78 (d, J = 13.4 Hz, 1H), 2.33 (d, 
J = 13.4 Hz, 1H), 2.09 (s, 3H), 1.55 (s, 3H), 1.19 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): 
δ = 204.2, 173.1, 135.9, 134.9, 130.3, 129.8, 129.4, 127.3, 126.3 (2C), 125.7, 123.5, 83.3, 
69.3, 44.2, 29.5, 29.4, 27.2 ppm; IR (film): v~ = 1750, 1715, 1270, 1181, 1138, 780 cm–1; 
HRMS (ESI): m/z calcd for C18H18O3Na: 305.1148 [M+Na]+; found: 305.1147. 
 
Methyl 3-isobutyl-2-oxo-2,3-dihydrobenzofuran-3-carboxylate (146da) 
Table 14, entry 9: A flame-dried Schlenk tube (10 mL; threaded PTFE 
plug) was charged with silyl ketene acetal 145d (27.7 mg, 106 µmol, 
1.00 eq) and with a flame-dried stir bar. Another flame-dried Schlenk 
tube (2 mL; threaded PTFE plug) was charged with a solution of 
catalyst Λ-T18' (4.4 mg, 3.2 µmol, 3 mol%) in CH2Cl2, the CH2Cl2 subsequently carefully 
removed in vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo for 1 h. 
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Then, the catalyst was dissolved in dry CH2Cl2 (1.3 mL) and this solution transferred to the 
Schlenk tube containing 145d. Finally, acetic anhydride (144a; 13.0 µL, 138 µmol, 1.30 eq) 
was added via microliter syringe[155] and the resulting mixture stirred at rt for 43 h under 
nitrogen atmosphere. All volatiles were removed in vacuo, the crude product dissolved in 
CH2Cl2, adsorbed on silica gel, and purified by flash chromatography (hexanes/Et2O 20:1). 
After solvent removal and drying in vacuo, 12 mg of a colorless oil were obtained which 
contained desired 146da and 274, which is the hydrolysis product of 145d, in a 2.5:1 ratio. 
Accordingly, the oil contained calculated 9.1 mg of desired product 146da (39.0 µmol, 37%). 
Apparently, the reaction was not yet complete when it was stopped. Enantiomeric excess 
determined by chiral HPLC analysis: 66% ee (Chiralcel OJ-H, 5 µm, 25 cm x 4.6 mm; 
n-hexane/i-PrOH 99.4:0.6, λ = 254 nm, 1.0 mL/min, t (column) = 15 °C; tR (major) = 
11.0 min, tR (minor) = 13.3 min); 1H NMR (300 MHz, CDCl3): δ = 7.35–7.01 (m, 4H), 2.19 
(dd, J = 14.3 Hz, J = 5.8 Hz, 1H), 2.09 (dd, J = 14.4 Hz, J = 7.6 Hz, 1H), 2.08 (s, 3H), 1.45–
1.26 (m, 1H), 0.70 (d, J = 6.6 Hz, 3H), 0.64 (d, J = 6.6 Hz, 3H) ppm; 13C NMR (75 MHz, 
CDCl3): δ = 198.9, 175.3, 153.7, 130.1, 126.3, 125.0, 124.8, 111.2, 65.2, 42.3, 26.4, 25.3, 
23.9, 22.8 ppm; HRMS (ESI): m/z calcd for C14H16O3Na: 255.0992 [M+Na]+; found: 
255.0995. 
 
4.10.5  Steglich-Type Rearrangements of O-Acylated Oxindoles  
The Steglich-type rearrangements of O-acylated oxindoles from Table 15 where the desired 
C-acylated products could be isolated (entries 5–7) are described in detail below. All other 
experiments from Table 15 were analogously performed.  
 
Gliocladin C Precursor 148b[90] 
Table 15, entry 5: An amber glas vial[154] with a micro stir bar was 
charged with gliocladin C precursor 147b[90] (29.3 mg, 44.9 µmol, 
1.00 eq), precatalyst Λ-T18 (3.5 mg, 2.3 µmol, 5 mol%), Cs2CO3 
(2.1 mg, 6.5 µmol, 15 mol%), and THF (55 µL). Then, the vial was 
capped with a PTFE-sealed screw cap[154] and the mixture stirred at 
40 °C. After 48 h, TLC analysis (hexanes/Et2O 6:1) indicated incomplete conversion (<50%). 
After a total of 130 h at 40 °C, TLC analysis indicated full although unclean conversion. All 
volatiles were removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed on silica 
gel, and purified via flash chromatography (hexanes/Et2O 6:1). After solvent removal and 
drying in vacuo, compound 148b was obtained as a pale orange solid (4.8 mg, 7.4 µmol, 
16%). Enantiomeric excess determined by chiral HPLC analysis: 28% ee (Chiralpak AD-H, 
5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 99.3:0.7, λ = 254 nm, 1.0 mL/min, t (column) = 
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25 °C; tR (major) = 8.2 min, tR (minor) = 9.9 min); 1H NMR (300 MHz, DMSO-d6): δ = 8.07 
(d, J = 8.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.56 (ddd, J = 8.2 Hz, J = 7.6 Hz, J = 1.2 Hz, 
1H), 7.46 (dd, J = 7.5 Hz, J = 1.6 Hz, 1H), 7.41 (s, 1H), 7.40–7.20 (m, 4H), 1.88 (s, 3H), 1.65 
(s, 3H), 1.60 (s, 9H), 1.55 (s, 9H) ppm.  
 
Diphenyl 3-methyl-2-oxoindoline-1,3-dicarboxylate (150a)[23f] 
Table 15, entry 6: An amber glas vial[154] with a micro stir bar was 
charged with substrate 149a (20.0 mg, 51.6 µmol, 1.00 eq), catalyst 
Λ-T18' (1.5 mg, 1.1 µmol, 2 mol%), and THF (110 µL). The vial was 
capped with a PTFE-sealed screw cap[154] and the mixture stirred at rt. 
After 12 h, TLC indicated considerable conversion (~50%) and after 48 h TLC indicated full 
conversion. All volatiles were removed in vacuo and the crude product purified by short-
column chromatography (CH2Cl2). After solvent removal and drying in vacuo, product 150a 
was obtained as a colorless solid (19.6 mg, 50.6 µmol, 98%). Enantiomeric excess determined 
by chiral HPLC analysis: < 5% ee (Chiralpak AD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/ 
i-PrOH 97:3, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR1 = 24.4 min, tR2 = 36.7 min; 
1H NMR (300 MHz, CDCl3): δ = 8.10–8.02 (m, 1H), 7.50–7.18 (m, 11H), 7.03–6.93 (m, 2H), 
1.90 (s, 3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 172.5, 167.7, 150.5, 150.3, 149.4, 139.3, 
130.0, 129.8 (2C), 129.6 (2C), 126.7, 126.5, 125.8, 123.1, 121.6 (2C), 121.3 (2C), 121.1, 
116.1, 56.1, 21.0 ppm; IR (film): v~ = 1778, 1745, 1480, 1346, 1215, 1180, 1162, 1094, 743, 
683, 498 cm–1; HRMS (ESI): m/z calcd for C23H17N1O5Na: 410.0999 [M+Na]+; found: 
410.0998.  
 
Diphenyl 3-benzyl-2-oxoindoline-1,3-dicarboxylate (150b)[23f] 
Table 15, entry 7: An amber glas vial[154] with a micro stir bar was 
charged with substrate 149b (23.8 mg, 51.3 µmol, 1.00 eq), catalyst 
Λ-T18' (1.5 mg, 1.1 µmol, 2 mol%), and THF (110 µL). The vial was 
capped with a PTFE-sealed screw cap[154] and the mixture stirred at rt. 
After 12 h, TLC indicated considerable conversion (80–90%) and after 48 h TLC indicated 
full conversion. All volatiles were removed in vacuo and the crude product purified by short-
column chromatography (CH2Cl2). After solvent removal and drying in vacuo, product 150b 
was obtained as a colorless solid (22.8 mg, 49.2 µmol, 96%). Enantiomeric excess determined 
by chiral HPLC analysis: 59% ee (Chiralpak AD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 
97:3, λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 29.2 min, tR (minor) = 
34.2 min; 1H NMR (300 MHz, CDCl3): δ = 7.81–7.72 (m, 1H), 7.55–7.47 (m, 1H), 7.46–7.05 
(m, 13H), 7.05–6.98 (m, 2H), 6.96–6.88 (m, 2H), 3.78 (d, J = 13.3 Hz, 1H), 3.67 (d, 
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J = 13.3 Hz, 1H) ppm; 13C NMR (75 MHz, CDCl3): δ = 171.3, 167.3, 150.5, 150.2, 148.9, 
140.0, 133.5, 130.2 (2C), 130.0, 129.7 (2C), 129.6 (2C), 128.2 (2C), 127.5, 126.6, 126.6, 
126.3, 125.5, 123.8, 121.6 (2C), 121.3 (2C), 115.8, 61.8, 41.2 ppm; IR (film): v~ = 1747, 1480, 
1346, 1289, 1182, 1151, 1097, 1069, 1028, 739, 688, 499 cm–1; HRMS (ESI): m/z calcd for 
C29H21NO5Na: 486.1312 [M+Na]+; found: 486.1315.  
 
4.10.6  Asymmetric Reactions with Phenyl Ethyl Ketene (153a) as Substrate 
The asymmetric reactions between phenyl ethyl ketene (153a) and various reaction partners 
from Table 16 where the desired products could be isolated (entries 1, 2, and 5) are described 
in detail below. All other experiments from Table 16 were analogously performed. 
Remark: The reaction between phenyl ethyl ketene (153a) and 2-cyanopyrrole (162) from 
Table 16, entry 6 is described in chapter 4.10.3. 
 
Diethyl 3-ethyl-4-oxo-3-phenyl-1,2-diazetidine-1,2-dicarboxylate 155a[26j] 
Table 16, entry 1: A flame-dried Schlenk tube with a stir bar (10 mL; 
threaded PTFE plug) was charged with phenyl ethyl ketene (153a; 22.9 mg, 
157 µmol, 1.00 eq) and dry CH2Cl2 (10 mL). Another flame-dried Schlenk 
tube (2 mL; threaded PTFE plug) was charged with a CH2Cl2 solution of 
catalyst Λ-T18' (6.5 mg, 4.7 µmol, 3 mol%), the CH2Cl2 subsequently carefully removed in 
vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo for 1 h. Then, the 
catalyst was dissolved in dry CH2Cl2 (1.0 mL) and this solution transferred to the Schlenk 
tube containing ketene 153a. Immediately, DEAD (154; 26.5 µL, 168 µmol, 1.07 eq) was 
added via microliter syringe[155] and the resulting mixture stirred at rt for 6 h under nitrogen 
atmosphere. After that, TLC analysis (hexanes/EtOAc 6:1) indicated full conversion. 
However, 155a was not formed as major product (TLC comparison with a racemic sample of 
155a; one major unwanted spot which was not characterized). After a total of 25 h at rt, TLC 
analysis gave the same result. Then, all volatiles were removed in vacuo, the crude product 
dissolved in CH2Cl2, adsorbed on silica gel, and desired 155a isolated via flash chromato-
graphy (hexanes/EtOAc 10:1). After solvent removal and drying in vacuo, 155a was isolated 
as a colorless oil (5.9 mg, 18 µmol, 12%). Enantiomeric excess determined by chiral HPLC 
analysis: 64% ee (Chiralcel OD-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 95:5, 
λ = 254 nm, 1.0 mL/min, t (column) = 25 °C; tR (major) = 10.0 min, tR (minor) = 13.8 min); 
1H NMR (300 MHz, CDCl3): δ = 7.61–7.50 (m, 2H), 7.46–7.30 (m, 3H), 4.36 (q, J = 7.1 Hz, 
2H), 4.30–4.12 (m, 2H), 2.50–2.35 (m, 1H), 2.35–2.17 (m, 1H), 1.37 (t, J = 7.2 Hz, 3H), 1.23 
(t, J = 7.2 Hz, 3H), 1.08 (t, J = 7.4 Hz, 3H) ppm; HRMS (ESI): m/z calcd for C16H20N2O5Na: 
343.1264 [M+Na]+; found: 343.1266. 
N
N
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CO2Et
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Perchloroprop-1-en-2-yl 2-chloro-2-phenylbutanoate 157a[26h,27c] 
Table 16, entry 2: A flame-dried Schlenk tube with a stir bar (10 mL; 
threaded PTFE plug) was charged with phenyl ethyl ketene (153a; 
17.6 mg, 120 µmol, 1.00 eq) and dry toluene (6.0 mL). Another flame-
dried Schlenk tube (2 mL; threaded PTFE plug) was charged with 
hexachloroacetone (156; 22.0 µL, 145 µmol, 1.20 eq) and dry toluene (0.7 mL). And another 
flame-dried Schlenk tube (2 mL; threaded PTFE plug) was charged with a CH2Cl2 solution of 
catalyst Λ-T18' (5.0 mg, 3.6 µmol, 3 mol%), the CH2Cl2 subsequently carefully removed in 
vacuo, and the Schlenk tube with the solidified catalyst dried in vacuo for 1 h and Λ-T18' 
redissolved in dry toluene (0.25 mL). 
The ketene solution (153a) was then cooled to –78 °C and the hexachloroacetone solution 
(156) added, which was immediately followed by the catalyst solution (Λ-T18'). The 
resulting mixture was then stirred at –78 °C for 1 h under nitrogen atmosphere after which 
TLC analysis (hexanes/EtOAc 20:1) indicated full conversion. The mixture was allowed to 
warm to rt, all volatiles removed in vacuo, the crude product dissolved in CH2Cl2, adsorbed 
on silica gel, and purified by flash chromatography (hexanes/EtOAc 40:1). After solvent 
removal and drying in vacuo, desired product 157a was obtained as a colorless oil (46.3 mg, 
113 µmol, 94%). Enantiomeric excess determined by chiral HPLC analysis: 9% ee (Chiralcel 
OJ-H, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 98.7:1.3, λ = 254 nm, 0.7 mL/min, 
t (column) = 20 °C; tR (minor) = 7.8 min, tR (major) = 8.7 min); 1H NMR (300 MHz, CDCl3): 
δ = 7.75–7.53 (m, 2H), 7.48–7.28 (m, 3H), 2.75–2.42 (m, 2H), 1.03 (t, J = 7.2 Hz, 3H) ppm; 
13C NMR (75 MHz, CDCl3): δ = 166.4, 142.7, 136.6, 129.0, 128.6 (2C), 127.2 (2C), 124.8, 
90.7, 74.7, 34.6, 8.9 ppm; IR (film): v~ = 1773, 1156, 1061, 994, 817, 759, 684 cm–1; HRMS 
(CI): m/z calcd for C13H1035Cl537Cl1O2H: 410.8843 [M+H]+; found: 410.8861. 
 
2-(tert-Butyl)phenyl 2-phenylbutanoate (161a)[26e] 
Table 16, entry 5: A flame-dried Schlenk tube with a stir bar (10 mL; 
threaded PTFE plug) was charged with a CH2Cl2 solution of catalyst 
Λ-T18' (4.9 mg, 3.5 µmol, 3 mol%), the CH2Cl2 carefully removed under 
reduced pressure, and the Schlenk tube with the solidified catalyst dried in 
vacuo for 1 h. Then, dry toluene (9.5 mL) and 2-tert-butylphenol (160; 19.0 µL, 124 µmol, 
1.05 eq) were added to this Schlenk tube. Another flame-dried Schlenk tube (2 mL; threaded 
PTFE plug) was charged with phenyl ethyl ketene (153a; 17.2 mg, 118 µmol, 1.00 eq) and 
dry toluene (0.25 mL). The ketene solution (153a) was then added to the other Schlenk tube 
via microliter syringe[155] and the ketene's Schlenk tube rinsed with dry toluene (0.25 mL) and 
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the resulting solution added to the reaction's Schlenk tube with the same microliter syringe in 
order to transfer the ketene as completely as possible. The reaction mixture was then stirred at 
rt for 2.5 h under nitrogen atmosphere after which TLC (hexanes/Et2O 10:1) indicated full 
conversion. All volatiles were removed in vacuo, the crude product dissolved in CH2Cl2, 
adsorbed on silica gel, and purified by flash chromatography (hexanes/Et2O 20:1). After 
solvent removal and drying in vacuo, desired 161a was obtained as a colorless oil (22.0 mg, 
74.2 µmol, 63%). Enantiomeric excess determined by chiral HPLC analysis: 13% ee 
(Chiralpak IC, 5 µm, 25 cm x 4.6 mm; n-hexane/i-PrOH 96:4, λ = 254 nm, 1.0 mL/min, 
t (column) = 25 °C; tR (minor) = 4.0 min, tR (major) = 4.5 min); 1H NMR (300 MHz, CDCl3): 
δ = 7.46–7.23 (m, 6H), 7.21–7.06 (m, 2H), 6.84 (dd, J = 7.6 Hz, J = 1.7 Hz, 1H), 3.73 (t, 
J = 7.7 Hz, 1H), 2.39–2.19 (m, 1H), 2.06–1.86 (m, 1H), 8.90 (s, 9H), 1.01 (t, J = 7.4 Hz, 
3H) ppm; 13C NMR (75 MHz, CDCl3): δ = 172.6, 149.7, 141.2, 138.2, 128.9 (2C), 128.5 (2C), 
127.6, 127.2, 126.9, 125.7, 123.7, 54.3, 34.5, 30.1 (3C), 26.5, 12.4 ppm; IR (film): v~ = 1751, 
1185, 1137, 1107, 1090, 751, 697 cm–1; HRMS (ESI): m/z calcd for C20H24O2Na: 319.1679 
[M+Na]+; found: 319.1671. 
 
4.10.7  Exemplary Michael Addition of Octanal (167b) to trans-β-Nitrostyrene (182)  
The Michael addition of octanal (167b) to trans-β-nitrostyrene (182) to give Michael addition 
products 183b and epi-183b with catalyst rac-T29 from Table 23, entry 1 is described below. 
Other experiments from Table 23 were analogously performed.  
 
Michael Addition Products 183b and epi-183b (Table 23, Entry 1) 
Table 23, entry 1: An amber glas vial[154] was charged 
with trans-β-nitrostyrene (182; 15.0 mg, 100 µmol, 
1.00 eq), complex rac-T29 (4.8 mg, 4.0 µmol, 4 mol%), 
and NaBArF24 (5.3 mg, 6.0 µmol, 6 mol%). Then, dry 
toluene (100 µL) and freshly distilled octanal (167b; 23.5 µL, 150 µmol, 1.50 eq) were added, 
the vial capped with a PTFE-sealed screw cap[154] and the mixture stirred at rt for 30 h after 
which TLC indicated full conversion (hexanes/Et2O 5:1). The solvent was removed in vacuo, 
the crude product dissolved in CH2Cl2, adsorbed on silica gel (42 °C), and purified by flash 
chromatography (hexanes/Et2O 8:1 → 10:1). Diastereomers 183b and epi-183b could be fully 
resolved and were obtained as colorless oils after solvent removal and drying in vacuo (first 
eluting diastereomer 183b: 5.5 mg, 19.8 µmol, 20%; second eluting diastereomer epi-183b: 
13.7 mg, 49.4 µmol, 49%; isolated d.r.: 2.5:1; total yield: 69%). 
Note: In a control experiment, the same reaction conditions gave no product when complex 
rac-T29 was absent. 
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I.) Analytical data for diastereomer 183b: 
1H NMR (300 MHz, CDCl3): δ = 9.41 (d, J = 3.0 Hz, 1H), 7.32–7.20 (m, 3H), 7.14–7.04 (m, 
2H), 4.80–4.61 (m, 2H), 3.80–3.65 (m, 1H), 2.61–2.48 (m, 1H), 1.70–0.70 (m, 13) ppm; 
13C NMR (75 MHz, CDCl3): δ = 203.5, 136.4, 129.3 (2C), 128.4 (2C), 128.4, 78.1, 53.7, 44.7, 
31.6, 29.3, 27.7, 27.2, 22.7,14.1 ppm; IR (film): v~ = 2954, 1722, 1552, 1378, 701 cm–1; 
HRMS (ESI): m/z calcd for C16H23N1O3Na: 300.1570 [M+Na]+; found: 300.1575. 
 
II.) Analytical data for diastereomer ent-183b: 
1H NMR (300 MHz, CDCl3): δ = 9.70 (d, J = 2.6 Hz, 1H), 7.41–7.25 (m, 3H), 7.23–7.12 (m, 
2H), 4.79–4.56 (m, 2H), 3.77 (td, J = 9.5 Hz, J = 5.5 Hz, 1H), 2.76–2.60 (m, 1H), 1.66–0.71 
(m, 13H) ppm; 13C NMR (75 MHz, CDCl3): δ = 203.3, 137.0, 129.3 (2C), 128.3, 128.2 (2C), 
78.6, 54.1, 43.3, 31.5, 29.2, 27.5, 26.5, 22.5, 14.1 ppm; IR (film): v~ = 2923, 2854, 1721, 1553, 
1377, 700 cm–1; HRMS (ESI): m/z calcd for C16H23N1O3Na 300.1570 [M+Na]+; found: 
300.1570. 
 
4.10.8  Preparation of Racemic References for Chiral HPLC Analysis 
Racemic references for chiral HPLC analysis were obtained in case of the reactions from 
chapter 2. by relying on the procedures described in chapters 4.10.1–4.10.6 but by using  
10–20 mol% of DMAP instead of the respective nucleophilic Ir(III) catalyst. In case of the 
reactions from chapter 3., racemic Ir(III) catalyst rac-T29 was employed in the same way to 
obtain racemic references. 
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4.11  CD Spectra of Complexes Λ/∆-(S)-T18, Λ/∆-T18-(MeCN)2, and Λ/∆-T18 
CD spectra were recorded of diastereomers Λ- and ∆-(S)-T18, bisacetonitrile intermediates 
Λ- and ∆-T18-(MeCN)2, and precatalysts Λ- and ∆-T18 in HPLC grade methanol or aceto-
nitrile at 25.0 °C and conc = 0.20 mM using an actively thermostatted cell with a path length 
of d = 1.0 mm (Figures 40–42). Raw data obtained in millidegrees (θ [mdeg]) was converted 
into molar circular dichroism data (∆ε [M–1·cm–1]) with the aid of Eq. 3.[156] 
 
             ∆ε[M−1cm−1] = θ[mdeg]10 ∙ conc[mol ∙ L−1] ∙ d[cm] ∙ 32980                              (Eq. 3) 
 
 
The absolute configurations of the iridium(III) complexes were assigned by comparison of the 
obtained CD spectra with literature reported CD spectra of closely related stereogenic-at-
metal iridium(III) complexes.[38a,66,67,69] Importantly, absolute stereochemical assignments of 
the Ir(III) complexes from refs. 38a, 66, and 69 are based on X-ray structural analyses of 
enantiopure Ir(III) complex samples. 
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Figure 40. CD spectra of diastereomers Λ-(S)-T18 and ∆-(S)-T18. 
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Figure 41. CD spectra of bisacetonitrile intermediates Λ-T18-(MeCN)2 and ∆-T18-(MeCN)2. 
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Figure 42. CD spectra of precatalysts Λ-T18 and ∆-T18. 
 
4.12  Preparation of Catalysis Intermediate Analog rac-T18-TfO 
 
 
 
 
Scheme 97. Preparation of catalysis intermediate analog rac-T18-TfO. 
 
A flask (10 mL) was charged with catalyst rac-T18' (310 mg, 222 µmol, 1.00 eq) and CH2Cl2 
(1 mL). A solution of 2,2,2-trichloro-1,1-dimethylethyl chloroformate (62.8 mg, 262 µmol, 
1.18 eq) in CH2Cl2 (3.5 mL) was added, the flask sealed with a septum, and the mixture 
stirred at rt for 6.5 h (formation of rac-T18-Cl). Then, a solution of AgOTf (67 mg, 
261 µmol, 1.18 eq) in CH2Cl2/MeOH 1:1 (2 mL) was added and the mixture stirred at rt for 
5 min. The mixture was subsequently diluted with CH2Cl2 and rapidly passed through a short 
plug of silica gel with CH2Cl2/MeOH 20:1. All volatiles were removed in vacuo at 32 °C 
(higher temperatures lead to significant methanolysis of the product), which yielded desired 
rac-T18-TfO as a yellow solid. Rac-T18-TfO was used without further purification and cha-
racterization to grow X-ray quality crystals as described in the crystallographic section.  
 
Remarks: 
• Prior to the synthesis of rac-T18-TfO, there had been attempts to crystallize primary 
chloride salt rac-T18-Cl. However, all crystal growing attempts with rac-T18-Cl had 
only provided tiny crystals unfeasible for X-ray diffraction analysis. 
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• When racemic catalyst rac-T18' (21 mg) was mixed with 3 eq of 2,2,2-trichloro-1,1-
dimethylethyl chloroformate in a flame-dried NMR tube in dry CD2Cl2 (conc = 25 mM), 
full and clean conversion from rac-T18' to rac-T18-Cl took place in less than 10 min 
(formation of rac-T18-Cl confirmed by 1H and 13C NMR as well as by HRMS analysis).    
 
4.13  1H NMR Spectra Comparisons 
4.13.1  Comparison of Precatalyst Λ-T18 with Catalyst Λ-T18' 
Figure 43 shows the 1H NMR spectra of precatalyst Λ-T18 (blue) and catalyst Λ-T18' (red). 
Both spectra are calibrated to the residual signal of CD2Cl2 (δ = 5.32 ppm). 
 
 
 
Figure 43. 1H NMR spectra of precatalyst Λ-T18 and catalyst Λ-T18' (500 MHz, CD2Cl2). 
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4.13.2  Comparison of Freshly Prepared Λ-T18' with Reisolated Λ-T18' 
Figure 44 shows the 1H NMR spectra of freshly prepared catalyst Λ-T18' (blue) and reiso-
lated catalyst Λ-T18' (red; see chapter 2.3.3, Table 13, entries 14, 15 and the reisolation 
procedure from chapter 4.10.2.2). HPLC analysis revealed for both samples >99% ee (see 
chapter 5.2). Both spectra are calibrated to the residual signal of CD2Cl2 (δ = 5.32 ppm). 
 
 
 
Figure 44. 1H NMR spectra of freshly prepared and of reisolated catalyst Λ-T18' (CD2Cl2). 
 
4.13.3 1H NMR Spectra of Enantiomeric Catalysts Λ-T18' and ∆-T18' 
Figure 45 shows the 1H NMR spectra of enantiomeric catalysts Λ-T18 (blue) and ∆-T18' 
(red). Both spectra are calibrated to the residual signal of CD2Cl2 (δ = 5.32 ppm). 
 
 
 
Figure 45. 1H NMR spectra comparison of enantiomeric catalysts Λ-T18' and ∆-T18' (CD2Cl2). 
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4.14  Evaluation of the Stability of Catalyst ∆-T18' in Solution 
Figure 46 shows the 1H NMR spectra of freshly prepared catalyst ∆-T18' (green), catalyst 
∆-T18' after one week in CD2Cl2 at 4 °C (blue), and catalyst ∆-T18' after one week in 
CD2Cl2 at 25 °C (red; for each experiment: 7 mg of catalyst ∆-T18' in 0.6 mL CD2Cl2). All 
spectra are calibrated to the residual signal of CD2Cl2 (δ = 5.32 ppm). 
 
 
 
Figure 46. Catalyst ∆-T18' after one week in CD2Cl2 at 4 °C and at 25 °C (300 MHz, CD2Cl2). 
 
While basically no decomposition is observable in case of the catalyst which was kept in 
CD2Cl2 for one week at 4 °C, traces of decomposition products are observable in case of the 
catalyst which was kept in CD2Cl2 for one week at 25 °C. However, when the latter catalyst 
sample was recovered and used without any purification in a catalysis experiment, exactly the 
same result was obtained as with freshly prepared catalyst (see chapter 2.3.2, Table 10, entries 
11 and 12,). Furthermore, chiral HPLC analysis revealed for both samples >99% ee (see 
chapter 5.2). In this context, it is also worth mentioning that neither any decomposition nor 
any racemization of precatalyst Λ/∆-T18 or catalyst Λ/∆-T18' were observed when they were 
stored as solids for about 6 months at 4 °C (refrigerator) under standard atmospheric condi-
tions. 
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4.15  Mechanistic Experiments 
4.15.1  Crossover Experiment with O-Acylated Benzofuranones 
 
 
 
Scheme 98. Crossover experiment with O-acylated benzofuranones. 
 
A flask was charged with substrate 142i (50.9 mg, 145 µmol, 0.50 eq) and 142g (49.7 mg, 
144 µmol, 0.50 eq). Then, a solution of rac-T18' (4.1 mg, 2.94 µmol, 1.0 mol%) in 2:1 
TAA/CPME (1.4 mL; conc = 0.2 M) was added at −15 °C and the mixture stirred for 48 h at  
−15 °C. All volatiles were removed in vacuo and the crude mixture analyzed by 1H and 
13C NMR analysis (Figure 47). Both spectra confirmed the formation of scrambled 143b and 
143e besides non-scrambled 143g and 143i (143g:143i:143b:143e; ratio approx. 4.5:4.5:1:1). 
 
 
 
 
 
Figure 47. Excerpts from the 1H NMR spectrum (top) and the 13C NMR spectrum (bottom) of the crude mixture 
of the crossover experiment (blue) and the NMR spectra of the related pure products (300 MHz, CDCl3). 
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4.15.2 Mixing of Catalyst rac-T18' with p-Chlorophenyl Isopropyl Ketene (153d) 
 
 
 
Scheme 99. Does mixing of catalyst rac-T18' with p-chlorophenyl isopropyl ketene (153d) lead to the formation 
of a zwitterionic ketene enolate species? 
 
A flame-dried NMR-tube was charged with catalyst rac-T18' (33 mg, 23.6 µmol, 1.00 eq) 
and dry CD2Cl2 (0.65 mL) and an 1H NMR spectrum was recorded. Then, 6 eq of p-chloro-
phenyl isopropyl ketene (153d) were added and again a spectrum recorded (15 min after 
initial mixing). Another 12 eq were added and a third spectrum was recorded (10 h after initial 
mixing). In addition, a spectrum of pure ketene 153d was recorded. 
Figure 48 shows all four spectra, each calibrated to the residual signal of CD2Cl2 
(δ = 5.32 ppm). As it is apparent from Figure 48, the formation of a zwitterionic catalyst-
ketene adduct, as depicted in Scheme 99, could not be observed with these NMR experiments. 
 
 
 
Figure 48. 1H NMR spectra: Mixing of p-chlorophenyl isopropyl ketene (153d) with catalyst rac-T18' 
(300 MHz, CD2Cl2). 
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4.15.3  Mixing of Catalyst rac-T18' with 2-Cyanopyrrole (162) 
 
 
Scheme 100. Does Mixing of rac-T18' with 2-cyanopyrrole (162) lead to the formation of an ion-pair? 
 
A flame-dried NMR-tube was charged with catalyst rac-T18' (15 mg, 10.7 µmol, 1.00 eq) 
and dry CD2Cl2 (0.65 mL) and an 1H NMR spectrum was recorded. Then, 6 eq of 2-cyano-
pyrrole (162) were added and again a spectrum recorded (15 min after initial mixing). 
Another 12 eq were added and a third spectrum was recorded (2 h after initial mixing). In 
addition, two spectra were recorded of pure 2-cyanopyrrole (162) in CD2Cl2, one with 5 µL 
(6 eq) of 162 and one with 15 µL (18 eq) of 162. 
Figures 49–51 show all five spectra and additionally the spectrum of precatalyst rac-T18 
(spectrum on the top). The signals of catalyst rac-T18' and its HPF6 salt rac-T18 differ from 
each other in particular in the downfield region of their spectra. Excess of 162 with respect to 
rac-T18' causes these decisive signals of rac-T18' to shift downfield towards the δ-values of 
its corresponding HPF6 salt rac-T18, which indicates an interaction between the acidic proton 
of 2-cyanopyrrole (162) and the basic nitrogen of the imidazoquinoline ligand of rac-T18'. 
 
 
 
Figure 49. 1H NMR spectra: Mixing of 2-cyanopyrrole (162) with catalyst rac-T18' 
(δ-range depicted from 8.5–5.0 ppm; recorded in CD2Cl2). 
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Figure 50. 1H NMR spectra: Mixing of 2-cyanopyrrole (162) with catalyst rac-T18'  
(δ-range depicted from 10–5.0 ppm; recorded in CD2Cl2). 
 
In addition, a change of the NH-signal's shape is observable (see Figure 50). This shape 
alteration can be explained with an increased proton exchange caused by the interaction of the 
acidic NH of 162 with Brønsted basic rac-T18'. This is further affirmed by the fact that the 
presence of rac-T18' in case of 6 eq of 162 leads to a downshift of the NH-signal of almost 
1 ppm (see Figure 50). In this context, it should be noted that the NH-signal of HPF6 salt 
rac-T18 appears at about δ = 11–12 ppm (see Figure 51). The presence of 18 eq of 162 results 
in a smaller downshift than 6 eq of 162, which is understandable taking into account that a 
smaller absolute fraction of 162 is then in interaction with rac-T18' (see Figure 50). Figure 51 
shows the same spectra as Figures 49 and 50 but the entire ppm δ-range from 12–0 ppm. 
 
 
 
Figure 51. 1H NMR spectra: Mixing of 2-cyanopyrrole (162) with catalyst rac-T18' 
(entire δ-range from from 12–0 ppm; recorded in CD2Cl2). 
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Apparently, rac-T18' and 2-cyanopyrrole (162) do not react under ion-pair formation as 
depicted in Scheme 100. However, it is apparent from Figures 49–51 that there are strong 
indications for a hydrogen-bonding interaction between the basic imidazoquinoline ligand of 
rac-T18' and the acidic proton of 162.  
 
4.15.4  Inactivity of N-Methylated Λ-T18-Me and Inactivity of Λ-T18 in Absence of Base 
The experiments in Scheme 101 below show that precatalyst Λ/∆-T18 in not catalytically 
active in the absence of a Brønsted base and that N-methylated complex Λ/∆-T18-Me is 
neither catalytically active in the absence nor in the presence of a Brønsted base. 
 
 
 
Scheme 101. Top: Catalytic activity experiments with N-methylated Λ-T18-Me.   
Bottom: Catalytic activity experiments with precatalyst Λ-T18. 
  
– 4.16 Quantum Chemical Calculations – 
 
~ 283 ~ 
 
4.16  Quantum Chemical Calculations 
The quantum chemical calculations included in the present thesis and described in detail in 
chapters 4.16.1 and 4.16.2 were planned in close collaboration with and designed and per-
formed by cooperation partner Michael G. Medvedev, who was at the time of the calculations 
affiliated with the 'A. N. Nesmeyanov Institute of Organoelement Compounds RAS'[94] and 
with the 'N. D. Zelinsky Institute of Organic Chemistry RAS'[95] (ORCID M. G. M.: 0000-
0001-7070-4052). 
 
4.16.1  Quantum Chemical Modeling of the Conformations of rac-T18-TfO 
The molecular geometries of the two conformers of the rac-T18-TfO complex cation – one 
with the carbonyl group oriented towards the quinoline subunit and one with it oriented other-
wise (see chapter 2.3.8, Figure 22; conformers A and B) – were optimized at the PBE0[96]-
D3[97]/IMCP-SR1[98,99]//PBE0-D3/SBKJC[100] SMD[101] (butanol) level of theory using the 
GAMESS-US[157] program package. The PBE0 functional was chosen because it is known to 
be accurate for organic chemistry calculations[96b] and has recently been shown to be well-
grounded in theory.[96c] The IMCP-SR1 basis set was chosen as it incorporates scalar-relati-
vistic effects, which are important for heavy elements, such as iridium in the studied case,[99] 
and belongs to model core potential basis sets which retain the correct nodal structures of 
atoms.[98] 
The calculations revealed that the π-conjugated conformer which was also found in the crystal 
structure of rac-T18-TfO is about 5.3 kcal·mol–1 lower in energy than the alternative one.  
 
4.16.2  Quantum Chemical Modeling of the Black Rearrangement's Stereogenic Step 
The chirality-introducing step of the Black rearrangement is the nucleophilic attack of the 
benzofuranone enolate to the trigonal carbonyl atom of the corresponding N-acylated catalyst 
(see for example Λ-T18-Int in chapter 2.3.8, Scheme 36). The approaching routes available 
for the enolate are defined by two criteria: (1.) The two approaching carbons should have their 
bonds in staggered conformation and (2.) the benzene ring of the incoming enolate should not 
encounter with the closely disposed 2,6-dimethylphenyl group. These requirements led to the 
four possible transition states (TSs), which are depicted in chapter 2.3.8, Figure 25. The 
methods which led to their location are described in the following paragraphs.  
To establish the true mechanism of the reaction, it was attempted to locate each of the 
corresponding TSs (see chapter 2.3.8, Figure 25). The reaction leading to product 143h from 
substrate 142h with R1 = R2 = Me was modeled with model catalyst Λ-T18'-QM lacking the 
non-involved 2,6-dimethylphenyl group, the non-involved methyl group of the involved 
2,6-dimethylphenyl group and two non-involved isopropyl groups of the involved 2,4,6-triiso-
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propylphenyl group (Λ-T18'-QM is depicted in chapter 2.3.8, Figure 24). "Involved" ["non-
involved"] means in this context that the said group is [not] part of the 'active center' and is 
[not] involved in the shaping of the mentioned 'molecular cavity'. Consequently, the shape of 
the catalyst's active center / molecular cavity remained entirely unchanged by these simpli-
fications (compare Figures 23 and 26 from chapter 2.3.8 for an illustration). 
The methodology applied to locate each of the four possible TSs is described in detail in 
ref. 158 and is an advanced version of the one recently applied by M. G. M. and co-workers to 
locate all 728 TSs feasible for an SpnF-catalyzed Diels–Alder cycloaddition.[107,158] At first, it 
was aimed to get as good transition state guesses as possible. Therefore, the geometries of 
four manually constructed initial TS guesses were optimized at the PBE0[96]-D3[97]/SBKJC[100] 
SMD[101](butanol) level of theory in GAMESS-US[157] with harmonic constraints on the for-
ming C-C bonds (one constraint per TS), which held their lengths to be closely around 2.2 Å. 
The PBE0 functional was chosen because it is known to be accurate for organic chemistry 
calculations[96b] and has recently been shown to be well-grounded in theory.[96c]  
After convergence of the preliminary geometry optimizations, the Hessians were computed 
for each conformation at the PBE[159]/SBKJC SG1 level of theory. Then, the actual searches 
for transition states were initiated at the PBE0-D3/SBKJC SMD(butanol) level of theory with 
QA[160] optimization algorithm (maximum step: 0.05 Bohr) using the calculated Hessians as 
initial guesses and updating them on each step using the POWELL[161] method. 
After convergence of the transition state searches, single-point energy calculations were 
performed at the PBE0-D3/IMCP-SR1[98] SMD(butanol) level of theory. The IMCP-SR1 
basis set was chosen for the final energy evaluations as it incorporates scalar-relativistic 
effects, which are important for heavy elements, such as iridium in the studied case,[99] and 
belongs to model core potential basis sets which retain the correct nodal structures of 
atoms.[98] Importantly, the performed calculations benefit from a favorable error cancellation, 
which rises from the fact that the studied TSs are very similar in nature, so systematic errors 
in them largely cancel out.[107,109] 
In order to account for the interplay between the located transition states, the Curtin–Hammett 
principle[108] was finally invoked by M. G. M. to calculate the percentaged contribution (C) of 
each of the four transition states, which is described in detail in chapter 2.3.8. Based on the 
percentaged contributions (C), an enantiomeric excess of 48.4% (R) was calculated for pro-
duct 143h, which is, in consideration of the applied approximations, in a very good agreement 
with the experimentally found 70% ee (R) for product 143h with actual catalyst Λ-T18' (see 
chapter 2.3.3, Table 13, entry 11). 
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4.17  Crystallographic Data 
Single crystal X-ray diffraction data were collected at a temperature of 100 K (rac-T18-dimer, 
rac-T18', rac-T18-TfO) or 110 K ((S)-143i) on a Bruker D8 Quest diffractometer using 
Mo-Kα-radiation (Incoatec Microsource) and a PHOTON 100 CMOS area detector system. 
Scaling and absorption correction was performed by using the SADABS[162] software package 
from Bruker. Structures were solved using direct methods in SHELXT[163] and refined using 
the full-matrix least-squares procedure in SHELXL.[164] Hydrogen atoms were placed in 
calculated positions and refined as riding on their respective C atom and Uiso(H) was set at 
1.2 Ueq(Csp2) and 1.5 Ueq(Csp3). Disorder was refined using restraints for both the geometry 
and the anisotropic displacement factors. 
Structures of rac-T18-dimer, catalyst rac-T18', catalysis intermediate analog rac-T18-TfO, 
and catalysis product (S)-143i are depicted in Figures 52–55. The corresponding crystal data 
and details of the structure determination are presented in Tables 24–27. The four structures 
have been deposited in the Cambridge Structural Database (http://www.ccdc.cam.ac.uk/)  
as CCDC 1536877 for rac-T18-dimer, CCDC 1536878 for rac-T18', CCDC 1536879 for 
rac-T18-TfO, and CCDC 1545358 for (S)-143i. 
 
Iridium(III) Dimer rac-T18-dimer. X-ray quality crystals of rac-T18-dimer were obtained 
by slow diffusion of MeOH into a concentrated acetone solution of rac-T18-dimer at rt 
(vapor diffusion technique). 
 
 
Figure 52. Crystal structure of iridium(III) dimer rac-T18-dimer with 50% probability of thermal ellipsoids. 
Cocrystallized solvent molecules and positional disorder are omitted for clarity (CCDC 1536877).[85]  
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Catalyst rac-T18'. X-ray quality crystals of catalyst rac-T18' were obtained by slow evapo-
ration of CH2Cl2 out of a CH2Cl2/MeCN solution of rac-T18' at rt (low solubility of rac-T18' 
in MeCN; slow evaporation technique). 
 
 
 
Figure 53. Structure of active catalyst Λ-T18' with 50% probability of thermal ellipsoids generated from the 
crystal structure obtained for rac-T18'. Cocrystallized solvent molecules and positional disorder are omitted for 
clarity.[85] Λ-T18' is shown from two different perspectives (CCDC 1536878). 
 
Catalysis Intermediate Analog rac-T18-TfO. X-ray quality crystals of catalysis interme-
diate analog rac-T18-TfO were obtained by slow diffusion of n-hexane into a concentrated 
toluene solution of rac-T18-TfO at rt (vapor diffusion technique). 
 
 
 
 
 
Figure 54. Structure of catalysis intermediate analog Λ-T18-TfO with 60% probability of thermal ellipsoids 
generated from the crystal structure obtained for rac-T18-TfO. Cocrystallized solvent molecules and positional 
disorder are omitted for clarity (CCDC 1536879).[85]  
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C-Acylated Benzofuranone (S)-143i 
X-ray quality crystals of C-acylated benzofuranone 143i were obtained by slow evaporation 
from a solution of 143i in Et2O at 4 °C (batch from Table 13, entry 13 with 93% ee). The 
absolute configuration of 143i present in the measured crystal was determined as S using the 
anomalous dispersion method (Flack parameter: 0.012(12)).[165] This result is in accordance 
with the assignment for C-acylated benzofuranone 143e based on the literature known optical 
rotation of 143e (see chapter 4.10.2 for details) as well as in accordance with the calculated 
enantiomeric excess for C-acylated benzofuranone 143h (see chapter 4.16 for details). 
 
 
 
Figure 55. Left: Structure of both symmetry-independent molecules (S)-143i in the asymmetric unit with 60% 
probability of thermal ellipsoids (CCDC 1545358).[85] Right: Molecular overlay of the two symmetry-indepen-
dent molecules. 
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Table 24. Crystal data and structure refinement for TCDimer_0m (= rac-T18-dimer). 
 
 
Crystal data  
 
Identification code  TCDimer_0m 
Habitus, colour prism,  pale yellow 
Crystal size 0.51 x 0.42 x 0.20 mm3 
Crystal system  Triclinic 
Space group  P-1 Z = 2 
Unit cell dimensions a = 16.2758(9) Å α = 77.283(2)°. 
 b = 16.4350(9) Å β = 83.441(2)°. 
 c = 27.5378(14) Å γ = 65.571(2)°. 
Volume 6540.0(6) Å3 
Cell determination  9331 peaks with Theta 2.3 to 25.3°. 
Empirical formula  C153 H170 Cl2 Ir2 N4 O7 
Moiety formula  C144 H152 Cl2 Ir2 N4 O4, 3(C3 H6 O) 
Formula weight  2632.22 
Density (calculated) 1.337 Mg/m3 
Absorption coefficient 2.132 mm-1 
F(000) 2720 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.242 to 25.325°. 
Index ranges -19<=h<=19, -19<=k<=19, -33<=l<=33 
Data collection software  APEX3 (Bruker AXS Inc., 2015)[166]  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)[167]  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 139346 
Independent reflections 23847 [R(int) = 0.0410] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  20411[I > 2σ(I)]  
Reflections used for refinement  23847 
Absorption correction Semi-empirical from equivalents[162] 
Max. and min. transmission 0.68 and 0.46 
Largest diff. peak and hole 1.330 and -1.228 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[163]  
 SHELXL-2014/7 (Sheldrick, 2014)[164]  
 DIAMOND (Crystal Impact)[168]  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[169]  
Data / restraints / parameters 23847 / 39 / 1562 
Goodness-of-fit on F2 1.037 
R index (all data) wR2 = 0.0559 
R index conventional  [I > 2σ(I)] R1 = 0.0254 
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Table 25. Crystal data and structure refinement for TCracneu2_0m_sq (= rac-T18'). 
 
 
Crystal data  
 
Identification code  TCracneu2_0m_sq 
Habitus, colour plate, yellow 
Crystal size 0.26 x 0.21 x 0.11 mm3 
Crystal system  Triclinic 
Space group  P-1 Z = 2 
Unit cell dimensions a = 13.1876(8) Å α = 102.843(2)°. 
 b = 14.7823(8) Å β = 95.416(2)°. 
 c = 20.8556(12) Å γ = 106.648(2)°. 
Volume 3743.0(4) Å3 
Cell determination  9435 peaks with Theta 2.7 to 27.6°. 
Empirical formula  C83.65 H83.50 Cl Ir N5.83 O2 
Moiety formula  C82 H81 Cl Ir N5 O2, 0.826(C2 H3 N) 
Formula weight  1430.06 
Density (calculated) 1.269 Mg/m3 
Absorption coefficient 1.869 mm-1 
F(000) 1472 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.148 to 27.639°. 
Index ranges -17<=h<=17, -19<=k<=19, -27<=l<=27 
Data collection software  APEX3 (Bruker AXS Inc., 2015)[166]  
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)[167] 
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 157290 
Independent reflections 17277 [R(int) = 0.0452] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  15431[I > 2σ(I)]  
Reflections used for refinement  17277 
Absorption correction Semi-empirical from equivalents[162] 
Max. and min. transmission 0.82 and 0.66 
Largest diff. peak and hole 2.986 and -1.566 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[163]  
 SHELXL-2014/7 (Sheldrick, 2014)[164] 
 DIAMOND (Crystal Impact)[168] 
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[169] 
 PLATON (“SQUEEZE”)[170] 
Data / restraints / parameters 17277 / 316 / 961 
Goodness-of-fit on F2 1.057 
R index (all data) wR2 = 0.0810 
R index conventional  [I > 2σ(I)] R1 = 0.0322 
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Table 26. Crystal data and structure refinement for TCZPOTf_0m (= rac-T18-TfO). 
 
 
Crystal data  
 
Identification code  TCZPOTf_0m 
Habitus, colour plate, yellow 
Crystal size 0.37 x 0.17 x 0.08 mm3 
Crystal system  Triclinic 
Space group  P-1 Z = 2 
Unit cell dimensions a = 16.3328(8) Å α = 101.062(2)°. 
 b = 18.4786(9) Å β = 113.044(2)°. 
 c = 19.2514(10) Å γ = 91.864(2)°. 
Volume 5209.8(5) Å3 
Cell determination  9726 peaks with Theta 2.2 to 25.3°. 
Empirical formula  C115 H125 Cl4 F3Ir N5 O7 S 
Moiety formula  C87 H87 Cl4Ir N5 O4, C F3 O3 S, 3(C7 H8), C6 H14 
Formula weight  2112.25 
Density (calculated) 1.346 Mg/m3 
Absorption coefficient 1.467 mm-1 
F(000) 2188 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  100(2) K 
Theta range for data collection 2.194 to 25.335°. 
Index ranges -19<=h<=19, -22<=k<=22, -23<=l<=23 
Data collection software  APEX3 (Bruker AXS Inc., 2015)[166] 
Cell refinement software  SAINT V8.35A (Bruker AXS Inc., 2015)[167]  
Data reduction software  SAINT V8.35A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 169407 
Independent reflections 18983 [R(int) = 0.0425] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  17508[I > 2σ(I)]  
Reflections used for refinement  18983 
Absorption correction Semi-empirical from equivalents[162] 
Max. and min. transmission 0.89 and 0.75 
Largest diff. peak and hole 1.140 and -0.837 e.Å-3 
Solution  Direct methods 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[163] 
 SHELXL-2014/7 (Sheldrick, 2014)[164] 
 DIAMOND (Crystal Impact)[168]  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[169]  
Data / restraints / parameters 18983 / 324 / 1316 
Goodness-of-fit on F2 1.065 
R index (all data) wR2 = 0.0733 
R index conventional  [I > 2σ(I)] R1 = 0.0286 
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Table 27. Crystal data and structure refinement for TCEN1_0m (= (S)-143i). 
 
 
Crystal data  
 
Identification code  TCEN1_0m 
Habitus, colour  needle, colourless 
Crystal size 0.511 x 0.059 x 0.042 mm3 
Crystal system  Monoclinic 
Space group  P21 Z = 4 
Unit cell dimensions a = 7.1346(3) Å α = 90°. 
 b = 14.8376(6) Å β = 98.492(2)°. 
 c = 15.0064(6) Å γ = 90°. 
Volume 1571.17(11) Å3 
Cell determination  9800 peaks with Theta 2.7 to 27.5°. 
Empirical formula  C14 H13 Cl3 O4 
Moiety formula  C14 H13 Cl3 O4 
Formula weight  351.59 
Density (calculated) 1.486 Mg/m3 
Absorption coefficient 0.594 mm-1 
F(000) 720 
 
Data collection:  
 
Diffractometer type  Bruker D8 QUEST area detector 
Wavelength  0.71073 Å 
Temperature  110(2) K 
Theta range for data collection 2.745 to 27.558°. 
Index ranges -9<=h<=9, -19<=k<=19, -19<=l<=19 
Data collection software  APEX3 (Bruker AXS Inc., 2015)[166] 
Cell refinement software  SAINT V8.37A (Bruker AXS Inc., 2015)[167] 
Data reduction software  SAINT V8.37A (Bruker AXS Inc., 2015) 
 
Solution and refinement: 
 
Reflections collected 37928 
Independent reflections 7247 [R(int) = 0.0329] 
Completeness to theta = 25.242° 99.9 %  
Observed reflections  6771[I > 2σ(I)]  
Reflections used for refinement  7247 
Absorption correction Semi-empirical from equivalents[162] 
Max. and min. transmission 0.97 and 0.91 
Flack parameter (absolute struct.)   0.012(12)[165]  
Largest diff. peak and hole 0.330 and -0.244 e.Å-3 
Solution  Dual space algorithm 
Refinement  Full-matrix least-squares on F2 
Treatment of hydrogen atoms  Calculated positions, constr. ref. 
Programs used  XT V2014/1 (Bruker AXS Inc., 2014)[163]  
 SHELXL-2016/6 (Sheldrick, 2016)[164] 
 DIAMOND (Crystal Impact)[168]  
 ShelXle (Hübschle, Sheldrick, Dittrich, 2011)[169] 
Data / restraints / parameters 7247 / 1 / 385 
Goodness-of-fit on F2 1.036 
R index (all data) wR2 = 0.0539 
R index conventional [I > 2σ(I)] R1 = 0.0249 
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5.  Appendix 
In chapter 5.1, the 1H NMR and 13C NMR spectra of the Ir(III) complexes are shown that are 
closely linked to catalyst Λ- and ∆-T18', namely of diastereomeric auxiliary complexes 
Λ- and ∆-(S)-T18, of bisacetonitrile intermediate Λ-T18-(MeCN)2, of precatalyst Λ-T18, of 
active catalyst Λ-T18' itself, and of N-methylated complex Λ-T18-Me. 
 
In chapter 5.2, the chiral HPLC traces of catalysts rac-, Λ-, and ∆-T18' are shown. Moreover, 
the chiral HPLC trace of reisolated catalyst Λ-T18' from chapter 2.3.3, Table 13, entry 14 is 
shown there as well as the chiral HPLC trace of the sample of catalyst ∆-T18' which had been 
kept in CD2Cl2 for one week at 25 °C before HPLC analysis and use in a catalysis experiment 
(see chapter 2.3.2, Table 10, entry 14). 
 
In chapter 5.3, the 1H and 13C NMR spectra of catalysis products 14a–i (chapter 2.3.2, 
Table 10), 143b–i (chapter 2.3.3, Table 13), and 163a–h (chapter 2.3.7, Table 19) are shown. 
 
In chapter 5.4, the chiral HPLC traces of catalysis products 14a–i (chapter 2.3.2, Table 10), 
143a–i (chapter 2.3.3, Table 13), and 163a–h (chapter 2.3.7, Table 19) are shown. 
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5.1  1H and 13C NMR Spectra of Iridium(III) Complexes that are Linked to Λ/∆-T18' 
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Figure 56. 1H NMR spectrum of auxiliary complex Λ-(S)-T18. 
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Figure 57. 13C NMR spectrum of auxiliary complex Λ-(S)-T18. 
150210_23667_TC571_Dia2.001.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
No
rm
al
ize
d 
In
te
ns
ity
8.963.068.913.009.0811.986.033.051.012.951.011.091.093.130.950.940.910.930.931.990.981.042.051.021.061.021.071.071.156.253.111.051.05
DICHLOROMETHANE-d2
Diastereomer 
∆-(S)-T18
TMS
 
Figure 58. 1H NMR spectrum of auxiliary complex ∆-(S)-T18. 
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Figure 59. 13C NMR spectrum of auxiliary complex ∆-(S)-T18. 
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Figure 60. 1H NMR spectrum of bisacetonitrile intermediate Λ-T18-(MeCN)2. 
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Figure 61. 13C NMR spectrum of bisacetonitrile intermediate Λ-T18-(MeCN)2. 
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Figure 62. 1H NMR spectrum of precatalyst complex Λ-T18. 
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Figure 63. 13C NMR spectrum of precatalyst complex Λ-T18. 
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Figure 64. 1H NMR spectrum of active catalyst Λ-T18'. 
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Figure 65. 13C NMR spectrum of active catalyst Λ-T18'. 
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Figure 66. 1H NMR spectrum of N-methylated catalyst Λ-T18-Me. 
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Figure 67. 13C NMR spectrum of N-methylated catalyst Λ-T18-Me.
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5.2 Chiral HPLC Traces of Iridium(III) Complexes rac-, Λ-, and ∆-T18' 
 
 
 
Figure 68. Chiral HPLC trace of racemic catalyst rac-T18'. 
 
 
 
 
Figure 69. Chiral HPLC trace of enantiopure catalyst Λ-T18'. 
 
 
 
 
Figure 70. Chiral HPLC trace of reisolated catalyst Λ-T18' (Table 13, entries 14 and 15). 
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Figure 71. Chiral HPLC trace of enantiopure catalyst ∆-T18'. 
 
 
 
Figure 72. Chiral HPLC trace of enantiopure catalyst ∆-T18'  after one week in CD2Cl2 at 25 °C 
(Table 10, entry 14). 
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5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) 
5.3.1  1H and 13C NMR Spectra of C-Acylated Azlactones 14 (Table 10)  
TC1150_2.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rm
al
iz
ed
 In
te
ns
ity
0.990.993.042.002.034.995.001.98
CHLOROFORM-d
N
O
OO
Bn
BnO
OMe
C-Acylated Azlactone 14a
 
 
TC1150_2.011.001.1r.esp
170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
17
3.
83
16
5.
87 16
3.
67
16
2.
85
13
4.
90
13
3.
04
13
0.
52
13
0.
20
12
8.
72
12
8.
05
12
7.
60
11
7.
37
11
4.
29
77
.6
5
77
.5
8
77
.1
6
76
.7
4
68
.3
3
55
.5
6
40
.2
7
N
O
OO
Bn
BnO
OMe
C-Acylated Azlactone 14a
 
 
TC757.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
No
rm
al
ize
d 
In
te
ns
ity
6.041.021.060.993.092.072.075.122.00
CHLOROFORM-d
N
O
OO
BnO
OMe
TMS
C-Acylated Azlactone 14b
 
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 300 ~ 
 
150705_26367_TC757.001.001.1r.esp
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
23
.1
5
23
.8
7
24
.7
4
42
.8
4
55
.6
8
68
.2
3
76
.4
6
76
.9
1
77
.1
6
77
.4
1
11
4.
46
11
7.
64
12
8.
0212
8.
71
13
0.
39
13
4.
95
16
2.
6716
3.
81
16
6.
17
17
5.
07
N
O
OO
BnO
OMe
C-Acylated Azlactone 14b
 
 
TC761.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
No
rm
al
ize
d 
In
te
ns
ity
2.943.042.112.045.161.90
CHLOROFORM-d
N
O
OO
Me
BnO
OMe
TMS
C-Acylated Azlactone 14c
 
 
TC761.011.001.1r.esp
180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
20
.7
0
55
.6
768
.2
5
72
.9
8
76
.7
4
77
.1
6
77
.5
8
11
4.
46
11
7.
65
12
7.
9313
0.
41
13
4.
97
16
3.
1316
3.
86
16
6.
24
17
5.
31
N
O
OO
Me
BnO
OMe
C-Acylated Azlactone 14c
 
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 301 ~ 
 
TC760.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
No
rm
al
iz
ed
 In
te
ns
ity
1.031.023.003.052.085.091.99
CHLOROFORM-d
N
O
OO
Bn
MeO
OMe
TMS
C-Acylated Azlactone 14d
 
 
150705_26366_TC760_Hand.001.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
40
.4
3
53
.8
4
55
.6
3
76
.9
1
77
.1
6
77
.4
1
77
.5
1
11
4.
35
11
7.
33
12
7.
68
12
8.
37
13
0.
2613
0.
55
13
3.
02
16
2.
8416
3.
74
16
6.
52
17
3.
87
N
O
OO
Bn
MeO
OMe
C-Acylated Azlactone 14d
 
 
TC756.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
No
rm
al
ize
d 
In
te
ns
ity
6.031.020.993.002.025.001.98
CHLOROFORM-d
N
O
OO
Bn
O
OMe
Cl3C
TMS
C-Acylated Azlactone 14e
 
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 302 ~ 
 
TC756.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
21
.3
2
39
.1
6
55
.5
8
76
.7
3
77
.1
6
77
.5
8
78
.3
3
91
.0
5
10
5.
27
11
4.
34
11
7.
53
12
7.
59
12
8.
38
13
0.
15
13
0.
49
13
3.
17
16
3.
46
16
3.
58
16
3.
66
17
3.
75
N
O
OO
Bn
O
OMe
Cl3C
C-Acylated Azlactone 14e
 
 
TC759.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
No
rm
al
ize
d 
In
te
ns
ity
9.250.990.972.085.004.902.091.98
CHLOROFORM-d
N
O
OO
Bn
BnO
TMS
C-Acylated Azlactone 14f
 
 
150705_26368_TC759.001.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
17
3.
80
16
5.
74
16
3.
31
15
7.
17
13
4.
86 13
2.
98
13
0.
52
12
8.
76
12
8.
41
12
8.
11
12
5.
91
12
2.
26
77
.7
1
77
.4
1
77
.1
6
76
.9
1
68
.4
3
40
.2
0
35
.3
1
31
.1
7
N
O
OO
Bn
BnO
C-Acylated Azlactone 14f
 
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 303 ~ 
 
TC762.010.001.1r.esp
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
No
rm
al
ize
d 
In
te
ns
ity
1.031.012.103.032.295.021.062.051.001.061.010.98
CHLOROFORM-d
N
O
OO
Bn
BnO
TMS
C-Acylated Azlactone 14g
 
 
TC762.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
40
.1
4
68
.5
3
76
.7
477
.1
6
77
.5
8
78
.3
6
12
1.
55
12
4.
66
12
6.
00
12
6.
73
12
7.
75
12
8.
13
12
8.
51
12
8.
80
13
0.
57
13
3.
80
13
3.
88
13
4.
89
16
3.
39
16
5.
59
17
3.
56
N
O
OO
Bn
BnO
C-Acylated Azlactone 14g
 
 
TC1149.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
No
rm
al
ize
d 
In
te
ns
ity
1.001.002.015.105.052.063.001.021.00
CHLOROFORM-d
N
O
OO
Bn
BnO
TMS
C-Acylated Azlactone 14h
 
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 304 ~ 
 
TC1149.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
17
3.
64
16
5.
66
16
3.
32
13
5.
60 13
2.
91
13
0.
52
12
8.
76
12
8.
39
12
8.
11
12
7.
98
12
7.
70
12
7.
15
12
3.
57
12
2.
29 77
.9
0
77
.5
8
77
.1
6
76
.7
4
68
.4
7
40
.3
3
N
O
OO
Bn
BnO
C-Acylated Azlactone 14h
 
 
TC1089.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
No
rm
al
ize
d 
In
te
ns
ity
8.991.991.030.982.003.085.03
CHLOROFORM-d
N
O
OO
Bn
BnO
C-Acylated Azlactone ent-14i
 
 
TC1089.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
No
rm
al
ize
d 
In
te
ns
ity
CHLOROFORM-d
17
4.
65
17
3.
61 16
5.
61
13
4.
94 13
3.
02
13
0.
66
12
8.
75
12
8.
31
12
7.
98
12
7.
69
77
.5
8
77
.1
6
76
.7
4
68
.2
6
39
.5
0
34
.1
2
26
.3
6
N
O
OO
Bn
BnO
C-Acylated Azlactone ent-14i
 
  
       – 5.3  1H and 13C NMR Spectra of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) – 
 
~ 305 ~ 
 
5.3.2  1H and 13C NMR Spectra of C-Acylated Benzofuranones 143 (Table 13)  
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5.3.3  1H and 13C NMR Spectra of α-Chiral N-Acyl Pyrroles 163 (Table 19)  
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5.4  HPLC Traces of Products 14 (Table 10), 143 (Table 13), 163 (Table 19) 
5.4.1  HPLC Traces of C-Acylated Azlactones 14 (Table 10)  
Product 14a from Table 10: 
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Product 14b from Table 10: 
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Product 14c from Table 10: 
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Product 14d from Table 10: 
 
 
 
Product 14e from Table 10: 
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Product 14f from Table 10: 
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Product 14g from Table 10: 
 
 
 
Product 14h from Table 10: 
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Product 14i from Table 10 
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5.4.2  HPLC Traces of C-Acylated Benzofuranones 143 (Table 13)  
Product 143a from Table 13 (not isolated; determined from crude product mixture): 
 
 
Product 143b from Table 13: 
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Product 143c from Table 13: 
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Product 143d from Table 13: 
 
 
 
Product 143e from Table 13: 
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Product 143f from Table 13: 
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Product 143g from Table 13: 
 
 
 
Product 143h from Table 13: 
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Product 143i from Table 13: 
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5.4.3 HPLC Traces of N-Acyl Pyrroles 163 (Table 19)  
Product 163a from Table 19: 
 
 
Product 163b from Table 19: 
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Product 163c from Table 19: 
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Product 163d from Table 19: 
 
 
 
Product 163e from Table 19: 
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Product 163f from Table 19: 
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Product 163g from Table 19: 
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Product 163h from Table 19: 
 
 
 – 6. List of Synthesized Compounds – 
 
~ 340 ~ 
 
6.  List of Synthesized Compounds 
6.1  Synthesized Iridium(III) Complexes (without their Precursor Complexes) 
The syntheses of the following iridium(III) complexes are described in detail in chapter 4.7. 
Their corresponding precursor complexes, i.e., their corresponding iridium(III) dimers and 
auxiliary complexes, are not listed here. Nevertheless, the syntheses and characterizations of 
their precursor complexes are included in chapter 4.7. 
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6.2  Synthesized Cyclometalating Ligands (with their Precursor Molecules) 
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6.3  Synthesized Non-Cyclometalating Ligands (with their Precursor Molecules) 
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6.4  Synthesized Substrates for Catalysis Experiments (without their Precursors) 
 
 
 
 
6.5  Isolated Catalysis Products (Each with the Best Achieved Enantiomeric Excess) 
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7.  Abbreviations and Symbols 
[α]D23 specific rotation α in degrees at the sodium D line (λ = 589 nm) at 23 °C 
1x, 2x, 3x... one time, two times, three times... 
3D three-dimensional 
Å ångström (unit of length; 1Å = 10–10 m) 
acc. according  
AK Arbeitskreis  
APCI atmospheric pressure chemical ionization 
approx. approximately 
aq aqueous 
arom aromatic 
atm atmosphere (unit of pressure; 1 atm = 101.3 kPa = 1013 mbar) 
ATR attenuated total reflection 
BArF24 tetrakis(3,5-bis(trifluoromethyl)phenyl)borate 
BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
BINOL 1,1'-bi-2-naphthol 
Bn benzyl 
Boc tert-butyloxycarbonyl 
BrCamSulf– 3-bromo-camphor-8-sulfonate anion 
Bz benzoyl 
C conversion (see chapter 1.2, Eq. 1) 
C contribution (see chapter 2.3.8, Eq. 2) 
Cq quaternary carbon, carbon atom without attached hydrogen(s) (NMR) 
c  concentration in g/100 mL (only used for specific rotation values) 
C^N C,N-coordinating bidentate ligand 
Cn n-fold rotational axis of symmetry 
calcd calculated 
cat. catalyst or catalytic 
Cbz carboxybenzyl 
CCDC Cambridge Crystallographic Data Centre 
CD circular dichroism 
CI chemical ionization 
CIP rules Cahn–Ingold–Prelog priority rules (see ref. 88) 
cis / trans cis-trans isomerism of a) organic compounds or b) of complexes 
cod cyclooctadiene 
coe cyclooctene 
conc concentration or concentrated 
conv conversion 
CPME cyclopentyl methyl ether 
δ chemical shift in ppm (NMR) 
∆ / Λ absolute stereochemical descriptors: left- (Λ), right- (∆) handed propeller  
∆ε molar circular dichroism in M–1cm–1 (see chapter 4.11, Eq. 3) 
d, s, t, q, sept, m doublet, singlet, triplet, quartet, septet, multiplet (NMR) 
d length, thickness of a layer 
d.r. diastereomeric ratio 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DEAD diethyl azodicarboxylate 
decomp. decomposition 
DFT density functional theory 
DIPA diisopropylamine 
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DKR dynamic kinetic resolution 
DMAP 4-(dimethylamino)pyridine 
DME 1,2-dimethoxyethane 
DMF N,N-dimethylformamide 
DMF-DMA N,N-dimethylformamide-dimethylacetal 
dmp 2,9-dimethyl-1,10-phenanthroline 
DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO dimethyl sulfoxide 
dppf 1,1'-bis(diphenylphosphino)ferrocene 
dtbpy 4,4'-di-tert-butyl-2,2'-dipyridyl 
e.g. for example (Latin: exempli gratia) 
ee enantiomeric excess  
EI electron (impact) ionization 
en ethylenediamine 
eq equivalent(s) 
Eq. equation 
ESI electrospray ionization 
et al. and others (Latin: et alii) 
EWG electron-withdrawing group 
exp natural exponential function 
ex situ opposite of in situ (see below)  
f extent of labeling / degree of functionalization (resin) 
f. c. flash chromatography 
FD field desorption ionization 
flow flow rate (HPLC) 
GAMESS General Atomic and Molecular Electronic Structure System 
GDCh Gesellschaft Deutscher Chemiker 
h hour(s) 
HOMO highest occupied molecular orbital 
HPLC high-performance liquid chromatography 
HRMS high-resolution mass spectrometry 
i- iso- (compound prefix) 
i.e. that is to say / namely (Latin: id est) 
in silico performed on computer / via computer simulation  
in situ  in the reaction mixture / in the course of the reaction 
in vacuo in a vacuum / within a vacuum 
in vitro in glass / reaction vessel; meant as opposite of in silico (see above) 
incomp. incomplete 
IR infrared 
ISC intersystem crossing 
J coupling constant in Hz (NMR) 
k reaction rate constant 
KIE kinetic isotope effect 
KR kinetic resolution 
λ wavelength 
LED light-emitting diode 
ln natural logarithm 
LUMO lowest unoccupied molecular orbital 
M molecule / compound of interest (HRMS) 
M molar concentration, molarity 
m- meta- (compound prefix) 
M. G. M. Michael Gennadiyevich Medvedev 
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m/z mass-to-charge ratio (HRMS) 
min minute(s) 
mol% molar percentage 
mp melting point 
MS  molecular sieves or mass spectrometry 
MTBE methyl tert-butyl ether 
n- normal- (compound prefix) 
n.d. not determined 
n.c. no conversion 
N^N N,N-coordinating bidentate ligand 
NCS N-chlorosuccinimide 
NHC N-heterocyclic carbene 
NMM N-methylmorpholine 
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
M / P absolute stereochemical descriptors M and P for helical-chiral compounds 
NRC National Research Center 
o- ortho- (compound prefix) 
OC-FPR Organisch-chemisches Fortgeschrittenenpraktikum 
OC-MPR Organisch-chemisches Masterpraktikum 
ORCID Open Researcher and Contributor ID (https://orcid.org) 
p- para- (compound prefix) 
p. / pp. page (p.) / pages (pp.) 
PCET proton-coupled electron transfer 
Pd/C palladium metal finely dispersed on charcoal 
phgly phenylglycinate 
pH pH = –log10 a(H+); a(H+): activity of hydrogen ions in solution 
Piv pivaloyl 
ppm parts per million 
PPY 4-pyrrolidinopyridine 
PS  photosensitizer or polystyrene 
PTFE polytetrafluoroethylene 
quant. quantitative 
R ideal gas constant (8.314 J·mol–1K–1; see chapter 4.11, Eq. 3) 
R / S absolute stereochemical descriptors R and S 
r radius 
rac racemic or racemate 
RAS Russian Academy of Sciences 
RDS rate determining step 
ref. / refs. reference (ref.) / references (refs.) 
rt room temperature (~25 °C, no active thermostatization) 
σ mirror plane 
s second(s) 
S selectivity factor (see chapter 1.2, Eq. 1) 
S1 lowest excited singlet state 
sat. saturated 
SET single-electron transfer 
SPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl 
SpnF enzyme SpnF 
t temperature (in °C) 
t- tert- (compound prefix) 
T temperature (in K) 
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T. C. Thomas Cruchter 
T1 lowest excited triplet state 
TAA tert-amyl alcohol 
TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxyl, free radical 
TES triethylsilane 
Tf triflyl, trifuoromethanesulfonyl 
Tf O– triflate anion 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TLC thin-layer chromatography 
TMHI 1,1,1-trimethylhydrazinium  iodide 
Tol tolyl 
TON turnover number 
tR retention time 
TRIS(PHAT) tris(tetrachloro-1,2-benzenediolato)phosphate(V) 
TS transition state 
UV ultraviolet 
v~  wavenumbers in cm–1 
vol% percentage by volume 
w week(s) 
wt% percentage by weight 
X. S.  Xiaodong Shen 
XRD X-ray diffraction 
Z. L. Zhijie Lin 
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